The German Arthroplasty Registry (EPRD)

## Annual Report 2023

Annual Report 2023

## The German Arthroplasty Registry

An initiative of the
German Society for Orthopaedics
and Orthopaedic Surgery (DGOOC)

## DEUTSCHE GESELLSCHAFT FÜR ORTHOPÄDI

 UND ORTHOPÄDISCHE CHIRURGIEGerman Society for Orthopaedics \& Orthopaedic Surgery

## Imprint

EPRD Deutsche Endoprothesenregister gGmbH
Straße des 17. Juni 106-108
10623 Berlin

Phone: +49-(0)30-3406036-40
Fax: +49-(0)30-3406036-4
Email: info@eprd.de
www.eprd.de
© 2023 EPRD

ISBN: 978-3-949872-03-7
DOI: 10.36186/reporteprd092024

Bibliographic Information of the German National Library:
The German National Library lists this publication in the German
National Bibliography; detailed bibliographic information is available on the internet at http://portal.dnb.de

Typeset and designed by: Corinna Märting, Berlin

## Copyrights:

Images:
Prof. Carsten Perka, MD: Charité/Wiebke Peitz
Prof. Klaus-Peter Günther, MD: UKD;
Prof. Arnd Steinbrück, MD: Arlett Mattescheck, Thomas Hedrich;
Prof. Heiko Reichel, MD: RKU/Hans Botzenhardt
Illustrations on pp. 14, 16, 18, 19, and 152: © EPRD
For better readability, we refrain from gender-specific wording in the text
This publication is inclusive of the male, female and diverse genders.
with partners
${ }^{B V}$ Med
Die Stimme der deu
MedTech-Branche

Annual Report 2023

## Authors:

Alexander Grimberg, Jörg Lützner, Oliver Melsheimer, Michael Morlock, Arnd Steinbrück

Managing Director:
Timo Stehn

## Executive Committee of the EPRD

For the DGOOC:
Klaus-Peter Günther; Karl-Dieter Heller; Bernd Kladny;
Carsten Perka (Spokesperson); Heiko Reichel; Dieter Wirtz

## For the health insurance providers:

Sascha Dold; Claus Fahlenbrach; Thomas Hopf; Dorothee Krug;
Jürgen Malzahn (Deputy Spokesperson); Christian Rotering

For the manufacturers:
Björn Kleiner; Marc Michel; Michael Morlock; Michaela Münnig
Norbert Ostwald (Deputy Spokesperson); Matthias Spenner

We are very grateful to the members of the working groups for their suggestions and feedback regarding this annual report!

For the EPRD, 2022 was a very successful year. As one of the world's largest registries for hip and knee arthroplasties, this year, we were once again able to demonstrate that the EPRD is more than simply a means of communicating implant survival.
The primary reason that the EPRD has evolved into a success story over the past 10 years is because the fundamental idea of measuring and monitoring the safety of hip and knee implants has been complemented by patient-specific risk-factors and a comparison of revision rates on hospital-level. These opportunities offered by the EPRD are both valued nationally and increasingly recognised internationally. This is not only reflected in the increasing number of topranked publications which include data from the EPRD, but also in the fact that Hamburg, and thus the EPRD, was picked to host next year's Congress of the International Society of Arthroplasty Registries (ISAR).

In recent years, we have been able to continuously monitor the correlation between arthroplasty volume and revision risk on hospital level and thereby provide policymakers with important indicators for setting quality parameters. The EPRD's current data has thus also found its way into the inevitable discussion about a necessary German hospital reform. Nevertheless, it is also necessary to focus on other factors that impact arthroplasty quality. These include, for example,
important patient-specific risk factors affecting both morbidity and mortality following arthroplasty procedures, thus facilitating an individualised risk assessment - by the operating surgeon and also by the patients themselves.

With over two million data sets, the EPRD is currently the second largest registry in Europe and the third largest registry in the world. In 2022 more data has been collected than in any other previous year. The almost 100 percent follow-up rate of patients from participating health insurance providers is unique. These high EPRD follow-up percentages, which are based on voluntary data submissions from individual hospitals, can only be achieved if all healthcare providers maintain their committment to continuously assess and improve the quality of arthroplasties performed. We would therefore like to thank all those who have contributed to the success of the EPRD by submitting data over the last years.

We will continue to develop the registry, for example, by recording individual surgeon data, which would allow surgeon-specific outcome analyses on a voluntary basis.

Moreover, the company, RSG Register Solutions gGmbH , a 100 percent subsidiary of the DGOOC, was founded to leverage the EPRD's experience in setting up a registry for
other societies and clinical entities and to advance technologies for the automated acquisition of text and, in future, image data

Why is a registry like the EPRD needed? Why are randomised clinical trials not enough? The answer to these questions is simple: only with a registry like the EPRD the quality of arthroplasty surgery will continuously be monitored and maintained in our country This is because results obtained under controlled study conditions, from individual highly specialised hospitals, cannot be extrapolated to the "real world" in general Unlike clinical trials, registries do not apply specific patient inclusion and exclusion criteria, as these do not exist in "normal life", because patients are treated as part of everyday clinical practice. Moreover, routine data from health care insurance providers, with all of its unique features, add value to a comprehensive assessment of outcome, which can even be superior to the design of clinical studies, which mostly focus on specific questions. For example, the EPRD reveals a significantly higher failure rate for septic hip procedures compared to clinical trials and meta-analyses.

Let us solve these and other challenges together. We hope that this report will provide you with many helpful insights for the successful management of your arthroplasty patients.


Prof. C. Perka, MD Chair, Scientific Advisory Board


Prof. K.-P. Günther, MD Scientific Advisory Board (International Relations)


Prof. A. Steinbrück, MD Scientific Advisory Board (Study Coordination)

## Message from the Chair of the Outlier Assessment Committee



Prof. H. Reichel, MD Chair, Outlier Assessment
rom the outset, the EPRD not only focused on long-term arthroplasty outcomes, but also on establishing an early warning system for implants. To this end, specific implant systems and combinations have been analysed every six months since 2020 - taking into account known confounding factors - in order to identify so-called "statistical outliers" with increased revision probabilities after primary surgery.

The correct interpretation of the results based on adjusted data requires appropriate expertise. For this reason, the Outlier Assessmen Committee evaluates the identified statistical outliers in terms of their medical relevance. The members of this working group include the EPRD's medical statisticians as well as designated representatives of the medical society, manufacturers and health insurance providers. Implant outliers that cannot be explained, e.g., by biased patient selection, are reported to the manufacturers and operating hospitals with a request for comment. To date, the notified institutions have been respon sible for assessing the abnormalities and deciding on possible consequences. In addition to the individual arthroplasty survival analyses that manufacturers and hospitals routinely receive, this early warning system is therefore a supplemental awareness-raising
measure. Past analyses of outliers have predominantly focused on short-term implant outcomes. However, many of the statistical outliers observed during the first few postoperative years cannot be attributed to individual implant systems. Rather, the sometimes significantly different revision rates between individual hospitals implanting the same arthroplasty system indicate that the effect of the operating surgeon or the hospital on the short-term outcomes is often greater than that of the implant system itself. This is also reported to the respective hospitals and manufacturers.

As short-term implant outcomes therefore depend more on the surgeon and on pa-tient-related factors, the early warning system has recently been expanded to include an additional level of analysis. In this additional analysis - and only in this analysis - early revisions within the first three years are disregarded. Only the implant-dependent medium and long-term performance of the implants is analysed. Atypical increases in revision probabilities can therefore be identified as implant related abnormalities, earlier than before. The EPRD is constantly refining its early warning system to ensure the valid detection and classification of these abnormalities.

## Table of contents

1 Introduction .....  10
2 Registry development .....  12
3 Summary of statistical methodology and data linkage. .....  18
4 The 2022 operating year .....  28
4.1 Primary hip arthroplasty .....  28
4.2 Hip arthroplasty reoperations .....  36
4.3 Primary knee arthroplasty. .....  40
4.4 Knee arthroplasty reoperations .....  47
5 Hip and knee arthroplasty survival .....  52
5.1 Outcome by type of arthroplasty .....  52
5.1.1 Comparison by type of hip arthroplasty ..... 52
5.1.2 Comparison by type of knee arthroplasty ..... 58
5.2 Non-implant-related factors. .....  .64
5.3 Correlation between implant characteristics and arthroplasty outcome. .....  80
5.3.1 Impact of implant characteristics in hip arthroplasties ..... 80
5.3.2 Impact of implant characteristics in knee arthroplasties ..... 94
5.4 Outcomes of specific implant systems (brands) and combinations ..... 102
5.5 Re-revision probability of hip and knee arthroplasties. ..... 142
6 Patient mortality ..... 146
7 Mismatch detection for more patient safety. .....  152
8 Summary ..... 158
Glossary ..... 162
References ..... 169
List of figures ..... 170
List of tables ..... 172
Appendix: Separate implant outcomes for acetabular and femoral components. ..... 176
Appendix: Publications based on EPRD data ..... 192

## 1 Introduction

The German Arthroplasty Registry (EPRD) has been collecting data on hip and knee arthroplasties for over 10 years, now. The registry, a joint initiative of the German Society for Orthopaedics and Orthopaedic Surgery (DGOOC), industry and health insurance providers, has amassed a considerable amount of data: To date, the EPRD has documented more than two million procedures from data provided on a strictly voluntary basis. More than one million of these are currently under long-term follow-up by the participating health insurance providers.

This immense amount of data not only offers the opportunity to paint a detailed picture of past and current arthroplasty practices, but also to provide increasingly reliable information on arthroplasty quality and potential for improvement. The EPRD thus makes an important contribution to enhancing quality. This year, the ten years of data acquisition, have prompted the registry to take a closer look at emerging trends - not only with regard to the type and characteristics of selected arthroplasties, but also in terms of their survival. To this end, separate panels in this report highlight various developments over the past ten years of the EPRD.

The development of the registry to date and plans for the future are discussed in detail in Chapter 2. Chapter 3 explains the organisation of the EPRD, the data sources involved, including their reconciliation, and thus provides the basis for understanding the analyses in subsequent chapters. These analyses span several chapters: Chapter 4 deals descriptively with the data submissions for the year 2022 and the changes that have become apparent in arthroplasty practice over the years.

Chapter 5 focuses on the survival of primary and revision arthroplasties across all years. Chapter 6 analyses post-arthroplasty patient mortality and compares its own outcomes with data from the German Federal Statistical Office for the corresponding age groups.

Chapter 7 focuses on so-called mismatch cases and the contribution of the EPRD to detect them at an early stage and prevent them in the long run. These are arthroplasty cases where incompatible components have been documented. The concluding section Chapter 8 summarises the most important results.

2

## Registry development

## 2 Registry development

## History to date

The EPRD started to document hip and knee arthroplasties, as part of a trial period, in November 2012. Initially, only a few pilot hospitals submitted their surgical documentation to the registry, but since the beginning of 2014 participation has been open to all interested hospitals.

The annual documentation rates rose steadily until 2019, but this was not simply due to the growing number of participating hospitals. When the COVID-19 pandemic reached Germany, in 2020, the number of arthroplasty procedures and thus also the number of documented procedures submitted to the registry declined significantly for the first time. In 2021, the numbers climbed slightly once again despite the ongoing pandemic, but only exceeded pre-pandemic levels in 2022. The 347,702 documented procedures for 2022 represent an increase of almost $9 \%$ compared to the previous record figure from 2019. Figure 1 summarises the annual procedure volume.

|  | 2018 | 2019 | 2020 | 2021 | 2022 |
| :--- | :---: | :---: | :---: | :---: | :---: |
| Primary arthroplasties | 272,455 | 285,700 | 263,000 | 277,512 | 314,909 |
| Reoperations | 31,271 | 33,457 | 32,057 | 32,654 | 32,793 |
|  |  |  |  |  | © EPRD Anual Report 2023 |

Table 1: Annual primary arthroplasty and reoperation volumes. The number of documented procedures includes both hip and knee arthroplasties.

The documentation of primary arthroplasties in the EPRD fell at the onset of the pandemic, but rose again significantly after it subsided. The number of documented reoperations has remained fairly constant in recent years (Table 1).

The renewed increase in procedure volume cannot be attributed to an increase in the number of participating hospitals. Although the number of hospitals that submitted surgical documentation to the EPRD rose continuously from 2012 to 2021, in the 2022 operating year 751 hospitals submitted data which for the first time did not exceed the previous year's total (see Figure 2).


Figure 1: Annual procedure volume by operation date. The total number of documented procedures is shown in black above the respective bar.


Figure 2: Number of hospitals submitting data each year. A hospital is considered a "data provider", if it submitted at least one surgical document to the EPRD during the calendar year.

## Future developments

The EPRD is organised as a strictly voluntary registry where neither hospitals nor patients are required to participate. However, in 2019, the German Parliament decided to establish the German Implant Registry (Implantateregister Deutschland - IRD), a national implant registry mandatory for all parties and to which all hip and knee arthroplasty procedures will be reported. The IRD is currently scheduled to start regular operations on January 1, 2025 ${ }^{1}$. It is not yet clear how the EPRD and the data it compiles will be incorporated into this new national registry.

The EPRD will therefore not only continue its own data collection, but also expand it in the future to include standardised and validated patient surveys. The spring of 2023 has already seen the start of trial operations to collect so-called PROMs (Patient Report ed Outcome Measures) in pilot hospitals.

These are subjective assessments of treatment outcomes by the patients themselves. To date, the EPRD has only been able to assess arthroplasty quality based on the arthroplasty survival analysis. These PROMs are therefore intended to complement another important quality criterion in the future by providing information on joint function, quality of life and patient satisfaction.

When selecting the underlying catalogue of survey questions, the EPRD opted for the Oxford Hip Score (OHS) and the Oxford Knee Score (OKS). As both scores are also employed in other national registries,[1] they lend themselves to international comparisons. In order to measure treatment efficacy, the surveys are administered to the patient both pre- and post-operatively at defined points in time. Each questionnaire comprises 12 separate questions on pain and physical function of the affected joint, each with five possible answers (see Illustration 1).

See website of the German Federal Ministry of Health: https://www.bundesgesundheitsministerium.de/implantateregister-deutschland.html

Willkommen im Befragungsportal des Endoprothesenregister Deutschland Hüft-Fragebogen Oxford Hip Score (OHS) -
O Oxford University Innovation Limited, 1996. Alle Rechte vorbehalten.

## Befragung zu lhrer linken Hüfte.

In den vergangenen 4 Wochen ...

1. Wie würden Sie die Hưftschmerzen beschreiben, die gewöhnlich bei Ihnen auftreten?

| Keine Schmerzen | Sehr leichte <br> Schmerzen | Leichte Schmerzen | Mäßige Schmerzen | Starke Schmerzen |
| :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  |

In addition, patients are asked postoperatively about their general satisfaction with the arthroplasty treatment

Starting in 2024, patients at all participating hospitals will be able to take part in this survey. In order to minimise the additional workload for hospitals as much as possible, the survey is conducted entirely online. The hospital merely retrieves a PDF document in advance via a portal of the registry, which it then hands out to each corresponding patient. The information provided in the pdf then allows patients to independently participate in the initial survey directly via the web portal. Patients who register with their own email address will then be invited to participate in subsequent surveys.

The EPRD also has plans for the coming years: Starting in 2026, the registry would like to offer a voluntary option for documenting the surgeon performing the hip and knee arthroplasty. In future, participating surgeons would also receive personalised outcome reports on their procedures and will be able to "take their outcomes with them" when changing hospitals. These outcomes are treated with absolute confidentiality and are only made available to the respective surgeon.

## In brief

- In 2022, more than 347,000 operations were documented in the EPRD by 751 hospitals.
- In 2023, the EPRD started its PROM questionnaire trial period.


## Evolution of the analysis over time

Over the years, the EPRD has developed an extensive analysis system. Part of the results of these analyses are presented in the annual report in transparent fashion for the public. In addition, participating hospitals and manufacturers receive customised reports.

Each spring, hospitals supplying data receive a descriptive comparison of the arthroplasty procedures they performed in the previous year and the total number of cases documented in the EPRD during this period. This allows them to see, for example, whether they differ from other participating hospitals in terms of the type of arthroplasty, type of stem etc. employed.

Twice a year since 2018, the EPRD has also been providing hospitals with analyses of their own arthroplasty procedures. These take into account in detail and across years the respective arthroplasty survival periods and compare outcomes with those of the other hospitals (see figure on Page 69).

At the end of each year, participating implant manufacturers receive comprehensive analyses of the hip and knee arthroplasties performed with their products. These include both descriptive summaries and analyses of the corresponding service lives. By now, the analyses are so detailed that manufacturers can see exactly how the procedures carried out with their respective prosthetic systems and subsystems fare - e.g., in certain age groups or restricted to arthroplasties with certain characteristics.

In addition, the EPRD has established an early warning system. The outcomes of all implants and implant combinations in the registry are monitored automatically and - in the event of a statistical discrepancy - discussed by a panel of experts. If the EPRD classifies a discrepancy as medically suspect and relevant, it contacts the manufacturer concerned and, if necessary, the hospital in question and asks them to respond.


Illustration 2: Representative excerpts from a hospital evaluation

# Summary of statistical methodology and data linkage 

## 3 Summary of statistical methodology and data linkage



Illustration 3: The flow of data from hospitals, health insurance providers and implant manufacturers to the EPRD

The EPRD essentially obtains its data from three sources: The registry documentation of the participating hospitals, the product database provided and maintained by the participating implant manufacturers, and from the routine data of the participating health insurance providers. As the EPRD is a strictly voluntary registry that cannot ensure a one hundred percent coverage, the data from the health insurance companies in particular enables the EPRD to draw valid conclusions about arthroplasty survival. Illustration 3 and the following description detail the data from the three sources and their consolidation:

- With the patients' consent, the participating hospitals may document their arthroplasty procedures directly in the EPRD (Illustration 4). This registry documentation provides the EPRD with basic data on the procedure and the patient. This includes details of the date of the operation, the joint operated on,
the type of procedure, as well as the patient's age, sex and, since 2017, height and weight, and since 2020 information on the patient's general state of health via the ASA classification. No information allowing patient identification is submitted to the registry. Moreover, the hospitals also document exactly which components were implanted during the procedure - usually by simply scanning the barcode.
- The participating implant manufacturers enter information on their products into the EPRD product database. The database not only contains basic product information, e.g., part number and trade name, but also more detailed classification data with specific information on material, size, condition, etc. The product database has been further refined in recent years through international exchange with the National Joint Registry (NJR) in the UK and currently contains data
on over 72,000 individual products. The clas sification data may be linked directly to the registry documentation via the documented part numbers. This allows the reported registry documentation to be categorised and arthroplasties with the same characteristics to be grouped together for analysis purposes. The product database is continuously undergoing improvements and corrections. As these changes may impact the analysi results, documentation from previous years are also retrospectively re-evaluated for the annual report based on the current version of the product database. To some extent this limits comparisons of the results presented in this report with previous annual reports.
- A major hallmark of the EPRD is its co-operation with the federal associations of health insurance providers (AOK-Bundesverband GbR) and the Verband der Ersatzkassen e. V (vdek). By consenting to participate in the registry, the patients agree that their health insurance fund may provide the EPRD with further information - in accordance with data protection regulations - on both the documented surgery and any subsequent reoperations. From the German

ICPM and ICD codes contained in this routine data, the EPRD can derive details of the procedure and its accompanying circumstances. Once the health insurance provider has reported the relevant patient data to the EPRD, the former will from then on independently check the system for changes to the patient's arthroplasty and status. Any reoperations and censoring events, such as the death of a patient, are then automatically reported to the EPRD by the federal health insurance association. In this way, the EPRD gets notified of reoperations even though they have not been documented directly in the registry.

The purely descriptive analysis of the current arthroplasty situation as described in Chapter 4 of this annual report only requires the registry documentation and data from the product database. However, in order to calculate and analyse arthroplasty survival as in Chapter 5, it is essential to also include the routine data from the health insurance providers. This is the only way that the EPRD, as a purely voluntary registry, can ensure that it does not miss any reoperation or censoring event.


Illustration 4: For registry documentation, hospitals may enter their data via the EPRD-Edit software, among others.

Thus, the number of data sets available for the arthroplasty survival analysis will always be significantly smaller than the total number of data sets compiled in the EPRD. Since the EPRD only receives such routine data from patients insured with one of the regional health insurance providers (Allgemeine Ortskrankenkasse) or one of the other statutory health insurance providers (Ersatzkasse), the data sets of patients from other health insurance providers are not included in the survival analysis. The EPRD is currently negotiating co-operations with the other health insurance providers.

In order to ensure the highest data quality possible, the EPRD thoroughly reviews incoming data sets for plausibility and consistency and notifies the hospitals of any documentation issues. The routine data of the health insurance providers is also included in these reviews to identify any inconsistencies. The EPRD excludes all data sets with contradictory or questionable information from the analysis until the issues have been resolved. The current annual report is based on survival data from more than 960,000 primary arthroplasties and 102,000 revision procedures under follow-up.

Arthroplasty survival is evaluated based on the probability of a first revision or repeat revisions (re-revisions) as well as any complementary operations. Chapter 5 of this annual report analyses three different end points and time lines:

1. Time span between primary arthroplasty and first revision for any reason (including explantation of components) (sections 5.1 to 5.4 except for Table 51): Subsequent (secondary) patellar resurfacing is explicitly not counted as revision, even if during the same procedure the insert was replaced prophylactically. If the procedure involves revision or explantation, this is considered to be the end-
point of the analysis - regardless of whether implant components were actually left in situ during the surgery or replaced. In particular, when presenting revision probabilities for specific implant systems in Section 5.4, it should thus be noted that these are arthroplasty revisions of specific implants and that the respective implant may not necessarily have been replaced in every case. Patient-specific censoring events include patient death, leg amputation and the termination of the follow-up, e.g., due to the patient changing health insurance provider.
2. Time span between the primary arthroplasty and subsequent secondary patellar resurfacing (Table 51 in Section 5.4): In order for a reoperation to count as secondary patellar resurfacing, no prosthetic components other than the actual patellar component and possibly an insert must be documented for the procedure. Moreover, the only arthroplasties eligible for analysis are those without patellar resurfacing during the primary surgery. For the purpose of this analysis, revision arthroplasties, as defined in number 1 above, are counted as additional censoring events.
3. Time span between first and second revision arthroplasty including explantation (Section 5.5): Only revisions of primary arthroplasties already documented in the registry are considered as the starting point for the calculation. As described in number 1 above, secondary patellar resurfacing does not count as a revision procedure and is therefore not considered here. If the first revision was carried out in two stages i.e., components were explanted and re-implanted at two different dates - the second follow-up starts at re-implantation. For primary arthroplasty patients previously documented in the registry, additional analyses that differentiate between first, second and third revisions are also included.

Chapter 6 addresses patient mortality af ter primary arthroplasty and reoperations When a patient dies, the respective health insurance provider only provides the EPRD with the month of death, not the day. For deceased patients, the calculations in this re port are therefore based on the middle day of the month of death. Subsequent arthroplasties are not taken into account as censoring events for the calculation of cumulative mot tality rates.

## In brief

- Arthroplasty survival analyses: Based on 960,000 primary procedures and 102,000 revision arthroplasties followed up. The following explanatory sections provide more detailed information on the methodology employed and the the figures shown thereafter.


## Presentation of descriptive data in Chapter 4

In Chapter 4, data sets submitted to the EPRD were categorised separately by type of arthroplasty, and the following descriptive parameters were determined for each category:

| Parameter | Description |
| :--- | :--- |
| Proportion $[\%]$ | Percentage of procedures in each category |
| Age | Median age in years of patients in this category. Thus, at least $50 \%$ of patients in this category <br> are not older and at least $50 \%$ are not younger than this age. |
| m/f $[\%]$ | Percentage of male and female patients in this category |
| BMI | Median BMI of patients in this category. In each case, the figure refers to the subgroup of these <br> patients for whom valid data on weight and height had been provided. |
| ASA | Mean ASA classification of the patients in this category. |

The documentation is classified into the different arthroplasty categories. This is based on the products documented for the procedure and the classification information stored in the product database. As a rule, the categories are designed so that they do not overlap. Most stated percentages add up to $100 \%$. They refer to the total number of data sets to which the correspond-

## Category A <br> Category B

## Subcategory B1 <br> Subcategory B2 <br> Subcategory B3

ing rule could be applied. If analysis rules could not be applied to data sets because, for example, the classification was not known for all essential products, these data sets were excluded from the pertinent analysis. As illustrated by the following example, results of the descriptive analyses are presented as a mix of tables (numerical values for the parameters) and graphs (additional visual elements). In addition to numeric (adncrentage values, percentages are also displamed as horizontal bars relative to a left-hand baseline The horizo the bars rentage, the a longer the baseline. The median BMI and mean ASA are symbolised by additionne in in in "Age" "BMI" and "ASA" column at horizontallines respectively, spanning ranges from 50 to 90 years, 20

35 points, and ASA I to V. The further left a line is the younger the patients are or the lower the BMI or ASA classification of the patients in this category. The sex ratio is visualised by two complementary bars: the light blue bar on the left represents the male patients, while the pink bar on the right stands for the female patients. If the light blue bar dominates, the patients in

| Proporion [\%] | Age m/f [\%] |  | BMI ASA |  |
| :---: | :---: | :---: | :---: | :---: |
| 97.7 | 72 | $40 / 60$ | 26.9 | 2.3 |
| 2.3 | 67 | $38 / 62$ | 25.9 | 2.3 |
| 0.4 | 59 | 48/52 | 26.6 | 2.1 |
| 1.8 | 70 | 37/63 | 25.7 | 2.4 |
| 0.1 | 53.5 | $30 / 70$ | 26.2 | 2.0 |

this category are predominantly male; if the pink bar dominates, they are predominantly female.
There are two exceptions to the above rule where percentages indicated in tables do not add up to $100 \%$. Firstly, indented category names that indicate subcategories of the category previously listed but not indented (also refer to tables 4, 19, 22, 24, and 37). Apart from rounding errors, the sum of the shares of the subcategories again equals the share of their parent category. Secondly, tables $3,18,21$, and 36 , which describe the patients treated in more detail, present the respective distribution by age, sex and BMI in different colours, with the percentages for each of these three categories adding up to $100 \%$.

## Illustration of registry trends over time in Chapter 4

To analyse the evolution of the registry over time, percentages of the various arthroplasty categories were also determined for prior operating years (Chapter 4). Results are presented as stacked bar graphs, with each bar representing the outcomes of one operating year:


Example: Presentation of the percentages of specific arthroplasties over time

The only exception is the EPRD trial period from November 2012 to the end of 2013: In the illustrations, this phase is combined into a common bar with a different colour gradient, as data from this period was presumably not yet representative due to the smal umably not yet representative due to the small
number of participating hospitals. The size of the bars represents the respective share of the category. If this percentage is $5 \%$ or higher, it is also shown as a numerical value in the centre of the respective bar.

Calculation of revision and complementary arthroplasty probabilities from Chapter 5 onwards

Chapter 5 and thereafter focuses on arthroplasty survival and revision probabilities. The EPRD defines the endpoint "arthroplasty failure" as any arthroplasty subsequently requiring revision surgery. Kaplan-Meier estimators are used to calculate the probability that no such (re)operation will be required within a certain time frer primary aktroplasty or first revision in place. It is taken into account that
at the time of the analysis the monitoring of the arthroplasty has not yet been completed in most cases and
or such as patient death or amputa an arthroplasty

## Revision probabilities graph

Revision probabilities are depicted as follows. The legends below the graphs show how many arthroplasties were still followed up at any given time, i.e., how many arthroplasties had already been followed up over a correspondingly long period without revision or the patients terminating the follow-up for other reasons.

The EPRD proceeds in a similar fashion when calculat ing the probability of secondary patellar resurfacing Revisions in these cases are considered as additional censoring events and taken into account accordingly.
The results of the estimates are presented as figures and tables (see the explanations below). The reciprocal probabilities of the Kaplan-Meier estimators, i.e., the cumulative probabilities of arthroplasty revision or complementary arthroplasty, are presented together with their $95 \%$ confidence intervals. Most of the figure and table legends specify the corresponding p -value of the test for parity of revision arthroplasty probabilities over the entire course of the arthroplasty.

The graphs in sections 5.1 and 5.2 present cumulative evision probabilities for each group but only for those periods during which at least 500 patients were stil any confidence intervals.

## Tables of revision and complementary arthroplasty probabilities

When presenting the outcomes by indication and type of arthroplasty in Section 5.1. by risk factors in Section 5.2, by implant characteristics in Section 5.3, and by implant-related outcomes in Section 5.4. the following parameters are presented in tables:

| Parameter | Description |
| :--- | :--- |
| Number | Number of treatments under follow-up in each category. The sum total from all displayed <br> subcategories may be smaller than the total number listed for the superordinate category. <br> This may either occur because only subcategories for which a minimum treatment threshold <br> has been reached are included (see below), or because a subcategory cannot be assigned <br> due to missing information. |
| Age | Median age and the age quartiles of the patients who received these arthroplasties. |
| m/f $[\%]$ | Percentage of male and female patients in this category |
| BMI | Median body mass index of arthroplasty patients. The figure refers to the subgroup of patients <br> for whom valid BMI data had been provided. The tables on the outcomes of specific arthroplasty <br> systems do not include the BMI. |
| Hosp. | Number of hospitals documenting these arthroplasties. |

In the revision probability fields, the corresponding $95 \%$ confidence intervals (in brackets) and the number of arthroplasties still followed up at the respective time points (in parentheses) are listed as a percentage after the actual revision probability - unless the latter is zero. Results are only presented if at least 300 primary ar throplasties from at least three different hospitals ar
available for the analysis of this type of arthroplasty, implant system or implant combination. If the number of arthroplasties being followed up is less than 150 at any one time, both the revision probability and confidence interval are shown in italics; if the number is less than 50 , the results are not reported


Representative example of the revision probability of two arthroplasty subgroups. Below the graph displaying revision probabilities with their corresponding $95 \%$ confidence intervals, a table lists the actual number of arthroplasties under observation
at the given time points examined.

## The 2022 operating year

## 4 The 2022 operating year

Between January 1 and December 31, 2022, the EPRD registered a total of 347,702 hip and knee arthroplasty procedures. This chapter details the documentation of these procedures and describes emerging trends since the inception of the EPRD, 10 years ago.

Table 2 shows how the documented operations are distributed between hip and knee arthroplasties and total femoral replacement on the one hand, and primary procedures and reoperations on the other

The following sections focus on the documentation submitted for the 2022 calendar year separately by the operated joint and the type of surgery.

### 4.1 Primary hip arthroplasty

In 2022, the EPRD registered 177,826 primary hip arthroplasties. A total of $40 \%$ of
patients were men. The percentage is significantly higher in the younger age groups, but continues to decline with increasing age (Table 3).

Significant operations prior to primary hip arthroplasty were reported in only $3.1 \%$ of patients (Table 4). About half of these cases nvolved osteosynthesis or osteotomy in the femoral region.

Tables $\underline{5}$ to $\underline{17}$ provide a detailed view of the types of primary hip arthroplasties performed in 2022 and the corresponding patient characteristics. The percentages of the various types of arthroplasties at some hospitals may differ greatly from the overall figures presented below, as the preferences in the choice of arthroplasty sometimes vary greatly. For example, the EPRD reveals that in almost two thirds of hospitals short stems account for less than $5 \%$ of THA cases. However, there are also over 50 hospitals that use them in more than half of such procedures.

All data sets submitted Primary hip arthroplasties Hip arthroplasty reoperations Primary knee arthroplasties Knee arthroplasty reoperations Total femoral replacements

| Proporion [\%] | age | $\mathrm{m} / \mathrm{f}$ [\%] | вм | ASA |
| :---: | :---: | :---: | :---: | :---: |
| $100.0{ }_{(3477.02)}$ | 71 | $41 / 59$ | 28.0 | 2.3 |
| 51.1 | 72 | $40 / 60$ | 26.8 | 2.3 |
| $5.2{ }_{(18,145)}$ | 76 | $42 / 58$ | 26.9 | 2.6 |
| $39.4{ }_{(1377000}$ | 69 | $41 / 59$ | 29.7 | 2.2 |
| $4.1{ }^{(14,379)}$ | 70 | $43 / 57$ | 30.1 | 2.4 |
| 0.1 | 74 | $38 / 62$ | 28.4 | 2.6 |

All arthroplasties considered
<45 years
45-54 years
55-64 years
65-74 years
75-84 years
>85 years
Male
Female
BMI $\leq 25$
BMI $>25$ to $\leq 30$
BMI $>30$ to $\leq 35$
BMI $>35$ to $\leq 40$
BMI >40
BMI unknown/implausible

| Proportion [\%] | Age | m/f $1 \%$ | вм | ASA |
| :---: | :---: | :---: | :---: | :---: |
| 100.0 | 72 | $40 / 60$ | 26.8 | 2.3 |
| 1.7 |  | 55/45 | 27.3 | 1.8 |
| 6.3 |  | $52 / 48$ | 28.4 | 1.9 |
| 21.1 |  | 48/52 | 28.1 | 2.1 |
| 30.1 |  | $40 / 60$ | 27.5 | 2.2 |
| 29.9 |  | 34166 | 26.0 | 2.5 |
| 10.9 |  | $30 / 70$ | 24.6 | 2.8 |
| 40.0 | 69 | $100 / 0$ | 27.5 | 2.3 |
| 60.0 | 73 | $0 / 100$ | 26.2 | 2.3 |
| 33.7 | 75 | $31 / 69$ |  | 2.3 |
| 36.0 | 72 | $46 / 54$ |  | 2.2 |
| 18.0 | 69 | 45/55 |  | 2.3 |
| 6.4 | 66 | $41 / 59$ |  | 2.4 |
| 2.4 | 63 | 35/65 |  | 2.6 |
| 3.5 | 72 | $38 / 62$ |  | 2.2 |

Table 3: Primary hip arthroplasties in 2022 by patient age, sex and BMI

No prior surgery
Osteosynthesis / Osteotomy
Pelvis
Femur
Pelvis and femur
Femoral head necrosis
Arthrodesis
Other prior surgery

| Proporion [\%] | Age | m/f $1 \%$ ] | вм |  |
| :---: | :---: | :---: | :---: | :---: |
| 96.9 | 72 | $40 / 60$ | 26.8 | 2.3 |
| 2.0 | 68 | $39 / 61$ | 25.9 | 2.3 |
| 0.4 | 62 | $48 / 52$ | 26.6 | 2.2 |
| 1.5 | 70 | $37 / 63$ | 25.7 | 2.4 |
| 0.1 | 55 | $33 / 67$ | 27.0 | 2.0 |
| 0.2 | 64 | $50 / 50$ | 26.7 | 2.3 |
| <0.1 | 72 | $33 / 67$ | 27.5 | 2.1 |
| 0.9 | 66 | $44 / 56$ | 27.2 | 2.3 |

Table 4: Previous surgeries reported for primary hip arthroplasties in 2022

Total arthroplasty
Hemiarthroplasty


Table 5: Types of primary hip replacements in 2022

Uncemented implants
Hybrid implants
Cemented implants
Reverse hybrid implants Unknown

Table 6: Fixations in primary total hip arthroplasties in 2022

## Cemented implants

Uncemented implants
Unknown

Table 7: Fixations in primary hip hemiarthroplasties in 2022

Femoral stem with modular head
Short stem
Femoral neck prosthesis
Revision or tumour stem
Modular stem
Surface replacement
Unknown

Table 8: Stem types in primary total hip arthroplasties in 2022

Femoral stem with modular head
Revision or tumour stem
Short stem
Modular stem
Femoral neck prosthesis
Unknown

| Prooortion [\%] | Age | $\mathrm{m} / \mathrm{f}$ [\%] | вM | ASA |
| :---: | :---: | :---: | :---: | :---: |
| 84.7 | 71 | $40 / 60$ | 27.2 | 2.2 |
| 13.3 | 63 | $48 / 52$ | 27.6 | 2.1 |
| 1.0 | 62 | $48 / 52$ | 27.5 | 1.9 |
| 0.5 | 78 | $35 / 65$ | 26.0 | 2.6 |
| 0.3 | 74 | $32 / 68$ | 26.9 | 2.3 |
| 0.1 | 59 | 95/5 | 28.4 | 1.9 |
| 0.1 | 73 | 29171 | 28.3 | 2.2 |


| Proportion [\%] | Age m/f l \% $]$ |  | BMI ASA |  |
| :---: | :---: | :---: | :---: | :---: |
| 77.2 | 67 | 45/55 | 27.7 | 2.2 |
| 17.9 | 79 | $27 / 73$ | 26.0 | 2.4 |
| 3.7 | 81 | $25 / 75$ | 25.4 | 2.6 |
| 1.0 | 74 | $26 / 74$ | 26.4 | 2.4 |
| 0.1 | 73 | $31 / 69$ | 27.2 | 2.2 |


| Proportion [\%] | Age m/f $\left.{ }^{\circ} \mathrm{l}\right]$ |  | вм |  |
| :---: | :---: | :---: | :---: | :---: |
| 88.8 | 85 | $32 / 68$ | 24.2 | 2.9 |
| 11.1 | 83 | $38 / 62$ | 24.4 | 2.8 |
| 0.1 | 81 | 41/59 | 25.0 | 3.0 |

28 mm
32 mm
36 mm

Unknown

|  |  | f $17 /$ |  |  |
| :---: | :---: | :---: | :---: | :---: |
| 4.7 | 73 | $17 / 83$ | 26.3 | 2.3 |
| 47.8 | 70 | $30 / 70$ | 27.0 | 2.2 |
| 47.1 | 69 | 55/45 | 27.5 | 2.2 |
| 0.5 | 71 | $32 / 68$ | 26.0 | 2.2 |
| <0.1 | 75.5 | 0/100 | 23.6 | 2.0 |

Table 12: Head sizes in primary total hip arthroplasties in 2022

[^0]Without reconstruction shell With reconstruction shell

| orrion $1 \%$ | Age m/f \% $\%$ |  | BMI ASA |  |
| :---: | :---: | :---: | :---: | :---: |
| 99.8 | 70 | $41 / 59$ | 27.2 | 2.2 |
| 0.2 | 78 | 34166 | 24.9 | 2.6 |

Table 11: Reconstruction shells in primary total hip arthroplasties in 2022
S. . . . .

| Proporion [\% | Age | m/f 10$]$ | BM1 | ASA |
| :---: | :---: | :---: | :---: | :---: |
| 88.3 | 70 | $42 / 58$ | 27.3 | 2.2 |
| 8.8 | 73 | $37 / 63$ | 26.8 | 2.3 |
| 1.9 | 79 | $33 / 67$ | 26.0 | 2.6 |
| 0.8 | 72 | $32 / 68$ | 26.1 | 2.3 |
| 0.1 | 57 | 9911 | 27.2 | 1.9 |
| 0.1 | 73 | $35 / 65$ | 25.9 | 2.2 |

Table 10: Acetabular components in primary total hip arthroplasties in 2022

Tati: Recontruction shis in primary tor

## Other diameter <br> m <br> mm

| Proportion [\%] | Age | m/f $[1 \%]$ | вм | ASA |
| :---: | :---: | :---: | :---: | :---: |
| 0.6 | 72 | $34 / 66$ | 26.7 | 2.3 |
| 40.8 | 70 | $34 / 66$ | 26.9 | 2.2 |
| 36.3 | 70 | $42 / 58$ | 27.3 | 2.2 |
| 16.4 | 69 | $50 / 50$ | 27.6 | 2.2 |
| 4.2 | 69 | $58 / 42$ | 27.8 | 2.2 |
| 0.3 | 69.5 | 60/40 | 27.8 | 2.3 |
| <0.1 | 65.5 | $56 / 44$ | 24.6 | 2.6 |
| 1.4 | 75 | 44/56 | 26.9 | 2.4 |

hXLPE
hXLPE + antioxidant
Ceramic
mXLPE
PE

Meta
mXLPE + antioxidant
Unknown

| roportion [\%) | Age | $\mathrm{m} / \mathrm{f}$ [\%] | вм | ASA |
| :---: | :---: | :---: | :---: | :---: |
| 58.0 | 70 | $40 / 60$ | 27.2 | 2.2 |
| 22.7 | 69 | 42 / 58 | 27.4 | 2.2 |
| 7.5 | 63 | $46 / 54$ | 27.4 | 2.1 |
| 6.1 | 73 | $44 / 56$ | 27.3 | 2.3 |
| 5.5 | 78 | $32 / 68$ | 26.3 | 2.4 |
| 0.1 | 59 | 95/5 | 28.4 | 1.9 |
| <0.1 | 71 | $100 / 0$ | 26.2 | 2.0 |
| 0.1 | 79 | $26 / 74$ | 26.7 | 2.3 |

Table 14: Acetabular bearing materials in primary total hip arthroplasties in 2022

## Ceramic <br> Metal <br> Ceramicised metal

Unknown

| Proporion [\%] | Age | m/f ${ }^{[\%]}$ | вм | asa |
| :---: | :---: | :---: | :---: | :---: |
| 90.4 | 69 | $42 / 58$ | 27.3 | 2.2 |
| 6.6 | 80 | 34166 | 26.0 | 2.5 |
| 3.0 | 70 | $41 / 59$ | 27.8 | 2.3 |
| <0.1 | 75.5 | 0/100 | 23.6 | 2.0 |

Table 15: Modular head materials in primary total hip arthroplasties in 2022

Ceramic / hXLPE
Ceramic / hXLPE + antioxidant
Ceramic / ceramic
Ceramic / mXLPE
Ceramic / PE
Ceramicised metal / hXLPE
Metal / hXLPE
Metal / PE
Other or unknown

| Proportion [\%] | Age | m/f $\left.[1 \%]^{6}\right]$ | вм | AsA |
| :---: | :---: | :---: | :---: | :---: |
| 51.4 | 70 | 41/59 | 27.3 | 2.2 |
| 22.1 | 69 | 42/58 | 27.5 | 2.2 |
| 7.5 | 63 | $46 / 54$ | 27.4 | 2.1 |
| 5.5 | 72 | 44/56 | 27.4 | 2.2 |
| 3.8 | 75 | $33 / 67$ | 26.5 | 2.2 |
| 2.7 | 70 | $41 / 59$ | 27.8 | 2.3 |
| 3.8 | 80 | 35/65 | 26.2 | 2.5 |
| 1.5 | 81 | 29171 | 25.7 | 2.6 |
| 1.6 | 79 | 37/63 | 26.2 | 2.5 |

Table 16: Bearing materials in primary total hip arthroplasties in 2022. Only combinations with a share of more than $1 \%$ are listed.

## Metal <br> Ceramic

Ceramicised metal
Unknown

| Proportion [\%] | Age m/fiv] BM1 |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
| 95.3 | 84 | $32 / 68$ | 24.2 | 2.9 |
| 3.3 | 83 | $32 / 68$ | 24.2 | 2.6 |
| 1.3 | 85 | $33 / 67$ | 24.5 | 2.8 |
| <0.1 | 85 | $50 / 50$ | 29.6 | 3.5 |

Trends in primary hip arthroplasty

The following developments are evident in the EPRD regarding the percentages of the different primary THA characteristics:


Figure 3. Trends in THA fixations over tim

- Figure 3 presents changes in the percentage of THA fixation types in the overall analysis. On the whole, the percentage of completely uncemented THAs has remained at a consistently high leve of around $77 \%$ in recent years. Hybrid fixation have increased slightly, while fully cemented ar throplasties continued to decrease. Both developments can essentially be attributed to patients aged 75 years and older. Between 2015 and 2022 the share of hybrid fixations in this age group rose from $31.1 \%$ to $39.1 \%$, while the share of fully cemented fixations declined from $17.9 \%$ to $8.8 \%$. After an initial increase to $54.6 \%$ starting in 2018, the percentage of completely uncemented fixations in the 75 years and older age group decreased to 50.6 \% again in 2022
- After a slight decline in the use of short stems in the early years of the EPRD, their share has risen steadily since 2015 and, at $13.3 \%$, is about twice as high as seven years ago ( $6.6 \%$ ).
- In terms of the type of acetabular component, modular cups have increased continuously since 2014 - by 4 percentage points up to 88.3 \% now. In contrast, the share of monobloc cups fell by more than 5 percentage points from $14.4 \%$ to $8.8 \%$ in the same period.
- The most significant increases can be seen in acetabular inserts made of highly cross-linked polyethylene (hXLPE) (Figure 4). Between 2014 and 2022, their share rose from $52.0 \%$ to $80.7 \%$.


Figure 4: Trends in THA insert materials over tim


Figure 5: Trends in THA head sizes over time


Figure 6: Trends in THA head-neck lengths over time

The use of other insert materials decreased accordingly. Ceramic inserts, for example, fell by more than half in the same period (from $15.5 \%$ to $7.5 \%$ ).

- In terms of head materials, more and more ceramic heads were used between 2014 and 2022 , most recently in over $90 \%$ of THA cases. This increase was at the expense of conventional metal heads, whose share was halved from $13.2 \%$ to $6.6 \%$. The use of ceramicised metal head components increased until 2018, but has since stagnated at around $3 \%$.
- In terms of head components, the EPRD reveals a clear trend favouring the use of larger heads: in 2014, the proportion of 32 mm heads was almost twice that of 36 mm heads; by 2022, they were almost the same (Figure 5). This is accompanied by a trend towards shorter headneck lengths: From 2014 to 2022, the combined use of XS and S head-neck lengths increased by more than 8 percent (Figure 6).


## In brief:

- Since 2014, the use of insert components made from highly cross-linked PE has risen by more than 28 percent.
- The percentage of short-stem femoral components has roughly doubled to 13.3 \% since 2015.
- 36 mm heads and shorter head-neck lengths have become increasingly popular.


### 4.2 Hip arthroplasty reoperations

For the 2022 calendar year, 18,145 hip reoperations were documented in the EPRD, 14,997 of these were one-stage procedures. The EPRD also registers explantations and re-implantations as part of twostage revisions. However, explantations are documented much less often in the registry ( 1,134 explantations compared to 2,014 two-stage revisions).

Tables 18 and 19 present the age, BMI and sex, patient distribution, as well as reasons given for the documented reoperations. As in previous years, the most common reasons for reoperations were loosening ( $22.7 \%$ ), infections ( $16.4 \%$ ), periprosthetic fractures ( $15.9 \%$ ), and dislocations ( $13.6 \%$ ) - although the percentages have shifted (also refer to Figure 7).

Table 20 shows which components were newly implanted and thus possibly replaced in how many of the reoperations performed in 2022. Previously implanted head components and inserts were therefore replaced in $97.4 \%$ and $74.7 \%$ of reoperations, respectively.

Slightly more than one in four reoperations involved a complete replacement of the entire implant system, in which both the stem and the acetabular components were re-implanted ( $26.2 \%$ ).

In almost three quarters of procedures ( $73.5 \%$ ), at least one of the bone-anchored components was re-implanted. Replacement of stems and acetabular components ( $50.1 \%$ and $49.6 \%$ respectively) was almost even. Revision-specific stem or acetabular components were re-implanted in $31.0 \%$ of reoperations.

All arthroplasties considered
$<45$ years
45-54 years
$55-64$ years
$65-74$ years
75-84 years
>85 years
Male
Female
BMI $\leq 25$
BMI $>25$ to $\leq 30$
BMI $>30$ to $\leq 35$
BMI >35 to $\leq 40$
BMI $>40$
BMI unknown/implausible

| Proporition [\%] | Age | m/f $\mathrm{f}_{6} / \mathrm{l}$ | вм | AsA |
| :---: | :---: | :---: | :---: | :---: |
| 100.0 | 76 | $42 / 58$ | 26.9 | 2.6 |
| 1.5 |  | 56/44 | 27.2 | 2.0 |
| 4.4 |  | $49 / 51$ | 28.3 | 2.1 |
| 15.1 |  | 52/48 | 28.9 | 2.3 |
| 25.9 |  | 45/55 | 28.3 | 2.5 |
| 36.4 |  | 38/62 | 26.2 | 2.6 |
| 16.8 |  | $30 / 70$ | 25.2 | 2.8 |
| 41.5 | 73 | $100 / 0$ | 27.5 | 2.5 |
| 58.5 | 77 | 0/100 | 26.4 | 2.6 |
| 33.4 | 79 | $34 / 66$ |  | 2.6 |
| 35.1 | 77 | 48/52 |  | 2.5 |
| 17.5 | 72 | 44/56 |  | 2.5 |
| 6.9 | 69 | 45/55 |  | 2.6 |
| 3.4 | 66 | $30 / 70$ |  | 2.7 |
| 3.8 | 75 | 38/62 |  | 2.5 |

Infection
Loosening
Cup
Stem
Cup and stem
Osteolysis with fixed component
Cup

Cup and stem
Periprosthetic fracture
Dislocation
Wear
Component failure
Malalignment
Progression of arthrosis
Condition after removal
Other reasons

| Proportion [\%] | Age | m/f[\%] | вM | ASA |
| :---: | :---: | :---: | :---: | :---: |
| 16.4 | 73 | $50 / 50$ | 28.1 | 2.6 |
| 22.7 | 75 | $42 / 58$ | 26.9 | 2.5 |
| 12.0 | 75 | $35 / 65$ | 26.7 | 2.4 |
| 8.7 | 75 | $51 / 49$ | 27.4 | 2.4 |
| 2.0 | 77 | $46 / 54$ | 26.5 | 2.6 |
| 0.6 | 73 | 58/42 | 26.4 | 2.3 |
| 0.3 | 74.5 | 65/35 | 27.2 | 2.2 |
| 0.2 | 68.5 | 67/33 | 25.7 | 2.4 |
| 0.1 | 75 | $35 / 65$ | 26.4 | 2.3 |
| 15.9 | 81 | $34 / 66$ | 25.8 | 2.7 |
| 13.6 | 79 | $35 / 65$ | 26.1 | 2.6 |
| 5.8 | 74 | 42 / 58 | 27.0 | 2.4 |
| 2.1 | 75 | $38 / 62$ | 26.4 | 2.5 |
| 1.9 | 73 | $31 / 69$ | 26.4 | 2.4 |
| 0.5 | 69 | $33 / 67$ | 25.7 | 2.3 |
| 11.1 | 72 | $49 / 51$ | 27.8 | 2.6 |
| 9.3 | 74 | $39 / 61$ | 27.0 | 2.4 |

Table 19: Reasons for hip reoperations in 2022

Stem, head, cup, insert
Head, cup, insert
Head, inser
Stem, head
Head
Stem, head, insert
Cup, insert
Insert
Accessory parts only (e.g., screws)

| Proportion [\%] | Age | /f $/$ \% $\%$ | BM1 | ASA |
| :---: | :---: | :---: | :---: | :---: |
| 26.2 | 73 | $48 / 52$ | 27.5 | 2.6 |
| 22.0 | 77 | $33 / 67$ | 26.2 | 2.5 |
| 17.6 | 73 | 45/55 | 27.8 | 2.5 |
| 17.1 | 79 | 39/61 | 26.2 | 2.6 |
| 7.7 | 79 | $40 / 60$ | 26.5 | 2.7 |
| 6.7 | 75 | $48 / 52$ | 27.4 | 2.5 |
| 1.4 | 77 | $35 / 65$ | 26.6 | 2.5 |
| 0.7 | 73 | $40 / 60$ | 26.3 | 2.5 |
| 0.5 | 78 | $36 / 64$ | 27.0 | 2.7 |

Table 20: Components replaced or complemented ${ }^{2}$ in hip reoperations in 2022

[^1]Endoprothesenregister

## Trends in hip reoperations

Over time, the indications for hip reoperations have seen a massive decline in the number of aseptic loosening cases (Figure 7)

|  | $\begin{aligned} & \text { Loosening } \\ & \text { Infection } \end{aligned}$ |  | Periproth. fracture Dislocation |  | $\begin{aligned} & \text { Wear } \\ & \text { Implant failure } \end{aligned}$ |  | - Other reasons |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 16.9 \% | 18.5 \% | 22.1 \% | 26.5 \% | 24.4\% | 22.5 \% | 23.4\% | 24.3\% | 23.5 \% | 23.4\% |
|  | 8.7\% | 7.2\% | 6.3\% |  | 7.6\% | 8.0\% | 8.0\% | 6.4\% | 5.8 \% | 5.8\% |
|  | 6.9\% | 9.2\% | 9.8 \% | 6.8\% |  |  |  |  |  |  |
|  | 10.8 \% | 8.3\% | 9.0\% | 9.8 \% | 11.3\% | 11.7\% | 11.9\% | 13.0\% | 13.1 \% | 13.6\% |
|  |  | 10.1\% | 13.1\% | 9.8 \% | 10.7\% | 11.0\% | 12.1\% | 13.6\% | 14.4 | 15.9\% |
|  |  |  |  | 11.3\% | 12.9\% | 15.3\% | 15.7\% | 15.9\% | 16.7\% | 16.4\% |
|  |  |  | 37.9 \% | 34.1\% | 31.3\% | 29.7\% | 26.9 \% | 24.5 \% | 24.3\% | 22.7 \% |
|  | 2012/13 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |

Figure 7: Trends in the reasons given for hip reoperations over time

Most recently, their share of 22.7 \% was only about half that of the first years of EPRD documentation. One possible explanation for this is the increased use of more wear-resistant bearing materials. On the other hand, dislocations and periprosthetic fractures have increased, as have infections - at least until 2021

In the EPRD, there is a continuing trend in infec-tion-related procedures favouring implant retaining reoperations (DAIR) (Figure 8). This implant retaining procedure involves the excision of nonviable soft tissue and infected bone. It may be indicated in cases of early infection and if bone components are firmly anchored. While in 2014 at least one component with bone fixation was
replaced in over two thirds of reoperations due to infection, in 2022 this was only the case in slightly less than half of patients ( $48.2 \%$ ).

If a new acetabular component is implanted during hip reoperation, surgeons increasingly opt for dual mobility systems rather than monobloc cups (Figure 9). Compared to 2014, the percentage of dual mobility acetabular components in reoperations has more than tripled, while the share of monoblocs has fallen by almost two thirds.

### 4.3 Primary knee arthroplasty

In 2022 , a total of 137,030 primary knee arthroplasties were registered in the EPRD Data on the patients treated and any prior operations they may have had are summarised in tables $\underline{21}$ and $\underline{22}$.

Patients undergoing primary knee arthroplasty tend to be younger than hip arthroplasty patients (Section 4.1), but have a higher body mass index. In the EPRD, the median BMI of patients undergoing primary knee arthroplasty is 29.7 , which, according to the definition of the World Health Or ganisation (WHO), is just below the morbid obesity threshold. Over $48 \%$ of patients would therefore be categorised as morbidly obese at the time of knee arthroplasty surgery. This percentage is even higher in younger age groups ( $60.6 \%$ in patients up to 64 years of age), but somewhat lower
All arthroplasties considered
$<45$ years
$45-54$ years
$55-64$ years
$65-74$ years
$75-84$ years
$>85$ years
Male
Female
BMI $\leq 25$
$\mathrm{BMI}>25$ to $\leq 30$
$\mathrm{BMI}>30$ to $\leq 35$
$\mathrm{BMI}>35$ to $\leq 40$
$\mathrm{BMI}>40$

BMI >40
BMI unknown/implausible
in older patients (only $31.3 \%$ in patients 75 years and older). This suggests that severe obesity plays an important role in premature osteoarthritis of the knee

Tables $\underline{23}$ to $\underline{35}$ present the number of primary arthroplasties documented in the EPRD for 2022, the type of arthroplasty and implant characteristics. However, the percentages may vary greatly between hospitals. This can be illustrated with the primary patellar resurfacing procedures, for example: While around $46 \%$ of hospitals do not perform primary patellar resurfacing at all and almost $30 \%$ of hospitals perform the procedure in less than one in twenty TKAs, $5 \%$ of hospitals resurface the patella in more than half of their primary TKAs.

## No prior surgery

Osteosynthesis / Osteotomy

## Femur

Tibia
Patella
Several locations
Capsule and ligaments
Arthrodesis
Other prior surgery

| Prooortion [\%] | Age | m/f $[10]$ | вм | ASA |
| :---: | :---: | :---: | :---: | :---: |
| 92.6 | 70 | $40 / 60$ | 29.8 | 2.2 |
| 1.7 | 64 | $54 / 46$ | 28.7 | 2.2 |
| 0.4 | 67 | $44 / 56$ | 28.7 | 2.3 |
| 1.0 | 63 | $56 / 44$ | 28.7 | 2.2 |
| 0.1 | 67 | 55/45 | 29.4 | 2.2 |
| 0.2 | 62 | $58 / 42$ | 28.7 | 2.2 |
| 2.4 | 62 | $57 / 43$ | 29.1 | 2.1 |
| $<0.1$ | 70 | $56 / 44$ | 32.5 | 2.4 |
| 3.3 | 66 | 47/53 | 29.5 | 2.2 |

Table 22: Prior surgeries reported for knee arthroplasties in 2022

Total knee arthroplasty Unicondylar knee arthroplasty Patellofemoral knee arthroplasty Other arthroplasties

| Proporionly) |  | 隹为 | AM ASA |  |
| :---: | :---: | :---: | :---: | :---: |
| 87.1 | 70 | $40 / 60$ | 29.8 | 2.3 |
| 12.7 | 64 | 52/48 | 29.3 | 2.1 |
| 0.2 | 57.5 | $33 / 67$ | 27.8 | 2.0 |
| <0.1 | 60.5 | $50 / 50$ | 29.5 | 2.5 |

Table 23: Types of primary knee replacements in 2022

Standard systems<br>Cruciate-retaining<br>Posterior-stabilised<br>Cruciate-sacrificing<br>Cruciate-retaining/sacrificing<br>Pivot<br>Constrained systems<br>Hinged<br>Varus-valgus-stabilised<br>Unknown

| Proportion [\%] | Age | m/f $\mathrm{l}^{\text {\% }}$ ] |  | ASA |
| :---: | :---: | :---: | :---: | :---: |
| 95.0 | 70 | 40/60 | 29.9 | 2.2 |
| 44.5 | 70 | $41 / 59$ | 30.0 | 2.2 |
| 24.3 | 70 | $40 / 60$ | 29.8 | 2.2 |
| 11.4 | 71 | $37 / 63$ | 29.9 | 2.3 |
| 10.2 | 69 | $41 / 59$ | 29.7 | 2.2 |
| 4.5 | 70 | 41/59 | 30.0 | 2.3 |
| 4.8 | 73 | $29 / 71$ | 28.5 | 2.4 |
| 2.8 | 75 | 26174 | 27.8 | 2.4 |
| 2.0 | 71 | $32 / 68$ | 29.4 | 2.3 |
| 0.2 | 66 | $41 / 59$ | 30.0 | 2.3 |


| Cemented implants | Proportion [ | Age | m/fic) |  | ASA |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | 95.6 | 70 | $39 / 61$ | 29.8 | 2.3 |
| Hybrid implants | 3.0 | 70 | $47 / 53$ | 30.0 | 2.1 |
| Uncemented implants | 1.3 | 67 | 44/56 | 29.8 | 2.2 |
| Reverse hybrid implants | <0.1 | 64.5 | $29 / 71$ | 34.4 | 2.2 |
| Unknown | 0.1 | 72 | $36 / 64$ | 25.9 | 2.6 |

Table 25: Fixations in primary total knee arthroplasties in 2022

## Cemented implants

Uncemented implants
Hybrid implants
Unknown


Table 26: Fixations in primary unicondylar knee arthroplasties in 2022

## Fixed bearing <br> Mobile bearing

| Proportion [\%] | Age | m/f $[\%]$ | BMI ASA |  |
| :---: | :---: | :---: | :---: | :---: |
| 90.7 | 70 | $40 / 60$ | 29.8 | 2.3 |
| 9.3 | 70 | 39161 | 29.8 | 2.3 |

Table 27: Bearing mobility in primary total knee arthroplasties in 2022

## Mobile bearing <br> Fixed bearing



Table 28: Bearing mobility in primary unicondylar knee arthroplasties in 2022

Without patellar resurfacing
With patellar resurfacing

| Proportion [\%] | Age | $\mathrm{m} / \mathrm{f}$ [0] | вм | ASA |
| :---: | :---: | :---: | :---: | :---: |
| 89.5 | 70 | $40 / 60$ | 29.8 | 2.3 |
| 10.5 | 70 | 37/63 | 29.9 | 2.3 |

Table 29: Patellar resurfacing in primary total knee arthroplasties in 2022

## Uncoated metal

Coated metal
Ceramicised meta
Ceramic

| Proportion [\%] | Age m/f ${ }^{\text {che }}$ |  | BMI ASA |  |
| :---: | :---: | :---: | :---: | :---: |
| 90.8 | 70 | 41/59 | 29.7 | 2.3 |
| 5.3 | 66 | 18/82 | 30.9 | 2.2 |
| 3.8 | 65 | 24176 | 31.0 | 2.2 |
| <0.1 | 62 | 7193 | 29.5 | 2.5 |

Table 30: Femoral bearing materials in primary total knee arthroplasties in 2022


## PE

mXLPE
hXLPE + antioxidant
hXLPE
mXLPE + antioxidant
Unknown

| Proporition [\%] | Age | m/f 10$]$ | вм | ASA |
| :---: | :---: | :---: | :---: | :---: |
| 43.9 | 70 | $39 / 61$ | 29.7 | 2.2 |
| 30.6 | 70 | $39 / 61$ | 29.8 | 2.3 |
| 12.8 | 69 | 42 / 58 | 29.8 | 2.2 |
| 12.2 | 69 | $38 / 62$ | 30.0 | 2.2 |
| 0.5 | 70 | 43/57 | 30.4 | 2.4 |
| <0.1 | 69 | $38 / 62$ | 29.0 | 2.2 |

Table 31: Tibial bearing materials in primary total knee arthroplasties in 2022

Uncoated metal / PE
Uncoated metal / mXLPE
Uncoated metal / hXLPE + antioxidant
Uncoated metal / hXLPE
Coated metal / mXLPE
Ceramicised metal / PE
Coated metal / PE
Other or unknown

| Proportion [\%] | Age m/f\%] |  | BMI ASA |  |
| :---: | :---: | :---: | :---: | :---: |
| 39.0 | 71 | $41 / 59$ | 29.7 | 2.3 |
| 27.7 | 71 | $42 / 58$ | 29.7 | 2.3 |
| 12.5 | 69 | $43 / 57$ | 29.8 | 2.3 |
| 11.1 | 69 | $39 / 61$ | 29.8 | 2.2 |
| 2.9 | 66 | 15/85 | 31.1 | 2.2 |
| 2.8 | 66 | $24 / 76$ | 30.9 | 2.2 |
| 2.1 | 67 | $24 / 76$ | 30.5 | 2.2 |
| 1.9 | 66 | $26 / 74$ | 31.1 | 2.3 |

Table 32: Bearing materials in primary total knee arthroplasties in 2022. Only combinations with a share of more than $1 \%$ are listed

Uncoated metal
Coated metal
Ceramicised metal

| Proporion [\%] | Age m/f 0 \% |  | BMI ASA |  |
| :---: | :---: | :---: | :---: | :---: |
| 92.2 | 64 | 54/46 | 29.2 | 2.1 |
| 4.6 | 60 | $16 / 84$ | 30.4 | 2.1 |
| 3.1 | 62 | 38/62 | 29.3 | 2.1 |

Table 33: Femoral bearing materials in primary unicondylar knee arthroplasties in 2022

## mXLPE

PE
hXLPE + antioxidant
hXLPE
Unknown

| Proporion [\%] | Age | m/fiol | BM | ASA |
| :---: | :---: | :---: | :---: | :---: |
| 55.4 | 64 | 50/50 | 29.4 | 2.1 |
| 23.6 | 63 | $52 / 48$ | 29.0 | 2.1 |
| 15.4 | 64 | 55/45 | 29.1 | 2.1 |
| 5.5 | 63 | 54/46 | 29.3 | 2.0 |
| 0.1 | 65 | $31 / 69$ | 31.2 | 2.4 |

Table 34: Tibial bearing materials in primary unicondylar knee arthroplasties in 2022

## Uncoated metal / mXLPE

Uncoated metal / PE Uncoated metal / hXLPE + antioxidant

Uncoated metal / hXLPE
Coated metal / mXLPE
Ceramicised metal / PE
Other or unknown

| Proportion [\%] | Age | m/f ${ }^{[\%]}$ | вм |  |
| :---: | :---: | :---: | :---: | :---: |
| 50.9 | 64 | 53/47 | 29.4 | 2.1 |
| 20.3 | 63 | 55/45 | 29.0 | 2.1 |
| 15.4 | 64 | 55/45 | 29.1 | 2.1 |
| 5.5 | 63 | $54 / 46$ | 29.3 | 2.0 |
| 3.8 | 60 | 11 / 89 | 30.6 | 2.1 |
| 2.4 | 61 | $36 / 64$ | 29.4 | 2.0 |
| 1.6 | 62 | 41/59 | 28.9 | 2.1 |

Table 35: Bearing materials in primary unicondylar knee arthroplasties in 2022. Only combinations with a share of more than $1 \%$ are listed.

## In brief:

- More than $95 \%$ of primary total kne arthroplasties and almost $89 \%$ of unicondylar arthroplasties were fully cemented
- The use of mobile bearings in TKAs continued to decrease
- Since 2016, the proportion of posteriorstabilised (PS) systems has increased by 9 percent to $25.6 \%$


## Trends in primary knee arthroplasties

In recent years, the proportion of male patients in the EPRD has increased slightly. Until 2016, it was below 37 \% for TKAs, since 2020 it is 39 \% and above. As of 2021, more than half of unicondylar knee arthroplasty patients registered in the EPRD are men.

Fully cemented fixations are by far the most common type of fixation in both TKAs and unicondylar arthroplasties. After initially declining slightly to $90.7 \%$ by 2016, the share of TKA procedures has risen steadily since then, reaching a new high of $95.6 \%$ in 2022 . For unicondylar arthroplasties, on the other hand, the share of uncemented arthroplasties once again increased from 2021 to 2022 (from $8.8 \%$ to $10.5 \%$ ).



Figure 10: Trends in the types of TKA bearings over time
or-stabilised systems were used more frequently, with their share in the same period rising from 16.6 \% to $25.6 \%$. Pivot systems were also used more often, although their share in the EPRD still accounts for less than $5 \%$. Highly cross-linked polyethylene inserts are also being used more and more often in TKAs (Figure 12). At $25 \%$, they reached a new high in the EPRD in 2022. However,


Figure 11: Trends in standard TKA knee systems over time


Figure 12: Trends in TKA insert materials over time

| All arthroplasties considered | Proportion [\%) | Age | $\mathrm{m} /\left[{ }^{[6]}\right]$ | вм | ASA |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | 100.0 | 70 | $43 / 57$ | 30.1 | 2.4 |
| <45 years | 1.0 |  | $46 / 54$ | 29.9 | 2.0 |
| 45-54 years | 6.7 |  | $41 / 59$ | 31.8 | 2.2 |
| 55-64 years | 26.1 |  | $46 / 54$ | 31.6 | 2.3 |
| 65-74 years | 31.8 |  | 45/55 | 30.8 | 2.4 |
| 75-84 years | 28.5 |  | 41/59 | 28.4 | 2.6 |
| >85 years | 5.8 |  | $30 / 70$ | 26.9 | 2.8 |
| Male | 42.9 | 69 | $100 / 0$ | 29.6 | 2.4 |
| Female | 57.1 | 70 | $0 / 100$ | 30.5 | 2.4 |
| BMI $\leq 25$ | 15.8 | 75 | 38/62 |  | 2.4 |
| BMI $>25$ to $\leq 30$ | 31.4 | 72 | 50/50 |  | 2.4 |
| BMI $>30$ to $\leq 35$ | 27.1 | 69 | 45/55 |  | 2.4 |
| BMI > 35 to $\leq 40$ | 13.2 | 67 | 37/63 |  | 2.5 |
| BMI $>40$ | 8.4 | 64 | $29 / 71$ |  | 2.6 |
| BMI unknown/implausible | 4.1 | 69 | $38 / 62$ |  | 2.4 |

Table 36: Knee reoperations in 2022 by patient age, sex and BMI

## Infection

Loosening
Femoral component
Tibial tray
Patellar component
Several components
Osteolysis with fixed component
Femoral component
Tibial tray
Patellar component
Several components
Periprosthetic fracture
Ligament instability
Wear
Component failure
Prosthetic malalignment / Malrotation Restricted mobility

Progression of arthrosis
Condition after removal
Other reasons

| Proportion $1 \%$ ] | Age | m/f $5 \%$ \% |  | ASA |
| :---: | :---: | :---: | :---: | :---: |
| 14.5 | 71 | $54 / 46$ | 30.2 | 2.6 |
| 22.8 | 70 | 42/58 | 30.4 | 2.4 |
| 4.4 | 72 | 44/56 | 29.8 | 2.4 |
| 8.1 | 68 | $38 / 62$ | 30.9 | 2.3 |
| 0.6 | 68 | 49/51 | 31.6 | 2.4 |
| 9.7 | 71 | $44 / 56$ | 30.2 | 2.4 |
| 1.0 | 71 | $59 / 41$ | 30.1 | 2.4 |
| 0.2 | 72 | $54 / 46$ | 30.1 | 2.4 |
| 0.2 | 73 | 61/39 | 30.4 | 2.4 |
| 0.1 | 71.5 | 50/50 | 32.4 | 2.2 |
| 0.4 | 70 | $62 / 38$ | 29.8 | 2.3 |
| 4.1 | 79 | $21 / 79$ | 28.6 | 2.7 |
| 8.4 | 67 | $32 / 68$ | 30.1 | 2.4 |
| 5.6 | 71 | $41 / 59$ | 30.5 | 2.4 |
| 2.3 | 69 | 45/55 | 30.8 | 2.4 |
| 1.4 | 68 | 34166 | 29.4 | 2.3 |
| 5.2 | 66 | $39 / 61$ | 30.5 | 2.3 |
| 6.9 | 69 | $39 / 61$ | 29.8 | 2.3 |
| 13.3 | 70 | 52/48 | 29.5 | 2.6 |
| 14.6 | 68 | $40 / 60$ | 29.8 | 2.2 |

Table 37: Reasons for knee reoperations in 2022

## Femoral component, tibial tray, insert

Insert
Patellar arthroplasty
Femoral component, tibial tray, insert, patellar arthroplasty Insert, patellar arthroplasty
Tibial tray, insert
Femoral component, insert
Accessory parts only (e.g., screws)

## Femoral component

Tibial tray, insert, patellar arthroplasty
Femoral component, insert, patellar arthroplasty
Femoral component, patellar arthroplasty

| Proportion [\%] | Age | m/f $1 \%$ \% |  | ASA |
| :---: | :---: | :---: | :---: | :---: |
| 49.3 | 70 | 43/57 | 30.0 | 2.5 |
| 21.3 | 69 | 47/53 | 30.0 | 2.4 |
| 6.7 | 68 | $40 / 60$ | 30.5 | 2.3 |
| 6.5 | 69 | $42 / 58$ | 30.0 | 2.4 |
| 6.4 | 69 | $39 / 61$ | 30.1 | 2.3 |
| 3.8 | 69 | 39161 | 30.5 | 2.4 |
| 3.2 | 71 | $42 / 58$ | 29.9 | 2.5 |
| 1.6 | 71 | 45/55 | 30.0 | 2.5 |
| 0.5 | 75 | $38 / 62$ | 29.7 | 2.4 |
| 0.4 | 68 | $31 / 69$ | 30.7 | 2.4 |
| 0.3 | 64.5 | $40 / 60$ | 30.0 | 2.4 |
| 0.1 | 57 | $22 / 78$ | 28.5 | 1.9 |

Table 38: Components replaced or complemented ${ }^{3}$ during knee reoperations in 2022

## In brief:

- The most common reasons for knee revisions included loosening ( $22.8 \%$ ) and infection (14.5 \%)
- Secondary patellar resurfacing accounted for $13 \%$ of reoperations
- In almost $56 \%$ of reoperations all of the prior arthroplasty components were exchanged. In more than $60 \%$ of cases, this involved switching to a more constrained system

[^2]
## Trends in knee reoperations

Just as with hip reoperations, loosening of knee arthroplasties as an indication for reoperation has decreased over time. Compared to hip reoperations, however, this decline of "only" 11 percentage points from 33.8 \% in 2014 to 22.8 \% in 2022, is less pronounced. Nevertheless, it cannot be ruled out that these changes in the reasons for revision are at least partly due to a learning effect of the participating hospitals when
documenting the procedures in the registry. In-fection-related knee reoperations are also increasingly being performed as implant-retaining revisions (DAIR) (Figure 13). However, in line with hip reoperations, knee reoperations involving replacement of at least one bone fixation component decreased - from over two thirds in 2014 to exactly half in 2022.


Figure 13: Trends in bone fixation component replacements for infection-related knee reoperations over time. Here, two-stage revisions are regarded as a single procedure.

# Hip and knee arthroplasty survival 

## 5 Hip and knee

arthroplasty survival

Arthroplasty survival is the key quality cri"arthroplasty survival" denotes the period of time an arthroplasty system remains unchanged in the patient's body until implanted components need to be removed or replaced. The EPRD considers such an event as a failure of the prior arthroplasty and all components implanted in the process. Since most cases are still being followed up, the next subsections discuss the revision probabilities of primary procedures (Section 5.1 t 5.4) and revisions (Section 5.5) over time.

Section 5.1 presents the outcomes of the basic types of primary arthroplasties and addresses the influences of the different indications for arthroplasty, on survival. Section 5.2 then looks at the impact of non-implant-related factors, such as the patients themselves and the hospitals performing the procedures. Section 5.3 addresses the effects of different implant and arthroplasty characteristics on arthroplasty survival. As some arthroplasty systems are only implanted in certain hospitals and patients, it is not always possible to unequivocally determine whether a good or poor outcome is due to the implant itself or to the circumstances associated with the surgery. This possible overlapping of various contributing factors complicates the interpre tation of some outcomes in Section 5.3 and should be taken into account, particularly when assessing the outcomes of the specific arthroplasty systems presented in Section 5.4.

The tables at the end of each subchapter summarise and supplement all the outcomes, provided that certain minimum case numbers have been reached. In its annual report,
the EPRD presents outcomes for a period of up to eight years after primary arthroplasty or first revision. In terms of the expected arthroplasty survival of 15 to 20 years, this time span considered is still rather short. The following statements therefore only apply to the short to mid-term phase of an arthroplasty, and arthroplasties with good short-term outcomes do not necessarily do as well in the medium to long term.

### 5.1 Outcome by type of arthroplasty

The following subsections address the revision probabilities for different types of hip (Section 5.1.1) and knee arthroplasties (Section 5.1.2) as well as the influences of the different indications for arthroplasty.
5.1.1 Comparison by type of hip arthroplasty
Apart from planned operations, the EPRD also documents emergency femoral fracture procedures close to the hip joint. Whilst total hip arthroplasties are usually planned or elective procedures, trauma surgery involving partial hip arthroplasties are more often performed on older patients with fractures. Figure 14 reveals marked differences with regard to the revision probabilities of partial hip arthroplasties.

Most EPRD analyses also differentiate between the type of femoral fixation in elective THA. In Germany, most femoral fixations are not cemented (also refer to Table 6). Unlike uncemented femoral components, cemented stems are mainly employed in older
patients and in younger patients with comorbidities. The differences in the revision probabilities of arthroplasties with uncemented and cemented femoral components (Figure 15) may therefore be attributed to the marked outcome differences in elderly patients (Figure 22).

As can be seen in Figure 14, the revision probabilities strongly depend on whether the surgery was performed for a femoral fracture close to the hip joint or for other reasons. However, the diagnosis also plays an important role beyond this. Elective hip arthroplasties are at higher risk of revision when the primary diagnosis is post-trau matic hip osteoarthritis compared to other forms of hip osteoarthritis. (Figure 16). In non-elective hip arthroplasties, the revision probabilities for fractures of the femoral neck are lower than for other types of femoral fractures (Table 41).


Figure 14: Revision probabilities of elective and non-elective hip arthroplasties ( $p<0.0001$ )

Revision probabilities of hip arthroplasties over time

The explicit objective of the EPRD is not only to present the arthroplasty reality in each hospital, but also to reduce avoidable revision procedures over the long term. However, when considering the revision probabilities by operating year (Table 39), this envisaged development is not yet reflected in the short and medium-term outcomes currently available for elective THAs.

| Elective THAs wit | mented stems | Revision probabilities after ... |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Operating year | Number | 1 year | 2 years | 3 years | 4 years | 5 years |
| 2012/13 | 2,983 | $2.5\left[\begin{array}{l} {[2.0873} \\ 2.03] \\ 3 \end{array}\right.$ | $3.3[2.7 ; 4 ; 0]$ | $3.4\left[\begin{array}{l} {[2.517)} \\ \hline \end{array}\right.$ | $3.7\left[\begin{array}{l} {[3.1 / 4 ; 4.5]} \\ (x .48) \end{array}\right.$ | $4.0\left[\begin{array}{l} {[3.363 ; 4.7]} \\ \hline \end{array}\right.$ |
| 2014 | 7,200 |  | $3.0\left[\begin{array}{l}\text { [2.7.76 } 3.5] \\ (2.56)\end{array}\right.$ | $3.3\left[\begin{array}{l} (2.9504) \\ \hline(3) 7] \end{array}\right.$ | $3.5\left[\begin{array}{l} {[3.1 ; 36)} \\ \hline(3,9] \end{array}\right.$ | $3.7[3.2 ; 4.1]$ |
| 2015 | 21,936 | $2.4\left[\begin{array}{ll} {[21.2022)} \\ 2.6] \end{array}\right.$ | $2.8\left[\begin{array}{l} {[2.60630} \\ \hline 1.0] \end{array}\right.$ | $3.1\left[\begin{array}{l} {[1.99 ; 9.3]} \\ (1,9 i n \end{array}\right.$ | $\begin{gathered} 3.3[3.1 ; 3.6] \\ (19,48) \\ \hline \end{gathered}$ | $3.5[3.3 ; 3.8]$ |
| 2016 | 37,787 | $2.7\left[\begin{array}{l} {[25.5744)} \\ \hline \end{array}\right.$ | $3.2\left[\begin{array}{l} {[35.0 ; 100} \\ 3.4] \\ \hline \end{array}\right.$ | $\begin{gathered} 3.5[3.3 ; 3.6] \\ (3.4419) \end{gathered}$ | $3.6[3.4 ; 3.8]$ | $3.8[(33.6 ; 435) .0]$ |
| 2017 | 44,452 | $2.8\left[\begin{array}{l} {[2.6 ; 60,2.9]} \\ \hline(420) \end{array}\right.$ | $3.1[3.0 ; 3.3]$ |  | $3.6[3.4 ; 9 ; 9.8]$ |  |
| 2018 | 48,425 |  | $3.1\left[\begin{array}{l} {[25.9 ; 617)} \\ \hline(2] \end{array}\right.$ | $\underset{[(34,752]}{3.3]}$ | $3.5\left[\begin{array}{c} {[3,3.308]} \\ {[3.6]} \\ \hline \end{array}\right.$ |  |
| 2019 | 51,479 | $2.8\left[\begin{array}{l} {[4,640,60} \\ {[2.9]} \end{array}\right.$ | $3.2\left[\begin{array}{l} {[4,0,452]} \\ 3.3] \\ \hline \end{array}\right.$ | $3.4[3.3 ; 53.6]$ |  |  |
| 2020 | 47,172 | $2.9\left[\begin{array}{l} {[25.828]} \\ (4.1] \end{array}\right.$ | $\underset{\substack{33.233]}}{3.3[3]}$ |  |  |  |
| 2021 | 49,346 | ${ }_{2} 2.8[2.7 .73 .30]$ |  |  |  | ual Rep |

Table 39: Revision probabilities of elective total hip arthroplasties with uncemented stems by operating year ( $p=0.2$ )

| Elective THAs with cemented stems |  | Revision probabilities after ... |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Operating year | Number | 1 year | 2 years | 3 years | 4 years | 5 years |
| 2012/13 | 949 | $2.2[1.553 .4]$ | $2.5\left[\begin{array}{c} {[1.743]} \\ (8,8] \\ 3 \end{array}\right.$ | $\left.3.0\left[\begin{array}{c} {[2.170} \\ (70) \end{array}\right] .4\right]$ |  |  |
| 2014 | 2,523 | $1.9[1.4 ; 2.5]$ | $2.3[1.7 ; 2.9]$ | $2.7\left[\begin{array}{l} {[2.1 ; 3.4]} \\ (2,28) \end{array}\right.$ | $3.0\left[\begin{array}{l} {[2.4 ; 3 ; 3]} \\ (2.03) \end{array}\right.$ | ${ }^{3.2}\left[\begin{array}{l}\text { [2, } 2.655 \\ 4.0]\end{array}\right.$ |
| 2015 | 6,906 | $2.1[1.8 ; 2.5]$ | $2.5[(2.2 ; 2.9]$ | $\left.2.7\left[\begin{array}{l} (2.5983) \\ \hline \end{array}\right] .2\right]$ | $3.1\left[\begin{array}{c} {[2.888)} \\ \hline \end{array}\right.$ | $3.4\left[\begin{array}{l} (2.982) \\ \hline, 3.8] \end{array}\right.$ |
| 2016 | 10,355 | $2.2[1.972 .50$ | $2.6\left[\begin{array}{l} {[2.3 ; 3 ;} \\ (9.35) \\ \hline \end{array}\right.$ | ${ }_{2} 2.8$ [2.9.55] 3.1$]$ | $3.0{ }_{[8.568)}^{[2.73 .4]}$ | $\left.{ }^{3.2}{ }_{[8.0 .95)}^{[2.95} 3.6\right]$ |
| 2017 | 11,982 | $2.3\left[\begin{array}{ll} {[1.0 .362)} \\ 2.6] \end{array}\right.$ | $2.7\left[\begin{array}{c} {[1.4,4 ; 3)} \\ {[4.0]} \\ \hline \end{array}\right.$ | $2.9\left[\begin{array}{l} {[2.7 ; 5 ; 3.3]} \\ (10.5) \end{array}\right.$ | $3.0[2.7 ; 3 ; 3.3]$ | $3.2{ }_{[0,250}[2,93.6]$ |
| 2018 | 12,597 | 2.3 [2.1.1.2.6] |  | 2.8 [12.5036 3.1] | $3.0{ }_{[8.015}^{[2.75} 3$ |  |
| 2019 | 13,361 | $2.3\left[\begin{array}{c} (12.12399) \\ {[2.6]} \end{array}\right.$ | $2.6\left[\begin{array}{l} {[2.4 ; 165)} \\ (12.9] \end{array}\right.$ | $2.9\left[\begin{array}{l} {[2.692]} \\ \hline 9.2] \\ \hline \end{array}\right.$ |  |  |
| 2020 | 12,320 | $2.5\left[\begin{array}{c} {[12.353 ; 2.8]} \\ \hline(1,53) \end{array}\right.$ | $\left.2.9\left[\begin{array}{l} {[2.63 ;} \\ (0.53) \\ 3 \end{array}\right) 2\right]$ |  |  |  |
| 2021 | 13,221 |  |  |  |  |  |

Table 40: Revision probabilities of elective total hip arthroplasties with cemented stems by operating year ( $p=0.3$ )
The EPRD is nevertheless a relatively young registry with ten years of data collection and has only started within the last three years to make cautious recommendations for certain types of arthroplasties for defined patient groups, which show significantly lower revision probabilities (see pages 64 and 65). It will be several years before such recommendations are implemented on a large scale in practice and then reflected in the registry outcomes


Figure 15: Revision probabilities of elective total hip arthroplasties with cemented and uncemented stems ( $p<0.0001$ )


Figure 16: Revision probabilities of elective total hip arthroplasties with uncemented stems by primary diagnosis ( $p<0.0001$ )

Table 41 lists the revision probabilities for various types of hip arthroplasties by indication

## In brief:

Revision probabilities markedly higher in non-elective procedures.

To date, there has been no noticeable decline in revision probabilities.

|  |  |  |  |  |  |  | Revision probabilities after ... |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Type of arthroplasty / category | Type | Number | Age | m/f | BMI | Hosp. | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Elective THAs with uncemented stems |  | 352,072 | $6_{(59.74)}$ | 41/59 | 27.8 | 732 |  |  |  |  |  | ${ }^{3.9}$ [3.9\%94.4.0] |  |  |
| Primary diagnosis | Primary osteoarthritis | 275,824 | $68{ }_{(61-75)}$ | 41/59 | 28.0 | 728 | $2.6[22.6 ; 2.7]$ | $3.0[(182,897)]$ | $\begin{aligned} & 3.3[3.2 ; 3.3] \\ & 1(14.4533 \end{aligned}$ | $3.5\left[\begin{array}{c} {[35,4 ; 341)} \\ (105] \end{array}\right.$ | $3.6_{(70.579)}^{[3 ; 5]}$ | $3.8\left[\begin{array}{c} {[3,7.783]} \\ {[3.9]} \\ \hline \end{array}\right.$ | $3.9\left[\begin{array}{c} {[16,8488)} \\ \hline 4.0] \end{array}\right.$ | $4.2\left[\begin{array}{l} {[4.0956} \\ 4.36] \\ 4.3] \end{array}\right.$ |
|  | Dysplastic osteoarthritis | 32,633 | $58_{(51-66)}$ | 31/69 | 27.1 | 685 | $2.3[2.1 ; 2.5]$ | $2.8\left[\begin{array}{c} {[2.62 ; 921)} \\ \hline(22) \end{array}\right.$ | $3.1 \begin{aligned} & {[21.9 ; 5 ; 2)} \\ & \hline(12)] \end{aligned}$ | $3.3\left[\begin{array}{l} {[3.19 ; 53.5]} \\ (125) \end{array}\right.$ | $3.4 \underset{(8.7,28)}{[3 ; 2]}$ | $3.6\left[\begin{array}{l} {[3.4 ; 49 ; 3.9]} \end{array}\right.$ |  |  |
|  | Secondary osteoarthritis or not otherwise specified | 28,058 | $65_{(57-73)}$ | 43/57 | 27.7 | 644 |  | $3.3\left[\begin{array}{l} {[3,1 ; 3.5]} \\ \hline 1,56) \end{array}\right.$ | $3.5\left[\begin{array}{ll} {[15,3,3,3.8]} \\ \hline \end{array}\right.$ | $3.7\left[\begin{array}{ll} {[1.51,54,3.9]} \\ 3 \end{array}\right.$ | $3.9\left[\begin{array}{l} {[3.7 .724 .4 .2]} \\ {[0.34} \end{array}\right.$ |  | $4.2{ }_{[1.4 .913}^{[4.6]}$ | $\left.4.7{ }_{\text {[4.30] }} \mathbf{5} 5.3\right]$ |
|  | Other diagnosis | 12,030 | ${ }^{62}{ }_{(52-73)}$ | 51/49 | 27.0 | 684 | $5.9[5.4 ; 6.3]$ | $6.5 \underset{(7,477)}{[6.0 ; 6]}$ | $6.8[6[5.4 ; 7.3]$ | $7.0 \underset{\substack{46,289\rangle}}{[6 ; 6]}$ | $7.4\left[\begin{array}{c} (6,977) \\ (7.9] \end{array}\right.$ | $\underset{(1.531)}{ } 7.6 .1]$ | $8.0[7.3 ; 8.8]$ | $8.6[7.5 ; 9.8]$ |
|  | Post-traumatic osteoarthritis | 3,527 | ${ }^{62}{ }_{(54-71)}$ | 55/45 | 26.6 | 548 |  |  | 4.9 [4.2; 5. 5.8] |  |  | $6.0\left[{ }^{[51.17)} 7.7 .0\right]$ |  | $\underset{(76)}{6.5[5.2 ; .0]}$ |
| Prior operations | No relevant prior operations | 339,119 | $67_{(60-75)}$ | 40/60 | 27.9 | 731 | $2.7\left[\begin{array}{l} {[27.6 ; 2 ; 236} \\ \hline 1.8] \\ \hline \end{array}\right.$ | $3.1 .133,0 ; 3.2]$ | $3.4\left[\begin{array}{l} {[37.3 ; 69.4]} \\ (120) \end{array}\right.$ | $3.5\left[\begin{array}{l} {[12,54,422} \\ 3.6] \end{array}\right.$ | $3.7\left[\begin{array}{l} (8.5,624) \\ {[3.8]} \end{array}\right.$ | $3.9\left[\begin{array}{l} {[3,8,8,023)} \\ {[14.0]} \end{array}\right.$ | $4.0[3.9 .9 .4 .1]$ | $4.3\left[\begin{array}{l} {[4.1 .730} \\ 4.4] \\ 4.4] \end{array}\right.$ |
|  | Osteosynthesis / Osteotomy | 7,363 | $5^{59}{ }_{(51-69)}$ | $39 / 61$ | 26.6 | 613 | $4.1\left[\begin{array}{l} [3.7955): 4.6] \end{array}\right.$ | $4.8[4.3 .35 .5]$ | $5.1 \underset{\substack{(3.888)}}{[4 ; 5} 5.7]$ |  | $5.6[(5.0 ; 6 ; 6.2]$ | $5.6[(15.1,144.3]$ | $5.9 \begin{gathered}\text { [5.3; } \\ (501) \\ 6.7]\end{gathered}$ | 6.4 [5.5; 7.7.4] |
|  | Other prior operations | 4,527 | $62_{(52-71)}$ | 43/57 | 27.6 | 472 | $2.9\left[\begin{array}{c} {[.547)} \\ (3,5) \\ \hline \end{array}\right.$ | $3.7\left[\begin{array}{l} {[3.221]} \\ \hline, 2 ; 3] \end{array}\right.$ | $4.0\left[\begin{array}{l} {[3.4,4,4.6]} \\ 2,033 \end{array}\right.$ | $4.1\left[\begin{array}{l} {[3.554} \\ {[2,54} \\ 4.8] \end{array}\right.$ | $4.3\left[\begin{array}{l} {[3,7,760} \\ (1,20] \\ 5 \end{array}\right.$ | $4.5\left[\begin{array}{l} {[3.935)} \\ (1,33) \\ 5.2] \\ \hline \end{array}\right.$ | $5.3\left[\begin{array}{c} {[4.3 i)} \\ \mid(2) \\ 6.4] \end{array}\right.$ |  |
|  | Femoral head necrosis | 1,019 | $57{ }_{(46-67)}$ | 59/41 | 27.8 | 313 | $5.4[4.1 .1 ; 7.0]$ | $5.8[4.5 \cdot 7.4]$ | $6.2[4.9 ; 8.0]$ |  | $7.0\left[\begin{array}{c} {[5.4 ; 9,9.0]} \\ {[123)} \end{array}\right.$ | $7.0\left[\begin{array}{l} \text { [5:4; } \\ (179) \end{array}\right.$ | 7.0 (5.4; 9 (7) 9.0$]$ |  |
| Elective THAs with cemented stems |  | 95,671 | $79_{(75-82)}$ | 25/75 | 26.6 | 707 | $2.4\left[\begin{array}{c} {[2.3 ; 4 ; 2.5]} \\ (16,74) \end{array}\right.$ | $2.7\left[\begin{array}{c} {[26.689)} \\ \hline 62.8] \\ \hline \end{array}\right.$ | $\underset{(48.399)}{2.9]}$ | $3.1_{(35.032)}^{[3.0 ; 3]}$ | $3.4\left[\begin{array}{c} {[23.23022} \\ \hline \end{array}\right.$ | $3.6 \underset{(13.287)}{[3.4 ; 3]}$ | $3.8[(3.657) ; 4.0]$ | $4.1\left[\begin{array}{ll} {[3.854 .84 .3]} \\ \hline \end{array}\right.$ |
| Primary diagnosis | Primary osteoarthritis | 76,701 | $79{ }_{75-82)}$ | 25/75 | 26.7 | 687 | $2.0[1.9 ; 2.1]$ | $2.3\left[\begin{array}{l} {[2.2 .2001)} \\ 2.4] \\ \hline \end{array}\right.$ | $2.5\left[\begin{array}{c} (2,4.40 ; 2.7] \\ (3,90) \end{array}\right.$ | $2.7\left[\begin{array}{l} {[2.68926]} \\ {[2.8]} \\ \hline \end{array}\right.$ | $2.9\left[\begin{array}{c} {[1,8.8,63.03]} \end{array}\right.$ | $3.1\left[\begin{array}{ll} {[11,3044} \\ {[2 ; 3]} \end{array}\right.$ | $3.3[3.1 .3 .3 .5]$ |  |
|  | Secondary osteoarthritis or not otherwise specified | 8,198 | $78_{(74-82)}$ | $24 / 76$ | 26.4 | 500 | $\underset{(6.59)]}{2.4} \underset{(2.1 ; 2]}{2}$ |  | ${ }^{3.1}\left[\begin{array}{l}\text { [2.7.78i } \\ \text { [4.5] }\end{array}\right.$ |  | ${ }^{3.6}$ [3.2729 4.1] |  | $4.2{ }_{\text {[3988] }}^{\text {[3, } 5.0]}$ | ${ }^{5.8} 8[4.1788 .80]$ |
|  | Other diagnosis | 6,162 | $79_{(72-84)}$ | $29 / 71$ | 25.4 | 606 | $6.6\left[\begin{array}{l} {[6,0 ; 7} \\ \langle 4,3] \end{array}\right]$ | $7.4\left[\begin{array}{l} {[6.702 ;} \\ (8.1] \end{array}\right.$ | $8.0\left[\begin{array}{c} {[7.328} \\ (2,28) \\ 8.8] \end{array}\right.$ | $8.8\left[\begin{array}{c} {[8.0009} \\ (1.50) \\ 9.7] \end{array}\right.$ | $9.4[8.5 ; 10.4]$ | $9.8\left[\begin{array}{l} {[8.8: 8)} \\ (430) \\ 10.8] \end{array}\right.$ |  | $10.7\left[\begin{array}{l} {[5 ; 8 ;} \\ (5 ;) \\ \hline \end{array} 12.8\right]$ |
|  | Dysplastic osteoarthritis | 3,350 | $76_{(00-81)}$ | 20/80 | 26.3 | 440 | $2.2\left[\begin{array}{l} {[1.775 ; 2.8]} \\ (2,5) \end{array}\right.$ | $2.5\left[\begin{array}{l} {[2,0,0,3.1]} \\ (2,24) \end{array}\right.$ | $2.7\left[\begin{array}{ll} {[2.2,50)} \\ 20.3] \end{array}\right.$ | $2.8\left[\begin{array}{ll} {[2.2363 .4]} \\ (0,2 b) \\ \hline \end{array}\right.$ | $3.2\left[\begin{array}{c} {[2.516} \\ (8,5) \\ 4.0] \\ \hline \end{array}\right.$ | $3.2\left[\begin{array}{l} {[2.53)} \\ (13.0] \\ \hline \end{array}\right.$ | 3.7 [2.88, 51.0$]$ |  |
|  | Post-traumatic osteoarthritis | 1,260 | $78_{(72-82)}$ | $29 / 71$ | 25.2 | 372 | $3.4[2.5 ; 4.6]$ | $3.9 \underset{(8093)}{[2.95} 5$ | $4.2\left[\begin{array}{l} {[32.26} \\ (620) \\ 5.5] \end{array}\right.$ | $4.7\left[\begin{array}{l} {[3.6 ;} \\ (43) \end{array}, 3.3\right]$ | $4.7\left[\begin{array}{l} 13.6 ; 9.3] \\ {[2.3)} \end{array}\right.$ | $5.1\left[\begin{array}{c} {[3.8: 6.8]} \\ (144) \\ \hline \end{array}\right.$ | $5.1\left[\begin{array}{c} {[3.88)} \\ (158) \\ \hline 6.8] \\ \hline \end{array}\right.$ |  |
| Prior operations | No relevant prior operations | 91,641 | $79_{(75-82)}$ | 25/75 | 26.6 | 704 | $2.3\left[\begin{array}{l} {[2.2 ; 3 ; 24]} \\ {[234]} \end{array}\right.$ | $2.6\left[\begin{array}{l} {[5.5278)} \\ 2.7] \\ \hline \end{array}\right.$ |  | $3.0\left[\begin{array}{l\|l\|:\|:\|c\|c\|}  & 3.1] \end{array}\right.$ | $3.2\left[\begin{array}{l} {[23.1 ; 3 ; 3.4]} \\ {[23,4]} \end{array}\right.$ | $3.4\left[\begin{array}{l} {[3.3 ; 3 ; 3.6]} \\ {[1273]} \end{array}\right.$ | $3.6\left[\begin{array}{c} {[5.549)} \\ 3,8] \end{array}\right.$ | $3.9[3.7 .74 .4 .2]$ |
|  | Osteosynthesis / Osteotomy | 2,432 | $79_{(73-83)}$ | 23/77 | 25.0 | 480 | $4.7\left[\begin{array}{l} {[3.9 .96 .5 .6]} \\ 10.86 \\ \hline \end{array}\right.$ | $5.3[4.5: 56.3]$ | $5.9[(4,0950) 7.0]$ | $6.4[5.4 ; 7.7 .6]$ | $6.9 \underset{(5.750)}{ } 68.2]$ | $\begin{gathered} \left.7.3\left[\begin{array}{c} {[6.1 ;} \\ (230 \end{array}\right) ; 8.8\right] \\ \hline \end{gathered}$ | $7.3\left[\begin{array}{c} {[63]} \\ {[8 ; 7} \\ \hline \end{array}\right.$ |  |
|  | Other prior operations | 1,292 | $78{ }_{(73-82)}$ | 30/70 | 26.7 | 261 | $3.9[3.0 ; 5.1]$ | $4.3\left[\begin{array}{c} {[3,3 ; 3 ;} \\ (9.5] \\ 5.5] \\ \hline \end{array}\right.$ | $4.9 \underset{(7822)}{[3.8 ;} 6$ | $5.3[44.2 ; 6.8]$ | $5.7[4.55 \cdot 7.3]$ | $6.1\left[\begin{array}{c} {[4.8 ; 7.8]} \\ (308) \end{array}\right.$ | $6.1[4.887 .8]$ |  |
| Non-elective THAs |  | 29,083 | $76_{668-82)}$ | 30/70 | 24.7 | 677 | $6.1[5.8 ; 6.3]$ <br> $(20,003)$ | $6.6[6[3 ; 6 ; 69]$ |  | 7.4 [7.0; 7 (7.00) 7.7$]$ | $\begin{gathered} 7.6[7.3 ; 3.00] \\ 4.318] \end{gathered}$ | $7.9[7.5 ; 5.3]$ | 8.4 [7.99; 9.0] | 8.8 [7.9\% $(1.40 .8]$ |
| Primary diagnosis | Femoral neck fracture | 27,002 | $76_{(68-82)}$ | 30/70 | 24.6 | 667 | $5.8 \text { [5.6:6;6.1]}$ | $6.4\left[\begin{array}{c} {[1.9,955)} \\ \hline(6.7] \end{array}\right.$ | $6.8\left[\begin{array}{c} {[6.590)} \\ (6,90) \end{array}\right.$ | $7.2\left[\begin{array}{c} {[6.827)} \\ (6,5] \end{array}\right.$ |  | $7.7\left[\begin{array}{c} {[7.3 ; 82 ;} \\ (2,22) \\ \hline \end{array}\right.$ | $8.3 \text { [7.7.7; } 8.9]$ | $\underset{(127)}{8.7} 9.9]$ |
|  | Other femoral fracture | 1,413 | $81_{(74-86)}$ | $24 / 76$ | 24.8 | 419 | $9.3[7.9 ; 11.1]$ | $10.0[8.4 ; 4 ; 11.8]$ | $10.3[8.7 ; 12.2]$ | $\underset{\substack{8298) \\ 18.9 ; \\ 10.5]}}{10.5}$ | $\begin{gathered} 10.5[8.9 ; 12.5] \\ (170) \end{gathered}$ | $10.5[8.9 ; 12.5]$ |  |  |
|  | Pathologic fracture | 668 | $75_{(67-82)}$ | $24 / 76$ | 25.5 | 312 | $7.9\left[\begin{array}{l} {[6.1 ; 1 ; 10.4]} \\ (44 i) \end{array}\right.$ | $8.2\left[\begin{array}{l} {[6.33} \\ {[3 / 4} \\ {[3 / 4} \\ 10.7] \end{array}\right.$ | $9.4\left[\begin{array}{l} {[7.3 ;} \\ (23) \\ (2.3) \end{array}\right.$ | $9.4[7.3 ; 12.3]$ | 9.4[7.3; 12.3] | $9.4[7.3 ; 12.3]$ |  |  |
| Prior operations | No relevant prior operations | 27,871 | $76{ }_{\text {(68-82) }}$ | 30/70 | 24.6 | 673 | $5.9\left[\begin{array}{c} {[5,7,7640.2]} \\ \hline(10)] \end{array}\right.$ | $6.5\left[\begin{array}{l} {[1,2,256]} \\ \hline 6.8] \end{array}\right.$ |  | $7.3\left[\begin{array}{c} {[6.9775]} \\ (6.6] \end{array}\right.$ | $7.5\left[\begin{array}{c} {[7.1,984)} \\ \hline(7.9] \end{array}\right.$ | $7.7\left[\begin{array}{c} (7.3,300 \\ (x, 20) \\ \hline \end{array}\right.$ | $8.3\left[\begin{array}{c} {[7.7 ; 7} \\ (12 \lambda) \\ 8.9] \end{array}\right.$ | $\underset{(132)}{8.7} \mathbf{~} 9.8]$ |
|  | Osteosynthesis / Osteotomy | 774 | $77_{(67-84)}$ | 28/72 | 25.0 | 344 | $9.0[7.17111 .3]$ |  | $10.4 \underset{(8007}{[8.3 ;} ; 12.9]$ | $10.4\left[\begin{array}{c} \text { 8.3:3; } 12.9] \\ 1027 \end{array}\right.$ | $\begin{aligned} & 11.0[8.7 .7 ; 13.9] \\ & \text { (129) } \end{aligned}$ | $11.7[9.1 .10 ; 14.9]$ |  |  |
|  | Other prior operations | 415 | $77{ }_{(68-82)}$ | 30/70 | 24.5 | 145 | $\left.8.9{ }_{\substack{\text { [6.406 } \\ \text { Biob }}} 12.1\right]$ |  |  |  | $10.1[7.4 ; 43.13 .8]$ |  |  |  |


|  |  |  |  |  |  |  | Revision probabilities after ... |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Type of arthroplasty / category | Type | Number | Age | m/f | BMI | Hosp. | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Hip hemiarthroplasties |  | 59,874 | $84_{\text {(80-89) }}$ | $29 / 71$ | 24.2 | 596 | $4.5\left[\begin{array}{c} (32.31 / 44 \\ {[4.7]} \end{array}\right.$ | $4.7[4.6 ; 3 ; 4.9]$ | $4.9\left[\begin{array}{c} {[1.37756} \\ \hline 4.1] \end{array}\right.$ |  | $5.1[4.9,955]$ | $5.4\left[\begin{array}{l} {[5.17 .75 .5]} \\ 1(2)] \end{array}\right.$ | $5.4[5.1 ; 5.7]$ |  |
| Primary diagnosis | Femoral neck fracture | 54,760 | $84_{\text {(80-89) }}$ | 28/72 | 24.2 | 579 | $4.3[4.1 ; 4.5]$ |  | $\left.4.6{ }_{[1.4 .4,45} 4.8\right]$ |  |  | $5.0\left[\begin{array}{c} 4.7 .7 .5 .5] \\ (4.64) \\ \hline \end{array}\right.$ | $5.0{ }_{[4.83)}^{[4.75 .5]}$ | $5.0\left[4.760^{\text {(6) }} 5.3\right]$ |
|  | Other diagnosis | 3,243 | $82_{(76-87)}$ | $36 / 64$ | 24.5 | 486 | $7.1$ | $7.5 \underset{\substack{(6.684 \\(8,6)}}{ } 8.6]$ | $7.8 \underset{(657)}{[6 ; 9} 9.0]$ | $8.2\left[\begin{array}{c} {[7.1928)} \\ (132) \\ 9.5] \\ \hline \end{array}\right.$ | $8.2\left[\begin{array}{c} \text { [7.17 } 17)^{9.5]} \end{array}\right.$ | $9.5[7.5 ; 12.0]$ |  |  |
|  | Other femoral fracture | 1,211 | $85_{(80-90)}$ | 22/78 | 24.5 | 325 | 7.7 [6.3; $\left.{ }_{\text {(54, }} 9.5\right]$ | $8.3\left[\begin{array}{l} {[6.8: 8} \\ \text { (354) } \\ 10.3] \end{array}\right.$ | $8.7[7.0 ; 10.9]$ | $8.7[7.0 ; 10.9]$ | $8.7[7.0 ; 10.9]$ |  |  |  |
|  | Pathologic fracture | 502 | $83^{77-88)}$ | 21/79 | 24.1 | 227 | $4.6\left[\begin{array}{l} {[3,0 ; 9} \\ (2,5) \\ 7.1] \end{array}\right.$ | $4.6[3.0 ; 7.7 .1]$ |  | $5.3[3.4488 .8 .2]$ |  |  |  |  |
| Prior operations | No relevant prior operations | 58,140 | 84 (80-89) | $29 / 71$ | 24.2 | 593 | $4.4[4.3 ; 3 ; 4.6]$ | $4.6\left[\begin{array}{l} {[20.578)} \\ \hline \end{array} 4.8\right]$ | $4.8\left[\begin{array}{c} {[1.69505} \\ (120) \\ \hline \end{array}\right.$ | $5.0\left[\begin{array}{l} {[4,8: 840} \\ (0,40 \end{array}\right)$ | $5.0\left[\begin{array}{c} {[4.889} \\ \text { B.8 } \\ \hline \end{array}\right.$ | $5.3\left[\begin{array}{l} {[5.0 ; 979} \\ 5.6] \\ 5.6] \end{array}\right.$ | $5.3 \underset{(4,02]}{[5.6]}$ | $5.3 \underset{(5,0 ;)}{(6.6]}$ |
|  | Osteosynthesis / Osteotomy | 909 | $85_{(80-89)}$ | 23/77 | 24.8 | 313 | $10.0[88.1 ; 12.2]$ | $10.2\left[\begin{array}{c} \text { [8365 } 3 ; \\ (36.5] \end{array}\right.$ | $\left.10.2\left[\begin{array}{l} {[8.36} \\ (26) \end{array}\right] 12.5\right]$ | $10.2 \text { [8.3; } 12.5]$ | $10.2[8.3 ; 3 ; 12.5]$ |  |  |  |
|  | Other prior operations | 798 | $83_{(79 .-88)}$ | 31/69 | 24.5 | 171 | $4.6\left[\begin{array}{l} {[3 ; 3 ; 7.4]} \\ (467) \end{array}\right.$ | $5.0\left[\begin{array}{l} {[3263} \\ {[36} \end{array} 6.9\right]$ | $5.4\left[\begin{array}{l} {[3,915} \\ {[2, ~ 7.6]} \\ \hline \end{array}\right.$ | $5.9[4.2 ; 8.3]$ | $5.9[4.2 ; 8.8 .3]$ | $5.9[4.2 ; 8.83]$ |  |  |

Table 41 (continued)
5.1.2 Comparison by type of knee arthroplasty
The EPRD documents three principal types of knee arthroplasties. The most common type of knee replacement is a total knee arthroplasty, where both the medial and lateral parts of the joint are replaced. In contrast, unicondylar arthroplasties only replace the affected medial or lateral part of the joint - the objective being to preserve
intact articulating surfaces and ligaments as much as possible in order to ensure the best possible natural kinematics and starting point for any subsequent reoperations that may become necessary. However, as is evident from Figure 17, unicondylar arthroplasties have a revision probability that is almost twice that of total knee arthroplasties. Patellofemoral resurfacing procedures are much less common than TKAs and uni-


Figure 17: Revision probabilities of total and unicondylar knee arthroplasties ( $p<0.0001$ )
condylar replacements. Their revision probabilities are markedly higher than those of other types of arthroplasties (see Table 44 at the end of this section).

Total knee arthroplasties can be further differentiated according to their degree of stabilisation. The most common type of sys-
tem employed are standard systems without For the following analyses, hinged and varadditional lateral stabilisation. However, in us-valgus stabilised systems are combined


Figure 18: Revision probabilities of total knee arthroplasties by degree of constraint ( $p<0.0001$ )

## Revision probabilities of knee arthroplasties over time

Unlike with THAs (Page 54), TKAs reveal a decrease in the revision probability by the three-year outcomes (Table 42).

| Standard TKAs |  | Revision probabilities after |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Operating year | Number | 1 year | 2 years | 3 years | 4 years | 5 years |
| 2012/13 | 3,056 | $1.6[1.2 ; 2.2]$ | $2.9\left[\begin{array}{l} {[2.4 ; 3 ; 3.6]} \\ (k, 25) \end{array}\right.$ | $3.4\left[\begin{array}{l} (2.8588) \\ \hline \end{array}\right.$ | $3.7\left[\begin{array}{l} (3.1448) \\ \hline(4.5] \end{array}\right.$ | $3.9[3.2 ; 4.6]$ |
| 2014 | 7,513 | $1.7[1.5 ; 2.1]$ | $2.8\left[\begin{array}{c} (2.4777) \\ {[3.2]} \end{array}\right.$ | $3.3\left[\begin{array}{c} {[2.9783]} \\ {[6.8]} \\ \hline \end{array}\right.$ | $3.7[3.3 ; 4.2]$ | $4.0[3.6 ; 4.5]$ |
| 2015 | 23,119 | $1.9[1.7 ; 2.1]$ | $2.9\left[\begin{array}{c} {[21,74583} \\ \hline 1.1] \end{array}\right.$ | $\underset{\text { 320.855 }}{3.5[3.7]}$ | $3.8[3.6 ; 4.1]$ | $4.1\left[\begin{array}{c} {[3.8 ; 84.4]} \\ (19,99] \end{array}\right.$ |
| 2016 | 37,740 | $1.7\left[\begin{array}{c} (1,63,6 ; 1.9] \\ \hline 1.9] \end{array}\right.$ | $2.7\left[\begin{array}{l} {[2.52 \cdot 2.9]} \\ (3,27) \\ 2 \end{array}\right.$ | $3.2\left[\begin{array}{l} (3.4,0 ; 3) ; 3.3] \end{array}\right.$ | $3.6\left[\begin{array}{c} {[3.4 ; 3 ; 3.8]} \\ (3,33) \end{array}\right.$ | $3.8[3.6 ; 4.0]$ |
| 2017 | 45,314 | $\begin{gathered} 1.7[1.6 ; 1.9] \\ (43.991) \end{gathered}$ | $2.6 \underset{(42.908)}{[2.5]}$ | $\begin{gathered} 3.1\left[\begin{array}{l} {[12.9993} \\ (42.29] \\ \hline \end{array}\right] \\ \hline \end{gathered}$ | $3.4\left[\begin{array}{c} {[3.2 ; 3,3,5]} \\ (4,09) \end{array}\right.$ | $3.6\left[\begin{array}{c} (2,4,55) \\ \hline \end{array}\right.$ |
| 2018 | 48,772 | $\underset{\substack{41.4244}}{1.7 .7]}$ | $2.4\left[\begin{array}{l} {[2.3,3006)} \\ {[2.6]} \end{array}\right.$ | $2.9[2.7 .7 ; 3.0]$ | $3.2[3.1 ; 3.4]$ |  |
| 2019 | 51,062 | $1.6[1.5 ; 1.7]$ | $2.3\left[\begin{array}{c} {[2.2 ; 549.5]} \end{array}\right.$ | $2.8\left[\begin{array}{c} {[2.6 ; 2 ; 2.9]} \\ (3591) \end{array}\right.$ |  |  |
| 2020 | 45,986 | $1.8[11.7 ; 1.9]$ | $2.5\left[\begin{array}{c} {[2.4 ; 574)} \\ \hline(3) 7] \end{array}\right.$ |  |  |  |
| 2021 | 47,540 | 1.6 [1.5; 1.8] |  |  |  |  |

Table 42: Outcomes for standard total knee arthroplasties by operating year ( $p<0.0001$ )

It is unlikely that this decline can be attributed to the presence and findings of the EPRD (as already mentioned in the trends in hip reoperations section on Page 38). Incidentally, it is somewhat more pronounced for systems with mobile bearings than for those with a fixed bearing.

The outcomes for unicondylar arthroplasties have also improved, but only since 2015 (see Table 43).

| Unicondylar knee arthroplasties |  | Revision probabilities after ... |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Operating year | Number | 1 year | 2 years | 3 years | 4 years | 5 years |
| 2012/13 | 410 | $2.9 \underset{(137)}{[1.7 ; 5.1]}$ | $\underset{\substack{3371}}{5.2[7.8]}$ | $\underset{(352)}{6.0} 5$ | $7.0 \underset{(3.9 ; 103)}{10.0]}$ | $8.4\left[\begin{array}{c} (630) \\ (330) \end{array}\right.$ |
| 2014 | 962 | $\underset{\substack{1099}}{2.8 .1 .1]}$ | $4.6\left[\begin{array}{c} 3.48 ; 6.1] \\ (800) \end{array}\right.$ | $5.1\left[\begin{array}{c} {[3.9 ;} \\ (857) \\ 6.7] \\ \hline \end{array}\right.$ | $6.4\left[\begin{array}{c} {[500 ; 8.2]} \\ (827) \end{array}\right.$ | $\underset{\substack{\text { B8; } \\ \text { (8i0 }}}{ } .8 .6]$ |
| 2015 | 2,465 | $3.2\left[\begin{array}{l} {[2.6,649} \\ 12.09 \end{array}\right.$ | $5.3[4.5 ; 6.2]$ | $6.5\left[\begin{array}{c} {[5.6 ; 7.6]} \\ (2,18) \end{array}\right.$ | $7.8\left[\begin{array}{c} {[6.8 ; 9.0]} \\ k .125) \end{array}\right.$ | $8.4\left[\begin{array}{c} {[7.3 ; 9.5]} \\ (203) \end{array}\right.$ |
| 2016 | 5.114 | $3.5\left[\begin{array}{l} 3.0,044.0] \\ 4.84) \\ \hline \end{array}\right.$ | $5.4 \underset{(4.870)}{[4.8 ; 6.1]}$ | $6.2\left[\begin{array}{c} {[5.6 ; 6.9]} \\ (4.59) \end{array}\right.$ | $7.1\left[\begin{array}{l} {[6.4577 .9]} \\ {[4.97} \end{array}\right.$ | $\begin{gathered} 7.6[6.9 ; 8.4] \\ \langle 4.329) \end{gathered}$ |
| 2017 | 6,476 | $3.0\left[\begin{array}{l} {[2.6 ; 219]} \\ (12.5] \end{array}\right.$ | $5.0\left[\begin{array}{l} \text { [4.5; } 5.5] \\ (.024) \end{array}\right.$ | $6.1\left[\begin{array}{c} (5.567) \\ \hline 5.6 .7] \end{array}\right.$ | $6.7\left[\begin{array}{c} {[6.2730} \\ \hline(7.4] \\ \hline \end{array}\right.$ | $\underset{\substack{6,755) \\ \hline(6.0]}}{ }$ |
| 2018 | 7,292 | $2.9\left[\begin{array}{l} {[2.5001)} \\ \hline(7.3] \end{array}\right.$ | $4.6[4.1 ; 5.1]$ | $5.6[5.1 ; 6.2]$ | $6.5[5.9 ; 7.1]$ |  |
| 2019 | 8,001 | $2.7\left[\begin{array}{c} (1.720) \\ {[7.42]} \end{array}\right.$ | $4.4\left[\begin{array}{l} {[4.0 ; 45} \\ (0.45] \end{array}\right.$ | $5.5[5.17 ; 6.1]$ |  |  |
| 2020 | 7,333 | $2.8$ | $4.9\left[\begin{array}{c} {[5.4 ; 55.4]} \\ {[5.45]} \end{array}\right.$ |  |  |  |
| 2021 | 7,453 | $2.5 \underset{(5.334)}{[2.2 ; 2.9]}$ |  |  |  |  |



Figure 19: Revision probabilities of standard total knee arthroplasties by primary diagnosis (based on the documented ICD-10 odes) $(p<0.0001)$
into a single group of constrained TKAs due to the relatively low number of cases. No further distinction is therefore made be tween them.

In knee arthroplasties, the risk of revision surgery also depends greatly on the primary diagnosis documented. The highest probabil ity of revision is seen in post-traumatic osteo arthritis (Figure 19).

Table 44 details the revision probabilities of different types of knee arthroplasties for different indications.

In brief:

- Unicondylar arthroplasties have a revision probability that is still almost twice that of TKAs.
Over the last ten years, the revision probability of standard TKAs has been on the decline.

|  |  |  |  |  |  |  | Revision probabilities after ... |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Type of arthroplasty / category | Type | Number | Age | m/f | вмI | Hosp. | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Standard TKAs |  | 351,531 | $70_{(62-77)}$ | 34166 | 30.1 | 722 | $1.7[1.6 ; 1.7]$ | $\begin{gathered} 2.5[2.5: 52.6] \\ {[23,690]} \end{gathered}$ |  | $3.3[3.3 ; 3.4]$ | $3.6[3.5 ; 3.7]$ | ${ }^{3.8}[3.7$ [50.05) 3.9$]$ | $4.0[3.9 .94 .1]$ |  |
| Primary diagnosis | Primary osteoarthritis | 305,248 | $70{ }_{(63-77)}$ | 34166 | 30.2 | 719 | $1.6[1.6 ; 1.7]$ | $2.5\left[\begin{array}{l} {[20.4 ; 925]} \\ (0,5] \\ \hline \end{array}\right.$ | $2.9\left[\begin{array}{l} 2.9 .93 .0] \\ {[1623,36} \end{array}\right]$ | $\begin{aligned} & 3.3[3.2 .2 ; 3.3] \\ & (11.8944) \\ & \hline \end{aligned}$ | $3.5\left[\begin{array}{l} {[78.4 ; 10)} \\ {[3.6]} \end{array}\right.$ | $3.7\left[\begin{array}{l} {[34.6 ; 12)} \\ {\left[\begin{array}{l} 4 \\ \hline \end{array}\right)} \\ \hline \end{array}\right.$ | $3.9[3.8 .8 ; 4.0]$ | $4.2[4.0 .04 .4 .3]$ |
|  | Secondary osteoarthritis or not otherwise specified | 37,102 | $6_{(61-76)}$ | 35/65 | 29.8 | 637 | $1.6[1.5 ; 51.8]$ | $2.5[2.5 .42 .2 .7]$ | $3.0\left[\begin{array}{ll} {[20.823)} \\ \hline 23.2] \end{array}\right.$ |  | $3.7\left[\begin{array}{l} {[3.4 ; 4,42,3]} \\ 3.9] \end{array}\right.$ | $3.9[3.7 .7 ; 4.2]$ | ${ }_{4} 4.2[3.9 .92 .4 .5]$ |  |
|  | Post-traumatic osteoarthritis | 6,702 | $61_{(55-70)}$ | 56/44 | 28.7 | 608 | $2.7\left[\begin{array}{l} {[2.332 ; 3} \\ \hline .3] \\ \hline \end{array}\right.$ | ${ }^{3} 8.8[3.4 .454 .4 .4]$ | $4.6[4.1 .15 .5 .2]$ | $5.2\left[\begin{array}{l} {[4.4,6 ; 8)} \\ \hline(2) .9] \end{array}\right.$ |  | $6.5[5.7 .7 ; 7.3]$ |  |  |
|  | Other diagnosis | 2,479 | $70_{(60-77)}$ | 30/70 | 28.7 | 496 | $4.0\left[\begin{array}{l} {[3.3 ; 4.9]} \\ {[2074} \end{array}\right.$ | $5.1[4.2 ; 6.0]$ | $\left.6.0\left[\begin{array}{ll} {[1.1 .1989} \end{array}\right], 7.1\right]$ | ${ }^{6.6} \begin{gathered} {[5.10664)} \\ {[1.8]} \\ \hline \end{gathered}$ | $6.9 \underset{(5694) \cdot 9.1]}{6.9 .1}$ | $\left.7.1 \begin{array}{c} {[6.0 ; 9.4]} \\ (39) \end{array}\right]$ | $7.6\left[\begin{array}{c} \left(6,2 ; i_{i} 9.3\right] \\ 9.3] \end{array}\right.$ |  |
| Prior operations | No relevant prior operations | 325,012 | $70{ }_{(63-77)}$ | $34 / 66$ | 30.1 | 721 | $1.7[1.6 ; 1.7]$ | $2.5[21.4 ; 2.5]$ |  |  |  | $3.7\left[\begin{array}{l} {[3.655944} \\ \hline 1.8] \end{array}\right.$ | $4.0[(3.9 ; 9 ; 941.1]$ | $4.2[4.17 .4 .3]$ |
|  | Other prior operations | 14,289 | $6_{(59}{ }^{(74)}$ | 40/60 | 30.0 | 549 | $2.0 .0(1.8 ; 2 ; 2.2]$ | $3.0\left[\begin{array}{ll} {[10.7686} \\ {[1.3]} \end{array}\right.$ | $3.6\left[\begin{array}{ll} {[3,3555} \\ \hline, 3.9] \end{array}\right.$ | $4.0[3.7 .7 .4 .4]$ | $4.2\left[\begin{array}{l} {[4.9993)} \\ \hline 4.6] \end{array}\right.$ | $4.5\left[\begin{array}{l} {[3.1,122)} \\ \hline 1.9] \end{array}\right.$ | $4.6[4.2 \cdot 2 ; 5.0]$ | $5.2[4.6 ; 6.0]$ |
|  | Osteosynthesis / Osteotomy | 6,163 | $64_{\text {(57-73) }}$ | 47/53 | 29.5 | 572 | $2.3\left[\begin{array}{l} {[2.0127]} \\ 2.8] \\ \hline \end{array}\right.$ | $3.4\left[\begin{array}{l} {[3,0.554} \\ 3.9] \end{array}\right.$ | $4.2\left[\begin{array}{l} {[3.720,4.8]} \\ (3.20 \end{array}\right.$ | $4.7\left[\begin{array}{l} 4.2 .25050 \\ 2.4] \end{array}\right.$ | $5.2[4.6 ; 5.9]$ | $5.3\left[\begin{array}{c} {[4,759} \\ (959 \\ \hline 6.1] \\ \hline \end{array}\right.$ | 5.3 [4.79\%9 6.1$]$ |  |
|  | Capsule/ligaments | 5,990 | $6_{(55-70)}$ | 52/48 | 29.4 | 516 | $1.7\left[\begin{array}{c} (1.4 ; 44 ; 2.1] \end{array}\right.$ | $2.8\left[\begin{array}{l} (2.46474) \\ \hline \end{array}\right.$ | $3.4\left[\begin{array}{l} {[2.915)} \\ \hline(4.0] \end{array}\right.$ | $4.1\left[\begin{array}{l} (3.515 ; 4.7] \end{array}\right.$ | $4.77_{\left.\left[\begin{array}{l} {[4.1399} \end{array}\right]: 5.5\right]}$ | $5.2[4.4 ; 6 ; 6.1]$ | $5.2[4.4 ; 6.1]$ | $5.2\left[4.44 i_{i} 6.1\right]$ |
| Constrained TKAs |  | 17,600 | $75_{(66-80)}$ | $24 / 76$ | 28.8 | 663 |  |  | $5.8[5.4 ; 4 ; 2.2]$ | $6.1\left[\begin{array}{l} {[5.7 .7626 .5]} \\ \hline 6.022 \end{array}\right]$ |  |  | ${ }^{6.8} 8$ [6.35; 18.3$]$ |  |
| Primary diagnosis | Primary osteoarthritis | 12,524 | $75{ }_{\text {(67-81) }}$ | 22/78 | 29.4 | 626 | $3.5\left[\begin{array}{l} {[3.1 ; 93.8]} \\ \{9,98) \\ \hline \end{array}\right.$ | $4.4\left[\begin{array}{l} {[4.0565} \\ \hline 4.8] \\ \hline \end{array}\right.$ | $4.9[4.5 .55 .4]$ | $5.2 \underset{(4.580)}{[4.8]}$ |  | $5.7[(5.575) 6.2]$ | $5.7\left[\begin{array}{l} (5.2 ; 9 ; \\ (6.2] \\ \hline \end{array}\right.$ | $6.9{ }_{(5.755)}^{(1,7.2]}$ |
|  | Secondary osteoarthritis or not otherwise specified | 2,441 | $73_{(65-80)}$ | 25/75 | 28.4 | 413 |  | $\left.5.2\left[\begin{array}{ll} {[4.54,42 ;} \end{array}\right) \cdot 2\right]$ | $5.9\left[\begin{array}{l} {[5.0909} \\ 7.190 \end{array}\right]$ | 6.3 (5.3; 7 (17) 7.5 ] | 6.6 [5.5.7.7.9] | $6.6\left[\begin{array}{l}{[5.5 ;)} \\ (26)^{\prime} \\ 7.9]\end{array}\right.$ |  |  |
|  | Other diagnosis | 1,436 | $76_{(66-82)}$ | $24 / 76$ | 26.4 | 393 |  | $10.8[9.2 .2 ; 12.8]$ | $12.2[10.4 ; 14.3]$ | 13.1 [11.2; 15.5 (33) | $13.7[11.6 ; 16.1]$ | $13.7[11.6 ; 16.1]$ |  |  |
|  | Post-traumatic osteoarthritis | 1,199 | $6_{(58-76)}$ | 41/59 | 28.0 | 383 | $4.7 \begin{gathered} {[3.7 ; 2 ; 6.1]} \\ (982) \end{gathered}$ | $6.4\left[\begin{array}{l} {[571 ; 1 ;} \\ (7.0] \end{array}\right.$ | $6.9[5.5 ; 8.7]$ | $7.1\left[\begin{array}{c} {[5.720} \\ 4.8 .9] \end{array}\right.$ | $8.4 \text { [6.6; } 10.5]$ | $9.2[7.2 ; 71.7]$ | $9.2[7.2 ; 71.7]$ |  |
| Prior operations | No relevant prior operations | 15,665 | $75{ }_{\text {(67-81) }}$ | 22/78 | 29.0 | 652 | $3.8 \underset{\substack{\text { (312.2;4) } \\(1.1]}}{ }$ | $4.8\left[\begin{array}{c} (4.5572) \\ (9.82] \end{array}\right.$ |  | $5.7[5.3 ; 3 ; 6.2]$ | $6.0\left[\begin{array}{c} {[3.6 ; 6 ; 3)} \\ \hline(3) 5] \end{array}\right.$ |  | $6.3[5.9 ; 6.9]$ | $7.4(6.3 .3 ; 8.6]$ |
|  | Osteosynthesis / Osteotomy | 959 | $69_{(60-77)}$ | $34 / 66$ | 27.9 | 346 | $5.9[4.5 ; 7.6]$ | $8.5[6.8 .8 ; 10.6]$ | $8.7\left[\begin{array}{l} {[7.0 ; 0 ; 0} \\ \text { i46) } \\ 10.9] \\ \hline \end{array}\right.$ | $9.2[7.4,41.5]$ | $9.6[7.6 ; 12.0]$ | $10.7 \text { [8.4.4. } 13.7]$ | $10.7\left[8\left[5 ; f_{(5)} 13.7\right]\right.$ |  |
|  | Other prior operations | 655 | $71_{\text {(61-78) }}$ | 35/65 | 28.7 | 234 | $4.6\left[3.2 ;{ }_{[526)} 6.6\right]$ | $7.2\left[\begin{array}{c} {[54 ; 4 ; 9.7]} \\ (4 i) \end{array}\right.$ | $8.0\left[\begin{array}{l} {[6.0 ; 0 ; 12} \\ (3,2) \\ 10.6] \end{array}\right.$ | $8.6[6.5 ; 11.3]$ | $9.7[7.3 ; 12.7]$ | $9.7[7.3 ; 12.7]$ |  |  |
|  | Capsule/ligaments | 304 | $65_{(57-75)}$ | 42/58 | 28.9 | 162 |  | $6.1\left[\begin{array}{c} (382) \\ (189) \\ 9.7] \end{array}\right.$ | $6.7[4.2 ; 120.4]$ | $8.2[5.2 ; 12.7]$ |  |  |  |  |
| Unicondylar knee arthroplasties |  | 51,875 | $63_{(57-72)}$ | 44/56 | 29.5 | 645 | $2.9\left[\begin{array}{l} {[2.8950,3.1]} \\ \hline \end{array}\right.$ | $4.7[4.5 ; 4.9]$ | $5.7[5.5 ; 6.0]$ | $6.6[6.4 ; 4,6.9]$ | $7.2\left[\begin{array}{c} {[16.9 .97 .5]} \\ (1,199] \end{array}\right.$ | $7.9[7.6 ; 6.2]$ | 8.4 [8.0; 8.8 .8$]$ | 8.8 [8.3; $\left.{ }_{\text {[774) }} 9.3\right]$ |
| Primary diagnosis | Primary osteoarthritis | 44,058 | $64_{(57-72)}$ | 44/56 | 29.7 | 628 | $2.9\left[\begin{array}{l} [2.85 ; 73) \cdot 1] \\ \hline \end{array}\right.$ | $4.7\left[\begin{array}{l} {[4.5 .7555} \\ \hline 1.9] \end{array}\right.$ | $5.7\left[\begin{array}{l} {[12,52465} \\ \hline 15.9] \end{array}\right.$ | $6.6\left[\begin{array}{c} (6.5 .81 ; 9) \\ \hline 6.9] \end{array}\right.$ | $7.1 \begin{gathered} {[6.09 ; 7.4]} \\ (1010 \end{gathered}$ | $7.9[7.5 \cdot 8 \cdot 8.2]$ | $8.4\left[\begin{array}{c} {[8.0 .0,8.8]} \\ (2.03) \end{array}\right.$ | $8.8[8.2 ; 9.3]$ |
|  | Secondary osteoarthritis or not otherwise specified | 6,830 | $62_{(56-70)}$ | 46/54 | 29.3 | 429 | $2.8\left[\begin{array}{l} {[2.4,4 ; 3]} \\ {[53]} \end{array}\right.$ | $4.6[4.1 .19 .5 .2]$ | $5.9\left[\begin{array}{c} (5.3,355) 6.6] \\ \hline \end{array}\right.$ | $6.6\left[\begin{array}{l} [5,993) 7.4] \\ \hline(23) \end{array}\right.$ | $7.4\left[\begin{array}{l} {[6.6 ; 8 ; 8.2]} \end{array}\right.$ | $8.3 \text { [7.3: } 3 \text {, 9.3] }$ |  | $9.0[7.7 .7,10.5]$ |
|  | Other diagnosis | 778 | $66_{(58-75)}$ | 44/56 | 29.0 | 216 |  | $6.0[4.5 ; 8 ; 8.0]$ | $6.7 \begin{gathered} {[5.138]} \\ (138) \\ 8.9] \end{gathered}$ | $8.0\left[\begin{array}{l} \text { [6.17; } 1 ; 10 \\ (3) \\ 10.5] \end{array}\right.$ |  | $8.5\left[\begin{array}{l} {[6.5 ;} \\ (110) \\ \text { (10) } \\ 11.3] \end{array}\right.$ |  |  |
| Prior operations | No relevant prior operations | 48,253 | $64_{(57-72)}$ | 44/56 | 29.6 | 641 | $2.9\left[\begin{array}{l} {[2.8,834]} \\ 3.1] \end{array}\right.$ | $4.7\left[\begin{array}{l} (3.51 .544) \\ \hline 4.9] \end{array}\right.$ | $5.7\left[\begin{array}{l} {[54,4 ; 42)} \\ \hline 5.9] \end{array}\right.$ | $6.5\left[\begin{array}{ll} {[17.3551)} \\ 6.8] \\ \hline \end{array}\right.$ | $7.1 \begin{aligned} & {[16.8 ; 7.7 .4]} \\ & (10,725) \end{aligned}$ | $7.8\left[\begin{array}{l} {[7.5950} \\ {[50.2]} \\ \hline \end{array}\right.$ | $8.3\left[\begin{array}{c} {[7,9 ; 90} \\ (2,90 \end{array}\right)$ |  |
|  | Other prior operations | 2,532 | $61_{(55-68)}$ | 46/54 | 29.4 | 297 |  | $5.3[4.4 ; 6.3]$ | $6.6[5.6,67.8]$ | $7.7 \text { [6.6; 9.0] }$ | $8.1 \text { [6.9.99.5] }$ | $8.5[7.2 ; 2 ; 9.9]$ | $9.1[7.6 \cdot 6 \cdot 10.9]$ |  |
|  | Capsule/ligaments | 727 | $5_{(53-66)}$ | 52/48 | 28.7 | 157 | $\underset{[1537]}{2.3]}$ | $6.1[4.3 ; 8.5]$ | $7.5\left[\begin{array}{l} {[5.4 ;} \\ \text { Bai) } \end{array} 10.2\right]$ | $8.2\left[\begin{array}{l} {[6.0 ;} \\ i 214) \\ \mid 1.2] \end{array}\right.$ | $9.2[6.7 ; 12.5]$ | $9.8[7.2 ; 13.4]$ |  |  |
|  | Osteosynthesis / Osteotomy | 355 | $58_{(52-65)}$ | 57/43 | 29.0 | 151 | 2.9 [1.68 $\left.{ }_{\text {(28) }} 5.4\right]$ | $5.1\left[\begin{array}{c} {[3.1 ; 3.8 .2]} \\ (230 \end{array}\right)$ | $6.9[4.5 ; 10.6]$ | $8.5[5.7 .7 .12 .7]$ | $10.1\left[\begin{array}{l} {[6.7 \%} \\ {[8 ;)} \\ 14.9] \end{array}\right.$ | $11.0[7.4 ; 16.3]$ |  |  |
| Patellofemoral arthroplasties |  | 849 | $54_{(48-61)}$ | 27/73 | 28.4 | 200 | $4.6{ }^{[3.373}(6.6 .4]$ | $7.6\left[\begin{array}{c} (52.8 ;) \\ \hline 9.8] \end{array}\right.$ | $9.7[7.6 ; 12.2]$ | $12.8[10.3 ; 15.9]$ | $15.2[12.2 ; 18.9]$ | $\begin{gathered} 15.8[12.6 ; 19.6] \\ \substack{89} \\ \hline 8.0 \end{gathered}$ |  |  |
| Primary diagnosis | Primary osteoarthritis | 432 | $56_{(49-62)}$ | 29/71 | 28.7 | 144 | $3.4 \underset{(3,08)}{[2 ; 8]} 5$ | $5.9\left[\begin{array}{l} 3.966 \\ {[260} \end{array} 8.9\right]$ | $8.6\left[\begin{array}{ll} {[6.0 ; 1} \\ (18) \end{array} 12.4\right]$ | $9.8\left[\begin{array}{l} 6.8 ; \\ (124) \\ \hline 13.9] \end{array}\right.$ | $14.8[10.2 ; 21.2]$ |  |  |  |
| Prior operations | No relevant prior operations | 685 | $56_{(49-62)}$ | 27/73 | 28.8 | 182 | $4.4\left[\begin{array}{l}\text { [3.0; }\end{array} 66.3\right]$ |  |  | $12.5{ }_{\text {[9.7.76 }}(16.0]$ | $14.5[11.3 ; 18.5]$ | $\begin{gathered} 15.3[11.8 ; 19.6] \\ (66) \\ \hline \end{gathered}$ |  |  |

Table 44: Revision probabilities for different types of knee arthroplasties and diagnoses

### 5.2 Non-implant-related factors

Individual characteristics of the patients and the hospitals performing the procedure may also impact the risk of revision surgery. Patient sex is indeed a significant established risk factor in the early post-operative phase: For most types of knee arthroplasties, men are more likely to suffer from higher revision probabilities than women (see example Figure 20). This is largely due to the higher
risk of infection in men and is also evident in other registries.

Another significant factor is patient age, although this appears to impact hip and knee arthroplasties differently. For knee arthroplasties, the probability of revision surgery decreases with increasing patient age (see example Figure 21). In the case of hip replacements, this tendency is masked by the fact that older patients with uncemented femoral components have a significantly


Figure 20: Revision probabilities of standard total knee arthroplasties by patient sex ( $p<0.0001$ )


Figure 21: Revision probabilities of standard total knee arthroplasties by age group ( $p<0.0001$ )
higher revision probability (Figure 22). As weight or overweight. According to the clasthe risk of periprosthetic fractures in par- sification of the World Health Organisation ticular greatly increases in older patients (WHO), people with a BMI of 30 or more with uncemented femoral components, the are considered obese (Figure 23).
EPRD recommends the use of cemented stems for this group of patients.[2] Patient The observed revision probabilities are also body weight also affects the probability of associated with patient health status. In orrevision. The body mass index is a measure der to measure this, the EPRD analysed the of whether a person is underweight, normal clinical conditions listed in the Elixhauser


Figure 22: Revision probabilities of elective total hip arthroplasties with uncemented stems by age group ( $p<0.0001$ )


Figure 23: Revision probabilities of elective total hip arthroplasties with uncemented stems by patient body mass index ( $<0.0001$ ). As patient height and weight have only been documented in the EPRD since 2017, the figure only includes the first five years after primary surgery

Comorbidity Index. This comorbidity index the number of comorbidities present for each was designed as a predictor for the proba- patient at the time of the primary arthroplasbility of short-term patient mortality and ty.[3] Although patients tend to have more includes a number of concomitant physical comorbidities with increasing age and older and mental conditions, such as diabetes, age tends to reduce the risk for many arthrodepression, high blood pressure, and heart plasties (Figure 21), the revision probability failure. Using the billing data provided by health insurance providers, the EPRD can check the ICD codes associated with diseases represented in the index and thus determine for patients with many diagnosed comorbidities increases markedly (Figure 24). These differences already become apparent in the first few weeks after arthroplasty.


Fiqure 24: Revision probabilities of standard total knee arthroplasties by concomitant disease diagnoses included in the Elixhauser Comorbidity Score ( $p<0.0001$ )


Figure 25: Revision probabilities of elective total hip arthroplasties with uncemented stems by the hospital's annual volume of primary elective hip arthroplasties ( $p<0.0001$ )

The hospitals performing the surgery, and often ${ }^{4}$ - at least for elective arthroplasties in particular their experience with the corre- (Figures $\underline{25}$ to $\underline{27}$ ). This is especially true for sponding arthroplasty procedures, may also unicondylar arthroplasties. considerably impact outcome. The EPRD
tends to find lower revision probabilities However, the correlation between hospitals' for hospitals that, according to their qual- annual case volume and arthroplasty outity reports, perform such procedures more comes only reflects a general trend. The EPRD


Figure 26: Revision probabilities of standard total knee arthroplasties by the hospital's annual volume of primary total knee arthroplasties not including unicondylar arthroplasties ( $p<0.0001$ )


Figure 27: Revision probabilities of unicondylar knee arthroplasties by the hospital's annual volume of primary unicondylar knee arthroplasties ( $p<0.0001$ )
includes exceptions in both directions: There are hospitals that achieve good results despite low case numbers and hospitals with high case numbers that achieve poorer outcomes. Figure 28 is based on the presentations provided by the EPRD to participating hospitals twice a year as part of the individual analyses (also refer to Page 16). These analyses detail how their arthroplasty performance compares to other hospitals in the EPRD. Each dot in the graph represents the outcome of one hospital. Unlike in the hospital analyses of the EPRD, however, the colour of the dots in Figure 28 corresponds to the annual number of specific arthroplasties performed.

The extensive or limited experience of surgeons can affect both the hospital outcomes and the outcomes of individual implants. Even though the EPRD cannot incorporate surgeon experience into the surveys and analyses of this annual report, it is an important factor. It may explain why there are hospitals in the EPRD with significantly poorer outcomes despite higher patient volumes and hospitals with good outcomes despite low case loads. In this context, the revision probability for a particular arthroplasty (see Section 5.4) is the result of what the surgeons were able to achieve with the implant. Starting in 2025, the EPRD will offer a voluntary option for documenting the surgeons in volved in the procedures. Surgeons will then be confidentially provided with the personal outcomes of the procedures they performed.

Table 45 presents the impact of non-im plant-related factors for different types of arthroplasties in a table.

## In brief:

Patient-specific parameters such as age, sex, BMI, and comorbidities have a significant impact on the probability of revision surgery
Higher elective arthroplasty volumes per hospital tend to reduce the risk of revision arthroplasty.

## Funnel plots for inter-hospital comparisons

Funnel plots show the outcomes from different hospitals. In these graphs, each hospital is represented by a dot. The location of each dot in the graph depends on how many of the primary arthroplasties performed by th hospital actually required revision surgery lat er on (observed number of revisions) and how many revisions would have been expected if the risk of revision over time had been the same for all hospitals.

The number of revision arthroplasties of a hospital is expected to increase as the number of its documented arthroplasties, and their follow-up times, increase. The calculation is stratified for the different types of arthroplasties, but does not include any further risk adjustment.

In the graph, the $x$-coordinate of each point corresponds to the number of expected revisions, while the $y$-coordinate represents the ratio of the number of observed revi-


Figure 28: Funnel plot comparing outcomes of elective primary hip arthroplasties with uncemented stems between hospitals


Table 45: Revision probabilities for different types of arthroplasties by non-implant-related factors

|  |  |  |  |  |  |  |  |  |  | Revision prob | bilities after ... |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Type of arthroplasty / category | Type | Number | Age | m/f | вMI | Hosp. | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Body Mass Index | less or equal to 25 | 25,012 | $80_{(76-83)}$ | 20/80 | 23.0 | 657 | $\left.2.0 \begin{array}{c} 11,8 ; 8.2 .2] \\ (1,400 \end{array}\right)$ | $2.3\left[\begin{array}{l} [1,1,3 ; 3) ; 2] \end{array}\right.$ | $2.4 \underset{(8,550}{[2.2 ;} 2.7]$ | $2.6[2.4 .42 .9]$ | $3.0\left[\begin{array}{ll} {[2.7050} \\ 1.3 .3] \end{array}\right.$ |  |  |  |
|  | $\rightarrow 25$ to $\leq 30$ | 26,303 | $80_{(76-83)}$ | 29/71 | 27.3 | 655 | $2.2\left[\begin{array}{l}\text { [1.9.950) } \\ 2\end{array}\right.$ |  | $2.7\left[\begin{array}{l} {[1.5 ; 2 ; 2.9]} \\ (1020) \end{array}\right.$ | $2.8\left[\begin{array}{l} {[2.560)} \\ \hline 0.0] \\ \hline \end{array}\right.$ |  |  |  |  |
|  | $\rightarrow 30$ to $\leq 35$ | 12,167 | $79_{(14-82)}$ | 25/75 | 31.6 | 619 | $\left.2.9\left[\begin{array}{ll} {[2,759} \\ \hline \end{array}\right], 3\right]$ | $3.3\left[\begin{array}{l} {[3.055)} \\ \hline(3.6] \end{array}\right.$ | $3.6[3.3 ; 4 ; 0]$ | $3.7\left[\begin{array}{l} (3.3612) \\ \hline 1.1] \end{array}\right.$ | $3.9[3.5 ; 4.4]$ |  |  |  |
|  | $\rightarrow 35$ to $\leq 40$ | 3,573 | $77_{(71-80}$ | 22/78 | 36.7 | 519 | ${ }_{4} 4.8[4.17 .55 .5]$ | $5.2[4.5 ; 6.0]$ | $5.3[4.6 ; 6.1]$ | $\left.5.7\left[\begin{array}{l}{[1992}\end{array}\right) 6.7\right]$ | $6.3{ }_{[1232}[\mathbf{3} 7.5]$ |  |  |  |
|  | above 40 | 1,307 | $73_{(67-78)}$ | 20/80 | 42.2 | 384 | $6.2\left[\begin{array}{c} {[50 ; 7)} \\ (987) \\ 7.7] \end{array}\right.$ | $\left.6.5\left[\begin{array}{c} {[5.3 ;} \\ 1260 \end{array}\right) 8.0\right]$ | $6.8[5.5: 8.4]$ |  | $7.2 \underset{(53) \cdot 79.1]}{ }$ |  |  |  |
| Comorbidities | no or one comorbidity | 11,761 | $77_{(73-81)}$ | 25/75 | 24.8 | 612 | $1.3[11.1 ; 1.5]$ | $1.5[1, .3 ; 1.8]$ | $1.8 \underset{(1.566)}{[1.5 ; 2]}$ | $2.0[11.7 ; 2.3]$ | $2.3\left[\begin{array}{c} (2.0449) \\ 2.7] \\ \hline \end{array}\right.$ |  | 2.8 [2.4.4.3.3] | $3.3[2.6 ; 4.1]$ |
|  | two to four comorbidities | 50,910 | $79_{(75-82)}$ | $24 / 76$ | 26.2 | 689 | $1.8$ | $2.1 .1\left[\begin{array}{l} {[2,0,533)} \\ \hline 2.2] \end{array}\right.$ | $2.4\left[\begin{array}{l} [22.2 ; 40), 2.5] \end{array}\right.$ |  | $2.7 \begin{aligned} & {[12.6 ; 044]} \\ & {[1.9]} \end{aligned}$ | $3.0\left[\begin{array}{l} {[2,575 \cdot 8)} \\ 3.1] \end{array}\right.$ | $3.1\left[\begin{array}{l} {[2,9261)} \\ {[3.3]} \end{array}\right.$ | $\underset{(94)}{3.4} \mathbf{( 3 . 1 ; 8 ]}$ |
|  | More than 4 comorbidities | 33,000 | $80_{(76-83)}$ | 26/74 | 28.0 | 684 | $3.7\left[\begin{array}{l\|l\|l\|l\|l\|l\|l\|l\|} {[25.9]} \\ \hline \end{array}\right.$ | $4.0[3.8 ; 4.3]$ | $4.3_{(14,752)}^{[4.1 ; 4]}$ | $4.5[4.2 ; 4.7]$ | $4.7\left[\begin{array}{l} {[4.555 \%} \\ 7.050 \\ 5.0] \end{array}\right.$ | $4.8 \underset{(3.928)}{[4,6 ; 5.1]}$ | $5.2\left[\begin{array}{l} {[4.832)} \\ \hline 1.8 ; 5] \end{array}\right.$ | $5.4\left[\begin{array}{c} {[5.0 ; 5 \cdot 5 \cdot 5]} \\ (5.54) \\ \hline \end{array}\right.$ |
| Hospital size* | Hospitals with low annual case volumes | 35,274 | $79_{(75-83)}$ | 26/74 | 26.7 | 480 | $2.9\left[\begin{array}{l} {[28,7414)} \\ \hline 3.1] \end{array}\right.$ | $\left.3.2{ }^{[3.30 .027)} 3.4\right]$ | $3.5\left[\begin{array}{l} {[1,3,337)} \\ \hline 3.8] \end{array}\right.$ |  | $4.1{ }_{\text {[8. } 8.925]}^{[3.3]}$ | $4.2[4.0004 .50$ |  | $5.0[4.4355 .5 .6]$ |
|  | Hospitals with average annual case volumes | 30,845 | $7{ }_{(75-82)}$ | 25/75 | 26.7 | 145 |  | $2.5\left[\begin{array}{l} {[2.3 ; 001)} \\ 2.7] \\ \hline \end{array}\right.$ | $2.72 .7 .5: 5.5 .9]$ | $2.9\left[\begin{array}{ll} {[1.72 ; 3)} \\ \hline, 3.1] \end{array}\right.$ | $\left.3.0\left[\begin{array}{ll} {[2,899} \end{array}\right] 3.3\right]$ | $\left.3.3\left[\begin{array}{l} {[3,0,0 ; 3)} \\ 3 \end{array}\right) .5\right]$ |  | $3.7\left[\begin{array}{l} (3,38) \\ \hline 3.1] \\ 4.1] \end{array}\right.$ |
|  | Hospitals with high annual case volumes | 28,430 | $7{ }_{(75-82)}$ | 23/77 | 26.2 | 54 | $2.0{ }^{[1.8 .8 .85)}$ 2.1] | $2.2\left[\begin{array}{l} {[1.1,781]} \\ 2.4] \end{array}\right.$ | $2.5\left[\begin{array}{c}\text { [2, 3; } \\ (1,46) \\ 7.75]\end{array}\right.$ |  | $2.8 \text { [2.6.6;96) 3.1] }$ | ${ }^{3.0}{ }_{\text {[3,776] }}^{[2.8 .3 .3]}$ | $3.3 \text { [3.0.000)} 3.7]$ | $\left.{ }_{3}^{3.6[3.17 ; ~} 4.0\right]$ |
| Non-elective THAs |  | 29,083 | $76_{(68-82)}$ | 30/70 | 24.7 | 677 | $6.1[5.8 ; 6.3]$ | $6.6\left[\begin{array}{c} (64.3 ; 29) \\ \hline 6.9] \end{array}\right.$ | $7.0\left[\begin{array}{l} {[6.7 .7 .7 .3]} \\ (10.041) \end{array}\right.$ | $7.4\left[\begin{array}{c} {[7.0000} \\ (x .00) \\ 7.7] \\ \hline \end{array}\right.$ | $7.6\left[\begin{array}{c} {[7.3: 3.0]} \\ 4.38] \end{array}\right.$ | $7.9[7.5 ; 8.3]$ | $8.4\left[\begin{array}{l} {[7.975} \\ (775) \\ 9.0] \\ \hline \end{array}\right.$ | $8.8[7.9 .9 .8]$ |
| Age group | $\leq 54$ years | 852 | $51_{(48-53)}$ | 53/47 | 24.2 | 403 | $7.8[6.2 \cdot 2 ; 9.9]$ |  |  | $9.1[7.2$ [29) 11.5$]$ | $9.5[7.5 ; 12.0]$ | $9.5[7.5 ; 12.0]$ |  |  |
|  | 55-64 years | 3,790 | ${ }^{61} 1_{(58-63)}$ | 40/60 | 24.2 | 573 | $7.2 \underset{(2.641)}{[6.4 ; 8.1]}$ | $7.9\left[\begin{array}{c} {[7.1 .186 .8 .9]} \\ 10.96 \end{array}\right.$ | $8.5\left[\begin{array}{ll} {[7.68 i} \\ 4,9.5] \end{array}\right)$ | $8.9[7.9 ; 9.9]$ | $9.3\left[8.3 ;{ }_{[58)} 10.5\right]$ | $9.6[8.5 ; 10.9]$ | $10.3 \text { [8.6; 12.3] }$ |  |
|  | 65-74 years | 8,046 | $70_{(67-72)}$ | 31/69 | 24.9 | 623 | $5.6[5.1,7 ; 6.1]$ | $6.2\left[\begin{array}{c} {[5.73 ; 6.86]} \\ 46.8] \end{array}\right.$ | $6.7[6.19 .7 .7 .3]$ | $7.0$ |  | $\left.7.2\left[\begin{array}{c} \text { [1.655 } \\ (135 \end{array}\right] .9\right]$ | $7.6 \underset{\substack{[685 \\[68 ;}}{ } 8.5]$ | $8.7\left[6.77\left[_{[5]} 11.3\right]\right.$ |
|  | 75-84 years | 11,801 | $79_{(77-82)}$ | 26/74 | 24.7 | 622 | $6.0\left[\begin{array}{l} {[5,355)} \\ \hline 6 ; 5] \end{array}\right.$ | ${ }^{6.5}{ }_{[6.6212]}^{[6.0]}$ | $6.8\left[\begin{array}{l} {[6.455} \\ \hline 4.4 .3] \\ 7 \end{array}\right.$ |  | $7.4 \text { [16.9.988.0] } 8.0]$ | $7.9\left[\begin{array}{c} \text { (79;3; } \\ (99) \\ \hline 8.7] \\ \hline \end{array}\right.$ | ${ }^{8.5}$ [7.6;99.5] | $8.5[7.6 ; 9.5]$ |
|  | 85 years and older | 4,594 | $88{ }_{(86-90)}$ | 26/74 | 24.2 | 502 | $5.7\left[\begin{array}{l} {[5.0,0 ; 6.5]} \\ (2,6) \end{array}\right.$ | $6.2\left[\begin{array}{l} {[5.500} \\ 4.50] \\ 7 \end{array}\right.$ | $6.6\left[\begin{array}{l} {[5.1 .813]} \\ 7.4] \end{array}\right.$ | $6.9 \underset{(6,09)}{(6,0 ;} 7.8]$ | $7.0 \begin{gathered} {[6.1 ; 1 ; .0]} \\ (340) \\ 3.0] \end{gathered}$ | $\begin{gathered} 7.0[6.1 ; 8.0] \\ \|(4,4)\| \\ \hline \end{gathered}$ |  |  |
| Sex | Male | 8,748 | $74_{(66-81)}$ | 100/0 | 25.1 | 618 | $7.4\left[\begin{array}{l} {[6.9942 ; 0]} \\ \hline 8.0] \end{array}\right.$ | $8.2[7.6 ; 8.8]$ | $8.8\left[\begin{array}{l} \left.[8.17)^{2} 9.4\right] \\ \hline(4) \end{array}\right.$ | $9.2[8.5 \cdot 9.9]$ | $9.5[8.7 .7: 10.2]$ | $9.6[8.8 ; 10.5]$ | $10.5 \underset{(1996)}{ } 19 ; 11.8]$ |  |
|  | Female | 20,335 | $77_{(00-82)}$ | 0/100 | 24.3 | 664 |  | $6.0[5.7 ; 6.3]$ | $6.3\left[\begin{array}{c} {[5.9 .963 .7]} \\ {[7.83)} \end{array}\right.$ | $6.6[6.3 .3 ; 7.0]$ | $6.9\left[\begin{array}{l} {[6.523 ; 7)} \\ \hline(3.3] \end{array}\right.$ | $7.2\left[\begin{array}{c} {[6.77 ; 7.7]} \\ (x .108) \end{array}\right.$ | $7.6[7.0 ; 8.2]$ | 7.6 [7.0; (i1) $^{\text {8 }}$ ) 2$]$ |
| Body Mass Index | less or equal to 25 | 11,841 | $76_{(68-82)}$ | 27/73 | 22.5 | 618 | $5.4\left[\begin{array}{l} {[5.5033} \\ {[, 5.9]} \\ 5.9 \end{array}\right.$ | $5.9[5.5 .5 ; 6.4]$ | $6.2(5.8,8 ; 6.7]$ | $6.8\left[\begin{array}{l} {[6.3 ; 33]} \\ (1.53] \end{array}\right]$ |  |  |  |  |
|  | $>25$ to $\leq 30$ | 7,330 | ${ }^{77}{ }_{(69-82)}$ | 35/65 | 26.9 | 592 |  | $6.8[6.2 .27 .7 .5]$ | $7.2\left[\begin{array}{l} {[6.5 \cdot 57.8]} \\ (2, i b) \end{array}\right.$ | $7.3 \text { [6.7.7: } 8.1]$ | $7.6 \underset{(633)}{[6.9 ;} 8.5]$ |  |  |  |
|  | $>30$ to $\leq 35$ | 2,064 | $75_{(68-81)}$ | 31/69 | 31.6 | 472 | $7.8 \text { [6.7.799.0]}$ |  | $8.9\left[\begin{array}{c} {[7,7,10,10.3]} \\ \hline 61) \end{array}\right.$ | $9.1\left[\begin{array}{c} {[7.8 ;} \\ {[30\rangle} \end{array} 10.6\right]$ | $9.1[7.8 ; 10.6]$ |  |  |  |
|  | $>35$ to $\leq 40$ | 414 | $73_{(65-79)}$ | 27/73 | 36.5 | 234 | $10.4 \underset{\substack{[7.799 \\(269}}{ } 13.8]$ | $10.4 \underset{\substack{[7.79 ; 1 \\(120}}{ } 13.8]$ | $10.4\left[\begin{array}{l} (727) 7 ; 13.8] \\ (12) \end{array}\right.$ | $10.4\left[\begin{array}{l} {[7.7 \%} \\ (i 6) \\ \hline 13.8] \end{array}\right.$ |  |  |  |  |
| Comorbidities | no or one comorbidity | 3,935 | $71_{(64-78)}$ | 31/69 | 23.9 | 566 | $\underset{\substack{[3,989}}{3.6 .3]}$ | $4.2\left[\begin{array}{l} {[3.602024} \\ {[2.9]} \end{array}\right.$ | $4.5\left[\begin{array}{l} {[3.9860} \\ 1.950 \\ \hline \end{array}\right.$ | $4.8\left[\begin{array}{l} {[4.196)} \\ (a, 5) \\ \hline \end{array}\right.$ | $5.0[4.2 ; 2 ; 5.8]$ | $5.0[4.2 ; 55) 5.8]$ | $5.3[4,4 ; 4,6.3]$ |  |
|  | two to four comorbidities | 13,128 | $75_{(67-81)}$ | 28/72 | 24.5 | 650 | $5.1\left[\begin{array}{c} {[4,8,899} \\ 9.505] \\ 5.5] \end{array}\right.$ | $5.6\left[\begin{array}{l} {[5,2 ; 20} \\ (0,20 \\ \hline \end{array}\right.$ | $5.9\left[\begin{array}{l} {[5.533)} \\ {[5.4]} \\ 6.4] \end{array}\right.$ | $6.3\left[\begin{array}{c} {[5.9 ; 50)} \\ (3,8) \\ 6.8] \end{array}\right.$ | $6.5\left[\begin{array}{l} {[6,0,0 ; 3)} \\ (20.0] \end{array}\right.$ | $6.9\left[\begin{array}{c} {[6.313]} \\ (13) \\ 7 \end{array}\right.$ |  |  |
|  | More than 4 comorbidities | 12,020 | $78{ }_{(71-84)}$ | 32/68 | 25.2 | 626 | $7.9[7.5 ; 5.5]$ | $8.6[8.1 .1 ; 9.2]$ | $9.1 \underset{(8.722)}{[8.6 ; 9.7]}$ | $9.5\left[\begin{array}{l} (8.9 ; 1) 10.2] \\ (2,351) \end{array}\right.$ | $9.9[9.2 ; 10.6]$ | $10.1\left[\begin{array}{l} \text { 9.4.4; } \\ (6,7) \\ \hline \end{array} 0.8\right]$ | $10.6\left[\begin{array}{c} 9.6 ; 5 \\ (125) \end{array} 11.6\right]$ |  |
| Hospital size* | Hospitals with low annual case volumes | 6,237 | $76_{(68-82)}$ | 29/71 | 24.7 | 267 | $5.9[5.4 ; 6.6]$ |  |  | $7.2 \begin{aligned} & \text { [6.5.5; 7.9] } \\ & (1.07 \end{aligned}$ |  | $7.8 \underset{\substack{(4900}}{7.0 ;} 8.7]$ | $8.5\left[\begin{array}{c} \text { (7176) } \\ \text { (17) } \\ 9.9] \\ \hline \end{array}\right.$ |  |
|  | Hospitals with average annual case volumes | 13,847 | $76_{(68-82)}$ | 31/69 | 24.7 | 294 | $\underset{(9,372)}{6.3} \mathbf{~ ( 5 . 9 ]}$ | $\left.{ }^{6.9} 9.9 .6 .4 ; 7.3\right]$ | $7.3\left[\begin{array}{l} {[6.820} \\ \hline 4.8] \\ \hline \end{array}\right.$ | ${ }_{\substack{(3.249}}^{7.7} \mathbf{[ 7 . 2 ; 8 ]}$ | $8.0 \begin{aligned} & 8.0 .5 ; 8.5] \\ & (1,292) \end{aligned}$ | $8.2\left[\begin{array}{c}(7.78)^{2} 8 \\ 8.9] \\ \hline\end{array}\right.$ | $9.0[8.1 ; 1 ; 10.0]$ | $9.0\left[8.1 ;{ }_{[56} 10.0\right]$ |

Table 45 (continued)

|  |  |  |  |  |  |  | Revision probabilities after ... |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Type of arthroplasty / category | Type | Number | Age | m/f | BMI | Hosp. | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Hospital size | Hospitals with high annual case volumes | 8,704 | $76_{(69-82)}$ | 30/70 | 24.5 | 92 | $5.7 \begin{aligned} & {[5.2 ; 2 ; 31]} \\ & {[6.2]} \\ & \hline \end{aligned}$ | $6.3(5.58 ; 6.9]$ | $6.6\left[\begin{array}{c} (6.118) \\ \hline 18.2] \end{array}\right.$ | $7.0$ | $7.1 \begin{aligned} & {[6.5597 .8]} \\ & {[(0.29)} \end{aligned}$ | $7.4 \begin{gathered} {[6.7780 .8]} \\ {[630} \\ \hline \end{gathered}$ | $7.4\left[\begin{array}{c} \text { [6.726 } \\ 126.1] \end{array}\right.$ |  |
| Hip hemiarthroplasties |  | 59,874 | $84_{\text {(80-89) }}$ | $29 / 71$ | 24.2 | 596 |  |  |  |  | $5.1[4.9 .95 .5 .3]$ | 5.4 [5.1.775) 5.7$]$ | $5.4{ }_{(5515)}^{[5.15} 5$ |  |
| Age group | 55-64 years | 1,109 | ${ }^{61}{ }_{(59 .-63)}$ | $49 / 51$ | 24.2 | 333 | $6.7\left[\begin{array}{l} {[5999)} \\ 59.3 \\ 8.5] \end{array}\right.$ | $6.9\left[\begin{array}{c} 5.4,4,8.7] \\ (106) \end{array}\right.$ | $7.5\left[\begin{array}{c} {[5.9 ; 3,9.5]} \\ {[263} \end{array}\right.$ | $7.9\left[\begin{array}{l} {[6.1710)} \\ (170) \end{array} 10.1\right]$ | $7.9[66.1 .10 .10 .1]$ | $7.9\left[6.17{ }_{(55)} 10.1\right]$ |  |  |
|  | 65-74 years | 4,550 | 71 (69-73) | 42/58 | 24.6 | 495 | 5.3 [4.7.765. 6.0$]$ | $5.9[5.2 ; 8 ; 6.7]$ | $6.2\left[\begin{array}{l} {[1.5007} \\ 7.51] \end{array}\right.$ | $6.5\left[\begin{array}{c} \left.\left.[5,79)^{(i 59}\right) 7.4\right] \end{array}\right.$ | $6.5\left[\begin{array}{l} (5.755 \\ \hline 4.7 .4] \\ \hline \end{array}\right.$ | $7.0\left[\begin{array}{l} {[6.0 ; 3} \\ {[23 i} \\ \hline \end{array} 8.2\right]$ |  |  |
|  | 75-84 years | 24,512 | $81_{(79.83)}$ | 30/70 | 24.6 | 573 | $4.8\left[\begin{array}{ll} {[1.55 \cdot 5 \cdot 5 \cdot 5)} \\ \hline 1.0] \end{array}\right.$ | $5.0[4.7 .7 .5 .3]$ | $5.2 \underset{(6.499)}{[4.9 ; 5]}$ | $5.4\left[\begin{array}{c} (3,0,0 ; 7) \\ 5.7] \end{array}\right.$ | $5.5\left[\begin{array}{l} {[5.1 .1 ; 3.8]} \\ (2.03) \end{array}\right.$ | $5.8\left[\begin{array}{c} 993)^{9.3 ;} \\ \hline 6.3] \\ \hline \end{array}\right.$ | $5.8[5[5.3 ; 6.3]$ |  |
|  | 85 years and older | 29,448 | $89^{(87-92)}$ | 25/75 | 24.0 | 565 | $4.1\left[\begin{array}{l} (1.8,8 ; 3 ;) .3] \end{array}\right.$ | $4.2\left[\begin{array}{l} {[3,955)} \\ \hline 9.4] \end{array}\right.$ | $4.3[4.0 .0 ; 4.5]$ | $4.3[4.1 .94 .6]$ | $4.4\left[\begin{array}{c} {[4.1 .515)} \\ (0.6] \end{array}\right.$ | $4.4[4.1 .1 ; 4.6]$ | $4.4[4.1 .1 ; 5.6]$ |  |
| Sex | Male | 17,145 | $83^{(78-88)}$ | 100/0 | 24.7 | 563 | $4.9\left[\begin{array}{ll} {[4.6 ; 979} \\ 5.3] \end{array}\right.$ | $5.3\left[\begin{array}{c} {[4.9 .909} \\ 4.7 .7] \\ \hline \end{array}\right.$ | $5.6 \underset{(2.846)}{[5.2 ; 6.0]}$ | $5.8 \underset{(1.521)}{[5.4 ; 6]}$ | $5.9[5.4 ; 4 ; 6.4]$ | $6.2 \underset{(5.63)}{(53)} 6.8]$ | $6.2[5.6 ; 6.8]$ |  |
|  | Female | 42,729 | $85_{(80-89)}$ | 0/100 | 24.0 | 587 | $4.4[4.2 \cdot 2.4 .6]$ | $4.6[4.3 ; 4.8]$ | $4.7 \text { [4.5; } 4.9 \text {. } 4.930]$ | $4.8[4.65 \cdot 5.0]$ | $4.9[4.6 \cdot 5.5 .1]$ | $5.1[4.8 ; 5.4]$ | $5.1\left[\begin{array}{l} {[4.8: 83)} \\ 4.4] \end{array}\right.$ |  |
| Body Mass Index | less or equal to 25 | 26,355 | $85{ }_{(80.90)}$ | 27/73 | 22.3 | 560 | $\left.4.2{ }^{[14.0 .27)} 4.5\right]$ | $4.4\left[\begin{array}{l} {[4.1,1 ; 9.4} \\ 4.7] \end{array}\right.$ | $4.5 \underset{(4.049]}{[4.3 ;} 4$ | $4.6[4.3 .3 .4 .9]$ |  |  |  |  |
|  | $>25$ to $\leq 30$ | 14,088 | $84_{\text {(80- 88) }}$ | 33/67 | 26.9 | 535 | $4.6[4.3,5.5 .0]$ | $4.8\left[\begin{array}{c} {[4.4,4 ; 5.5]} \\ 4.67) \end{array}\right.$ | $4.9[4.5 \cdot 5.53]$ | $5.1\left[\begin{array}{l} {[4.7965)} \\ 4.6] \end{array}\right.$ | $5.2\left[\begin{array}{c} {[4,8 i} \\ (26 i) \\ 5.8] \end{array}\right.$ |  |  |  |
|  | $\rightarrow 30$ to $\leq 35$ | 3,573 | $83_{(79.87)}$ | 26/74 | 31.2 | 492 | $6.5\left[\begin{array}{l} {[5.7 .774 .7 .4]} \\ 7.4] \end{array}\right.$ |  | $7.1 \text { [6.3; } 8.1]$ | $7.4\left[\begin{array}{l} {[6.5 ; 5]} \\ (35] \\ 8.5] \end{array}\right.$ | $7.4[6.5 ; 8.5]$ |  |  |  |
|  | $>35$ to $\leq 40$ | 693 | $81_{(77-86)}$ | 23/77 | 36.4 | 323 | $9.3[7.2 ; 2 ; 11.9]$ | $9.9[7.7 .72 .12 .6]$ | $10.4\left[\begin{array}{c} \text { [8.0.0; } 13.3] \\ \text { (129) } \end{array}\right.$ | $12.0[9.0 ; 16.0]$ |  |  |  |  |
| Comorbidities | no or one comorbidity | 3,247 | $83_{(78-88)}$ | 27/73 | 23.5 | 462 | $3.1[(2.5 ; 503.7]$ | $3.3\left[\begin{array}{l} {[2.74 ; 4.0]} \\ (0,49) \end{array}\right.$ | $3.8[3.19 ; 4.7]$ | $4.1\left[\begin{array}{l} {[3.32 ; 5.0]} \\ {[64)} \end{array}\right.$ | $4.1\left[\begin{array}{l} {[3.352} \\ \mid 3,50] \\ 5 \end{array}\right.$ |  | $4.1\left[\begin{array}{l} {[3.3 ; 5.0]} \\ (6,1) \end{array}\right.$ |  |
|  | two to four comorbidities | 20,992 | $84_{\text {(80-89) }}$ | 26/74 | 24.0 | 556 |  | $3.7\left[\begin{array}{l} {[8.550)} \\ \hline 8.0] \\ \hline \end{array}\right.$ | $3.9[3.6 ; 4.2]$ | ${ }^{4.0}\left[\begin{array}{c}\text { [3.720) } \\ 3,7.3]\end{array}\right.$ | $\left.4.0{ }^{[3.7 .755} 4.3 .3\right]$ | $4.2[3.8894 .67$ |  |  |
|  | More than 4 comorbidities | 35,635 | $8^{850-89)}$ | 30/70 | 24.5 | 580 | $5.3\left[\begin{array}{l} {[1 ., 0 ; 372)} \\ 5.5] \\ \hline \end{array}\right.$ | $5.5[5.2 ; 5.5]$ | $5.6[5.4 ; 5.9]$ | $5.8\left[\begin{array}{c} {[5.5455} \\ 5.56 .1] \end{array}\right.$ | $5.9\left[\begin{array}{l} {[5.6 ; 6 ; 6]} \\ 10.3] \end{array}\right.$ | $\left.6.3\left[\begin{array}{c} {[8,8 ;} \\ (8) 6 \\ 6 \end{array}\right) 7\right]$ | $6.3\left[\begin{array}{c} {[5.8 ; 8)} \\ {[23]} \end{array}\right)$ |  |
| Hospital size* | Hospitals with low annual case volumes | 12,523 | 84 (80-89) | 28/72 | 24.5 | 217 |  | $4.5\left[\begin{array}{l} 4.1,1818 \\ 4.9] \\ 4.9] \end{array}\right.$ | $4.7\left[\begin{array}{c} {[4.3: 024} \\ 1.025 \\ 5.1] \end{array}\right.$ | $4.9[4.5: 5.4]$ | 5.1 [4.6.656 5.7 ] | ${ }^{5.3}$ [4.7.70. 6.0$]$ | ${ }_{5}^{5.3}[4.7 .76 .6 .0]$ |  |
|  | Hospitals with average annual case volumes | 30,377 | $84{ }_{\text {(80-89) }}$ | $29 / 71$ | 24.3 | 274 | $4.7 \text { [4.4.4:4.9] }$ | $4.99[4.6 ; 5.5 .2]$ | $5.1\left[\begin{array}{l} {[4.853)} \\ \hline(4.4] \\ \hline \end{array}\right.$ |  | $5.3\left[\begin{array}{c} (5.0,0 ; 4) \\ (1,6] \end{array}\right.$ |  |  |  |
|  | Hospitals with high annual case volumes | 16,367 | $8{ }_{\text {(80-89) }}$ | 28/72 | 24.0 | 87 | $4.4\left[\begin{array}{c} {[8.3,136)} \\ \hline 4.8] \\ \hline \end{array}\right.$ | $4.6 \underset{(5.731)}{[4.3 ; 5.0]}$ | $4.8 \underset{(3.545)}{[4 ; 5 ; 5]}$ | $4.8\left[\begin{array}{c} (4.5050) \\ \hline(2.2] \end{array}\right.$ | $4.9[4.5 \cdot 5.5]$ | $5.0\left[\begin{array}{c} \text { [4.6;9; } 5.5] \end{array}\right.$ | $5.0\left[\begin{array}{l} {[4.6 ; 5.5]} \\ 432) \\ \hline 13) \end{array}\right.$ |  |
| Standard TKAs |  | 351,531 | $70_{(62-77)}$ | $34 / 66$ | 30.1 | 722 | $1.7[1.6 ; 1.7]$ | $2.5\left[\begin{array}{l} {[2.5, ~ 2.6]} \\ (23,689] \end{array}\right.$ | $3.0\left[\begin{array}{l} {[28,9 ; 3 ; 5)} \\ {[3.1]} \end{array}\right.$ | $\underset{(136.882)}{3.3 .4]}$ | $3.6[3.5 ; 3.7]$ | $3.8[3.7 ; 8 ; 5.9]$ |  | ${ }_{4} 4.3[4.2 ; 54.4]$ |
| Age group | $\leq 54$ years | 25,101 | $52_{\text {(49-53) }}$ | 36/64 | 33.2 | 687 | $2.4\left[\begin{array}{l} {[2.20 .202 .6]} \\ \hline 2.6] \end{array}\right.$ | $4.0\left[\begin{array}{l} {[3.8,8: 4.3]} \\ (1,3) \end{array}\right.$ | $5.0 .0[4.7 ; 5.3]$ | $5.7\left[\begin{array}{l} {[10.4063)} \\ {[5.1]} \end{array}\right.$ | $6.2[5.8 ; 6.6]$ | $6.6\left[\begin{array}{ll} {[6,2,2 ; 10} \\ 7.0] \end{array}\right.$ | $\left.7.2\left[\begin{array}{c} {[6.7597} \\ (1.55] \end{array}\right] .7\right]$ | $7.7[7.0 ; 8 ; 8.4]$ |
|  | 55-64 years | 87,380 | $60_{(58-62)}$ | 38/62 | 32.0 | 714 |  | $2.8\left[\begin{array}{l} {[5,7.720)} \\ 2.9] \\ \hline \end{array}\right.$ | $3.4\left[\begin{array}{l} {[44,7,782)} \\ \hline 3.5] \end{array}\right.$ | $3.9\left[\begin{array}{l} (32.751) \\ \hline 4.0] \end{array}\right.$ | $4.2\left[\begin{array}{ll} {[2.15075} \\ \hline 1.4] \end{array}\right.$ | $4.6[4.4 .4,4.8]$ | $4.9[4.7 .75 .51]$ | $5.3\left[\begin{array}{l} (5.423 ;) \\ 5.6] \end{array}\right.$ |
|  | 65-74 years | 118,762 | $70_{(67-72)}$ | $34 / 66$ | 30.7 | 713 | $1.5[1.4 ; 1.6]$ | $2.3\left[\begin{array}{c} {[2,2 ; 955)} \\ 2.4] \\ \hline \end{array}\right.$ | $2.7\left[\begin{array}{c} (23.6 ; 9 ;) \\ {[2.8]} \end{array}\right.$ | $3.0\left[\begin{array}{l} {[24,9.960 .10 .1]} \\ \hline \end{array}\right.$ | $3.2[3.1 ; 3.3]$ | $3.4\left[\begin{array}{c} (18.323 ; 3) \\ \hline(2) 5] \end{array}\right.$ | $3.6\left[\begin{array}{l} {[3.4,4 ; 3.8]} \\ (x, 73) \end{array}\right.$ |  |
|  | 75-84 years | 110,462 | $78{ }_{(76-81)}$ | 32/68 | 28.3 | 713 | $1.7[1.6 ; 1.8]$ | $2.3\left[\begin{array}{ll} {[2.2 .230)} \\ 2.4] \\ \hline \end{array}\right.$ | $2.6[2.5 ; 2.7]$ |  | $3.0\left[\begin{array}{c} {[2.88 ; 77)} \\ \hline 1.1] \end{array}\right.$ | $3.1\left[\begin{array}{c} {[1.9,9 ; 38)} \\ \hline 1.2] \end{array}\right.$ | $3.2\left[\begin{array}{l} {[3.007]} \\ (6.30] \end{array}\right.$ | $3.3\left[\begin{array}{c} {[3.2 ; 3 ; 9.5]} \\ \hline \end{array}\right.$ |
|  | 85 years and older | 9,826 | $86_{(85-87)}$ | 31/69 | 26.8 | 666 | $2.0$ | $2.3\left[\begin{array}{l} {[2.0000} \\ {[6.000} \\ 2.7] \\ \hline \end{array}\right.$ | $2.7\left[\begin{array}{l} {[2.3 ; 30.0]} \\ 4.56) \end{array}\right.$ | $2.8\left[\begin{array}{c} {[2.4063 \cdot} \\ (3.06) \\ \hline \end{array}\right.$ | $2.8 \text { [2.4.4; 3.2] }$ | $2.9\left[\begin{array}{l} {[.53 ;)} \\ \hline(3.4] \end{array}\right.$ | $2.9\left[\begin{array}{l} {[2.524} \\ (124) \\ 3.4] \end{array}\right.$ | $2.9[2.5: 3.4]$ |
| Sex | Male | 120,833 | $6^{69}{ }_{(61-76)}$ | 100/0 | 29.6 | 713 | $2.0[1.9 ; 2.1]$ | $2.9\left[\begin{array}{c} {[7.8,8 ; 3)} \\ \hline \end{array}\right.$ | $3.3[3.2,23.4]$ | $3.7[3.6 ; 3 ; 8]$ | $3.9[3.8 ; 4.0]$ | $4.2\left[\begin{array}{c} {[4.0 .0 ; 0.3]} \end{array}\right.$ | $4.5\left[\begin{array}{l} {[4.303} \\ 6.304) \\ 4.7] \end{array}\right.$ | $4.8 \text { [4.5; 5.1.1] }$ |
|  | Female | 230,698 | $71_{(63-77)}$ | 0/100 | 30.5 | 718 | $1.5[1.5 ; 1.6]$ | $2.4\left[\begin{array}{ll} {[15,3,253)} \\ 20.4] \end{array}\right.$ | $2.8\left[\begin{array}{l} {[22.8 ; 2 ; 9.9]} \\ (12550) \end{array}\right.$ | $3.2\left[\begin{array}{l} {[9.25488} \\ {[3.1 ; 3]} \end{array}\right.$ | $3.4\left[\begin{array}{c} {[6.3,3234} \\ {[6.5]} \end{array}\right.$ | $3.6[3.5 ; 3.7]$ | ${ }^{3.8} 8[3.7 .74363 .9]$ | $4.0\left[\begin{array}{c} (3.828) 9 \\ \hline 4.2] \end{array}\right.$ |
| Body Mass Index | less or equal to 25 | 35,752 | $75_{(67-80)}$ | 31/69 | 23.6 | 681 |  | $2.2\left[\begin{array}{ll} {[20.0506]} \end{array} 2.4\right]$ | $2.6[2.5 ; 2.8]$ | $3.0\left[\begin{array}{l} {[2.8,863} \\ {[.76} \\ 3 \end{array}\right.$ |  |  |  |  |
|  | $>25$ to $\leq 30$ | 85,750 | $72{ }_{(65-78)}$ | 41/59 | 27.7 | 691 | $1.5_{(66,232)}^{[1.4 ; 1.6]}$ | $2.2\left[\begin{array}{l} {[2.1 .1 ; 2.20]} \\ 50.3] \end{array}\right.$ | $2.6\left[\begin{array}{l} (2,587), 5 ; 2] \\ 2.7] \\ \hline \end{array}\right.$ | $2.9\left[\begin{array}{c} {[1,8: 8,3.1]} \\ 1(1,010) \end{array}\right.$ | $3.1\left[\begin{array}{l} {[3.0 .063 .3]} \\ 44.82) \end{array}\right.$ |  |  |  |

Table 45 (continued)

| Type of arthroplasty / category | Type | Number | Age | m/f | BMI | Hosp. | Revision probabilities after ... |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  |  |  | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Body Mass Index | $>30$ to $\leq 35$ | 72,530 | $69_{(62-76)}$ | $36 / 64$ | 32.0 | 686 | $1.6[1.5 \cdot 7.7]$ |  | $2.8\left[\begin{array}{l} {\left[2,7,7 z_{2}, 3.0\right]} \\ \hline \end{array}\right.$ | $3.1 .13 .00 ; 3.3]$ | $3.3[3.1 .3 .3 .4]$ |  |  |  |
|  | $>35$ to $\leq 40$ | 36,345 | $66_{(60-72)}$ | $29 / 71$ | 37.0 | 680 | $1.9[1.7 ; 2.0]$ | $2.8\left[\begin{array}{l} {[2,6,6,3.0]} \\ \hline 10,0] \end{array}\right.$ |  | $3.5\left[\begin{array}{l} {[3.3 ; 3 ; 3]} \\ (0,2) \\ \hline \end{array}\right.$ | $3.8\left[\begin{array}{l} {[3.622 ;)} \\ \hline 4.1] \end{array}\right.$ |  |  |  |
|  | above 40 | 20,108 | $62_{\text {(57 - } 68)}$ | 23/77 | 42.9 | 676 | ${ }_{2} 2.5\left[\begin{array}{l}\text { [15.50] } \\ \text { (1) } 2.7]\end{array}\right.$ | $3.3[3.0 ; 3.6]$ | $3.9\left[\begin{array}{l} {[3.695} \\ \hline 8.050 \\ 4.3] \\ \hline \end{array}\right.$ | $4.3[4.0 .4 .4 .7]$ | $4.7\left[\begin{array}{ll} {[4.3 .305 .1]} \\ u, 1] \end{array}\right.$ |  |  |  |
| Comorbidities | no or one comorbidity | 52,227 | $6_{(59-75)}$ | 40/60 | 27.5 | 709 | $1.4[1.3 ; 1.5]$ | $2.4\left[\begin{array}{l} {[2,3,355)} \\ \hline 2.5] \end{array}\right.$ | $2.9\left[\begin{array}{ll} {[2,7.734]} \\ {[2.0]} \end{array}\right.$ | $3.2\left[\begin{array}{l} {[30.1930 .4]} \\ \hline(23)] \end{array}\right.$ | $3.5_{(13,544)}^{[3.3 ; 3.7]}$ | $3.7 \underset{(7.552)}{[3 ; 53]}$ | $3.9{ }_{\substack{[3.7 .722}}^{4.2]}$ | $4.2\left[\begin{array}{c} 13.8465 \\ (9.5) \\ 4.5] \\ \hline \end{array}\right.$ |
|  | two to four comorbidities | 195,247 | $70_{(62-77)}$ | 35/65 | 29.7 | 717 | $1.5[1.4 ; 1.5]$ |  | $2.8\left[\begin{array}{l} {[2.7 .7 .2 .8]} \\ (10,0,06) \end{array}\right.$ | $3.1\left[\begin{array}{c} {[76.0466} \\ {[3.0]} \end{array}\right.$ | $3.3[3.2 ; 3 ; 4.4]$ | $3.6[3.4 ; 3.7]$ | $3.8 \text { (33.7.73.9] }$ | $4.1\left[\begin{array}{l} {[3.9244 .4 .3]} \\ \hline 10 . \end{array}\right.$ |
|  | More than 4 comorbidities | 104,057 | $72_{(64-78)}$ | 30/70 | 32.6 | 712 |  |  | $3.5[3.4,4 ; 3.6]$ | $3.8\left[\begin{array}{c} [3.74 ; 78), 4.0] \\ \hline(x) \end{array}\right.$ | $4.1\left[\begin{array}{l} {[4.00 ; 4.2]} \\ 20.2] \end{array}\right.$ | $4.3[4.2 \cdot 2 ; 4.5]$ | $4.5\left[\begin{array}{c} {[5.4 ; 90 ;} \\ \hline 5.7] \\ \hline \end{array}\right.$ | $4.7[4.55 .5 .9]$ |
| Hospital size* | Hospitals with low annual case volumes | 169,261 | $70_{(62-77)}$ | $34 / 66$ | 30.4 | 553 | $\underset{(138.2 i b)}{[1.9]}$ | ${ }_{2} 2.8$ [12.7.3i 2.9$]$ |  | $3.6[3.5 ; 3.37]$ | $3.9[33.7 ; 4.0]$ |  |  |  |
|  | Hospitals with average annual case volumes | 103,705 | $70_{(62-77)}$ | 35/65 | 30.1 | 104 | $\underset{\substack{1.6 \\[8,5678) \\[1.5] \\ 1.6]}}{ }$ | $2.4\left[\begin{array}{lll} {[28,3,34]} \\ 2,5] \end{array}\right.$ | $2.9\left[\begin{array}{c} (2,8,8,033) \\ {[5,0]} \\ \hline \end{array}\right.$ | $3.2\left[\begin{array}{c} 3.1,1 ; 3.3] \\ (3,462) \end{array}\right.$ | $3.5\left[\begin{array}{l} {[25.3,32]} \\ \hline 2.6] \end{array}\right.$ | $3.8\left[\begin{array}{ll} {[1,65344} \\ \hline 3.9] \end{array}\right.$ | $3.9\left[\begin{array}{l} {[3.83 i)} \\ \hline 4.1] \\ \hline \end{array}\right.$ | $4.3[4.004 .7]$ |
|  | Hospitals with high annual case volumes | 71,994 | ${ }^{69}{ }_{(62-76)}$ | $34 / 66$ | 30.0 | 30 | $1.4[1.3 ; 7.5]$ | $2.1 .1\left[\begin{array}{ll} {[24,0,022)} \\ \hline 4.2] \end{array}\right.$ | $2.5\left[\begin{array}{l} {[2,4,4,077)} \\ (3,6] \end{array}\right.$ | $2.8\left[\begin{array}{l} {[27.7 \times 040.9]} \\ {[27,04]} \end{array}\right.$ | $3.0\left[\begin{array}{l} {[12.8 ; 80)} \\ \hline 1.1] \end{array}\right.$ | $3.2\left[\begin{array}{l} {[3.00 ; 50]} \\ 3.4] \end{array}\right.$ | $3.5\left[\begin{array}{l} {[3.53,388} \\ \hline 5.7] \end{array}\right.$ | $3.7\left[\begin{array}{l} {[3,4 ; 4,4.0]} \\ (2, i 2) \end{array}\right.$ |
| Constrained TKAs |  | 17,600 | $75_{(66-80)}$ | $24 / 76$ | 28.8 | 663 | $4.0\left[\begin{array}{l} {[3.7 ; 4.3]} \\ {[13 / 50]} \end{array}\right.$ | $5.2[4.8 ; 5.5]$ <br> (11,063) | $5.8\left[\begin{array}{c} (5.577) \\ \hline \end{array}\right.$ | $6.1 \underset{(6.082)}{[5.7 ; 6.5]}$ | $6.4 \underset{(3.910)}{[6 ; 0 ; 6.8]}$ | $6.7\left[\begin{array}{l} {[6.2 ; 7.7]} \\ \hline(203) \end{array}\right.$ | 6.8 [6.3.3.7.3] | $7.7[6.7 ; 8.8]$ |
| Age group | $\leq 54$ years | 1,003 | $51{ }_{(47 .-53)}$ | $36 / 64$ | 32.8 | 314 | $4.4\left[\begin{array}{c} {[3.3 ; 9)} \\ (809) \\ 5.9] \\ \hline \end{array}\right.$ | $6.1\left[\begin{array}{c} {[4.8 ; 3,7.9]} \\ {[6.3]} \end{array}\right.$ | $7.6[6.0 ; 9.6]$ | $8.0\left[\begin{array}{l} {[6.3 ; 3)} \\ {[376} \\ 10.1] \end{array}\right.$ |  | $9.0[7.1,11.5]$ | $9.0[7.1,11.5]$ |  |
|  | 55-64 years | 2,810 | $60_{(55-63)}$ | $32 / 68$ | 32.0 | 506 | $4.6\left[\begin{array}{l} {[3.92000} \\ 2.5] \\ \hline \end{array}\right.$ | ${ }_{6} 6.3$ [5.4.472. 7.4$]$ | $7.2\left[\begin{array}{l} {[6.2 ; 2 ; 4]} \\ 10.310 \end{array}\right.$ |  | $\left.8.1{ }_{\text {[ }}^{\text {[ } 7.0059} 9.9 .4\right]$ | ${ }^{\text {a }}$ 8.3 $[7.1 ; 9.9 .6]$ |  |  |
|  | 65-74 years | 4.973 | $70{ }_{(68-72)}$ | 24/76 | 30.5 | 576 | $4.1\left[\begin{array}{l} {[3.6544} \\ 3.7] \\ \hline \end{array}\right.$ | $5.4\left[\begin{array}{l} (3,8,826 \\ \hline 6.6 .1] \end{array}\right.$ | $6.2\left[\begin{array}{l} {[5.5508 .59]} \\ 6.9] \end{array}\right.$ |  | $\left.6.9\left[\begin{array}{c} {[6.12 ; 16} \\ (1.26] \end{array}\right] .8\right]$ | $7.1 \begin{gathered} {[6.373)} \\ {[6.0]} \end{gathered}$ | $7.3 \begin{gathered} \text { [6.4.4:8.4. } 8.4] \\ (100) \end{gathered}$ | $8.8[7.0 ; 0 ; 0,11.0]$ |
|  | 75-84 years | 7.269 | $79_{(77-82)}$ | 20/80 | 27.5 | 604 | $3.6\left[\begin{array}{c} (3.526 ;) \\ \hline 4.1] \end{array}\right.$ | $4.5[4.005050$ [0] | $4.8\left[\begin{array}{c} (3.3020) \\ \hline \end{array}\right.$ | $5.0\left[\begin{array}{c} {[2.599)} \\ {[5.6]} \end{array}\right.$ | $5.3\left[\begin{array}{l} (4.578 ; \\ \hline 6.0] \end{array}\right.$ | $5.7[5.0 ; 6.4]$ |  |  |
|  | 85 years and older | 1,545 | $88_{\text {(95-88) }}$ | 18/82 | 25.8 | 465 | $4.0{ }_{\substack{(1.1 .195) \\(1.2 .2]}}$ | $4.7\left[\begin{array}{c} {[3.7375} \\ (8,5) \\ 5.9] \end{array}\right.$ | $4.9\left[\begin{array}{l} {[3.93]} \\ {[5.3]} \\ 6 \end{array}\right.$ | $4.9[3.9 ; 6.3]$ | $4.9[3.9 ; 6.3]$ | $4.9[3.9 ; 6.3]$ |  |  |
| Sex | Male | 4,208 | $72{ }_{(63-79)}$ | 100/0 | 28.4 | 548 | $5.2\left[\begin{array}{l} {[4.53 ; 53.9]} \end{array}\right.$ | $6.5[5.7 ; 7.3]$ | $7.3 \text { [6.5; } 8.2]$ | $7.7 \text { [6.8:8:8.7] }$ | $8.1[7.2 ; 9.1]$ | $8.2 \text { [7.3.3.9.3] }$ | $8.2\left[\begin{array}{c} \text { [7.3; } 3 ; 9 \\ \text { uise } \\ 9.3] \end{array}\right.$ |  |
|  | Female | 13,392 | $75_{(67-81)}$ | 0/100 | 29.0 | 653 | $3.6[3.3 ; 4.0]$ | $4.8\left[\begin{array}{l} {[8.484 ; 4} \\ \hline 1.1] \end{array}\right.$ | $5.3\left[\begin{array}{l} {[4.9999]} \\ 5.7] \\ \hline \end{array}\right.$ | $5.6[5.2 ; 2 ; 60]$ | $5.9 \underset{(5.020)}{[5.4 ; 6]}$ | $6.2\left[\begin{array}{l} {[5.72 ; 62)} \\ (1,7] \end{array}\right.$ | $6.3[5.8 ; 6.9]$ |  |
| Body Mass Index | less or equal to 25 | 3,040 | $79{ }_{(71-83)}$ | 20/80 | 23.1 | 520 | $3.5[2.9 .9 ; 4.3]$ | $4.7\left[\begin{array}{l} {[4.0955)} \\ (0.6] \end{array}\right.$ | $5.2\left[\begin{array}{l} \text { [4.4.4; } 6.2] \\ (4.2] \end{array}\right.$ | $5.6[4.7 .76 .67]$ | ${ }_{5} 5.8$ [4.8.8:4.6.9] |  |  |  |
|  | $\rightarrow 25$ to $\leq 30$ | 4,253 | $77_{(69-81)}$ | 30/70 | 27.5 | 559 | $3.7[(3.2 ; 2 ; 4.4]$ | $4.9\left[\begin{array}{l} {[2,333} \\ \hline 5.7] \\ 5.7] \\ \hline \end{array}\right.$ | $5.6[4.9 ; 6.4]$ | $5.7 \begin{gathered} {[5.085)} \\ (6.6] \\ \hline 6.6] \end{gathered}$ | $6.2\left[\begin{array}{l}\text { [5.2; } 24.7 .3]\end{array}\right.$ |  |  |  |
|  | $\rightarrow 30$ to $\leq 35$ | 2,963 | $73_{(66-79)}$ | 25/75 | 32.0 | 495 | $3.5[(2.9 ; 2 ; 4.3]$ | $4.5\left[\begin{array}{l} {[3.7555} \\ 4.3] \\ \hline \end{array}\right.$ | $4.8[4.0 .55 .7]$ | $5.3[4.4 ; 4.3]$ | $5.6[4.6 ; 6.8]$ |  |  |  |
|  | $>35$ to $\leq 40$ | 1,481 | $69_{(61-76)}$ | 20/80 | 37.0 | 391 |  | $6.3[5.1 .7 ; .7]$ | $7.1 \begin{gathered} {[5.888 .8]} \\ {[588)} \end{gathered}$ | $7.1 \underset{(5.815}{[5 ; 8.7]}$ | $7.6[6.0 ; 9.5]$ |  |  |  |
|  | above 40 | 1,008 | $64_{(58-70)}$ | 17/83 | 43.7 | 340 | $5.2[4.0 ; 9.6 .8]$ | $6.3[4.928 .81]$ | $7.7 \text { [6.0;9;9.8] } 9$ | $8.0\left[\begin{array}{l} {[6.2 ; 2 ;} \\ i z 00 \end{array}\right)$ | $8.0[6[5 ; 2 ; 10.1]$ |  |  |  |
| Comorbidities | no or one comorbidity | 1,923 | $71_{(62-79)}$ | 30/70 | 26.6 | 451 | $2.2\left[\begin{array}{ll} {[1.538]} \\ 10.53] \end{array}\right.$ | $3.5\left[\begin{array}{ll} {[1.728 ; 4.5]} \\ \hline \end{array}\right.$ | $3.8[3.05 ; 4.9]$ | $4.0\left[\begin{array}{c} {[3.1 .1 ;} \\ \mid 3.31] \\ 5.1] \end{array}\right.$ | $4.3[3.45 ; 5.6]$ | $4.6[3.555 .5]$ | $4.6[3.5 \cdot 5.5]$ |  |
|  | two to four comorbidities | 8.895 | $74{ }_{(66-80)}$ | 25/75 | 28.3 | 618 |  | $4.6[4.2 .2,5.1]$ | $5.3\left[\begin{array}{c} 4.4,893) \\ \hline 4.8] \end{array}\right.$ | $5.6\left[\begin{array}{c} {[5.1,1,78)} \\ 6.2] \end{array}\right.$ | $5.9\left[\begin{array}{l} {[5.3 ; 38)} \\ \hline 6.4] \end{array}\right.$ | $6.2\left[\begin{array}{l} {[5.6 \cdot 6 ; 6.8]} \\ (1,20) \end{array}\right.$ | $6.3 \underset{(4933}{[5.7} 7.7 .1]$ |  |
|  | More than 4 comorbidities | 6,782 | $76_{(68-81)}$ | 21/79 | 30.5 | 605 | $5.3[4.8 .85 .9]$ | $6.4 \underset{(5,4,86)}{ } 7.0]$ | $6.9\left[\begin{array}{l} {[6.3,373} \\ \hline(7) \\ 7.6] \end{array}\right.$ | $7.3\left[\begin{array}{l} {[6,773.0 .0]} \\ {[, 13} \end{array}\right.$ | $7.8\left[\begin{array}{c} {[7.0,0 ; 64)} \\ (1,5] \end{array}\right.$ | $7.9\left[\begin{array}{c} (7,2 ; 1 ; 1 \\ (j ; 1) \\ 8.8] \end{array}\right.$ | $7.9\left[\begin{array}{c} {[7.2 ; 2 ; 8)} \\ (24] \end{array}\right]$ |  |
| Hospital size* | Hospitals with low annual case volumes | 10,494 | $75_{(67-81)}$ | $24 / 76$ | 28.9 | 503 | $4.0\left[\begin{array}{l} {[3.6 ; 744} \\ 4.4] \end{array}\right.$ | $5.2\left[\begin{array}{c} {[4.8: 803} \\ \hline(6,5] \\ 5.7] \end{array}\right.$ | $5.995 .4 ; 4 ; 6.4]$ | $6.2\left[\begin{array}{l} {[5.7 .703} \\ \hline 8.03 \\ 6.8] \\ \hline \end{array}\right.$ | $6.6\left[\begin{array}{l} {[6.1292} \\ (2,2) \\ 7.2] \end{array}\right.$ | $\begin{gathered} 6.8 \text { [6.3;3; 7.5] } \\ \hline(1.20] \end{gathered}$ | $7.0 \begin{aligned} & {[6.453} \\ & \langle 4.4 \\ & \hline \end{aligned}$ | $9.0[7.17 .11 .5]$ |
|  | Hospitals with average annual case volumes | 4,488 | $74{ }_{(66-80)}$ | $24 / 76$ | 28.7 | 103 | $4.4\left[\begin{array}{c} {[3.88,84} \\ (3,0) \\ 5.0] \end{array}\right.$ | 5.7 [5.0; 7.44 | $6.0\left[\begin{array}{l} {[5.3,368)} \\ {[2.8]} \end{array}\right.$ | $\begin{gathered} 6.3(5.6 ; 7.1] \\ (1,25) \end{gathered}$ | $\underset{(887)}{6.8} \mathbf{6} .$ | $7.1\left[\begin{array}{l}\text { [6.224) } 8.2]\end{array}\right.$ | 7.1 [6.20; 8.2] |  |
|  | Hospitals with high annual case volumes | 2,270 | $73_{(64-79)}$ | $26 / 74$ | 28.7 | 30 | $3.4\left[\begin{array}{l} {[1.7 .75)^{4.2]}} \\ 4.2] \end{array}\right.$ | $4.1\left[\begin{array}{l} {[3.3: 3.56} \\ \hline 1.0] \end{array}\right.$ | $4.5\left[\begin{array}{l} {[3.7 .7515} \\ 10.5] \\ \hline 1.51 \end{array}\right.$ | $4.8\left[\begin{array}{l} {[3529} \\ \mid 352 \end{array} 5.9\right]$ | 4.8 [ 3.99 .95 .9$]$ |  |  | $5.0[4.7716 .6 .2]$ |

Table 45 (continued)

|  |  |  |  |  |  |  | Revision probabilities after ... |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Type of arthroplasty / category | Type | Number | Age | m/f | BMI | Hosp. | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Unicondylar knee arthroplasties |  | 51,875 | $63_{(57-72)}$ | 44/56 | 29.5 | 645 | $2.9[2.8 ; 3.1]$ | $4.7[4.5 ; 4.9]$ <br> $(33,637)$ | $5.7[5.5 ; 6.0]$ | $6.6\left[\begin{array}{c} {[6.4 ; 4 ; 6.9]} \\ \hline 18.808 \end{array}\right.$ | $7.2\left[\begin{array}{c} {[6.9 ; 7.9]} \\ (11.97) \end{array}\right.$ |  |  | 8.8 [8.3; 9 9.3] |
| Age group | $\leq 54$ years | 8,405 | $51{ }_{(49-53)}$ | 41/59 | 31.4 | 565 |  | $6.2{ }_{(5.5007}^{[5.6 .7]}$ | $7.6[7.0 ; 8.2]$ | $8.9\left[\begin{array}{c} (8.202 ; 2 ; 6] \\ 9.6] \end{array}\right.$ | $9.9\left[\begin{array}{l} \text { [9.2; ; ; } 10 \end{array} 10.8\right]$ | $11.1{ }^{[10.20 ; 2 ; 12.1]}$ | $11.8[10.8 ; 13.0]$ | $\left.12.1{ }^{[10.99 ;} 113.3\right]^{(16)}$ |
|  | 55-64 years | 19,297 | $60_{(57-62)}$ | 48/52 | 30.3 | 608 | $2.8\left[\begin{array}{ll} {[1.5330]} \\ {[.03]} \end{array}\right.$ | $4.9[4.6 ; 5.3]$ | $6.1[5.7 .76 .5]$ | $7.1\left[\begin{array}{l} {[6.7027} \\ {[6.5]} \\ \hline \end{array}\right.$ | $7.7\left[\begin{array}{c} {[7.3 ; 60)} \\ (4.20) \\ \hline \end{array}\right.$ | $8.6[8.0 ; 9.2]$ | $9.1\left[\begin{array}{c} 8.4,4 ; 9.8] \\ (8,4) \\ \hline \end{array}\right.$ | $9.7\left[\begin{array}{l} {[8.8 ; 8)} \\ (250) \end{array}\right.$ |
|  | 65-74 years | 14,828 | $69^{(67-72)}$ | 42/58 | 29.3 | 560 | $2.7\left[\begin{array}{l} {[2.4 ; 4 ; 93)} \\ (1,0] \end{array}\right.$ |  |  | $5.8 \underset{(5.4418)}{[5 ; 6]}$ | $6.1\left[\begin{array}{l} (3.7504) \\ \hline 6.6] \end{array}\right.$ | $6.5\left[\begin{array}{l} {[6.0 ; 973)} \\ (1.1) \\ 7.1] \end{array}\right.$ | $6.8\left[\begin{array}{c} {[6,2,2,4.4]} \\ (0,4) \end{array}\right.$ | $7.0{ }_{\substack{\text { [6.332 } \\ \text { (23) } \\ 7.7 .7]}}$ |
|  | 75-84 years | 8,758 | $78{ }_{(76-80)}$ | 43/57 | 27.7 | 465 | $3.0\left[\begin{array}{l} {[2.6244} \\ {[0.4]} \end{array}\right.$ | $4.0\left[\begin{array}{l} {[3.6078} \\ {[6.5]} \\ 4.5] \end{array}\right.$ | $4.6[4.1 ; 5.5 .1]$ | $5.0\left[\begin{array}{l} {[4.6506} \\ 5.65] \\ 5.6] \end{array}\right.$ | $5.3\left[\begin{array}{l} 4.8 .850 \\ 2.95] \\ 5.9] \end{array}\right.$ | $6.0\left[\begin{array}{c} {[5.3060} \\ (1.30) \\ 6.7] \end{array}\right.$ | $6.5\left[\begin{array}{c} {[5776} \\ {[37} \\ 7.4] \\ \hline \end{array}\right.$ | $7.2[5.77 .8 .9]$ |
|  | 85 years and older | 587 | $86_{(85-88)}$ | 42/58 | 26.4 | 184 | $2.2[1.3 ; 3.9]$ | $3.0\left[\begin{array}{c} 1.8 ; 8 ; 4.9] \\ {[377)} \end{array}\right.$ | $3.3\left[\begin{array}{l} {[2.054} \\ (254) \\ 5.3] \end{array}\right.$ |  | $3.7[2.306 .1]$ | $5.0[2.779 .90]$ |  |  |
| Sex | Male | 23,013 | $63_{(57-71)}$ | 100/0 | 29.4 | 612 | $2.8[(2.6 ; 3 ; 3.1]$ | $4.4\left[\begin{array}{ll} \left(1.4,1 ; 77^{4}, 7\right] \end{array}\right.$ |  | $6.0\left[\begin{array}{c} {[5.7355} \\ {[7.45]} \end{array}\right.$ |  | $7.2\left[\begin{array}{l} {[6.7 ; 7.7 .7]} \\ 2.601 \end{array}\right)$ | $7.6$ | ${ }^{8.0}{ }_{\text {c }}^{[7.3 ;} 8$ (339) 8.7$]$ |
|  | Female | 28,862 | $64_{(57-72)}$ | 0/100 | 29.7 | 621 | $3.0\left[\begin{array}{c} {[23.4749)} \\ \hline(2.2] \end{array}\right.$ | $5.0\left[\begin{array}{c} {[4.7 .75 .5]} \\ \hline 1.960) \end{array}\right.$ | $6.1 \begin{gathered} {[5.8 ; 6 ; 6.4]} \\ \hline(4,19) \end{gathered}$ | $7.1{ }_{(10,533)}^{[6.7 ; 7.4]}$ | $7.7\left[\begin{array}{c} {[7.4 ; 768)} \\ (6,1] \\ \hline \end{array}\right.$ | $8.5 \underset{(3.670)}{[8.0 ;} 8$ | $9.0[8.5 ; 9.6]$ | $9.4[8.8 ; 10.10 .2]$ |
| Body Mass Index | less or equal to 25 | 5,476 | $6^{67}{ }_{(59}$-75) | 38/62 | 23.7 | 512 | $2.6\left[\begin{array}{l} [4.107) ; 3.0] \\ \left.\hline()^{2}\right) \end{array}\right.$ | $4.5\left[\begin{array}{l} {[3.97975)} \\ (2.2] \end{array}\right.$ |  | $6.6\left[\begin{array}{l} {[5.750} \\ \hline(5) 7.5] \end{array}\right.$ |  |  |  |  |
|  | $>25$ to $\leq 30$ | 13,782 | $65_{(59-73)}$ | 51/49 | 27.7 | 573 | $2.4\left[\begin{array}{l} {[(1.1 .544)} \\ {[2.6]} \end{array}\right.$ |  | $5.1\left[\begin{array}{c} {[5.754)} \\ \hline 5.6] \end{array}\right.$ | $5.7\left[\begin{array}{c} {[5.2 ; 2 ; 1)} \\ (2.81) \end{array}\right.$ | $6.1 \begin{aligned} & \text { [5.6\% } 6.7 .7] \\ & (13)\end{aligned}$ |  |  |  |
|  | $>30$ to $\leq 35$ | 10,653 | $6^{657-70)}$ | 47/53 | 32.0 | 558 | $3.1\left[\begin{array}{c} (2.8 ; 70) \\ \hline \end{array}\right.$ |  | $6.1\left[\begin{array}{l} {[5.606 .6 .7]} \\ 40.05 \end{array}\right.$ | $7.0\left[\begin{array}{l} {[6,4 ; 4,7.6]} \\ (2, i 8) \end{array}\right.$ |  |  |  |  |
|  | $>35$ to $\leq 40$ | 4,639 | $60{ }_{(55-67)}$ | 40/60 | 36.9 | 473 | $3.2\left[\begin{array}{c} {[2.750} \\ (1.50 \end{array}\right)$ | $5.2\left[\begin{array}{l} {[4.6563} \\ 2.53) \\ 6 \end{array}\right.$ | $6.4\left[\begin{array}{c} {[5.6747)} \\ (1.6) \\ \hline \end{array}\right.$ | $7.1(6.2 ; 2 ; 80]$ |  |  |  |  |
|  | above 40 | 1,836 | $58{ }_{(53-63)}$ | 31/69 | 42.4 | 347 |  | $6.6[5.5 \cdot 8.0]$ | $7.0\left[\begin{array}{c} {[588 ;} \\ {[68)} \\ \hline \end{array}\right.$ | $8.0\left[\begin{array}{l} {[6.6 ; 9.9]} \\ (0,010 \end{array}\right)$ | $11.1[8.7 ; 14.0]$ |  |  |  |
| Comorbidities | no or one comorbidity | 11,835 | ${ }^{61} 1_{(55-68)}$ | 49/51 | 27.5 | 580 | $2.5\left[\begin{array}{ll} {[2.3 i \cdot 30} \\ 9.609] \end{array}\right.$ | $4.4[4.0 .0 ; 4.8]$ | $\left.{ }^{5.5}{ }_{5(5.9099} 5.9\right]$ | $6.2\left[\begin{array}{l} {[5.73 ; 6,6]} \\ 4.8] \end{array}\right.$ | $6.7\left[\begin{array}{l} {[6.2 ; 2 ; 9]} \\ (2,9] \end{array}\right.$ | $7.5\left[\begin{array}{l} {[6.9968 .2]} \\ (1.63) \end{array}\right.$ |  | ${ }^{8.5}{ }_{\text {[ }}^{\text {(325) }}$ \% 9.6$]$ |
|  | two to four comorbidities | 29,856 | $64_{(57-72)}$ | 44/56 | 29.7 | 619 | $2.9\left[\begin{array}{l} {[23,7 ; 8 ;)} \\ 20.1] \end{array}\right.$ | ${ }_{4}^{4.6}[1.4 .4 .4 .4 .9]$ | $5.7\left[\begin{array}{c} {[1.4,4,55)} \\ \hline 6.0] \\ \hline \end{array}\right.$ |  | $7.3\left[\begin{array}{c} {[6.977)} \\ (6.7] \\ 7 \end{array}\right.$ | $8.0$ | $\begin{gathered} 8.3 \text { (7.8.8; 8.8] } \\ (1,17 \eta \end{gathered}$ | $8.6\left[\begin{array}{l} (8,0,5) \\ \hline(9.2] \\ 9.2] \end{array}\right.$ |
|  | More than 4 comorbidities | 10,184 | $67_{(59}$-74) | 39/61 | 32.5 | 524 | $3.4\left[\begin{array}{l} {[3,259]} \\ \hline 1.8] \\ \hline \end{array}\right.$ | $5.4\left[\begin{array}{l} {[4.985)} \\ {[4.9]} \\ 5.8] \end{array}\right.$ | $6.3(5.8 ; 8 ; 6,8]$ | $7.0\left[\begin{array}{l} {[6.5950} \\ \hline 8.50 \\ 7.6] \end{array}\right.$ | $7.5\left[\begin{array}{l} {[6.9 ; 9018.1]} \end{array}\right.$ | $8.1\left[\begin{array}{c} {[7.4 ; 4,8.8]} \\ (1,20 \\ \hline \end{array}\right.$ | $9.1\left[\begin{array}{l} {[i .1 ; i ; 10.2]} \\ \langle 0.2] \end{array}\right.$ | $9.44_{\text {[8.3; }}^{\text {(104) }}$ ( 10.7$]$ |
| Hospital size* | Hospitals with low annual case volumes | 15,656 | ${ }^{62}{ }_{(56-70)}$ | 46/54 | 29.7 | 473 | $3.9\left[\begin{array}{c} 31.6,689 \\ \hline 12.2] \\ 4.2] \end{array}\right.$ | $6.6\left[\begin{array}{l} 6.1 .1 ; 7.00] \\ (10.050) \end{array}\right.$ | $8.0\left[\begin{array}{c} {[7.5 ; 53} \\ (1,5] \\ 8 \end{array}\right.$ | $9.1\left[\begin{array}{c} {[8.574)} \\ {[8.7]} \end{array}\right.$ | $10.0[9.5 ; 5 ; 10.7]$ | $11.0[10.4 ; 11.7]$ | $11.8\left[\begin{array}{c} 10.9 ; 12.6] \\ (710) \end{array}\right.$ | $11.9[11.1 ; 12.8]$ |
|  | Hospitals with average annual case volumes | 17,259 | $64_{(57-72)}$ | 45/55 | 29.4 | 124 | $2.7\left[\begin{array}{c} (2,4,734) \\ {[3.0]} \end{array}\right.$ | $4.5\left[\begin{array}{c} {[1.2 .2 ; 81)} \\ (12.9] \end{array}\right.$ | $5.6\left[\begin{array}{c} (5.221) ; .0] \\ (x) \end{array}\right.$ | $6.3\left[\begin{array}{c} {[5.94464)} \\ {[56]} \end{array}\right.$ | $6.8\left[\begin{array}{c} {[6.4,4 ; 505} \\ (3,3] \\ \hline \end{array}\right.$ | $7.8$ | $8.5\left[\begin{array}{c} (7675) \\ (6 ; 3] \\ \hline \end{array}\right.$ | $9.3[8.3 ; 10.5]$ |
|  | Hospitals with high annual case volumes | 18,138 | $65_{(58-73)}$ | 43/57 | 29.5 | 25 | $2.2\left[\begin{array}{l}\text { [12,0; } 274) \\ 2.5]\end{array}\right.$ |  |  | $4.7\left[\begin{array}{l} {[4.39616} \\ 6.0] \\ 5.0] \end{array}\right.$ | $5.0[4.6: 5.5]$ | $5.4\left[\begin{array}{l} {[4.95955} \\ 2.55] \end{array}\right.$ |  | $5.6\left[\begin{array}{c}\text { [4.17 } \\ 427\end{array}\right.$ |
| Patellofemoral arthroplasties |  | 849 | $54_{\text {(48-61) }}$ | $27 / 73$ | 28.4 | 200 | $4.6\left[\begin{array}{c} {[3.3 ;} \\ (677) \\ (6.4] \\ \hline \end{array}\right.$ | $7.6[5.8 ; 9.8]$ |  | $12.8 \underset{[10.3 ; 15.9]}{\text { (279) }}$ | $15.2[12.2 ; 18.9]$ | $15.8[12.6 ; 19.6]$ |  |  |
| Age group | $\leq 54$ years | 429 | $48{ }_{(43-51)}$ | 25/75 | 28.7 | 151 | $5.1 \begin{gathered} {[3.3,3 ;]^{(3,9]}} \\ 7.9] \\ \hline \end{gathered}$ | $8.9\left[\begin{array}{l} {[653)} \\ (25 i) \end{array} 12.3\right]$ | $10.5\left[\begin{array}{c} {[7.6 ; 1} \\ (194) \\ \hline \end{array} 1.3\right]$ | $15.6[11.7 ; 20.6]$ | $18.0[13.5 ; 23.7]$ | $19.1[14.3 ; 25.2]$ |  |  |
| Sex | Female | 616 | $54{ }_{488-61)}$ | 0/100 | 28.3 | 169 | $5.11\left[\begin{array}{c} {[3.560} \\ \hline 4.3] \\ 7.3] \end{array}\right.$ | $7.9\left[\begin{array}{c} {[5.8 ;} \\ \text { [80) } \\ 10.5] \end{array}\right.$ | $9.2\left[\begin{array}{l} \text { [6.9; } 12.12 .1] \\ {[22)} \end{array}\right.$ | $12.4\left[\begin{array}{l} {[9.5 ; 7)} \\ (10.0) \end{array}\right.$ | $15.2[11.7 ; 19.7]$ | $15.2[11.7 ; 19.7]$ |  |  |
| Comorbidities | two to four comorbidities | 431 | $56_{(49-63)}$ | 27/73 | 29.1 | 145 | $3.4\left[\begin{array}{l} {[2.000} \\ 50.8] \\ \hline \end{array}\right.$ | $6.2\left[\begin{array}{c} {[42.196} \\ {[26.3]} \end{array}\right.$ | $9.0\left[\begin{array}{l} {[6.3 ;} \\ (198) \end{array} 12.7\right]$ | $13.9[10.1 ; 18.9]$ | $16.4[12.0 ; 22.2]$ |  |  |  |
| Hospital size | Hospitals with low annual case volumes | 356 | $53_{47-60)}$ | 33/67 | 27.9 | 129 | $5.4\left[\begin{array}{l}{[12.43)} \\ \text { [2, 8.5] }\end{array}\right.$ | $7.7\left[\begin{array}{c}{[5.2 ; 10} \\ (210) \\ 11.4] \\ \hline\end{array}\right.$ | $10.1{ }_{\text {[7.0; }}^{\text {(15) }}$ 14.4] | 13.4 [9.508) 18.6 ] | $16.5[11.7 ; 23.0]$ |  |  |  |

* The ratings are based on the hospitals' quality reports for 2021 and the corresponding IQTIG quality indicators listed there. For elective THAs and TKAs, the case number limits for classification as low case volume are up to 200 , as medium volume 201 to 500 and for the high volume category as more than 500 corresponding procedures per year. For non-elective hip arthroplasties, the limits are speified as up to 50,51 to 100 , and more than 100 ; for unicondylar knee arthroplasties, the limits range up to 30 , 31 to 100 , and over 100 corresponding procedures per year

Table 45 (continued)

### 5.3 Correlation between implant characteristics and arthroplasty outcome

The following two subsections - divided into hip (Section 5.3.1) and knee (Section 5.3.2) arthroplasties - provide examples of some of the correlations between certain arthroplasty characteristics and short to medium-term outcomes. The tables at the end of each section detail the outcomes by implant characteristics.
5.3.1 Impact of implant characteristics in hip arthroplasties
For certain patient groups, the choice of femoral component fixation may decisively affect the arthroplasty outcome. While it makes practically no difference to the revision probability in younger patients whether the femoral component is cemented or not, this decision has a clear impact in older patients (compare with Figure 22 in Section 5.2). The overall revision probabilities observed across all age groups are lower for both elective and non-elective hip arthroplasties involving cemented femoral components (Figure 29).

In the EPRD total hip arthroplasty still mainly relies on three different head sizes: 28 mm ,
32 mm and 36 mm . For the period analysed,
the revision probabilities are higher in both elective and non-elective operations with smaller head components (Figure 30 and Table 46 respectively). This is probably due to a lower risk of dislocation with larger heads.

The larger the head diameter, the lower the probability of revision. However, this risk increases with longer head-neck lengths (Figure 31). However, it should be noted that cases with longer head-neck lengths - e.g., to compensate for a shorter leg length with a more cranial centre of rotation - may have fundamentally worse initial conditions than other arthroplasties. For the period analysed for uncemented femoral components, the EPRD finds better overall outcomes for for short stems when compared to standard stems (Figure 32). It should be noted that short stems are mainly favoured in younger and healthier patients. Nevertheless, the probability of infection for short stems is significantly lower, which cannot be explained solely by differences between patient groups. [4] In terms of the overall outcome, however, there are major differences between the various short and standard stem systems and there are certainly standard stem components whose outcomes approach those of the best short-stems (also refer to Table 61 in the appendix).

Figure 29: Revision probabilities of uncemented and cemented partial hip arthroplasties ( $p<0.0001$ )

Figure 30: Revision probabilities of elective total hip arthroplasties with cemented stems by head size ( $p<0.0001$ )


Figure 31: Revision probabilities of elective total hip arthroplasties with uncemented stems by head-neck lengths ( $p<0.0001$ )


Figure 32: Revision probabilities of elective total hip arthroplasties with uncemented stems by stem type ( $p<0.0001$ )

|  |  |  |  |  |  |  | Revision probabilities after ... |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Type of arthroplasty / category | Type | Number | Age | m/f | BMI | Hosp. | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Elective THAs with uncemented stems |  | 352,072 | $6_{(59.74)}$ | 41/59 | 27.8 | 732 | ${ }^{2} .7$ [2.7.7: 2.88 |  | $\begin{gathered} 3.4[3,3 ; 3.5] \\ (184,499) \end{gathered}$ | ${ }^{3.6}$ [13.55.5.34) 3.7$]$ | $3.8\left[\begin{array}{c} {[3,7826]} \\ \hline, 3.8] \\ \hline \end{array}\right.$ | $3.9\left[\begin{array}{l} {[3.9 ; 4 ; 40]} \\ {[50.0]} \\ \hline \end{array}\right.$ | $\left.4.1{ }_{\text {[20.3i9 }}^{[4.0} 4.2\right]$ |  |
| Bearing | Ceramic / hXLPE | 176,576 | $6^{67}{ }_{\text {(59-74) }}$ | 40/60 | 27.9 | 643 | $2.7\left[\begin{array}{l} {[1.6 ; 2 ; 2 ; 2)} \\ (12)] \end{array}\right.$ | $3.1\left[\begin{array}{l} (116,1,369) \\ \hline(3.2] \end{array}\right.$ | $3.4[3,3 ; 3,5]$ | $3.6[36.5 ; 3.7]$ | $3.7[3.6 ; 6.8]$ | $3.9\left[\begin{array}{c} {[3,8,5 ; 52)} \\ \hline 4.0] \end{array}\right.$ | $4.0\left[\begin{array}{l} {[3,9888)} \\ \hline 9.1] \end{array}\right.$ | $4.1 \underset{(2.2388}{[4.3]}$ |
|  | Ceramic / hXLPE+antioxidant | 66,907 | $67_{(60-75)}$ | 41/59 | 28.0 | 400 | $2.7\left[\begin{array}{l} {[5,53 ; 92)} \\ ; 2] \end{array}\right.$ | $3.0\left[\begin{array}{l} {[2.9 .976)} \\ {[16.1]} \end{array}\right.$ | $3.1\left[\begin{array}{l} {[30.0 ; 30)} \\ (303] \\ \hline \end{array}\right.$ | $3.2\left[\begin{array}{l} {[3.1 ; 73.4 .4]} \\ (20.75] \end{array}\right.$ |  | $3.4\left[\begin{array}{l} {[3.277) ;} \\ {[5.6]} \end{array}\right.$ | $\left.3.4{ }_{\text {[1. } 3.254 .3} 3.6\right]$ |  |
|  | Ceramic / ceramic | 37,919 | $62_{(55-69)}$ | 43/57 | 27.7 | 383 | $2.1\left[\begin{array}{l} {[2,0.92 ; 2]} \\ {[3.3]} \\ \hline \end{array}\right.$ | $2.5\left[\begin{array}{l} {[2.4,4,56)} \\ \hline 2.7] \\ \hline \end{array}\right.$ | $2.7\left[\begin{array}{l} {[21.6 ; 22.9]} \\ {[2,92]} \end{array}\right.$ | $2.9\left[\begin{array}{l} {[1.75 ; 29)} \\ (1.62) \end{array}\right.$ | $3.0\left[\begin{array}{l} {[2.9 ; 3,3.2]} \\ 11,204] \end{array}\right.$ | $3.2\left[\begin{array}{l} {[3.0 ; 13 ; 4]} \\ {[, 73)} \end{array}\right.$ | $3.3\left[\begin{array}{c} {[3.1 .208)} \\ 3.6] \\ \hline \end{array}\right.$ | $3.5\left[\begin{array}{l} {[3.2 ; 2 ; 3)} \\ (x, 8] \end{array}\right.$ |
|  | Ceramic / mXLPE | 28,135 | $70{ }_{(63-77)}$ | 41/59 | 27.8 | 266 | $2.6[2.5 ; 2.8]$ | $3.1[2.9 ; 9.3]$ | $3.5 \underset{\substack{136,3021 \\[13.3}}{ } 3.7]$ | $3.7\left[\begin{array}{c} {[3.5 ; 2 ; 40.0]} \end{array}\right.$ | $3.9\left[\begin{array}{ll} {[3.768)} \\ \hline 4.2] \end{array}\right.$ | $4.1\left[\begin{array}{l} {[3.9911)} \\ \hline 1.4] \end{array}\right.$ | $4.4\left[\begin{array}{l} {[4.1 .535} \end{array}\right)$ | $5.3[4.7 ; 6 ; 6.0]$ |
|  | Ceramic / PE | 18,773 | $72{ }_{(63-78)}$ | 34166 | 27.8 | 477 | $3.4\left[\begin{array}{l} {[31.1 ; 313)} \\ {[13.6]} \end{array}\right.$ |  | $4.5[4.2 .2,4.8]$ | $4.9[4.6 ; 5.2]$ | $5.2\left[\begin{array}{l} {[4,833} \\ {[, 33} \\ 5 \end{array} .5\right]$ | $5.4\left[\begin{array}{l} {[5.1 .1 .63)} \\ 5.8] \\ \hline 1.8 \end{array}\right.$ | $\left.5.8\left[\begin{array}{l} {[5.436} \\ {[236} \end{array}\right) 6.2\right]$ |  |
|  | Ceramicised metal / hXLPE | 9,573 | $67_{(59-74)}$ | 42/58 | 28.1 | 119 | $2.7\left[\begin{array}{l} {[2.4 ; 9 ; 3.1]} \\ {[0,9)} \end{array}\right.$ | $3.0{ }_{\substack{[2.053 \\[2.73 .4]}}^{3.4]}$ | $3.2\left[\begin{array}{l} {[2.9593 .6]} \\ 4.59 \end{array}\right.$ | $3.4 \underset{(3.003]}{[3.8]}$ | $3.6\left[\begin{array}{l} {[3.2 ; 5 ; 4.1]} \\ (4,58) \end{array}\right.$ | $3.7\left[\begin{array}{c} {[3.2,2 ; 4.2]} \\ (4.2] \end{array}\right.$ | $5.7[3.9,9.3]$ |  |
|  | Metal / hXLPE | 7,621 | $74{ }_{(65-79)}$ | 42/58 | 27.8 | 358 | $4.0\left[\begin{array}{l} {[3.6564 .5]} \\ {[65)} \end{array}\right.$ | $4.2\left[\begin{array}{l} {[3.830} \\ 5.850 \\ 4.7] \\ \hline \end{array}\right.$ | $4.6[4.1 .1 ; 5.1]$ | $4.8\left[\begin{array}{l} {[4.3750} \\ {[.75]} \end{array}\right.$ | $5.0[4.50 .5650 .5]$ | $5.1[(4.6 ; 77) 5.7]$ | 5.4 [4.84] 6.1 .1] |  |
|  | Metal / mXLPE | 2,503 | $75_{(68-80)}$ | 36/64 | 27.6 | 149 | $4.7\left[\begin{array}{l} {[3,9 ; 95.6]} \\ {[236} \end{array}\right.$ | $5.4[4.5 \cdot 5: 6.3]$ | $5.6\left[\begin{array}{l} (4.7534) \\ (1.64) \\ 6.6] \end{array}\right.$ | $5.8 \text { [4.9.9; 6.8] }$ | $\left.5.8\left[\begin{array}{c} {[9,922} \\ \hline 926 \end{array}\right] .8\right]$ | $5.9\left[\begin{array}{c} (539) \\ \hline(39) \\ 7.0] \end{array}\right.$ | $6.1 \begin{gathered} {[5.277)} \\ (3.3] \end{gathered}$ | $6.1\left[\begin{array}{l} \left.[5 ; 2)^{2} 7.3\right] \\ 7.3] \end{array}\right.$ |
|  | Metal / PE | 1,627 | $77_{(70-82)}$ | 31/69 | 27.0 | 312 | $6.3\left[\begin{array}{l} {[5.2 ; 2 ; 7.6]} \\ (1,29] \end{array}\right.$ | $6.5\left[\begin{array}{c} {[5.3 ; 7 ; 7)} \\ (1,2) \end{array}\right.$ | $6.7[5.6 ; 8.1]$ | $6.9[5.8 ; 8.8]$ | $7.5\left[\begin{array}{l} {[6.2 ; 9)} \\ (5.0) \\ \hline 9.0] \end{array}\right.$ | $7.7 \text { [6.3; } 1(3.2]$ | $8.1 \begin{aligned} & \text { [6.6; } 6 ; 9.9] \end{aligned}$ |  |
|  | Metal / hXLPE + antiox. | 1,077 | $77_{(70-81)}$ | 37/63 | 27.7 | 150 | $5.7[4.5 ; 7.3]$ | $6.2[4.9 .97 .9]$ | $6.3[5.0 ; 8.8 .0]$ | $6.3[5.0 ; 8.0]$ | $6.3\left[\begin{array}{l} {[5.0 ; 6} \\ 1260 \\ 8.0] \end{array}\right.$ | $6.8\left[\begin{array}{c} {[5.3,8.8]} \\ \text { (i56) } \end{array}\right.$ | ${ }_{6} 6.8$ [5:3; ib $\left.^{8} 8.8\right]$ |  |
|  | Ceramicised metal / PE | 931 | 74 (66-79) | $33 / 67$ | 27.9 | 56 | $4.0\left[\begin{array}{l} {[2.9 ; 5.5]} \\ (70) \\ 5.5] \end{array}\right.$ | $4.8\left[\begin{array}{c} {[3.620} \\ (62) \\ 6.5] \\ \hline \end{array}\right.$ | $5.1\left[\begin{array}{c} {[3.9 ; 6.8]} \\ {[563} \end{array}\right.$ | $5.5[4.1 ; 9 ; 7.3]$ | $5.5[4.1 ; 7.3]$ | $5.5[4.1 .77 .7 .3]$ |  |  |
| Acetabular articulating surface | hXLPE | 193,776 | $6^{67}{ }_{(59}$-74) | 40/60 | 27.9 | 654 |  | $3.2[3.1 ; 3.3]$ | $3.4[3.3 ; 3.5]$ | $3.6\left[\begin{array}{l} {[3,5 ; 6 ; 5)} \\ \hline 3.7] \end{array}\right.$ | $3.8\left[\begin{array}{c} 47.7,4 ; 3 ; \\ {[3.9]} \end{array}\right.$ | $3.9[3.8: 8 ; 4.1]$ | $4.1\left[\begin{array}{c} (1.00449) \\ (1.0) \\ \hline \end{array}\right.$ | $4.2\left[\begin{array}{l} {[4.17 ; 4.3]} \\ (23) \end{array}\right.$ |
|  | hXLPE + antiox. | 68,030 | $68{ }_{(60-75)}$ | 41/59 | 28.0 | 415 | $2.7\left[\begin{array}{c} [2.6 ; 2 ; 25) .8] \\ (520) \end{array}\right.$ | $3.0\left[\begin{array}{l} {[2,9.953]} \\ {[4.2]} \\ \hline \end{array}\right.$ | $3.2\left[\begin{array}{l} (3.13,0 ; 9) \\ \hline(3) 3] \end{array}\right.$ | $3.3[3.2 ; 3.4]$ | $3.4\left[\begin{array}{c} (1,2,4,48 \\ {[3.5]} \end{array}\right.$ | $3.5{ }_{(5.333)}^{[3 ; 3]}$ | $3.5\left[\begin{array}{l} {[3.3,3 i 4)} \\ (0,6] \end{array}\right.$ | $3.5\left[\begin{array}{l} {[3.3 ; 2 ;} \\ (326) \end{array}\right.$ |
|  | Ceramic | 37,923 | $62_{(55-69)}$ | 43/57 | 27.7 | 384 | $2.1\left[\begin{array}{l} {[2, .0 ; 8 ; 5.3]} \end{array}\right.$ |  | $2.8\left[\begin{array}{l} {[2.66,655)} \\ 2.9] \\ \hline \end{array}\right.$ | $2.9[(2.75 ; 33.1]$ | $3.0\left[\begin{array}{l} {[11.97055} \\ \hline 3.2] \end{array}\right.$ | $3.2\left[\begin{array}{c} (3,0 ; 13 ; 3) \\ 3.4] \end{array}\right.$ | $3.3 \underset{(3.228)}{[3.1 ; 3]}$ | $3.5\left[\begin{array}{l} {[3.2 ; 2 ; 3)} \\ (x, 8] \end{array}\right.$ |
|  | mXLPE | 30,660 | $71_{(63-77)}$ | 41/59 | 27.8 | 284 | $2.8[2.6 ; 3.0]$ | $3.3[3.1 ; 3.5]$ | $3.7[3.4 ; 3.9]$ | $3.9 \begin{gathered} {[3.7 ; 7 ; 4.2]} \end{gathered}$ | $4.0\left[\begin{array}{c} {[3.8 ; 8 ; 5.3]} \\ {[.50]} \end{array}\right.$ | $4.3[4.0504 .5]$ | $4.5\left[\begin{array}{c} (2,242) \\ \hline 1.8] \end{array}\right.$ | $5.3[4.8 ; 8 ; 6.0]$ |
|  | PE | 21,332 | 72 (64-78) | $34 / 66$ | 27.7 | 534 | 3.6 [13.4.3i 3.9$]$ | ${ }_{4} 4.3[4.0 .04 .4 .5]$ | $4.7{ }_{\substack{(14.3522)}}^{[4.4 .0]}$ |  | $5.4{ }_{\substack{\text { (1.003) }}}^{\text {[ } 5.7]}$ | $5.6[5.3020$ [ 6.0$]$ | $6.0{ }_{[2.4,421}[6.4]$ |  |

Table 46: Revision probabilities for different types and characteristics of hip arthroplasties

|  |  |  |  |  |  |  | Revision probabilities after ... |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Type of arthroplasty / category | Type | Number | Age | m/f | BMI | Hosp. | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Head component | Ceramic | 328,639 | ${ }^{67}{ }_{(59-74)}$ | 41/59 | 27.8 | 727 | 2.7 [2066.788) 2.7$]$ | $3.1 \underset{(2183 ; 38)}{[3.0 ;} 3]$ | $3.3[3.3 ; 3.4]$ |  | $3.7\left[\begin{array}{l} {[3.6,6 ; 3,3]} \\ (8,8] \\ \hline \end{array}\right.$ | $3.9\left[\begin{array}{l} 3,8.8: 3.90) \\ {[4,9]} \end{array}\right.$ |  | ${ }_{4} 4.3[4.1 .73 .4 .4]$ |
|  | Metal | 12,851 | $75_{(66-80)}$ | $39 / 61$ | 27.7 | 548 | $\left.4.6{ }_{\text {(10.57) }}^{[4.2 ; ~} 4.9\right]$ | $4.9\left[\begin{array}{c} {[8.5954)} \\ 5.3] \\ \hline \end{array}\right.$ |  | $5.4\left[\begin{array}{l} {[5.094)} \\ 5.8] \end{array}\right.$ |  | $5.7\left[\begin{array}{l}{[5.3060)} \\ (2.43) \\ \hline\end{array}\right.$ | $\left.6.0{ }_{\text {[1.5.4i) }} 6.6\right]$ | $6.1 \underset{(527)}{[56 ; 6.7]}$ |
|  | Ceramicised metal | 10,575 | ${ }^{67}{ }_{(60-75)}$ | 41/59 | 28.1 | 122 | $2.9\left[\begin{array}{l} {[2.525]} \\ {[3.2]} \\ \hline \end{array}\right.$ | $3.2\left[\begin{array}{l} {[2.870)} \\ (6,5) \end{array}\right]$ | $3.4\left[\begin{array}{l} {[3,097)} \\ {[3.8]} \end{array}\right.$ | $3.6\left[\begin{array}{l} {[3.2422)} \\ {[4.0]} \end{array}\right.$ | $3.8\left[\begin{array}{l} {[1.4 .422 .4 .2]} \\ 4.2] \end{array}\right.$ | $3.8\left[\begin{array}{c} \left(3,400^{2} ; 4.3\right] \\ (4.3] \end{array}\right.$ | $5.7[4.1 .18 .1]$ |  |
| Head size | 28 mm | 18,103 | $67_{(58-75)}$ | 11/89 | 27.3 | 622 | $3.3\left[\begin{array}{c} {[15.1,2366} \\ \hline 1.6] \end{array}\right.$ | $3.7 \begin{gathered} {[3.4,4988} \\ \hline 1.0] \end{gathered}$ | $4.0[3.7 ; 4.3]$ | $4.2\left[\begin{array}{c} (8.273), 9 \end{array} 4.5\right]$ | $4.3 \underset{(4.992]}{[4.0]}$ | $4.4\left[\begin{array}{l} {[3.554)} \\ 4.7] \\ 4.7] \end{array}\right.$ | $4.6[4.24 .4 .9]$ |  |
|  | 32 mm | 188,791 | $6^{67}{ }_{(60-75)}$ | 32/68 | 27.7 | 729 | $2.8\left[\begin{array}{l} {[2.7 \div 2.8]} \\ (15.300 \end{array}\right.$ | $3.2\left[\begin{array}{l} {[33.1 ; 3.3 .3]} \\ (130.68) \end{array}\right.$ | $3.4[13.3 ; 3.5]$ | $3.6{\underset{(76,569)}{[3.5 ; 3.7]}]}^{2}$ | $3.8\left[\begin{array}{l} {[3.7 .73 .9]} \\ (51,183) \end{array}\right.$ | $4.0[3.9 ; 4.1]$ | $4.1\left[\begin{array}{ll} {[1.0 .073)} \\ \hline 1.3] \end{array}\right.$ | $4.4[4.2 .2 ; 4.6]$ |
|  | 36 mm | 144,529 | ${ }^{67}{ }_{(59-74)}$ | 56/44 | 28.1 | 654 | $2.6\left[\begin{array}{l} {[113.6 ; 802)} \\ (123] \end{array}\right.$ | $3.1_{(90.571)}^{[3.0 ; 3.2]}$ | $3.3[33.2,3.4]$ | $3.5_{[49,953]}^{[3.4 ; 3]}$ |  | $3.8\left[\begin{array}{l} {[18,712)} \\ \hline 4.0] \end{array}\right.$ | $4.0$ | $4.2[4.0 .04 .4]$ |
| Head-neck length | XS | 2,671 | $70_{(62-76)}$ | 31/69 | 27.3 | 79 | $2.7\left[\begin{array}{l} {[2,1 ; 1 ; 30.4]} \\ (2,30 \end{array}\right)$ | $3.2\left[\begin{array}{ll} {[2.5750} \\ (0.70) \\ 3 \end{array}\right.$ | ${ }^{3.5}\left[\begin{array}{l}\text { [1.8.3; }\end{array}\right.$ | $3.7{ }^{\text {[ }}$ [3.0\%2) 4.5$]$ | $\left.{ }^{3.8}{ }^{[3.150]} 4.7 .7\right]$ | $4.0{ }_{(3334]}^{[3.27 .9]}$ |  |  |
|  | S | 142,072 | $68_{(60-75)}$ | 33/67 | 27.5 | 717 | $2.4$ | $2.8\left[\begin{array}{l} {[2,7.724]} \\ {[9,8]} \end{array}\right.$ | $3.0\left[\begin{array}{l} {[2,9,9 ; 11)} \\ 3.1] \end{array}\right.$ | $3.2\left[\begin{array}{l} {[3.1 .1 .3050} \\ {[5.3]} \end{array}\right.$ | $3.3\left[\begin{array}{l} (3,2,2 ; 71) \\ 3,4] \end{array}\right.$ | $3.5[3.4 ; 3 ; 3.6]$ | $3.6\left[\begin{array}{l} {[3,546} \\ \hline 7.56 \\ 3.8] \end{array}\right.$ | $3.9\left[\begin{array}{l} {[3.79 ; 4.1]} \\ {[.019} \end{array}\right.$ |
|  | M | 128,725 | ${ }^{67}{ }_{(59}{ }^{-744}$ | 42/58 | 28.0 | 726 | $2.7\left[\begin{array}{l} {[2.6 ; 5 ; 2.8]} \\ (1050.05] \end{array}\right.$ |  |  | $3.6\left[\begin{array}{c} {[49,580)} \\ {[3 ; 7]} \end{array}\right.$ | $3.7\left[\begin{array}{c} {[3.6 ; 2 ; 06} \\ 3.8] \end{array}\right.$ | ${ }^{3.9}{ }_{[13.8895]}^{[13.70]}$ | $4.0\left[\begin{array}{c} {[3.80 .89 .4 .1]} \\ 70.509 \end{array}\right.$ | $4.11\left[\begin{array}{l} {[2,0 ; 43: 4.3]} \end{array}\right.$ |
|  | L | 60,366 | $66_{(59-74)}$ | 50/50 | 28.4 | 720 | $3.2\left[\begin{array}{l} {[49,0,462)} \\ {[3.3]} \end{array}\right.$ | $3.6\left[\begin{array}{l} {[3.5 ; 9 ; 9]} \\ {[4.8]} \\ \hline \end{array}\right.$ | $3.9\left[\begin{array}{l} {[32.855)} \\ {[3.1]} \end{array}\right.$ | $4.1\left[\begin{array}{c} {[3.4 .9355} \\ \hline 4.3] \end{array}\right.$ | $4.2\left[\begin{array}{l} {[1,1.0074 .4]} \\ \hline 1.4] \end{array}\right.$ |  | $4.7\left[\begin{array}{l} {[4.5 \cdot 5 \cdot 5.0]} \\ 4.29] \end{array}\right.$ |  |
|  | XL | 14,508 | $66_{(58-73)}$ | 57/43 | 28.7 | 639 | $3.9\left[\begin{array}{l} {[11,672)} \\ \hline 4.3] \\ \hline \end{array}\right.$ | $4.4\left[\begin{array}{c} {[4.1 .704)} \\ 9.7 .7] \\ \hline \end{array}\right.$ | $4.7\left[\begin{array}{c} {[4.4552 .5 .1]} \\ (0,52) \end{array}\right.$ | $5.0\left[\begin{array}{l} {[5.759 ;)} \\ (5.4] \end{array}\right.$ | $5.4 \underset{(3,7), 0 ; 5)}{5.8]}$ | $5.6[(2.172)]$ | $6.1\left[\begin{array}{c} {[555)} \\ (65) \\ \hline 6.7] \\ \hline \end{array}\right.$ | $6.1[5.5 ; 6.7]$ |
|  | xxL | 1,429 | $6_{(59.74)}$ | 62/38 | 28.7 | 239 |  | $\underset{(993)}{5.8} \underset{[4.7}{ } 7.2]$ | $6.0\left[\begin{array}{c} (409) \\ (002) \\ 7.5] \end{array}\right.$ | $6.2 \underset{(562)}{[50} 7.6]$ | $6.5\left[\begin{array}{c} 5.3,3 ; 0) \\ (4000 \end{array}\right)$ | $6.5\left[\begin{array}{l} {[5.3 ; 5)} \\ (250) \\ 8.0] \end{array}\right.$ | 6.9 [5.5; 8 8.6] |  |
| Cup type | Modular cup | 324,758 | $6_{(159-74)}$ | 41/59 | 27.8 | 727 | $2.7\left[\begin{array}{l} {[2.7 ; 2.8]} \\ {[26,408)} \end{array}\right.$ | $3.1[331.1 ; 3.2]$ | $3.4\left[\begin{array}{ll} {[17.3 ; 3 ; 3)} \\ {[8]} \end{array}\right]$ | $3.6\left[\begin{array}{l} {[125,5 ; 53)} \\ 3.7] \\ \hline \end{array}\right.$ | $3.7$ | $3.9[33.8 ; 4.0]$ |  | $4.3[4.2,2 ; 4.5]$ |
|  | Monobloc cup | 22,700 | $68{ }_{(60-76)}$ | $39 / 61$ | 27.8 | 498 |  | $2.6\left[\begin{array}{l} {[2.4,4,2.9]} \\ {[14,43} \\ \hline \end{array}\right.$ |  | $3.0\left[\begin{array}{ll} {[2.790} \\ {[0,3.2]} \end{array}\right.$ | $3.2\left[\begin{array}{l} {[2,900)} \\ \hline 3.4] \end{array}\right.$ | $3.3\left[\begin{array}{l} {[3,0,0,3.6]} \\ (2,65 \end{array}\right.$ | 3.4 [1.19;93] 3.7$]$ | $3.5\left[\begin{array}{l} {[3.120} \\ (320) \\ 4.0] \\ \hline \end{array}\right.$ |
|  | Revision cup | 2,652 | $64_{(55-73)}$ | 32/68 | 27.3 | 316 | $6.6[5.7 .797 .6]$ | $7.8 \underset{(16.82 ;)}{[(1,8) 9]}$ |  | $8.2\left[\begin{array}{l} {[7.2 ; 9.9 .4]} \\ (0.018 \end{array}\right)$ | $8.5\left[\begin{array}{c} {[7.4 ; 5,9.7]} \\ (6,5) \end{array}\right.$ | $8.8[7.77 ; 10.1]$ |  |  |
|  | Dual mobility | 1,881 | $73_{(63-80)}$ | $38 / 62$ | 27.6 | 270 | $5.8\left[\begin{array}{c} (4.244) \\ (1,24) \\ 7.0] \end{array}\right.$ | $6.6\left[\begin{array}{c} {[5.566} \\ (86) \\ 7.9] \\ \hline \end{array}\right.$ | $6.9 \underset{\substack{5 \\ 5 \\ 5078}}{ } 7 ; 8.2]$ | $7.0\left[\begin{array}{c} \text { [3588) } \\ {[8.5]} \\ \hline \end{array}\right.$ | $7.0\left[\begin{array}{c} \text { [20.95 } \\ (8.5] \\ \hline \end{array}\right.$ | $7.0 \underset{(106)}{[5.9 ; 8]}$ |  |  |
| Acetabular component fixation | Uncemented | 347,108 | ${ }^{67}{ }_{(59.74)}$ | 41/59 | 27.8 | 732 | $2.7\left[\begin{array}{l} {[2,7 ; 2.8]} \\ (2220,04 \\ \hline \end{array}\right.$ | $3.1\left[\begin{array}{l} {[330.1 ; 933)} \\ \hline 1.2] \end{array}\right.$ | $3.4[138.3 ; 4.4 .4]$ | $3.6\left[\begin{array}{l} (133,5 ; 299) \\ \hline 1.6] \end{array}\right.$ | $3.7[3.6 ; 3.8]$ |  | $4.0\left[\begin{array}{l} {[2.00,021.1} \\ 4.1] \end{array}\right.$ | ${ }_{4} 4.3[4.2 .2 ; 4.4 .4]$ |
|  | Cemented | 4,849 | $74(66-80)$ | $24 / 76$ | 27.1 | 528 | $5.3[4.7,7 ; 6.0]$ |  | $6.5\left[\begin{array}{c} {[5.82727} \\ (2,3] \end{array}\right.$ | $6.7\left[\begin{array}{ll} {[6.999} \\ \hline 1.07 \\ 7 \end{array}\right.$ | $7.2\left[\begin{array}{ll} {[6.4942 ;)} \\ 0.1] \end{array}\right.$ | $7.4 \underset{\substack{6.63) \\(63) \\ \hline 8.3]}}{ }$ | $7.6\left[\begin{array}{c} {\left[6.76{ }_{2}(26.6]\right.} \\ \hline \end{array}\right.$ | $8.4[6.8 ; 8 ; 10.4]$ |
| Stem type | Femoral stem with modular head | 297,366 | $68_{(60-75)}$ | 40/60 | 27.9 | 730 | $2.8\left[\begin{array}{l} {[2,7,7,2.9]} \\ {[293)} \end{array}\right.$ | $3.2[33.2 ; 3.3]$ | $3.5[3.4 ; 4 ; 3.6]$ | $3.7\left[\begin{array}{ll} {[16.6 ; 2 ; 30} \end{array}\right]$ | $3.8\left[\begin{array}{c} {[37.760,3.9]} \\ (x, 76) \end{array}\right.$ | $4.0$ | $4.2[4.1 ; 4.3]$ | $4.4[4.3 .3 ; 4.4]$ |
|  | Short stem | 46,147 | $62_{(55-69)}$ | 44/56 | 27.8 | 391 | $2.1\left[\begin{array}{l} {[2.0,2 ; 2]} \\ \hline 2.3] \\ \hline \end{array}\right.$ | $2.5\left[\begin{array}{l} {[2,4,460)} \\ \hline(2,7] \end{array}\right.$ | $2.7\left[\begin{array}{l} {[2.51544)} \\ {[2.8]} \end{array}\right.$ | $2.8\left[\begin{array}{c} [1,6,6 ; 5) \cdot 3.0] \\ \hline \end{array}\right.$ |  | $3.1 \underset{(4.931)}{[2.93]}$ | $\left.3.1{ }^{[2.99523)} 3.4\right]$ | $3.1{ }_{(5855}^{[2.9 ; ~ 3.4]}$ |
|  | Femoral neck prosthesis | 5,469 | $60_{(53-67)}$ | 46/54 | 27.5 | 120 | $2.2[1.8 ; 2.6]$ | $2.6\left[\begin{array}{c} {[2.2383)} \\ {[3.0]} \\ \hline \end{array}\right.$ | $2.9$ | $3.1\left[\begin{array}{l} {[2.7273 .7]} \\ {[2.27)} \end{array}\right.$ | $3.3[(2.911)]$ | $3.3\left[\begin{array}{l} {[2.8283 .3 .9]} \\ (1,23 \end{array}\right.$ | $3.6\left[\begin{array}{l} {[3855} \\ \hline 0 ; 4.4] \end{array}\right.$ |  |
|  | Modular stem | 1,734 | $69_{(61-76)}$ | 38/62 | 27.7 | 109 | $4.3\left[\begin{array}{l} {[3.565)} \\ (1.4) \\ 5.4] \\ \hline \end{array}\right.$ | $4.9[4.090 .6 .1]$ | $5.3[4.3 ; 6.5]$ | $5.7[4.6 ; 6.9]$ | $5.9\left[\begin{array}{c} {[4087)} \\ {[7.2]} \\ 7 \end{array}\right.$ | $6.3[5.1 ; 7.6]$ | $6.5[5.3 ; 8.1]$ |  |
|  | Revision or tumour stem | 1,295 | $74{ }_{(63-80)}$ | 38/62 | 26.4 | 374 | $11.7[10.0 ; 13.6]$ | $13.2[11.3 ; 15.2]$ | $13.4\left[\begin{array}{c} {[11.6 ; 3 ;} \\ (5,3.5] \end{array}\right.$ | $13.6[11.7 ; 15.7]$ | $14.8[12.7 ; 17.2]$ | $14.8[12.7 ; 17.2]$ | $14.8[12.7 ; 17.2]$ |  |
| Reconstruction shell | Without reconstruction shell | 351,626 | $6_{(59-74)}$ | 41/59 | 27.8 | 732 | $2.7[2.7 ; 2.8]$ | $3.1{ }_{(233,3 ; 37)}^{[3.2]}$ | $3.4\left[\begin{array}{l} {[184,3,977)} \\ {[3.5]} \end{array}\right.$ | $3.6[33.5 ; 3.7]$ | $3.7[3.7 ; 7 ; 3.8]$ |  | $4.1[4.0 ; 4.2]$ | $4.3\left[\begin{array}{c} (5.528) \\ \hline 4.2 ; 5] \end{array}\right.$ |
|  | With reconstruction shell | 446 | ${ }^{69}{ }_{(59}$-78) | $36 / 64$ | 26.1 | 192 | $10.0\left[\begin{array}{c} {[7.5 ;} \\ (38) \\ 13.2] \end{array}\right.$ | $11.4\left[\begin{array}{l} {[8.7 ; 9 ; 1} \\ k 28.8] \\ \hline \end{array}\right.$ | $12.7 \text { [9.8; } 16.3]$ | $13.1[10.1 ; 16.8]$ | $14.1[10.9 ; 18.2]$ | $14.1\left[\begin{array}{c} {[(59.9 ;)} \\ (59.2] \end{array}\right.$ |  |  |
| Fixation | Uncemented | 347,108 | $67_{(59-74)}$ | 41/59 | 27.8 | 732 | $2.7\left[\begin{array}{l} {[282.7 ; 044)} \\ \hline 2.8] \end{array}\right.$ | $3.1[33.1 ; 3.2]$ |  | $3.6_{(133,299)}^{[33 ; 3.6]}$ | $3.7\left[\begin{array}{l} {[38,617)} \\ \hline 6 ; 3] \end{array}\right.$ | $3.9\left[\begin{array}{c} {[3,8,8,464.0]} \\ \hline 14.0 \end{array}\right.$ | $4.0[4.0 .04 .1]$ | $4.3[4.2 .2 ; 4.4]$ |
|  | Reverse-hybrid | 4,849 | $74(66-80)$ | $24 / 76$ | 27.1 | 528 |  | $5.9 \underset{(3.029)}{[5.3 ;} 6]$ | $6.5\left[\begin{array}{l} {[5.82727} \\ 7.3] \\ \hline \end{array}\right.$ |  | $7.2[6.4 ; 8.1]$ | $7.4 \underset{(637)}{[6.6 ; 8.3]}$ |  | $8.4\left[\begin{array}{c}\text { [62) } \\ \text { (62) } \\ \\ 0\end{array} 0.4\right]$ |

Table 46 (continued)

|  |  |  |  |  |  |  |  |  |  | Revision prob | ilities after ... |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Type of arthroplasty / category | Type | Number | Age | m/f | вMI | Hosp. | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Elective THAs with cemented ste |  | 95,671 | $79_{(75-82)}$ | 25/75 | 26.6 | 707 |  | $2.7\left[\begin{array}{c} {[2.6 ; 9 ; 2.8]} \\ (6,98] \end{array}\right.$ | $2.9[2.8 \cdot 3.3 .1]$ | $3.1\left[\begin{array}{l} {[3.0 ; 3.3 .3]} \\ (3030) \end{array}\right.$ | $3.4\left[\begin{array}{l} {[3.2 ; 3 ; 3.5]} \\ (2302) \end{array}\right.$ | $3.6[3.4 ; 3.7]$ | $3.8\left[\begin{array}{l}{[3.655]} \\ 4.0]\end{array}\right.$ | $4.1\left[\begin{array}{c} {[3.84 .84 .3]} \\ 10.3] \\ \hline \end{array}\right.$ |
| Bearing | Ceramic / hXLPE | 45,192 | $78{ }_{(74-82)}$ | 25/75 | 26.6 | 542 | $2.1[1(15,9 ; 23) 2.2]$ | $2.4{ }_{[20,9,45)}^{[2.5]}$ | $2.6[2.5 ; 2.8]$ | $2.8{ }_{[14,975)}^{[2,6 ; 3]}$ | $3.0\left[\begin{array}{l\|l\|:\|c:c\|} {[3.2]} \\ 3.2] \end{array}\right.$ | $3.2\left[\begin{array}{l} {[3,0,0 ; 3,3.4]} \\ \hline \end{array}\right.$ | $3.4\left[\begin{array}{l} {[3.1,13 i 3} \\ (2,7] \end{array}\right.$ |  |
|  | Ceramic / PE | 12,164 | $79_{(75-82)}$ | 23/77 | 26.6 | 461 | $2.3\left[\begin{array}{ll} {[2.1 .4} & 2.6] \\ \text { and } \end{array}\right.$ | $2.7\left[\begin{array}{l} {[2.5063} \\ \hline(3.1] \\ \hline \end{array}\right.$ | $3.0\left[\begin{array}{l} {[2.7533 .3]} \\ {[0.3]} \end{array}\right.$ | $3.1[2.8 ; 3.5]$ | $3.2\left[\begin{array}{l} {[2.9 .9 .93 .6]} \\ 4.50 \end{array}\right.$ | $3.5\left[\begin{array}{c} {[3.26 .23 .9]} \\ (2.81) \end{array}\right.$ | $3.6\left[\begin{array}{l} {[3.2355} \\ (1.250] \\ \hline \end{array}\right.$ | $3.9\left[\begin{array}{c} {[3.4 ; 4.5]} \\ (3,5) \\ \hline \end{array}\right.$ |
|  | Metal / hXLPE | 10,376 | $80_{(77-83)}$ | 27/73 | 26.6 | 362 | $2.8[(2.5 ; 5 ; 2]$ | $3.1[(2.8 ; 353.4]$ | $\left.3.2\left[\begin{array}{l} {[2.9515} \end{array}\right) 3.6\right]$ |  | $3.6\left[\begin{array}{l} {[3.2424 .4 .1]} \\ \hline \end{array}\right.$ | $4.0$ | $4.1\left[\begin{array}{l} {[3.635} \\ {[4.7]} \\ 4.7] \end{array}\right.$ |  |
|  | Ceramic / hXLPE+antioxidant | 8,350 | $79_{(74-83)}$ | 21/79 | 26.6 | 270 | $2.2[1.9,9.2 .5]$ | $2.4\left[\begin{array}{l} {[4.956)} \\ {[2.8]} \\ \hline \end{array}\right.$ |  | $2.9{ }_{[2.36,6)}^{[2.4]}$ |  | $3.4\left[\begin{array}{l} {[2.97)} \\ (6.0] \end{array}\right.$ | $3.6\left[\begin{array}{c} 13.004 \\ {[234} \\ 4.3] \end{array}\right.$ |  |
|  | Metal / PE | 7,420 | $81_{(77-84)}$ | 25/75 | 26.2 | 424 | $3.4 \underset{(6.013)}{[3.0 ;} 3.9]$ | $3.8[3.4 ; 4.3]$ | $4.1\left[\begin{array}{l} {[3.6828 .64} \\ 4.6] \\ \hline \end{array}\right.$ | $4.3\left[\begin{array}{l} (3.9092) \\ \hline 4.9] \\ \hline \end{array}\right.$ | $4.5[4.0 .05 .1]$ | $4.6[4.1 \cdot 5.5 .2]$ | $4.9[4.3 .55 .5]$ | $6.1[4.8 ; 7.9]$ |
|  | Ceramic / mXLPE | 5,189 | $79_{(74-82)}$ | 22/78 | 26.3 | 188 | $2.6\left[\begin{array}{l} {[2.2 ; 2 ; 3)} \\ (42)] \end{array}\right.$ | $3.1\left[\begin{array}{c} (2.277) \\ \hline 3 ; 3.6] \end{array}\right.$ | $3.3 \underset{(2,487)}{[2.8 ; 3.9]}$ | $3.7\left[\begin{array}{l} [1.1 .17) ; 4.3] \\ \hline \end{array}\right.$ | $4.1\left[\begin{array}{ll} {[3.558} \\ \hline 1.58 \\ 4.8] \\ \hline \end{array}\right.$ | $4.1\left[\begin{array}{c} {[3.508 .4 .9]} \\ (80) \end{array}\right.$ | $4.3[3.6 ; 5.0]$ |  |
|  | Metal / mXLPE | 2,155 | $881_{(78-85)}$ | $24 / 76$ | 26.0 | 162 | $3.8\left[\begin{array}{ll} {[3,1,766} \\ \hline 1.7 .7] \\ \hline \end{array}\right.$ | $4.1 \text { [3.3; } 5.1 .1]$ | $4.5[3.7 .75 .5]$ | $5.1\left[\begin{array}{c} {[4.2866} \\ \hline(6.2] \\ \hline \end{array}\right.$ | $5.8[4.7 .77 .0]$ | $5.8[4.7 .7 .7 .0]$ | $6.6[5.1 .18 .8]$ |  |
|  | Ceramic / ceramic | 1,560 | $76_{(70-80)}$ | $24 / 76$ | 26.9 | 123 | $1.4\left[\begin{array}{ll} {[0.9262 .92} \\ \hline 1.36 \end{array}\right.$ | $1.6[1.1 ; 2 ; 4]$ | $1.7\left[\begin{array}{ll} 1.2 .22 & 2.5] \\ (4.024 \end{array}\right)$ | $2.1[1.5 \cdot 3.1]$ | $2.7[1.9 \cdot 3.8]$ | $3.1\left[\begin{array}{l} {[2.2 ; 9 ; 9} \\ (3.4] \end{array}\right.$ | ${ }^{3.4}{ }^{[2.455]}$ [4.9] |  |
|  | Metal / hXLPE+antioxidant | 1,106 | $80_{(77-84)}$ | 27/73 | 26.3 | 145 | $3.3\left[\begin{array}{c} \text { 2.4.4: } 4.6] \\ (230) \end{array}\right.$ | $3.8[2.8 ; 5.2]$ | $4.0\left[\begin{array}{l} {[3 / 0 ; 9,5.5]} \\ \hline(4) \end{array}\right.$ | $4.3[3.1 .1 ; 5.8]$ | $4.3\left[\begin{array}{l} (2.14 ; 5) \\ 5.8] \\ \hline \end{array}\right.$ | $4.3\left[\begin{array}{l} 3.1715 .5 \\ (1 i 3) \\ 5.8] \end{array}\right.$ |  |  |
|  | Metal / Metal | 763 | $56_{(51-61)}$ | 93/7 | 28.0 | 31 | $0.9\left[\begin{array}{c} {[0.4 ; 3 ;} \\ (63) \\ 1.9] \\ \hline \end{array}\right.$ | ${ }^{1.5}{ }_{\text {[ } 0.9 \text { (iof) } 2.8]}$ |  |  | $2.7[1.644 .3]$ | $2.7{ }_{(1129}^{[1.6 ; ~ 4.3]}$ |  |  |
|  | Ceramicised metal / hXLPE | 737 | $79_{(75-83)}$ | $24 / 76$ | 26.7 | 54 | $2.3\left[\begin{array}{c} (1,49 ;) \\ (5 \cdot 7) \\ \hline \end{array}\right.$ | $2.5\left[\begin{array}{c} 13.5 ; 1) \\ (3.0] \end{array}\right.$ | $2.5\left[\begin{array}{c} (1255) \\ \hline, 5 ; 0] \\ \hline \end{array}\right.$ | $3.3 \begin{gathered} (1,0 ; 8) \\ (19.4] \\ 5.4] \end{gathered}$ | $3.3\left[\begin{array}{c} \left.(2,0 ;]^{2} 5.4\right] \\ 5.4] \end{array}\right.$ |  |  |  |
|  | Ceramicised metal / PE | 375 | $80_{(77-83)}$ | 20/80 | 26.4 | 34 | $2.5\left[\begin{array}{c} (1.30) \\ (300) \\ 4.7] \end{array}\right.$ | $3.2\left[\begin{array}{c} 11.8 ; 8) \\ 1238 \\ 5 \end{array}\right)$ | $3.2[1.8 ; 5.7]$ | $3.2[11.85 .5]$ | $3.2\left[\begin{array}{c} 11.8: 5.7] \\ \text { (iodic } \\ 5.7] \end{array}\right.$ |  |  |  |
| Acetabular articulating surface | hXLPE | 56,305 | $79_{(75-82)}$ | 25/75 | 26.6 | 578 | $2.2\left[\begin{array}{l} {[1.4,3,55)} \\ \hline 2.3] \end{array}\right.$ | $2.5\left[\begin{array}{\|c\|c\|c\|c\|c\|} {[2.7]} \\ \hline \end{array}\right.$ | $2.7\left[\begin{array}{ll} {[2.6970)} \\ {[2.9]} \end{array}\right.$ |  | $3.1{ }^{[3.0 .0,3.3]}[1,222]$ | 3.3 [3.1.7.3.5] | $3.5\left[\begin{array}{l} {[3,3 ; 7 i]} \\ (2,8] \\ \hline \end{array}\right.$ |  |
|  | PE | 19,960 | $80_{(76-83)}$ | $24 / 76$ | 26.4 | 551 | $2.7\left[\begin{array}{ll} {[1.5 .573)} \\ \hline 1.0] \end{array}\right.$ | $3.1[(14.937) 3.4]$ | $3.4\left[\begin{array}{c} {[1.1931 ; 37]} \\ (1,7] \end{array}\right.$ | $\text { 3.6 } 3.3 .3: 3.9]$ | $3.7\left[\begin{array}{l} {[3.4,4,4.0]} \\ \hline(2) \end{array}\right.$ | $3.9\left[\begin{array}{l} {[3,6: 63.4 .2]} \\ 4.43 \end{array}\right.$ | $4.0\left[\begin{array}{l} {[3.774 .4 .4]} \\ (1,98) \end{array}\right.$ | $4.6[4.1 .15 .5 .2]$ |
|  | hXLPE + antiox. | 9,466 | $79_{(75-83)}$ | 22/78 | 26.6 | 306 | $2.3\left[\begin{array}{ll} {[2,1 ; 999} \end{array} 2.7\right]$ | $2.6[2.3 ; 2 ; 2.9]$ | $2.9\left[\begin{array}{c} {[2.6 ; 7,3.3]} \\ {[4.3)} \\ \hline \end{array}\right.$ | $3.1\left[\begin{array}{l} {[2.7 .737 .5]} \\ 2.57 \end{array}\right.$ | $3.4\left[\begin{array}{c} {[3.0554 .09]} \\ 11.54] \end{array}\right.$ | $3.5\left[\begin{array}{l} (3,00) \\ (i 20) \\ 4.1] \end{array}\right.$ | $3.8\left[\begin{array}{c} {[3.268]} \\ 1.6] \\ \hline \end{array}\right.$ | $3.8[3.2 ; 4.6]$ |
|  | mXLPE | 7,345 | $79_{(75-83)}$ | 23/77 | 26.2 | 236 | $3.0\left[\begin{array}{c} {[2.6: 963.4]} \\ {[5.96} \end{array}\right.$ | $3.4\left[\begin{array}{l} {[3.0 ; 75]} \\ {[5.8]} \\ \hline \end{array}\right.$ | $3.7\left[\begin{array}{l} [3.3535) 4.2] \\ \hline \end{array}\right.$ | $4.1\left[\begin{array}{l} {[3.6 ; 64.6]} \\ \hline(2,73) \\ \hline \end{array}\right.$ | $4.6\left[\begin{array}{c} {[4.0 ; 7)} \\ (4.37) \\ 5.2] \\ \hline \end{array}\right.$ | $4.6[4.1,5 \cdot 5.3]$ | $5.0[4.3: 5.7]$ | $5.0[4.3 ; 5.5]$ |
|  | Ceramic | 1,560 | $76_{(00-80)}$ | $24 / 76$ | 26.9 | 123 | $1.4\left[\begin{array}{l} {[1.3262)} \\ \hline 1.1] \end{array}\right.$ | $1.6[(1.1,1 ; 2.4]$ | $1.7\left[\begin{array}{ll} (1.22 ; 24) \\ (4.5] \\ \hline \end{array}\right.$ | $2.1[1.5: 3.1]$ | $2.7\left[\begin{array}{c} 1.99 ; 3.8] \\ (629) \end{array}\right.$ | $3.1\left[\begin{array}{c} {[2.2 ; 9,4.4]} \\ (3,9) \end{array}\right.$ | $3.4[2.3: 4.9]$ |  |
|  | Metal | 763 | $56_{(51-61)}$ | 93/7 | 28.0 | 31 | $\left.0.9\left[\begin{array}{c} {[0.43)} \\ (683) \\ 1 \end{array}\right] .9\right]$ | $\left.1.5\left[\begin{array}{c} {[0.906} \\ (600 \\ 2 \end{array}\right) .8\right]$ | $2.3\left[\begin{array}{c} 1.45 ; 3] \\ (518) \\ 3 \end{array}\right]$ | $2.7[1.6 ; 4.3]$ | $2.7\left[\begin{array}{c} 1.664 .6] \\ i .24 j \end{array}\right)$ | $2.7\left[\begin{array}{c} (12 ;) \cdot 6 ; 3] \\ (1.3] \end{array}\right.$ |  |  |
| Head component | Ceramic | 72,513 | $78_{(74-82)}$ | $24 / 76$ | 26.6 | 682 | $2.2\left[\begin{array}{c} {[5,7.0,56} \\ {[20.3]} \end{array}\right.$ | $2.5\left[\begin{array}{l} {[2,4,452]} \end{array} 2.6\right]$ | $2.7\left[\begin{array}{l} (2,62,620) \\ \hline(20) \end{array}\right.$ | $2.9\left[\begin{array}{l} {[2.8,859.1]} \\ {[20.1]} \end{array}\right.$ |  | $\underset{\substack{9.990}}{3.3,5]}$ | $3.5\left[\begin{array}{l} {[3,3 ; 23)} \\ 4.7] \\ \hline \end{array}\right.$ | $3.7\left[\begin{array}{ll} {[3.552} \\ (1,52) \\ 4.0] \end{array}\right.$ |
|  | Metal | 22,034 | $80_{(77-84)}$ | 28/72 | 26.5 | 584 | $3.1[21.8 ; 3.3]$ | $3.4\left[\begin{array}{l} [3.1 ; 7 ; 43) 6] \\ (\mid, 4) \end{array}\right.$ | $3.6[31.4 ; 3.9]$ | $3.9\left[\begin{array}{c} {[3.627)} \\ (8.27 \\ 4.2] \\ \hline \end{array}\right.$ |  | $4.3[4.0 .54 .6]$ | $4.7 \underset{(1.349)}{[4.3 ;} 5.1]$ | $5.2[4.5896$ [0] |
|  | Ceramicised metal | 1,123 | $80_{(76-83)}$ | 23/77 | 26.6 | 63 | $2.5[1.7 .73 .3 .6]$ | $2.9[2.0 ; 4.2]$ | $2.9[2.0 ; 4.2]$ | $3.4\left[\begin{array}{c} {[2.4 ; 5 ; 5.9]} \\ (3.45 \end{array}\right.$ | $3.4\left[\begin{array}{l} {[2.4 ; 4,4.9]} \\ (n, 9) \end{array}\right.$ | $3.4\left[2\left[\frac{462}{(62)} 4.9\right]\right.$ |  |  |
| Head size | 28 mm | 6,417 | $79_{(75-83)}$ | $14 / 86$ | 26.1 | 490 | $3.5\left[\begin{array}{l} {[3.1 .983} \\ 4.930] \\ 4.0] \end{array}\right.$ | $3.8[3.4 ; 4.3]$ | $4.0[33.5 ; 5.54]$ | $4.3[3.8 ; 4.8]$ | $4.4\left[\begin{array}{c} {[3.94 .968 .0]} \\ 10.0] \end{array}\right.$ | $4.6[4.0 ; 5.2]$ | $4.7[4.1 .1 ; 5.3]$ |  |
|  | 32 mm | 60,287 | $79_{(75-82)}$ | 20/80 | 26.5 | 686 | $2.4\left[\begin{array}{l} {[2,2,2 ; 50)} \\ \hline 65] \\ 2.5] \end{array}\right.$ | $2.7 \begin{gathered} {[2.6 ; 20.8]} \\ \langle 0.64\rangle \end{gathered}$ | $2.9\left[\begin{array}{l} {[2.85 \cdot 59)} \\ 3.0] \\ \hline \end{array}\right.$ | $3.1\left[\begin{array}{l} {[3,0.042 .3]} \\ 3.3] \end{array}\right.$ | $3.3[(1.2 .2 ; 61)$ | $3.5\left[\begin{array}{c} {[3.3273)} \\ 9.73] \\ \hline \end{array}\right.$ | $3.7[3.5 ; 4.0]$ | $4.1\left[\begin{array}{ll} {[3.803} \\ (0,103 \\ 4.4] \end{array}\right.$ |
|  | 36 mm | 27,785 | $79_{(75-82)}$ | 36/64 | 26.8 | 555 | $2.1\left[\begin{array}{l} {[2.0 ; 3 ; 3.3]} \end{array}\right.$ | $2.5[(12.3 ; 2 ; 2.7]$ | $2.8\left[\begin{array}{l} {[12.65306} \\ \hline 1.0] \end{array}\right.$ | $2.9\left[\begin{array}{ll} \left.[2.7,7 ;)^{3}\right) & 3] \end{array}\right.$ | $3.2\left[\begin{array}{l} {[3.05 ; 3.5]} \\ (5.514) \end{array}\right.$ | $3.4\left[\begin{array}{l} {[3,2 ; 2 ; 2,3.7]} \\ \hline(2) \end{array}\right.$ | $3.6\left[\begin{array}{l} (3.1,3 ; 9) \\ \hline(4.0] \end{array}\right.$ | ${ }^{3} .8$ [3.4.4: 4.2 2] |
| Head-neck length | XS | 457 | $80_{(76-83)}$ | $19 / 81$ | 26.0 | 50 | $1.3\left[\begin{array}{c} {[0.655} \\ {[935} \end{array} 2.9\right]$ | $1.8 \underset{(0334)}{[0.9 ;} 3.6]$ | $1.8\left[\begin{array}{l} {[0.955} \\ \hline(26) \\ 3.6] \end{array}\right.$ | $1.8\left[\begin{array}{c} 1929 \end{array}\right)$ | $2.5[1.2 .5 .5 .2]$ | $2.5\left[\begin{array}{c} 1.2 ; 6) \\ (56) \\ 5.2] \end{array}\right.$ |  |  |
|  | S | 32,434 | $79{ }_{(75-83)}$ | 17/83 | 26.2 | 657 | $2.0[1.8 ; 2.1]$ | $2.3[2.1 ; 2.4]$ | $2.5\left[\begin{array}{ll} {[1.3530)} \\ 20.6] \end{array}\right.$ | $2.7\left[\begin{array}{ll} {[2.5 \cdot 50.92]} \\ \hline 10.93) \end{array}\right.$ |  | $3.0\left[\begin{array}{l} {[2.88 \cdot 8]} \\ {[3.3]} \\ \hline \end{array}\right.$ | $3.3\left[\begin{array}{l} {[3.023 .3 .6]} \\ (1.63) \end{array}\right.$ | $3.3\left[\begin{array}{l} {[3.0 ; 6 ; 0.6]} \\ (3.6] \end{array}\right.$ |
|  | M | 37,186 | $79_{(75-82)}$ | 24/76 | 26.6 | 679 | $2.2\left[\begin{array}{l} {[2,0,933]} \\ \hline 2.3] \end{array}\right.$ | $2.5\left[\begin{array}{l} {[2.3 ; 2 ; 3 ; 2]} \\ (2,7] \end{array}\right.$ | $2.8\left[\begin{array}{ll} {[12.6031)} \\ (12.9] \\ 2.9] \\ \hline \end{array}\right.$ | $2.9\left[\begin{array}{c} {[1,8,8 ; 80)} \\ \hline 3.1] \end{array}\right.$ | $3.1\left[\begin{array}{c} {[2.92929)} \\ \hline 9.3] \\ \hline \end{array}\right.$ | $3.3\left[\begin{array}{c} {[3.1,483)} \\ 5.5] \\ \hline \end{array}\right.$ | $3.5\left[\begin{array}{l} {[3.2333} \\ 1.33 \\ \hline 3.8] \end{array}\right.$ | $3.8\left[\begin{array}{c} {[3.4 ; 4.3]} \\ (68) \\ \hline \end{array}\right.$ |

[^3]|  |  |  |  |  |  |  | Revision probabilities after ... |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Type of arthroplasty / category | Type | Number | Age | m/f | BMI | Hosp. | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Head-neck length | L | 17,938 | $79_{(75-82)}$ | $32 / 68$ | 27.0 | 635 | $2.9\left[\begin{array}{l} {[1.7 .751]} \\ (1.2] \end{array}\right.$ | $3.3\left[\begin{array}{l} {[3.0 ; 3.6]} \\ (12,10) \end{array}\right.$ | $3.5\left[\begin{array}{l} {[3,3,32)} \\ (9,8) \\ 3.8] \end{array}\right.$ | $3.8\left[\begin{array}{l} {[3.5255} \\ {[4.1]} \end{array}\right.$ | $4.0\left[\begin{array}{l} {[3.79: 4.3]} \\ 4.9616 \end{array}\right.$ | $4.2\left[\begin{array}{l} {[3.833)} \\ \hline(4.5] \end{array}\right.$ | $4.3[4.0 .04 .7]$ |  |
|  | XL | 3,514 | $79_{(74-82)}$ | 41/59 | 27.2 | 459 | $3.8\left[\begin{array}{l} {[3.2,2 ; 4.5]} \\ (2,09 \\ \hline \end{array}\right.$ | $4.4\left[\begin{array}{c} {[3.779 .5 .1]} \\ {[2,59} \end{array}\right.$ | $4.8\left[\begin{array}{c} (4.1 .101) \\ 5.6] \end{array}\right.$ | $5.2\left[\begin{array}{l} (4.5152) \\ \hline 1.1] \end{array}\right.$ | $6.2\left[\begin{array}{c} {[53,2 ; 4} \\ {[8.2]} \\ 7 \end{array}\right.$ | $6.2\left[\begin{array}{c} {[5.258)} \\ \hline 4.2] \\ 7 \end{array}\right.$ | $6.4\left[\begin{array}{c} {[184,4 ; 4} \\ 7.6] \\ \hline \end{array}\right.$ |  |
|  | xXL | 392 | $79_{(14-82)}$ | 43/57 | 27.2 | 149 |  |  | $6.6\left[\begin{array}{c} \text { 4.4.40 } \\ (20) \end{array} 9.7\right]$ | $6.6[4.4 ; 9 ; 9.7]$ | $6.6[4.4 ; 49.7]$ | $6.6[4.4 ; 4 ; 9.7]$ |  |  |
| Cup type | Modular cup | 69,362 | $79_{(75-82)}$ | 25/75 | 26.6 | 685 | $2.2\left[\begin{array}{l} {[2.1,990)} \\ {[5.3]} \\ \hline \end{array}\right.$ | $2.5\left[\begin{array}{c} {[4,4,455)} \\ \hline 2.6] \\ \hline \end{array}\right.$ | $2.7\left[\begin{array}{l} (23.6869) \\ {[2.9]} \end{array}\right.$ | $3.0\left[\begin{array}{l} {[2,8,8,3,3.1]} \\ 3.1] \end{array}\right.$ | $3.2\left[\begin{array}{c} {[15.0813)} \\ {[3.3]} \end{array}\right.$ | $3.3 \underset{(8.733)}{[3,2 ; 3.5]}$ | $3.6\left[\begin{array}{c} {[3.4,4 ; 3,8]} \\ (3,27) \\ \hline \end{array}\right.$ | $3.9[3.65 ; 4.2]$ |
|  | Monobloc cup | 22,181 | $80_{(76.84)}$ | $24 / 76$ | 26.5 | 569 | $2.3\left[\begin{array}{ll} {[18,1,78)} \\ \hline \end{array}\right.$ | $2.7\left[\begin{array}{ll} {[1.5990)} \\ 2.9] \\ \hline \end{array}\right.$ | $3.0\left[\begin{array}{l} {[2.8 ; 373.2]} \\ (13,3) \end{array}\right.$ | $3.2\left[\begin{array}{l} {[9.972 ;} \\ 3.4] \end{array}\right.$ | $3.4\left[\begin{array}{c} {[3.2,255)} \\ \hline \end{array}\right.$ | $3.6\left[\begin{array}{l} {[3,35 i 5)} \\ \hline 4.9] \end{array}\right.$ | $\underset{[1.27 \mid}{3.8 .1]}$ |  |
|  | Dual mobility | 2,315 | $80_{(75-84)}$ | 26/74 | 25.9 | 284 | $4.0\left[\begin{array}{c} {[3.2 ; 54.9]} \\ (1.53) \\ \hline \end{array}\right.$ | $4.2\left[\begin{array}{c} 3.475 \\ (97) \\ 5.1] \end{array}\right.$ | $4.4 \underset{(627)}{[3 ; 5]}$ | $5.2[4.1 ; 6.6]$ | $5.2[4.1 ; 6.6]$ | $5.7\left[\begin{array}{c} (4.45) \\ 7.5] \end{array}\right.$ |  |  |
|  | Revision cup | 1,417 | $78{ }_{\text {(73-83) }}$ | 31/69 | 25.8 | 294 | $8.3[7.0 ; 10.0]$ | $9.0[7.6 ; 10.7]$ | $9.5\left[\begin{array}{l}\text { (5.0; } 0 \text { i) } 11.3] \\ \hline\end{array}\right.$ | $9.9[8.3 ; 11.8]$ | $10.2[8.5 ; 12.1]$ | $10.2\left[\begin{array}{c} {[8.5: 12.12]} \\ (120) \end{array}\right.$ | $10.2[8.5 ; 12.1]$ |  |
|  | Resurfacing cup | 377 | $55_{(51-59)}$ | 99/1 | 27.5 | 23 | $\left.1.1 \begin{array}{c} {[0.4 ; 402} \\ {[320} \end{array}\right)$ | $1.8\left[\begin{array}{l} {[0.800} \\ {[270)} \\ 4.0] \\ \hline \end{array}\right.$ | $2.2\left[\begin{array}{l} 1.02 ; 5.5] \\ {[125} \end{array}\right.$ | $2.2[11.0 ; 4.5]$ | $2.2[1.00 ; 4.5]$ | $2.2[1.0 ; 4.5]$ |  |  |
| Acetabular component fixation | Uncemented | 73,807 | $79_{(14-82)}$ | 25/75 | 26.6 | 694 | $2.2\left[\begin{array}{l} {[2.1 .5 ; 56.3]} \\ \hline 5.3] \end{array}\right.$ | $2.5\left[\begin{array}{l} {[24.455,4)} \\ 2.7] \\ \hline \end{array}\right.$ | $2.8\left[\begin{array}{l} {[2.6302 .92]} \\ 3(364) \end{array}\right.$ | $3.0\left[\begin{array}{l} {[2.95997)} \\ \hline(3.1] \end{array}\right.$ | $3.2\left[\begin{array}{l} (1.9 .969) \\ (1.4] \end{array}\right.$ | $3.4 \underset{(9.422 ;)}{[3.6]}$ | $3.7\left[\begin{array}{l} {[3.50,5 ; 9)} \\ 3.9] \\ \hline \end{array}\right.$ |  |
|  | Cemented | 21,811 | $80_{(77-84)}$ | 23/77 | 26.3 | 601 | $2.8\left[\begin{array}{ll} {[1,6,632]} \\ \hline \end{array}\right.$ | $3.2\left[\begin{array}{ll} {[1.4,0,33,3.4]} \end{array}\right.$ | $3.5\left[\begin{array}{l} {[3.2,2 ; 8)} \\ {[1.7]} \\ \hline \end{array}\right.$ | $3.7\left[\begin{array}{l} {[3,4,43} \\ \hline 9.0] \\ 4.0] \end{array}\right.$ | $3.9[3.6 ; 4.2]$ | $4.1 \begin{gathered} {[3.8,866} \\ \hline 3.4] \end{gathered}$ | $4.2\left[\begin{array}{c} {[3,9,950} \\ (1,50 \end{array}\right)$ | 4.5[4.17939.1] |
| Stem type | Femoral stem with modular head | 93,758 | $79{ }_{(75-82)}$ | $24 / 76$ | 26.6 | 703 | $2.3\left[\begin{array}{ll} {[25,2,23.2 .4]} \\ 2.4] \end{array}\right.$ | $2.7\left[\begin{array}{l} {[20.713)} \\ {[(2.8]} \end{array}\right.$ | $2.9\left[\begin{array}{l} {[24.827)} \\ \hline 1.0] \end{array}\right.$ | $3.1\left[\begin{array}{l} {[3.04 ; 15)} \\ \hline 3.2] \end{array}\right.$ | $3.3[(32,2 ; 3 ; 35)$ | $3.5 \begin{gathered} {[(31,4 ; 105)} \\ {[3 ; 3]} \end{gathered}$ | $3.7{ }_{(5.5007)}^{[3 ; 5]}$ | $4.0\left[\begin{array}{ll} {[3.83 i .8} & 4.3] \\ 10.5] \end{array}\right.$ |
|  | Surface replacement | 763 | $56_{(51-61)}$ | 93/7 | 28.0 | 31 | $0.9\left[\begin{array}{c} {[0.4 ; 3)} \\ (68) \\ 1 \end{array}\right)$ | $1.5\left[\begin{array}{c} {[0.906} \\ \mid 606 \\ 2.8] \\ \hline \end{array}\right.$ | $2.3\left[\begin{array}{c} 1.45 ; 3.7] \\ (518) \\ 3 \end{array}\right.$ | $2.7[1.6 ; 4.3]$ | $2.7\left[\begin{array}{l} 1.64 \\ (246) \end{array} 4_{4} .3\right]$ | $2.7[1.6 ; 4.3]$ |  |  |
|  | Revision or tumour stem | 505 | $78{ }_{(00-83)}$ | 29171 | 25.6 | 185 | $\left.11.2\left[\begin{array}{c} {[8.7 ; 1} \\ (291) \end{array}\right] .4\right]$ | $11.9 \text { [9.2.2; 15.2] }$ | $11.9[9.2 ; 163)$ | $13.7[10.5 ; 17.8]$ | $14.8[11.2 ; 19.5](62)$ |  |  |  |
|  | Modular stem | 448 | $80_{(77-83)}$ | 26/74 | 27.4 | 6 | $1.4 \underset{(0.68)}{[0.6 \cdot 1]}$ | $2.0[1.00 ; 4.0]$ | $2.8[1.5 ; 5.3]$ | $2.8\left[\begin{array}{c} (122) \\ (1.5 ; \\ \hline \end{array}\right.$ | $2.8 \underset{(61)^{[1.5 ; ~ 5.3] ~}}{ }$ |  |  |  |
| Reconstruction shell | Without reconstruction shell | 95,030 | $79_{755-82)}$ | 25/75 | 26.6 | 707 | $2.3\left[\begin{array}{c} {[2.2 .2069)} \\ \hline 7.4] \\ \hline \end{array}\right.$ | $2.6\left[\begin{array}{ll} {[6,5498)} \\ 2.7] \\ 2.7] \end{array}\right.$ |  | $3.1\left[\begin{array}{l} [3.0 ; 9 ; 3) 3] \\ 3.2] \end{array}\right.$ | $3.3\left[\begin{array}{l} {[3,2,2 ; 3.4]} \\ {[2,4]} \\ \hline \end{array}\right.$ | $3.5\left[\begin{array}{ll} [13.423 ; 3) 6] \end{array}\right.$ | $3.7\left[\begin{array}{l} {[3.532]} \\ 3.9] \end{array}\right.$ |  |
|  | With reconstruction shell | 641 | $79_{(74.84)}$ | $34 / 66$ | 25.2 | 229 | $10.5[8.3 ; 13.3]$ | $11.7 \text { [9.3; } 14.7]$ | $12.7\left[\begin{array}{l} {[10.15)} \\ (25) \end{array} 15.8\right]$ | $13.2[10.5 ; 16.5]$ | $13.2\left[\begin{array}{c} {[10.5 ;} \\ (88) \\ \hline \end{array} 16.5\right]$ | $13.2[10.5 ; 16.5]$ |  |  |
| Fixation | Hybrid | 73,807 | $79_{(74-82)}$ | 25/75 | 26.6 | 694 | $2.2\left[\begin{array}{l\|l\|l\|l\|l\|l\|}  & 2.3] \\ \hline \end{array}\right.$ | $2.5\left[\begin{array}{l} {[2,4,5511)} \\ (2.7] \\ \hline \end{array}\right.$ |  | $3.0\left[\begin{array}{l} {[25.9 ; 973} \\ \hline[.1] \end{array}\right.$ | $3.2\left[\begin{array}{ll} {[13,1 ; 96)} \\ \hline 1.4] \end{array}\right.$ | $3.4$ | $3.7\left[\begin{array}{c} [3.5 ; 9\rangle) \\ (3.9] \\ \hline \end{array}\right.$ |  |
|  | Cemented | 21,811 | $8{ }_{(77-84)}$ | 23/77 | 26.3 | 601 | $2.8\left[\begin{array}{l\|l\|l\|c:\|c\|c}  & 3.0] \end{array}\right.$ | $3.2\left[\begin{array}{l} {[3,0 ; 933)} \\ {[14.4]} \end{array}\right.$ | $3.5\left[\begin{array}{l} {[3.2,2 ; 87)} \\ {[1.7]} \\ \hline \end{array}\right.$ | $3.7\left[\begin{array}{c} {[3,413 ;} \\ \hline, 4.0] \end{array}\right.$ | $3.9\left[\begin{array}{l} {[3,6322)} \\ \hline(4.2] \end{array}\right.$ | $4.1\left[\begin{array}{c} {[3.8: 864} \\ {[.86]} \end{array}\right.$ | $4.2\left[\begin{array}{l} {[3,9,950} \\ (1.50 \end{array}\right.$ | $4.5\left[\begin{array}{l} \left.(439)^{2} \cdot 5.1\right] \\ \hline \end{array}\right.$ |
| Non-elective THAs |  | 29,083 | $76_{(68-82)}$ | 30/70 | 24.7 | 677 |  | $6.6\left[\begin{array}{l} {[6,3.3,6.9]} \\ {[14,929} \end{array}\right)$ | $7.0\left[\begin{array}{c} (16.7641) \\ {[1.3]} \end{array}\right.$ | $7.4\left[\begin{array}{c} {[7.0006} \\ 7.07] \\ 7.7] \\ \hline \end{array}\right.$ | $7.6\left[\begin{array}{l} {[7.3 ; 38.0]} \\ 4.38] \end{array}\right.$ |  | $8.4\left[\begin{array}{c} {[7.955} \\ (7,9.0] \end{array}\right.$ |  |
| Bearing | Ceramic / hXLPE | 10,666 | $74_{(66-80)}$ | 31/69 | 24.7 | 493 | $6.2[5.7 .7 ; 6.6]$ | $6.7\left[\begin{array}{l} {[6.2327)} \\ 7.2] \\ \hline \end{array}\right.$ | $7.1 \underset{(6.73)}{[6.6 ; 7.6]}$ | $7.5[6.9 ; 8 ; 1.1]$ |  | $7.7[7.1 ; 8 ; 8]$ | $7.9[7.2 ; 8 ; 8.6]$ |  |
|  | Ceramic / hXLPE+antioxidant | 4,190 | $74_{(67-80)}$ | $34 / 66$ | 24.7 | 242 | $6.4\left[\begin{array}{c} {[5,778 ; 7.2]} \\ (2,7) \end{array}\right.$ | $6.7\left[\begin{array}{l} {[6.0 ; 97.6]} \\ (1.97) \end{array}\right.$ | $7.0$ | $\left.7.3\left[\begin{array}{c} {[6.42 ; 4} \\ {[820} \end{array}\right] .2\right]$ | $7.3 \text { [6.4: } \cdot \frac{8.2]}{(444)}$ | $7.3\left[\begin{array}{l} (6.411) \\ (2.2] \end{array}\right.$ | $8.2[6.4 ; 4 ; 10.4]$ |  |
|  | Metal / PE | 3,238 | $81_{(76-86)}$ | 26/74 | 24.3 | 323 | $6.2\left[\begin{array}{c} {[5.4997} \\ (2.09) \\ 7.1] \end{array}\right.$ | $7.0\left[\begin{array}{l} {[6.1 .1000} \\ 10.0] \end{array}\right.$ | $7.4\left[\begin{array}{l} {[6.4: 4.8 .4]} \\ n, i 66 \end{array}\right.$ | $7.8\left[\begin{array}{c} \text { [6.8.8. } 9.00] \\ (776 \end{array}\right.$ | $8.1 \begin{gathered} {[7.0 .09 .3]} \\ \langle 48)^{\prime} \\ \hline \end{gathered}$ | $8.4\left[\begin{array}{c} {[7.2,2 ; 3,9]} \\ (2,8] \end{array}\right.$ |  |  |
|  | Metal / hXLPE | 3,171 | $79{ }_{74-84)}$ | 26/74 | 24.5 | 280 | $5.1\left[\begin{array}{l} {[4,4 ; 5 ; 6)} \\ (5) \end{array}\right.$ | $5.7\left[\begin{array}{l} {[4.929]} \\ (0.6) \\ 6.6] \end{array}\right.$ | $\left.6.2\left[\begin{array}{c} {[5.3 ;} \\ 1,120 \end{array}\right] .2\right]$ | $6.4\left[\begin{array}{c} (5,5 ;) \\ (7,4) \\ 7.4] \end{array}\right.$ | $6.7 \underset{(5.753}{[5]} 7.8]$ | $7.3 \text { [6.0;0;6.9] }$ | $8.6[6.2 ; 2 ; 11.9]$ |  |
|  | Ceramic / PE | 3,091 | $77_{\text {(71-83) }}$ | 27/73 | 24.5 | 345 | $5.5 \underset{(2,245)}{[4.7} \mathbf{6 . 3 ]}$ | $6.3[5.4 .4,7.2]$ | $6.5\left[\begin{array}{ll} {[5.738)} \\ 4.7 .5] \\ \hline \end{array}\right.$ | $6.9[5.977 .9]$ | $7.2\left[\begin{array}{l} {[6.255} \\ (6.3] \end{array}\right.$ | $7.7 \text { [6.5; 9.1] }$ | $8.6[7.0 .010 .6]$ |  |
|  | Ceramic / mXLPE | 1,771 | $74_{(66-79)}$ | $34 / 66$ | 25.0 | 169 | $5.7\left[\begin{array}{l} {[1.738)} \\ \hline 1.7 .9] \end{array}\right.$ | $6.1\left[\begin{array}{l} {[5.007 .07 .4]} \\ (1,0) \end{array}\right.$ | $6.8\left[\begin{array}{c} \text { [878) } 7: 8.2] \\ \hline \end{array}\right.$ | $7.5\left[\begin{array}{l} 6.2909 .0] \\ (50) \end{array}\right.$ | $8.1 \text { [6.76; 9.9] }$ | $8.1\left[\begin{array}{l} {[6.7 ; 9.9]} \\ (18) \end{array}\right.$ | $8.1{ }^{\left.[6.77]^{(13)} 9.9\right]}$ |  |
|  | Ceramic / ceramic | 1,037 | $69_{(62-77)}$ | 32/68 | 24.8 | 143 | $5.4[4.2$ [176) 7.0$]$ | $5.8\left[\begin{array}{c} \text { [4.5; } 5 \cdot 7.5] \\ \hline 7 \end{array}\right.$ | $6.2[4.8 ; 8.0]$ | $6.2[4.8 ; 8.0]$ |  | $7.1 \text { [5.5:5; 9.2] }$ | $7.1\left[\begin{array}{l} (5) 5 ; \\ \hline 5.2] \end{array}\right.$ |  |
|  | Metal / mXLPE | 938 | $80_{(75.85)}$ | $29 / 71$ | 24.8 | 120 | $9.0\left[\begin{array}{c} \text { [isid } \\ \text { (2id } \\ 11.1] \\ \hline \end{array}\right.$ | $9.3[7.6 ; 6211.5]$ | $10.0 \underset{(8,7)}{187)} 12.3]$ | $10.8\left[\begin{array}{l} {[8.80)} \\ (2,20) \\ 13.3] \end{array}\right.$ | $10.8[8.8 ; 13.3]$ | $11.7\left[\begin{array}{l} {[92 ;} \\ i 2 ; \end{array} 14.9\right]$ |  |  |
|  | Metal / hXLPE+antioxidant | 445 | $79{ }_{(72-85)}$ | 32/68 | 24.7 | 97 | $6.5\left[\begin{array}{c}{[27.5 ; ~ 9.4] ~}\end{array}\right.$ | $6.5[4.5 ; 9.4]$ | $7.1[4.99 .10 .3]$ | $7.1[4.9 .910 .3]$ |  |  |  |  |

Table 46 (continued)

|  |  |  |  |  |  |  | Revision probabilities after ... |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Type of arthroplasty / category | Type | Number | Age | m/f | BMI | Hosp. | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Bearing | Ceramicised metal / hXLPE | 373 | 72 (64-79) | 35/65 | 25.0 | 43 |  | $7.9[5.4 ; 4 ; 11.5]$ |  | $7.9[5.45 ; 11.5]$ |  |  |  |  |
| Acetabular articulating surface | hXLPE | 14,210 | $75_{(67-81)}$ | 30/70 | 24.6 | 525 | $5.9[5.6 .6 ; 6.4]$ | $6.5\left[\begin{array}{l} {[6.138)} \\ {[130} \end{array}\right]$ | $6.9\left[\begin{array}{l} {[6.557} \\ 4.4,4] \\ \hline \end{array}\right.$ | $7.3\left[\begin{array}{l} {[6,8990} \\ \hline, 7.8] \\ \hline \end{array}\right.$ | $7.4\left[\begin{array}{l} {[6.9897 .9]} \\ (1.84) \end{array}\right.$ | $7.7\left[\begin{array}{l} {[7.155} \\ (925) \\ 8.2] \end{array}\right.$ | $8.0\left[\begin{array}{c} 7.3 ; 3 ; \\ (301) \\ 8.9] \\ \hline \end{array}\right.$ | ${ }^{8.0}{ }^{[77.3 ;}$ (6) 8.9$]$ |
|  | PE | 6,418 | $79_{(73-85)}$ | 26/74 | 24.4 | 451 | $5.8\left[\begin{array}{c} {[5.2 ; 2 ; 6.4]} \\ 4.405 \end{array}\right.$ | $6.6\left[\begin{array}{c} {[6.30 \cdot 0 ; 7)} \\ 7.3] \end{array}\right.$ | $6.9\left[\begin{array}{l} {[6.37} \\ (2.534) \\ 7.6] \end{array}\right.$ | $7.3 \text { [6.6; 8.76.1] }$ | $7.6\left[\frac{16.9 ; ~}{(4,14)} 8.4\right]$ | $8.0[7.2 ; 94.9 .0]$ |  |  |
|  | hXLPE+antioxidant | 4,640 | $75_{(67-81)}$ | 33/67 | 24.7 | 265 | $6.4\left[\begin{array}{l} {[5.88 ; 60]} \\ (3.2] \\ \hline \end{array}\right.$ | $6.8\left[\begin{array}{l} {[6,0,055} \\ (2,6] \end{array}\right.$ | $7.0\left[\begin{array}{l} {[6.3 ; 7.37} \\ (0,48] \end{array}\right.$ | $7.3[6.58 ; 8.2]$ | $7.3[6.5 ; 8.2]$ | $7.3 \text { [6.5: } 8.2]$ | $8.6[6.8 ; 10.9]$ |  |
|  | mXLPE | 2,710 | $76{ }_{(69-81)}$ | 32/68 | 25.0 | 202 | $6.8\left[\begin{array}{c} {[5.993)} \\ (1.93) \\ 7.9] \end{array}\right.$ | $7.2\left[\begin{array}{c} (1,559) \\ {[1.3 ; ~ 8.3]} \end{array}\right.$ | $7.9\left[\begin{array}{ll} (6.995) \\ 9.1] \end{array}\right.$ | $8.6[7.5 ; 9.9]$ | $9.1\left[\begin{array}{l} {[7.8 ;} \\ (5 ; 9) \\ 10.4] \end{array}\right.$ | $9.4[8.0 ; 10 ; 9]$ | $9.4[8.0 ; 10.9]$ |  |
|  | Ceramic | 1,039 | $69_{(62-77)}$ | $32 / 68$ | 24.8 | 144 | $5.4[4.72 ; 7.7 .0]$ | $5.8\left[\begin{array}{c} (4641) \\ (4.5] \\ 7.5] \\ \hline \end{array}\right.$ |  | $6.2\left[\begin{array}{c} 4.87 \\ (30) \\ 7.9] \\ \hline \end{array}\right.$ | $7.1 \text { [5.5; 9.2] }$ | $7.1 \text { [5.5: } 1.50 .2]$ | $7.1[5[55 ; 9.2]$ |  |
| Head component | Ceramic | 20,794 | $74{ }_{(67-80)}$ | 31/69 | 24.7 | 657 | $6.0 .0[5.7 ; 6,6.4]$ | $6.6\left[\begin{array}{c} {[6.2 ; 835]} \\ (10.9] \end{array}\right.$ | $6.9\left[\begin{array}{c} {[6.6 ; 76]} \\ {[.73]} \end{array}\right.$ | $7.3\left[\begin{array}{c} {[6.9 ; 96]} \\ {[7.7]} \\ \hline \end{array}\right.$ | $7.5\left[\begin{array}{c} {[7,135)} \\ \hline 1.05] \end{array}\right.$ | $7.7 \begin{gathered} \substack{[7.3613 \\ (13)} \\ \hline \end{gathered}$ | $8.1\left[\begin{array}{c} {[753)} \\ (58) \\ 8 \end{array}\right.$ | $8.1\left[\begin{array}{c} {[7.58)} \\ (108) \\ 8.8] \end{array}\right.$ |
|  | Metal | 7,821 | $80_{(75-85)}$ | $27 / 73$ | 24.5 | 474 | $6.1\left[\begin{array}{c} {[5.6 ; 76,6.7]} \\ {[6]} \end{array}\right.$ | $6.7 \underset{(3.909)}{[6.2 ; 7.3]}$ |  | $\begin{gathered} 7.6\left[\begin{array}{l} {[7.052]} \\ (1.32] \end{array}\right] \end{gathered}$ |  | $8.4\left[\begin{array}{c} {[7.54,9.3]} \\ \hline(5) \end{array}\right.$ | $9.2[8.0 ; 10 \% 10.6]$ |  |
|  | Ceramicised metal | 467 | $73_{(64-80)}$ | $34 / 66$ | 24.8 | 54 | $6.7 \underset{(423)}{[4.8 ; 9.5]}$ | $7.8\left[\begin{array}{l} {[5.6 ;} \\ (184) \end{array} 10.9\right]$ | $7.8\left[\begin{array}{c} {[5.6 ;} \\ (125) \end{array} 10.9\right]$ | $7.8[5.6 ; 10.9]$ |  |  |  |  |
| Head size | 28 mm | 3,368 | $78{ }_{(70-84)}$ | $19 / 81$ | 24.1 | 450 | $6.9\left[\begin{array}{l} {[6.0 ; 7.75]} \\ (2,55) \end{array}\right.$ | $7.4\left[\begin{array}{l} {[6.5 ; 5 ; 8.4]} \\ \left(\begin{array}{l} 599 \end{array}\right) \end{array}\right.$ | $7.9[7.0 ; 9.0]$ | $8.5[7.4 ; 9.6]$ | $8.6[7.5 ; 9.8]$ | $8.8\left[\begin{array}{c} {[7.7 ; 10.1]} \\ (2 i j) \end{array}\right.$ | $9.5\left[\begin{array}{c} {[7.9 \cdot 11.4]} \\ i 13 \end{array}\right.$ |  |
|  | 32 mm | 15,945 | $76_{\text {(68-82) }}$ | 25/75 | 24.5 | 638 | $6.0[5.6 ; 6.4]$ | $6.5\left[\begin{array}{l} {[6.2222]} \\ \hline(9.0] \end{array}\right.$ | $6.9[6[5.5 ; 7.3]$ |  | $\left.7.4\left[\begin{array}{c} {[7,0 ; 99]} \end{array}\right] .9\right]$ | $7.8$ | $8.2{ }_{\text {c }}^{\text {[7.56i }}$ [ 8.9$]$ | 8.8 [7.5; 1920 |
|  | 36 mm | 9,437 | $75_{(67-81)}$ | 44/56 | 24.9 | 489 | $6.0\left[\begin{array}{c} {[5.587)} \\ \hline 6.5] \\ \hline \end{array}\right.$ | $6.5\left[\begin{array}{l} {[6,3,32]} \\ {[7.1]} \end{array}\right.$ | $\left.7.0\left[\begin{array}{l} {[6.4,4 ; 4)} \\ {[2,6]} \end{array}\right] .6\right]$ | $7.5 \begin{gathered} {[6.9 ; 8 ; 8.1]} \\ (1.85) \end{gathered}$ | $\underset{\substack{1.060}}{7.7} \mathbf{7}$ | $7.8 \text { [7.2;2; 8.6] }$ | $8.5\left[\begin{array}{c} (7.455) \\ (165) \\ 9.7] \\ \hline \end{array}\right.$ |  |
| Head-neck length | S | 7,777 | $76_{(68-82)}$ | $24 / 76$ | 24.3 | 585 | $5.3{ }_{(5.587)}^{[4 ; 8 ; 5]}$ | $5.7\left[\begin{array}{l} {[3.973)} \\ {[5.2]} \end{array}\right.$ | $6.0[5.5 \cdot 5 ; 6.6]$ |  | $6.6\left[\begin{array}{c} {[6.0 ; 0 ;)} \\ (1.03) \\ 7.3] \end{array}\right.$ | $6.7\left[\begin{array}{l} {[6.10,7.5]} \\ (5.5) \end{array}\right.$ | $6.9 \begin{gathered}\text { [6.2; } \\ \text { (200) } \\ 7.8]\end{gathered}$ |  |
|  | M | 11,006 | $76_{(68-82)}$ | 28/72 | 24.6 | 632 | $\left.5.6\left[\begin{array}{c} {[5.259 ;} \end{array}\right) ; .1\right]$ | $6.1\left[\begin{array}{c} {[5.7 ; 640} \\ {[5.6]} \\ \hline \end{array}\right.$ | $6.6\left[\begin{array}{l} {[4,133]} \\ \hline 1.1] \end{array}\right.$ | $7.2\left[\begin{array}{c} {[6.6 ; 6]} \\ {[2,65]} \end{array}\right]$ | $7.2\left[\begin{array}{c} {[6.6 ; 68)} \\ (1.38) \\ \hline \end{array}\right.$ | $7.5 \underset{(6882)}{[6.8 ;})$ | $8.1 \text { [7.2; } 9.1]$ | $8.1\left[7.2 ;{ }^{\text {(5i) }}\right.$ 9.1] |
|  | L | 6,642 | $76_{\text {(68-81) }}$ | $36 / 64$ | 24.9 | 586 | $6.8\left[\begin{array}{c} {[6,227)} \\ 4.5] \\ \hline \end{array}\right.$ | $7.6[6.9 .988 .3]$ | $7.9[7.2 ; 8.6]$ | $8.1\left[\begin{array}{c} {[7.4 ; 8,8.8]} \\ (1,99] \end{array}\right.$ | $8.5\left[\begin{array}{c} (7,7,749,9] \\ (4,3] \end{array}\right.$ | $8.6[7.8 ; 9.4]$ | $9.0[8.0 ; 10.0]$ |  |
|  | XL | 2,007 | $75_{(67-81)}$ | 46/54 | 25.1 | 434 | $7.7 \begin{gathered} {[6.6 ; 9.09} \\ (x .35) \\ \hline(0) \end{gathered}$ | $8.3[7.1 .9,9.6]$ | $8.9[7.6: 6 ; 10.3]$ | $9.0[7.77 ; 10.5]$ | $9.5[8.17 ; 11.2]$ | $9.9[8.3 .3 ; 11.7]$ | $11.2[8.5 ; 14.7]$ |  |
| Cup type | Modular cup | 20,750 | $74_{(67-80)}$ | 32/68 | 24.8 | 655 | $6.4\left[\begin{array}{ll} {[1,0,544)} \\ 6.7] \end{array}\right.$ | $6.9\left[\begin{array}{c} {[6.5952]} \\ (10.2] \\ 7 \end{array}\right.$ | $7.2\left[\begin{array}{c} {[6.996)} \\ (0,86 \\ 7.6] \end{array}\right.$ | $7.6[7.2 ; 8.0]$ | $7.9\left[\begin{array}{l} (7.5177) \\ \hline 8.4] \\ \hline \end{array}\right.$ | $8.1\left[\begin{array}{c} {[7.6 ; 8.65} \\ (1,5) \\ \hline \end{array}\right.$ | $8.6\left[\begin{array}{c} (7596) \\ \hline(9.2] \\ 9 \end{array}\right.$ | $9.1[8.0 ; 10.3]$ |
|  | Monobloc cup | 6.163 | $80_{(74-85)}$ | 25/75 | 24.4 | 429 |  | $5.7 \underset{(5.1364)}{[5.3]}$ | $6.0\left[\begin{array}{l} {[5.4 ; 4 ; 6.7]} \\ (2,24) \end{array}\right.$ | $6.3[5.6 ; 7.0]$ | $6.4\left[\begin{array}{c} {[5.77 ; 7.2]} \\ (x, 021 \end{array}\right.$ | $6.9[6.0 ; 7.8]$ | $7.5{ }_{\substack{\text { (16.6i) } \\ \text { (16) } \\ \text { e.9] }}}$ |  |
|  | Dual mobility | 1,814 | $81_{(74-86)}$ | 32/68 | 24.3 | 229 | $6.0[4.9 ; 7.2]$ | $6.5 \underset{(533)}{6 ; 4 ;} 7.8]$ | $6.9 \underset{(5822)}{[5 ; .4]}$ | $7.6 \underset{\substack{6996 \\ 1690}}{[9.4]}$ | $7.6[6.179 .9]$ |  |  |  |
|  | Revision cup | 353 | $79_{(70-84)}$ | $29 / 71$ | 24.7 | 122 | $8.4\left[\begin{array}{l} {[5.8: 12.0]} \\ 1206 \end{array}\right.$ | $9.8[6.9 ; 13.9]$ | $11.0[7.8 ; 15.4]$ | $11.0[7.8 ; 15.4]$ | $11.0[7.8 ; 15.4]$ |  |  |  |
| Acetabular component fixation | Uncemented | 22,537 | $75_{(67-80)}$ | 32/68 | 24.7 | 667 | $6.3[(16,0 ; 735) 6]$ |  | $7.3\left[\begin{array}{c} {[6.95517} \\ (6,6] \end{array}\right.$ | $7.7 \begin{gathered} {[7.3 ; 8.8 .1]} \\ (5,52) \\ \hline \end{gathered}$ | $7.9\left[\begin{array}{c} (7.530 \\ (, 50) \\ 8.4] \end{array}\right.$ | $8.1$ | $8.6\left[\begin{array}{c} {[8.0 ;} \\ (631) \\ 9.3] \end{array}\right.$ | $9.1\left[\begin{array}{l} {[8.17} \\ \text { and } 123 \end{array} 10.3\right]$ |
|  | Cemented | 6,541 | $81_{(75-86)}$ | 25/75 | 24.4 | 481 | $5.2{ }_{4}^{[4.2665}$ [5.7] | $5.8 \underset{(x, 339)}{[5.3 ;} \mathbf{6}]$ | $6.1[5.5 ; 6.8]$ | $\begin{gathered} 6.3(5.7 ; 7.0] \\ (1,33) \end{gathered}$ | $6.5\left[\begin{array}{c} {[58,8 ; 7.2]} \\ (8,7) \\ \hline \end{array}\right.$ | $7.3\left[\begin{array}{l} 6.33 ; \\ {[431} \end{array}\right)$ |  |  |
| Stem type | Femoral stem with modular head | 27,909 | $76_{(68-82)}$ | 30/70 | 24.7 | 674 |  | ${ }^{6.5} 5(16.2 ; 3 ; 3.8]$ | $6.9\left[\begin{array}{l} {[6.6 ; 2 ; 7.2]} \\ (124)] \end{array}\right.$ | $\underset{\substack{(6,000)}}{7.3} 7.7]$ | $7.6[7.2 ; 7.9]$ | $7.8\left[\begin{array}{l} {[7.4 ; 983]} \\ (2.38] \end{array}\right.$ |  |  |
|  | Revision or tumour stem | 579 | $80_{(72-86)}$ | 28/72 | 25.2 | 254 | $\underset{\substack{(33)}}{10.8 ;]^{[8.8]}}$ | $12.0\left[\begin{array}{l} 9.4 ; 4 ; 15.2] \\ 1200 \end{array}\right]$ | $12.4\left[\begin{array}{c} \text { (9.73) } \\ (183) \\ 15.7] \end{array}\right.$ | $12.4[9.7 .7215 .7]$ | $12.4\left[\begin{array}{l} {[9.7 ; 1} \\ \langle i 2]^{2} \\ 15.7] \end{array}\right.$ |  |  |  |
|  | Short stem | 396 | $6_{(61-77)}$ | 36/64 | 24.2 | 76 | $5.9\left[\begin{array}{c} 3.984 \\ {[284} \\ 8.8] \end{array}\right.$ | $5.9\left[\begin{array}{c} (3,9) 9 \\ (190) \\ 8.8] \\ \hline \end{array}\right.$ | $6.4\left[\begin{array}{c} {[4.38)} \\ (1.38 \\ \hline 9.6] \end{array}\right.$ | $6.4[4.3 ; 9,9,6]$ | $6.4\left[4\left[3 ;{ }_{(50)} 9.6\right]\right.$ |  |  |  |
| Reconstruction shell | Without reconstruction shell | 28,986 | $76_{(68-82)}$ | 30/70 | 24.7 | 677 | $6.0[(19,8 ; 99)]$ | $6.6\left[\begin{array}{ll} {[1.3884)} \\ \hline 6.9] \\ \hline \end{array}\right.$ | $7.0\left[\begin{array}{l} {[6.7 ; 7.7]} \\ (10.544) \end{array}\right.$ | $7.3\left[\begin{array}{c} {[7.0 ; 41} \\ (1,7) \\ 7.7] \end{array}\right.$ | $7.6[7.2 ; 8.0]$ | $7.8\left[\begin{array}{l} {[7.4 ; 8 ; 8.2]} \\ (2,63) \end{array}\right.$ | $8.3[7.8 ; 8.9]$ | $8.7[77.8 ; 9.8]$ |
| Fixation | Uncemented | 13,167 | $71_{(64-78)}$ | 35/65 | 24.8 | 634 | $7.2\left[\begin{array}{c} (6.30 ; 7) \end{array}\right]$ | $7.7\left[\begin{array}{l} {[7.2 ; 88)} \\ {[8.2]} \\ \hline \end{array}\right.$ | $8.0[7(5,6 ; 8.5]$ | $8.5[7.9,9.0]$ | $8.7 \text { [8.2; } 9.3]$ | $8.9\left[\begin{array}{c} {[8.3 ; 9,9.5]} \\ (112) \end{array}\right.$ | $9.5[8.7 .710 .4]$ | $9.5[8.77 .70 .10 .4]$ |
|  | Hybrid | 9,361 | $78_{(72-82)}$ | 28/72 | 24.6 | 573 |  |  | $6.2{ }_{(3,253)}^{[5.6} 6.77$ | $6.6\left[\begin{array}{l} {[6,0006} \\ {[7.2]} \\ \hline \end{array}\right.$ | $6.8\left[\begin{array}{l} {[6.259]} \\ (1,5) \\ \hline \end{array}\right.$ | ${ }^{7.0}{ }_{\substack{\text { [6.3; } \\ 630}}^{\text {7.7] }}$ |  |  |

Table 46 (continued)

|  |  |  |  |  |  |  | Revision probabilities after ... |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Type of arthroplasty / category | Type | Number | Age | m/f | BMI | Hosp. | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Fixation | Cemented | 5,791 | $81_{(76-86)}$ | $24 / 76$ | 24.3 | 445 | $4.6{ }_{[3,096}$ | $5.2[4.6 ; 5.9]$ | $5.5[4.996 .6 .2]$ |  | $5.8\left[\begin{array}{c} {[582)} \\ {[782)} \end{array}\right)$ | $\left.6.7\left[\begin{array}{c} {[5862} \\ {[38} \end{array}\right) 7.9\right]$ | $7.0\left[\begin{array}{c} {[5.82]} \\ \\| 12] \\ 8.4] \end{array}\right.$ |  |
|  | Reverse-hybrid | 745 | $77_{\text {(67-83) }}$ | 28/72 | 24.7 | 256 |  | $10.6\left[\begin{array}{c}(8,54) \\ (13.2]\end{array}\right.$ | $11.3\left[\begin{array}{l} \text { 9.0.0 } 2344 \\ 12.1] \end{array}\right.$ | 11.3 [9,0; 14.1$]^{(100)}$ | $11.9[9.4 ; 714.9]$ |  |  |  |
| Hip hemiarthroplasties |  | 59,874 | $84_{\text {(80-89) }}$ | $29 / 71$ | 24.2 | 596 | $4.5\left[\begin{array}{l} {[4.3,5 ; 4.4 .7]} \\ (36) \end{array}\right.$ | $4.7[4.6 ; 4 ; 4.9]$ | $4.9\left[\begin{array}{c} {[1.37756} \\ \hline 4.1] \end{array}\right.$ | $5.1[4.9 ; 5.3]$ | $5.1[4.9 ; 5.3]$ | $5.4\left[\begin{array}{c} {[5.1 .7 .75 .7]} \\ (x, 75) \end{array}\right.$ | $5.4\left[\begin{array}{l} {[515)} \\ \hline 5.7) \\ \hline \end{array}\right.$ |  |
| Head component | Metal | 56,985 | $84_{(80-89)}$ | 29/71 | 24.2 | 586 | $4.5[4.3 .3 .4 .7]$ | $4.7[4.5 ; 4.9]$ | $4.8 \text { [4.7.7;5;4)}$ | $5.0\left[\begin{array}{l} (4,8,810) \\ 5.2] \end{array}\right.$ | $5.1\left[\begin{array}{c} (3.827) \\ \hline \end{array}\right.$ | $5.3\left[\begin{array}{c} (5.070 .075) \\ 50.6] \end{array}\right.$ | $5.3\left[\begin{array}{l} {[5.0 ;} \\ (502) \end{array}\right)$ | $5.3\left[\begin{array}{l} {[50 ; 7} \\ (6) \\ \hline 6.6] \end{array}\right.$ |
|  | Ceramic | 2,057 | $84^{199-89}$ | 29/71 | 24.5 | 258 | $5.5\left[\begin{array}{l} (4,6,6 ; 6) \\ \hline 6.7] \end{array}\right.$ | $5.9[4.923 ; 7.1]$ | $6.2\left[\begin{array}{c} {[5.1 ; 7.7 .5]} \\ (528) \end{array}\right.$ | $6.9\left[\begin{array}{c} {[5.6 ; 6} \\ {[3 ; 2)} \\ 8.4] \\ \hline \end{array}\right.$ | $6.9[5.6 ; 8.4]$ | $7.8[5.8: 10.5]$ |  |  |
|  | Ceramicised metal | 384 | $84_{(80-89)}$ | 30/70 | 24.5 | 30 | $4.6\left[\begin{array}{l} {[2.8 ; 7} \\ (160) \end{array} 7.5\right]$ | $4.6[2.887 .5]$ |  |  |  |  |  |  |
| Head size | 28 mm | 56,119 | $84_{(80-89)}$ | 28/72 | 24.2 | 589 | $4.5\left[\begin{array}{c} {[4.3 .454 .4 .7]} \\ (36)] \end{array}\right.$ | $4.7\left[\begin{array}{c} {[4.5 ; 549.9]} \\ (1,949 \end{array}\right.$ | $4.9\left[\begin{array}{c} {[4.7 .4 ; 4 ;} \\ 4.1] \\ \hline 1.1] \end{array}\right.$ | $5.0[4.8 ; 5.2]$ | $5.1 \underset{(x, 762)}{[4.8 ; 5]}$ | $5.3 \underset{(1.5040)}{[5.6]}$ |  | ${ }^{5} 5.3$ [5.0; $(12)^{5.6]}$ |
|  | 32 mm | 2,379 | $83_{(79-88)}$ | 51/49 | 24.7 | 98 | $5.3 \text { [4.4.438. } 6.3]$ | $5.7\left[\begin{array}{l} {[1.896)} \\ {[4.8]} \end{array}\right.$ | $5.9 \underset{(7,98)}{[7.0]}$ | $6.2 \underset{(5233}{[52 ;} 7.4]$ | $\left.6.5\left[\begin{array}{c} {[538]} \\ {[238} \\ \hline \end{array}\right] .8\right]$ | $6.5\left[\begin{array}{c} {[5.3 ;} \\ \text { (1i0) } \\ 7.8] \\ \hline \end{array}\right.$ |  |  |
| Head-neck length | xS | 419 | $84_{(80-90)}$ | 32/68 | 24.0 | 28 | $3.1\left[\begin{array}{c} 12.876 \\ 125.4] \end{array}\right.$ | $3.1\left[\begin{array}{c} 11.8: 5.4] \\ 1203 \end{array}\right.$ | $3.1\left[\begin{array}{c} {[1.8 ; 5} \\ (118) \\ 5.4] \\ \hline \end{array}\right.$ | ${ }^{3.1}\left[17.85{ }_{(i 5)} 5.4\right]$ |  |  |  |  |
|  | S | 20,354 | 84 (80-89) | 25/75 | 24.2 | 519 | $4.3\left[\begin{array}{l} {[1.0 .0551]} \\ \text { an } \\ 4.6] \end{array}\right.$ | $4.5\left[\begin{array}{l} {[4.2,2 ; 44)} \\ 4.8] \end{array}\right.$ | $4.6\left[\begin{array}{c} {[4.375)} \\ (4,55) \end{array}\right.$ | $4.7\left[\begin{array}{c} {[4.43 ; 52)} \\ (4.1] \end{array}\right.$ | $4.9[4.55 .5 .3]$ | $5.1 \begin{gathered} \left.[499)^{4.6} 5.6\right] \\ 5.6] \end{gathered}$ | $5.1\left[\begin{array}{c} (4,6 ; 5) \\ (130) \\ 5.6] \end{array}\right.$ |  |
|  | M | 26,077 | $84_{(80-89)}$ | 30/70 | 24.2 | 545 | $\text { 4.3 } 34.0 .0 \cdot 4.6]$ | $4.5\left[\begin{array}{c} {[4.2,450)} \\ \hline(4.8] \end{array}\right.$ | $4.6[4.0 ; 4 ; 4.9]$ | $4.7 \underset{(4.533)}{[4.50]}$ | $4.7(4.4 .4 ; 5.0]$ | $4.9[4.675 \cdot 5.3]$ | $4.9[4.6 ; 5.3]$ |  |
|  | L | 5,576 | $84_{(80-89)}$ | 35/65 | 24.5 | 478 | $5.2\left[\begin{array}{c} (4.2,640) \\ \hline \end{array}\right.$ |  | $5.7 \underset{\substack{[5.0355 \\(1,55) \\ 6.4]}}{ }$ | $5.8\left[\begin{array}{c} (5884) \\ \hline, 2 ; 6] \\ 6.6] \end{array}\right.$ | $6.0[5.2 ; 2 ; .8]$ | $6.3\left[\begin{array}{l} {[5.4 ; 4 ; 7.3]} \\ k 230 \end{array}\right.$ |  |  |
|  | XL | 880 | $84{ }_{\text {(19-89) }}$ | 35/65 | 24.8 | 256 | $6.7 \begin{gathered} {[5.192]} \\ (4,7) \\ \hline \end{gathered}$ | $7.6 \underset{(530)}{[5 ; 8]}$ | $8.3\left[\begin{array}{l} {[6.3 ; 10 ; 10.7]} \\ {[223} \end{array}\right.$ | $9.1[7.0 ; 11.9]$ | $9.1[7.0 ; 0 ; 11.9]$ |  |  |  |
| Stem type | Femoral stem with modular head | 58,827 | $84_{(80-89)}$ | 29/71 | 24.2 | 590 | $4.4\left[\begin{array}{l} {[4,3,2 ; 2 ; 4.6]} \\ \hline \end{array}\right.$ | $4.7[4.5 ; 4.8]$ | $4.8\left[\begin{array}{c} {[1.3,6 ; 4)} \\ \hline(4,5] \end{array}\right.$ | $5.0\left[\begin{array}{l} (4,848) ; 5.2] \end{array}\right.$ | $5.0\left[\begin{array}{c} {[4.8: 824} \\ 4.3] \\ 5.3] \\ \hline \end{array}\right.$ | $5.3\left[\begin{array}{c} {[5.0 ; 5 ; 5)} \\ (1.5] \end{array}\right.$ | $5.3\left[\begin{array}{l} {[5.0 ;} \\ \left.\frac{5}{5}\right) \\ 5.6] \end{array}\right.$ | $5.3\left[\begin{array}{l} {[50,0} \\ (68) \\ 5.6] \end{array}\right.$ |
|  | Revision or tumour stem | 780 | $83_{(75-88)}$ | 29/71 | 25.3 | 229 | $9.9\left[\begin{array}{c} {[7.978)} \\ \substack{378} \\ \hline \end{array}\right.$ | $10.5\left[\begin{array}{l} \text { [8.452 } \\ (252) \end{array} 13.2\right]$ | $10.5 \text { [8:4:4; 13.2] }$ | $10.5[8.4 ; 13.2]$ |  |  |  |  |
| Reconstruction shell | Without reconstruction shell | 59,874 | $84_{(80-89)}$ | 29/71 | 24.2 | 596 | $4.5\left[\begin{array}{l} {[32.36: 4.7]} \\ \hline 14] \end{array}\right.$ | $4.7[4.6 ; 4.9]$ | $4.9\left[\begin{array}{c} {[4.73 ; 5.51]} \\ (13)] \end{array}\right.$ | $5.1 \begin{aligned} & {[4,9,959} \\ & {[0.3]} \end{aligned}$ | $5.1[4.9 .95 .3]$ | $5.4\left[\begin{array}{l} {[5.1755} \\ (1.75) \\ 5.7] \end{array}\right.$ | $5.4[5.1 ; 5.7]$ | $5.4\left[5 \left[\begin{array}{l} {[6 ;)} \\ (6,7) \\ 5.7] \\ \hline \end{array}\right.\right.$ |
| Fixation | Cemented | 52,432 | $8^{85}$ (80-89) | 28/72 | 24.2 | 580 | $4.2\left[\begin{array}{l} {[4.0 ; 4.4 .4]} \end{array}\right.$ | $4.4\left[\begin{array}{ll} {[1.25 \cdot 54.4 .6]} \\ \hline(2) \end{array}\right.$ | $4.5[4.3 ; 4.4]$ | $4.6[4.4 .4 .4 .8]$ | $4.7\left[\begin{array}{l} {[8.550 .51 .9]} \\ \hline \end{array}\right.$ | $4.9[4.65 \cdot 5.2]$ | $4.9[4.6 ; 5.2]$ | $4.9[4.6 ; 5.2]$ |
|  | Uncemented | 7,411 | $83_{(78-88)}$ | $34 / 66$ | 24.6 | 392 |  | $7.3\left[\begin{array}{l} {[6.689} \\ {[2.82)} \\ 7.9] \end{array}\right.$ |  |  | $8.0\left[\begin{array}{c} {[7,2 ; 2]} \\ \mid 512] \\ 8.8] \end{array}\right.$ | 8.7 [7.6.6; 9.9$]$ | 8.7 [7.68] 9.9$]$ |  |

5.3.2 Impact of implant characteristics in knee arthroplasties
There are differences in the outcomes of the various knee systems in standard TKA.

Cruciate-retaining systems have significantly lower revision probabilities than all other knee systems (Figure 33). However, it should be noted that in some hospitals, pure cruciate-retaining systems are probably only used in patients with good ligament conditions and stable joints, while other systems are more likely to be preferred in cases with poorer baseline conditions. When the analysis focuses on hospitals specialising in a knee system that is used in at least $80 \%$ of the standard TKAs considered, the differences between the systems are generally smaller and practically non-existent for cruciate-retaining and cruciate sacrificing systems.

At least during the first few years, total knee arthroplasties with fixed bearings have significantly lower revision probabilities than systems with mobile bearings (Figure 34). This is true even if the comparison is limited to data from hospitals that have specialised in one
type of bearing almost exclusively. However, the outcomes for various specific implant systems differ significantly not only within the groups of arthroplasties with mobile bearings. There are even systems with mobile bearings that have better outcomes than fixed bearing systems (in particular see Table 49).

A comparison of TKAs with and without primary patellar resurfacing reveals significantly lower revision probabilities for the latter (Figure 35). However, it should be noted that in the EPRD secondary patellar resurfacing has not yet been categorised as a revision of the primary arthroplasty (also refer to pages $\underline{20}$ and 21). However, if - as is customary in other arthroplasty registries - secondary patellar resurfacing were also categorised as a revision, this finding would be reversed: The outcomes for patellar resurfacing at primary TKA would be better overall. As some publications recommend primary patellar resurfacing across the board on the basis of such findings, [5] the EPRD has analysed this topic in detail in its last annual report. [6] The EPRD therefore believes that a blanket recommendation favouring patellar resurfacing

Figure 33: Revision probabilities of standard total knee arthroplasties by knee system ( $p<0.0001$ ). Confidence intervals have been omitted for clarity.
at primary TKA is just as unjustified as its blanket rejection. Moreover, as various knee systems also differ, the decision should also depend on the system actually implanted. In order to provide an appropriate basis for decision-making, this annual report presents the implant-specific outcomes in Section 5.4 separately for systems with and without patellar resurfacing at the primary TKA (tables 49 and 50).


Figure 34: Revision probabilities of standard total knee arthroplasties by bearing mobility ( $p<0.0001$ )


Figure 35: Revision probabilities of standard primary total knee arthroplasties with and without patellar resurfacing at primary TKA ( $p=0.001$ )

## In brief:

During the first few years, standard TKAs with fixed bearings have significantly lower revision probabilities
Whether or not surgery with patellar resurfacing at the primary TKA yields better outcomes strongly depends on the definition of the endpoint of arthroplasty survival and the knee system implanted.

|  |  |  |  |  |  |  | Revision probabilities after ... |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Type of arthroplasty / category | Type | Number | Age | m/f | BMI | Hosp. | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Standard TKAs |  | 351,531 | $70_{(62-77)}$ | $34 / 66$ | 30.1 | 722 | $1.7[1.6 ; 1.7]$ | $2.5[2.5 ; 2.6]$ | $3.0[(1897,3 ; 5) 3.1]$ |  | $3.6[3.5 ; 3.7]$ |  | $4.0[3.9 ; 4.1]$ | $4.3[4.2 ; 4.4]$ |
| Bearing mobility | Fixed bearing | 299,307 | $70_{(62-77)}$ | $34 / 66$ | 30.1 | 708 | $1.6[1.6 ; 1.7]$ | $2.5{ }_{(197,777)}^{[2,5]}$ | $2.9\left[\begin{array}{l} {\left[15.8 ; 0_{9} ; 3.0\right]} \\ \hline \end{array}\right.$ | ${ }_{\text {3 }} 3.3$ [3:2.2.3.3] | $3.5\left[\begin{array}{c} {[3.4,4 ; 3,6]} \\ \hline 7.088) \\ \hline \end{array}\right.$ | $3.8\left[\begin{array}{l} {[3.7933,8]} \\ (L 0.8] \\ \hline \end{array}\right.$ | $4.0\left[\begin{array}{l} {[3.9 ; 14.1]} \\ (1,121) \end{array}\right.$ | $\text { 4.3 }{ }_{[4.1 .712]}^{[4.4]}$ |
|  | Mobile bearing | 52,224 | $71_{(63-77)}$ | 34166 | 30.0 | 336 | $1.9\left[\begin{array}{c}{[1.8 ; 207)} \\ 4.1]\end{array}\right.$ |  | $3.4\left[\begin{array}{l} {[3.32 ; 36]} \\ 1326] \end{array}\right.$ | $3.8\left[\begin{array}{l} 3.6,6,4.0] \\ {[24,020} \end{array}\right.$ | $4.0[3.8 .8: 4.2]$ | $4.1\left[\begin{array}{l} {[4.087]} \end{array}\right]$ | $4.4\left[\begin{array}{l} {[4.2625} \\ \hline 1.6] \\ 4.6] \end{array}\right.$ | $4.5[4.2724 .8 .8]$ |
| Bearing | Uncoated metal / PE | 144,481 | $71_{(63-77)}$ | $36 / 64$ | 30.1 | 527 | $1.6[1.5 ; 1.6]$ | $2.3\left[\begin{array}{l} {[2,2,2627]} \end{array}, 4\right]$ | $2.7\left[\begin{array}{l} {[2,6,4 ; 45]} \\ \hline 1.8] \\ \hline \end{array}\right.$ | $3.0\left[\begin{array}{l} {[2.92 \cdot 9212.1]} \\ \hline \end{array}\right.$ | $3.3[3.1 .13 .4]$ | $3.5\left[\begin{array}{l} {[3.4 ; 4 ; 3.6]} \\ (2,34] \end{array}\right)$ | $3.7\left[\begin{array}{l} {[3.633} \\ 9.73 .9] \end{array}\right.$ | $4.0\left[\begin{array}{l} {[3,8 ; 54.2]} \\ {[2,51)} \end{array}\right.$ |
|  | Uncoated metal / mXLPE | 121,586 | $71{ }_{(63-77)}$ | 36/64 | 30.0 | 456 | $1.7\left[\begin{array}{ll} 11.7 ; 1.8] \\ (1028,8) \end{array}\right.$ | $2.7\left[\begin{array}{c} {[8.6,720]} \\ \hline \end{array}\right.$ | $3.2\left[\begin{array}{l} {[3.1 ; 9 ; 36]} \\ (69,3] \end{array}\right.$ | $3.5\left[\begin{array}{l} {[5.4,0037} \\ {[3.6]} \\ \hline \end{array}\right.$ |  |  | $4.1[4.0 ; 4.3]$ |  |
|  | Uncoated metal / hXLPE | 30,785 | $68{ }_{(61-76)}$ | $32 / 68$ | 30.4 | 389 | $1.7\left[\begin{array}{c} [1.5 ; 4 ; 5) .8] \\ (2,465 \end{array}\right.$ | $2.5\left[\begin{array}{c} {[2.3 ; 2.75]} \\ (19040 \end{array}\right.$ | $2.9\left[\begin{array}{l} {[1.77 ; 6 ; 3.1]} \\ 10.60 \end{array}\right.$ | $3.2\left[\begin{array}{c} (2.9,9 ; 3.4) \\ (1,224) \end{array}\right.$ | $3.4 \underset{(6.339)}{[3 ; 2 ; 3]}$ | $3.7\left[\begin{array}{l} {[3.4 ; 4 ; 4.0]} \\ \{3,6) \end{array}\right.$ | $3.9\left[\begin{array}{l} (3.563) \\ \hline(4.2] \end{array}\right.$ | $4.0\left[\begin{array}{c} 3.64 ; 4.4] \\ (36) 1 \end{array}\right.$ |
|  | Uncoated Metal / hXLPE+antioxidant | 26,066 | $69_{(61-76)}$ | 38/62 | 30.2 | 267 | $1.7[1.5 ; 1.9]$ | $2.5\left[\begin{array}{c} {[2.3 ; 32.72]} \\ (1324) \end{array}\right.$ | $2.9\left[\begin{array}{l} {[2,723]} \\ {[9.2]} \\ \hline \end{array}\right.$ | $3.3[3.0 ; 3.6]$ | $3.6\left[\begin{array}{c} {[3.3,3 i j)} \\ \hline 3.9] \end{array}\right.$ | $3.8\left[\begin{array}{c} (3.5061) \\ \hline 1.2] \end{array}\right.$ | $3.9[3.5 ; 4.3]$ | $3.9[3.5 ; 4.3]$ |
|  | Coated metal / mXLPE | 10,501 | $66_{(58-74)}$ | $14 / 86$ | 31.2 | 364 | $2.0[1.8 ; 2.3]$ | $3.5\left[\begin{array}{l} {[3,2 ; 3 ; 9]} \\ {[76)} \end{array}\right.$ | $4.3[3.9 ; 4.7]$ | $4.7\left[\begin{array}{l} {[4.22 \cdot 24.2 .2]} \\ 3.2] \end{array}\right.$ | $5.1\left[\begin{array}{l} {[2.433)} \\ \hline 4.7] \end{array}\right.$ | $5.6\left[\begin{array}{l} {[1.0020} \\ 1,26 \end{array}\right)$ | $5.8\left[\begin{array}{l} {[5.253} \\ 5 \cdot 6.4] \\ 6.4] \end{array}\right.$ |  |
|  | Ceramicised metal / PE | 8,088 | $65_{(58-73)}$ | 18/82 | 31.2 | 241 | $1.6[1.4 ; 2.0]$ | $2.7 \underset{(2,4,4 ; 3)}{[3.1]}$ | $3.2\left[\begin{array}{l} {[2.8 ; 3 ; 3)} \\ {[3.7]} \end{array}\right.$ | $3.5\left[\begin{array}{l} (2.1924) ; 4.0] \end{array}\right.$ | $3.7\left[\begin{array}{l} {[1.2755)} \\ \hline \end{array}\right.$ | $3.7\left[\begin{array}{ll} {[3.30: 4.3]} \\ (x .01) \end{array}\right.$ | $4.4\left[\begin{array}{c} {[3,7 ;)} \\ (4,5) \\ 5.2] \end{array}\right.$ | $4.8\left[\begin{array}{l} 32888 \\ {[5.9]} \\ 5 \end{array}\right.$ |
|  | Coated metal / PE | 4,913 | ${ }^{67}{ }_{(60-75)}$ | $19 / 81$ | 31.0 | 225 | $2.5\left[\left(\frac{1,71 ; 3]}{[3.0]}\right.\right.$ | $4.3\left[\begin{array}{l} {[3.7 ; 5.0]} \\ {[2,93} \end{array}\right.$ | $5.1\left[\begin{array}{c} {[4.3 ; 3 ; 5)} \\ (2,80 \end{array}\right]$ | $5.8\left[\begin{array}{l} {[5.1 .100} \\ (1,7) \\ 6.7] \end{array}\right.$ | $6.2\left[\begin{array}{l} {[5.40 ; 7.1]} \\ (1,201 \end{array}\right.$ | $6.6[5.7 ; 7.5]$ |  |  |
|  | Ceramicised metal / hXLPE | 4,138 | $65_{(58-73)}$ | $29 / 71$ | 30.8 | 127 | $2.5\left[\begin{array}{l} {[2.199]} \\ \hline(3) .1] \end{array}\right.$ | $3.7\left[\begin{array}{l} {[3.2 ; 5 ; 4.4]} \\ (2,55) \end{array}\right.$ | $4.4\left[\begin{array}{l} {[3.88 ; 5)} \\ \hline 5.1] \\ \hline \end{array}\right.$ | $5.0\left[\begin{array}{ll} 4.3,235 \\ 4.8] \\ 5.8] \end{array}\right.$ | $5.4\left[\begin{array}{l} {[4.63)} \\ \hline 983 \\ 6.3] \\ \hline \end{array}\right.$ | $5.8\left[\begin{array}{c} (4.9 ; 4) \\ \hline 6.8] \\ \hline \end{array}\right.$ |  |  |
|  | Coated metal / hXLPE+antioxidant | 762 | $65_{(59-72)}$ | $10 / 90$ | 31.4 | 49 | $1.1\left[\begin{array}{l} {[0.629} \end{array} 2.2\right]$ |  | $3.0\left[\begin{array}{c} {[1.755} \\ (195) \\ 5.1] \\ \hline \end{array}\right.$ | $3.0[1.7755 .1]$ |  |  |  |  |
| Femoral articulating surface | Uncoated metal | 322,991 | $70{ }_{(63-77)}$ | 36/64 | 30.1 | 717 | $1.7[1.6: 6: 1.7]$ | $2.5[2.4 ; 2.5]$ |  | $3.2\left[\begin{array}{l} {[32,2 ; 63,3.3]} \\ (1263) \end{array}\right.$ | $\begin{gathered} 3.5[3.4 ; 4 ; 3.5] \\ (83.941) \end{gathered}$ |  | $\begin{gathered} 3.9[3.8 ; 4.0] \\ (19.579) \end{gathered}$ | $4.2[45.0 ; 4.3]$ |
|  | Coated metal | 16,192 | $66_{(59}$-74) | 15/85 | 31.2 | 496 | $2.1[1.9 ; 9.4]$ | $3.7 \begin{aligned} & {[3.4 ; 4 ; 4.0]} \\ & (10.433 \end{aligned}$ | $4.4\left[\begin{array}{l} {[8.10 ; 6]} \\ {[4.8]} \\ \hline \end{array}\right.$ | $5.0\left[\begin{array}{c} (4.6 ; 909) \\ \hline 5.4] \end{array}\right.$ | $5.4\left[\begin{array}{l} {[5.0,0 ; 7)} \\ 5.8] \end{array}\right.$ | $5.8\left[\begin{array}{c} (5.3 ; 9 ; 6.3] \end{array}\right.$ | $5.9 \underset{(5.45)}{[5.4]}$ | $6.1\left[\begin{array}{l} {[5.5 ;} \\ 120 \\ \hline 10.7] \end{array}\right.$ |
|  | Ceramicised metal | 12,226 | $65_{(55-73)}$ | 22/78 | 31.1 | 267 | $1.9[1.7 .72 .2]$ | $3.1\left[\begin{array}{c} {[2.84 ; 4)} \\ \hline 3.4] \end{array}\right.$ | $3.6\left[\begin{array}{l} {[6.3 ; 12)} \\ \hline \end{array}\right.$ | $4.0\left[\begin{array}{l} {[3.7 .7 ; 4.5]} \\ 4.410 \end{array}\right.$ | $4.3\left[\begin{array}{l} {[3.9729} \\ (2,8] \end{array}\right.$ | $4.4[4.0 .054 .9]$ | $5.0[4.33 \cdot 5.7]$ | $\left.5.4\left[\begin{array}{l}{[4.459} \\ 239\end{array}\right) .4\right]$ |
| Tibial articulating surface | PE | 157,604 | $70_{(62-77)}$ | 35/65 | 30.1 | 593 | $1.6[1.5: 1.7]$ | $2.4\left[\begin{array}{c} {[2.3 ; 72.4 .4]} \\ (127) 40 \end{array}\right.$ | $2.8\left[\begin{array}{l} {[8.7530} \\ \hline 2.9] \\ \hline \end{array}\right.$ | $3.1\left[\begin{array}{c} {[3.0 .0,3.2]} \\ \text { [6.36) } \end{array}\right.$ |  | $3.6[3.5 ; 3 ; 7]$ | $3.8\left[\begin{array}{c} {[3.77360)} \\ (10.43] \\ \hline \end{array}\right.$ | $4.1\left[\begin{array}{l} {[3.9 ; 9 ; 4.3]} \\ {[312]} \end{array}\right.$ |
|  | mXLPE | 132,087 | $71_{(63-77)}$ | 34166 | 30.1 | 487 | $1.8[11.7 .71 .8]$ | $2.7\left[\begin{array}{l} {[2.6 ; 89)} \\ {[2.8]} \\ \hline \end{array}\right.$ | $3.3[3.1 ; 3.4]$ | $\underset{\substack{5.4,931)}}{3.7]}$ |  | $4.0\left[\begin{array}{c} {[3.9 ; 4 ; 4.2]} \\ (20.90) \end{array}\right.$ | $4.3\left[\begin{array}{l} {[4.1030} \\ {[.4 .4]} \\ \hline \end{array}\right.$ | $4.5[4.3 ; 4.8]$ |
|  | hXLPE | 34,923 | $68{ }_{(60-75)}$ | $32 / 68$ | 30.5 | 407 | $1.8[1.6 ; 1.9]$ | $2.7[2.5 ; 2.8]$ | $3.1\left[\begin{array}{ll} {[17.90055} \\ \hline \end{array}\right.$ | $3.4\left[\begin{array}{l} {[3,2,2 ; 3,6]} \\ (12,6) \end{array}\right.$ | $3.7\left[\begin{array}{ll} {[3,4536} \\ 70.50] \\ 3 \end{array}\right.$ | $4.0\left[\begin{array}{l} {[3.7 ; 7 ; 4.2]} \\ {[3} \end{array}\right.$ | $4.1\left[\begin{array}{ll} {[3.553 ;} \\ \hline 1.5] \end{array}\right.$ |  |

Table 47: Revision probabilities for different types and characteristics of knee arthroplasties

|  |  |  |  |  |  |  | Revision probabilities after ... |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Type of arthroplasty / category | Type | Number | Age | m/f | BMI | Hosp. | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Tibial articulating surface | hXLPE+antioxidant | 26,828 | $69_{(61-76)}$ | $37 / 63$ | 30.3 | 272 | $1.7 \begin{aligned} & [1.5 .5 ; 7), 9] \\ & (1,98) \end{aligned}$ | $2.5\left[\begin{array}{ll} {[1.3,3727)} \\ 2.7] \\ \hline \end{array}\right.$ | $2.9\left[\begin{array}{ll} {[2.7524} \\ \hline 9.72] \\ 3 \end{array}\right.$ | $3.3\left[\begin{array}{l} (6.0315) \\ \hline 1.6] \end{array}\right.$ | ${ }^{3.5}{ }_{[4,0,010}^{[3.9]}$ | $3.8\left[\begin{array}{l} {[3.5555} \\ 4.2] \\ 4.2] \end{array}\right.$ | $3.8\left[\begin{array}{l} {[3.564} \\ (364) \\ 4.2] \\ \hline \end{array}\right.$ | $3.8[3.5 ; 4.2]$ |
| Knee system | CR | 175,808 | $70_{(62-77)}$ | $36 / 64$ | 30.1 | 648 | ${ }^{1.5[1,4,4,1.5]}$ | 2.2 [2.2; 2. 2.3$]$ | $2.7\left[\begin{array}{ll} {[29.6939]} \\ \hline 2.7] \\ \hline \end{array}\right.$ | $3.0\left[\begin{array}{l} {[2,9.923 .1]} \\ {[1,26)} \end{array}\right.$ | $3.2\left[\begin{array}{ll} {[4,1,1,323} \\ \hline 1.3] \end{array}\right.$ |  |  |  |
|  | PS | 79,205 | $70{ }_{(62-77)}$ | $33 / 67$ | 30.1 | 591 |  | $3.0\left[\begin{array}{l} {[50.929 .96} \\ \hline 3.1] \end{array}\right.$ | $3.5\left[\begin{array}{c} (38,4644) \\ {[3.7]} \end{array}\right.$ | $3.9[3.8 .8,4.1]$ | $4.2\left[\begin{array}{c} {[1.0 .389)} \\ (1.4] \end{array}\right.$ | $4.5[4.3 .3 .4 .7]$ | $4.9\left[\begin{array}{l} {[4.6218)} \\ \hline 5.1] \end{array}\right.$ | 5.3 [5.0; 5.54$]$ |
|  | CS | 44,778 | $71_{(63-77)}$ | 31/69 | 30.1 | 385 | $1.7[1.6 ; 1.8]$ |  | $3.0[2.9 ; 3 ; 2]$ | $3.4\left[\begin{array}{l} {[13.2007)} \\ {[3.6]} \end{array}\right.$ | $3.7\left[\begin{array}{l} {[3.5 \cdot 5 \cdot 3.9]} \\ \substack{12.02)} \\ \hline \end{array}\right.$ | $4.1\left[\begin{array}{l} {[3.9995)} \\ \hline(4.4] \end{array}\right.$ |  | $4.5[4.2 .2 ; 4.9]$ |
|  | CR/CS | 42,377 | ${ }^{69}{ }_{(62-76)}$ | 35/65 | 30.0 | 313 | $1.9[1.7 .72 .0]$ | $2.9\left[\begin{array}{l} {[2.79 ; 3.1]} \\ (2,964) \end{array}\right.$ | $3.4\left[\begin{array}{l} {[3,3,071)} \\ \hline 3.6] \end{array}\right.$ | $3.8\left[\begin{array}{l} 31.68324 .0] \\ (1,23) \end{array}\right.$ | $4.0\left[\begin{array}{l} {[3.8 .8 .4 .2]} \\ {[12.83} \\ 4 \end{array}\right.$ | $4.1\left[\begin{array}{l} {[3.9 .936} \\ {[6.3]} \\ \hline \end{array}\right.$ | $4.3[4.0 ; 4.5]$ | $4.4\left[\begin{array}{l} {[6.1 ; 2)} \\ \hline 62) \\ \hline \end{array}\right.$ |
|  | Pivot | 9,363 | $69_{(62-77)}$ | $37 / 63$ | 30.1 | 118 | $1.9[1.6 ; 2.2]$ | $2.6\left[\begin{array}{l} {[2.3 .364 .0]} \\ 3.0] \end{array}\right.$ | $3.1\left[\begin{array}{l} (2.8 .55) ; 3.6] \end{array}\right.$ | $3.4\left[\begin{array}{l} {[3.050 .03 .9]} \\ 2.53 \end{array}\right.$ | $3.7\left[\begin{array}{ll} 13.220 \\ 4.2 .3] \\ \hline \end{array}\right.$ | $4.0\left[\begin{array}{c} {[3.4 / 4,4.6]} \\ {[8.6)} \end{array}\right.$ | $4.0\left[\begin{array}{l} {[3.465} \\ {[2.46]} \\ 4.6] \end{array}\right.$ |  |
| Patella | Without patellar resurfacing | 312,547 | $70_{(62-77)}$ | 35/65 | 30.1 | 720 | $1.7[1.6 ; 1.7]$ | $2.5[2.4,42.6]$ | $3.0\left[\begin{array}{ll} {[26,9 ; 42,3.0]} \\ {[162]} \end{array}\right.$ | $3.3[33.2 ; 3.4]$ | $3.5[3.5 \cdot 5,3.6]$ | $3.8[3.7 .73 .8]$ | $4.0\left[\begin{array}{c} (1.9655) \\ \hline(3.1] \end{array}\right.$ | $4.2\left[\begin{array}{l} {[4.1996 .4 .4]} \end{array}\right.$ |
|  | With patellar resurfacing | 38,984 | $70_{(62-77)}$ | 31/69 | 30.4 | 484 | $1.8[1.7 ; 1.9]$ | $2.7\left[\begin{array}{l} {[2.65 \cdot 535]} \\ 2.9] \end{array}\right.$ | $3.2\left[\begin{array}{c} {[3.19 .93 .3]} \\ (1,95] \end{array}\right.$ | $3.6\left[\begin{array}{l} (1.4,4725) \\ \hline \end{array}\right.$ | $3.9\left[\begin{array}{c} {[3.723 .74 .2]} \\ 9.23 \\ \hline \end{array}\right.$ | $4.2[4.0 .04 .5]$ | $4.4\left[\begin{array}{l} {[2.1333} \\ 4.7 .7] \end{array}\right.$ | $4.7[4.3 .35 \cdot 5.1]$ |
| Fixation | Cemented | 328,297 | $70_{(62-77)}$ | 34166 | 30.1 | 720 | $1.7[1.6 ; 1.7]$ | $2.5[2.5 ; 2.6]$ | $3.0\left[\begin{array}{l} {[12,933 i 3)} \\ {[17)} \end{array}\right.$ | $\underset{\substack{3.3 \\ 3.3,3 ; 864.4]}}{ }$ | $3.6\left[\begin{array}{c} {[32,5 ; 600} \\ {[3.7]} \end{array}\right.$ | $3.8[33.7 .3 .9]$ | $4.0\left[\begin{array}{c} (18.974) \cdot 9.1] \end{array}\right.$ | $4.3\left[\begin{array}{c} 4.2,22 ; 4.4] \end{array}\right.$ |
|  | Hybrid | 18,346 | $69_{(62-76)}$ | $39 / 61$ | 30.2 | 199 | $1.8[1.6 ; 2.0]$ | $2.7\left[\begin{array}{l} {[2.55 \cdot 2.9]} \\ {[14,235} \end{array}\right.$ | $3.1\left[\begin{array}{l} {[2.92720 .4]} \\ \hline 12.40 \end{array}\right.$ | $3.4\left[\begin{array}{l} {[3.1 .1050} \\ \hline 9.7 .7] \\ \hline \end{array}\right.$ | $\underset{\text { 3.6 }}{3.6364 .3 .9]}$ |  | $4.1\left[\begin{array}{l} {[3.8,875} \\ \hline 1.5] \\ \hline \end{array}\right.$ |  |
|  | Uncemented | 4,585 | ${ }^{68}{ }_{(60-75)}$ | 33/67 | 30.2 | 200 | $1.9[1.5 \cdot 5.3 .3]$ | $3.0\left[\begin{array}{l} {[2.515]} \\ {[3.6]} \end{array}\right.$ | $3.8\left[\begin{array}{l} {[3.2536} \\ (2.56] \end{array} 4.4\right]$ | $\underset{\substack{13.4,55 \\(1.75]}}{4.07}$ | $4.1\left[\begin{array}{c} {[3.535]} \\ (1.35] \\ 4.8] \end{array}\right.$ | $4.3\left[\begin{array}{c} 13.6: 5.1] \\ (144) \\ 5.1] \end{array}\right.$ | $4.3 \text { [3.67 } 5.11]$ | $\begin{gathered} 4.3[3.6 ; 5.1] \\ (8,1) \\ \hline \end{gathered}$ |
| Constrained TKAs |  | 17,600 | $75_{\text {(66-80) }}$ | $24 / 76$ | 28.8 | 663 |  | $5.2\left[\begin{array}{l} {[1.8 .865)} \\ \hline 1.5] \end{array}\right.$ | $5.8 \underset{(8.577)}{[5 ; 6 ; 2]}$ | $6.1[5.7 ; 6.5]$ | $6.4[6.0 ; 6 ; 6]$ | $6.7\left[\begin{array}{l} {[6.2 .27 .71]} \\ (2.065] \end{array}\right]$ | $\underset{\substack{\text { (888) } \\ \hline \text { [6.3 } \\ 7.3]}}{ }$ |  |
| Bearing mobility | Fixed bearing | 17,600 | $75_{\text {(66-80) }}$ | $24 / 76$ | 28.8 | 663 | $4.0 \left\lvert\, \begin{gathered} {[3.7 ; 7 ; 3.3]} \\ \mid 3,67\} \end{gathered}\right.$ | $5.2\left[\begin{array}{l} {[1, .853)} \\ \hline(1.06) \end{array}\right.$ | $5.8\left[\begin{array}{l} {[5.5477)} \\ \hline 8,2] \end{array}\right.$ | $6.1\left[\begin{array}{l} (5.708 ;) \\ \hline(6.5] \end{array}\right.$ | $6.4\left[\begin{array}{c} {[6.090 ; 6]} \\ (6,90 \end{array}\right)$ | $6.7\left[\begin{array}{l} {[6.2 .27 .7 .1]} \\ (2.036 \end{array}\right]$ |  | $7.7\left[\begin{array}{l} {[6.7 ; 7.8 .8]} \\ (201) \end{array}\right.$ |
| Bearing | Uncoated metal / PE | 12,095 | $75_{(67-81)}$ | $24 / 76$ | 28.5 | 569 | $4.0[3.6 ; 4.3]$ | $5.0\left[\begin{array}{l} {[4.6855} \\ \hline 0.55] \\ 5.5] \\ \hline \end{array}\right.$ | $5.6[5.2,2 ; 6.1]$ | $5.9[5.5 ; 6.4]$ | $6.3\left[\begin{array}{l} {[5,8 ; 946} \\ {[6.8]} \\ \hline \end{array}\right.$ | $6.6[6.0 .07 .1]$ | $6.7 \text { [6.1.198) } 7.3]$ | $8.0[6[.7 ; 9.6]$ |
|  | Uncoated metal / mXLPE | 3,125 | $74_{(66-80)}$ | 25/75 | 29.0 | 277 | $3.9\left[\begin{array}{l} 3.3 .3 .4 .7] \\ \hline(2.52) \end{array}\right.$ | $\left.5.1{ }_{(2,064)}^{[4.3 .9} 5.9\right]$ | $5.6[4.8 .866 .6]$ | $5.8\left[\begin{array}{l} {[5.0 ; 0 ; 68)} \\ u, i 8] \\ \hline \end{array}\right.$ | $5.9\left[\begin{array}{c} {[5.175)} \\ (775) \\ 6.9] \\ \hline \end{array}\right.$ | $6.2\left[\begin{array}{c} {[5455} \\ (475) \\ 7.3] \end{array}\right.$ |  |  |
|  | Coated metal / PE | 830 | $72{ }_{(63-79)}$ | 20/80 | 29.5 | 152 | $5.4[4.0 .7 .7 .3]$ | $8.2\left[\begin{array}{l} 6.4,4,40.6] \\ i(6) \end{array}\right]$ | $9.4[7.4,42.0]$ | $10.1 \begin{gathered} {[7.9 \cdot 9 \cdot 12.8]} \\ 1200 \end{gathered}$ | $11.1[8.6 ; 14.2]$ |  |  |  |
|  | Uncoated metal / hXLPE | 765 | $72{ }_{(63-79)}$ | 28/72 | 30.0 | 58 | $3.1\left[\begin{array}{l} {[5999} \end{array}\right]$ | $4.7 \text { [3.3; } 3.6]$ | $5.4\left[\begin{array}{l} {[3,907} \\ {[3.6]} \\ 7.6] \end{array}\right.$ | $6.6[4.7 ; 9.9 .1]$ | $6.6[4.7 .9 .9 .1]$ |  |  |  |
|  | Ceramicised metal / PE | 338 | $66_{(59.74)}$ | $19 / 81$ | 31.3 | 98 | $4.1\left[2.2 .455^{[1.0]}\right.$ | $4.1\left[\begin{array}{l} {[2.4 ; 7.0]} \\ (200) \end{array}\right.$ | $4.7[2.8 .8 .7 .8]$ | $4.7[2.8 ; 7.8]$ | $4.7\left[\begin{array}{l} {[2.8 ; 7.7]} \\ {[52]} \end{array}\right]$ |  |  |  |
|  | Coated metal / mXLPE | 313 | $70_{(62-78)}$ | 10/90 | 30.1 | 111 | $4.5\left[\begin{array}{l} 12.656 \\ 12.6] \end{array}\right.$ | $5.9[3.7 .79 .9]$ | $6.5[4.1 .1 ; 10.4]$ |  | $6.5[4.1 .1 .10 .4]$ |  |  |  |
| Femoral articulating surface | Uncoated metal | 16,118 | $75_{(66-81)}$ | $24 / 76$ | 28.7 | 658 | $3.9\left[\begin{array}{l} 13.6 ; 6 ; 6) \\ (12,2] \end{array}\right.$ | $5.0\left[\begin{array}{l} (1,7,72 ;) ; 5] \end{array}\right.$ | $5.6[5.2 ; 2 ; 60]$ | $5.9[5.5 ; 6.3]$ | $6.2 \underset{(5.3674)}{[5 ; 6]}$ | $6.5\left[\begin{array}{l} {[6.090 .07 .0]} \\ (0,92) \end{array}\right.$ | $6.6\left[\begin{array}{c} {[8.188)} \\ \hline(7.1] \end{array}\right.$ | ${ }^{7.5}{ }_{(16.58)}(1.7]$ |
|  | Coated metal | 1,143 | $71_{(63-79)}$ | 18/82 | 29.6 | 241 | $5.2\left[\begin{array}{l} {[450.0} \\ (85) \\ 6.7] \end{array}\right.$ | $7.6 \underset{(6,100)}{(6.5]}$ | $8.6\left[\begin{array}{c} {[6.9 ; 9)} \\ i(62) \\ 10.7] \end{array}\right.$ | $9.1\left[\begin{array}{c} {[7.3 ; 3 ; 11.3]} \\ {[313} \end{array}\right.$ | $9.8[7.8 ; 12.2]$ | $9.8[7.8,12.2]$ |  |  |
|  | Ceramicised metal | 338 | $66_{(59-74)}$ | $19 / 81$ | 31.3 | 98 | $4.1\left[\begin{array}{l} {[2.455} \\ {[2.0]} \end{array}\right]$ | $4.1\left[\begin{array}{l} {[2.4 ; 7.0]} \\ (20) \\ 7 \end{array}\right.$ | $4.7[2.8 .87 .8]$ | $4.7[2.8 ; 7.8]$ | $4.7\left[\begin{array}{l} {[2,8 ; 7} \\ {[5]} \end{array}\right]$ |  |  |  |
| Tibial articulating surface | PE | 13,264 | $75_{(66-81)}$ | $24 / 76$ | 28.7 | 580 | $4.1\left[\begin{array}{l} {[13.73 ; 4.4]} \\ (1) 34 \end{array}\right.$ | $5.2\left[\begin{array}{c} (4.8,8 ; 5) \\ 5.6] \end{array}\right.$ | $5.8\left[\begin{array}{c} {[5.44 ; 43)} \\ (6.2] \end{array}\right.$ | $6.1[5.7 ; 6.6]$ | $6.5\left[\begin{array}{l} {[6.09060} \\ (2.0] \end{array}\right.$ | $6.8\left[\begin{array}{c} {[6.3 ; 3 ; 9]} \\ 70.3] \\ \hline(2) \end{array}\right.$ | $6.9[6.3 .37 .5]$ | $8.2 \text { [6.9; 9. } 9.7]$ |
|  | mXLPE | 3,438 | $74_{(66-80)}$ | $24 / 76$ | 29.1 | 298 | $3.9\left[\begin{array}{l} {[3.3 ; 3.4 .7]} \\ k .73) \end{array}\right.$ | $5.1\left[\begin{array}{l} {[4.424 ; 6.0]} \end{array}\right.$ | $5.7(4.9 .96 .6 .6]$ | $5.9\left[\begin{array}{l} (5.1276) \\ \hline \end{array}\right.$ | $6.0\left[\begin{array}{c} {[5.2 ; 9} \\ (3,9) \\ 6.9] \\ \hline \end{array}\right.$ | $6.2[5.4 ; 4,7.3]$ | $6.2\left[\begin{array}{l} {[5.4 ; 7 ; 7.3]} \\ (20) \end{array}\right.$ | $6.2[5.4 ; 7.7 .3]$ |
|  | hXLPE | 765 | $72{ }_{(63-79)}$ | 28/72 | 30.0 | 58 | $3.1[2.1 .1 ; 4.7]$ | $4.75\left[\begin{array}{l} {[3.3 ;} \\ (4 / 4) \\ \hline 6.6] \\ \hline \end{array}\right.$ | $5.4\left[\begin{array}{l} {[3,9 ; 7} \\ (3,6] \\ 7.6] \end{array}\right.$ | $6.6[4.77 ; 9.1]$ | $6.6[4.7 .9 .9 .1]$ |  |  |  |
| Knee system | Hinged | 11,154 | $76{ }_{\text {(68-81) }}$ | 22/78 | 28.1 | 624 | $4.4[4.1 .54 .4]$ | $5.7\left[\begin{array}{l} {[5,2 ; 2 ; 62]} \end{array}\right.$ | $6.4[5.9 .9 ; 6.9]$ | $\underset{\substack{(3,388}}{6.8 ;} 7.3]$ | $\left.7.2\left[\begin{array}{l} {[6.664} \\ {[2.64} \end{array}\right] .7\right]$ | $7.3 \text { [6.7.797.9] }$ | $7.3[6.7977 .9]$ | $7.8[6.9 ; 9.8]$ |
|  | Varus-valgus-stabilised | 6,446 | $72{ }_{(63-79)}$ | 28/72 | 29.7 | 408 | $3.2\left[\begin{array}{l} {[2.803} \\ \hline .83 .7] \\ 3 \end{array}\right.$ | $4.3[(3.8,8 ; 4.8]$ | $4.6\left[\begin{array}{l} {[3.1018} \\ 4.15 .2] \\ 5.2] \end{array}\right.$ | $4.9[4.3 \cdot 5 \cdot 5.5]$ | $5.1[(4.5 ; 5.5]$ | $5.6\left[\begin{array}{c} {[4.95)} \\ \hline 6.4] \\ 6.4] \end{array}\right.$ | $5.8 \underset{\substack{[560 ; 7) \\(56)}}{6.8]}$ | $7.2[5.4 ; 4,9.7]$ |
| Patella | Without patellar resurfacing | 15,167 | $75_{(66-81)}$ | $24 / 76$ | 28.7 | 654 | $3.9[3.6 ; 6.2]$ |  | $5.7\left[\begin{array}{l} {[5.3686} \\ {[7.36} \\ \hline \end{array}\right.$ | $6.1\left[\begin{array}{l} {[5.63 ; 3)} \\ \hline 6.5] \end{array}\right.$ | $6.4\left[\begin{array}{l} {[5.999)} \\ 6.8] \\ \hline 6.8] \end{array}\right.$ | $\left.{ }^{6.7}{ }_{\substack{\text { [1.7.295 }}} 7.2\right]$ |  | 7.1 [6.4; $(17.9]$ |


|  |  |  |  |  |  |  | Revision probabilities after ... |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Type of arthroplasty / category | Type | Number | Age | m/f | вмі | Hosp. | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Patella | With patellar resurfacing | 2,433 | $73_{(65-79)}$ | 25/75 | 29.6 | 241 | $4.5\left[\begin{array}{c} {[3.89 .85 .5]} \\ \hline 10.92) \\ \hline \end{array}\right.$ | $5.4\left[\begin{array}{l} {[4.5 ; 52)} \\ \hline(4.4] \end{array}\right.$ | $6.1\left(\begin{array}{l} [5.1991) ; 7.2] \end{array}\right.$ | $6.3[5.3 ; 7.4]$ | $6.7\left[\begin{array}{l} {[5,6 ; 8.0]} \\ {[597)} \end{array}\right.$ | $6.7\left[\begin{array}{c} {[5.6 ; 8)} \\ (28) \\ 8 \end{array}\right.$ | $6.7\left[\begin{array}{l} {[5.6 ; 6 ; 0]} \\ (165) \end{array}\right.$ |  |
| Fixation | Cemented | 17,257 | $75_{(66-80)}$ | $24 / 76$ | 28.9 | 661 | $3.9\left[\begin{array}{c} {[3.6 ; 54.2]} \\ (1350) \end{array}\right.$ | $5.0 \underset{(10.934)}{[4.7 ; 5.4]}$ | $5.5\left[\begin{array}{l} {[5.5 ; 50)} \\ 50.9] \\ \hline \end{array}\right.$ | $5.9 \text { [5.5; } 6.6 .3]$ | $6.2 \underset{(3,881)}{[5.8 ; 6.6]}$ | $6.4\left[\begin{array}{l} {[6.0062)} \\ (2.09] \end{array}\right.$ | $6.5\left[\begin{array}{c} (6.154) \\ \hline(7.0] \end{array}\right.$ | $7.4\left[\begin{array}{l} {[6.5 ; 1)} \\ (2021) \end{array}\right.$ |
| Unicondylar knee arthroplasties |  | 51,875 | $63_{(57-72)}$ | 44/56 | 29.5 | 645 |  | $4.7\left[\begin{array}{c} (33.53 ; 7) \\ {[4.9]} \end{array}\right.$ | ${ }^{5.7}{ }_{\text {[25.8.85] }}[5.50]$ | $6.6\left[\begin{array}{l} {[18.4040)} \\ {[6.9]} \\ \hline \end{array}\right.$ | $7.2\left[\begin{array}{l} {[6.9,9.9 .5]} \\ \substack{11,697} \end{array}\right.$ | $7.9\left[\begin{array}{c} (7,6271) \\ (6,2] \\ \hline \end{array}\right.$ | $\left.{ }^{8.4}{ }_{[8,373)}^{[8.0} 8.8 .8\right]$ | 8.8 [8.3; $\left.{ }_{\text {(774) }} 9.3\right]$ |
| Bearing mobility | Mobile bearing | 30,846 | $64_{(57-72)}$ | 44/56 | 29.7 | 454 | $3.1[2.9 ; 2 ; 3.3]$ | $4.8[4.6 ; 5.1]$ | $5.8\left[\begin{array}{c} \left.[16.241)^{2}\right) \\ 6.0] \\ \hline \end{array}\right.$ | $6.6\left[\begin{array}{l} (16.7979) \\ (1) .9] \end{array}\right.$ | $7.1 \underset{\substack{(7.616)}}{[6.8 ;} 7.5]$ | $8.0[77.6 ; 8.4]$ | $8.3\left[\begin{array}{c} (1.684) \\ \hline 1.8 \\ 8.7] \end{array}\right.$ | $8.6\left[\begin{array}{l} {[892]} \\ 9.9 .1] \\ \hline \end{array}\right.$ |
|  | Fixed bearing | 21,029 | $63_{(57-71)}$ | 45/55 | 29.4 | 446 | $2.6\left[\begin{array}{c} {[12.4,450,2.8]} \\ 2.8] \end{array}\right.$ | $4.6\left[\begin{array}{c} 14.3,90 ; 1 \end{array}\right)$ | $5.7[5.4 ; 6.6 .1]$ | $6.7\left[\begin{array}{l} {[6.3 ; 7} \\ (6.611) \\ 7.1] \\ \hline \end{array}\right.$ | 7.3 [6.8; 7.8 ] | $7.8[7.3 ; 8.3]$ | $8.6[8.0 ; 9.4]$ | $9.4[8.3 ; 10.7]$ |
| Bearing | Uncoated metal / mXLPE | 29,402 | $64_{(58-73)}$ | 46/54 | 29.6 | 423 | $2.9\left[\begin{array}{l} {[2,7.7091)} \\ (2.1] \end{array}\right.$ | $4.5[4.3 ; 4.8]$ | $5.4\left[\begin{array}{l} {[15.1515)} \end{array}\right.$ | $6.2\left[\begin{array}{c} {[11,8 ; 79)} \\ {[1.5]} \end{array}\right.$ | $6.7\left[\begin{array}{c} {[6.309} \\ {[7.30} \\ 7.0] \end{array}\right.$ | $7.4\left[\begin{array}{c} (7.0330 \\ \hline(7.8] \\ 7.8] \end{array}\right.$ | $7.7\left[\begin{array}{c} {[1.39282} \\ \hline 1.2] \\ \hline \end{array}\right.$ | $\underset{\substack{(509)}}{8.0 .6]}$ |
|  | Uncoated metal / PE | 9,001 | $63_{(57-72)}$ | 48/52 | 29.4 | 271 | $2.3\left[\begin{array}{l} {[2.0 ; 0 ; 2.7]} \\ (0,06) \end{array}\right.$ | $4.1\left[\begin{array}{l} {[3,773)} \\ \hline 4.6] \\ \hline \end{array}\right.$ | $5.2 \underset{(4.321)}{[4.7 ; 5]}$ | $6.0\left[\begin{array}{c} {[3.526 .56 .7]} \\ \hline \end{array}\right.$ | $6.7\left[\begin{array}{l} {[6,0 ; 53)} \\ {[3.3]} \end{array}\right.$ | $7.2\left[\begin{array}{l} {[6.55: 50.0]} \end{array}\right.$ | $8.5\left[\begin{array}{c} (7.4 ; 9,9.7] \\ (830) \end{array}\right.$ | $9.7[8.0 ; 11.8]$ |
|  | Uncoated metal / hXLPE | 4,524 | $63_{(56-71)}$ | 46/54 | 29.3 | 127 | $2.2\left[\begin{array}{c} {[1.8 ; 05)} \\ (3,7] \\ \hline \end{array}\right.$ | $4.1{ }_{(3,264)}^{[3.64 .8]}$ | $5.2\left[\begin{array}{c}(2.554) \\ \hline\end{array}\right)$ | $6.2\left[\begin{array}{l} {[5.4,464.4} \\ \hline 1.0] \\ \hline \end{array}\right.$ | ${ }_{\substack{\text { (1.301 }}}^{[5.8 ; 5]}$ | $\left.7.2\left[\begin{array}{c} \text { [6.30; } \\ (120) \end{array}\right] .2\right]$ | $\left.7.5 \begin{array}{c} {[6.5 ;} \\ (277) \end{array} 8.7\right]$ |  |
|  | Uncoated Metal / hXLPE+antioxidant | 3,691 | $63_{(57-71)}$ | 48/52 | 29.5 | 118 | $2.6\left[\begin{array}{l} {[2.12,120} \end{array}\right)$ | $4.1\left[\begin{array}{l} {[1.44 .455} \\ 4.9] \\ \hline \end{array}\right.$ | $5.1[4.2 ; 6.1]$ | $5.9[4.777 .3]$ |  |  |  |  |
|  | Coated metal / mXLPE | 3,659 | $61_{(55-68)}$ | $24 / 76$ | 30.1 | 320 | ${ }^{3.8}{ }_{\text {[3. } 3.266} \mathbf{4 . 5 ]}$ | $7.0\left[\begin{array}{l} {[6.1995)} \\ {[7.9]} \\ \hline \end{array}\right.$ | $8.7 \text { (7.7.7;98) } 9.7]$ | $10.1\left[\begin{array}{ll} {[9.035)} \\ 10.351 .2] \end{array}\right.$ | $10.8 \text { [9,79; 12.1] }$ | $11.8[10.5 ; 13.3]$ | 11.8 [10.5; 13.3$]^{(176)}$ | $12.5[10.7 ; 14.5]$ |
|  | Ceramicised metal / PE | 1,066 | ${ }^{60}(54 .-66)$ | 32/68 | 30.0 | 140 | $4.7\left[\begin{array}{l\|l\|l\|:\|} \hline 86 \\ 6.2] \\ \hline \end{array}\right.$ | $7.3 \text { [5.8:9.3] }$ | $8.9\left[\begin{array}{c} [7.1 ; i) 11.0] \\ \langle\langle 82) \end{array}\right.$ | $9.5\left[\begin{array}{c} (722) \\ (322) \\ \hline 11.8] \\ \hline \end{array}\right.$ | $11.0\left[\begin{array}{c} {[8,72 ;)} \\ (192) \end{array}\right.$ | $11.5\left[\begin{array}{c} {[9.17} \\ (88) \\ 14.5] \\ \hline \end{array}\right.$ |  |  |
|  | Coated metal / PE | 458 | $60_{(54-67)}$ | 25/75 | 30.1 | 80 | $9.3\left[\begin{array}{l} {[6.99 .9 .12 .5]} \\ (3,6) \end{array}\right.$ | $14.7\left[\begin{array}{l} {[1.5 ; 18.7]} \\ (228) \end{array}\right.$ | $15.8[12.4 ; 19.9]$ | $19.4[15.5 ; 24.1]$ | $21.9[17.5 ; 27.2]$ | $25.2\left[\begin{array}{l} 19.8 ; 31.7] \\ (50) \end{array}\right.$ |  |  |
| Femoral articulating surface | Uncoated metal | 46,629 | $64_{(57-72)}$ | 46/54 | 29.4 | 622 | $2.7\left[\begin{array}{c} {[3,6 ; 509)} \\ {[2.9]} \end{array}\right.$ | $4.4\left[\begin{array}{l} {[30.2077)} \\ 4.6] \end{array}\right.$ | $5.3\left[\begin{array}{l} {[52,1 ; 200)} \\ \hline 12.5] \end{array}\right.$ | $6.1[5.9 ; 6.6 .4]$ |  | $7.3\left[\begin{array}{l} {[7.022)} \\ 7.7] \\ \hline \end{array}\right.$ | $7.8[7.4 ; 8.2]$ | 8.3 [7.7.78.8.8] |
|  | Coated metal | 4.118 | ${ }^{61} 1_{(55-68)}$ | $24 / 76$ | 30.1 | 369 | $4.4\left[\begin{array}{l} {[3.58 \cdot 8 \cdot 5.12]} \end{array}\right.$ | $7.8\left[\begin{array}{l} {[6.9,9 ; 9)} \\ {[2.7]} \end{array}\right.$ |  | $11.0\left[\begin{array}{l} 10.0 ; 0 ; \\ k, 1,90) \\ 12.2] \end{array}\right.$ | $12.0\left[\begin{array}{c} 10.99 ; 13.3] \\ \substack{9,06} \end{array}\right.$ | $13.3[11.9 ; 14.9]$ |  | $13.9[12.2 ; 15.9]$ |
|  | Ceramicised metal | 1,128 | $60_{(54-66)}$ | 33/67 | 29.8 | 142 |  | $7.2\left[\begin{array}{l} {[57.79,9.1]} \\ (6)] \end{array}\right.$ | $8.7[7.0 ; 10 ; 8]$ | $9.3[7.5 ; 11.6]$ | $10.8[8 \text { [8:62; } 13.6]$ | $\begin{gathered} 11.3[8.98 ; 14.3] \\ (8 ;) \end{gathered}$ |  |  |
| Tibial articulating surface | mXLPE | 33,123 | $64_{(57-72)}$ | 44/56 | 29.7 | 460 |  | $4.8[4.6 ; 5.50]$ |  |  | $7.1$ | $7.9[7.5 ; 5.3]$ | $8.2\left[\begin{array}{c} {[7.8888)} \\ \text { [1.68) } \\ \hline \end{array}\right.$ |  |
|  | PE | 10,525 | $63_{(57-71)}$ | 45/55 | 29.4 | 329 |  | $4.9[4.5 .555 .4]$ | $6.0[5.5 ; 56.6]$ | $\underset{\substack{(3,703}}{[6.4,7.6]}$ | $7.8\left[\begin{array}{c} {[7.1,5650} \\ (2,5] \\ \hline \end{array}\right.$ | $8.5\left[\begin{array}{l} (7,8 ; 89.3] \\ (1,3) \end{array}\right.$ | $9.6\left[8.6 ; 0_{420} 10.7\right]$ | $10.7[9.1 .1212 .6]$ |
|  | hXLPE | 4,524 | $63_{(56-71)}$ | 46/54 | 29.3 | 127 |  | $4.1\left[\begin{array}{l} {[3.6 ; 264.8]} \\ \hline(2) \end{array}\right.$ | $5.2[4.5 ; 5.9]$ | $6.2\left[\begin{array}{l} {[5.4 ; 7,7.0]} \\ (x, 943) \end{array}\right.$ | $6.6\left[\begin{array}{c} {[5.87307} \\ (4.5] \end{array}\right.$ | $7.2\left[\begin{array}{l} {[6.3 ;} \\ (270) \end{array} 8.2\right]$ | $7.5\left[\begin{array}{c} \text { [6.5; } \\ (277) \end{array} 8.7\right]$ | $7.5[6.5 ; 8.7]$ |
|  | hXLPE+antioxidant | 3,692 | $6_{(57-71)}$ | 48/52 | 29.5 | 118 | $2.6\left[\begin{array}{l} {[2.12 ; 23)} \\ 3.2] \end{array}\right.$ | $\text { 4.1 } 13.4 .4 .4 .9]$ | $5.1[4.2 ; 2 ; 6.1]$ | $5.9[4.7 .7 .7 .3]$ |  |  |  |  |
| Fixation | Cemented | 45,650 | $63_{(57-72)}$ | 43/57 | 29.5 | 641 | $2.8\left[\begin{array}{l} (2,6,782] \\ \\ \hline 2.9] \\ \hline \end{array}\right.$ |  | $5.7\left[\begin{array}{l} {[52.5 ; 3 ; 3)} \\ \hline 1.9] \end{array}\right.$ | $6.6\left[\begin{array}{c} {[6.4,4 ; 6.9]} \\ {[16,9]} \\ \hline \end{array}\right.$ | $7.2\left[\begin{array}{l} {[6.9 .900 .5]} \\ (10.06) \end{array}\right.$ | $8.0\left[\begin{array}{l} {[7.7000} \\ {[5.4]} \\ 8.4] \end{array}\right.$ | $8.6[8.1,19.90]$ | $9.0[88.559 .6]$ |
|  | Uncemented | 5,686 | $63_{(57-71)}$ | 55/45 | 29.7 | 101 | $3.7\left[\begin{array}{l} {[3.2 .25 .54 .2]} \\ 4.650 \end{array}\right.$ | $5.0\left[\begin{array}{c} {[4.4,405} \\ \hline, 5.6] \\ \hline \end{array}\right.$ | $5.9\left[\begin{array}{c} {[5,3,366)} \\ \hline 6.6] \end{array}\right.$ | $6.4\left[\begin{array}{l} {[5.795} \\ {[2,7.2]} \\ \hline \end{array}\right.$ | $6.8\left[\begin{array}{l} 6.0 .094 .6] \\ (x, 64) \end{array}\right.$ | $7.3\left[\begin{array}{l} {[6.52)} \\ (862) \\ 8.2] \end{array}\right.$ | $7.3\left[\begin{array}{c} 1989] \end{array}\right.$ | $7.6 \underset{(6,73)}{[6.78]}$ |
|  | Hybrid | 476 | $66_{(59-74.5)}$ | $37 / 63$ | 28.6 | 46 | $4.3\left[\begin{array}{ll} {[2.87)} \\ \hline 4.6] \end{array}\right.$ | $5.5\left[\begin{array}{c} (3.8 ; 7) \\ (3.1] \end{array}\right.$ | $6.3[4.43 ; 9.1]$ | $6.3 \underset{(1275)}{[4.4 ; 9.1]}$ | $7.2[5.0 ; 10.2]$ | $7.2[5.0 ; 0 ; 10.2]$ |  |  |
| Patellofemoral arthroplasties |  | 849 | $54_{(48-61)}$ | $27 / 73$ | 28.4 | 200 | $4.6\left[\begin{array}{c} {[3.377)} \\ (6.4] \\ \hline \end{array}\right.$ | $7.6[5.8 ; 9.8]$ | $9.7[7.6 ; 12.2]$ | $12.8[10.3 ; 15.9]$ | $15.2[12.2 ; 18.9]$ | $15.8[12.6 ; 19.6]$ |  |  |
| Femoral articulating surface | Uncoated metal | 482 | $55_{(48.62)}$ | 28/72 | 28.4 | 122 | $3.5\left[\begin{array}{l} {[2,188)} \\ {[18.8]} \\ 5.8] \end{array}\right.$ | $5.8 \underset{(303)}{[3.9 ; ~ 8.6]}$ | $7.8[5.55 \cdot 11.1]$ | $11.0\left[\begin{array}{l} \text { (7i,94: } \\ \text { (14. } 15.1] \end{array}\right.$ | $\begin{gathered} 14.2[10.4 ; 19.3] \\ \left.(13)^{2}\right) \end{gathered}$ | $14.2[10.4 ; 19.3]$ |  |  |
|  | Ceramicised metal | 348 | $54_{(48-60)}$ | 28/72 | 28.7 | 100 | $6.4[4.2 ; 9.7]$ | $10.1\left[\begin{array}{l} {[7.2 ;} \\ (20) 1 \end{array} 14.2\right]$ | $12.1\left[\begin{array}{l} {[8.75 ; 16.6]} \\ (154) \end{array}\right.$ | $15.4[11.3 ; 20.8]$ | $16.3[12.0 ; 22.0]$ |  |  |  |
| Patella | With patellar resurfacing | 693 | $54{ }_{(48-61)}$ | 27/73 | 28.7 | 168 |  | $7.2 \underset{[5.32]}{[5 ; ~ 9.6]}$ | $9.3\left[\begin{array}{l}\text { [7.1; } \\ (32)\end{array}\right.$ |  | 14.0 [10.8; 18.00 | $14.8[11.4 ; 19.1]$ |  |  |

### 5.4 Outcomes of specific implant systems (brands) and combinations

The following tables present the revision probabilities for primary arthroplasties with specific implant systems and components. The probabilities that arthroplasties with the corresponding components subsequently required changes are listed. However, these changes do not necessarily affect the listed components themselves (also refer to the explanations on the analyses in Chapter 3). Hip arthroplasty outcomes are presented as femoral stem and acetabular component pairs (Table 48) and knee arthroplasties as femoral and tibial component pairs. Sepa-
rate outcomes for TKAs with ( Table 50) and without (Table 49) primary patellar resurfacing are also given. In addition, Table 51 also lists the probabilities of secondary patellar resurfacing for various total knee arthroplasty systems.

The outcomes for the stem and acetabular component in hip arthroplasties, obtained by considering each component in isolation across all combinations, are also listed separately in the appendix (tables $\underline{61}$ and 62). For the following presentations, groups of comparable systems were created, since the baseline conditions for various implant systems may differ. In the case of hip arthroplasties, grouping into comparable systems
is based on the specified type of fixation, and figures fall below the limit of 150 arthroplasin knee arthroplasties on the type of arthro- ties over time, this is highlighted in italics in plasty, the type of fixation, knee system, and the tables to indicate the resulting higher unbearing mobility. Within each group, the implants are listed alphabetically by name.

For hip arthroplasty outcomes, only elective procedures are analysed. The calculation does not include hemiarthroplasties and total hip arthroplasties implanted because of a femoral fracture close to the hip joint. To ensure that the final results obtained were robust, only outcomes for implant combinations or implants based on a minimum of 300 primary arthroplasties in follow-up and sourced from at least three different hospitals were considered below. If the follow-up

| Elective total hip arthroplasties |  | Number | Hosp. | Age | m/f | Period | Revision probabilities after ... |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Femoral stem | Cup |  |  |  |  |  | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Hybrid fixation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| ABG II Stem (Stryker) | Trident Cup (Stryker) | 444 | 9 | $79^{16-82)}$ | $22 / 78$ | 2014-2022 | $2.5{ }_{(1433)}^{[4.4]}$ | $\underset{\substack{1000}}{3.0[1.7 ; 5]}$ | $3.0[1.73 ; 5.0]$ | $3.0\left[\begin{array}{c} 11.7 ; 5.0] \\ 1234 \\ 5 \end{array}\right.$ | $3.7\left[\begin{array}{l} {[2,1 ;)^{6}} \\ 6.5] \\ \hline \end{array}\right.$ |  |  |  |
| Avenir (Zimmer Biomet) | Allofit (Zimmer Biomet) | 3,425 | 122 | $80_{\text {(76--83) }}$ | 23/77 | 2014-2022 | $2.0 \begin{aligned} & {[1.6 ; 28)} \\ & {[1.6]} \end{aligned}$ | $\left.2.2\left[\begin{array}{ll} {[1.822]} \\ 42 \end{array}\right) .8\right]$ | $2.5\left[\begin{array}{l} {[2.0 ; 6} \\ (926) \end{array}\right]$ | $2.5\left[\begin{array}{l}(527) \\ \text { 2, }\end{array}\right.$ |  | $2.9{ }_{(1,83)}^{[2.2 ; 3.8]}$ | ${ }_{2} 2.9[2.2 ; 3.8]$ |  |
| Avenir (Zimmer Biomet) | Allofit IT (Zimmer Biomet) | 419 | 17 | $78{ }_{755-82)}$ | $19 / 81$ | 2014-2022 | $3.6{ }_{(2296)}$ [2; 6.1] | ${ }^{3.6}$ [2.2; $\left.{ }_{\text {(18) }} 6.17\right]$ | $3.6[2.2 ; 6.1]$ |  |  |  |  |  |
| BHR (Smith \& Nephew) | BHR (Smith \& Nephew) | 375 | 23 | $55_{(51-59)}$ | 99/1 | 2014-2022 | $1.1\left[\begin{array}{c} {[3.48 ;} \\ (38) \end{array}\right.$ | $1.8\left[\begin{array}{l} {[0.88)} \\ {[268)} \\ 4.0] \end{array}\right.$ | $2.2[1.0 ; 4.6]$ | $2.2[1.0 ; 4.6]$ | $2.2[1.004 .6]$ | $2.2[1.0 ; 4.6]$ |  |  |
| BICONTACT (Aesculap) | PLASMACUP (Aesculap) | 334 | 21 | $78{ }_{\text {(76-82) }}$ | 30/70 | 2013-2022 | $2.1 \begin{gathered} 1.0 .04 .4] \\ (103) \\ 4.4] \end{gathered}$ | $2.5[1.2727 .4 .9]$ | $2.5[1.2 ; 4.9]$ | 2.8 [1.55:5.4] | $2.8[1.55 \cdot 5.4]$ | $2.8[1.5 \cdot 5.4]$ | 2.8 [17.55 5.4 . ${ }^{\text {a }}$ |  |
| BICONTACT (Aesculap) | PLASMAFIT (Aesculap) | 1,702 | 80 | $79^{174-82)}$ | 22/78 | 2013-2022 | $2.1[1.5 ; 2.9]$ | $2.3[1.7 ; 3.2]$ | $2.8[(2.1 ; 3.8]$ | $3.0\left[\frac{2.2 ; 52}{} ; 4.0\right]$ | $3.2\left[\begin{array}{l} {[2,4 ; 3)} \\ \hline 4.2] \end{array}\right.$ | $3.2\left[\begin{array}{l} (2149) \\ \hline 1.2] \end{array}\right.$ | $3.2[(2.488) 4.2]$ |  |
| C-STEMTM AMT-Hüftschaft (DePuy) | PINNACLE ${ }^{\text {TM }}$ Press Fit-Hüftpfanne (DePuy) | 492 | 9 | $80_{(76-84)}$ | 17/83 | 2014-2022 | $1.7 \begin{gathered} {[.0 .937} \\ (38) \\ 3.4] \end{gathered}$ | $1.7 \begin{gathered} {[0.990)} \\ (300) \\ 3.4] \\ \hline \end{gathered}$ | $2.0 \underset{(125)}{[1.1 ; 3.9]}$ | $2.5{ }_{\substack{\text { c12 } \\(128)}}^{4.7 .7]}$ | $3.0[1.6 ; 5.6]$ | $3.0[1.6 ; 5.6]$ |  |  |
| CCA (Mathys) | Allofit (Zimmer Biomet) | 433 | 4 | $76{ }_{(73.80)}$ | $32 / 68$ | 2013-2022 | $2.3[1.3 ; 4.3]$ | $3.3\left[\begin{array}{l} {[2.033} \\ 5.5] \\ 5 \end{array}\right.$ | $3.8\left[\begin{array}{\|c\|c\|c\|c\|} {[2 ;} & 6.2] \end{array}\right.$ | $4.4 \underset{(2346)}{[2 ; 8 ;} 6$ |  | $5.3\left[\begin{array}{l} {[3.5 ; 8)} \\ \hline(8.0] \\ \hline \end{array}\right.$ | $5.8 \text { [3.8; } 1.8 .8]$ |  |
| CCA (Mathys) | RM Pressfit vitamys (Mathys) | 320 | 12 | $79^{166-82)}$ | 25/75 | 2013-2022 | $0.6[0.2 ; 2 ; 2]$ | $0.6[0.2 ; 2 ; 5]$ | $0.6[0.2 ; 2 ; 2.5]$ | $0.6[0.2 ; 2 ; 5]$ | $1.3[0.4 ; 4.4 .4]$ | $1.3\left[\begin{array}{ll} {[0.4 ; 4.4]} \\ \text { app } \end{array}\right.$ | $1.3[0.4,4.4 .4]$ |  |
| CORAILTM AMT-Hüftschaft ohne Kragen (DePuy) | PINNACLE ${ }^{\text {TM }}$ Press Fit-Hüftpfanne (DePuy) | 5,415 | 142 | $79{ }_{(75-83)}$ | 21/79 | 2012-2022 | 2.8 [2.3.376) 3.2$]$ | $3.2\left[\begin{array}{l}\text { [2, } 214\end{array}\right.$ | $3.4[2.9 .9 ; 4.0]$ | 3.9 [3.4.779 4.6] |  |  |  |  |
| COREHIP (Aesculap) | PLASMAFIT (Aesculap) | 368 | 29 | $81_{(77-84)}$ | 15/85 | 2018-2022 | $3.3 \begin{gathered} {[1.8 ; 5.8]} \\ (157) \end{gathered}$ |  |  |  |  |  |  |  |
| EXCEPTION (Zimmer Biomet) | Allofit (Zimmer Biomet) | 633 | 11 | $78{ }_{(44-82)}$ | $19 / 81$ | 2016-2022 | $2.4[1.45 ; 3.9]$ | $2.6 \underset{(1884)}{[1.6 ; 4.1]}$ | $\underset{\substack{(3,9)}}{2.8 ; 4]}$ | $2.8[1.77 ; 4.4]$ | $3.3[2.0 ; 5.5]$ |  |  |  |
| EXCIA (Aesculap) | PLASMAFIT (Aesculap) | 2,941 | 92 | $\left.79^{14} 4.82\right)$ | $22 / 78$ | 2014-2022 | $2.1\left[\begin{array}{c} (1.653) \\ (1,253) \end{array}\right.$ | $2.3[1.8 ; 2.9]$ | $2.8[(1.2 ; 2 ; 3) 5]$ | $3.1\left[\begin{array}{l} {[2,533} \\ \hline 1.9] \\ \hline \end{array}\right.$ | $3.1[2.5 ; 3.9]$ | $3.1\left[\begin{array}{l} {[2.500} \\ {[200} \\ 3.9] \end{array}\right.$ |  |  |
| ICON (IO-International Orthopaedics) | ICON (IO-International Orthopaedics) | 304 | 13 | $56_{(51-62)}$ | 87/13 | 2013-2022 | $\left.1.0{ }_{[0.355}^{[0.3 ; ~} 3.0\right]$ |  | $2.0[0.9 ; 4.5]$ |  | $\left.{ }_{2}^{2.8[1.435} \times 5.5\right]$ | $2.8[1.475 .5 .5]$ |  |  |

Table 48: Implant outcomes for stem/cup combinations in elective total hip arthroplasties. For each type of fixation, the combinations are listed alphabetically by the stem component.

| Elective total hip arthroplasties |  | Number | Hosp. | Age | m/f | Period | Revision probabilities after ... |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Femoral stem | Cup |  |  |  |  |  | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Hybrid fixation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| LCU Hip System, cemented, CoCrMo (Waldemar Link) | MobileLink, Cluster Hole (Waldemar Link) | 318 | 7 | $78{ }_{(74-81)}$ | 28/72 | 2019-2022 | 3.7 [2.1.165] 6.6] | ${ }^{3.7}{ }_{\text {[2.7.7) }}^{(6,6.6]}$ |  |  |  |  |  |  |
| M.E.M. Geradschaft (Zimmer Biomet) | Allofit (Zimmer Biomet) | 19,279 | 162 | $79{ }_{(75-82)}$ | 26/74 | 2012-2022 | $2.0 \begin{gathered} (11.8 .822) \\ (1.3] \\ 2.3] \end{gathered}$ | $2.3\left[\begin{array}{l\|l\|:\|:\|c\|} {[25]} \\ \hline \end{array}\right.$ | $2.5\left[\begin{array}{l} {[(2,2,205)} \\ \hline 2.7] \\ \hline \end{array}\right.$ |  | $2.8 \text { [2.6; } 2.3 .1]$ |  | $3.1 \underset{(1,888}{[2 ;} ; 3]$ | ${ }^{3.3}{ }_{(159)}$ (2.8; 3.8$]$ |
| M.E.M. Geradschaft (Zimmer Biomet) | Allofit IT (Zimmer Biomet) | 431 | 17 | $79{ }_{(75-83)}$ | 22/78 | 2013-2022 |  | 2.7 [1.574.4.9] | 2.7 [1.599\% 4.9$]$ | $\left.{ }_{4} 4.0[2.2 .23]^{(13)} 7.1\right]$ | $4.0\left[\begin{array}{l}\text { [2; 2 } 27.7 \\ 7.1]\end{array}\right.$ |  |  |  |
| M.E.M. Geradschaft (Zimmer Biomet) | Trilogy (Zimmer Biomet) | 1,452 | 12 | 78 (74-81) | 28/72 | 2012-2022 | $1.6[1.0 ; 2.3]$ | $1.7 \text { [1.2.2; 2.6] }$ | $1.8\left[\begin{array}{c} 1.2,2,2.7] \\ (980) \end{array}\right.$ | $1.8\left[\begin{array}{c} (1,290 \\ (192) \\ 2.7] \end{array}\right.$ | $1.9[1.3 .32 .9]$ | $1.9\left[\begin{array}{c} 1.3 ; 3 ; \\ (411) \\ 2.9] \\ \hline \end{array}\right.$ | $2.2\left[\begin{array}{c} 12.56 \\ (120) \\ 3.4] \\ \hline \end{array}\right.$ | $2.2\left[\begin{array}{c} {[1.57)} \\ \hline 9.4] \\ \hline \end{array}\right.$ |
| M.E.M. Geradschaft (Zimmer Biomet) | Trilogy IT (Zimmer Biomet) | 330 | 3 | $81_{(78-83)}$ | 25/75 | 2015-2022 | $1.9\left[\begin{array}{c} {\left[0.8 i_{i}, ~ 4.1\right]} \\ (2.1] \end{array}\right.$ | $1.9\left[\begin{array}{c} {[0.8 ; 9} \\ {[19} \end{array}\right)$ | 1.9 [0.8.85 4.17 | ${ }^{1.9} 9[0.884 .4 .1]$ | $3.1\left[\begin{array}{c} (1.28) \\ (68) \\ 7.6] \end{array}\right.$ |  |  |  |
| METABLOC (Zimmer Biomet) | Allofit (Zimmer Biomet) | 1,508 | 24 | $78{ }_{(75-82)}$ | 28/72 | 2013-2022 | $2.3 \text { [1.7.7.3.2] } 3.2]$ | $\underset{(1.331)}{2.7} \underset{(2.0 ;}{3.6]}$ | $2.9\left[\begin{array}{l} {[2.22,23.9]} \\ 10.28 \end{array}\right.$ | $2.9\left[\begin{array}{c} (2851) \\ 2.2 ; 9] \\ 3.9] \end{array}\right.$ | $3.11 \begin{gathered} (2.351)^{(601)} \\ \hline \end{gathered}$ | $3.2\left[\begin{array}{c} (2,470) \\ (3.4] \end{array}\right.$ | 3.2 [2.4.49\% 4.4$]$ |  |
| MS-30 (Zimmer Biomet) | Allofit (Zimmer Biomet) | 3,514 | 31 | $78{ }_{(73-81)}$ | 26/74 | 2014-2022 | $1.6\left[\begin{array}{ll} {[1.355 j)} \\ \hline(2.1] \\ \hline \end{array}\right.$ | $1.8 \underset{(1.455)}{[1.4]}$ |  | $2.2\left[\begin{array}{l} (1.7,7,75) \\ (4,8] \end{array}\right.$ | $2.3[1.8 .82 .9]$ | $2.4{ }_{(1766)}(1.93 .0]$ | $2.4[1.98 ; 3.0]$ |  |
| Müller Geradschaft <br> (OHST Medizintechnik) | R3 (Smith \& Nephew) | 922 | 14 | $78{ }_{(75-81)}$ | 31/69 | 2015-2022 | $2.9\left[\begin{array}{l} (2,0 ; 4) \\ 4.2] \end{array}\right.$ | $3.1 \begin{gathered} {[2.2597} \\ (1.5] \\ 4.5] \end{gathered}$ | $3.1[(5.2 ; 4.5]$ | $\left.3.1{ }^{[2.273)} 4.5\right]$ | 3.1 [ 1.2364 .56 |  |  |  |
| Polarschaft Cemented (Smith \& Nephew) | R3 (Smith \& Nephew) | 1,359 | 59 | ${ }^{79}{ }_{(75-82)}$ | 23/77 | 2013-2022 | $2.8\left[\begin{array}{ll} {[2.000} & 3.8] \\ 10.02) \end{array}\right.$ | $2.9\left[\begin{array}{c} (2.1090 \\ (8.9] \\ \hline \end{array}\right.$ | $3.1\left[\begin{array}{c} {[2.3 .3: 4.3]} \\ (134) \end{array}\right.$ | $3.5\left[\begin{array}{l} {[2.555} \\ 4.85 \\ 4.8] \\ \hline \end{array}\right.$ | $3.5[2.5 ; 4.8]$ | $3.5[2.5 ; 4.8]$ |  |  |
| QUADRA-C (Medacta) | VERSAFITCUP CC TRIO (Medacta) | 1,713 | 42 | $80_{(77-83)}$ | 22/78 | 2015-2022 | $2.4 \underset{\substack{11.7 .729 \\ 1(3.2]}}{ }$ | $2.6[1.9 ; 3 ; 5]$ | $2.6[1.9 .9 .5]$ | $2.6[1.9: 3.5]$ | $2.6[1.9 .9 .3]$ | $2.6[1.9: 3.5]$ |  |  |
| SPECTRON (Smith \& Nephew) | R3 (Smith \& Nephew) | 348 | 7 | $7{ }^{(75-83)}$ | 27/73 | 2013-2022 | $0.9\left[\begin{array}{c} {[0.3 ; 3 ;} \\ {[273} \end{array}\right)$ | $0.9\left[\begin{array}{c} {[0.32 ;} \\ 124 \\ \hline \end{array}\right.$ | $0.9\left[\begin{array}{ll} {[1755} \\ \hline 175 & 2.7] \\ \hline \end{array}\right.$ | $0.9[0.3 ; 2.7]$ | $0.9\left[\begin{array}{l} {[0.3 ;} \\ (8 ;)^{3} \\ 2.7] \end{array}\right.$ | $0.9[0.3 ; 2.3]$ |  |  |
| SPII Model Lubinus Hip Stem (Waldemar Link) | Allofit (Zimmer Biomet) | 5,493 | 55 | 78 (74-81) | 28/72 | 2013-2022 | $2.2[1.9 .92 .7]$ |  | ${ }^{3.0}{ }_{\text {[2.337) }}(2.63 .6]$ |  | $3.3 \begin{aligned} & {[2.8,8,3.9]} \\ & {[1.28)} \\ & \hline \end{aligned}$ |  | 4.7 [3.77 3 [80) 5.9$]$ | $\left.4.7{ }_{\substack{\text { [3, } \\(133)}} 5.9\right]$ |
| SPII Model Lubinus Hip Stem (Waldemar Link) | CombiCup (Waldemar Link) | 1,328 | 32 | 78 (74-81) | 28/72 | 2014-2022 | $1.0[0.6 ; 1.7]$ | $\begin{gathered} 1.8[1.2 ; 2 ; .7] \\ (4.021) \end{gathered}$ | $2.0 \begin{gathered} {[1.38]^{2}} \\ (1.9] \\ \hline \end{gathered}$ | $\underset{\substack{\text { (ibait }}}{2.0]}$ | $3.2\left[\begin{array}{c} \mid 2.312 \\ \mid 42 \\ 4.6] \end{array}\right.$ |  |  |  |
| SPII Model Lubinus Hip Stem (Waldemar Link) | HI Lubricer Schale (Smith \& Nephew) | 331 | 4 | $77{ }_{(73-81)}$ | 27/73 | 2014-2022 | $0.9\left[\begin{array}{l} {\left[0.3{ }_{2}^{1255} 5\right.} \\ \hline 2.8] \end{array}\right.$ | $0.9 \begin{gathered} {[0.3 ;} \\ (250 \\ \hline 2.8] \\ \hline \end{gathered}$ | $1.4\left[\begin{array}{c} 0.5 .53 .7] \\ 1206 \\ 3.7] \end{array}\right.$ | $1.4\left[\begin{array}{l} {[0.54,3.7]} \\ (1,54) \end{array}\right.$ | $2.0[0.8 ; 5.1]$ |  |  |  |
| SPII Model Lubinus Hip Stem (Waldemar Link) | MobileLink, Cluster Hole (Waldemar Link) | 737 | 24 | $78{ }_{(22-82)}$ | 26/74 | 2017-2022 | $2.5[1.55,4.0]$ | $3.4 \underset{(1464)}{[2.25 .4]}$ |  |  |  |  |  |  |
| Standard C, cemented (Waldemar Link) | CombiCup (Waldemar Link) | 369 | 4 | $77{ }_{(73-80)}$ | 32/68 | 2014-2022 |  | $2.0\left[\begin{array}{c} {[0.9 ; 9 ; 0} \\ (3,0) \\ 4.0] \end{array}\right.$ | $\underset{\substack{1300}}{2.5 ; 4.8]}$ | $3.2\left[\begin{array}{c}{[1283 ;} \\ 1.8 \\ 5\end{array}\right.$ | $3.2[1.885) 5.6]$ | $3.2\left[\begin{array}{c}(1.87) \\ \text { (107) } \\ 5.6]\end{array}\right.$ |  |  |
| Taperloc Cemented (Zimmer Biomet) | Allofit (Zimmer Biomet) | 422 | 24 | $79{ }_{(75-82)}$ | 20/80 | 2015-2022 | $2.9[1.6 .65 .2]$ | $3.5\left[\begin{array}{c} (1.951 \\ (151) \\ \hline 6.2] \\ \hline \end{array}\right.$ | $3.5[1.996 .2]$ |  |  |  |  |  |
| Taperloc Cemented (Zimmer Biomet) | G7 (Zimmer Biomet) | 434 | 11 | $80_{(75-83)}$ | 25/75 | 2015-2022 | $1.7\left[\begin{array}{c} (0.85) \\ (355) \\ 3.4] \end{array}\right.$ | $2.5\left[\begin{array}{c} 1,4 ; 4 ; 4] \\ 1220 \end{array}\right)$ | $2.5\left[\begin{array}{c} 1.4,4,4.7] \\ 1288 \\ \hline \end{array}\right.$ |  | $2.5\left[\begin{array}{c} (1.402) \\ (102) \end{array}\right.$ | $2.5\left[1.452^{(52)} 4.7\right]$ |  |  |
| TRENDHIP (Aesculap) | PLASMAFIT (Aesculap) | 496 | 31 | $80_{(75-83)}$ | 25/75 | 2016-2022 | $2.5[1.4 ; 4.4 .4]$ | $2.5\left[\begin{array}{l} 1.45 ; 2 ; 4 \\ (302) \end{array}\right.$ | $2.5[1.4 .48 .4 .4]$ | $2.5[1.444 .4 .4]$ | $2.5[1.4 ; 4.4]$ |  |  |  |
| twinSys cem. (Mathys) | RM Pressfit vitamys (Mathys) | 921 | 25 | $78{ }_{(72-82)}$ | 23/77 | 2014-2022 | $2.5[1.6 ; 3.7]$ | $2.6[1.7 ; 3 ; 9]$ |  | $2.8[1.93 ; 4.2]$ |  |  |  |  |
| Reverse-hybrid fixation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Avenir (Zimmer Biomet) | Flachprofil (Zimmer Biomet) | 358 | 61 | $73{ }_{(66-79)}$ | 17/83 | 2013-2022 | $4.3\left[\begin{array}{l} {[2.6,64.0]} \\ (264) \end{array}\right.$ | $5.1\left[\begin{array}{l} \text { [32.2; } \\ 120 \end{array} 8.2\right]$ | $5.6[3.5 ; 8.8]$ | $5.6\left[\begin{array}{c} \text { (10.5] } \\ \text { (108) } 8.8] ~ \end{array}\right.$ | $5.6\left[\begin{array}{c} (3,5) \\ (3,8) \\ 8.8] \end{array}\right.$ |  |  |  |
| BICONTACT (Aesculap) | All Poly CuP (Aesculap) | 385 | 60 | $76_{(00-80)}$ | 23/77 | 2013-2022 | $3.4\left[\begin{array}{l} {[2,0.046} \\ {[5.8]} \end{array}\right.$ | $3.7\left[\begin{array}{l} (2289) \\ \hline 6.2] \end{array}\right.$ | $4.0\left[\begin{array}{l} {[2.555} \\ 1.55 \\ 6.6] \end{array}\right.$ | $\left.4.0\left[\begin{array}{l} {[2.50} \\ \mid 201 \end{array}\right) 6.6\right]$ | $4.5[2.8 ; 7.4]$ |  |  |  |
| Uncemented fixation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| A2 Kurzschaft (ARTIQO) | ANA.NOVA® Alpha Pfanne (ARTIQO) | 3,866 | 46 | $64_{(58-77)}$ | 43/57 | 2016-2022 | $2.1\left[\begin{array}{c} (1.7685) \\ 2.7] \end{array}\right.$ | $2.3[1.9 ; 2.9]$ |  | $2.8[2.2 .2 ; 3.6]$ | $2.8\left[\begin{array}{c} {[2.2,238]} \\ {[3.6]} \end{array}\right.$ | $3.2[2.4 ; 4.4]$ |  |  |
| A2 Kurzschaft (ARTIQO) | ANA.NOVA® Hybrid Pfanne (ARTIQO) | 5,015 | 38 | $63_{(57-70)}$ | 37/63 | 2016-2022 |  | $2.1\left[\begin{array}{c} {[1.7 ; 9 ; 2.5]} \\ (1,29) \end{array}\right.$ | $2.2\left[\begin{array}{l} 1.8: 8,2.7] \\ k, 37 \end{array}\right.$ | $2.3\left[\begin{array}{l} 1.9 .9 ; 2.8] \\ (1.33) \end{array}\right.$ | $2.3[1.9 .92 .2]$ | $2.6[1.9 \cdot 3.3]$ |  |  |
| ABG II Stem (Stryker) | Trident Cup (Stryker) | 414 | 12 | $66_{(59-77)}$ | 42/58 | 2014-2022 |  | $5.1{ }_{\substack{\text { [3.36) } \\ \text { [3, } 7.7]}}$ | $5.6{ }_{\substack{\text { [305] }}}^{[3.78 .4]}$ | ${ }_{5} 5.9$ [4.0.08) 8.8$]$ |  |  | ${ }^{6.5[4.4 .47)}$ 9.7] |  |

Table 48 (continued)

| Elective total hip arthroplasties |  | Number | Hosp. | Age | m/f | Period | Revision probabilities after ... |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Femoral stem | Cup |  |  |  |  |  | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Uncemented fixation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Accolade II Stem (Stryker) | Trident Cup (Stryker) | 6,778 | 45 | $67{ }_{(60-75)}$ | 42/58 | 2014-2022 | $2.5[(5.10 ; 2.9]$ | $2.8\left[\begin{array}{l} {[2.4 ; 3 ; 2]} \\ \langle, 24] \end{array}\right.$ | $2.9[2.5 ; 933]$ |  | $3.1\left[\begin{array}{l} {[8.730} \\ {[8.6]} \\ \hline \end{array}\right.$ | $3.3\left[\begin{array}{c} {\left[2.733_{3} 3.9\right]} \\ 3.9 \end{array}\right.$ | $3.3[2.7 .73 .3]$ |  |
| Accolade II Stem (Stryker) | Trident TC Cup (Stryker) | 482 | 10 | $69_{(62-75)}$ | $36 / 64$ | 2015-2021 | $1.7\left[\begin{array}{l} \left.[0.83)^{3} 3.3\right] \\ \hline(4) \end{array}\right.$ | $2.1\left[\begin{array}{c} 1.1 .1 ; 54 \\ (4.9] \\ \hline \end{array}\right.$ | $2.3[1.3 ; 4.2]$ | $2.8[1.6 ; 4.7]$ | $\left.{ }^{3.5}{ }_{(12.179}^{(37)} 5.6\right]$ | $3.5\left[\begin{array}{l}\text { [27, } 171\end{array}\right.$ |  |  |
| Accolade II Stem (Stryker) | Tritanium Cup (Stryker) | 2,489 | 23 | $69_{(62-76)}$ | 40/60 | 2014-2022 | $2.8\left[\begin{array}{l} {[2.28 ; 3]} \\ {[8]} \end{array}\right.$ | $3.3\left[\begin{array}{l} (2.717) \\ \hline \end{array}\right.$ | $3.6\left[\begin{array}{l} (2.2927) \\ \hline \end{array}\right.$ | $4.0 \underset{(3837)}{[3 ; 5]}$ | $4.2\left[\begin{array}{l} {[3.453} \\ {[5.1]} \end{array}\right.$ | $4.2\left[\begin{array}{c} 3.4,4 ; 5 \\ {[290} \\ 5 \end{array}\right.$ | $4.7\left[\begin{array}{l} {[3.513 .6]} \\ (113) \\ 6 \end{array}\right.$ |  |
| Actinia cementless (Implantcast) | EcoFit cpTi (Implantcast) | 623 | 13 | $70_{(62-76)}$ | 41/59 | 2015-2022 | $2.8 \underset{[1573)}{[1.7 ; 4]}$ | $3.6 \underset{(5,488)}{[5.4]}$ | $3.6\left[\begin{array}{l} {\left[2433^{2}\right.} \\ 5.4] \\ \hline \end{array}\right.$ | $4.0 \underset{(2320}{[2.7 ; 6.0]}$ |  |  |  |  |
| Actinia cementless (Implantcast) | EcoFit NH cpTi (Implantcast) | 1,383 | 7 | $72{ }_{\text {(65-78) }}$ | 30/70 | 2015-2022 | $2.9\left[\begin{array}{l} {[1.22 ; 4.0]} \\ (1,26) \end{array}\right.$ | $3.0\left[\begin{array}{l} {[2.22 ; 4.1]} \\ \hline \end{array}\right.$ | $3.1\left[\begin{array}{l} [882) ; 4.2] \end{array}\right.$ | $3.1[2.3 ; 4.2]$ | $3.1[2.3 ; 4.2]$ |  |  |  |
| ACTISTM-Hüftschaft (DePuy) | PINNACLETM Press Fit-Hüftpfanne (DePuy) | 1,574 | 35 | $62_{(55-69)}$ | 43/57 | 2018-2022 | $1.5[1.0 ; 2.3]$ | $1.9 \begin{gathered} \text { 1.2.2aic } \\ \text { li. } \\ \hline \end{gathered}$ | $1.9[1.2 .22 .9]$ |  |  |  |  |  |
| Alloclassic (Zimmer Biomet) | Alloclassic (Zimmer Biomet) | 396 | 8 | $67^{(59-75)}$ | 32/68 | 2014-2022 | $3.8[2.3 ; 6.3]$ | $4.4\left[\begin{array}{l} {[2.754 ;} \\ {[6.9]} \\ \hline \end{array}\right.$ | $4.9 \underset{(3,20)}{[3.6]}$ | $5.5\left[\begin{array}{c} (3.60 ; 4 \\ (304) \\ \hline \end{array}\right.$ | $5.5\left[\begin{array}{l} 13.6 ; 4 \\ (24.3] \\ \hline \end{array}\right.$ |  | $5.9[3.9 .9 .9]$ |  |
| Alloclassic (Zimmer Biomet) | Allofit (Zimmer Biomet) | 8,874 | 67 | $70_{(62-77)}$ | 35/65 | 2012-2022 | $2.7\left[\begin{array}{l} {[2.4 ; 0 ; 3]} \\ {[, 76} \end{array}\right.$ |  | $3.5[3,1.1 ; 3.9]$ | $3.8[3.4 ; 4.3]$ | $4.1 \text { [3.7.7:4.6] }$ | $4.4\left[\begin{array}{l} {[3.999)} \\ {[4.9]} \\ \hline \end{array}\right.$ | $4.5[4.00 ; 5.1]$ | $4.9\left[\frac{4.3 ; 3 ;}{253} 5\right.$ |
| Alloclassic (Zimmer Biomet) | Trilogy (Zimmer Biomet) | 535 | 5 | 67 (64-70) | $34 / 66$ | 2015-2022 | $3.3[2.055 .5 .2]$ | $3.9[2.5 ; 6.0]$ | $3.9\left[\begin{array}{l} {[2.500} \\ (300) \\ \hline \end{array}\right.$ | $4.5\left[\begin{array}{l} {[3.0 ; 9} \\ (209) \\ \hline 6.8] \end{array}\right.$ | $4.5(3.0 ; 6.8]$ | $4.5\left[\begin{array}{l} 3.0 .06 .8] \\ (12) \end{array} 6\right.$ |  |  |
| Alpha-Fit (Corin) | Trinity no Hole (Corin) | 451 | 3 | $75_{\text {(69 - 78) }}$ | $33 / 67$ | 2014-2022 | $1.6\left[\begin{array}{c} {[0.730 i 4} \\ 4.3 .2] \\ \hline \end{array}\right.$ | $1.8 \underset{(0.97\rangle}{[4.5]}$ | $\underset{\substack{4008}}{2.3}\left[\begin{array}{l} 1.1] \\ \hline \end{array}\right.$ | $\underset{(1341)}{2.3} \underset{(1.2 ; 4]}{ }$ | $\underset{\substack{1200}}{2.7} \mathbf{1 . 5 ;}$ | $2.7[1.5 ; 4.8]$ | $\begin{aligned} & 3.9[2.2,7.1] \\ & \text { (i02) } \\ & \hline \end{aligned}$ |  |
| AMISTEM-H (Medacta) | VERSAFITCUP CC TRIO (Medacta) | 962 | 26 | $67{ }_{(58-74)}$ | 42/58 | 2015-2020 | $3.2\left[\begin{array}{l} {[2,302} \\ \hline 9.6] \end{array}\right.$ | $3.6\left[\begin{array}{l} (2899) \\ \hline \end{array} 4.9\right]$ | $3.8\left[\begin{array}{l} {[2,8 ; 7)} \\ \mid(7.2] \\ \hline \end{array}\right.$ | $4.3\left[\begin{array}{l} {[3.17 ;} \\ 5.8] \\ \hline \end{array}\right.$ | $4.7 \underset{(3159)}{[3.5]}$ | ${ }_{6} 6.0\left[4.3 .380^{(8.5]}\right.$ |  |  |
| AMISTEM-H ProxCoat (Medacta) | VERSAFITCUP CC TRIO (Medacta) | 347 | 3 | $60_{(52-66)}$ | 48/52 | 2016-2022 | $1.8\left[\begin{array}{c} {[0.8: 84.3} \\ {[2.9]} \end{array}\right.$ | $2.1[1.0 ; 4.5]$ | $2.6[1.3 ; 5.2]$ | $3.3[1.7 ; 6.5]$ |  |  |  |  |
| AMISTEM-P (Medacta) | VERSAFITCUP CC TRIO (Medacta) | 735 | 21 | $66_{(59-73)}$ | 41/59 | 2019-2022 | $2.5[1.6 ; 4.0]$ | $\left.2.5[11.63]_{1.0]} 4.0\right]$ |  |  |  |  |  |  |
| ANA.NOVA® ${ }^{\text {® }}$ Alpha Schaft (ARTIQO) | ANA.NOVA® Alpha Pfanne (ARTIQO) | 969 | 7 | $70_{(63-76)}$ | 44/56 | 2015-2022 | $3.2[2.2 ; 4.5]$ | $3.5[2.5 ; 5 ; 4]$ | $3.8\left[\begin{array}{c} {[2.700} \\ (6.3] \\ \hline \end{array}\right.$ | $4.3\left[\begin{array}{l} (3055 \\ 4.7 ; 5] \\ \hline \end{array}\right.$ | $4.8[3.5 ; 6.6]$ |  |  |  |
| ANA.NOVA® Alpha Schaft (ARTIQO) | ANA.NOVA® Hybrid Pfanne (ARTIQO) | 1,144 | 11 | $69{ }_{(63-76)}$ | $37 / 63$ | 2015-2022 | $1.4\left[\begin{array}{c} {[0.9 ; 94} \\ (0,9) \\ 2.3] \\ \hline \end{array}\right.$ | $\left.2.0\left[\begin{array}{c} {[1.33 i} \\ (13 i) \end{array}\right) .0\right]$ | $2.1 \underset{\substack{1568] \\[1.4 ; ~ 3.2]}}{ }$ |  | $2.1[1.4 ; 3 ; 3]$ | $2.6[1.6 ; 4.2]$ |  |  |
| ANA.NOVA ${ }^{\oplus}$ SL-complete ${ }^{\oplus}$ Schaft (ARTIQO) | ANA.NOVA® Alpha Pfanne (ARTIQO) | 308 | 5 | $73_{(64-78)}$ | $39 / 61$ | 2015-2022 | $3.1[1.6 .65 .8]$ | $3.1\left[\begin{array}{c} {[1.6 ; 5} \\ 120 \\ \hline 10.8] \\ \hline \end{array}\right.$ | $3.1[1.6 ; 5.8]$ | $3.6\left[\begin{array}{c} (11999) \\ {[6.6]} \end{array}\right.$ | $3.6{ }_{[531}^{[1.9 ; 6.6]}$ |  |  |  |
| ANA.NOVA* Solitär Schaft (ARTIQO) | ANA.NOVA® Hybrid Pfanne (ARTIQO) | 491 | 7 | $74_{(65-80)}$ | 35/65 | 2015-2022 | $3.9[2.5 ; 5 ; 1]$ | $4.2\left[\begin{array}{l} {[3.766} \\ \hline 1.4] \\ \hline \end{array}\right.$ | $4.7 \begin{aligned} & {[3,12 ; 7.0]} \\ & (2,2) \end{aligned}$ | $5.2\left[\begin{array}{l} [3.4 ; 7) 7.9] \\ (i, 7) \end{array}\right.$ | 6.1 [3:9,99, 9.7$]$ |  |  |  |
| Anato Stem (Stryker) | Trident Cup (Stryker) | 392 | 9 | $68{ }_{(60-75)}$ | 45/55 | 2016-2022 | $2.9[1.6 ; 5.1]$ | $3.5[2.0 ; 5.9]$ | $3.5[2.0 ; 5.9]$ | $3.5{\underset{(1556}{[2.00} 5.9]}^{5}$ | $3.5\left[\begin{array}{l} {[20 ; 9} \\ (9,0 \\ \hline \end{array} .9\right]$ |  |  |  |
| Avenir (Zimmer Biomet) | Allofit (Zimmer Biomet) | 23,874 | 180 | $69_{(62-76)}$ | 40/60 | 2013-2022 | $2.9\left[\begin{array}{l} (2.73 ; 20) \\ (1.2]) \end{array}\right.$ | $3.2\left[\begin{array}{c} {[3.0 ; 3 ; 3.4]} \\ (1,35) \end{array}\right.$ | $3.4\left[\begin{array}{l} {[3,192 ;} \\ (9,2) \\ \hline \end{array}\right.$ | $3.4\left[\begin{array}{l} {[6,2 ; 5 ;} \\ (6,7) \end{array}\right.$ | $3.5\left[\begin{array}{l} {[3.3 ; 3 ; 3)} \\ {[3,8]} \\ \hline \end{array}\right.$ |  | $3.6\left[\begin{array}{l} {[3.3 ;} \\ (51) \end{array}\right)$ | $3.6[3.3 ; 3.9]$ |
| Avenir (Zimmer Biomet) | Allofit IT (Zimmer Biomet) | 2,845 | 49 | $67{ }_{(59-75)}$ | $40 / 60$ | 2014-2022 | $3.4\left[\begin{array}{l} {[2,890)} \\ \hline 1.2] \end{array}\right.$ | $3.9\left[\begin{array}{c} (3.3813) \\ (1.8] \end{array}\right.$ | $4.2\left[\begin{array}{l} {[3.585} \\ u, 28) \\ \hline \end{array}\right.$ | $4.2\left[\begin{array}{l} {[3595} \\ \hline(5.1] \\ \hline \end{array}\right.$ | $4.8\left[\begin{array}{l} {[3.9 ;} \\ (4,9) \\ 5.8] \\ \hline \end{array}\right.$ |  |  |  |
| Avenir Complete (Zimmer Biomet) | Allofit (Zimmer Biomet) | 1,208 | 38 | $67{ }_{\text {(59 - } 73)}$ | $39 / 61$ | 2020-2022 | $2.8[2.0 ; 4.0]$ | $2.8\left[\begin{array}{ll} {[20.0 ;} \\ (30) \\ \hline \end{array}\right.$ |  |  |  |  |  |  |
| BICONTACT (Aesculap) | PLASMACUP (Aesculap) | 4,841 | 31 | 70 (63-76) | 40/60 | 2013-2022 | $2.3\left[\begin{array}{c} (1.93 ; 28) .8] \\ (438) \end{array}\right.$ | $2.6\left[\begin{array}{l} {[2.2623)} \\ \hline .36) \end{array}\right.$ | $2.7 \text { [2.3; } 3.323]$ | $2.9\left[\begin{array}{l} {[2.48 ; 83]} \\ {[.4]} \end{array}\right.$ | $2.9\left[\begin{array}{l} {[2.52 ;} \\ {[2.49]} \end{array}\right.$ | $2.9\left[\begin{array}{l} {[2.55 \cdot 54.4]} \\ 10.54] \end{array}\right.$ |  | $2.9\left[\begin{array}{ll} {[254 ;} \\ {[124} \end{array}\right]$ |
| BICONTACT (Aesculap) | PLASMAFIT (Aesculap) | 12,300 | 106 | $71_{(64-77)}$ | 40/60 | 2013-2022 | $3.5\left[\begin{array}{l} {[3.2 ; 2 ; 3 ;} \\ \mid 1.9] \end{array}\right.$ | $3.8[3.5 ; 4.2]$ | $4.0\left[\begin{array}{l} {[3.7,7 ; 4.4]} \\ {[(32)} \end{array}\right.$ | $4.1\left[\begin{array}{c} {[3.7944 .4]} \\ {[594]} \end{array}\right.$ | $4.1\left[\begin{array}{l} {[3.888)} \\ \hline \end{array}\right.$ | $4.1\left[\begin{array}{l} {[3.882 ; 2} \\ \hline 2.5] \end{array}\right.$ | $4.1\left[\begin{array}{c} {[3.8: 84.54} \\ {[1.5]} \\ \hline \end{array}\right.$ | $4.3 \underset{(321)}{[3.8 ; 7]}$ |
| BICONTACT (Aesculap) | SCREWCUP SC (Aesculap) | 695 | 31 | $72_{(64-77)}$ | 35/65 | 2013-2022 | $3.4 \underset{(5922)}{[2.3 ;} 5.1]$ | $4.8\left[\begin{array}{l} {[3.4 ; 6 ; 6} \\ (506] \\ \hline \end{array}\right.$ | $5.2\left[\begin{array}{c} {[3,76 ; 7.2]} \\ (416) \end{array}\right.$ | $5.7\left[\begin{array}{l} {[3.11 ; 7} \\ \hline 311 \end{array}\right)$ | $7.1\left[\begin{array}{l} {[5.0 ; 9.9]} \\ (171) \end{array}\right.$ |  |  |  |
| Brexis (Zimmer Biomet) | Allofit (Zimmer Biomet) | 753 | 29 | $61_{(55-67)}$ | 45/55 | 2016-2022 | $2.6[1.6: 4.0]$ | $3.0[2.0 ; 4.6]$ | $3.0\left[\begin{array}{l} 2.034 ; 4.6] \\ {[24} \end{array}\right.$ | $3.0\left[\begin{array}{l} {[200]} \\ (800 \end{array} 4.6\right]$ |  |  |  |  |
| CLS Spotorno (Zimmer Biomet) | Allofit (Zimmer Biomet) | 22,372 | 178 | $65_{(58-72)}$ | 43/57 | 2012-2022 | $2.8\left[\begin{array}{c} {[1.69 ; 9.95]} \\ (1.995) \end{array}\right.$ | $3.2\left[\begin{array}{c} {[1.03 ; 33]} \\ (1.53] \end{array}\right.$ | $3.5 \begin{aligned} & {[3.3 ; 3 ; 8]} \\ & (1,3 i n) \end{aligned}$ | $\underset{\substack{[3.4,000 \\(1.00]}}{3.0]}$ | $3.8[3.5 ; 4.1]$ | $4.0{ }_{\text {[3.7.706 }}$ 4.3] |  | $4.2[3.9 .9 ; 4.6]$ |

Table 48 (continued)

| Elective total hip arthroplasties |  | Number | Hosp. | Age | m/f | Period | Revision probabilities after ... |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Femoral stem | Cup |  |  |  |  |  | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Uncemented fixation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| CLS Spotorno (Zimmer Biomet) | Allofit IT (Zimmer Biomet) | 1,636 | 33 | $66_{(59-74)}$ | 41/59 | 2013-2022 | $1.5_{(1.543)}^{[1.0 ; 2.3]}$ | $2.3\left[\begin{array}{c} (1.6 ; 3) \\ (1.36) \\ \hline \end{array}\right.$ | $2.3[1.6 .63 .1]$ | $2.4[1.7 ; 3.2]$ | $2.5[1.8: 3.4]$ | $2.6 \underset{(1555)}{[1.9 ; 3]}$ | $2.6 \underset{(1355}{[1.9 ; ~ 3.6]}$ | $2.6\left[1.99{ }_{(196)} 3.6\right]$ |
| CLS Spotorno (Zimmer Biomet) | Trilogy (Zimmer Biomet) | 345 | 7 | $65_{(57-71)}$ | 40/60 | 2014-2022 | $3.8\left[\begin{array}{l} {[2.2 ; 8 ; 8} \\ 128 \\ 6 \end{array} .4\right]$ | $4.8[3.0 ; 7.7]$ | $4.8\left[\begin{array}{c} {[3.087} \\ 1288 \\ 7.7] \end{array}\right.$ | $4.8\left[\begin{array}{l} {[3,0 ; 0} \\ (2,7) \\ 7 \end{array}\right.$ | $5.2\left[\begin{array}{c} {[3.3 ; 3,8.3]} \\ k 2045 \end{array}\right.$ | $5.2\left[\begin{array}{c} {[3,3 ; 8.3]} \\ (170) \end{array}\right.$ | $5.2[3.3 ; 8.3]$ |  |
| CLS Spotorno (Zimmer Biomet) | Trilogy IT (Zimmer Biomet) | 1,046 | 3 | $68_{(61-74)}$ | 42/58 | 2014-2022 | 3.5 [2888; 4.8] | $\left.{ }^{3.7}{ }_{\text {[2.7.75] }} 5.1\right]$ | $4.3\left[\begin{array}{c} (3678) \\ \hline 6.8] \\ 5.8] \\ \hline \end{array}\right.$ | $4.3\left[\begin{array}{l} {[3,26]} \\ {[5.8]} \\ \hline \end{array}\right.$ | $4.5 \underset{(387)}{43 ;} ; 6.0]$ |  |  |  |
| CORAILTM AMT-Hüftschaft mit Kragen (DePuy) | Allofit (Zimmer Biomet) | 303 | 8 | ${ }^{60}(54-70)$ | 18/82 | 2015-2022 | $1.7\left[\begin{array}{c} {[0.722} \\ 1202 \end{array}\right)$ | $2.1\left[\begin{array}{c} {[0.9 ; 54.6]} \\ 1255 \end{array}\right.$ | $2.1 \begin{gathered} {[0.9 .98)^{4.6]}} \\ \hline(8) \end{gathered}$ | $2.1\left[\begin{array}{c} (1.97) \\ \hline 4.6] \end{array}\right.$ | $2.1\left[\begin{array}{c} {[.9 .966} \\ 1.36] \\ 4.6] \\ \hline \end{array}\right.$ | $2.1\left[\begin{array}{c} \left.[0.93]^{(93)} 4.6\right] \\ \hline \end{array}\right.$ |  |  |
| CORAILTM AMT-Hüftschaft mit Kragen (DePuy) | PINNACLETM Press Fit-Hüftpfanne (DePuy) | 11,330 | 97 | ${ }^{69}{ }_{(61-76)}$ | 37/63 | 2012-2022 | $1.6[1.4: 4.9]$ | $2.1\left[\begin{array}{c} {[1.8 ; 2 ; 3)} \\ (1,3] \\ \hline \end{array}\right.$ | $2.3 \text { [1.0.0; } 2.6]$ |  | $2.5\left[\begin{array}{ll} (2.2551) \\ \hline(2.9] \end{array}\right.$ | $2.9 \underset{(886)}{2.5 ; ~ 3.4]}$ | $2.9 \underset{(2007}{[2.5 ; ~ 3.4]}$ | $\left.2.9 \underset{(59)^{[25}}{ } 3.4\right]$ |
| CORAILTM AMT-Hüftschaft ohne Kragen (DePuy) | Allofit (Zimmer Biomet) | 1,475 | 17 | $70{ }_{(62-77)}$ | 38/62 | 2015-2022 |  | $3.0\left[\begin{array}{l} {[2.2 ; 20)} \\ (1.0) \end{array}\right.$ | $3.44\left[\begin{array}{ll} {[1.5511} \\ (1.04] \end{array}\right.$ | $3.4\left[\begin{array}{l\|l\|:\|c\|} {[2,4]} \\ 4.4] \end{array}\right.$ | $3.5\left[\begin{array}{l} (2,69)^{2} \\ 4.7] \\ \hline \end{array}\right.$ | $3.5 \underset{(1661}{[2.6 ; ~ 4.7]}$ |  |  |
| CORAILTM AMT-Hüftschaft ohne Kragen (DePuy) | Allofit IT (Zimmer Biomet) | 382 | 4 | $72{ }_{(66-77)}$ | 39/61 | 2015-2022 | $3.2\left[\begin{array}{c} 1.8 ; 805 \\ (300) \\ 5.5] \\ \hline \end{array}\right.$ | $4.0{ }_{\substack{(2,4,45)}}^{(6.5]}$ |  | $4.3\left[\begin{array}{c} {[2.63)} \\ (320) \\ 6.9] \end{array}\right.$ | $4.6\left[\begin{array}{c} (2092) \\ (302) \\ 7.2] \end{array}\right.$ | 4.9 [3.1.7.7.7.7] |  |  |
| CORAILTM AMT-Hüftschaft ohne Kragen (DePuy) | DURALOCTM OPTION ${ }^{\text {TM }}$ Press Fit-Hüftpfanne (DePuy) | 569 | 8 | $6^{67}{ }_{(60-74)}$ | 42/58 | 2013-2022 |  | $4.3\left[\begin{array}{l} \left.[2.95)^{2} 6.3\right] \\ \hline \end{array}\right.$ | $\underset{(372)}{4.3[2.3]}$ | $4.6\left[\begin{array}{c} 3.1 .1 ; 6) \\ (300) \\ 6.7] \\ \hline \end{array}\right.$ |  | $\left.4.6 \underset{(361)^{[17}}{ } ; 6.7\right]$ | $4.6\left[\begin{array}{l} (3,1) ; \\ (6.7] \end{array}\right.$ |  |
| CORAILTM AMT-Hüftschaft ohne Kragen (DePuy) | PINNACLETM Press Fit-Hüftpfanne (DePuy) | 31,019 | 165 | $70_{(62-76)}$ | 38/62 | 2012-2022 | $2.8\left[\begin{array}{l} {[25,6,640]} \\ \hline 2.0] \end{array}\right.$ | $3.3\left[\begin{array}{l} {[30.1713} \\ \hline 13.5] \end{array}\right.$ | ${ }^{3.6}$ [3.4.43.83] | $3.9[3.6,6 ; 4.1]$ | $4.0\left[\begin{array}{ll} {[1,7.722} \\ \hline, 4.2] \end{array}\right.$ | $4.2\left[\begin{array}{c} {[4.0,519} \end{array}\right.$ | $4.5[4.2 ; 2 ; 4.9]$ | $5.4\left[\begin{array}{l} 4.76 ;) \\ \hline(6.2] \end{array}\right.$ |
| COREHIP (Aesculap) | PLASMACUP (Aesculap) | 925 | 4 | $70_{(66-75)}$ | 33/67 | 2017-2022 | $1.7[1.0 ; 2.8]$ | $1.9[1.1 .3 ; 3.2]$ |  |  |  |  |  |  |
| COREHIP (Aesculap) | PLASMAFIT (Aesculap) | 3,325 | 54 | 68 (60-75) | 39/61 | 2017-2022 | $2.0\left[\begin{array}{ll} 1.66 & 62.6] \\ (1.62) \end{array}\right.$ | $2.6\left[\begin{array}{l\|l\|l\|c\|} {[576} \\ \hline \end{array}\right.$ | $3.4\left[\begin{array}{c} (2,2 ; 59 \\ (139) \\ 5.4] \\ \hline \end{array}\right.$ |  |  |  |  |  |
| EcoFit $133^{\circ} \mathrm{cpTi}$ (Implantcast) | EcoFit EPORE (Implantcast) | 418 | 5 | $73_{(67-79)}$ | 28/72 | 2019-2022 | $4.7\left[\begin{array}{l} {[3,0 ; 0)} \\ (2.4] \end{array}\right.$ | $5.5[3.558 .4]$ |  |  |  |  |  |  |
| EcoFit cpTi (Implantcast) | EcoFit cpTi (Implantcast) | 333 | 8 | $72_{(64-76)}$ | 35/65 | 2014-2022 | $5.8 \text { [3.7; } 8.9]$ | $6.1 \text { [4.07; 9.3] }$ | $6.1\left[\begin{array}{l} {[4.0 ; 9.3]} \\ (24) \\ \hline \end{array}\right.$ | $6.5[4.3$ [17) 9.8 ] | $6.5[4.3 \cdot 9.9]$ | $6.5[4.3 ; 9.8]$ |  |  |
| EcoFit cpTi (Implantcast) | EcoFit EPORE (Implantcast) | 548 | 4 | $75{ }_{\text {(6, } 5 \text { - } 79)}$ | 25/75 | 2016-2022 | $4.4[3[.0 ; 6.5]$ | $5.3[3.7 .7 .7 .6]$ | $6.1\left[\begin{array}{c} \text { [4.4; } \\ 4.46 .5] \end{array}\right.$ | $6.7 \text { [4.8; } 9.2]$ | $7.1\left[\begin{array}{l} \left.[5.1 ;)^{\prime} 9.8\right] \\ \hline(5)] \end{array}\right.$ |  |  |  |
| EcoFit Short cpTi (Implantcast) | EcoFit EPORE (Implantcast) | 314 | 5 | $70{ }_{(63-77)}$ | 38/62 | 2019-2022 | $5.6\left[\begin{array}{c} {[3.508} \\ {[208} \\ 8.8] \end{array}\right.$ | $5.6\left[\begin{array}{l} {[3,53]} \\ 4123] \\ 8 \end{array}\right.$ |  |  |  |  |  |  |
| EXCEPTION (Zimmer Biomet) | Allofit (Zimmer Biomet) | 1,459 | 12 | ${ }^{69}{ }_{(61-75)}$ | 49/51 | 2015-2022 | $4.4\left[\begin{array}{l} {[3.5250} \\ (1.36) \\ 5.6] \end{array}\right.$ | $4.9\left[\begin{array}{l} {[3.9 ; 20.1]} \\ (1,20) \end{array}\right.$ |  | $5.4[4.3 ; 6.7]$ | $6.2[4.8 .87 .7 .8]$ |  |  |  |
| EXCIA (Aesculap) | PLASMAFIT (Aesculap) | 11,070 | 113 | $70_{62-76)}$ | 40/60 | 2014-2022 | $3.3\left[\begin{array}{l} {[3,0,030} \\ \hline 3.6] \end{array}\right.$ | $3.7\left[\begin{array}{c} {[3.3 ; 424.1]} \\ {[726} \end{array}\right.$ | $3.8[33.4 ; 4.2]$ | $3.9[3.554 .53$ |  | $\underset{(888)}{4.0} \mathbf{[ 3 . 6 ;} 4.4]$ | $4.0[3.6 .64 .4]$ |  |
| Fitmore (Zimmer Biomet) | Allofit (Zimmer Biomet) | 21,713 | 202 | $6^{(56-70)}{ }_{\text {( }}$ | 46/54 | 2012-2022 | $2.3[2.1 .1 ; 2.5]$ | $2.6[2.4 ; 2.9]$ | $2.9\left[\begin{array}{ll} {[1.67643} \\ 10.14] \end{array}\right]$ | $3.0 \underset{[8.457)}{[2 ; 8 ; 3]}$ | $3.1\left[\begin{array}{l} {[2.8 .860 .3]} \\ 5.3] \end{array}\right.$ | $3.2\left[\begin{array}{l} {[2.932]} \\ \hline 1.4] \\ \hline \end{array}\right.$ | $3.2\left[\begin{array}{l} {[2.9 ; 3 ; 3.5]} \\ (0,44] \end{array}\right.$ |  |
| Fitmore (Zimmer Biomet) | Allofit IT (Zimmer Biomet) | 2,760 | 61 | $58{ }_{(52-664}$ | 47/53 | 2012-2022 | $3.0 \underset{(2.299)}{[2.8]}$ | $3.8\left[\begin{array}{l} {[3.1,92 ; 4.6]} \\ \langle 2] \end{array}\right.$ | $4.2\left[\begin{array}{l} {[3.55: 5.5 .1]} \\ 11.38) \end{array}\right.$ | $4.3[3.5 .55 .2]$ | $4.6[3,8 ; 5.5]$ | $4.9[4.0 \cdot 5.5 \cdot 9]$ | $4.9[4.0 .85 .9]$ | $5.6[4.1 ; 7.7]$ |
| Fitmore (Zimmer Biomet) | Trilogy (Zimmer Biomet) | 2,508 | 14 | $62_{(55-68)}$ | 44/56 | 2012-2022 | $1.6 \underset{(1,2 ; 25)}{[1.2]}$ | $2.1[1.6 ; 2.7]$ | $2.3[1.7 .73 .3 .0]$ | $2.4\left[\begin{array}{ll} {[1.9595]} & 3.2] \\ \hline \end{array}\right.$ | $2.6\left[\begin{array}{c} {[2.0 ; 7)} \\ (8,4] \\ 3 \end{array}\right.$ | $2.7 \underset{[5,199]}{[2.6]}$ | $2.7 \underset{(2293)}{[2.1 ; 3]}$ |  |
| GTS (Zimmer Biomet) | Allofit (Zimmer Biomet) | 812 | 19 | $65_{(57-71)}$ | 46/54 | 2014-2022 | $3.2[2.2 ; 4.7]$ | $3.9[2.7 ; 5.5]$ | $4.4[3.1 .1 ; 6.2]$ | $4.4\left[\begin{array}{l} {[3.177)} \\ {[3.2]} \end{array}\right.$ | $4.4[3.10 ; 6.2]$ | $4.4[3[1.165) 6.2]$ |  |  |
| GTS (Zimmer Biomet) | G7 (Zimmer Biomet) | 445 | 10 | $66_{(55-75)}$ | 36/64 | 2014-2022 | $4.1\left[\begin{array}{c} {[2.6 ; 6.4]} \\ (30) \end{array}\right.$ | $5.2\left[\begin{array}{c} {[3.4 ; 2)} \\ (3,7) \\ 7.7] \end{array}\right.$ | $5.2\left[\begin{array}{c} {[3.4,4,7.7]} \\ 1233 \\ \hline \end{array}\right.$ | $6.0[4.00 \cdot 8.8]$ | $6.0[4.0 .08 .8]$ | $6.0[4.0 ; 8.8]$ |  |  |
| Konusprothese (Zimmer Biomet) | Allofit (Zimmer Biomet) | 577 | 81 | $54_{(46-61)}$ | $19 / 81$ | 2013-2022 | $3.2[2.0 ; 5.0]$ | $3.6 \underset{(2427)}{[2.37} 5.6]$ | $\left.3.9{ }_{(3,55)}^{[255} 5.9\right]$ | $3.9\left[\begin{array}{l} 2.550 \\ 1267 \\ 5.9] \\ \hline \end{array}\right.$ | $4.3\left[\begin{array}{l\|l\|l\|:\|:\|} \hline 19] \\ 6.5] \\ \hline \end{array}\right.$ | $4.9[3.1 .7 .7 .7]$ | $4.9\left[\begin{array}{l} \left.[3,17)^{2} 7.7\right] \\ \hline .7] \end{array}\right.$ |  |
| Konusprothese (Zimmer Biomet) | Allofit IT (Zimmer Biomet) | 419 | 17 | $68_{(58-76)}$ | 10/90 | 2013-2022 |  | $3.0\left[\begin{array}{l} {[1,73 ; 3} \\ \hline 1.2] \\ \hline \end{array}\right.$ | $3.6\left[\begin{array}{l} {[20,1 ; 3)} \\ \hline 6.0] \\ \hline 6.0] \end{array}\right.$ | $3.9\left[\begin{array}{l} {[2.46 ; 6.5]} \\ {[264} \end{array}\right.$ | $3.9\left[\begin{array}{l} {[2.42 ;} \\ \mid 22) \\ 6.5] \end{array}\right.$ | $3.9[2.4 ; 6 ; 6]$ | $3.9[2.4 .40 .6]$ | $3.9[2.4,4.6 \cdot 5]$ |
| LCU Hip System, cementless (Waldemar Link) | Allofit (Zimmer Biomet) | 721 | 6 | ${ }^{68}{ }_{(62-75)}$ | 48/52 | 2015-2022 | $\underset{(5844)}{1.8 .2]}$ | $2.0\left[\begin{array}{c} 1.2 ; 2 ; 3.4] \\ \left\|b b_{1}\right\| \end{array}\right.$ | $\underset{\substack{(155)}}{2.54 .1]}$ | $2.5[1.5 ; 5.1]$ | $3.1\left[\begin{array}{l} {[1.8 ; 8)} \\ (133) \\ 5.2] \end{array}\right.$ |  |  |  |
| LCU Hip System, cementless (Waldemar Link) | CombiCup (Waldemar Link) | 1,624 | 23 | ${ }^{67}{ }_{(59}$-74) | 45/55 | 2014-2022 | $2.3\left[\begin{array}{c} {[1.75 ; 3.2]} \\ 4.506 \end{array}\right.$ | $2.6\left[\begin{array}{l} {[2.0 ; 3 ; 3)} \\ \left\{\begin{array}{l} 3 \end{array}\right) \\ \hline \end{array}\right.$ |  | $2.9[2.2 .2,3.9]$ | $3.0\left[\begin{array}{c} \left.[2.37)^{4} 4.1\right] \end{array}\right.$ | $4.0[2.7 .75 .5]$ |  |  |
| LCU Hip System, cementless (Waldemar Link) | MobileLink, Cluster Hole (Waldemar Link) | 732 | 23 | 68 (61-74) | 40/60 | 2017-2022 |  |  | $4.8\left[\begin{array}{c} (3,4 ; 6.8] \\ i, 7) \\ \hline \end{array}\right.$ |  |  |  |  |  |

Table 48 (continued)

| Elective total hip arthroplasties |  | Number | Hosp. | Age | m/f | Period | Revision probabilities after ... |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Femoral stem | Cup |  |  |  |  |  | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Uncemented fixation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| M/L Taper (Zimmer Biomet) | Allofit (Zimmer Biomet) | 5,255 | 23 | $69_{(61-75)}$ | 42/58 | 2013-2022 | $3.2\left[\begin{array}{l} {[2.746\}} \\ (4,76) \end{array}\right.$ | $3.6\left[\begin{array}{l} (3,12 ; 1 ; 4.2] \end{array}\right.$ | $4.0\left[\begin{array}{l} (3.4,47) \\ \hline 1.5] \\ \hline \end{array}\right.$ | $4.2\left[\begin{array}{l} {[3.6478} \\ {[4.8]} \\ \hline \end{array}\right.$ | $4.3[33.7 .74 .9]$ | $4.5\left[\begin{array}{l} {[3,9 ; 9} \\ \hline 89.1] \\ 5.1] \end{array}\right.$ |  | $5.2[4.2$ [ 63.5$]$ |
| M/L Taper (Zimmer Biomet) | Trilogy (Zimmer Biomet) | 546 | 3 | $69_{(63-72)}$ | $33 / 67$ | 2012-2022 | $2.0 \underset{(150)}{[1.1 ; 3.7]}$ | $2.4 \underset{\substack{16.464}}{[1.2]}$ | $2.4[1.45 ; 4.2]$ | $2.4[1.4 ; 4.2]$ | $2.7[1.6 .64 .5]$ |  | $2.7 \underset{(1,69 ;}{[1.5]}$ | $2.7[11.64 .5]$ |
| METABLOC (Zimmer Biomet) | Allofit (Zimmer Biomet) | 500 | 13 | $72.5{ }_{(66-78)}$ | $38 / 62$ | 2012-2020 | $2.0\left[\begin{array}{c} {[1.1 ; 32 ;} \\ (43) \end{array}\right.$ | $\left.2.4{ }_{\text {[1.54 }}^{4} 4.4 .2\right]$ | $2.6[1.5 ; 4.5]$ | $3.6\left[\begin{array}{l} {[2.353)} \\ (3,5) \\ 5 \end{array}\right.$ | $3.6 \text { [2.3.3:5.7] }$ | $3.6\left[\begin{array}{l} {[2.3 ; 505} \\ 120.7] \end{array}\right.$ | $3.6[2.3 .3 .5 .7]$ |  |
| Metafix (Corin) | Trinity Hole (Corin) | 701 | 13 | $73{ }_{(65-79)}$ | $36 / 64$ | 2014-2022 | $1.7\left[\begin{array}{l} {[5.975)} \\ 3.0] \\ \hline \end{array}\right.$ | $1.7 \begin{aligned} & {[0.9 ; 3 ; 0]} \\ & (4.0] \end{aligned}$ | $1.9[1.17 ; 3.3]$ | $1.9\left[\begin{array}{ll} {[1.1 ; 3.3 .3]} \\ {[26]} \end{array}\right.$ | $1.9[1.1 .3 ; 3.3]$ | $1.9[1.1 .13 .3]$ |  |  |
| Metafix (Corin) | Trinity no Hole (Corin) | 899 | 10 | $71_{(64-76)}$ | 47/53 | 2014-2022 | $1.7[1.0 ; 2.8]$ | $2.2\left[\begin{array}{l} 1.47 ; 3.4] \\ (724) \end{array}\right.$ | $2.3[1.5 ; 3.5]$ | $2.5[1.63 ; 3.8]$ | $2.8[1.9 .94 .3]$ |  | $2.8[1.9 .94 .3]$ |  |
| METHA (Aesculap) | PLASMACUP (Aesculap) | 1,322 | 34 | $58{ }_{(52-63)}$ | 44/56 | 2013-2022 | $1.5 \underset{(1,2,08)}{[1.4]}$ | $2.3[1.6 ; 3.3]$ | $2.3[1.6 ; 3.3]$ | $2.4\left[\begin{array}{c} 1.7 .7 ; 3.4] \\ (9,4) \end{array}\right.$ | $2.4[1.7 .73 .4]$ | $2.4[1.7 .7 .3 .4]$ | $2.4 \underset{\substack{1279}}{[1.7 ; 3]}$ | $2.4[11.7 \cdot 3.4]$ |
| METHA (Aesculap) | PLASMAFIT (Aesculap) | 5,913 | 138 | $57_{(52-62)}$ | 48/52 | 2013-2022 | $3.0[(5.5 ; 3 ; 4]$ | $3.6[3.1 ; 2 ; 4.1]$ | $3.8\left[\begin{array}{l} {[3.3 ; 750.4]} \\ \hline \end{array}\right.$ | $3.9\left[\begin{array}{l} {[3.5555} \\ \hline 2.5] \\ \hline \end{array}\right.$ | $4.0\left[\begin{array}{l} {[3.55} \\ (x, 36) \\ 4.6] \end{array}\right.$ | $4.3\left[\begin{array}{l} {[3.70 .74 .9]} \\ (0.05) \end{array}\right.$ | $4.3[3.7 .74 .9]$ | $4.3[3.77 .4 .9]$ |
| MiniHip (Corin) | Trinity Hole (Corin) | 1,320 | 35 | ${ }^{61.5}{ }_{(55-68)}$ | 50/50 | 2013-2022 | $2.3(1.6 ; 3 ; 3]$ | $2.6 \underset{(1886)}{[1.9 ;} 3$ | $\left.2.7\left[\begin{array}{l\|l\|l\|:\|c\|} {[15 ;} \end{array}\right] .8\right]$ | $2.9\left[\begin{array}{l} {[2.12]} \\ {[62]} \end{array}\right]$ | $3.1\left[\begin{array}{l} {[2.2 ; 5 ;} \\ \langle .5 .3] \end{array}\right.$ | $3.1\left[\begin{array}{l} {[2.2,2 ; 2.3]} \\ \mid 272 \end{array}\right.$ | 3.1 [2.2.24. 4.3$]$ |  |
| MiniHip (Corin) | Trinity no Hole (Corin) | 903 | 23 | $60_{(54-66)}$ | 46/54 | 2014-2022 | $3.4[2.4 ; 788) 4.8]$ | $4.2 \underset{(3.000}{[5.7]}$ | $4.6[3.4 ; 4 ; 6.3]$ | $4.6[3.4 ; 6.3]$ |  | $6.0[4.3 \cdot 8.3]$ |  |  |
| Nanos Schenkelhalsprothese (OHST/Smith \& Nephew) | Allofit (Zimmer Biomet) | 885 | 19 | $6^{(56-70)}$ | 48/52 | 2014-2022 |  |  | $2.9[1.994 .3]$ | $2.9[1.99 ; 4.3]$ | $2.9[1.9,94.3]$ | $2.9\left[\begin{array}{c} 1.989 \\ 1289 \end{array}\right)$ | $2.9[1.9 .9 .3]$ |  |
| Nanos Schenkelhalsprothese (OHST/Smith \& Nephew) | EP-FIT PLUS (Smith \& Nephew) | 481 | 28 | $57_{(52-63)}$ | 55/45 | 2013-2022 | $\underset{\substack{1379}}{3.1 .8 ;} 5.2]$ | $\underset{(3313}{3.1} \mathbf{1 . 8 ;} 5.2]$ | $3.1\left[\begin{array}{c} (1284) \\ \hline 1.8 ; 5] \end{array}\right.$ | $3.5\left[\begin{array}{c} (248) \\ {[2.1 ; 5]} \\ \hline \end{array}\right.$ | $3.5\left[\begin{array}{l} (212) \\ \hline 2.1 ; 5.8] \end{array}\right.$ | ${ }^{3.5}$ [2.1.750) 5.8$]$ | $3.5\left[\begin{array}{c} {[60)} \\ (2,7 ; 8] \\ 5.8] \\ \hline \end{array}\right.$ |  |
| Nanos Schenkelhalsprothese (OHST/Smith \& Nephew) | HI Lubricer Schale (Smith \& Nephew) | 492 | 12 | $60.5{ }_{(54-68)}$ | 48/52 | 2013-2022 | $1.2\left[\begin{array}{c} \left.[0.6 ;)^{4} 2.7\right] \\ \hline 2.7 \end{array}\right.$ | $2.1\left[\begin{array}{c} {[1.155)} \\ \langle 3.9] \\ \hline \end{array}\right.$ | $3.7 \underset{(397 \eta}{[2.3 ;} 5.9]$ | $4.5\left[\begin{array}{c} {[2.977)} \\ {[3.9]} \\ \hline \end{array}\right.$ | $5.11\left[\begin{array}{l} {[3.455} \\ 1.55) \\ 7.7] \end{array}\right.$ | $5.1\left[\begin{array}{c} {[3,43)} \\ (133) \\ 7.7] \\ \hline \end{array}\right.$ |  |  |
| Nanos Schenkelhalsprothese (OHST/Smith \& Nephew) | R3 (Smith \& Nephew) | 1,731 | 69 | $59{ }_{(52-65)}$ | 46/54 | 2013-2022 | $2.5\left[\begin{array}{ll} (1.936) \\ (1.30 .4] \end{array}\right.$ |  | 2.7 [ $2.0 ; 374.7]$ |  | 3.2 [2.4.42:4.4] |  |  |  |
| Nanos Schenkelhalsprothese (OHST/Smith \& Nephew) | REFLECTION (Smith \& Nephew) | 479 | 4 | $68_{(59 .-76)}$ | $34 / 66$ | 2013-2022 | $1.5\left[\begin{array}{c} \left.[0.79)^{[39}\right) \\ 3.1] \end{array}\right.$ | $1.8 \underset{\substack{[319 \\[0.9 ;}}{ } 3.5]$ | $2.1[1.1 .1 ; 4.0]$ | $2.1\left[\begin{array}{ll} {[1.138]} \\ {[1.30]} \\ \hline \end{array}\right.$ | $2.1[1.1 .1 ; 4.0]$ | $2.1\left[\begin{array}{ll} {[1.123} \\ 4123 \\ 4.0] \end{array}\right.$ |  |  |
| optimys (Mathys) | Allofit (Zimmer Biomet) | 3,813 | 31 | $63_{(56-69)}$ | 46/54 | 2013-2022 | $1.9[1.5 ; 2.4]$ | $2.0\left[\begin{array}{c} {[1,6 ; 26} \\ {[2,5]} \end{array}\right.$ | $2.2[1.8 ; 2.8]$ | $2.3\left[\begin{array}{ll} 1.8323 \\ 4.33] \end{array}\right.$ | $2.3\left[1.8{ }^{1865} \mathbf{2} 2.9\right]$ | $2.3\left[1.8{ }_{(1.560} 2.9\right]$ |  |  |
| optimys (Mathys) | aneXys Flex (Mathys) | 3,111 | 58 | $61_{(55-66)}$ | 47/53 | 2016-2022 | $1.7\left[\begin{array}{l} {[1.259)} \\ \hline 1.2] \end{array}\right.$ | $2.1\left[\begin{array}{c} {[1.6 ; 2 ; 2.8]} \\ (1.36) \end{array}\right.$ | $2.2[1.7 ; 2.9]$ | $2.2\left[\begin{array}{ll} {[1.7660} \\ (186) \\ 2.9] \end{array}\right.$ | $2.2\left[\begin{array}{c} 1.7 .70 .2 .9] \\ \text { kisi } \end{array}\right.$ |  |  |  |
| optimys (Mathys) | aneXys Uno (Mathys) | 315 | 12 | $54_{\text {(48-63) }}$ | 42/58 | 2019-2022 | $2.1\left[\begin{array}{l} {[0.9 ; 5 ; 4.7]} \\ \hline \end{array}\right.$ | $3.2[1.6 ; 6.5]$ |  |  |  |  |  |  |
| optimys (Mathys) | RM Pressfit (Mathys) | 657 | 8 | $72_{\text {(63-78) }}$ | 43/57 | 2013-2022 | $2.6[1.6 ; 5 ; 4.2]$ | $3.1\left[\begin{array}{l\|l\|l\|} {[513 ;} \end{array} 4.8\right]$ | $3.1\left[\begin{array}{l} {[4.0 ; 4)} \\ \text { jus } \end{array}\right.$ | $3.6\left[\begin{array}{c} {[2.4 ; 4,5.5]} \\ (304) \end{array}\right.$ |  | $4.0[2.606 .0]$ |  |  |
| optimys (Mathys) | RM Pressfit vitamys (Mathys) | 13,099 | 84 | $66_{(59-73)}$ | 44/56 | 2013-2022 | $1.7[1.5 ; 1.9]$ | $1.9[1.7 ; 2 ; 2]$ | $2.0[1.7 ; 2.3]$ | $2.1[1.8 .8 ; 2.3]$ | $2.2\left[\begin{array}{ll} {[1,9 ; 92)} \\ k, 5] \end{array}\right.$ | $2.2[1.99 .9 .5]$ | $2.2\left[\begin{array}{c} (1,988) \\ {[1.5]} \end{array}\right.$ | $2.2[1.9 .92 .5]$ |
| Polarschaft (Smith \& Nephew) | EP-FIT PLUS (Smith \& Nephew) | 1,297 | 33 | $69_{(61-75)}$ | 45/55 | 2013-2022 | $2.4[1,7 ; 3 ; 4]$ | $2.7\left[\begin{array}{l} {[2.027]} \\ {[1.02]} \end{array}\right.$ | $\left.2.7 \begin{array}{l} 2.900 ; 3.8] \\ {[9.090} \end{array}\right]$ | $2.7\left[\begin{array}{ll} {[2,0 ; 9} \\ \langle i, ~ 3.8] \\ \hline \end{array}\right.$ | $2.9\left[\begin{array}{l\|l\|l\|l\|} {[5.0]} \\ \hline \end{array}\right.$ | $2.9\left[\begin{array}{l} {[2.1 ; 7)} \\ {[260]} \end{array}\right.$ |  |  |
| Polarschaft (Smith \& Nephew) | HI Lubricer Schale (Smith \& Nephew) | 2,857 | 17 | $70_{(62-76)}$ | 35/65 | 2013-2022 | $2.3[1.8 ; 2.9]$ | $2.7\left[\begin{array}{l} {[2.1030} \\ (2.30) \end{array}\right.$ | $2.7\left[\begin{array}{ll} {[2.17630} & 3.3] \end{array}\right.$ | $2.9\left[\begin{array}{l} {[2.3 ; 3.3 .6]} \\ (1.39) \end{array}\right.$ | $3.1[2.5 \cdot 3.9]$ | $3.5\left[\begin{array}{c} {[2.70 ; 4.5]} \\ \mid\langle 67 \end{array}\right.$ | $4.0\left[\begin{array}{l} {[3.0 ; 5} \\ \hline 181) \\ 5.4] \end{array}\right.$ | $4.0[3.0 ; 5.5]$ |
| Polarschaft (Smith \& Nephew) | R3 (Smith \& Nephew) | 8,472 | 96 | $6^{69}$ (61-75) | 43/57 | 2013-2022 | $2.9[2.6 ; 3.3]$ | $3.1{ }_{(5.523)}^{[2.8 ; 3.6]}$ | $3.4\left[\begin{array}{l} {[3.0 ; 3 ; 3]} \\ {[4,2]} \end{array}\right.$ | $3.5\left[\begin{array}{l} {[3.1,744.0]} \\ (2,74) \end{array}\right.$ | $3.5\left[\begin{array}{ll} {[3.1 .11 i 1} \\ 1.0 .0] \end{array}\right.$ | $3.5\left[\begin{array}{l} {[3,1.13]^{[1.0]}} \\ 4.0] \end{array}\right.$ | $3.5\left(\frac{3198)}{[1980]}\right.$ |  |
| Polarschaft (Smith \& Nephew) | REFLECTION (Smith \& Nephew) | 331 | 4 | $73{ }_{(64-79)}$ | $39 / 61$ | 2013-2022 | $\left.\begin{array}{l} 0.0 \\ 1292 \end{array}\right)$ | $\left.0.3\left[\begin{array}{c} {[0.0 ; 9} \\ (269) \end{array}\right] .4\right]$ | $0.3\left[\begin{array}{l} {[0.045} \\ (2,5) \end{array} 2.4\right]$ | $0.3\left[\begin{array}{c} {[0.0 ; 0} \\ (1,0) \\ 2.4] \end{array}\right.$ | $0.3\left[\begin{array}{lll} 0.0 ; 9 \\ (1,39 \end{array} 2.4\right]$ | $0.3[0.0 ; 2.4]$ |  |  |
| PROFEMUR ${ }^{\oplus}$ GLADIATOR CLASSIC (MicroPort) | PROCOTYL® L BEADED (MicroPort) | 341 | 12 | ${ }^{69}{ }_{(64-75)}$ | $39 / 61$ | 2014-2021 | $2.9 \underset{(13297}{[5.4]}$ | $3.8[2.2 ; 6.5]$ | $4.2[2.5 ; 6.9]$ | $4.2\left[\begin{array}{l} 12,5 ; 2 ; 6] \\ \hline(142) \end{array}\right.$ | $4.2\left[{ }_{(900}(2.569]\right.$ |  |  |  |
| PROFEMUR ${ }^{\text {GLADIATOR CLASSIC }}$ (MicroPort) | PROCOTYL® P (MicroPort) | 404 | 10 | 70 (63-77) | 35/65 | 2020-2022 | $3.1 \begin{gathered} {[1.7 .75 .5]} \\ (i 7)^{2} \end{gathered}$ |  |  |  |  |  |  |  |
| PROFEMUR®Preserve (MicroPort) | PROCOTYL® P (MicroPort) | 331 | 14 | $64_{(56-70)}$ | 45/55 | 2020-2022 | $2.6[11.3 ; 5.1]$ |  |  |  |  |  |  |  |
| Proxy PLUS Schaft (Smith \& Nephew) | EP-FIT PLUS (Smith \& Nephew) | 342 | 13 | $70_{(62-75)}$ | 46/54 | 2013-2020 | $3.8\left[\begin{array}{l} {[2244} \\ \text { [2] } \end{array}\right.$ | $4.7\left[\begin{array}{c} (2.906 \\ {[3.6]} \\ \hline \end{array}\right.$ | $5.0\left[\begin{array}{c} 3.2 ; 2 ; 6 \\ 1280 \\ 8.0] \end{array}\right.$ | $5.4\left[\begin{array}{c} {[3.4 ; 8.4]} \\ (27) \end{array}\right.$ | $5.4\left[\begin{array}{c} {[3.4 ; 8 ; 8.4]} \\ 1230 \end{array}\right.$ | $5.4\left[\begin{array}{c} \text { [3:4; } 4 ; 0 \\ (4.4] \end{array}\right.$ | $5.4\left[\begin{array}{l}\text { [3, 49; } \\ \hline 9.4]\end{array}\right.$ |  |

Table 48 (continued)

| Elective total hip arthroplasties |  | Number | Hosp. | Age | m/f | Period | Revision probabilities after ... |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Femoral stem | Cup |  |  |  |  |  | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Uncemented fixation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Pyramid (Atesos) | Pyramid (Atesos) | 2,823 | 24 | $71_{(64-77)}$ | 36/64 | 2014-2022 | $3.0\left[\begin{array}{l} {[2.4 ; 4 ; 3.7]} \\ 2.517 \end{array}\right.$ | $3.3\left[\begin{array}{c} {[2.720 ; 4.0]} \\ (2,0) \end{array}\right.$ | $\underset{\substack{1.245) \\(3.6 ; 4]}}{ }$ |  | $3.8\left[\begin{array}{l} {[3.1 .1494} \\ \hline(4.6] \\ \hline \end{array}\right.$ | $3.9\left[\begin{array}{l} (3,27) \\ \hline 4.7] \\ \hline \end{array}\right.$ | $3.9\left[\begin{array}{l} 1.22] \\ 4.7] \\ \hline \end{array}\right.$ |  |
| QUADRA-H (Medacta) | VERSAFITCUP CC TRIO (Medacta) | 9,076 | 62 | $68{ }_{(61-75)}$ | $39 / 61$ | 2015-2022 |  | $\left.3.0{ }_{[(5.527}^{[2.7} 3.4\right]$ | $3.4\left[\begin{array}{l} {[3.0 ; 2 ; 3)} \\ \langle 4.8] \\ \hline \end{array}\right.$ | $3.8\left[\begin{array}{l} (3.3021) \\ \hline \end{array}\right.$ | $4.1[3.6 ; 4.6]$ | $4.4\left[\begin{array}{l} {[357)} \\ (56) \\ 5.1] \end{array}\right.$ | $4.7[3.9 ; 5.6]$ |  |
| S-ROM ${ }^{\text {TM }}$-Hüftschaft (DePuy) | PINNACLETM Press Fit-Hüftpfanne (DePuy) | 319 | 19 | $59_{(51-68)}$ | 30/70 | 2014-2022 | $4.1\left[\begin{array}{l} {[2.33 \cdot 7.1]} \\ {[234} \\ \hline \end{array}\right.$ | $4.1\left[\begin{array}{l} \left.[1.35)^{2} 7.1\right] \\ \hline \end{array}\right.$ | $4.1\left[\begin{array}{l} \left.[2.37]^{7} 7.1\right] \\ \hline \end{array}\right.$ |  |  |  |  |  |
| SL-PLUS Schaft (Smith \& Nephew) | Allofit (Zimmer Biomet) | 590 | 13 | $64.5{ }_{(58-71)}$ | 36/64 | 2012-2022 | $3.6\left[\begin{array}{l} {[2.354} \\ 5.4] \\ 5.4] \end{array}\right.$ | $4.5\left[\begin{array}{l} {[321]} \\ \hline 5.5] \\ \hline \end{array}\right.$ | $4.8\left[\begin{array}{l} {[5.40 ; 6} \\ (504) \\ \hline \end{array}\right.$ | $5.0\left[\begin{array}{c} {[3,52]} \\ (4.2] \\ \hline \end{array}\right.$ | $5.6[4.0 .07 .9]$ | $6.1\left[\begin{array}{c} {[4.4 ; 3)} \\ \hline(8.4] \end{array}\right.$ | $6.9\left[\begin{array}{c} {[5390} \\ {[3 ; 9} \end{array} 9.4\right]$ | $7.2\left[\begin{array}{c} {[5.2 ; 50} \\ (2,5) \\ 9.8] \end{array}\right.$ |
| SL-PLUS Schaft (Smith \& Nephew) | BICON-PLUS (Smith \& Nephew) | 1,346 | 26 | $72_{(65-78)}$ | 36/64 | 2013-2022 | $2.3[1.6 .63 .2]$ | $3.3\left[\begin{array}{ll} {[2.508} \\ (0.08) \\ 4.5] \end{array}\right.$ | $4.2\left[\begin{array}{c} {[3,2 ; 8)} \\ (930) \\ 5.5] \\ \hline \end{array}\right.$ | $5.1[4.0 ; 9 ; 6.6]$ | $5.5[4.3 ; 7.0]$ | $6.4\left[\begin{array}{c} {[50.0 ; 9.8} \\ (46) \end{array}\right.$ | $7.2 \text { [5.7.79.2] } 9.2]$ | $7.2\left[\begin{array}{l} {[5,7} \\ (0,7) \\ 9.2] \end{array}\right.$ |
| SL-PLUS Schaft (Smith \& Nephew) | EP-FIT PLUS (Smith \& Nephew) | 409 | 12 | $66_{(62-72)}$ | 44/56 | 2014-2022 | $2.5\left[\begin{array}{c} 11.376 .4 .6] \\ 1376 \end{array}\right.$ | $2.7 \underset{\substack{[1.500}}{ } 4.9]$ | $2.7 \underset{\substack{13040}}{[1.5 ; ~ 4.9]}$ | $3.1 \underset{1}{[12866} 50.4]$ | $3.1[1.8 ; 5.4]$ | $3.5\left[\begin{array}{ll} (2,0 ; 7) & 6.0] \\ \hline \end{array}\right.$ | ${ }^{3.5[20.06}(120)$ |  |
| SL-PLUS Schaft (Smith \& Nephew) | HI Lubricer Schale (Smith \& Nephew) | 320 | 8 | $71_{(62-77)}$ | 36/64 | 2014-2022 | $1.0\left[\begin{array}{l} {[0.37\rangle} \\ {[287} \end{array} 2.9\right]$ | $1.0\left[\begin{array}{c} 0.3 ; 3 ; 0 \\ 1270 \end{array}\right)$ |  | $1.4 \underset{\substack{0040 \\ \text { (0.5) }}}{ } 3.7]$ | $1.4\left[\begin{array}{l} {[.575)} \\ (137) \\ 3.7] \end{array}\right.$ | $1.4\left[\begin{array}{c} {[0.50} \\ (00) \\ \hline 3.7] \end{array}\right.$ |  |  |
| SL-PLUS Schaft (Smith \& Nephew) | R3 (Smith \& Nephew) | 2,069 | 26 | $69_{(63-76)}$ | 35/65 | 2013-2022 | $3.7\left[\begin{array}{l} {[3.0,041.7]} \\ 14.7] \end{array}\right.$ | $4.6\left[\begin{array}{l} {[3.75: 5.5]} \\ (1.50) \end{array}\right.$ | $4.9(4.0 ; 2 ; 6.0]$ | $5.0[4.14 ; 6.1]$ | $5.4[4.4536 .6 .6]$ | $5.6[4.6 ; 6.9]$ |  |  |
| SL MIA HA Schaft (Smith \& Nephew) | Allofit (Zimmer Biomet) | 2,127 | 15 | 70 (60-78) | 32/68 | 2014-2022 | $2.7\left[\begin{array}{ll} {[1.1 .1: 06)} \\ 3.6] \end{array}\right.$ | $3.2[1.5 ; 4.1]$ | $3.5\left[\begin{array}{l} {[870)} \\ {[7.4]} \\ \hline \end{array}\right.$ | $3.6\left[\begin{array}{l} {[2474)} \\ {[4.7]} \\ \hline \end{array}\right.$ | $3.6\left[\begin{array}{l} {[2.8 ;} \\ \mid 282 \\ \hline 4.7] \end{array}\right.$ | $3.6[2.8 ; 4.7]$ |  |  |
| SL MIA HA Schaft (Smith \& Nephew) | BICON-PLUS (Smith \& Nephew) | 768 | 16 | $71_{(6,5.57)}$ | 35/65 | 2013-2022 | $2.4\left[\begin{array}{c} 10.503 \\ {[103} \end{array}\right]$ | $3.1\left[\begin{array}{l} {[(6.1) ; 4.6]} \\ \hline(4) \end{array}\right.$ | $3.7\left[\begin{array}{l} {[2.504} \\ \text { [60 } \\ 5.3] \\ \hline \end{array}\right.$ |  | $4.7[3.4 ; 46.6]$ | $5.7 \text { [4.2; 7.8] }$ | $6.8\left[\begin{array}{c} {[50,0 ; 2} \\ {[292} \end{array}\right)$ |  |
| SL MIA HA Schaft (Smith \& Nephew) | EP-FIT PLUS (Smith \& Nephew) | 676 | 10 | $72_{(64-78)}$ | 40/60 | 2014-2022 | $2.8[1.89 ; 4.4]$ | $3.7\left[\begin{array}{l} (2.552) \\ \hline 5.4] \end{array}\right.$ | $3.8\left[\begin{array}{l} {[2.67 \%} \\ {[5.6]} \end{array}\right.$ | $3.8[2.6 ; 5.6]$ | $3.8\left[\begin{array}{l} (2355) \\ \hline 1.6] \end{array}\right.$ | $3.8\left[\begin{array}{l} {\left[2.64 j^{2} 5.6\right]} \\ (2.6] \end{array}\right.$ | ${ }^{3.8[2.6 ; ~} 9.67$ |  |
| SL MIA HA Schaft (Smith \& Nephew) | HI Lubricer Schale (Smith \& Nephew) | 337 | 7 | $6^{69}(61-75)$ | 35/65 | 2015-2022 |  | $1.6[0.7 .73 .3 .7]$ | $2.0[0.9 ; 4.5]$ | $2.0[0.9 .9,4.5]$ | $2.0[0.9 ; 4.5]$ |  |  |  |
| SL MIA HA Schaft (Smith \& Nephew) | R3 (Smith \& Nephew) | 1,745 | 29 | $69_{(61-76)}$ | 39/61 | 2015-2022 | $3.1\left[\begin{array}{l} {[1.498 ;)} \\ \hline 1.0] \end{array}\right.$ | $3.4\left[\begin{array}{l} (2,25 i) \\ \hline 1.3] \end{array}\right.$ | $3.4[2.79 ; 4.4]$ | $3.5[2.7 ; 4.6]$ | $3.9\left[\begin{array}{l} {[3355} \\ {[3.0]} \\ 5.0] \end{array}\right.$ | $3.9[3[0 ; 500]$ |  |  |
| SP-CL Hip Stem, uncemented (Waldemar Link) | Allofit (Zimmer Biomet) | 1,904 | 13 | $63_{(56-69)}$ | 40/60 | 2015-2022 | $3.1\left[\begin{array}{l} {[1.544)} \\ \hline \end{array}\right.$ | $3.6\left[\begin{array}{c} {[1.310)} \\ \hline(1.30) \end{array}\right.$ | $4.0\left[\begin{array}{l} {[3.2 ; 5\rangle} \\ (1.03) \\ \hline \end{array}\right.$ | $4.0\left[\begin{array}{l} {[3,2 ; 8)} \\ \hline 1.0] \\ \hline \end{array}\right.$ | $4.5[3.50 ; 5.7]$ | $4.7\left[\begin{array}{l} {[3.77 ;} \\ (18 i) \\ \hline \end{array}\right.$ |  |  |
| SP-CL Hip Stem, uncemented (Waldemar Link) | CombiCup (Waldemar Link) | 706 | 23 | $6^{(58-72)}$ | 40/60 | 2014-2022 |  | $4.0\left[\begin{array}{l} {[5986} \\ 5.85] \\ 5.8] \end{array}\right.$ | $4.4\left[\begin{array}{l} {[3,1 ; 2]} \\ (562] \end{array}\right]$ |  | $\left.4.4\left[\begin{array}{c} {[3.1966} \\ {[286} \\ 6 \end{array}\right] .2\right]$ |  |  |  |
| SP-CL Hip Stem, uncemented (Waldemar Link) | MobileLink, Cluster Hole (Waldemar Link) | 635 | 21 | $65_{(57-72)}$ | 37/63 | 2017-2022 | $3.9\left[\begin{array}{l} {[2.751)} \\ \hline 5.8] \\ \hline \end{array}\right.$ | $5.2\left[\begin{array}{c} 3.66 ; 3 \\ 1230 \\ 7.5] \\ \hline \end{array}\right.$ | $5.2\left[\begin{array}{c} \text { [3.6i) } \\ \text { (10i) } \end{array}\right.$ |  |  |  |  |  |
| SPS Evolution (Symbios) | APRIL Poly (Symbios) | 359 | 4 | $61_{(55-67)}$ | 46/54 | 2015-2022 | $1.1 \underset{(318)}{[0.4 ; 2.9]}$ | $1.7\left[\begin{array}{c} {[0.88} \\ 1288 \\ 3 \end{array} 3\right]$ | $1.7 \text { [0.8.8.3.9] }$ | $2.2[1.0 ; 4.5]$ | $2.2[1.0 ; 4.5]$ |  |  |  |
| Stemcup (IO-International Orthopaedics) | Stemcup (IO-International Orthopaedics) | 359 | 5 | $68_{(60-74)}$ | 42/58 | 2018-2022 | $1.4\left[\begin{array}{c} {[0.6 ; 8,3.4]} \\ 128) \end{array}\right.$ | $\left.1.4\left[\begin{array}{c} {[0.6 ; 0} \\ 1200 \end{array}\right] .4\right]$ | $1.4\left[\begin{array}{c} {[.64]} \\ (64) \\ 3.4] \end{array}\right.$ |  |  |  |  |  |
| Taperloc (Zimmer Biomet) | Allofit (Zimmer Biomet) | 2,077 | 30 | $68{ }_{(61-75)}$ | 40/60 | 2015-2022 | $2.9\left[\begin{array}{l} {[2.2,235} \\ 10.75] \end{array}\right.$ | $3.1\left[\begin{array}{l} {[2.4 ; 0 ;} \\ (9.9] \\ \hline \end{array}\right.$ | $3.2\left[\begin{array}{l} {[5844} \\ \hline 1.5 ; ~ 4.1] \\ \hline \end{array}\right.$ | $3.2\left[\begin{array}{l} {[251)} \\ \hline 1.1] \\ \hline \end{array}\right.$ | $3.2[2.5 ; 4.1]$ |  |  |  |
| Taperloc (Zimmer Biomet) | G7 (Zimmer Biomet) | 2,099 | 11 | $70{ }_{(62-76)}$ | 36/64 | 2014-2022 | $2.6\left[\begin{array}{ll} {[1.050 .05} \\ 3.4] \end{array}\right.$ | $3.3\left[\begin{array}{l} (2.620) \\ \hline 1.2] \end{array}\right.$ | $4.1\left[\begin{array}{c} {[3.3 .39 .5 .1]} \\ 1(3,9) \\ \hline \end{array}\right.$ | $4.7\left[\begin{array}{l} [3.9 ; 95) .8] \\ \hline(13) \end{array}\right.$ | $5.5[4.5 ; 6.7]$ |  |  |  |
| TAPERLOC COMPLETE <br> (Zimmer Biomet) | Allofit (Zimmer Biomet) | 1,009 | 23 | $64_{(58-70)}$ | 52/48 | 2017-2022 | $2.99$ | $3.3\left[\begin{array}{l} (246) \\ \hline \end{array}\right.$ | $3.3[(189)$ | $3.3 \underset{(64)}{[2.3 ;} 4.7]$ |  |  |  |  |
| TAPERLOC COMPLETE <br> (Zimmer Biomet) | G7 (Zimmer Biomet) | 917 | 8 | $68{ }_{(60-75)}$ | 37/63 | 2015-2022 | $3.7 \begin{gathered} (2.774) \\ (6.2] \\ 5.2] \end{gathered}$ | $\left.4.5\left[\begin{array}{l} {[3232} \end{array}\right) ; .2\right]$ | $5.3\left[\begin{array}{l} {[3.955} \\ {[125} \\ 7 \end{array}\right.$ | $5.7\left[\begin{array}{c} {[4,2 ; 7,8]} \\ (i 0) \end{array}\right]$ |  |  |  |  |
| TAPERLOC COMPLETE <br> (Zimmer Biomet) | PLASMAFIT (Aesculap) | 2,440 | 3 | $6^{659-73)}$ | 43/57 | 2015-2022 | $1.4\left[\begin{array}{c} {[1.0 ; 399} \\ 12.39 \end{array}\right]$ | $1.5\left[\begin{array}{c} {[1.12 ; 2.1]} \\ (2.34 i \end{array}\right)$ | $1.5[1.1 ; 2.1]$ | $1.6 \text { (1.2; 2; 2.2] }$ | $1.6[1.2 ; 2.2]$ | $1.6[1.2 ; 2.2]$ |  |  |
| TRENDHIP (Aesculap) | PLASMAFIT (Aesculap) | 5,404 | 55 | ${ }^{69}(62-76)$ | 41/59 | 2014-2022 | $2.5\left[\begin{array}{l} {[2.1 .144 .2 .9]} \\ \hline 4.9] \end{array}\right.$ | $2.7\left[\begin{array}{c} {[., 37 \pi)} \\ {[2 ; 2]} \\ 3 \end{array}\right.$ | $2.77_{[(2,070}^{[2.3 .2]}$ | $2.9\left[\begin{array}{l} {[2.4 ; 4 ; 3)} \\ {[2.4]} \\ \hline \end{array}\right.$ | $2.9\left[\begin{array}{ll} {[1.4055} \\ \hline(4.4] \end{array}\right.$ | $3.0\left[\begin{array}{c} {[259)} \\ (59) \\ 3.6] \end{array}\right.$ | $3.0{ }_{[123)}^{[2.5]} 3$ |  |
| TRENDHIP (Aesculap) | SCREWCUP SC (Aesculap) | 465 | 10 | $71{ }_{\text {(63 - 78) }}$ | 35/65 | 2015-2022 | $2.8\left[\begin{array}{c} 1.6 ; 6 \\ \mid 141) \\ 4.8] \\ \hline \end{array}\right.$ | $3.3[(2.0 ; 75.4]$ | $4.2\left[\begin{array}{l} 2.664 \\ (264) \\ \hline 6.6] \end{array}\right.$ | $4.6\left[\begin{array}{l} \text { [1699 } \\ \text { [is } \\ 7.2] \\ \hline \end{array}\right.$ | $6.8[4.2: 2 ; 10.8]$ |  |  |  |
| TRILOCK ${ }^{\text {TM-Hüftschaft ( }}$ (DePuy) | PINNACLETM Press Fit-Hüftpfanne (DePuy) | 4,084 | 49 | $60_{(55-67)}$ | 49/51 | 2013-2022 | $1.8\left[\begin{array}{c} {[1.4 ; 32)} \\ (1.32] \end{array}\right.$ | $2.4\left[\begin{array}{l} {[2,0,59]} \\ 3.0] \end{array}\right.$ | $2.7\left[\begin{array}{l} {[2.2 ; 30} \\ (2,30 \end{array}\right]$ | $3.0\left[\begin{array}{ll} (1.550) \\ {[1.5 ;} \end{array}\right.$ | $3.0{ }_{(1,013)}^{[2.5 ; ~ 3.6]}$ | $3.1\left[\begin{array}{l} (622) \\ {[2.5 ;} \end{array}\right)$ | $3.4[2.78 ; 4.4]$ | $4.2[2.88 ; 6.3]$ |
| TRJ (Aesculap) | PLASMACUP (Aesculap) | 434 | 7 | $72{ }_{(65-77)}$ | 31/69 | 2014-2022 | $2.3[1.3 ; 4.3]$ | $2.6[1.4 ; 4.6]$ | $2.6[1.4 ; 4.46]$ | $3.0\left[\begin{array}{c} {[1.73 ; 5} \\ 1238 \\ 5 \end{array}\right.$ | $3.0[1.7 .75 .5]$ | $3.0[11.7 \cdot 5.2]$ | $\left.{ }^{3.0}{ }_{(150)}^{[5]} 5.2\right]$ |  |

Table 48 (continued)

| Elective total hip arthroplasties |  | Number | Hosp. | Age | m/f | Period | Revision probabilities after ... |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Femoral stem | Cup |  |  |  |  |  | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Uncemented fixation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| TRJ (Aesculap) | PLASMAFIT (Aesculap) | 482 | 21 | 70 (63-77) | 33/67 | 2013-2022 | $3.4 \underset{(2300}{[2.1 ;} 5.6]$ | $\left.5.1\left[\begin{array}{c} {[3.3 ; 7} \\ (250 \\ \hline \end{array}\right] .8\right]$ | $5.5\left[\begin{array}{l} (3,60) \\ (180) \\ 8.4] \end{array}\right.$ | $5.5[3.6: 8.4]$ | $5.5[3(6.6 ; 8.4]$ |  |  |  |
| twinSys uncem. (Mathys) | aneXys Flex (Mathys) | 1,207 | 28 | $71_{(65-77)}$ | 42/58 | 2016-2022 | $3.8\left[\begin{array}{l\|l\|c\|r\|}  & 5.1] \\ \hline \end{array}\right.$ | $4.0 \underset{(3.058)}{[5.3]}$ | $4.0\left[\begin{array}{l} {[3.0 .55} \\ (5.3] \\ 5.3] \end{array}\right.$ | $4.3\left[\begin{array}{l} {[32.26} \\ (225) \\ 5.7] \\ \hline \end{array}\right.$ | $4.3[3[.2 ; 5.7]$ |  |  |  |
| twinSys uncem. (Mathys) | RM Classic (Mathys) | 816 | 10 | $76_{(11-81)}$ | 30/70 | 2013-2022 | 1.3 [0.773) ${ }_{(13)}$ | $1.7\left[\begin{array}{c} 1.0022 \\ \mid 612) \\ 2.9] \\ \hline \end{array}\right.$ | $2.1 \begin{gathered} {[1.3 ; 3,3.5]} \\ \langle 473 \end{gathered}$ | $\underset{\substack{13,43)}}{2.3]}$ |  | ${ }^{3.0}{ }_{(123)} 18 ; 4.8$ ] |  |  |
| twinSys uncem. (Mathys) | RM Pressfit (Mathys) | 469 | 9 | 75 (69-79) | 40/60 | 2013-2022 | $2.8[1.6 ; 4.7]$ | $3.4\left[\begin{array}{l} {[41717)} \\ 5.6] \end{array}\right.$ | $3.7\left[\begin{array}{l} {[2,3 ; 2 ;} \\ {[3.8]} \\ \hline \end{array}\right.$ | $3.9[2.5 ; 6.2]$ | $3.9[2.5 ; 6.2]$ | $3.9[(2.5 ; 4) 6.2]$ | $3.9[2.56 .5 .2]$ |  |
| twinSys uncem. (Mathys) | RM Pressfit vitamys (Mathys) | 2,590 | 35 | 72 (64-78) | 36/64 | 2013-2022 | $2.2\left[\begin{array}{c} {[1.7 ; 3 i 2.8]} \\ (2,3 i) \end{array}\right.$ | $2.4\left[\begin{array}{c} {[1.9 ; 760} \\ 4.1] \end{array}\right.$ | $2.5\left[\begin{array}{ll} {[1.30,38} \\ 3.2] \\ \hline \end{array}\right.$ | $\underset{\substack{(224)}}{2.7} \mathbf{1 . 5 ]}$ | $2.7 \underset{(555)}{[2.1 ; 3.5]}$ | $3.3[2.4 ; 5 ; 4.5]$ | $3.3[2.4 ; 4.5]$ |  |
| Cemented fixation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Avenir (Zimmer Biomet) | Flachprofil (Zimmer Biomet) | 947 | 74 | $81_{(77-84)}$ | 22/78 | 2014-2022 | $3.2[2.2 ; 4.6]$ | $3.4[2.44 ; 4.9]$ | $3.4\left[\begin{array}{c} {[2.4,4.4 .9]} \\ {[30)} \\ \hline \end{array}\right.$ | $3.4[2.4 ; 44.9]$ | $3.4[2.4 .454 .9]$ |  |  |  |
| BICONTACT (Aesculap) | All Poly Cup (Aesculap) | 1,529 | 66 | 81 (77-84) | 22/78 | 2013-2022 | $2.4 \underset{(1.736)}{(1.36]}$ | $2.4\left[\begin{array}{l} {[1.72 ; 303} \\ (1.3) \end{array}\right.$ | $2.7\left[\begin{array}{ll} {[2.0000} \\ (1.75] \\ 3.7] \end{array}\right.$ | $2.9\left[\begin{array}{c} \text { [280) } 2 ; ~ \\ 3 \end{array}\right)$ | $3.0\left[\begin{array}{c} {[2.20)} \\ (6.1] \end{array}\right.$ | $3.2\left[\begin{array}{l} {[3.40 ; 0} \end{array}\right)$ | $3.5\left[{ }_{(212)}\right.$ [5; 4.7] |  |
| CORAILTM AMT-Hüftschaft ohne Kragen (DePuy) | TRILOC® II-PE-Hüftpfanne (DePuy) | 911 | 74 | $80_{(76-84)}$ | 18/82 | 2013-2022 | $2.8[1.9 ; 4.1]$ | $3.0\left[\begin{array}{l} {[2.051)} \\ \hline 4.3] \\ \hline \end{array}\right.$ |  | $3.3\left[\begin{array}{l} {[1400} \\ 4.3 ; \\ \hline \end{array}\right.$ | $3.9\left[\begin{array}{l} 2.791) \\ 5.6] \end{array}\right.$ | $4.3[(1,92 ; 6) .2]$ |  |  |
| CS PLUS Schaft (Smith \& Nephew) | Müller II Pfanne <br> (OHST Medizintechnik) | 485 | 21 | 79 (77-82) | 26/74 | 2014-2019 | $1.0\left[\begin{array}{c}(4.45) \\ 2.5]\end{array}\right.$ | $1.7\left[\begin{array}{ll} {[0.93 ;} \\ ; 3.4] \\ \hline \end{array}\right.$ | $2.2[1.2 .254 .0]$ | $2.2[1.2 .2 ; 4.0]$ |  | $2.2[1.2 ; 84.0]$ |  |  |
| EXCIA (Aesculap) | All Poly Cup (Aesculap) | 1,108 | 66 | $80_{(75-83)}$ | $24 / 76$ | 2014-2022 | $2.3[1.5 ; 3.3]$ | $2.8\left[\begin{array}{l} 12.0 ; 6 \\ 136 \end{array}\right)$ | $3.0\left[\begin{array}{l} {[2.17)} \\ \hline 5.3] \\ \hline \end{array}\right.$ | $3.0\left[\begin{array}{l} {[2.153)} \\ 4.3] \\ \hline \end{array}\right.$ | $3.2\left[\begin{array}{l\|l\|l\|l\|} {[2 ; 6} \\ 4.6] \end{array}\right.$ | $3.2\left[\begin{array}{c} (2.25) \\ \hline \end{array}\right.$ | $3.2[2[2 ; 2 ; 4.6]$ |  |
| M.E.M. Geradschaft (Zimmer Biomet) | Flachprofil (Zimmer Biomet) | 4,661 | 136 | 80 (77-84) | $24 / 76$ | 2012-2022 | $2.4\left[\begin{array}{l} {[.3 .075)} \\ {[2.9]} \end{array}\right.$ | $2.8\left[\begin{array}{l} (2,45 ; 5) \\ \hline 1.4] \end{array}\right.$ |  | $3.2\left[\begin{array}{l} {[2.7 ; 3 ; 8]} \\ {[.016)} \end{array}\right.$ | $\begin{gathered} 3.3[2.8 ; 3 ; 3.9] \\ \{1,32] \end{gathered}$ | $3.4\left[\begin{array}{l} {[859)} \\ {[8.8 ; 0]} \end{array}\right.$ |  | $\left.{ }^{3.5}{ }_{(2,95}(125) 4.2\right]$ |
| METABLOC (Zimmer Biomet) | Flachprofil (Zimmer Biomet) | 420 | 17 | $79_{(76-83)}$ | 26/74 | 2013-2022 | $2.7\left[\begin{array}{c} {[1.589} \\ (389) \end{array} 4\right]$ | $2.9 \underset{(1359}{[1.7 ;} 5.1]$ | $3.2\left[\begin{array}{c} 1.9,9 ; 3.5] \\ k 23,5] \end{array}\right.$ | $3.2[1.9: 5.5]$ | ${ }^{3.8}{ }_{(2,551}(2 ; 5.4]$ |  |  |  |
| MS-30 (Zimmer Biomet) | Flachprofil (Zimmer Biomet) | 491 | 28 | $79^{176-83)}$ | 23/77 | 2013-2022 | $1.7\left[\begin{array}{l} {[0.8 ; 4]} \\ (4.3] \\ \hline \end{array}\right.$ | $1.9\left[\begin{array}{l} 1.0 ; 0 ; 0.6] \\ \langle 430 \end{array}\right.$ | $2.1 \begin{gathered} {[1.1 .1 ; 3.9]} \\ {[83)} \\ \hline \end{gathered}$ | $2.1\left[\begin{array}{c} 1.1 .1 ; 3.9] \\ (285 \\ 3 \end{array}\right.$ | $2.1[1.1 ; 3.9]$ | $2.1\left[\begin{array}{ll} {[132]} \\ (132) \\ 3.9] \end{array}\right.$ | $\left.2.1\left[\begin{array}{c} {[1.1 ; 7} \\ {[50]} \end{array}\right] .9\right]$ |  |
| Polarschaft Cemented (Smith \& Nephew) | Müller II Pfanne (OHST Medizintechnik) | 633 | 31 | $80_{(76-84)}$ | 23/77 | 2014-2022 |  | $3.9[2.6 ; 5.8]$ |  | $3.9[2.6 ; 5.8]$ | $4.7{ }_{(13,2 ; 5]}^{[3.0]}$ |  |  |  |
| SPII Model Lubinus Hip Stem (Waldemar Link) | Cemented Acetabular Cup System, Endo-Model Cup, UHMWPE (Waldemar Link) | 493 | 6 | 77 (73-81) | 18/82 | 2012-2022 | $2.1[1.1 ; 5.8]$ | $2.7 \underset{(124 i 4}{[1.6 ; 4.7]}$ | $2.7 \underset{\substack{1.682 \\(1.7]}}{ }$ | $3.0\left[\begin{array}{c}1.8 ; 8.50] \\ (34) \\ 5\end{array}\right.$ | $\underset{\substack{3010 \\(130)}}{3.0]}$ | $3.0 \begin{gathered} {[1.8 ; 5.0]} \\ (123) \end{gathered}$ | $3.0\left[\begin{array}{c} {[1.8 ; 5.0]} \\ 1200 \end{array}\right.$ | $3.4\left[\begin{array}{l} {[1,0,5)} \\ \hline 1.7] \end{array}\right.$ |
| SPII Model Lubinus Hip Stem (Waldemar Link) | Cemented Acetabular Cup System, <br> IP Cup, UHMWPE (Waldemar Link) | 406 | 15 | 80 (77-83) | 26/74 | 2013-2022 | $2.0[1.0 ; 4.0]$ | $2.6[1.4 ; 4.7]$ | $2.9[1.65 \cdot 5.1]$ | $2.9[1.6 ; 5.1]$ | $2.9[1.6 ; 5.1]$ | $2.9[11.6 ; 5.1]$ | $2.9[1.6 ; 5.1]$ |  |
| SPII Model Lubinus Hip Stem (Waldemar Link) | Cemented Acetabular Cup System, <br> IP Cup, X-Linked (Waldemar Link) | 831 | 23 | $81_{(78-84)}$ | 26/74 | 2014-2022 | $2.5\left[\begin{array}{c} 1,63 i 4) \\ (13.8] \\ \hline \end{array}\right.$ | $\underset{\text { (1600 }}{2.7} \mathbf{2}$ | $3.2[2.2 ; 4.7]$ | 3.8 [2.6; 5.6] | $3.8\left[\begin{array}{l} {[305)} \\ \hline(3.65] \end{array}\right.$ | $4.2\left[\begin{array}{l} {[1.97\rangle} \\ {[1.9 ;} \end{array}\right]$ |  |  |
| SPII Model Lubinus Hip Stem (Waldemar Link) | Cemented Acetabular Cup System, Lubinus, UHMWPE (Waldemar Link) | 429 | 16 | $81_{(76-84)}$ | 18/82 | 2013-2022 | $1.4 \underset{\substack{(374) \\[0.7 ; ~ 3.2]}}{ }$ | $1.4 \underset{\substack{3122 \\[027}}{[0.2]}$ | $2.1 \begin{aligned} & 1.1 .14 .43] \\ & 1260 \end{aligned}$ | $2.6 \underset{(1212)}{[1.3 ;} 5.0]$ | $3.1[1.6 ; 5.8]$ | $3.1[11.6 ; 5.8]$ | $3.1[1.6 ; 5.8]$ |  |
| SPII Model Lubinus Hip Stem (Waldemar Link) | Cemented Acetabular Cup System, Lubinus, X-Linked (Waldemar Link) | 501 | 13 | $79{ }_{(75-83)}$ | 28/72 | 2014-2022 | $1.4 \underset{\substack{[4.741 \\(4.7}}{ } 3.0]$ | $1.9[1.03 ; 3.6]$ | $2.2\left[\begin{array}{c} 1.2 ; 2 ; 9.1] \\ k 289 \end{array}\right.$ | $2.2\left[\begin{array}{c} (189) \\ (189) \\ \hline \end{array}\right.$ |  | $2.2\left[\begin{array}{l} {[1.2 ; 3} \\ \hline \end{array}\right.$ |  |  |
| twinSys cem. (Mathys) | CCB (Mathys) | 517 | 21 | $80_{(76-83)}$ | 23/77 | 2014-2022 |  | $2.2\left[\begin{array}{l}(133) \\ \text { (3) }\end{array}\right.$ | $2.2[1.25 ; 4.0]$ | ${ }^{2.6}$ [1.482) 4.9$]$ |  |  |  |  |


| Knee arthroplasties without primary patellar resurfacing |  | Number | Hosp. | Age | m/f | Period | Revision probabilities after ... |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Femoral component | Tibial component |  |  |  |  |  | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Constrained TKA, hinged, fixed bearing, cemented |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Endo-Model - M, Rotating Hinge (Waldemar Link) | Endo-Model - M, Rotating Hinge, cemented (Waldemar Link) | 1,057 | 119 | 77 (68-82) | 23/77 | 2013-2022 | $5.6\left[\begin{array}{l} {[4007)} \\ 5.3 ; \\ 7 \end{array}\right.$ | $7.0 \underset{(5654)}{ } 5.58]$ | $7.1\left[\begin{array}{c} (5468) \\ \hline 49 \end{array}\right)$ | $7.9 \begin{gathered} {[6.232)} \\ (3,9) \\ 9.9] \end{gathered}$ | $7.9\left[\begin{array}{c} (6.293) \\ 119.9] \\ 9.9] \end{array}\right.$ | $\begin{gathered} 7.9[6.2 ; 9.9] \\ (80) \end{gathered}$ |  |  |
| Endo-Model SL, Femoral Component, cemented (Waldemar Link) | Endo-Model SL, Tibial Component, Monoblock, cemented (Waldemar Link) | 490 | 50 | $75.5{ }_{(68-82)}$ | 22/78 | 2013-2022 |  | $8.5{ }_{\text {[6.3; }}^{\text {(302) }}$ (1.5] |  |  | $11.0\left[8.17{ }^{1 / 2} 14.8\right]$ | $11.0[8.7 .744 .8]$ |  |  |
| Endo-Model, Rotating Hinge, cemented (Waldemar Link) | Endo-Model, Rotational Hinge, cemented (Waldemar Link) | 1,330 | 164 | 77 (69-82) | 18/82 | 2013-2022 | 3.7 [1.030) 4.9$]$ | $4.8\left[\begin{array}{c}{[385)} \\ (836 \\ \hline\end{array}\right.$ |  | $6.0\left[\begin{array}{c} 4.777) \\ (4.6] \end{array}\right.$ | $6.5\left[\begin{array}{c} (51.15) \\ (315) \\ 8.2] \end{array}\right.$ | $6.5\left[5.17\right.$ [ 8.2 . ${ }^{\text {a }}$ ] |  |  |
| ENDURO (Aesculap) | ENDURO (Aesculap) | 1,635 | 160 | 76 (68-81) | 21/79 | 2013-2022 | $3.5\left[\begin{array}{ll} {[1.7 .704 .4 .5]} \\ 11.34) \end{array}\right.$ | $4.5\left[\begin{array}{ll} {[3.505051} \\ 50.7] \end{array}\right.$ |  |  | $5.4[4.3 ; 6.8]$ | $5.7[4.5 ; 7.2]$ | $5.7[4.97]^{(97.2]}$ |  |
| MUTARS GenuX MK cemented (Implantcast) | MUTARS GenuX MK cemented (Implantcast) | 332 | 73 | $77^{(67-82)}$ | 27/73 | 2015-2022 | $2.4[1.1 .4 ; 4.9]$ | $5.1\left[\begin{array}{l} {[3,0 ; 28)} \\ (187] \end{array}\right.$ | $5.1\left[\begin{array}{c} \text { (1,0; } 30 \\ (1,8) \\ \hline \end{array}\right.$ | $6.2[3.5 ;$ |  |  |  |  |
| NexGen RHK (Zimmer Biomet) | NexGen RHK (Zimmer Biomet) | 1,043 | 140 | $76_{(68-81)}$ | 23/77 | 2012-2022 | $2.7[1.9 .93 .9]$ | $3.7[2.7 .75 .51]$ | $4.2\left[\begin{array}{l} {[3.000} \\ (500) \\ 5.7] \end{array}\right.$ | $4.6[3.4 ; 6 ; 6]$ | $4.9[3.6 ; 6.8]$ | $\left.4.9{ }_{(1,42)^{[36}} 6.8\right]$ | $4.9[3.6 ; 6.8]$ |  |
| RT-Plus (Smith \& Nephew) | RT-Plus (Smith \& Nephew) | 2,033 | 136 | $77^{(17-81)}$ | 21/79 | 2013-2022 | ${ }^{3.8}\left[\begin{array}{l}\text { [3.0; } \\ 4.70) \\ 4.8] \\ \hline\end{array}\right.$ | $4.7 \text { [3.8.8.5.7] }$ | 5.2 [4.2; 2 6, 6.3] | $5.5[4.5 ; 6.7]$ | $5.7[4.7 .7 \cdot 6.9]$ | $5.7 \begin{gathered} {[4272 ;} \\ (32.9] \\ \hline \end{gathered}$ | ${ }_{5} 5.7[4.79 \% 6.97]$ |  |
| RT-Plus Modular (Smith \& Nephew) | RT-Plus Modular (Smith \& Nephew) | 560 | 106 | $75_{\text {(66-80.5) }}$ | 28/72 | 2013-2022 | $4.6\left[\begin{array}{l} {[3.150} \\ \hline 6.76] \\ 6.7] \\ \hline \end{array}\right.$ | $5.5\left[\begin{array}{l} {[3,882} \\ (3,7) \\ 7.8] \end{array}\right.$ | $6.3[4.5 ; 8.8]$ | $6.3[4.5 ; 8.8]$ | $6.7[4.8 ; 9.4]$ | $7.4[5.2 ; 10.6]$ |  |  |
| Constrained TKA, varus-valgus stabilised, fixed bearing, cemented |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| LEGION PS COCR (Smith \& Nephew) | Genesis II (Smith \& Nephew) | 763 | 71 | 71 (63-78) | $29 / 71$ | 2015-2022 | $2.5[1.6 \cdot 6 ; 3.9]$ | $4.0\left[\begin{array}{l} {[2.75 \cdot 5.5]} \\ (3,9) \end{array}\right.$ | $4.3\left[\begin{array}{l} {[2.955} \\ {[2.3]} \\ \hline 6.3] \end{array}\right.$ | $4.3[2.9 .96 .6]$ |  |  |  |  |
| LEGION Revision COCR (Smith \& Nephew) | LEGION Revision (Smith \& Nephew) | 447 | 64 | 71 (65-79) | $29 / 71$ | 2014-2022 | $4.5\left[\begin{array}{l} {[3.955} \\ {[7.0]} \end{array}\right.$ | $\left.5.0\left[\begin{array}{c} {[3,3 ; 7} \\ {[27} \\ 7 \end{array}\right] .6\right]$ | $5.4\left[\begin{array}{c} {[3.6 ; 7)} \\ {[24]} \end{array}\right]$ | $5.4\left[\begin{array}{l} {[3,6 ; 8)} \\ (187) \\ \hline \end{array}\right.$ | $5.9[3.9 ; 8.8]$ | $5.9[3.9 ; 8.8]$ |  |  |
| NexGen LCCK (Zimmer Biomet) | NexGen CR (Zimmer Biomet) | 1,473 | 106 | 72 (64-79) | $29 / 71$ | 2012-2022 | $2.77\left[\begin{array}{l} {[2,0,0,3.7]} \\ (x, 16) \end{array}\right.$ | $2.9\left[\begin{array}{c} {[2.1 .1 ; 50} \\ (3.9] \end{array}\right.$ | $3.2\left[\begin{array}{l} {[2.4 ; 5 ; 4.4]} \end{array}\right.$ | $3.5\left[\begin{array}{l} {[2.6 ; 0)} \\ (5.8] \end{array}\right.$ | $3.5 \underset{(236)}{[2.6 ; 8.8]}$ | $3.9[2.8 ; 5.3]$ | $4.8[3.0 ; 7.4]$ |  |
| Triathlon PS (Stryker) | Triathlon TS (Stryker) | 380 | 37 | $73_{(63-79)}$ | 26/74 | 2013-2022 | $2.0\left[\begin{array}{c} {[0.979} \\ {[2.1]} \end{array}\right.$ | $3.9[2.2 ; 6.9]$ | $4.5\left[\begin{array}{c} {[2.6 ;} \\ (127) \\ 7.9] \end{array}\right.$ | $5.3\left[\begin{array}{l} (7.1 ;) \\ (7.1] \end{array}\right.$ |  |  |  |  |
| Standard TKA, cruciate-retaining, fixed bearing, hybrid |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| balanSys BICONDYLAR uncem. (Mathys) | balanSys BICONDYLAR fix (Mathys) | 341 | 5 | $7_{1(64-77)}$ | 46/54 | 2016-2022 | $0.6\left[\begin{array}{c} 0.2 ; 2 \\ \text { in2 } \end{array} 2.4\right]$ | $1.1\left[\begin{array}{c} {[1.39)} \\ (193) \\ 3.3] \\ \hline \end{array}\right.$ | $1.6\left[\begin{array}{l} {[1.6 ; 9} \end{array} 4.2\right]$ | $2.5\left[\begin{array}{l} 1,0 ; 0 \\ \|i 2\rangle \end{array}, 6.5\right]$ |  |  |  |  |
| COLUMBUS (Aesculap) | COLUMBUS (Aesculap) | 729 | 5 | $69_{(62-77)}$ | 38/62 | 2014-2022 | $3.3\left[\begin{array}{c} {[2.2000} \\ {[6.9]} \\ 4.9] \end{array}\right.$ | $3.9\left[\begin{array}{l} (2699) \\ (6.7] \end{array}\right.$ | $4.4\left[\begin{array}{l} {[3.1 .10 .6]} \\ (560) \end{array}\right.$ | $4.6\left[\begin{array}{l} {[3.30]} \\ 420.4] \\ 6.4] \end{array}\right.$ | $4.6\left[\begin{array}{l} {[3.36 \cdot 6.4]} \\ {[276} \end{array}\right.$ | $5.0 \underset{(134)}{[3.5 ; ~ 7.0]}$ |  |  |
| EFK Femur zementfrei (OHST Medizintechnik) | EFK Tibia zementiert (OHST Medizintechnik) | 1,271 | 14 | 70 (63-76) | 42/58 | 2014-2022 | $1.2\left[\begin{array}{l} {[0.772 ; 2.0]} \end{array}\right.$ | $1.6[1.002 .4]$ | $1.8[1.2 ; 2 \cdot 2.8]$ | $2.1 \begin{gathered} \text { [1879) } \\ (173.2] \\ 3.2] \end{gathered}$ | $\left.2.5\left[\begin{array}{l} (1,79) \\ (i 79 \end{array}\right] .6\right]$ | 3.3 [2.4; 4.4 .7$]$ | $4.0 \underset{(2277)}{[2.9 ; 5]}$ |  |
| GENESIS II CR COCR (Smith \& Nephew) | Genesis II (Smith \& Nephew) | 445 | 6 | $68_{(62-75)}$ | 44/56 | 2012-2022 | $1.0\left[\begin{array}{c} {[0.42)^{4} 2} \\ \langle 4.5] \end{array}\right.$ | $1.5\left[\begin{array}{c} {[0.72 ; 2]} \\ (3,2] \\ \hline \end{array}\right.$ | $1.7 \begin{gathered} {[0.827\rangle} \\ 323] \\ 3.6] \end{gathered}$ | $1.7\left[\begin{array}{c} {[0.8 ; 6 ;} \\ 1286 \\ 3.6] \\ \hline \end{array}\right.$ | $1.7{ }_{\substack{0.0 .8 i \mid}}^{2.6]}$ | $2.2\left[\begin{array}{c} (1,1 ; 9) \\ (169) \\ 4.4] \\ \hline \end{array}\right.$ | $2.2\left[\begin{array}{c} 11.1 / 4.4 .4] \\ \text { (114) } \end{array}\right.$ | $2.2 \underset{(55)}{2[1.74]}$ |
| LEGION CR COCR (Smith \& Nephew) | Genesis II (Smith \& Nephew) | 533 | 8 | $6^{69}(62-77)$ | 50/50 | 2017-2022 | $2.4[1.36 ; 4.1]$ | $3.7[2.3 ; 6.1]$ | $3.7\left[\begin{array}{l} {[2.300} \\ \text { (150) } \\ 6.1] \end{array}\right.$ | $4.4[2.6 ; 7.3]$ |  |  |  |  |
| NexGen CR-Flex (Zimmer Biomet) | NexGen CR (Zimmer Biomet) | 581 | 18 | $699_{(61-75)}$ | 52/48 | 2014-2022 | $0.5\left[\begin{array}{l} {[0.2 ; 41} \\ (54) \\ ; 1.6] \end{array}\right.$ | $1.9[1.0 ; 3.4]$ | $2.1\left[\begin{array}{ll} {[1.1 .56]} \\ 1.56] \\ 3 \end{array}\right]$ | $2.3[1.374 .0]$ | $2.6[1.53: 4.4]$ | $2.6\left[1.55{ }_{(130)}^{[4.4]}\right.$ | $2.6[1.5 ; 4.4]$ |  |
| NexGen CR (Zimmer Biomet) | NexGen CR (Zimmer Biomet) | 522 | 7 | $69_{(62-75)}$ | $49 / 51$ | 2014-2022 | $\left.0.6\left[\begin{array}{c} {[0.296} \\ 102 ; \end{array}\right], 8\right]$ |  |  | $\left.1.0\left[\begin{array}{c} {[0.4 ;} \\ \langle 0.0 ; \end{array}\right) .4\right]$ | $1.3\left[\begin{array}{l} (0.644) \\ (324) \end{array}\right.$ | $1.6[0.7 ; 3.3]$ | $1.6\left[\begin{array}{c} \left.[0.76)_{i} 3.3\right] \\ (8) \end{array}\right.$ |  |
| SIGMA ${ }^{\text {TM }}$ Femur (DePuy) | SIGMA ${ }^{\text {TM Tibia (DePuy) }}$ | 915 | 22 | $68^{(61-76)}$ | 41/59 | 2014-2022 | $1.1 \begin{gathered} {\left[0.60_{166} 2.1\right]} \end{gathered}$ | $1.5\left[\begin{array}{c} {[0.9 ; 12.6]} \\ (171 \end{array}\right)$ | $1.8\left[\begin{array}{c} 1.1 .13 .30] \\ \hline 600 \end{array}\right]$ | $2.0\left[\begin{array}{c} 1.2,2,3.3] \\ \hline 164) \\ \hline \end{array}\right.$ | $2.5[1.664 .1]$ | $2.5[1.6 ; 4.1]$ | $2.5[1.6 ; 4.1]$ |  |
| TC-PLUS CR (Smith \& Nephew) | TC-PLUS (Smith \& Nephew) | 543 | 12 | 71 (63-76) | 40/60 | 2014-2022 | $2.5[1.4 ; 4.2]$ | $2.9[1.8 ; 4.9]$ | $2.9[1.89 ; 4.9]$ | $2.9[1.8 ; 4.9]$ | $\begin{gathered} 2.9[1.8 ; 4.9] \\ (120) \end{gathered}$ |  |  |  |
| Triathlon CR (Stryker) | Triathlon (Stryker) | 437 | 17 | $70_{(63-75)}$ | 40/60 | 2014-2022 | $1.0 \begin{gathered} {[0.45 ;} \\ (36) \\ \hline 2.6] \end{gathered}$ | $1.6[0.7 .73 .5]$ | $1.6\left[\begin{array}{ll} {[0.79)^{\prime 2}} & 3.5] \\ \hline \end{array}\right.$ | $2.0[0.9 ; 4.3]$ | $2.0\left[\begin{array}{l} {[0.9: 4.3]} \\ (i, 6) \\ 4.3] \end{array}\right.$ | $2.0[0.99 ; 4.3]$ |  |  |
| Vanguard CR (Zimmer Biomet) | Vanguard Tibia Cruciate <br> (Zimmer Biomet) | 1,057 | 13 | $68{ }_{(61-75)}$ | 42/58 | 2015-2022 | $2.0{ }_{(1829}^{[1.3 ; ~ 3.1]}$ | $\left.3.1{ }_{(6,49)}^{[2.2} 4.5\right]$ |  | $4.2{ }_{\text {[ }}^{(3554)}$ [0; 5.9$]$ | $4.5[3.2$ [27) 6.3$]$ | ${ }^{4.5}{ }^{\text {(31.2] }}$ (3) 6.3$]$ |  |  |

[^4]the combinations are listed alphabetically by the femoral component.

| Knee arthroplasties without primary patellar resurfacing |  | Number | Hosp. | Age | m/f | Period | Revision probabilities after ... |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Femoral component | Tibial component |  |  |  |  |  | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Standard TKA, cruciate-retaining, fixed bearing, cemented |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| ACS cemented (Implantcast) | ACS FB cemented (Implantcast) | 800 | 43 | $66.5{ }_{\text {(59-74) }}$ | 21/79 | 2014-2022 |  | $3.9 \underset{(2099}{[28 ;} 5.6]$ | $5.5[44.0 ; 7.5]$ |  | $7.2\left[\begin{array}{c} {[5.43)} \\ (183) \\ 9.7] \end{array}\right.$ | $7.9{ }_{\text {[5.8; }}^{\text {ip }}$ ] 10.7] |  |  |
| ACS LD cemented (Implantcast) | ACS LD FB cemented (Implantcast) | 362 | 10 | $70_{(63-76)}$ | 48/52 | 2015-2021 | $2.8\left[\begin{array}{c} 1.5575 .51] \\ (34) \\ 5.1] \\ \hline \end{array}\right.$ | $3.6[2.19 ; 6.2]$ | $3.6\left[\begin{array}{l} {[2.12]} \\ \mid 220 \end{array} 6.2\right]$ | $3.6[(1.1 ; 5) 6.2]$ | $3.6\left[\begin{array}{l} {[2,1 ; 3)} \\ (3,2) \\ 6 \end{array}\right]$ |  |  |  |
| balanSys BICONDYLAR cem. (Mathys) | balanSys BICONDYLAR fix (Mathys) | 2,465 | 24 | $71_{(64-78)}$ | $37 / 63$ | 2014-2022 | $2.1\left[\begin{array}{ll} {[1.6 ; 62.7]} \\ (2.04) \end{array}\right.$ | $2.7\left[\begin{array}{l} {[2.1 .1 .3 .3]} \\ (x .64) \end{array}\right.$ | $3.2\left[\begin{array}{ll} {[2.5727} \\ \hline 1.17 \end{array}\right.$ | $3.4[2.72 ; 4.3]$ | $3.7\left[\begin{array}{l} {[59.9 ;} \\ {[4.7]} \\ \hline \end{array}\right.$ | $3.9[3.0: 5.0]$ | $3.9\left[\begin{array}{l} {[3 ; 0 ; 5} \\ {\left[i_{3}\right]} \\ 50] \end{array}\right.$ |  |
| COLUMBUS (Aesculap) | COLUMBUS (Aesculap) | 17,681 | 142 | $70_{(62-77)}$ | $34 / 66$ | 2013-2022 | $1.3[11.1 .1 .51 .5]$ | $2.0[11.8 ; 2.2]$ | $2.4\left[\begin{array}{l} {[2,2545)} \\ (2,2) \\ 20] \end{array}\right.$ | $2.6[2.4 ; 2.29]$ | $2.8\left[\begin{array}{l} {[1.6 ; 3 ; 2]} \\ \langle, 20) \end{array}\right.$ | $3.0\left[\begin{array}{ll} {[2.7060} \\ {[2.4]} \\ 3 \end{array}\right]$ | $3.3\left[\begin{array}{l} {[2.96 ; 6 ;} \\ (3.8] \\ \hline \end{array}\right.$ |  |
| EFK Femur zementiert (OHST Medizintechnik) | EFK Tibia zementiert (OHST Medizintechnik) | 3,050 | 39 | $72_{(64-77)}$ | 38/62 | 2014-2022 |  | $1.8 \text { [1.3.32.3] }$ | $2.0\left[\begin{array}{ll} (1.552) \\ 2.52 .6] \end{array}\right.$ | $2.4\left[\begin{array}{l} {[1.9 .930 .0]} \\ 2.30] \end{array}\right.$ | $2.8\left[\begin{array}{l} {[2.2076)} \\ (2.5) \\ \hline \end{array}\right.$ |  | $3.9\left[\begin{array}{c} {[3.255} \\ \hline \end{array}\right.$ |  |
| EFK Femur zementiert TiNbN (OHST Medizintechnik) | EFK Tibia zementiert TiNbN (OHST Medizintechnik) | 472 | 44 | $66_{(59-73)}$ | 7/93 | 2014-2022 | $2.0\left[\begin{array}{l} 1.0 ; 3.37 \\ (129) \end{array}\right]$ | $\underset{\substack{(1387}}{2.5 ; 4.6]}$ | $3.7 \underset{(355)}{[2.3 ; ~ 6.0]}$ | $4.2\left[\begin{array}{l} {[2316} \\ {[266} \\ \hline 6.7] \end{array}\right.$ | $4.9\left[\begin{array}{c}\text { (2.25) } \\ 7.5] \\ 7.5 \\ \hline\end{array}\right.$ | $4.9\left[\begin{array}{c} {[3,2 ;)} \\ 123 ; \\ 7.5] \end{array}\right.$ | $4.9[3.2 ; 7.5]$ |  |
| GEMINI SL Total Knee System, Femoral Component, Mobile Bearing/Fixed Bearing CR, cemented (Waldemar Link) | GEMINI SL Total Knee System, Tibial Component, Fixed Bearing, cemented (Waldemar Link) | 316 | 23 | $73{ }_{(65-78)}$ | 38/62 | 2014-2022 |  | $4.7{ }_{[1235]}^{[2.87 .7]}$ | $6.2\left[\begin{array}{l}\text { [1327) } \\ \text { 9, } 9.6]\end{array}\right.$ | $7.2\left[4.7\right.$ ifi $^{\text {a }}$ ) 11.0$]$ |  |  |  |  |
| GENESIS II CR COCR (Smith \& Nephew) | Genesis II (Smith \& Nephew) | 9,088 | 91 | $70_{(62-76)}$ | 35/65 | 2013-2022 | $1.6[1.4,41.9]$ | $2.5\left[\begin{array}{c} (2.288) \\ 2 ; 2.8] \end{array}\right.$ |  | $3.3\left[\begin{array}{l} (2,920) \\ {[3.7]} \\ 3.7 \end{array}\right.$ | $3.5\left[\begin{array}{l} {[3.020 ; 20} \\ (2,9] \end{array}\right.$ | $3.5\left[\begin{array}{l} 3.1 .1 ; 4.04 \\ 1.54 \\ \hline \end{array}\right.$ | $3.6 \underset{(6676)}{3.2 ;} 4.1]$ | $3.6\left[\begin{array}{l} 1.222 \\ 1.52 \\ 4.1] \\ \hline \end{array}\right.$ |
| GENESIS II CR OXINIUM (Smith \& Nephew) | Genesis II (Smith \& Nephew) | 2,528 | 115 | $65_{(58-73)}$ | 20/80 | 2012-2022 | $1.7 \begin{aligned} & {[1.2 ; 2.2 .3]} \\ & \text { (2.23) } \end{aligned}$ | $2.5\left[\begin{array}{l} {[1.079]} \\ \hline 0.3] \end{array}\right.$ | $\underset{[1.579]}{2.8[2 ; 5]}$ | $\left.3.0 \begin{array}{l} {[2.4 ; 3,8]} \\ (1.264 \end{array}\right]$ | $\underset{\substack{1907}}{3.3 ;} 4.2]$ | $3.3\left[\begin{array}{c} (2576) \\ \hline 5.2] \\ 4.2] \end{array}\right.$ | $3.7 \begin{gathered} {[2.9 ; 4.9]} \\ (297) \end{gathered}$ | $3.7\left[\begin{array}{l} 1.955 \\ \hline 1.9 .9] \\ \hline \end{array}\right.$ |
| GENESIS II LDK COCR (Smith \& Nephew) | Genesis II (Smith \& Nephew) | 1,703 | 16 | $70_{(62-76)}$ | 38/62 | 2013-2022 | $2.3[1.7 .73 .1]$ | $3.1\left[\begin{array}{ll} {[2.4586} \\ 10.0] \end{array}\right.$ | $3.7\left[\begin{array}{ll} {[1.971)} \\ 4.7] \end{array}\right.$ | $3.8\left[\begin{array}{l} {[3.0372} \\ 1.34] \\ 4.9] \end{array}\right.$ | $4.1\left[\begin{array}{c} {[3.2 ; 55.2]} \\ (1,05) \end{array}\right.$ | $4.1\left[\begin{array}{l} {[3255} \\ \mid i 25 \\ 5.2] \end{array}\right.$ | $\left.4.1 \begin{array}{c} {[3.2 ; 56} \\ (336 \\ 5 \end{array}\right)$ | $4.1\left[\begin{array}{l} {[3,2 ; 5)^{(9.2]}} \end{array}\right.$ |
| INNEX CR (Zimmer Biomet) | Innex Fix (Zimmer Biomet) | 1,271 | 27 | $73{ }_{(65-78)}$ | 41/59 | 2013-2022 | $2.0[1.3 .32 .9]$ | $2.5[1.8 .83 .3]$ | $2.7[1.953 .3 .9]$ | $3.0[2.1 .1 ; 4.2]$ | $3.2\left[\begin{array}{l} {[2.3 ; 5 ; 4.4]} \\ {[4 / 7)} \end{array}\right.$ | $3.2\left[\begin{array}{l} {[2.3 ; 4.4]} \\ \mid 267) \end{array}\right.$ | $3.2\left[\begin{array}{l} {[2.350} \\ (130) \\ 4.4] \\ \hline \end{array}\right.$ |  |
| INNEX CR GSF (Zimmer Biomet) | Innex Fix (Zimmer Biomet) | 360 | 18 | $73{ }_{(65-78)}$ | 18/82 | 2013-2022 | $1.7\left[\begin{array}{l} {[0.828]} \\ \hline 12.7] \\ \hline \end{array}\right.$ | $2.3\left[\begin{array}{c} 12,2 ; 4 ; 4.5] \\ (12) \end{array}\right.$ | $3.0[1.6 ; 5.5]$ | $3.0[1.6 ; 5.5]$ | $3.0[1,6 \cdot 5.5]$ | 3.8[2.0; 8 (80) 7.0$]$ |  |  |
| JOURNEY II CR COCR (Smith \& Nephew) | JOURNEY (Smith \& Nephew) | 368 | 14 | $71_{(62-77)}$ | 37/63 | 2018-2022 | 2.0 [1.0; 48.4 .2$]$ | $3.3\left[\begin{array}{c} 1.8202 \\ (202) \end{array}\right)$ | $4.6[2.5 ; 8.8 .3]$ |  |  |  |  |  |
| JOURNEY II CR OXINIUM (Smith \& Nephew) | JOURNEY (Smith \& Nephew) | 1,029 | 28 | $64_{(58-72)}$ | 36/64 | 2015-2022 | $3.0\left[\begin{array}{c} (2.1,14)^{(9.2]} \\ 4.2] \end{array}\right.$ | $4.1 \begin{gathered} {[3559} \\ (350) \\ \hline \end{gathered}$ |  | $6.2\left[\begin{array}{c} {[586]} \\ (530 \\ \hline \end{array}\right.$ | $\left.6.4\left[\begin{array}{l} {[2535} \end{array}\right) 8.2\right]$ | $7.3[5.2 ; \text {; 10.1] }$ |  |  |
| LEGION CR COCR (Smith \& Nephew) | Genesis II (Smith \& Nephew) | 11,776 | 136 | $71_{(63-77)}$ | 38/62 | 2014-2022 | $1.6[1.4 ; 4.9]$ | $2.4\left[\begin{array}{ll} {[2.1,78)} & 2.7] \\ \hline(2.7] \end{array}\right.$ | $2.8\left[\begin{array}{ll} {[2,583} \\ \hline, 53.2] \\ 3.2] \end{array}\right.$ | $\left.3.1\left[\begin{array}{c} {[2,8 ; 50} \\ (2,50 \end{array}\right] .5\right]$ | $\begin{gathered} 3.3[(2,9 ; 35) \\ {[1.8]} \\ \hline \end{gathered}$ | $3.3\left[\begin{array}{l} {[2.93 i)} \\ \mid 2.8] \end{array}\right.$ |  |  |
| LEGION CR OXINIUM (Smith \& Nephew) | Genesis II (Smith \& Nephew) | 2,991 | 144 | $64_{(58-72)}$ | 16/84 | 2012-2022 | $1.6[1.2 ; 2.21]$ | $\underset{(1.501)}{2.7 .7]}$ |  | $3.7 \underset{(1607)}{[2.9 ; 4]}$ | $\underset{\substack{1285 \\[2.9 ; 4.6]}}{3}$ | $3.7\left[\begin{array}{l} (9.9 ;) \\ \hline 9.6] \\ \hline \end{array}\right.$ |  |  |
| LEGION PS COCR (Smith \& Nephew) | Genesis II (Smith \& Nephew) | 890 | 49 | $72{ }_{(63-79)}$ | 25/75 | 2015-2022 | $1.1\left[\begin{array}{c} {[0.6 ; 2} \\ {[350} \\ 2.3] \end{array}\right.$ | $2.1\left[\begin{array}{l} {[1.2 ; 3.3]} \\ \mid 261 \end{array}\right.$ | $3.1[1,7.75 .7]$ | $3.1\left[1.77{ }^{(i 0)} 5.7\right]$ |  |  |  |  |
| NexGen CR-Flex-Gender (Zimmer Biomet) | NexGen CR (Zimmer Biomet) | 4.944 | 103 | $70_{(62-76)}$ | 10/90 | 2012-2022 | $0.9\left[\begin{array}{l} {[0.7,7,1.2]} \\ 4,262) \end{array}\right.$ | $1.6[1.3 ; 2.0]$ | $1.8\left[\begin{array}{l} 1.5 .52 .3] \\ (2.34) \\ 2.3] \end{array}\right.$ | $\left.2.0 \begin{array}{l} 1.6 ; 62.5] \\ (2.270 \end{array}\right)$ | $\begin{gathered} 2.3[1.9 ; 2.8] \\ (1.52 i) \end{gathered}$ | $2.4\left[\begin{array}{c} 1.9,9 ; 0.0] \\ (9,4) \\ 3.0 \end{array}\right.$ | $2.5\left[\begin{array}{l} {[5.56]} \\ \hline 3.2] \\ \hline \end{array}\right.$ |  |
| NexGen CR-Flex (Zimmer Biomet) | NexGen CR (Zimmer Biomet) | 17,062 | 124 | $72_{(64-78)}$ | 42/58 | 2012-2022 | $1.4[1.2 ; 1.6]$ | $1.9[1.7 .7 ; 2.1]$ | $2.1\left[\begin{array}{c} 1.9 .92 .24] \\ \hline 9.640) \end{array}\right.$ | $2.4\left[\begin{array}{l} {[2.1,2 ; 5)} \\ 20.7] \end{array}\right.$ | $2.5\left[\begin{array}{l} {[2.2 ; 23)} \\ \langle 2.8] \\ \hline \end{array}\right.$ | $2.6\left[\begin{array}{ll} {[2.35 i)} \\ (2.9) \\ 2.9] \end{array}\right.$ | $2.7\left[\begin{array}{l} {[2.43 ; 53)} \\ \hline(0)] \end{array}\right.$ |  |
| NexGen CR (Zimmer Biomet) | NexGen CR (Zimmer Biomet) | 3,685 | 57 | $70{ }_{(63-76)}$ | 42/58 | 2013-2022 | $1.11\left[\begin{array}{l} {[0.8,113} \\ \hline 3.13 \\ 1.5] \end{array}\right.$ | $1.8[1.4 ; 2.2]$ | $2.3\left[\begin{array}{c} 1.84 ; 2.9] \\ (1.46) \end{array}\right.$ | $2.9\left[\begin{array}{l} {[2.303,3.5]} \\ {[2.009} \end{array}\right.$ | $3.0\left[\begin{array}{l} {[2.4 ; 42 ; 3]} \\ (k, 72) \end{array}\right.$ | $3.3[2.6 ; 4.0]$ | $\left.3.6{ }_{(5551}^{[2.9 ;} 4.5\right]$ | $3.9[3.0 ; 4.9]$ |
| Persona CR (Zimmer Biomet) | Persona Tibia (Zimmer Biomet) | 6,103 | 103 | $6_{(62-77)}$ | 40/60 | 2013-2022 | $1.0\left[\begin{array}{l} {[0.87 \%} \\ 4.179 \end{array} 1.3\right]$ | $1.4[1.1 ; 1.8]$ | $1.5\left[\begin{array}{l} {[1.2011)} \\ {[2.0]} \end{array}\right.$ | $1.9[1.5 ; 2.4]$ | $2.0[1.5 ; 2.5]$ | $2.2\left[\begin{array}{c} 1.69 ; \\ (299) \end{array}\right.$ | $2.2[11.6 ; 2.9]$ |  |
| SIGMA ${ }^{\text {TM }}$ Femur ( (ePuy) | SIGMA ${ }^{\text {TM Tibia ( }}$ (ePuy) | 23,480 | 135 | $71{ }_{(63-77)}$ | 36/64 | 2012-2022 | $\begin{aligned} & 1.3[1,2 ; 2 ; 1.4] \\ & (1,924) \end{aligned}$ | $2.11[1.9 ; 2.2]$ | $2.5\left[\begin{array}{ll} {[12.3,322)} \\ 1,8] \end{array}\right.$ | $2.8\left[\begin{array}{ll} {[2.658,3.1]} \\ \hline(0.95) \end{array}\right.$ | $3.0[2,8 ; 8.3]$ | $3.2{ }_{\left[\frac{12.398}{[29.9} 3\right.}^{3.5]}$ | $\begin{gathered} 3.3\left[\begin{array}{l} {[3.0 ; 53} \\ (1.55] \end{array}\right] \end{gathered}$ | $3.6[3.1 .74 .1]$ |
| TC-PLUS CR (Smith \& Nephew) | TC-PLUS (Smith \& Nephew) | 3,949 | 42 | $71_{(66-78)}$ | 36/64 | 2014-2022 | $1.0 \begin{gathered} \substack{(3.7 .708 \\ 1308} \\ 1.3] \end{gathered}$ | $1.4\left[\begin{array}{c} {[1,1.1641 .8]} \\ \hline(2) \end{array}\right.$ | $1.6[1.2 .2 .20] 2.0]$ | $1.9[1.5 \cdot 2.2]$ | $1.9[1.53 ; 2.4]$ | $1.9[1.5 ; 2.4]$ | $1.9\left[1 . 5 \left[_{(95)^{2}}^{2.4]}\right.\right.$ |  |
| Triathlon CR (Stryker) | Triathlon (Stryker) | 8,322 | 80 | $70_{(63-77)}$ | $37 / 63$ | 2013-2022 | $1.6[1.3 ; 1.9]$ | $2.6[2.2 ; 3 ; 3]$ | $3.1\left[\begin{array}{l} {[2.7 .73 .5]} \\ {[4.56} \end{array}\right.$ |  | $3.6\left[\begin{array}{l} {[3.12 ; 1 ; 4]} \end{array}\right.$ |  | $3.9\left[\begin{array}{c} {[3.4 ; 9 ; 4} \\ (54) \\ \hline \end{array}\right.$ |  |
| Vanguard CR (Zimmer Biomet) | Vanguard Tibia Cruciate <br> (Zimmer Biomet) | 11,741 | 79 | $72(64-77)$ | $37 / 63$ | 2012-2022 | ${ }_{\substack{\text { a } \\ \text { 9.55i) }}}^{1.80}$ |  | ${ }_{3.0}^{[2.6 .646]}$ 3.3] |  | $\left.{ }_{3.6}^{[2.92635} 4.0\right]$ | $3.7\left[\begin{array}{l} {[1.3,35)} \\ (1.1)] \end{array}\right.$ |  |  |

Table 49 (continued)

| Knee arthroplasties without primary patellar resurfacing |  | Number | Hosp. | Age | m/f | Period | Revision probabilities after ... |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Femoral component | Tibial component |  |  |  |  |  | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Standard TKA, cruciate-retaining, fixed bearing, cemented |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Vanguard CR TiNbN (Zimmer Biomet) | Vanguard Tibia TiNbN (Zimmer Biomet) | 1,151 | 68 | $65_{(58-72)}$ | $8 / 92$ | 2013-2022 | $\left.1.4{\underset{c}{9955}}_{[0.8 ;} ; 2.2\right]$ |  | $4.1{\underset{[1523}{[3.0 ;} 5.5 .6]}^{(5)}$ | $4.5\left[\frac{3.36 \cdot 3.1]}{(3,6)}\right.$ | $4.8\left[\begin{array}{l} {[1977} \\ \hline 1.5 ; 6] \\ \hline \end{array}\right.$ | ${ }_{\substack{\text { a } \\ 4.8[3.55] \\ 10.5]}}$ |  |  |
| Standard TKA, cruciate-retaining, mobile bearing, hybrid |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| TC-PLUS CR (Smith \& Nephew) | TC-PLUS SB (Smith \& Nephew) | 477 | 7 | $69_{(61-76)}$ | 35/65 | 2015-2022 | $2.9[1.7064 .9]$ | $4.4\left[\begin{array}{l} {[3,86} \\ {[8 ; 6} \\ \hline 6.7] \\ \hline \end{array}\right.$ | $4.6\left[\begin{array}{l} {[320 ;} \\ \hline 120 \end{array}\right)$ | $\left.5.3\left[\begin{array}{c} {[3.58]} \\ {[289} \\ 7 \end{array}\right] .9\right]$ | $5.3\left[\begin{array}{l} {[3.56} \\ (264 \\ 7.9] \\ \hline \end{array}\right.$ | $5.3[3.5 \cdot 7.9]$ |  |  |
| Standard TKA, cruciate-retaining, mobile bearing, cemented |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| ACS cemented (Implantcast) | ACS MB cemented (Implantcast) | 796 | 22 | $70_{(62-77)}$ | 30/70 | 2013-2022 | $\begin{gathered} 1.8[1.1,3.1] \\ (100) \end{gathered}$ | $3.5\left[\begin{array}{c}\text { (12.39) } \\ \text { (by } \\ 5.3] \\ \hline\end{array}\right.$ | $3.7\left[\begin{array}{l} \left.[2.57)^{5} 5.6\right] \end{array}\right.$ | $4.8\left[\begin{array}{c} 13.386 \\ 1296 \\ 7 \end{array}\right.$ | $4.8\left[\begin{array}{l} \text { [3044 } 3 ; 7.1] \\ 104 \end{array}\right.$ | $5.4\left[\begin{array}{l} 3.6 .67 .9] \\ 1166 \end{array}\right]$ |  |  |
| COLUMBUS (Aesculap) | COLUMBUS (Aesculap) | 2,525 | 25 | $71{ }_{(63-77)}$ | $36 / 64$ | 2013-2022 | $1.6[1.2 ; 2.2]$ | $\left.2.1\left[\begin{array}{c} {[1,699} \\ (1,69 \end{array}\right) .8\right]$ | $2.4[1.9 ; 3 ; 2]$ | $2.6\left[\begin{array}{ll} {[1.0066} \\ 3.3] \end{array}\right.$ | $2.7 \underset{\substack{\left.[2,1 ;)^{2} ; 3.4\right] \\ \hline}}{ }$ | $2.7 \underset{(4266}{[2.1 ; 3.4]}$ | $2.7\left[\begin{array}{l} [2.17) ; 3.4] \\ (12) \end{array}\right.$ |  |
| INNEX CR (Zimmer Biomet) | Innex Mobile (Zimmer Biomet) | 1,288 | 65 | $70{ }_{(62-77)}$ | 97/3 | 2013-2022 | $1.8[1.2 ; 2.7]$ | $2.6[1.903 .7]$ | $3.0[(2,1 ; 3 ; 4.1]$ | $3.5[2.5 ; 4.8]$ | $3.8\left[\frac{2.855}{(435)} 5\right.$ | $4.3\left[\begin{array}{l} {[3.1 ; 66} \\ 1236 \\ \hline 6.0] \\ \hline \end{array}\right.$ | $4.3[3.1 ; 7.0]$ |  |
| INNEX CR GSF (Zimmer Biomet) | Innex Mobile (Zimmer Biomet) | 348 | 33 | $70{ }_{(63-76)}$ | 82/18 | 2014-2022 | $2.1[1.0 ; 4.3]$ | $3.1[1.7 ; 5.8]$ | $3.6[(1.044) 66.5]$ | $3.6[2.0 .06 .5]$ | $4.3[2.4 ; 7,7.7]$ |  |  |  |
| NexGen CR-Flex (Zimmer Biomet) | NexGen CR (Zimmer Biomet) | 596 | 9 | $71_{(64-76)}$ | 42/58 | 2013-2022 | $0.5\left[\begin{array}{l} {[0.28} \\ {[58)} \\ ; 1.6] \\ \hline \end{array}\right.$ | $0.9[0.4 ; 5 ; 2.2]$ | $1.8[1.0 .03 .5]$ | $2.9[1.7 .75 .50]$ | $2.9[1.775 .0]$ | $2.9\left[1.77{ }_{(1 ; 8)} 5.0\right]$ | $2.9[1.7750 .0]$ |  |
| TC-PLUS CR (Smith \& Nephew) | TC-PLUS SB (Smith \& Nephew) | 405 | 11 | $71{ }_{(63-77)}$ | 30/70 | 2015-2022 | $3.0[1.7855 .2]$ | $3.2 \underset{\substack{13,93 \\[1.9: 5]}}{ }$ | $\left.4.4\left[\begin{array}{l} {[283 ;} \end{array}\right] .0\right]$ | $4.8\left[\begin{array}{l} {[3,0 ; 7} \\ {[297} \end{array} 7.5\right]$ | $4.8[3.0 ; 7.5]$ | 4.8 [ [3.0; 797.5$]$ |  |  |
| ZEN Femur STD zementiert (OHST Medizintechnik) | ZEN Tibia STD zementiert (OHST Medizintechnik) | 858 | 6 | $71{ }_{(65-78)}$ | 35/65 | 2015-2022 | $1.0 \underset{(0.52 ;)}{ } ; 2.0]$ | $\left.1.2\left[\begin{array}{c} {[0.600} \\ (50) \\ 2 \end{array}\right) .3\right]$ | $\underset{\substack{1884}}{1.8} \mathbf{( 1 . 0 ;} 3.2]$ | $2.1\left[\begin{array}{c} 12,2 ; 4] \\ (124) \\ \hline \end{array}\right.$ | $2.1\left[\begin{array}{ll} \left.[1.2 ;)^{3} 3.8\right] \\ (10) \end{array}\right.$ |  |  |  |
| Standard TKA, cruciate-retaining/sacrificing, fixed bearing, hybrid |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| BPK-S Integration (Peter Brehm) | bPK-S Integration (Peter Brehm) | 380 | 3 | $69_{(62-76)}$ | $36 / 64$ | 2016-2022 | $1.5\left[\begin{array}{c} {[0.6 ; 3.5]} \\ (316) \end{array}\right.$ | $2.5[1.2 ; 4.9]$ | $4.0\left[\begin{array}{l} {[2.3 ; 6} \\ {[160} \end{array}\right.$ | $4.6[2.7 .78 .0]$ |  |  |  |  |
| Standard TKA, cruciate-retaining/sacrificing, fixed bearing, cemented |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| ATTUNE ${ }^{\text {TM }}$ Femur (DePuy) | ATTUNETM Tibia (DePuy) | 7,186 | 119 | $67_{(60-75)}$ | $39 / 61$ | 2013-2022 |  | $\left.2.5\left[\begin{array}{l} {[4.1660} \end{array}\right] .0\right]$ |  | $3.3\left[\begin{array}{l} {[2,9292]} \\ {[2.9]} \end{array}\right.$ | $3.5\left[\begin{array}{l} 1.098 \\ {[.58]} \end{array}\right.$ | $\underset{(8441)}{3.6} 3$ | $\underset{(387)}{3.6[3.2]}$ | $3.6\left[\begin{array}{c} (3,7) ; 1.2] \\ (1,2) \\ 4.2] \end{array}\right.$ |
| SIGMA ${ }^{\text {TM }}$ Femur (DePuy) | SIGMA ${ }^{\text {am Tibia ( }}$ (ePuy) | 2,066 | 23 | $69_{(61-76)}$ | 35/65 | 2015-2022 | $1.4[1.0 ; 2.0]$ | $2.0[1.5 ; 2.8]$ | $2.5\left[\begin{array}{l} (1,0 ; 52]) \\ (1.3] \end{array}\right.$ | $2.5[1.8 ; 3.3]$ | $2.6 \underset{(135 j)}{[1.9 ; 3.6]}$ | $3.2[2.2,2 ; 4.5]$ |  |  |
| Unity CR cmtd (Corin) | Unity cmtd (Corin) | 587 | 15 | $73_{(65-78)}$ | $29 / 71$ | 2014-2022 | $1.2[0.5 ; 2.6]$ | $2.2[1.2 ; 4.2]$ | $3.4\left[\begin{array}{l\|l\|l\|l\|} {[2.03} \\ \hline \end{array}\right.$ | $3.4\left[\begin{array}{l} {[2.0 ; 9 ; 9} \\ (2.8] \end{array}\right.$ | $3.8[2.3 ; 6.3]$ | $3.8\left[\begin{array}{c} {[2.3 ; 7)} \\ (103) \\ \hline \end{array}\right.$ | $3.8[2.3 ; 6.3]$ |  |
| Standard TKA, cruciate-retaining/sacrificiing, mobile bearing, hybrid |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| LCS $^{\text {TM }}$ COMPLETETM Femur (DePuy) | MBT Tibia (DePuy) | 2,967 | 35 | $70_{(62-77)}$ | 35/65 | 2012-2022 | $2.5\left[\begin{array}{l} {[2,0 ; 84]} \\ (2.1] \end{array}\right.$ | $3.4\left[\begin{array}{l} {[2.8564} \\ {[2.59} \end{array}\right.$ | $4.1\left[\begin{array}{c} {[3.4 ; 204} \\ {[2,9]} \end{array}\right.$ | $4.4\left[\begin{array}{ll} {[3.7 .703} \\ 10.3] \\ 5.3] \end{array}\right.$ | $4.6\left[\begin{array}{l} {[3,8,85} \\ \hline(5) .4] \\ 5.4] \end{array}\right.$ | $4.7 \underset{(3637}{[3.9 ; 5]}$ | $\left.5.0\left[\begin{array}{c} {[4.1 ; 34} \\ (234 \end{array}\right) ; .2\right]$ | $5.0[4.1,7 ; 6.2]$ |
| Standard TKA, cruciate-retaining/sacrificing, mobile bearing, uncemented |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| ATTUNE ${ }^{\text {TM }}$ Femur (DePuy) | ATTUNETM Tibia RP zementfrei (DePuy) | 575 | 12 | $66_{(59-73)}$ | $39 / 61$ | 2017-2022 | $0.9\left[\begin{array}{c} {[.474 ;} \\ (274 \end{array}\right)$ | $1.4\left[\begin{array}{c} {[0.6 ; 3.2]} \\ (9,1) \end{array}\right.$ |  |  |  |  |  |  |
| LCS $^{\text {TM }}$ COMPLETETM Femur (DePuy) | LCS ${ }^{\text {TM }}$ COMPLETETM Tibia (DePuy) | 653 | 76 | $64_{(58-73)}$ | 7/93 | 2014-2022 | $2.3 \underset{(1547)}{[1.3 ; 3]}$ | $4.1\left[\begin{array}{l} {[2.8 ; 0 ; 6.1]} \\ \hline \text { an } \end{array}\right.$ | $5.3 \underset{(30) 7}{5 \cdot 7.5]}$ | $5.5\left[\begin{array}{l} {[3,973.9} \\ l .8] \end{array}\right.$ | $5.5\left[\begin{array}{l} [3.9 ; 7) 7.8] \\ \hline(1) \end{array}\right.$ | $5.5\left[\begin{array}{l} (3 ; 9) \\ \hline 7.8] \end{array}\right.$ |  |  |
| LCS $^{\text {TM }}$ COMPLETETM Femur (DePuy) | MBT Tibia (DePuy) | 1,224 | 23 | $700_{(61-76)}$ | 36/64 | 2012-2022 | $1.5\left[\begin{array}{ll} {[0.9783)} \\ (0,3) \\ 2.3] \end{array}\right.$ | $2.7 \underset{(1,9 i 1 i)}{[3.7]}$ | $\left.3.4{ }_{(9952)}^{[2.5 ;} 4.6\right]$ | $3.7\left[\begin{array}{c} {[2,85)} \\ \hline 10.0] \end{array}\right.$ | $3.7\left[\begin{array}{l} {[2.83} \\ {[53} \end{array}\right)$ | $3.7 \underset{(322)}{[2.8 ;} 5.0]$ | $3.7\left[\begin{array}{l} (2,8 i j \\ (13 i) \\ 5.0] \end{array}\right.$ | $3.7\left[\begin{array}{l} \left.[2,80)_{(20)} 5.0\right] \\ \hline \end{array}\right.$ |
| SCORE (Amplitude) | SCORE (Amplitude) | 554 | 5 | $69_{(62-77)}$ | 32/68 | 2015-2022 | $1.2\left[\begin{array}{c} {\left[0.500^{2}\right.} \\ (4.6] \\ \hline \end{array}\right.$ | $1.9 \underset{(1346)}{[1.0 ;} 3.6]$ | $2.6[1.4 ; 4.77]$ | $2.6[1.4,4.7]$ | $2.6[1.4 ; 4.7]$ |  |  |  |
| Standard TKA, cruciate-retaining/sacrificing, mobile bearing, cemented |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| ATTUNE ${ }^{\text {TM }}$ Femur (DePuy) | ATTUNE ${ }^{\text {TM }}$ Tibia ( ${ }^{\text {dePuy }}$ | 2,022 | 29 | ${ }^{69}{ }_{(62-75)}$ | $37 / 63$ | 2015-2022 | $\begin{gathered} 1.8[1.3 ; 2.5] \\ (1.512) \end{gathered}$ | $2.4[1.7 ; 3.2]$ | $2.8\left[\begin{array}{l} {[298)} \\ \hline 1.1 ; 3] \end{array}\right.$ | $3.2\left[\begin{array}{l} {[2.455} \\ \hline \end{array}\right.$ | $3.2[2.4 ; 4.3]$ | $3.2[2.4 ; 4.3]$ | $3.2[2.4,4 ; 4.3]$ |  |
| E.MOTION (Aesculap) | E.MOTION (Aesculap) | 10,626 | 87 | 70 (62-77) | 34166 | 2012-2022 | $1.9[1.7 ; 2.2]$ | $3.2\left[\begin{array}{l}{[2,47\rangle} \\ \hline 2.8 .6]\end{array}\right.$ |  |  | $4.4\left[\begin{array}{l}{[3,999}\end{array}\right.$ |  |  |  |

Table 49 (continued)

| Knee arthroplasties without primary patellar resurfacing |  | Number | Hosp. | Age | m/f | Period | Revision probabilities after ... |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Femoral component | Tibial component |  |  |  |  |  | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Standard TKA, cruciate-retaining/sacrificiing, mobile bearing, cemented |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| LCS $^{\text {TM }}$ COMPLETETM ${ }^{\text {Femur ( }}$ ( dePuy) $^{\text {a }}$ | MBT Tibia (DePuy) | 5,188 | 58 | $72_{(64-77)}$ | $36 / 64$ | 2013-2022 | $2.1[1,8 ; 2.5]$ | $3.1\left[\begin{array}{l} {[2.7 .72 .3 .6]} \\ 4.550 \end{array}\right.$ | $3.6[3.1 ; 4.1]$ | $3.9[3.4 .4,4.5]$ | $4.1\left[\begin{array}{l} {[3.623) 3} \\ \hline(4.8] \end{array}\right.$ | $4.3[3.7 .74 .4]$ | $4.6[4.0 ; 5.54]$ | $4.6[4.0 \cdot 5.5]$ |
| SCORE (Amplitude) | SCORE (Amplitude) | 322 | 7 | $72_{(62-77)}$ | 30/70 | 2014-2022 | $1.9\left[\begin{array}{c} {[0.86]^{306}} \\ 4.1] \end{array}\right.$ | $3.2\left[\begin{array}{c} 1.8 .853 .5] \\ {[273} \end{array}\right.$ |  | $5.1\left[\begin{array}{l} {[3.0 ; 0.8 .5]} \\ \text { U100 } \end{array}\right.$ | $5.1[3.0: 8.5]$ | $6.5[3.6 \cdot 6 ; 11.7]$ |  |  |
| SIGMA'M Femur (DePuy) | MBT Tibia (DePuy) | 2,081 | 29 | $72(64-78)$ | $37 / 63$ | 2013-2022 | $\underset{[1.920}{2.6} \mathbf{2 . 3 ]}$ | $3.2\left[\begin{array}{ll} {[1.594)} \\ 4.1] \end{array}\right.$ | $4.0\left[\begin{array}{l} {[3.23 ; 5)} \\ (1.2) \\ \hline \end{array}\right.$ | $4.3\left[\begin{array}{c} \text { Bi46) } \\ \text { B6t } \\ 5.3 .3] \\ \hline \end{array}\right.$ | $4.3\left[\begin{array}{c} (3,44 ; \\ (54.3] \\ \hline \end{array}\right.$ | $4.3\left[\begin{array}{c} 3.4 ; 4 ; 5 \\ 1200 \\ \hline \end{array}\right.$ | $\left.4.3[3.45]^{(5)} 5.3\right]$ |  |
| Standard TKA cruciate-sacrificing, fixed bearing, hybrid |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| balanSys BICONDYLAR uncem. (Mathys) | balanSys BICONDYLAR fix (Mathys) | 1,078 | 9 | 70 (63-77) | 44/56 | 2013-2022 | $2.4 \underset{(1,73)}{[1.73 .6]}$ | $3.5\left[\begin{array}{c} (2.6 ;) \\ (90 ;) \\ 4.8] \end{array}\right.$ |  | $4.0\left[\begin{array}{c} {[3,08]} \\ 4,085 \\ 5.5] \\ \hline \end{array}\right.$ | $4.3 \underset{(317)}{[3.1 ; 5.8]}$ | $4.3 \underset{\substack{3.1 .1 ; 5.5] \\ 157}}{ }$ | $4.3\left[\begin{array}{c} (3,7) ; 5.8] \\ (8)] \end{array}\right.$ |  |
| INNEX CR (Zimmer Biomet) | Innex Fix (Zimmer Biomet) | 313 | 4 | $711_{(64-76)}$ | 48/52 | 2014-2022 | $2.0\left[\begin{array}{c} {[0.9 ; 94} \\ (279 \end{array}\right]$ |  | $3.5\left[\begin{array}{ll} {[1.933} \\ {[13)^{6}} & 6.4] \end{array}\right.$ | $3.5[1.9 .96 .4]$ | $4.1 .1\left[\begin{array}{l} {[2 ; 3 ;} \\ {[9 ; 3]} \end{array}\right.$ | $\left.4.7{ }_{[123}^{[23}\right]^{[7.3]}$ |  |  |
| Standard TKA, cruciate-sacrificing, fixed bearing, cemented |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| balanSys BICONDYLAR cem. (Mathys) | balanSys BICONDYLAR fix (Mathys) | 2,181 | 28 | 70 (62-77) | $29 / 71$ | 2013-2022 |  | $2.9 \text { [2.2.23.7] }$ | $\underset{(639)^{2}}{3.6[2.7}$ | $4.1\left[\begin{array}{l} \left.[37.17)^{2} 5.3\right] \\ \hline \end{array}\right.$ | $\underset{(311)}{4.8[3.6 ; 6]}$ | $4.8[3(1,600 \cdot 6.3]$ | ${ }_{4}^{4.8[3.6 ; 6.3]}$ |  |
| COLUMBUS (Aesculap) | columbus (Aesculap) | 3,687 | 92 | $70_{(62-77)}$ | 27/73 | 2013-2022 | $2.2\left[\begin{array}{l} {[1.89 ; 3)} \\ (1.8] \end{array}\right.$ | $3.2\left[\begin{array}{l} {[2.6 ; 3 ; 3)} \\ (2.30) \end{array}\right.$ | $3.6\left[\begin{array}{c} {[3.84 ; 4)} \\ \hline(0.3] \end{array}\right.$ |  | $4.1\left[\begin{array}{l} {[3.505} \\ 1800 \\ 50 \end{array}\right.$ | $4.6[3.8 .8 .5 .6]$ | $5.2\left[\begin{array}{l} \text { 3.9.9; } \\ \text { (134) } \\ \hline .9] \end{array}\right.$ |  |
| INNEX CR (Zimmer Biomet) | Innex Fix (Zimmer Biomet) | 1,276 | 45 | $72_{(64-78)}$ | 40/60 | 2013-2022 | $1.0[0.5 ; 1.7]$ | $1.2\left[\begin{array}{ll} {[0.80} \\ (1.08) \\ 2.1] \end{array}\right.$ | $1.9[1.2 .2 ; 2.8]$ | $2.2[1.5: 3.3]$ |  | $3.2\left[\begin{array}{l}\left.\text { [20.2; } 4.7]^{20}\right]\end{array}\right.$ | $3.2[2.2 ; 4.7 .7]$ |  |
| INNEX CR GSF (Zimmer Biomet) | Innex Fix (Zimmer Biomet) | 719 | 34 | $72{ }_{(65-78)}$ | 20/80 | 2013-2022 | $\underset{\substack{\text { (6488) } \\ 2.6 ; 4]}}{ }$ | $3.1\left[\begin{array}{l} {[2.066} \\ \text { L56 } \\ 4.7] \end{array}\right.$ | $3.2\left[\begin{array}{l} {[2.1955} \\ (4.9] \\ \hline \end{array}\right.$ | $3.7\left[\begin{array}{l} {[2.5 ; 5 ; 5]} \\ (3,4] \end{array}\right.$ | $4.2\left[\begin{array}{l} {[2.9 ; 2 ; 6} \end{array}\right)$ | $4.2\left[\begin{array}{l} {[2.9 ; 9) 6} \\ (140) \\ \hline \end{array}\right.$ | $4.2[2.9 ; 6 ; 6]$ |  |
| Natural Knee NK II (Zimmer Biomet) | Natural Knee NK II (Zimmer Biomet) | 335 | 8 | $73_{(67-77)}$ | 28/72 | 2013-2017 |  |  | $3.0[1.6 ; 5.6]$ |  | $3.7\left[\begin{array}{l} {[2,195} \\ \hline 1.6] \end{array}\right.$ | $4.1\left[\begin{array}{l} {[2.42 ; 7} \\ {[12]} \end{array}\right]$ | $4.1\left[\begin{array}{l} {[(1,46 ;)} \\ \hline 7.0] \\ \hline \end{array}\right.$ | $4.1\left[\begin{array}{l} {[2.4 ; 7.0]} \\ (6) 1 \end{array}\right.$ |
| Persona CR (Zimmer Biomet) | Persona Tibia (Zimmer Biomet) | 4,726 | 90 | $69{ }_{(61-76)}$ | $37 / 63$ | 2013-2022 | $1.3 \underset{(1.995)}{[1.0 ;} 1.7]$ | $2.0\left[\begin{array}{c} {[1.6702 .5]} \\ (4,90) \end{array}\right.$ | $2.5\left[\begin{array}{ll} {[2.0515} \end{array} 3.2\right]$ |  | $3.0\left[\begin{array}{c} {[2.3 ; 3 ;} \\ \mid 461 \end{array}\right)$ | $3.3[2.5 ; 4.3]$ | $3.3[2.5 ; 4.3]$ |  |
| Triathlon CR (Stryker) | Triathlon (Stryker) | 1,870 | 26 | $69_{(61-77)}$ | 37/63 | 2014-2022 | $1.7\left[\begin{array}{l} {[1.2542 ; 2.4]} \\ (4,64) \end{array}\right.$ | $2.8$ | $3.4\left[\begin{array}{l\|l\|l\|l\|} {[18 ; 4]} \end{array}\right.$ | $3.5[2.75 ; 4.5]$ | $3.9\left[\begin{array}{l} {[3.0 ; 5} \\ (270) \\ 5.2] \\ \hline \end{array}\right.$ | 4.3 [3.2; $\left.{ }_{\text {(160) }} 5.9\right]$ |  |  |
| Vanguard CR (Zimmer Biomet) | Vanguard Tibia Cruciate (Zimmer Biomet) | 7,266 | 72 | $72_{(64-78)}$ | $33 / 67$ | 2013-2022 | $1.5(1.2 ; 1.8]$ | $2.2[1.9 .92 .6]$ | $2.7\left[\begin{array}{l} {[2.36 \cdot 36} \\ \hline 3.2] \end{array}\right.$ | $3.1\left[\begin{array}{l} {[2.7 .7 ; 7.3 .6]} \end{array}\right.$ | $3.2\left[\begin{array}{ll} {[1.857)} \\ 10.8] \end{array}\right.$ | $3.3\left[\begin{array}{l} {[8.98 ;} \\ \hline 8 ; 9] \end{array}\right.$ | $3.5\left[\begin{array}{l} {[3.971} \\ \hline 1.1] \end{array}\right.$ |  |
| Vanguard CR TiNbN (Zimmer Biomet) | Vanguard Tibia TiNbN (Zimmer Biomet) | 551 | 59 | $67_{(59-75)}$ | 6/94 | 2014-2022 | $1.1\left[\begin{array}{c} 0.52 \\ (429) \end{array} 2.5\right]$ | $2.4 \underset{(1.33)}{ } 2.4]$ | $3.0\left[\begin{array}{c} 1.7 .75 .5 .2] \\ k 253 \\ 5.2] \end{array}\right.$ | $3.9\left[\begin{array}{c} 2.3,3,6.6] \\ (160) \end{array}\right.$ | $3.9[2.3 ; 6.6]$ | $4.9\left[\begin{array}{l\|l\|l\|} (51)^{2} \\ 8.6] \\ \hline \end{array}\right.$ |  |  |
| Standard TKA, cruciate-sacrificing, mobile bearing, hybrid |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| balanSys BICONDYLAR uncem. (Mathys) | balanSys BICONDYLAR RP (Mathys) | 705 | 6 | $70_{(62-77)}$ | 40/60 | 2013-2022 | $1.0\left[\begin{array}{c} {[0.53 ;} \\ (63) \\ 2.1] \\ \hline \end{array}\right.$ | 2.6 [1.6; $(59.2]$ | $2.8\left[\begin{array}{c} \left.1.807)^{2} 4.4\right] \\ \hline \end{array}\right.$ |  |  | 3.4 [2.2; 5124.4$]$ | $3.4[2.20 .5 .4]$ |  |
| Standard TKA, cruciate-sacrificing, mobile bearing, cemented |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| COLUMBUS (Aesculap) | COLUMBUS (Aesculap) | 1,164 | 5 | $6^{69}{ }_{(62-76)}$ | 41/59 | 2014-2022 | $1.0\left[\begin{array}{c} {[0.59 ;} \\ (1.7] \end{array}\right.$ | $1.6\left[\begin{array}{c} 190 ; 0 \\ (190) \\ 2.6] \end{array}\right.$ | $1.9[1.3 .3 .3 .0]$ | $2.2\left[\begin{array}{c} 1.4 ; 3,3.3] \\ \mid 692) \end{array}\right.$ | $\underset{\substack{(555)}}{2.3 ; 3]}$ | $2.6 \underset{(1384)}{2.7 ; 3]}$ | $2.9{ }_{(1886}^{[1.9 ; ~ 4.4]}$ |  |
| INNEX CR (Zimmer Biomet) | Innex Mobile (Zimmer Biomet) | 5,006 | 67 | $73_{(65-78)}$ | 32/68 | 2012-2022 | $2.3\left[\begin{array}{c} (1.938) ; 2.8] \\ \hline(2) \end{array}\right.$ | $3.1 \underset{(3,883)}{[2.7} ; 3.7]$ | $3.8\left[\begin{array}{c} {[3,3,3 i 81} \\ \hline, 4.4] \end{array}\right.$ | $4.0\left[\begin{array}{l} {[3.5 ; 4.5]} \\ (k .49) \end{array}\right.$ | $\begin{gathered} 4.3\left[\begin{array}{l} 3.7 .7 ; 5.0] \\ (1.60) \end{array}\right) \end{gathered}$ | $4.5\left[\begin{array}{l} \text { [384j4, } 9.3] \\ 5 \end{array}\right.$ | $4.6\left[\begin{array}{l} {[2033} \\ \hline 103 \end{array}\right)$ |  |
| INNEX CR GSF (Zimmer Biomet) | Innex Mobile (Zimmer Biomet) | 4,092 | 62 | $72{ }_{(64-78)}$ | $19 / 81$ | 2013-2022 | $1.4 \underset{(1.1 .1 ; 3)}{[1.8]}$ | $2.0\left[\begin{array}{c} {[1.60,63)} \\ (3,5] \\ \hline \end{array}\right.$ | $2.3[1.9 .92 .9]$ | $2.5\left[\begin{array}{ll} {[2.00 .015} \\ (1.15] \end{array}\right]$ | $2.7\left[\begin{array}{l} {[2.2 ; 2 ; 3]} \\ (213) \\ \hline \end{array}\right.$ | $3.0\left[\begin{array}{l} {[2.40 ; 2 ; 7]} \\ (620) \end{array}\right.$ | $4.1\left[\begin{array}{l} {[2.949)} \\ (14.6] \end{array}\right.$ |  |
| Standard TKA, pivot, fixed bearing, cemented |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| ADVANCE ${ }^{\text {® }}$ (MicroPort) | ADVANCE® II (MicroPort) | 455 | 8 | $72(64-78)$ | 51/49 | 2014-2022 | $4.2\left[\begin{array}{c} {[4171} \\ \hline 1.7 \\ \hline \end{array}\right.$ |  | $5.7\left[\begin{array}{l} {[39.95} \\ {[8.4]} \end{array}\right.$ | $5.7\left[\begin{array}{l} {[3.923} \\ 123 \\ 8.4] \end{array}\right.$ | $6.8\left[\begin{array}{c} {[4.6: 6 \cdot 4} \\ \text { and } \\ \hline 10.0] \\ \hline \end{array}\right.$ | $6.8[4.6 ; 6 ; 10.0]$ |  |  |
| EVOLUTION* (MicroPort) | EVOLUTION* (MicroPort) | 1,908 | 24 | $69_{(61-76)}$ | $36 / 64$ | 2016-2022 | $1.0\left[\begin{array}{l} {[0.6 ; 21.6]} \\ (1.32) \end{array}\right.$ | $1.7\left(\begin{array}{ll} (1.1 .00) \\ (1.5) \\ 2.5] \end{array}\right.$ | $2.2\left[\begin{array}{c} \left.1.5 ; 5)^{(108}\right) \\ 3.2] \end{array}\right.$ | $2.4 \underset{\left.(1.67)^{2}, 5\right]}{[3.5]}$ | $2.4\left[\begin{array}{c} \left.(181)^{1.6 ;} 3.5\right] \\ \hline \end{array}\right.$ |  |  |  |
| GMK SPHERE (Medacta) | GMK (Medacta) | 1,707 | 35 | $69{ }_{(61-76)}$ | 42/58 | 2014-2022 | $2.0[1.4 ; 2 ; 9]$ | $2.5\left[\begin{array}{l} {[1,8 ; 8)} \\ (135] \\ 3 \end{array}\right.$ | $2.8\left[\begin{array}{l} {[2.03)} \\ (130) \\ 4.0] \end{array}\right.$ | $2.8\left[\begin{array}{l} {[2.051} \\ \hline 2.0 \\ 4.0] \end{array}\right.$ | $3.4[2.2 ; 5.3]$ |  |  |  |

Table 49 (continued)

| Knee arthroplasties without primary patellar resurfacing |  | Number | Hosp. | Age | m/f | Period | Revision probabilities after ... |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Femoral component | Tibial component |  |  |  |  |  | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Standard TKA, pivot, fixed bearing, cemented |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| GMK SPHERE (Medacta) | GMK SPHERE (Medacta) | 310 | 27 | $68{ }_{(62-76)}$ | 7/93 | 2015-2022 | $4.2\left[\begin{array}{c} {[2.3 ; 7.7 .6]} \\ (197 \end{array}\right.$ | $6.4[3.9 ; 10.5]$ |  |  |  |  |  |  |
| Legacy 3D Knee (Mathys) | Legacy 3D Knee (Mathys) | 1,566 | 21 | $71_{(63-77)}$ | 36/64 | 2014-2022 | $2.2\left[\begin{array}{l} {[1.6993} \\ 1.39 \end{array}\right)$ | $2.9\left[\begin{array}{l} {[2.2 ; 2 ; 3)} \\ (1.27) \end{array}\right.$ | $3.5[2.7 ; 4.64$ | $4.0\left[\begin{array}{c} (3,0 ; 8) \\ \hline(5.1] \end{array}\right.$ | $4.4\left[\begin{array}{l} {[3.4 ; 7)} \\ (5.6] \end{array}\right.$ | $4.7 \underset{(3448 ; 6 ; 6]}{[3.0]}$ | $4.7\left[\begin{array}{l} {[3,6 ; 3 ; 6} \\ \hline 10.0] \\ \hline \end{array}\right.$ |  |
| Persona CR (Zimmer Biomet) | Persona Tibia (Zimmer Biomet) | 1,660 | 20 | $70{ }_{(62-77)}$ | 40/60 | 2016-2022 | $1.3\left[\begin{array}{l} {[0.80)} \\ (9,2.1] \end{array}\right.$ | $1.9\left[\begin{array}{c} 1.2,2 ; 2.9] \\ \langle 49] \end{array}\right.$ | $2.1\left[\begin{array}{c} {[1.3 ; 3 ; 3]} \\ (181) \end{array}\right.$ | $2.1\left[\begin{array}{ll} {[1.3 ; 3.3]} \\ \text { (1in) } \end{array}\right.$ |  |  |  |  |
| PHYSICA KR FEMUR. CEMENTED (Lima) | PHYSICA SYSTEM TIBIA. CEMENTED (Lima) | 307 | 14 | $69_{(61-76)}$ | $39 / 61$ | 2015-2022 | $2.7\left[\begin{array}{c} 1.474 .4 .4] \\ 124 \\ 5.4] \end{array}\right.$ | $3.5\left[\begin{array}{c} 1.929 \\ 129) \end{array} 6.4\right]$ | $3.5\left[\begin{array}{c} (1,99) \\ (189) \\ 6.4] \\ \hline \end{array}\right.$ | $4.1\left[\begin{array}{c} (2,27) \\ \hline 147 \\ \hline \end{array}\right.$ | $4.1\left[\begin{array}{l} {[2.2 ; 8)} \\ \hline 1.3] \\ \hline \end{array}\right.$ |  |  |  |
| Standard TKA, posterior-stabilised, fixed bearing, cemented |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| ATTUNE ${ }^{\text {TM }}$ Femur (DePuy) | ATTUNETM Tibia (DePuy) | 3,079 | 91 | $71_{(62-78)}$ | 38/62 | 2013-2022 | $2.1[1.6 ; 2.7]$ | $3.1\left[\begin{array}{ll} {[2.553} \\ {[1.53)} \\ 3.9] \end{array}\right.$ | $3.4\left[\begin{array}{c} {[2.7 .722]} \\ 1.2] \\ \hline \end{array}\right.$ | $4.2\left[\begin{array}{l} {[3,3 ; 5 ;} \\ (i 51) \\ 5.2] \end{array}\right.$ | $4.7\left[\begin{array}{c} \left.[3.73]^{2} 5.9\right] \\ \hline 5 . \end{array}\right.$ | $4.9 \begin{gathered} {[3.9 ; 9 ; 3]} \\ \text { ki9 } \end{gathered}$ | $5.3[4.1 .16 .9]$ |  |
| balanSys BICONDYLAR PS cem. (Mathys) | balanSys BICONDYLAR fix (Mathys) | 1,371 | 26 | $71_{(64-78)}$ | 40/60 | 2013-2022 | $\begin{gathered} 2.0 \\ \text { (1.099) } 4 ; 3.0] \end{gathered}$ | $3.6[2.713 ; 4.9]$ | $\underset{(663)}{4.8[3.7 ; 6]}$ | $5.5[4.2 \cdot 7.7 .2]$ | $5.8\left[\begin{array}{c} {[2,52} \\ \hline, 7.6] \end{array}\right.$ | 5.8 [4.5; 7.6] |  |  |
| COLUMBUS (Aesculap) | COLUMBUS (Aesculap) | 572 | 40 | $699_{(62-76)}$ | 35/65 | 2013-2022 | $3.6[2.4 ; 5.5 .6]$ | $5.5\left[\begin{array}{l} {[3 / 9 ; 7)} \\ \hline(4.9] \end{array}\right.$ |  | $7.0\left[\begin{array}{c} {[5.0 ; 2} \\ (125) \\ 9.7] \end{array}\right.$ |  | $7.4 \text { [5.3; } 10.2]$ | $8.6[5.8 ; 12.8]$ |  |
| E.MOTION (Aesculap) | E.MOTION (Aesculap) | 2,597 | 39 | $6_{(62-76)}$ | 36/64 | 2012-2022 | $2.3\left[\begin{array}{l} {[1,8 ; 3 ; 30]} \\ k, 0] \end{array}\right.$ | $3.8\left[\begin{array}{l} {[3.1 .1,4.7]} \\ (x, 73) \end{array}\right.$ | $4.5\left[\begin{array}{l} [3.73 ; 5) .4] \\ (x, 32) \end{array}\right.$ | $5.1[4.2 ; 2 ; 6.2]$ | $5.2\left[\begin{array}{c} \left.[4.36)^{3}\right] \\ 6.3] \\ \hline \end{array}\right.$ | $5.8\left[\begin{array}{l} {[3.8 ; 7} \\ \hline 18) \\ 7.2] \end{array}\right.$ | $\left.5.8\left[\begin{array}{c} 4.8 ; 7 \\ (181) \end{array}\right] .2\right]$ |  |
| E.MOTION PS PRO (Aesculap) | E.MOTION (Aesculap) | 428 | 26 | $64_{\text {(57 - 73) }}$ | $19 / 81$ | 2015-2022 | $1.0\left[\begin{array}{l} {[0.40)} \\ \hline(50) \end{array} 2.7\right]$ | $3.5\left[\begin{array}{l} {[2000} \\ \hline 280 \\ 6.1] \end{array}\right.$ |  | $3.5[2.00 .6 .1]$ | $3.5[2.00 ; 6.1]$ |  |  |  |
| GEMINI SL Total Knee System, Femoral Component, Fixed Bearing PS, cemented (Waldemar Link) | GEMINI SL Total Knee System, Tibial Component, Fixed Bearing, cemented (Waldemar Link) | 1,203 | 22 | $71{ }_{(64-78)}$ | 36/64 | 2014-2022 | $2.0{ }_{\substack{\text { [1965) } \\ \text { (14. } 3.1]}}$ |  | $3.2\left[\begin{array}{l}\text { [20.35 } \\ \text { [65 } \\ 4.5]\end{array}\right.$ | 3.7 [2.660 5.3 ] | 4.8 [3.2; 71.29 | $4.8[3.257 .2]$ |  |  |
| GENESIS II PS COCR (Smith \& Nephew) | Genesis II (Smith \& Nephew) | 3,075 | 65 | $71_{(63-77)}$ | 36/64 | 2013-2022 | $2.6\left[\begin{array}{l} {[2.1655} \\ \hline 1.3] \\ \hline \end{array}\right.$ | $3.4\left[\begin{array}{ll} {[2.836} \\ {[.85} \end{array}\right)$ | $\left.{ }^{3.8}{ }_{\text {[13.2.23] }} 4.6\right]$ | $4.2\left[\begin{array}{l} {[1.5539} \\ \hline 1.530 \\ 5.0] \end{array}\right.$ | $\left.4.7{ }^{[13.9094} \mathbf{5} 5.6\right]$ | 5.1 [4.2; 4.65$)^{6.1]}$ | $\left.5.1[4.2 ; 8]^{6} 6.1\right]$ |  |
| GENESIS II PS OXINIUM (Smith \& Nephew) | Genesis II (Smith \& Nephew) | 616 | 54 | $64_{(58-72)}$ | 23/77 | 2013-2022 | $1.4 \underset{(1675)}{[0.7} \mathbf{2 . 9 ]}$ | $2.1\left[\begin{array}{c} 1388) \\ \hline(38) \\ 3.9] \end{array}\right.$ | $2.7 \underset{(138)}{21.5: 5]} 4.6]$ | $3.0\left[\begin{array}{c} 1.8,8.8 .1] \\ 1240 \end{array}\right)$ | $\left.3.0\left[\begin{array}{c} 1.88 \\ (180 j \end{array}\right) 5.1\right]$ | $3.6\left[\begin{array}{l} {[9717} \\ (9.7 \\ 6.1] \end{array}\right.$ |  |  |
| JOURNEY II BCS COCR (Smith \& Nephew) | JOURNEY (Smith \& Nephew) | 873 | 32 | $70_{(22-77)}$ | 42/58 | 2017-2022 | $2.4\left[\begin{array}{c} (1.524) \\ \hline .3 .7] \\ \hline \end{array}\right.$ | $3.4\left[\begin{array}{l} (2,39) \\ 5.1] \end{array}\right.$ | ${ }^{3.9}$ [2.7.74. 5.8$]$ | $4.6\left[\begin{array}{l} \text { (100) } \\ \text { (100 } \end{array} 7.1\right]$ |  |  |  |  |
| JOURNEY II BCS OXINIUM (Smith \& Nephew) | JOURNEY (Smith \& Nephew) | 1.441 | 36 | $68{ }_{(61-75)}$ | 32/68 | 2014-2022 | $3.5\left[\begin{array}{l} {[1.7254 .4]} \\ (1.7) \end{array}\right.$ | $4.8\left[\begin{array}{l} {[3.178)} \\ \hline(8) 6.0] \\ \hline \end{array}\right.$ | $5.2\left[\begin{array}{l} {[4.1 .160} \\ (6.5] \\ 6.5] \end{array}\right.$ | $5.5\left[\begin{array}{c} {[4 ; 4 ;\}} \\ (i, 6.9] \end{array}\right.$ | $6.0\left[\begin{array}{c} 4.87\rangle 7 \\ \langle 127 \end{array} 7.6\right]$ | $6.4(5.0 ; 8.0]$ |  |  |
| LEGION PS COCR (Smith \& Nephew) | Genesis II (Smith \& Nephew) | 6,767 | 113 | $70_{(62-77)}$ | 40/60 | 2014-2022 | $2.0\left[\begin{array}{l} [1.7085), 2.4] \\ \hline \end{array}\right.$ | $2.8\left[\begin{array}{l} (2.4475) \\ \hline \end{array}\right.$ | $3.3[2.8 ; 3.8]$ | $3.5\left[\begin{array}{ll} 13.0044 \\ \hline 1.1] \end{array}\right.$ | $3.7\left[\begin{array}{c} {[3.20,} \\ {[6.4]} \\ 4.4] \\ \hline \end{array}\right.$ | $4.2\left[\begin{array}{l} {[3.4 ; 9 ;} \\ {[3.2]} \\ \hline \end{array}\right.$ |  |  |
| LEGION PS OXINIUM (Smith \& Nephew) | Genesis II (Smith \& Nephew) | 1,913 | 112 | $66_{(59-74)}$ | 22/78 | 2012-2022 | $1.1\left[\begin{array}{c} {[0.7 ; 1.81 .8]} \\ (1,0) \end{array}\right.$ | $2.4\left[\begin{array}{c} {[1.8 .84} \\ (0.04 \\ 3.4] \\ \hline \end{array}\right.$ | $2.9{\underset{(122)}{[2.1 ; 4.0]}]}^{(2)}$ | $3.0\left[\begin{array}{l} (249) \\ \hline 2 ; 4.1] \\ \hline \end{array}\right.$ | $3.5\left[\begin{array}{c} (2.50) \\ (300) \\ 4.8] \\ \hline \end{array}\right.$ | $3.5{\underset{(1882}{ }[2.5 ; 4.8]}^{2}$ | $5.6 \underset{\left.(38)]^{2}, ~ 9.1\right]}{ }$ |  |
| NexGen LPS-Flex-Gender (Zimmer Biomet) | NexGen CR (Zimmer Biomet) | 3,537 | 82 | $69{ }_{(61-76)}$ | 9/91 | 2012-2022 | $\underset{\substack{1.004] \\(1.0]}}{1.8]}$ | $2.0[1.6 ; 62.5]$ | 2.5 [2.0.000 3.1] | $\underset{\substack{1.643}}{2.1 .13 .2]}$ | $2.7{ }_{(0.1023}^{[2 ; 3.4]}$ |  |  | $4.5[3.00 ; 6.8]$ |
| NexGen LPS-Flex (Zimmer Biomet) | NexGen CR (Zimmer Biomet) | 12,640 | 220 | $6^{69}{ }_{(61-76)}$ | 30/70 | 2012-2022 | $1.7[1.5 ; 2.0]$ | $2.7\left[\begin{array}{l} {[2.4 .4,30]} \\ (8,40) \end{array}\right.$ | $3.1\left[\begin{array}{l} {[6.873)} \\ {[3.5]} \\ \hline \end{array}\right.$ |  | $3.8\left[\begin{array}{c} {[3.4 .4: 4.2]} \\ (3) 2] \end{array}\right.$ | $4.0[3.5 ; 4.4]$ | $4.4\left[\begin{array}{l} {[3.8: 5 \cdot 5.0]} \\ \hline 104) \end{array}\right.$ | $4.7[4.0 .50 .5 .6]$ |
| NexGen LPS (Zimmer Biomet) | NexGen CR (Zimmer Biomet) | 9,566 | 36 | $6_{(62-76)}$ | 41/59 | 2012-2022 |  | $1.7\left[\begin{array}{c} [1.577), 2.0] \\ ([.87) \end{array}\right.$ | $2.1\left[\begin{array}{c} {[1.508)} \\ \hline(5) .4] \\ \hline 2.4] \end{array}\right.$ | $2.3\left[\begin{array}{l} {[2.0,2,2.6]} \\ \left.4,2)^{2}\right) \end{array}\right.$ | $2.4\left[\begin{array}{l} {[2.1,0924)} \\ {[2.8]} \\ \hline \end{array}\right.$ | $2.7 \begin{aligned} & {[2.3 ; 3 ; 1]} \\ & (2.03) \end{aligned}$ | $3.0\left[\begin{array}{l} [2.5 ; 9) 3.5] \\ (u, 09) \end{array}\right.$ | $\left.3.0\left[\begin{array}{l} {[2.54} \\ {[54)} \\ 3 \end{array}\right] .5\right]$ |
| Persona PS (Zimmer Biomet) | Persona Tibia (Zimmer Biomet) | 2,985 | 70 | $71_{(62-78)}$ | 37/63 | 2013-2022 | $2.3[1.8 ; 2.9]$ | $3.0\left[\begin{array}{l} {[2.4 ; 3.3]} \\ \text { undin) } \end{array}\right.$ | $3.8[3[.054 .8]$ | $3.8\left[\begin{array}{l} {[3.0 ; 7} \\ \langle .07) \\ 4.8] \end{array}\right.$ |  | $3.8\left[\begin{array}{l} (9.0) \\ \hline 95) \\ \hline \end{array}\right.$ |  |  |
| SIGMA ${ }^{\text {TM }}$ Femur (DePuy) | MBT Tibia (DePuy) | 657 | 40 | $73_{(66-79)}$ | 30/70 | 2014-2022 | $2.2[1.35 ; 3.7]$ | $3.2[2.0 ; 4.9]$ | $3.8[2.5 ; 5.8]$ | $4.1\left[\begin{array}{l} {[2.752 ;} \\ \mid 252] \end{array}\right.$ |  | $4.5[3.0 ; 6.8]$ |  |  |
| SIGMA ${ }^{\text {TM }}$ Femur (DePuy) | SIGMA ${ }^{\text {TM Tibia ( }}$ ( ${ }^{\text {a Puy }}$ ) | 3,343 | 107 | $71_{(64-78)}$ | 33/67 | 2013-2022 | $2.4\left[\begin{array}{c} {[1.9911} \\ (2.0) \\ 3 \end{array}\right.$ | $3.5\left[\begin{array}{l} {[2.975)} \\ {[2.2]} \\ 4.2] \end{array}\right.$ | $3.9[3.2 ; 4.6]$ | $4.8\left[\begin{array}{ll} 4.0 .554 \\ 10.54] \\ 5.6] \end{array}\right.$ | $5.0[4.2 ; 6.0]$ | $5.4[4.5 ; 6.4]$ | $5.6[4.77 ; 6.7]$ |  |
| Triathlon PS (Stryker) | Triathlon (Stryker) | 3,552 | 65 | $71_{(64-78)}$ | $36 / 64$ | 2013-2022 | $\left.2.5\left[\begin{array}{l} {[2.195 ;} \end{array}\right] .1\right]$ | $3.6[3.0 .0 ; 4.3]$ | $3.9[3.3 .3: 4.7]$ | $4.1\left[\begin{array}{l} {[3.5 \cdot 5 \cdot 5.0]} \\ (1,121) \end{array}\right.$ | $4.1\left[\begin{array}{l} {[5756} \\ 5.50] \\ 5.0] \end{array}\right.$ | $4.7\left[\begin{array}{c} {[3.755} \\ {[250} \\ 5.8] \end{array}\right.$ | $4.7\left[\begin{array}{l} \left.[3,70)^{5} 5.8\right] \\ \hline \end{array}\right.$ |  |
| Triathlon PS (Stryker) | Triathlon TS (Stryker) | 369 | 35 | $6^{69}(61-77)$ | $36 / 64$ | 2013-2022 | $2.9[1.6 ; 5.3]$ | $3.3[1.8: 5.9]$ | $3.3[1.8 .85 .9]$ | $4.2\left[\begin{array}{l} \left.[2,35)^{2} 7.7\right] \\ \hline(7) \end{array}\right.$ |  |  |  |  |
| Vanguard PS (Zimmer Biomet) | Vanguard Tibia Cruciate (Zimmer Biomet) | 2,680 | 47 | $72{ }_{(64-78)}$ | 35/65 | 2014-2022 | $2.7\left[\begin{array}{l} {[2.1 .55 j)} \\ \hline 1.4] \end{array}\right.$ | $4.0\left[\begin{array}{ll} {[3.3,3 ; 7)} \\ {[1.9]} \end{array}\right.$ | $\begin{gathered} 4.3[3.55 .5 .3] \\ (4.066) \end{gathered}$ | $5.0\left[\begin{array}{l} (670) \\ {[4.1]} \end{array}\right.$ | $5.3[4.3$ [21] 6.5$]$ |  | $5.3[4.3 ; 6.5]$ |  |

Table 49 (continued)

| Knee arthroplasties without primary patellar resurfacing |  | Number | Hosp. | Age | m/f | Period | Revision probabilities after ... |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Femoral component | Tibial component |  |  |  |  |  | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Standard TKA, posterior-stabilised, fixed bearing, cemented |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| VEGA (Aesculap) | VEGA (Aesculap) | 1,659 | 49 | $70_{(61-77)}$ | 31/69 | 2013-2022 | $1.5\left[\begin{array}{l} (1,2060 \\ (1,26) \end{array}\right)$ | $2.1\left[\begin{array}{ll} 1.4 .403 .0] \\ 10.006 \end{array}\right.$ | $3.7\left[\begin{array}{l} {[2,8 ; 2 ; 5} \\ (1,0] \end{array}\right.$ | $4.5\left[\begin{array}{l} {[3,47)} \\ \hline(6) \cdot 0] \\ \hline \end{array}\right.$ | $5.7\left[\begin{array}{l} {[3.3 ; 7)} \\ \hline(3) 7] \end{array}\right.$ | $7.3[5.3 ; 9.9]$ |  |  |
| Unicondylar knee arthroplasties, fixed bearing, cemented |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| balanSys UNI (Mathys) | balanSys UNI fix (Mathys) | 595 | 27 | $62_{(56-71)}$ | 50/50 | 2013-2022 | $3.1\left[\begin{array}{l} {[2,0 ; 4]} \\ 4.0] \\ \hline \end{array}\right.$ | $5.1 \begin{gathered} {[3.57)} \\ \hline 137 \\ 7.5] \\ \hline \end{gathered}$ | $6.8[4.9 ; 9 ; 9.5]$ | $7.1\left[\begin{array}{l} {[1299)} \\ (12.9] \\ \hline \end{array}\right.$ | $7.5[5.4 ; 10.4]$ | $8.2[5.8 ; 11.5]$ |  |  |
| JOURNEY UNI COCR (Smith \& Nephew) | JOURNEY UNI (Smith \& Nephew) | 1,266 | 81 | $63_{(57-70)}$ | 48/52 | 2014-2022 |  | $4.2\left[\begin{array}{c} (3,2 ;\rangle) \\ (i, 6] \\ 5.6] \end{array}\right.$ | $5.2[3.9 ; 6,6.8]$ | $5.6\left[\begin{array}{c} {[4.35]} \\ (825) \\ 7.4] \\ \hline \end{array}\right.$ | $7.7\left[\begin{array}{l} {[5.6 ;} \\ (18 i) \end{array} 10.4\right]$ | $7.7\left[5.6 ; \text { [8i) }_{\text {[8; }} 10.4\right]$ |  |  |
| JOURNEY UNI OXINIUM (Smith \& Nephew) | JOURNEY UNI (Smith \& Nephew) | 1,044 | 138 | $60_{(54-66)}$ | 32/68 | 2013-2022 | $4.8[3.6 ; 96]^{6.3]}$ | $7.5 \text { [5.9;9.5] }$ | $9.0\left[\begin{array}{c} {[7.2 ; 2)} \\ (i n 2) \end{array} 11.3\right]$ | $9.7\left[\begin{array}{c}{[7.8 ; 12.0]} \\ (3.5) \\ \hline\end{array}\right.$ | $11.2[8.99 ; 14.0]$ | $11.7\left[9.3 ;{ }_{(85)^{\prime}} 14.8\right]$ |  |  |
| LINK SLED (Waldemar Link) | Link SLED, All-Poly (Waldemar Link) | 725 | 32 | $64_{(56-73)}$ | 50/50 | 2013-2022 | $2.8[1.8 ; 4.3]$ | $6.2[4.5 \cdot 8.8]$ | $7.8\left[\begin{array}{l} {[5.909} \\ 4003 \end{array} 10.2\right]$ | $9.8[7.6 ; 12.7]$ | $10.9\left[\begin{array}{c} 8.4 ; 4 ; \\ (203) \\ 14.0] \end{array}\right.$ | $11.6[8.9215 .0]$ | $12.5\left[9\left(4 ; i_{i} ; 16.5\right]\right.$ |  |
| LINK SLED (Waldemar Link) | Link SLED, metal-backed (Waldemar Link) | 966 | 63 | $62_{(56-71)}$ | 43/57 | 2013-2022 | $\left.2.9\left[\begin{array}{l} {[200 ;} \end{array}\right) ; 4.3\right]$ | $6.6\left[\begin{array}{c} {[5.1 ; 8)} \\ {[58]} \\ 8.6] \end{array}\right.$ | $8.6\left[\begin{array}{c} {[6.8 ; 82)} \\ {[i 22)} \\ 11.0] \end{array}\right.$ | $10.3\left[\begin{array}{c} {[8.1 ; 1 ; 1} \\ (28) \\ 13.0] \end{array}\right.$ | $10.9[8.6 ; 6 ; 13.8]$ | $13.0[10.1 ; 16.6]$ |  |  |
| Mako MCK (Stryker) | Mako MCK (Stryker) | 707 | 15 | $62_{(57-69)}$ | 53/47 | 2017-2022 | $0.8\left[\begin{array}{l}{[0.355} \\ 1.9] \\ 1.9 \\ \hline\end{array}\right.$ | $1.4\left[\begin{array}{l} {[0.655} \\ {[2.0]} \\ 3.0] \\ \hline \end{array}\right.$ | $3.0[1.5 ; 6.0]$ |  |  |  |  |  |
| Oxford (Zimmer Biomet) | Oxford Fixed Lateral Tibia (Zimmer Biomet) | 952 | 52 | $71_{(61-78)}$ | 18/82 | 2015-2022 |  | $2.4[1.6 ; 3.7]$ |  | $3.9\left[\begin{array}{\|c\|c\|} {[2.6 ;} \\ 5.7] \\ \hline \end{array}\right.$ | $4.3[(1.94) ; 6.4]$ | ${ }^{4.3}[2.96 ; 6.4]$ |  |  |
| Persona Partial Knee (Zimmer Biomet) | Persona Partial Knee (Zimmer Biomet) | 3,406 | 102 | $63_{(57-71)}$ | 48/52 | 2017-2022 | $2.6\left[\begin{array}{l} {[2.0 ; 4)} \\ (2,24 \end{array}\right)$ |  | $4.9[4.005060]$ | $5.8[4.655)^{7.2]}$ |  |  |  |  |
| SIGMA ${ }^{T M}$ HP Partial-Kniesystem (DePuy) | SIGMA ${ }^{\text {TM }}$ HP Partial-Kniesystem (DePuy) | 3,966 | 96 | $63_{(56-71)}$ | 46/54 | 2012-2022 | $1.8\left[\begin{array}{c} {[1.4 .42 .2 .3]} \\ (3.41) \end{array}\right.$ | $3.7\left[\begin{array}{l} {[3.1,7 ; 9} \end{array} 4.3\right]$ | $4.7 \underset{(2,246 \cdot 0}{[4.5]}$ |  | $5.9[5.1 .1 ; 6.8]$ | $6.4 \underset{(6.58)}{ } 7.5]$ | $\left.6.8\left[\begin{array}{c} {[523]} \\ {[23} \end{array}\right) 8.0\right]$ | $6.8[5.5 ; 8,8.0]$ |
| Triathlon PKR (Stryker) | Triathlon PKR (Stryker) | 558 | 33 | $62_{(56-70)}$ | 46/54 | 2014-2022 | $5.1\left[\begin{array}{l} {[3.564} \\ \text { list } \\ 7.4] \\ \hline \end{array}\right.$ | $7.7 \text { [5.7.7. } 10.4]$ | $8.7\left[\begin{array}{l} {[6.525} \\ {[320} \end{array} 11.6\right]$ | $10.2\left[\begin{array}{c} {[7.8 ; 2)} \\ (262) \end{array}\right]$ | $11.0[8: 4 ; 7 ; 14.4]$ | $12.3[9.3: 16.1]$ | $12.3[9.3$ [54) 16.1$]$ |  |
| UNIVATION (Aesculap) | UNIVATION (Aesculap) | 1,601 | 72 | $6^{(56-70)}$ | 44/56 | 2014-2020 | $4.8\left[\begin{array}{l} {[3.9 ; 5 ; 6.0]} \\ (1.50) \end{array}\right.$ |  | $10.7\left[\begin{array}{c} \text { [9.2.2: } 12.3] \\ \text { und } \end{array}\right.$ | $12.0[10.5 ; 13.9]$ | $12.8\left[\begin{array}{ll} {[1.175]} \\ (14.8] \\ \hline \end{array}\right.$ | $13.2[11.4 ; 15.4]$ |  |  |
| ZUK (Lima) | ZUK (Lima) | 4.419 | 112 | $64_{(58-73)}$ | 45/55 | 2012-2022 | $2.0\left[\begin{array}{c} [1,6 ; 2 ; 3) .5] \\ (1,35) \end{array}\right.$ | $2.9\left[\begin{array}{l} {\left[2.4 ; 3_{2} 3.5\right]} \\ (2.23 \end{array}\right.$ | $3.5\left[\begin{array}{l} {[2.9992)} \\ \hline(2.2] \end{array}\right.$ | $4.4\left[\begin{array}{l} {[3.7 .763 .5 .2]} \\ \hline 1.63 \end{array}\right.$ |  | $4.9 \text { [4.2.758. } 5.8]$ |  |  |
| Unicondylar knee arthroplasties, mobile bearing, uncemented |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Oxford (Zimmer Biomet) | Oxford Tibia (Zimmer Biomet) | 5,646 | 91 | $63_{(57-71)}$ | 55/45 | 2012-2022 | $3.5[3.0 ; 4.00]$ | $4.7 \begin{gathered} {\left[\frac{1}{3} .8,2899\right.} \\ 5.4] \\ \hline \end{gathered}$ | $5.7\left[\begin{array}{c} {[3.0 ; 140)} \\ 5.4] \end{array}\right.$ | $6.1\left[\begin{array}{l} [5.5279) 6.9] \end{array}\right.$ | $6.5\left[\begin{array}{l} {[5.877 .7 .3]} \\ (x, 43) \end{array}\right.$ | $7.1\left[\begin{array}{l} {[6.300} \\ {[880} \\ 8.0] \end{array}\right.$ | $7.1\left[\begin{array}{l} {[6.3 ; 8 ; 8]} \\ (8,0] \end{array}\right.$ | $7.4\left[\begin{array}{l} {[6.4 ; 3)} \\ \hline 1.5] \end{array}\right.$ |
| Unicondylar knee arthroplasties, mobile bearing, cemented |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Oxford (Zimmer Biomet) | Oxford Tibia (Zimmer Biomet) | 21,748 | 398 | $65_{\text {(58-73) }}$ | 45/55 | 2012-2022 | $2.8\left[\begin{array}{l} [1.6 ; 8 ; 3) .0] \\ (1,8) \end{array}\right.$ | $4.4\left[4.1 \cdot \frac{14.7]}{4}\right.$ | $5.3\left[\begin{array}{c} {[5.0 ; 7.5]} \\ (11,192) \end{array}\right.$ | $6.2\left[\begin{array}{c} (5.8075) \\ {[6.5]} \end{array}\right.$ | $6.6[6.2 .2 ; 7.1]$ | $7.5\left[\begin{array}{l} {[7,0,0 ; 2)} \\ (2.0] \end{array}\right.$ | $8.0[7.4 ; 8.6]$ | $8.2 \underset{\substack{31212 \\[7.6 ; 9 \\ \hline 9.0]}}{ }$ |
| Oxford TiNbN (Zimmer Biomet) | Oxford Tibia TiNbN (Zimmer Biomet) | 2,180 | 279 | $60_{(55-67)}$ | 12/88 | 2012-2022 | $3.0\left[\begin{array}{c} 2.4 ; 7 ; 3.9] \\ (u, 79) \end{array}\right.$ | $5.8\left[\begin{array}{c} 4.8 ; 8 ; 7.0] \\ 0,410) \end{array}\right.$ | $6.7\left[\begin{array}{c} {[1 ., 6 ; 9)} \\ \hline 1.0] \\ \hline \end{array}\right.$ | $7.4 \text { [6.2.2; } 8.8]$ | $8.3\left[\begin{array}{c} (7.07) \\ \langle 9.9] \\ 9.9] \end{array}\right.$ | $9.0\left[\begin{array}{l} {[7.5 ; ~ 10.7]} \\ \text { (00) } \end{array}\right.$ | $9.0[7.5 ; 10.7]$ | $9.8[7.7 ; 12.3]$ |


| Knee arthroplasties with primary patellar resurfacing |  | Number | Hosp. | Age | m/f | Period | Revision probabilities after ... |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Femoral component | Tibial component |  |  |  |  |  | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Constrained TKA, hinged, fixed bearing, cemented |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| ENDURO (Aesculap) | ENDURO (Aesculap) | 464 | 38 | $73{ }_{(65-79)}$ | $27 / 73$ | 2014-2022 |  | $5.4 \underset{(3200}{[36 ; 8.1]}$ | $\begin{gathered} 6.3[4.2 ; 9,9.4] \\ 48\rangle) \end{gathered}$ | $6.8[4.6: 1.60 .2]$ | $6.8[4.6 \cdot 6 ; 10.2]$ | $6.8\left[4.6 ; 6 \text { ifo }_{(60)}^{10.2]}\right.$ |  |  |
| Constrained TKA, varus-valgus-stabilised, fixed bearing, cemented |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| NexGen LCCK (Zimmer Biomet) | NexGen CR (Zimmer Biomet) | 362 | 25 | $73{ }_{(62-79)}$ | 28/72 | 2013-2022 |  | $2.9[1.6 ; 5.3]$ | $2.9[1.6 ; 5.3]$ | $2.9[11.6 ; 5.3]$ | $2.9[1.6 ; 5.3]$ | ${ }^{2} .9\left[17.655^{[53} 5\right.$ |  |  |
| Standard TKA, cruciate-retaining, fixed bearing, cemented |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| COLUMBUS (Aesculap) | COLUMBUS (Aesculap) | 700 | 52 | $68{ }_{(61-76)}$ | $24 / 76$ | 2014-2022 | $1.3\left[\begin{array}{c} {\left[0.7{ }^{603}\right)} \\ 2.6] \\ \hline \end{array}\right.$ | $4.3[(2.97 ; 6.2]$ | $4.6\left[\begin{array}{l} {[329 ;} \\ (429] \end{array} 6.7\right]$ | $5.1\left[\begin{array}{c} {[3.624} \\ (324) \\ 7 \end{array}\right.$ | $5.5\left[\begin{array}{l} 3.8 ; 7 \times 7] \\ 127 \end{array}\right.$ | $5.9[4.1 .18 .4]$ |  |  |
| GENESIS II CR COCR (Smith \& Nephew) | Genesis II (Smith \& Nephew) | 933 | 40 | $69{ }_{(61-76)}$ | 32/68 | 2013-2022 | $2.2\left[\begin{array}{c} 1.4 ; 5 ; 3.4] \\ (151) \end{array}\right.$ | $2.3[1.5 \cdot 5.3]$ | $3.1 \underset{\substack{[4477}}{[2.1 ; 4.6]}$ | $3.3\left[\begin{array}{c} (2399 \\ (23) \\ 4.9] \\ \hline \end{array}\right.$ |  | $3.6\left[\begin{array}{c} (2,4 ;)^{\prime} \\ \hline 5.4] \end{array}\right.$ |  |  |
| LEGION CR COCR (Smith \& Nephew) | Genesis II (Smith \& Nephew) | 475 | 44 | $71{ }_{(63-78)}$ | $29 / 71$ | 2015-2022 | $2.0{ }_{\text {[1.0.0 }}^{131}$ 3.8] |  | $2.7[1.5 ; 5.0]$ | $\begin{array}{ll} 3.3[1.8 ; 6.0] \\ (151) \end{array}$ |  |  |  |  |
| LEGION CR OXINIUM (Smith \& Nephew) | Genesis II (Smith \& Nephew) | 361 | 44 | $65_{(58-72)}$ | $7 / 93$ | 2016-2022 | $\left.1.2\left[\begin{array}{c} 0.593 \\ \angle 289 \end{array}\right] .2\right]$ | ${ }^{2} 8.8$ [1.4.40; 5.5] | $4.0\left[\begin{array}{l}\text { [1.1.76 } 7.7 .4]\end{array}\right.$ | 4.0 [2.17:7.7.4] |  |  |  |  |
| NexGen CR-Flex (Zimmer Biomet) | NexGen CR (Zimmer Biomet) | 2,600 | 47 | $72{ }_{(64-78)}$ | $34 / 66$ | 2013-2022 | $1.7\left[\begin{array}{ll} 11.3: 2.92] \\ (2.10) \end{array}\right.$ | $2.2[1.7 ; 2.8]$ | $2.3[1.8 ; 3.0]$ | $2.5\left[\begin{array}{ll} (1.952) \\ (1.25) \\ 3 \end{array}\right.$ | $2.7\left[\begin{array}{c} {[2.1 ; 9 ; 9.5]} \\ (8.89 \end{array}\right]$ | $2.7\left[\begin{array}{l} {[538]} \\ \hline .13 .5] \\ \hline \end{array}\right.$ | $3.0 \underset{(2821)}{[2 ; ~ 3.9]}$ |  |
| SIGMA ${ }^{\text {TM }}$ Femur ( ${ }^{\text {dePuy }}$ ) | SIGMA ${ }^{\text {am Tibia ( }}$ (ePuy) | 4,534 | 74 | $71_{(63-78)}$ | 33/67 | 2012-2022 | $1.4[(1.1 .1 ; 1.8]$ | $2.0\left[\begin{array}{c} {[1,6 ; 24]} \\ (1.5] \\ \hline \end{array}\right.$ | $2.4\left[\begin{array}{l} {[2.053} \\ {[2.512} \end{array}\right]$ |  | $2.9\left[\begin{array}{ll} {[2.437} & 3.6] \end{array}\right.$ | $3.4\left[\begin{array}{l} (2.787) \\ (5.3] \end{array}\right.$ | $3.4\left[\begin{array}{l} {[2.70 ;)^{2}} \\ \hline 1.3] \end{array}\right.$ |  |
| Triathlon CR (Stryker) | Triathlon (Stryker) | 3,703 | 39 | $68_{(62-75)}$ | 40/60 | 2013-2022 | $1.4\left[\begin{array}{c} {[1.1 .18 ; 8]} \\ (2,80 \end{array}\right)$ | $1.9[1.5: 2.4]$ | $2.3[1.8 ; 3.0]$ | $2.7\left[\begin{array}{c} {[2.12 ; 3)} \\ (820) \\ \hline \end{array}\right.$ | $3.0\left[\begin{array}{c} {[2.3 ; 3,3.9]} \\ \mid 4, ~ \end{array}\right.$ | $3.0\left[\begin{array}{l} {[2.33 ;} \\ 123 \end{array}\right)$ | $3.0\left[\begin{array}{c} 2.3: 3: 3.9] \\ \text { and } \end{array}\right.$ |  |
| Vanguard CR (Zimmer Biomet) | Vanguard Tibia Cruciate (Zimmer Biomet) | 434 | 34 | $72_{(64-78)}$ | 31/69 | 2013-2022 | $2.8[1.65 \cdot 4.9]$ | $4.8[3.1 ; 7.4]$ |  | $5.4[3.5 ; 8.2]$ | $6.1[4.0 ; 9.9 .4]$ |  |  |  |
| Standard TKA, cruciate-retaining/sacrificing, fixed bearing, cemented |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| ATTUNETM Femur (DePuy) | ATTUNE ${ }^{\text {TM Tibia ( }}$ (ePuy) | 1,813 | 51 | $68{ }_{(61-75)}$ | 36/64 | 2013-2022 | $1.8[1.3 .3 .2 .5]$ | $2.1\left[\begin{array}{ll} {[1.50} \\ 40.08) \\ 2.9] \end{array}\right.$ | $2.6[1.9 ; 3.5]$ | $2.6[1.993 .5]$ |  |  |  |  |
| SIGMA ${ }^{\text {TM }}$ Femur ( DePuy $^{\text {a }}$ | SIGMA ${ }^{\text {am Tibia ( }}$ (ePuy) | 815 | 12 | $70{ }_{(63-76)}$ | 33/67 | 2015-2022 | $1.0\left[\begin{array}{c} {[0.5 ;} \\ (641) \\ 2.0] \\ \hline \end{array}\right.$ | $1.8[1.1 .3 \cdot 3.2]$ | $1.8[1.1 ; 3.2]$ | ${ }_{\text {2 }}^{2.3[17.3 .3 .4 .1] ~}$ |  |  |  |  |
| Standard TKA, cruciate-retaining/sacrificing, mobile bearing, cemented |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| ATTUNE ${ }^{\text {TM Femur ( }}$ ( PePuy ) | ATTUNETM Tibia (DePuy) | 315 | 7 | $73_{(65-78)}$ | $24 / 76$ | 2015-2022 | $1.0\left[\begin{array}{c} {[0.3 ; 3 ;} \\ k 81) \\ 3.1] \end{array}\right.$ | $1.4\left[\begin{array}{c} {[0.53} \\ 123) \\ 3.7] \\ \hline \end{array}\right.$ | $\underset{\substack{1006 \\ 1.8 ; ~ 4.3]}}{1.8}$ | $1.8\left[\begin{array}{c} (0.83) \\ (173] \\ 4.3] \end{array}\right.$ | $2.4[11.1 ; 5.4]$ | $2.4\left(\begin{array}{c} 1,1,1 ;(5.4] \\ (i, 4) \end{array}\right.$ |  |  |
| E.MOTION (Aesculap) | E.MOTION (Aesculap) | 492 | 37 | $67{ }_{(60-74)}$ | 17/83 | 2013-2022 | $5.3\left[\begin{array}{c} (3.6 ; 7) \\ (3.8] \\ 7 \end{array}\right.$ | $7.1\left[\begin{array}{l} {[5.1 ; 1 ; 10} \\ {[3 i j)} \\ 10.0] \end{array}\right.$ | $7.8[5.6 ; 10.7]$ | $8.6\left[\begin{array}{l} {[6 ; 2 ; 2 ; 11.8]} \\ (72) \end{array}\right.$ | $8.6[6.2 ; 2 ; 11.8]$ | $8.6\left[6.2 ; 5^{\text {[5] }}\right.$ [1.8] |  |  |
| Standard TKA, cruciate-sacrificing, fixed bearing, cemented |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| balanSys BICONDYLAR cem. (Mathys) | balanSys BICONDYLAR fix (Mathys) | 401 | 14 | $70{ }_{(61-77)}$ | 26/74 | 2013-2022 | 2.7 [1.4742) 4.9] | $4.3\left[\begin{array}{l} {[2.63)} \\ 1.53 .1] \\ \hline \end{array}\right.$ | 4.3 [2.6; 7.1.1] | $5.5\left[\begin{array}{l} (3.4 ; 7) \\ (100) \end{array}\right.$ | $5.5[3.3$ (154) 9.0$]$ |  |  |  |
| INNEX CR (Zimmer Biomet) | Innex Fix (Zimmer Biomet) | 306 | 16 | $72{ }_{(65-77)}$ | 40/60 | 2015-2022 | $2.3[1.1 .1 ; 4.8]$ | $3.4[1.9 ; 6 ; 3]$ | $4.8[2.8 ; 8.1]$ | $5.4[3.2 ; 2 ; 9.1]$ |  |  |  |  |
| Persona CR (Zimmer Biomet) | Persona Tibia (Zimmer Biomet) | 1,874 | 22 | $70_{(61-77)}$ | $32 / 68$ | 2013-2022 | $1.0 \begin{gathered} {[0.6 ; 61.6]} \\ (1.36) \end{gathered}$ | $1.5[1.0 ; 2.0]$ | $1.6[1.1 ; 2 ; 2]$ | $2.3[1.5 ; 3.4]$ | $2.4\left[\begin{array}{l} {[1.6 ; 3.6]} \\ (3,3) \end{array}\right.$ | $2.4\left[\begin{array}{l} {[1.6 ; 30} \\ (130) \\ 3.6] \end{array}\right.$ |  |  |
| Triathlon CR (Stryker) | Triathlon (Stryker) | 331 | 13 | $72{ }_{(65-78)}$ | 31/69 | 2014-2022 | $2.5\left[\begin{array}{c} 1.2 .2,4.8] \\ (108) \\ 4.8] \end{array}\right.$ | $3.1\left[\begin{array}{l} {[1.773: 5.7]} \\ {[123} \end{array}\right.$ | $3.9[2.2 ; 2 ; 6.7]$ |  | $5.3\left[\begin{array}{l} 3.0 .0 .9 .1] \\ (100) \end{array}\right.$ | $5.3[3.0 ; 9.9 .1]$ | 5.3 [3.0; $\left.{ }_{\text {(50) }} 9.1\right]$ |  |
| Vanguard CR (Zimmer Biomet) | Vanguard Tibia Cruciate (Zimmer Biomet) | 599 | 29 | $71_{(63-77)}$ | 21/79 | 2014-2022 |  | $2.2{ }_{(1,242 ;}^{[1.8]}$ | $2.4 \underset{(1,4 ; 9)}{[4.2]}$ | $2.8[1.664 .8]$ | 2.8 [11.65] 4.8$]$ | $3.5[2.0 .6 .3 .3]$ |  |  |
| Standard TKA, cruciate-sacrificing, mobile bearing, cemented |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| balanSys BICONDYLAR cem. (Mathys) | balanSys BICONDYLAR RP (Mathys) | 521 | 5 | $74{ }_{(65-79)}$ | $27 / 73$ | 2013-2022 |  | $0.4\left[\begin{array}{c}\text { [0.179 }\end{array}\right.$ | 1.1 [0.404, 2.9] | 1.1 [0.4; 2.9] |  |  |  |  |

Table 50 : Implant outcomes for femoro-tibial combinations in primary knee arthroplasties with patellar resurfacing at primary TKA. Within the groups comprising type of arthroplasty, type of fixation, knee system, and degree of constraint, the combinations are listed alphabetically by the femoral component.

| Knee arthroplasties with primary patellar resurfacing |  | Number | Hosp. | Age | m/f | Period | Revision probabilities after ... |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Femoral component | Tibial component |  |  |  |  |  | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Standard TKA, cruciate-sacrificing, mobile bearing, cemented |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| INNEX CR (Zimmer Biomet) | Innex Mobile (Zimmer Biomet) | 736 | 27 | $73_{(66-79)}$ | $22 / 78$ | 2013-2022 | $2.11[1.3 ; 3.5]$ | $3.4\left[\begin{array}{l} {[233]} \\ \hline 5.3 .1] \end{array}\right.$ | $4.0\left[\begin{array}{c} {[2.700} \\ {[3.90} \\ 5.9] \\ \hline \end{array}\right.$ | $4.5 \underset{(363)}{[3.1 ; 6]}$ | $4.5\left[\begin{array}{l} {[3.1 / 4)} \\ \hline 1.5] \\ \hline \end{array}\right.$ | $4.8\left[\begin{array}{l} {[3,3 ; 5} \\ {[15.9]} \\ \hline \end{array}\right.$ | $5.3[3.6 ; 7.7]$ |  |
| INNEX CR GSF (Zimmer Biomet) | Innex Mobile (Zimmer Biomet) | 503 | 24 | 72 (63-77) | 13/87 | 2013-2022 | $2.5[1.4 ; 4.3]$ | $3.9\left[\begin{array}{l} {\left[2322_{2}\right.} \\ 6.2] \end{array}\right.$ | $3.9[2.5 ; 6.2]$ | $4.2[2.7 .78 .6 .6]$ | $4.7\left[\begin{array}{ll} {[3,0 ; 8)} \\ \hline 1.3] \end{array}\right.$ | $5.2{ }^{\text {[3, }}$ (119] 3 8. 8.1$]$ |  |  |
| Standard TKA, posterior-stabilised, fixed bearing, cemented |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| ATTUNE ${ }^{\text {TM }}$ Femur (DePuy) | ATTUNE ${ }^{\text {m }}$ Tibia ( ${ }^{\text {dePuy }}$ ) | 489 | 45 | $69_{(59-77)}$ | $36 / 64$ | 2014-2022 | $1.6\left[\begin{array}{l} {[0.8 ; 2 ; 3]} \\ (3,2) \\ \hline \end{array}\right.$ | $1.9[1.0 .03 .8]$ | $2.4[1.2 ; 4.7]$ | $4.5\left[\begin{array}{l} {[2.4 ; 4 ;} \\ (123) \\ 8.4] \end{array}\right.$ | $4.5[2.4 ; 8 ; 4]$ | $6.0[3.0 ; 711.7]$ |  |  |
| balanSys BICONDYLAR PS cem. (Mathys) | balanSys BICONDYLAR fix (Mathys) | 1,641 | 9 | 70 (63-76) | 38/62 | 2014-2022 | $1.5[1.0 ; 2.3]$ | $2.9 \underset{(886)}{2.1 .14 .0]}$ | $3.4\left[\begin{array}{l} {[5656} \\ {[56} \\ \hline \end{array}\right.$ | $3.8 \underset{\substack{[267\rangle \\ \text { 20, } \\ \hline}}{5.2]}$ | $4.3[3.00 ; 6.0]$ |  |  |  |
| LEGION PS COCR (Smith \& Nephew) | Genesis II (Smith \& Nephew) | 996 | 44 | $70{ }_{(63-78)}$ | 34166 | 2015-2022 | $1.9[1.2 ; 3.0]$ | $3.0\left[\begin{array}{l} {[2.02\rangle} \\ \langle 4.02 \\ 4.5] \end{array}\right.$ | $3.5\left[\begin{array}{l} {[2.40 ; 7} \\ (307) \\ 5.2] \\ \hline \end{array}\right.$ | $3.5[(2.4 ; 54.2]$ |  |  |  |  |
| NexGen LPS-Flex-Gender (Zimmer Biomet) | NexGen CR (Zimmer Biomet) | 603 | 27 | 68 (61-76) | 2/98 | 2012-2022 | $1.9[1.1 ; 3.4]$ |  |  |  | $4.6 \underset{\substack{[3002 \\ 1027}}{[7.2]}$ | $5.8\left[\begin{array}{l} {[3,77)} \\ \mid 120 \end{array}\right)$ | $6.8[4.2 ; 10.97$ |  |
| NexGen LPS-Flex (Zimmer Biomet) | NexGen CR (Zimmer Biomet) | 2,416 | 87 | $69_{(62-76)}$ | 35/65 | 2012-2022 | $2.0\left[\begin{array}{l} {[1.5 ; 2 ; 2.7]} \\ (124) \end{array}\right.$ | $3.0\left[\begin{array}{ll} {[2.43 i j} \\ \hline 1.3 .8] \end{array}\right.$ | $3.6\left[\begin{array}{l} {[1.943 ; 4.5]} \\ \hline \end{array}\right.$ | $4.1\left[\begin{array}{l} {[3.3: 5915} \\ 5.1] \\ \hline 1.0 \end{array}\right.$ | $4.1[(3.3 ; 51) .1]$ | $4.1\left[\begin{array}{l} {[3 / 355} \\ \hline(5.1] \\ \hline \end{array}\right.$ | $4.6\left[\begin{array}{l} {[12.6 ; 8} \\ \hline 18.8] \\ \hline \end{array}\right.$ | $5.1\left[\begin{array}{l}{[3.8 ;} \\ (74) \\ \hline 6.9]\end{array}\right.$ |
| NexGen LPS (Zimmer Biomet) | NexGen CR (Zimmer Biomet) | 378 | 14 | $70{ }_{(62-77)}$ | 30/70 | 2013-2022 | $1.1\left[\begin{array}{l} (3.40) \\ \hline(2.9] \end{array}\right.$ | $2.0[1.0 ; 4.2]$ | $2.7 \text { [1.4.4:5.2] }$ | $3.2[1.775 .5 .9]$ | $3.9[2.1 ; 7.1]$ | $5.1\left[\begin{array}{l} \left.[2,6 ;)^{9} 9.6\right] \\ \hline \end{array}\right.$ |  |  |
| SIGMA ${ }^{\text {TM }}$ Femur (DePuy) | SIGMA ${ }^{\text {am Tibia ( }}$ (ePuy) | 1,568 | 49 | $70{ }_{(62-77)}$ | 32/68 | 2012-2022 | $2.1[1.5 ; 2.9]$ | $3.2[2.4 ; 4 ; 4.2]$ | $4.2\left[\begin{array}{l} {[3.3 .355 .5]} \\ (x, 105) \end{array}\right.$ | $4.9 \begin{gathered} {[3.8 ; 6 ; 6]} \\ (883) \end{gathered}$ | $5.4\left[\begin{array}{l} (4.31) \\ (61) \end{array}\right)$ | $5.9[4.6 ; 7.5]$ | $6.2[4.8 \cdot 8.0]$ | $7.2[5.1 .1210 .2]$ |
| Triathlon PS (Stryker) | Triathlon (Stryker) | 1,082 | 28 | $71{ }_{(63-78)}$ | 35/65 | 2013-2022 | $1.5 \underset{\substack{(0.966)}}{[2.5]}$ | $3.1\left[\begin{array}{l} {[2.1255} \\ (625] \\ \hline \end{array}\right.$ | $3.6 \underset{(4274)}{[2.5: 1]}$ | $3.6 \underset{(311)}{2.5 ;} 5.1]$ | $3.6[2.5 ; 5.1]$ | $3.6[2.545 .1]$ |  |  |
| Patellofemoral arthroplasties |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| JOURNEY PFJ OXINIUM (Smith \& Nephew) |  | 302 | 90 | $54{ }_{\text {(48-60) }}$ | 26/74 | 2013-2022 | $5.2\left[\begin{array}{l} {[3212]} \\ (23) \\ \hline \end{array}\right.$ | $8.8[\underset{(17 i)}{[5 ; 13.1]}$ | $11.1 \text { [7.6; } 16.0]$ | $13.6[9,4 ; 19.4]$ |  |  |  |  |


| Knee arthroplasties without primary patellar resurfacing |  | Number | Hosp. | Age | m/f | Period | Probability of secondary patellar resurfacing ... |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Femoral component | Tibial component |  |  |  |  |  | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Constrained TKA, hinged, fixed bearing, cemented |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Endo-Model - M, Rotating Hinge (Waldemar Link) | Endo-Model - M, Rotating Hinge, cemented (Waldemar Link) | 1,057 | 119 | $77_{\text {(68-82) }}$ | 23/77 | 2013-2022 |  | $\underset{\substack{(0.488}}{0.8 ;}$ | 0.9 [0.5; $\left.{ }_{\text {(497) }} 2.0\right]$ |  |  | ${ }^{1.2}$ [0.6; $\left.0_{\text {cig }} 2.5\right]$ |  |  |
| Endo-Model SL, Femoral Component, cemented (Waldemar Link) | Endo-Model SL, Tibial Component, Monoblock, cemented (Waldemar Link) | 490 | 50 | 75.5 (68-82) | 22/78 | 2013-2022 | 0.7 [0.2\% 2.2 .3$]^{(88)}$ | 0.7 [0.2; 2.3 .3] | 1.1 [0.4.48] 2.9$]$ | $1.1\left[\begin{array}{c} {[0.4 ; 9 ;} \\ (169) \end{array}\right)^{2.9]}$ | $1.1\left[\begin{array}{l} {[0.45} \\ (415) \\ 2.9] \end{array}\right.$ | $1.1{ }^{[0.45)^{63}} \mathbf{2 . 9 ]}$ |  |  |
| Endo-Model, Rotating Hinge, cemented (Waldemar Link) | Endo-Model, Rotational Hinge, cemented (Waldemar Link) | 1,330 | 164 | 77 (69-82) | 18/82 | 2013-2022 | $0.4{ }^{[0.1027} 10$ 1.0] | $0.9\left[\begin{array}{c} {[0.57)} \\ (82) \\ 1.7] \\ \hline \end{array}\right.$ | $\left.0.9{ }_{\text {[0.588 }}^{\text {(68) }} 1.7\right]$ |  | 0.9 [0.5517) 1.7$]$ |  | $\left.{ }^{0.9}{ }_{\text {[0.53 }}^{(33)} 1.7\right]$ |  |
| ENDURO (Aesculap) | ENDURO (Aesculap) | 1,635 | 160 | $76{ }_{(68-81)}$ | 21/79 | 2013-2022 | $0.5\left[\begin{array}{l} {[0.2 ; 2 ; 1.0]} \\ (1,27] \end{array}\right.$ | $1.2\left[\begin{array}{l} {[0.7002} \\ (1.050 \end{array}\right)$ | $1.9[1.2 .2 .28]$ | $2.2[1.4 ; 73.3]$ | $2.2\left[\begin{array}{c} {[1.453: 3.3]} \\ (382) \end{array}\right.$ | $2.6[1.63: 4.0]$ | $2.6[1.654 .0]$ |  |
| MUTARS GenuX MK cemented (Implantcast) | MUTARS GenuX MK cemented (Implantcast) | 332 | 73 | $77{ }_{(67-82)}$ | $27 / 73$ | 2015-2022 | $0.3[0.0 ; 2.3]$ | $0.9[0.2 ; 3.5]$ |  | $2.0\left[\begin{array}{c} {[0.78)} \\ (68) \\ 5.3] \end{array}\right.$ |  |  |  |  |
| NexGen RHK (Zimmer Biomet) | NexGen RHK (Zimmer Biomet) | 1,043 | 140 | $76{ }_{(68-81)}$ | 23/77 | 2012-2022 |  | $0.7\left[\begin{array}{l} {[0.3 ;} \\ (0,04 \\ (0) .6] \end{array}\right.$ | $1.2[0.66 ; 2.4]$ | $1.2\left[\begin{array}{c} {[0.600} \\ (0,0) \\ 2.4] \end{array}\right.$ | $1.2\left[\begin{array}{l} {[0.660} \\ {[2.60} \end{array} 2.4\right]$ | $1.2\left[\begin{array}{c} {[0.6 ;} \\ (4,4) \\ 2.4] \end{array}\right.$ | $2.2\left[\begin{array}{c} {[0.95} \\ (0,9) \\ (0.4] \end{array}\right.$ |  |
| RT-Plus (Smith \& Nephew) | RT-Plus (Smith \& Nephew) | 2,033 | 136 | $77{ }_{(71-81)}$ | 21/79 | 2013-2022 | $0.4\left[\begin{array}{c} {[0.2 ; 0 ; 0]} \\ (1,20] \end{array}\right.$ |  | $0.9\left[\begin{array}{c} {[0.6 ; 1.6]} \\ (x, 16) \end{array}\right.$ | $1.1 \begin{gathered} {[0.7 ; 1.8]} \\ (851) \\ \hline \end{gathered}$ | $1.1 \underset{(568)}{[0.7} ; 1.8]$ | $1.3\left[\begin{array}{ll} {[0.8: 8} \\ \substack{36 \\ \hline} & 2.2] \\ \hline \end{array}\right.$ | $1.3[0.8 .82 .2]$ |  |
| RT-Plus Modular (Smith \& Nephew) | RT-Plus Modular (Smith \& Nephew) | 560 | 106 | $75_{(66-80.5)}$ | 28/72 | 2013-2022 | $0.6[0.2 ; 1.9]$ | $0.8\left[\begin{array}{l} {[0.378)} \\ 0 \end{array}\right)$ | $0.8\left[\begin{array}{c} {[0.30 ;} \\ \text { (030 } \end{array}\right.$ | $0.8\left[\begin{array}{c} {[0.3 ; 2 ; 2.2]} \\ 129 \end{array}\right.$ | $0.8\left[\begin{array}{ll} {[0.364} \\ (164) & 2.2] \\ \hline \end{array}\right.$ | 0.8 [ $0.3 ; 9 \times 2.2]$ |  |  |
| Constrained TKA, varus-valgus-stabilised, fixed bearing, cemented |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| LEGION PS COCR (Smith \& Nephew) | Genesis II (Smith \& Nephew) | 763 | 71 | $71_{(63-78)}$ | $29 / 71$ | 2015-2022 | $0.3\left[\begin{array}{ll} {[5.1 / 3 ;} \\ (53) \\ 1.2] \\ \hline \end{array}\right.$ |  |  | $0.3\left[\begin{array}{lll} 0.10 ; 1 \\ (101) \end{array}\right]$ |  |  |  |  |
| LEGION Revision COCR (Smith \& Nephew) | LEGION Revision (Smith \& Nephew) | 447 | 64 | 71 (65-79) | $29 / 71$ | 2014-2022 | $0.3 \underset{(054)}{[0.0 ;} ; 1.9]$ | $0.6 \underset{\substack{[0.129 \\(22)}}{2.4]}$ | $0.6\left[\begin{array}{c} \left.[0.145)^{2} 2.4\right] \\ \hline(2.4] \end{array}\right.$ | $\underset{(1855}{0.6[0.1 ; ~ 2.4]}$ | $2.1 \begin{aligned} & {\left[0.77 i_{126} .6 .1\right]} \\ & \hline 10 \end{aligned}$ |  |  |  |
| NexGen LCCK (Zimmer Biomet) | NexGen CR (Zimmer Biomet) | 1,473 | 106 | $72{ }_{(64-79)}$ | $29 / 71$ | 2012-2022 | $0.2\left[\begin{array}{l}\text { [0.0; } 062 \\ 0.0 \\ 0.6]\end{array}\right.$ | $0.6\left[\begin{array}{ll} {[0.3 ; 3)} \\ (9.3] \end{array}\right.$ | $0.6\left[\begin{array}{l}\text { [0.354 } \\ \text { (154) } 1.3]\end{array}\right.$ | $0.6\left[\begin{array}{l}\text { [0.356) } \\ \text { [57) } \\ 1.3]\end{array}\right.$ | 0.6 [0.334) 1.31 | 0.6 [0.3: 1291.31 | 0.6 [0.3; 1.37 |  |
| Triathlon PS (Stryker) | Triathlon TS (Stryker) | 380 | 37 | $73_{(63-79)}$ | 26/74 | 2013-2022 | $\begin{gathered} 0.0 \\ \text { (27) } \end{gathered}$ | $0.8[0.2 ; 3.3]$ | $0.8[0.2 .23 .3]$ | 2.8 [ $17.0 ; 7.7 .8]$ |  |  |  |  |
| Standard TKA, cruciate-retaining, fixed bearing, hybrid |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| balanSys BICONDYLAR uncem. (Mathys) | balanSys BICONDYLAR fix (Mathys) | 341 | 5 | $71_{\text {(64-77) }}$ | 46/54 | 2016-2022 | ${ }_{0}^{0.0}$ | ${ }^{0.0}$ | 0.0 <br> $1.39)$ | ${ }_{\substack{0 \\ 192)}}^{0.0}$ |  |  |  |  |
| COLUMBUS (Aesculap) | COLUMBUS (Aesculap) | 729 | 5 | $6_{(62-77)}$ | 38/62 | 2014-2022 | (80) | (0.0) | ${ }_{\text {(560) }}^{0.0}$ | 0.0 | ${ }_{0}^{0.0}$ | $\xrightarrow{0.0}$ |  |  |
| EFK Femur zementfrei (OHST Medizintechnik) | EFK Tibia zementiert (OHST Medizintechnik) | 1,271 | 14 | $70_{(63-76)}$ | 42/58 | 2014-2022 | $0.2\left[\begin{array}{l} {[0.1750} \\ (0,8] \end{array}\right.$ | $\begin{gathered} \left.0.6\left[\begin{array}{l} {[0.3 ;} \\ (1.069) \end{array}\right] .3\right] \end{gathered}$ | $0.6\left[\begin{array}{c} 0.3 ; 3 \pi) \\ \hline 987) \\ 1.3] \end{array}\right.$ | $\underset{(8774)}{0.6]}$ | ${ }_{0} 0.7$ [0.4.4i 1.51 .5 | $\left.0.7\left[\begin{array}{c} {[0.4 ; 2 ;} \\ (652) \end{array}\right] .5\right]$ | $0.9 \underset{\substack{[0.575 \\(27)}}{ } 1.8]$ |  |
| GENESIS II CR COCR (Smith \& Nephew) | Genesis II (Smith \& Nephew) | 445 | 6 | $68_{(62-75)}$ | 44/56 | 2012-2022 | $0.2\left[\begin{array}{c} {[0.0 ; 11.7]} \\ (41) \end{array}\right.$ | $0.2 \underset{(377)}{[0.0 ;} 1.7]$ | $0.8\left[\begin{array}{c} {[0.32} \\ 32 j \end{array} 2.6\right]$ | $0.8 \underset{\substack{[0.384 \\(020)}}{2.6]}$ |  |  |  |  |
| LEGION CR COCR (Smith \& Nephew) | Genesis II (Smith \& Nephew) | 533 | 8 | $69_{(62-77)}$ | 50/50 | 2017-2022 | $0.6[0.2 ; 2.0]$ | $1.0\left[\begin{array}{l} {[2.4 ; 4 ;} \\ (24) \\ 2.7] \end{array}\right.$ | $1.4[0.6 ; 3.5]$ | $1.4[0.6 ; 3.5]$ |  |  |  |  |
| NexGen CR-Flex (Zimmer Biomet) | NexGen CR (Zimmer Biomet) | 581 | 18 | $69_{(61-75)}$ | 52/48 | 2014-2022 | $0.5\left[\begin{array}{l} {[5.2 ; 8)} \\ \hline 1.7] \end{array}\right.$ | $0.9\left[\begin{array}{c} {[0.4 ; 0 ;} \\ (4,2) \\ \hline \end{array}\right.$ | $0.9\left[\begin{array}{ll} {[0.453} \\ \langle 4.4 & 2.2] \\ \hline \end{array}\right.$ | $0.9\left[\begin{array}{c} {[0.4 ; 9 ; 2} \\ (369) \end{array}\right.$ | $\left.0.9\left[\begin{array}{ll} {[.43 ;} \\ {[.3 ;} \end{array}\right) 2.2\right]$ | $0.9[0.40 .40 .2]$ | $0.9\left[\begin{array}{l}\text { [0.7) } \\ 0.7 \\ 0.0\end{array}\right.$ |  |
| NexGen CR (Zimmer Biomet) | NexGen CR (Zimmer Biomet) | 522 | 7 | $69_{(62-75)}$ | 49/51 | 2014-2022 | $\begin{aligned} & 0.0 \\ & 4.88) \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 1, k i v) \end{aligned}$ | - 0.0 | $\xrightarrow{0.0}$ | $\xrightarrow{0.0}$ | $\xrightarrow{0.0}$ | $\begin{gathered} 0.0 \\ (84) \end{gathered}$ |  |
| SIGMA ${ }^{\text {TM }}$ Femur ( ${ }^{\text {dePuy }}$ | SIGMATM Tibia (DePuy) | 915 | 22 | $68{ }_{(61-76)}$ | 41/59 | 2014-2022 | $0.1\left[\begin{array}{c} {[8.0 ; 5} \\ {[0.8]} \\ 0 \end{array}\right.$ | $0.4 \underset{(008)}{[0.1 ;} 1.2]$ | $0.8\left[\begin{array}{c} {[0.43)} \\ (6,9) \\ 1.9] \\ \hline \end{array}\right.$ | $\underset{\substack{4600}}{0.8 ; ~} 1.9]$ | $0.8\left[\begin{array}{c} {[0.40 ; 1.9]} \\ (004) \\ \hline \end{array}\right.$ | $0.8\left[\begin{array}{c} {[.472 ;} \\ (172) \\ 1.9] \end{array}\right.$ | $0.8\left[\begin{array}{c} 0.4 ; 4 ; \\ (6,9) \\ 1.9] \end{array}\right.$ |  |
| TC-PLUS CR (Smith \& Nephew) | TC-PLUS (Smith \& Nephew) | 543 | 12 | $71_{(63-76)}$ | $40 / 60$ | 2014-2022 | $0.2\left[\begin{array}{l} {[0.0 ; 1.5]} \\ \substack{443} \\ \hline \end{array}\right.$ | $0.2\left[\begin{array}{l} {[0.0 ; 7} \\ (37) \\ 1.5] \\ \hline \end{array}\right.$ | $0.2\left[\begin{array}{l} {[0.0 ; 8 ;} \\ (1.5] \end{array}\right.$ | $0.2\left[\begin{array}{l} {[0.0 ; 2 ; 1.5]} \\ (2,2) \end{array}\right.$ | $0.2\left[\begin{array}{ll} {[0.0 ; 1.5]} \\ \text { cip } \end{array}\right.$ |  |  |  |
| Triathlon CR (Stryker) | Triathlon (Stryker) | 437 | 17 | $70_{(63-75)}$ | 40/60 | 2014-2022 | $\begin{aligned} & 0.0 \\ & (356) \end{aligned}$ | $0.6\left[\begin{array}{l} {[0.2 ; 2 ; 2} \\ \substack{302} \\ \hline \end{array}\right.$ | $1.0\left[\begin{array}{l} {[0.3 ; 5 ; 3.1]} \\ 0.250 \end{array}\right.$ | $1.0\left[\begin{array}{l} {[0.3 ; 3 ; 1]} \\ 1,190 \end{array}\right.$ | $1.0[0.3 .3 .3 .1]$ | $1.0\left[\begin{array}{c} {[0.3: 3.31]} \\ (64) \\ \hline \end{array}\right.$ |  |  |
| Vanguard CR (Zimmer Biomet) | Vanguard Tibia Cruciate (Zimmer Biomet) | 1,057 | 13 | $68{ }_{(61-75)}$ | 42/58 | 2015-2022 | $\begin{aligned} & 0.0 \\ & 1829) \end{aligned}$ |  |  | ${ }^{1.2}\left[\begin{array}{c}\text { [0.6; } \\ \text { a }\end{array}\right.$ |  |  |  |  |


| Knee arthroplasties without primary patellar resurfacing |  | Number | Hosp. | Age | m/f | Period | Probability of secondary patellar resurfacing ... |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Femoral component | Tibial component |  |  |  |  |  | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Standard TKA, cruciate-retaining, fixed bearing, cemented |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| ACS cemented (Implantcast) | ACS FB cemented (Implantcast) | 800 | 43 | $66.5{ }_{\text {(59-74) }}$ | 21/79 | 2014-2022 | $0.1\left[\begin{array}{l} {[0.0 ;} \\ (15) \end{array} 0.9\right]$ | $0.8\left[\begin{array}{c} {[0.45 ;} \\ (65) \\ 1.9] \\ \hline \end{array}\right.$ | $1.6\left[\begin{array}{l} \text { [0.86j } \\ \hline \end{array}\right.$ | $1.6\left[\begin{array}{l} {[.081)} \\ \hline 13) \\ 2.9] \\ \hline \end{array}\right.$ | $1.6\left[\begin{array}{c} {[0.8 ; 82} \\ (182) \end{array} 2.9\right]$ |  |  |  |
| ACS LD cemented (Implantcast) | ACS LD FB cemented (Implantcast) | 362 | 10 | 70 (63-76) | 48/52 | 2015-2021 | $0.3 \underset{\substack{3 \\[366}}{0 ; 0} 2.0]$ | $1.2\left[\begin{array}{l} {[0.4 ; 3 ; 3.1]} \\ (23) \end{array}\right.$ | $1.2\left[\begin{array}{c} {[0.4: 3.3 .1]} \\ \mid 28) \end{array}\right.$ | $1.2\left[\begin{array}{l} {[0.4 ; 35} \\ (1,3) \\ 3.1] \end{array}\right.$ | $1.2[0.4 ; 3.1]$ |  |  |  |
| balanSys BICONDYLAR cem. (Mathys) | balanSys BICONDYLAR fix (Mathys) | 2,465 | 24 | ${ }^{71}{ }_{(664-78)}$ | 37/63 | 2014-2022 | $0.0\left[\begin{array}{c} {[0.0040} \\ (2,06) \end{array}\right]$ | $0.1\left[\begin{array}{ll} {[0.040,0.4]} \\ 0.4] \end{array}\right.$ |  | $\left.0.2\left[\begin{array}{c} {[0.1800} \\ \text { and } \\ \hline 80 \end{array}\right] .6\right]$ | $0.2\left[\begin{array}{l}\text { [0.170) } \\ \text { [80, } \\ 0.6]\end{array}\right.$ |  | $0.2\left[\begin{array}{c}\text { [0.17 } \\ i 22\end{array} 0.6\right]$ |  |
| COLUMBUS (Aesculap) | COLUMBUS (Aesculap) | 17,681 | 142 | 70 (62-77) | $34 / 66$ | 2013-2022 | $0.2\left[\begin{array}{l}\text { [0.1.758) } 0.3]\end{array}\right.$ |  | $0.7\left[\begin{array}{ll} {[0.6882} \\ \hline 9.620 .9] \end{array} 0\right.$ | $0.8[0.6 ; 1.0]$ | $0.9\left[\begin{array}{l} 0.8 ; \\ \langle 4.224) \\ ; 1.1] \\ \hline \end{array}\right.$ | $0.9\left[\begin{array}{ll} {[0.8273} \\ {[2,2]} \\ 1.2] \end{array}\right.$ | $0.9[0.8 ; 1.2]$ | $0.9\left[\begin{array}{c} {[0.8 ;} \\ (26) \\ 1.2] \\ \hline \end{array}\right.$ |
| EFK Femur zementiert (OHST Medizintechnik) | EFK Tibia zementiert (OHST Medizintechnik) | 3,050 | 39 | $72(64-77)$ | 38/62 | 2014-2022 | $0.1\left[\begin{array}{c} {[0.0540]} \\ (2,3] \end{array}\right.$ | $0.3\left[\begin{array}{ll} {[0.1 .1033} \\ 2,0.6] \end{array} 0 .\right.$ | $0.4\left[\begin{array}{l} {[0.2,233} \\ {[2.53} \\ 0.7] \end{array}\right.$ | $0.4\left[\begin{array}{l} {[0.2 ; 22]} \\ {[2,7]} \\ 0.7] \end{array}\right.$ | $0.5\left[\begin{array}{c} {[0.3 ; 08)} \\ (2,8) \\ 0 \end{array}\right.$ | $0.5\left[\begin{array}{l} {[0.3030 .9]} \\ (1,30) \end{array}\right.$ | $0.5\left[\begin{array}{c} (4.35)^{2} \\ 0.9] \end{array}\right.$ |  |
| EFK Femur zementiert TiNbN (OHST Medizintechnik) | EFK Tibia zementiert TiNbN (OHST Medizintechnik) | 472 | 44 | $66_{(59-73)}$ | 7/93 | 2014-2022 | $0.2\left[\begin{array}{c} {[0.0 ;} \\ (428) \end{array}\right]$ | $0.2\left[\begin{array}{c} {[0.008} \\ (38) \\ 1.6] \end{array}\right]$ | $0.5\left[\begin{array}{c} {[0.149)} \\ (34) \\ 2.0] \end{array}\right.$ | $0.5\left[\begin{array}{c} {[0.1414} \\ (314) \\ 2.0] \end{array}\right.$ | $\underset{(1283}{0.8} \mathbf{0 . 3 ;}$ | $0.8\left[\begin{array}{c} {[0.320} \\ (230) \end{array} \mathbf{2}^{2.6]}\right.$ | $\underset{\substack{(80)}}{0.8 ;}$ |  |
| GEMINI SL Total Knee System, Femoral Component, Mobile Bearing/Fixed Bearing CR, cemented (Waldemar Link) | GEMINI SL Total Knee System, Tibial Component, Fixed Bearing, cemented (Waldemar Link) | 316 | 23 | $73_{(65-78)}$ | 38/62 | 2014-2022 | $0.3\left[\begin{array}{c}{[0.0 ; 8)} \\ (28.4] \\ \hline\end{array}\right.$ | $0.3\left[\begin{array}{l} {[0.02} \\ (262) \end{array} 2.4\right]$ | $0.3\left[\begin{array}{c} {[0.0 ; 26} \\ 1226 \end{array}\right)$ | $0.3[(1.05) ; 2.4]$ | 0.3 [0.0; 3 (84) 2.4$]$ |  |  |  |
| GENESIS II CR COCR (Smith \& Nephew) | Genesis II (Smith \& Nephew) | 9,088 | 91 | 70 (62-76) | 35/65 | 2013-2022 |  | $\begin{gathered} 1.3[1.1 ; 1.6] \\ \mid 1.201 \end{gathered}$ | $1.6[1.3: 1.9]$ | $1.7 \underset{(1.4642)}{[1.4 ; 2]}$ | $1.8[1.5 ; 2.2]$ | $1.8[1.5 ; 2.2]$ | $1.9[1.5: 2.3]$ | $2.2[1.6 ; 3.0]$ |
| GENESIS II CR OXINIUM (Smith \& Nephew) | Genesis II (Smith \& Nephew) | 2,528 | 115 | $65_{(58-73)}$ | 20/80 | 2012-2022 | $0.5\left[\begin{array}{c} {[0.3 ; 93} \\ (2,93) \end{array}\right.$ |  | $\begin{gathered} 1.6[1.1 ; 2.2 .3] \\ (4.544) \end{gathered}$ | $1.8$ | $\underset{(1890)}{2.0} \underset{\substack{1.4 ;}}{2.7]}$ | $\underset{(565)}{2.0} \underset{(1.4 ; 2.7]}{ }$ | $2.0\left[\begin{array}{c} {[1.4 ; 2.7]} \\ (120) \end{array}\right)$ |  |
| GENESIS II LDK COCR (Smith \& Nephew) | Genesis II (Smith \& Nephew) | 1,703 | 16 | 70 (62-76) | 38/62 | 2013-2022 | $0.3\left[\begin{array}{ll} {[1.130)} \\ 0.030 \end{array}\right.$ | $1.1 \begin{aligned} & {[0.7 .7 \times 1.8]} \\ & \hline 1.568) \end{aligned}$ | ${ }^{1.5}{ }_{\text {[1.0.0. }}^{\text {(1.45) }}$ 2.2] | $\begin{gathered} 1.8 \\ \substack{1.3 .366} \\ \text { (1.6] } \end{gathered}$ | 1.8 [1.3; 2.6] | 1.9 [1.4.4it 2.8$]$ |  | ${ }^{2.1}[1.55 ; 3.0]$ |
| INNEX CR (Zimmer Biomet) | Innex Fix (Zimmer Biomet) | 1,271 | 27 | $73_{(65-78)}$ | 41/59 | 2013-2022 | $0.2\left[\begin{array}{l} {[0.0 ; 132)} \\ 0.7] \end{array}\right.$ | $0.4\left[\begin{array}{ll} {[0.197)} \\ {[1.0]} \end{array}\right.$ | $0.7\left[\begin{array}{l} \left.[0.39)^{1} 1.5\right] \\ \hline 1.5] \end{array}\right.$ | $0.7\left[\begin{array}{l} {[0.35)^{1.5]}} \\ 1.5] \end{array}\right.$ | $0.7\left[\begin{array}{l} {[0.3 ;} \\ \substack{464} \\ ; 1.5] \\ \hline \end{array}\right.$ | $0.7\left[\begin{array}{l} {\left[0.355^{1}\right.} \\ 1.5] \end{array}\right.$ | ${ }^{0.7}{ }_{\substack{\text { [0.37 } \\(129}}^{1.5]}$ |  |
| INNEX CR GSF (Zimmer Biomet) | Innex Fix (Zimmer Biomet) | 360 | 18 | $73_{(65-78)}$ | 18/82 | 2013-2022 | $0.3\left[\begin{array}{c} {[0.027} \\ (32.1] \\ \hline \end{array}\right.$ | $\left.0.9\left[\begin{array}{c} {[0.3 ;} \\ (29) \\ 2 \end{array}\right) .9\right]$ | $0.9\left[\begin{array}{c} {[0.3 ; 5} \\ (2,5) \\ 2.9] \\ \hline \end{array}\right.$ | $\left.0.9\left[\begin{array}{c} {[0.300} \\ (200 \end{array}\right) 2.9\right]$ | $0.9\left[0.30^{[162)} 2.9\right]$ | $0.9\left[0.30_{(85)^{2}} 2.9\right]$ |  |  |
| JOURNEY II CR COCR (Smith \& Nephew) | JOURNEY (Smith \& Nephew) | 368 | 14 | 71 (62-77) | 37/63 | 2018-2022 | $\begin{gathered} 0.0 \\ 1284) \end{gathered}$ | $0.4\left[\begin{array}{c} {[0.12} \\ 102) \end{array} 2.7\right]$ |  |  |  |  |  |  |
| JOURNEY II CR OXINIUM (Smith \& Nephew) | JOURNEY (Smith \& Nephew) | 1,029 | 28 | $64{ }_{(58-72)}$ | 36/64 | 2015-2022 | $0.4\left[\begin{array}{c} (0.200 \\ (920) \\ 1.1] \end{array}\right.$ | $1.1\left[\begin{array}{c} {[0.650} \\ (80) \\ ; \end{array}\right.$ | $1.3\left[\begin{array}{c} (0.83 ; \\ (13) \\ 2.3] \\ \hline \end{array}\right.$ | $2.1\left[\begin{array}{c} 1.320 \\ (520) \\ 3.4] \\ \hline \end{array}\right.$ | $\underset{\substack{(2288}}{2.1 .4]}$ | $2.1\left[\begin{array}{c} 1.3 ; 3,3] \\ (100) \\ 3.4] \\ \hline \end{array}\right.$ |  |  |
| LEGION CR COCR (Smith \& Nephew) | Genesis II (Smith \& Nephew) | 11,776 | 136 | ${ }^{71}{ }_{(63-77)}$ | 38/62 | 2014-2022 | $\left.0.2\left[\begin{array}{l} {[0.22 ; 20} \end{array}\right) .4\right]$ |  | $0.9[0.7 .7 ; 1.1]$ | $1.1\left[\begin{array}{l} {[0.823)} \\ \hline 1.3] \end{array}\right.$ | $1.2[0.9 ; 1.5]$ | $1.2\left[\begin{array}{c} {[.9 .97\rangle} \\ \mid 127] \end{array}\right]$ |  |  |
| LEGION CR OXINIUM (Smith \& Nephew) | Genesis II (Smith \& Nephew) | 2,991 | 144 | $64_{(58-72)}$ | 16/84 | 2012-2022 |  |  | $1.5[1.0 .02 .2]$ | $1.5(1.0 ; 2.2]$ |  | $\underset{\text { (89) }}{2.0 \text { [1.2; 3.5] }}$ |  |  |
| LEGION PS COCR (Smith \& Nephew) | Genesis II (Smith \& Nephew) | 890 | 49 | $72(63-79)$ | 25/75 | 2015-2022 | $\left.0.2\left[\begin{array}{l} {[0.0 ;} \\ {[529} \end{array}\right] 1.2\right]$ | $1.1\left[\begin{array}{l} {[0.4 ; 0.4} \\ 1200 \end{array}\right)$ | $1.1\left[\begin{array}{l} {[0.4 ; 4 ;} \\ \hline(14) \\ 2.9] \end{array}\right.$ | $1.1\left[\begin{array}{c} {\left[0.4 ; i_{i}\right.} \\ \hline 6.9] \end{array}\right.$ |  |  |  |  |
| NexGen CR-Flex-Gender (Zimmer Biomet) | NexGen CR (Zimmer Biomet) | 4,944 | 103 | 70 (62-76) | 10/90 | 2012-2022 | $0.1\left[\begin{array}{l} {[0.0 ; 230} \\ \langle 0.2] \end{array}\right.$ |  |  | $0.6\left[\begin{array}{l} {[0.4 ; 50.9]} \\ (2,26) \end{array}\right.$ |  | 0.7 [0.4.4i. 1.0$]$ |  | 0.7 [0.4.4; 1.00 |
| NexGen CR-Flex (Zimmer Biomet) | NexGen CR (Zimmer Biomet) | 17,062 | 124 | ${ }^{72}$ (64-78) | 42/58 | 2012-2022 | $0.1\left[\begin{array}{l} {[0.0 ; 182)} \\ \hline(14,1] \end{array}\right.$ | $0.2\left[\begin{array}{c} {[0.2 ; 2,0.3]} \\ (1,96) \\ \hline \end{array}\right.$ | $0.3\left[\begin{array}{ll} {[0,2,231} \\ 9,0.5] \\ 0.5] \end{array}\right.$ | $0.4\left[\begin{array}{l} {[0.3030} \\ {[, .20} \\ 0 \end{array}\right.$ | $0.4 \underset{[4.3060}{[0.5]}$ | $0.4\left[\begin{array}{c} {[0.388} \\ (2.38) \\ 0.5] \end{array}\right.$ | $0.4\left[\begin{array}{ll} {[0.3: 366} \\ 10.6] \\ 0.6] \end{array}\right.$ | $0.4\left[\begin{array}{l} {[0.302} \\ (502) \end{array} 0.6\right]$ |
| NexGen CR (Zimmer Biomet) | NexGen CR (Zimmer Biomet) | 3,685 | 57 | $70_{(63-76)}$ | 42/58 | 2013-2022 | $0.1\left[\begin{array}{l} {[0.000000} \\ (3,3] \end{array}\right.$ | $0.4\left[\begin{array}{l} {[0.2 ; 2 ; 0]} \\ (2,7 \pi) \end{array}\right]$ | $0.7\left[\begin{array}{l} {[0.4 ; 4 ; 1.0]} \\ (2,2001) \end{array}\right.$ | $0.8\left[\begin{array}{c} 0.5 ; 1.2] \\ (1,92] \end{array}\right]$ | $0.8\left[\begin{array}{c} {[0.6 ; 1.3]} \\ (1, i 11) \end{array}\right.$ | $0.9\left[\begin{array}{ll} {[0.65} \\ (9.52) & 1.4] \end{array}\right.$ | $0.9\left[\begin{array}{l} {[0.6 ; 1.4]} \\ (547) \end{array}\right.$ | $0.9\left[\begin{array}{ll} {[0.6 ; 6} & 1.4] \\ \text { (150) } \end{array}\right.$ |
| Persona CR (Zimmer Biomet) | Persona Tibia (Zimmer Biomet) | 6,103 | 103 | $69_{(62-77)}$ | 40/60 | 2013-2022 | $0.1\left[\begin{array}{l} {[0.0 ; 0} \\ \langle 4.76) \\ 0.2] \\ \hline \end{array}\right.$ | $0.3\left[\begin{array}{l} {[0.2 ; 800} \\ 2,50 \\ 0.5] \end{array}\right.$ | $0.4\left[\begin{array}{l} {[0.2: 2006} \\ \hline 2.06] \end{array}\right.$ | $0.5[0.3 ; 0.8]$ | $0.5[0.3 ; 0.8]$ | $0.5\left[\begin{array}{ll} {[0.3 ; 8)} \\ {[2 ; 8]} \end{array}\right]$ | $0.5\left[\begin{array}{l} {[0.3 ;} \\ {[5 ;)} \\ 0.8] \end{array}\right.$ |  |
| SIGMA ${ }^{\text {TM }}$ Femur (DePuy) | SIGMA ${ }^{\text {atm Tibia ( }}$ (ePuy) | 23,480 | 135 | $71_{(63-77)}$ | 36/64 | 2012-2022 | $0.2[0.22 ; 0.3]$ | $0.5\left[\begin{array}{l} {[0.4,4 ; 52)} \\ \hline 1.6] \end{array}\right.$ |  | $0.6[0.5 ; 0.8]$ | $0.7 \begin{gathered} {[0.6550} \\ (0.85) \\ 0 \end{gathered}$ | $0.8\left[\begin{array}{c} {[0.6 ; 80} \\ {[3010} \end{array}\right)$ | $0.8\left[\begin{array}{ll} {[0.653} \\ {[1.530} \\ 0.9] \end{array}\right.$ | $0.8\left[\begin{array}{c} {[0.655} \\ \hline(6) .9] \\ 0.0 \end{array}\right.$ |
| TC-PLUS CR (Smith \& Nephew) | TC-PLUS (Smith \& Nephew) | 3,949 | 42 | $71_{(66-78)}$ | 36/64 | 2014-2022 | $0.1\left[\begin{array}{c} {[0.103 ; 0.3]} \\ \{0.3] \end{array}\right.$ | $0.2\left[\begin{array}{l} {[0.1 .157)} \\ 0.5] \\ 0.5] \end{array}\right.$ | $0.3\left[\begin{array}{ll} {[0.2,299} & 0.5] \\ (2.50 \end{array}\right.$ | $0.3\left[\begin{array}{ll} {[0.2,26)} \\ 0.6] \\ 0.6] \end{array}\right.$ | $0.4\left[\begin{array}{l} {[0.29 ;} \\ 1929 \end{array}\right)$ | $0.4 \underset{\substack{0389}}{0.2 ;} ; 0.7]$ | $0.4[0.2 ; 0 ; 7]$ |  |
| Triathlon CR (Stryker) | Triathlon (Stryker) | 8,322 | 80 | $70_{(63-77)}$ | 37/63 | 2013-2022 | $0.3\left[\begin{array}{c} {[0.2 ; 83)} \\ (1.83) \\ 0.4] \\ \hline \end{array}\right.$ | $0.8\left[\begin{array}{ll} {[0.643} \\ \hline 6 & 1.0] \\ \hline \end{array}\right.$ | $1.1\left[\begin{array}{l} {[0.927)} \\ {[4.4]} \end{array}\right.$ | $1.3\left[\begin{array}{l} (1,007) \\ \hline 1.7] \end{array}\right.$ | $1.4\left[\begin{array}{c} (1.1 .08) ; 1.7] \end{array}\right.$ | $1.5[1.2 ; 1.9]$ | $1.5\left[1.2 ;{ }_{[599} 1.9\right]$ | $1.5[1.2 ; 1.9]$ |
| Vanguard CR (Zimmer Biomet) | Vanguard Tibia Cruciate (Zimmer Biomet) | 11,741 | 79 | ${ }^{72}(66-77)$ | 37/63 | 2012-2022 | $0.1\left[\begin{array}{c} {[0.1 ; 37)} \\ (0.2] \end{array}\right.$ | $0.4\left[\begin{array}{ll} {[0.3 ; 973} \\ {[0,5]} \\ 0.5] \end{array}\right.$ | $0.6[0.5 ; 0.8]$ | $0.7\left[\begin{array}{l} {[0.5555} \\ \hline(4.9] \\ 0.9] \end{array}\right.$ | $0.8[0.6 ; 1.0]$ | $0.8\left[\begin{array}{ll} {[0.65 ;} & 1.0] \end{array}\right.$ | $0.8\left[\begin{array}{ll} {[0.655} & 1.0] \\ \hline 10] \end{array}\right.$ |  |
| Vanguard CR TiNbN (Zimmer Biomet) | Vanguard Tibia TiNbN (Zimmer Biomet) | 1,151 | 68 | $65_{(58-72)}$ | $8 / 92$ | 2013-2022 | $0.1\left[\begin{array}{l} {[0.0 ; 5)} \\ (954) \\ 0.7] \end{array}\right.$ | 0.8 [0.4.4; 1.7] | $1.1\left[\begin{array}{l} (5069) \\ (5.1] \end{array}\right.$ | $1.1\left[\begin{array}{c} {[0.63)} \\ (331) \\ 2.1] \\ \hline \end{array}\right.$ | $1.1{ }^{[0.664 .2 .1]}$ | $1.1\left[\begin{array}{l} {[0.6 ; 2.1]} \\ (101) \end{array}\right.$ |  |  |

Table 51 (continued)

| Knee arthroplasties without primary patellar resurfacing |  | Number | Hosp. | Age | m/f | Period | Probability of secondary patellar resurfacing ... |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Femoral component | Tibial component |  |  |  |  |  | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Standard TKA, cruciate-retaining, mobile bearing, hybrid |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| TC-PLUS CR (Smith \& Nephew) | TC-PLUS SB (Smith \& Nephew) | 477 | 7 | $69_{(61-76)}$ | 35/65 | 2015-2022 | $0.2\left[\begin{array}{ll} {[0.0 ; 5} \\ (0,5) \\ 1.6] \end{array}\right.$ | $0.2\left[\begin{array}{ll} {[0.045} \\ (3,5) \\ 1.6] \end{array}\right.$ | $0.2\left[\begin{array}{l} {[0.0 ; 2} \\ (32) \end{array} 1.6\right]$ | $\left.0.6\left[\begin{array}{ll} {[0.1} \\ {[28\rangle} \end{array}\right) 2.3\right]$ | $0.6\left[\begin{array}{ll} {[0.1 .1} & 2.3] \\ (2.3] \end{array}\right.$ | $0.6\left[\begin{array}{l} 0.17 ; \\ u, 3 j \\ \mid 2.3] \end{array}\right.$ |  |  |
| Standard TKA, cruciate-retaining, mobile bearing, cemented |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| ACS cemented (Implantcast) | ACS MB cemented (Implantcast) | 796 | 22 | $70_{(62-77)}$ | 30/70 | 2013-2022 | $0.2[0.0 ; 1.1]$ | ${ }^{0.5}$ [0.2.2 $4.68{ }^{1.5]}$ |  |  | $1.0\left[\begin{array}{c} {[0.4 ; 2 ; 2.3]} \\ (020) \end{array}\right.$ | ${ }_{\text {1 }} 1.0$ [0.4.4 2.3 .3$]$ |  |  |
| COLUMBUS (Aesculap) | COLUMBUS (Aesculap) | 2,525 | 25 | $71_{(63-77)}$ | $36 / 64$ | 2013-2022 | $0.2\left[\begin{array}{l} {[0.1 ; 20)} \\ (0,5] \end{array}\right.$ | $\left.0.3\left[\begin{array}{c} {[0.1,930} \\ u, 93 \end{array}\right) .7\right]$ | $0.4\left[\begin{array}{l} {[0.2990} \\ {[0.7]} \\ \hline \end{array}\right.$ | $0.5\left[\begin{array}{l} {[0.2 ; 62)} \\ 0.9] \end{array}\right.$ | $0.5\left[\begin{array}{ll} {[0.255)} & 0.9] \\ \hline(6) \end{array}\right.$ | $0.5[0.2 ; 0.9]$ | $0.5[0.2 ; 0 ; 0]$ |  |
| INNEX CR (Zimmer Biomet) | Innex Mobile (Zimmer Biomet) | 1,288 | 65 | $70_{(62-77)}$ | 97/3 | 2013-2022 | $0.3[0.1 ; 0.8]$ | $0.3\left[\begin{array}{c} 0.1 .156 \\ 1956 \\ 0.9] \\ 0 \end{array}\right.$ | $0.5[0.2 ; 1.1]$ | $0.6\left[\begin{array}{c} {[0.302} \\ 1620 \\ 1.3] \\ \hline \end{array}\right.$ | $0.8\left[\begin{array}{l} {[0.4 ;} \\ (34 i) \\ 1.6] \\ \hline \end{array}\right.$ | $1.0[0.5 ; 2.3]$ | ${ }^{1.0}$ [0.5; $\left.{ }_{\text {(60) }} 2.3\right]$ |  |
| INNEX CR GSF (Zimmer Biomet) | Innex Mobile (Zimmer Biomet) | 348 | 33 | $70{ }_{(63-76)}$ | 82/18 | 2014-2022 | $\begin{aligned} & 0.0 \\ & 1200 \\ & \hline \end{aligned}$ |  | $0.4 \underset{(0,183}{[0.6]} ; 2.6]$ | $0.4\left[\begin{array}{ll} {[0.10 \cdot 12.6]} \\ (140) \end{array}\right.$ | $0.4\left[0.1 ;\left[_{(9)^{2}} 2.6\right]\right.$ |  |  |  |
| NexGen CR-Flex (Zimmer Biomet) | NexGen CR (Zimmer Biomet) | 596 | 9 | $71_{(66-76)}$ | 42/58 | 2013-2022 |  |  | 0.8 [0.3; $\left.{ }_{\text {(385) }} 2.0\right]$ | 0.8 [0.33: 3180 | $0.8\left[\begin{array}{l}\text { [0.35] } \\ (23) \\ \text { 2.0] }\end{array}\right.$ | 0.8 [0.33 $\left.{ }_{\text {(175) }} 2.0\right]$ |  |  |
| TC-PLUS CR (Smith \& Nephew) | TC-PLUS SB (Smith \& Nephew) | 405 | 11 | $71{ }_{(63-77)}$ | 30/70 | 2015-2022 | $0.5 \underset{(8,3)}{[0.1 ; ~ 2.0]}$ | $1.0\left[\begin{array}{c} {[0.49)^{(2,2.7]}} \\ \hline \end{array}\right.$ | $1.3[0.0 .6 ; 3.2]$ | $1.3[0.6 .63 \cdot 3.2]$ | $1.3\left[\begin{array}{ll} {[0.63]} \\ (183) \end{array}\right.$ | $1.3[0.6 ; 6 ; 3.2]$ |  |  |
| ZEN Femur STD zementiert (OHST Medizintechnik) | ZEN Tibia STD zementiert (OHST Medizintechnik) | 858 | 6 | $71_{(65-78)}$ | 35/65 | 2015-2022 |  | $0.2\left[\begin{array}{c} {[0.0 ; 99)^{(53)} 1} \\ 1.3] \end{array}\right.$ | $0.4\left[\begin{array}{c} {[0.1 ; 2)} \\ (832) \\ 1.5] \end{array}\right.$ | 0.8 [0.2.2 2. 2.5$]$ | ${ }^{0.8} 0$ [0.2.2. 2.5$]$ |  |  |  |
| Standard TKA, cruciate-retaining/sacrificing, fixed bearing, hybrid |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| BPK-S INTEGRATION (Peter Brehm) | BPK-S INTEGRATION (Peter Brehm) | 380 | 3 | $69_{(62-76)}$ | $36 / 64$ | 2016-2022 | ${ }_{\text {(3ib) }} 0$ | $\begin{aligned} & 0.0 \\ & 12(2) \end{aligned}$ | $\begin{gathered} 0.0 \\ 216) \end{gathered}$ | $0.5\left[\begin{array}{ll} {[0.1 .13 .3]} \\ 133] \end{array}\right.$ | $0.5[0.1 ; 3.3]$ |  |  |  |
| Standard TKA, cruciate-retaining/sacrificing, fixed bearing, cemented |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| ATTUNE ${ }^{\text {TM }}$ Femur (DePuy) | ATTUNETM Tibia (DePuy) | 7.186 | 119 | $67^{(60-75)}$ | $39 / 61$ | 2013-2022 | $0.2\left[\begin{array}{l}\text { [0.1. } 1.004 \\ 0.4]\end{array}\right.$ | $0.6\left[\begin{array}{l} {[0.4,4,0.9]} \\ 44.43 \end{array}\right.$ | $0.8\left[\begin{array}{c} {[0.6 ; 410} \\ {[0,41} \\ \hline 1.0] \end{array}\right.$ | $0.9\left[\begin{array}{l} {[0.6 ;} \\ {[211)} \end{array} 1.2\right]$ | $1.0\left[\begin{array}{ll} {[0.7531 .3]} \\ 10.53) \end{array}\right.$ | $1.0 \underset{(0332)}{[0.7 ; ~ 1.4]}$ | $1.0 \underset{(0.733 ; 1.4]}{[1.4]}$ | $1.0\left[\begin{array}{l} {[0.77} \\ \text { (i1) } \\ 1.4] \end{array}\right.$ |
| SIGMA ${ }^{\text {TM }}$ Femur (DePuy) | SIGMATM Tibia (DePuy) | 2,066 | 23 | $6^{69}{ }_{(61-76)}$ | 35/65 | 2015-2022 | $0.1\left[\begin{array}{l} {[0.0 ; 780} \\ (1,28) \end{array}\right.$ | $0.4\left[\begin{array}{lll} {[0.2,255} \\ 0.9] \\ 0.9] \end{array}\right.$ | $0.8[0.5 ; 1.5]$ | $0.8\left[\begin{array}{c} {[0.57} \\ (67) \\ 1.5] \end{array}\right.$ | $0.8\left[\begin{array}{ll} {[0.5 ; 2)} & 1.5] \\ (3,5) \end{array}\right.$ | $0.8[0.5 ; 1.5]$ |  |  |
| Unity CR cmtd (Corin) | Unity cmtd (Corin) | 587 | 15 | $73{ }_{(65-78)}$ | $29 / 71$ | 2014-2022 |  | $0.9\left[\begin{array}{c} {[0.3 ; 2} \\ (3,2) \\ 2.5] \end{array}\right.$ | $0.9{ }^{\text {[0.30) }}$ (300) 2.5$]$ | $1.2\left[\begin{array}{l} {[0.555} \\ (2,5) \\ 3 \end{array}\right.$ | $1.2\left[\begin{array}{ll} {[0.5 ; ~} & 3.0] \\ (1,0) \end{array}\right.$ | ${ }^{1.2}$ [0.55 [i0] 3.0$]$ | $1.2\left[0.5{ }_{\text {[5] }} 3.0\right]$ |  |
| Standard TKA, cruciate-retaining/sacrificiing, mobile bearing, hybrid |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| LCSTM ${ }^{\text {COM M }}$ COMPLETE ${ }^{\text {TM }}$ Femur (DePuy) | MBT Tibia (DePuy) | 2,967 | 35 | $70_{(62-77)}$ | 35/65 | 2012-2022 | $0.1\left[\begin{array}{l} {[0.1 ; 700} \\ {[2.4]} \end{array}\right.$ | $0.5[0.3: 0.9]$ | $0.6\left[\begin{array}{l} {[0.3 ;} \\ k, 260) \\ 0 \end{array}\right.$ | $0.6\left[\begin{array}{ll} {[0.4 ; 4 ; 4)} & 1.0] \end{array}\right.$ |  | $0.6[0.4 ; 4 ; 1.0]$ | $0.6\left[\begin{array}{ll} {[0.4 ; 3 ;} \\ 1.0] \\ \hline \end{array}\right.$ | $0.6[0.4 ; 1.0]$ |
| Standard TKA, cruciate-retaining/sacrificiing, mobile bearing, uncemented |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| ATTUNE ${ }^{\text {TM }}$ Femur (DePuy) | ATTUNETM Tibia RP zementfrei (DePuy) | 575 | 12 | $6_{(59-73)}$ | $39 / 61$ | 2017-2022 |  | ${ }^{1.5}$ [0.5; 3.98$]$ |  |  |  |  |  |  |
| LCSTM ${ }^{\text {COM }}$ COMPLETETM Femur (DePuy) | LCS $^{\text {TM }}$ COMPLETE ${ }^{\text {m }}$ Tibia (DePuy) | 653 | 76 | $64_{(58-73)}$ | 7/93 | 2014-2022 | $0.2\left[\begin{array}{c} {[0.0 ;} \\ (566) \\ ; 1.3] \\ \hline \end{array}\right.$ | $0.6\left[\begin{array}{c} [0.2 ; 5\rangle\rangle \\ \langle, 5] \end{array} 1.9\right]$ | $\left.1.3\left[\begin{array}{c} {[0.6 ; 9} \\ (309 \end{array}\right) 2.9\right]$ | $1.6\left[\begin{array}{c} {[0.8 ; 7} \\ k 27 \end{array}\right]$ | $1.6\left[\begin{array}{c} (1.8) i \\ \hline .8 .5] \end{array}\right.$ | $1.6[0.08 ; 3.5]$ |  |  |
| LCS ${ }^{\text {TM }}$ COMPLETE ${ }^{\text {TM }}$ Femur ( ${ }^{\text {dePuy }}$ ) | MBT Tibia (DePuy) | 1,224 | 23 | $70_{(61-76)}$ | $36 / 64$ | 2012-2022 |  | $0.7\left[\begin{array}{ll} {[0.303} \\ 40.103) \\ 1.3] \end{array}\right.$ | 0.7 [0.3; 1.4 .3$]$ |  | $0.8\left[\begin{array}{ll} {[0.458} \\ {[58)} \\ \hline 1.6] \end{array}\right.$ | ${ }^{0.8} 8$ [0.4.4i8) 1.6$]$ |  | ${ }^{0} 0.8[0.45 ; 1.6]$ |
| SCORE (Amplitude) | SCORE (Amplitude) | 554 | 5 | $69_{(62-77)}$ | 32/68 | 2015-2022 | $\begin{aligned} & 0.0 \\ & (4.0) \end{aligned}$ | $0.2\left[\begin{array}{ll} {[0.045} \\ (3,5) \\ 1.6] \end{array}\right.$ | $0.2\left[\begin{array}{l} {[0.0 ; 2 ; 1} \\ (2,6] \end{array}\right.$ | $0.2\left[\begin{array}{l} {[0.0 ; 7)} \\ (1.6] \end{array}\right.$ | $0.2[0.0 ; 7.6]$ |  |  |  |
| Standard TKA, cruciate-retaining/sacrificiing, mobile bearing, cemented |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| ATTUNE ${ }^{\text {TM }}$ Femur (DePuy) | ATTUNE ${ }^{\text {TM Tibia ( }}$ (ePuy) | 2,022 | 29 | $69_{(62-75)}$ | $37 / 63$ | 2015-2022 | $0.2\left[\begin{array}{l} {[0.150 ; 0.5]} \\ (1,50) \end{array}\right.$ | $0.5\left[\begin{array}{l} {[0.2 .21 .1]} \\ 0.1550) \end{array}\right.$ | $0.7\left[\begin{array}{ll} {[0.4 ; ; 1.3]} \\ (2, i) \end{array}\right.$ | 0.8 [0.4.478 1.5$]$ | $0.8[0.4 .451 .5]$ | 0.8 [0.4.48; 1.5] | 0.8 [0.4; ifi $\left.^{1} 1.5\right]$ |  |
| E.MOTION (Aesculap) | E.MOTION (Aesculap) | 10,626 | 87 | $70{ }_{(22-77)}$ | $34 / 66$ | 2012-2022 | $\underset{\substack{(0,500]}}{0.8]}$ | $1.5[1.3 ; 1.8]$ | $1.8[1.5 ; 2.1]$ | $2.0\left[\begin{array}{ll} {[1.825 ; 2.4]} \\ \hline 4.25] \end{array}\right.$ | $2.1\left[\begin{array}{ll} {[1.850} \\ (2.50) \\ 2.4] \end{array}\right.$ | $2.1\left[\begin{array}{c} {[1.83 ; 2 ; 5]} \\ (4.5] \\ \hline \end{array}\right.$ | $2.1 \underset{(15,3 ; 3}{[2.5]}$ | $2.1[1.8 ; 2.5]$ |
| LCS $^{\text {TM }}$ COMPLETE ${ }^{\text {TM }}$ Femur ( DePuy $^{\text {a }}$ | MBT Tibia (DePuy) | 5,188 | 58 | $72_{(64-77)}$ | $36 / 64$ | 2013-2022 | ${ }^{0.3}{ }^{\text {[ }}$ [0.92999 0.5$]$ | $0.8\left[\begin{array}{l} {[0.6 ; 47)} \\ (0.10) \end{array}\right.$ | $1.1 \underset{(3.885)}{[0.8 ; 1.4]}$ | $1.1 \begin{gathered} [0.83 ; 3) .4] \\ (3,32) \end{gathered}$ | $1.2\left[\begin{array}{ll} {[0.994} & 1.5] \end{array}\right.$ | $1.2\left[\begin{array}{c} {[0.930} \\ 10.30 \\ 1.5] \end{array}\right.$ |  | $\left.1.2{ }^{\text {[0.9.98] }} 1.6\right]$ |
| SCORE (Amplitude) | SCORE (Amplitude) | 322 | 7 | $72_{(62-77)}$ | 30/70 | 2014-2022 | $0.3\left[\begin{array}{l} \text { [0.05 } \\ 0.3 \\ \hline 2.3] \\ \hline \end{array}\right.$ | $0.7\left[\begin{array}{l} {[0.2 ; 2} \\ (222) \\ 2.6] \end{array}\right.$ | $\left.1.1\left[\begin{array}{l} {[0.302} \\ {[202} \end{array}\right] .4\right]$ | $1.1\left[\begin{array}{c} {[0.3 ; 3.3]} \\ (150) \end{array}\right.$ | $1.1\left[\begin{array}{ll} {[0.3: 3.3]} \\ \text { (102) } \end{array}\right.$ | $1.1\left[\begin{array}{l} {[0.3 ;} \\ \mid 62] \\ \hline .4] \end{array}\right.$ |  |  |

Table 51 (continued)

| Knee arthroplasties without primary patellar resurfacing |  | Number | Hosp. | Age | m/f | Period | Probability of secondary patellar resurfacing ... |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Femoral component | Tibial component |  |  |  |  |  | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Standard TKA, cruciate-retaining/sacrificicing, mobile bearing, cemented |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| SIGMA ${ }^{\text {TM }}$ Femur ( ${ }^{\text {dePuy }}$ ) | MBT Tibia (DePuy) | 2,081 | 29 | $72_{(66-78)}$ | 37/63 | 2013-2022 | $0.3\left[\begin{array}{l} {[0.1 ; 210} \\ (1,32) \end{array}\right)$ |  | $1.1\left[\begin{array}{l} {[0.722 ; 1.7]} \end{array}\right.$ | $1.2\left[\begin{array}{c} {[0.73 ; 1.8]} \\ (83) \\ \hline \end{array}\right.$ | $1.2\left[\begin{array}{l} {[0.7731} \\ (53) \\ 1.8] \\ \hline \end{array}\right.$ | $1.2\left[\begin{array}{c} {[0.786} \\ 1286 \\ 1.8] \\ \hline \end{array}\right.$ | $1.2\left[0.7{ }^{(57)} 7.8\right]$ |  |
| Standard TKA, cruciate-sacrificing, fixed bearing, hybrid |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| balanSys BICONDYLAR uncem. (Mathys) | balanSys BICONDYLAR fix (Mathys) | 1,078 | 9 | $70{ }_{(63-77)}$ | 44/56 | 2013-2022 | $0.2\left[\begin{array}{c} {[0.0 ; 0,0.8]} \\ (1,01 \end{array}\right.$ | $0.8\left[\begin{array}{c}{[0.499 ; 1.6]} \\ 0.0\end{array}\right.$ | $0.8\left[\begin{array}{c} {\left[0.433^{2}\right.} \\ (1.6] \end{array}\right.$ | $1.0\left[\begin{array}{l}{\left[0.5 \sum_{i}\right)} \\ 4.8] \\ 0.0\end{array}\right.$ | 1.0$[0.5 ;$ <br> 1312 <br> $0.8]$ <br> $1.8]$ | $1.3\left[\begin{array}{c}\text { (1.64i } \\ 0.2 \\ 2.6]\end{array}\right.$ |  |  |
| INNEX CR (Zimmer Biomet) | Innex Fix (Zimmer Biomet) | 313 | 4 | $71{ }_{(64-76)}$ | 48/52 | 2014-2022 | (200) | $\begin{aligned} & 0.0 \\ & 1.252) \end{aligned}$ | $\begin{aligned} & 0.0 \\ & (213) \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 1.122) \end{aligned}$ | $0.0$ | $\begin{aligned} & 0.0 \\ & (53) \end{aligned}$ |  |  |
| Standard TKA, cruciate-sacrificing, fixed bearing, cemented |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| balanSys BICONDYLAR cem. (Mathys) | balanSys BICONDYLAR fix (Mathys) | 2,181 | 28 | $70_{(62-77)}$ | 29/71 | 2013-2022 | $0.1\left[\begin{array}{l} {[0.0 ; 0 ; 0.4]} \\ (1,51) \end{array}\right.$ | $0.7 \text { [0.4,474)} 1.3]$ |  | $1.1\left[\begin{array}{c} {[0.75)^{2}} \\ 1.8] \\ \hline \end{array}\right.$ | $1.1\left[\begin{array}{c} {[0.73 ; 3} \\ (630) \\ 1.8] \end{array}\right.$ | $1.1\left[\begin{array}{l} {\left[0.77{ }_{(150)} 1.8\right]} \\ \hline(1.8] \end{array}\right.$ | $1.1\left[\begin{array}{c} {[0.77 ; 1.8]} \\ (81) \end{array}\right]$ |  |
| COLUMBUS (Aesculap) | COLUMBUS (Aesculap) | 3,687 | 92 | $70_{(62-77)}$ | $27 / 73$ | 2013-2022 |  | $\left.0.2{ }^{[0.12 .155)} 0.4\right]$ |  |  |  | $0.3\left[\begin{array}{l} {[0.1 ; 3)} \\ (4.6] \\ 0.6] \end{array}\right.$ | ${ }^{0.8} 8[0.232 .93]$ |  |
| INNEX CR (Zimmer Biomet) | Innex Fix (Zimmer Biomet) | 1,276 | 45 | $72{ }_{(64-78)}$ | 40/60 | 2013-2022 |  | $0.5\left[\begin{array}{ll} {[0.2 ; 2 ;} & 1.2] \end{array}\right.$ | $0.5\left[\begin{array}{c} {[0.2 ; 5 ; 1.2]} \\ (85) \end{array}\right.$ | $0.8\left[\begin{array}{c} {[.454)} \\ \hline(1.6] \end{array}\right.$ | $0.8\left[\begin{array}{c} {[0.40 ;} \\ 4400 \end{array}\right]$ | $0.8\left[\begin{array}{c} {[0.4 ; 1.6]} \\ (201) \end{array}\right.$ | $\left.0.8\left[0.540^{[58}\right) 1.6\right]$ |  |
| INNEX CR GSF (Zimmer Biomet) | Innex Fix (Zimmer Biomet) | 719 | 34 | $72_{\text {(65-78) }}$ | 20/80 | 2013-2022 | $0.1\left[\begin{array}{l} {[0.0 ; 7} \\ (b i n) \\ 1.0] \end{array}\right.$ | $0.5\left[\begin{array}{l} {[0.2,2,1.5]} \\ {[65]} \end{array}\right.$ | $0.5\left[0.2 ;{ }_{\text {[42] }} 1.5\right]$ |  | $0.5\left[\begin{array}{l} {[0.2 ;} \\ (24 i) \\ 1.5] \end{array}\right.$ | $0.5[0.2 ; 1.5]$ | $0.5\left[0.2 ; i_{\text {[5] }} 1.5\right]$ |  |
| Natural Knee NK II (Zimmer Biomet) | Natural Knee NK II (Zimmer Biomet) | 335 | 8 | $73_{(67-77)}$ | 28/72 | 2013-2017 | $0.3\left[\begin{array}{c} {[0.0 ;} \\ (320) \end{array} 2.2\right]$ | 0.3 [0.0; 312.2$]$ | $0.3\left[\begin{array}{c} {[0.03)^{(303)}} \\ 2.2] \\ \hline \end{array}\right.$ |  |  | 0.3 [0.0; 212.2$]$ | $0.3\left[\begin{array}{c} {[0.020} \\ (150) \\ 2.2] \\ \hline \end{array}\right.$ | 0.3 [0.0; 3.2 .2$]$ |
| Persona CR (Zimmer Biomet) | Persona Tibia (Zimmer Biomet) | 4,726 | 90 | $6^{691-76)}$ | 37/63 | 2013-2022 | $0.1\left[\begin{array}{l} {[0.1 ; 92} \\ {[2.92]} \end{array}\right.$ | $0.4\left[\begin{array}{c} {[0.2 ; 84)} \\ (0.76) \\ 0.7] \end{array}\right.$ | $0.4\left[\begin{array}{c} {[0.2 ; 2 \pi)} \\ (1,7] \end{array}\right.$ | $0.4\left[\begin{array}{c} {[0.2 ; 56} \\ 1056 \\ 0.7] \\ 0 \end{array}\right.$ | $0.6\left[\begin{array}{c} {[0.359} \\ 4.35) \\ 1.2] \end{array}\right.$ | $1.2\left[\begin{array}{c} (0.515 \\ (215) \end{array}\right)$ | $1.2\left[\begin{array}{c} {[0.5 ;} \\ (61) \\ 2.5] \\ \hline \end{array}\right.$ |  |
| Triathlon CR (Stryker) | Triathlon (Stryker) | 1,870 | 26 | $69_{(61-77)}$ | $37 / 63$ | 2014-2022 | $0.1\left[\begin{array}{l} {[0.0 ; 035)} \\ {[1.4]} \end{array}\right.$ |  | $0.9[0.5 ; 1.6]$ | $1.1\left[\begin{array}{l} (549) \\ \hline 5 ; 9 \end{array}\right)$ | $1.1[0.6 ; 1.8]$ | $1.1\left[\begin{array}{l} {[0.660} \\ 1.60] \end{array} 1.8\right]$ | $1.1\left[\begin{array}{l} {[0.6 ; 1.8]} \\ (97) \end{array}\right]$ |  |
| Vanguard CR (Zimmer Biomet) | Vanguard Tibia Cruciate (Zimmer Biomet) | 7,266 | 72 | $72{ }_{(66-78)}$ | 33/67 | 2013-2022 | $0.2[(0.1 ; 5 i) \cdot 4]$ | $0.6\left[\begin{array}{l} {[0.4 ; 3 i)} \\ 4.8] \\ 4.8] \end{array}\right.$ | $0.8\left[\begin{array}{c} {[0.686} \\ \hline(.68) \\ 1.1] \end{array}\right.$ | $0.9\left[\begin{array}{l} {[0.75 ; 1.3]} \\ (2.52) \end{array}\right.$ | $0.9\left[\begin{array}{l} {[0.7 .751 .3]} \\ (1.56) \end{array}\right.$ | $0.9\left[\begin{array}{c} {[0.74 ; 1.3]} \\ (184) \\ 1.3] \end{array}\right.$ | $\left.1.1\left[\begin{array}{c} {[0.8 ;} \\ 1309 \end{array}\right] .6\right]$ |  |
| Vanguard CR TiNbN (Zimmer Biomet) | Vanguard Tibia TiNbN (Zimmer Biomet) | 551 | 59 | $6_{(59-75)}$ | 6/94 | 2014-2022 | $0.2\left[\begin{array}{l}{[0.0 ;} \\ \langle 23)\end{array} 1.6\right]$ | $1.3\left[\begin{array}{c} {[336 j} \\ \hline(3) \\ 3.1] \end{array}\right.$ | $1.6\left[\begin{array}{c} {[.7 .730} \\ 1.50 \\ 3.6] \end{array}\right.$ | $1.6\left[\begin{array}{c} {[0.7 ; 0)} \\ (160) \\ 3.6] \\ \hline \end{array}\right.$ |  | ${ }^{\left.1.6[0.7 .7]_{1} 3.6\right]}$ |  |  |
| Standard TKA, cruciate-sacrificing, mobile bearing, hybrid |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| balanSys BICONDYLAR uncem. (Mathys) | balanSys BICONDYLAR RP (Mathys) | 705 | 6 | $70_{(22-77)}$ | 40/60 | 2013-2022 | $0.6\left[\begin{array}{c} {[.227\rangle} \\ \mid 62 ; \end{array}\right)$ | $0.9\left[\begin{array}{l} {[.54 / 4,2.1]} \end{array}\right.$ | $1.1\left[\begin{array}{c} {[0.5 ;} \\ (501) \end{array}\right) .3 .3$ | $\left.1.3\left[\begin{array}{c} {[1.79} \\ 419 \end{array}\right) .6\right]$ | $1.6\left[\begin{array}{c} {[1287} \\ 1.8 ; \\ 3.0] \\ \hline \end{array}\right.$ | $1.6\left[\begin{array}{c} {[0.8 ; 6} \\ 1210 \\ \hline \end{array}\right.$ | $2.2\left[\begin{array}{c} 1.1 .74 .4 .6] \\ (124) \\ \hline \end{array}\right.$ | $\underset{(83)}{2.2[1.7 ; 4.6]}$ |
| Standard TKA, cruciate-sacrificing, mobile bearing, cemented |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| COLUMBUS (Aesculap) | COLUMBUS (Aesculap) | 1,164 | 5 | $6^{69}{ }_{(62-76)}$ | 41/59 | 2014-2022 | $0.2\left[\begin{array}{l}{[0.0 ; ~}\end{array}\right.$ | $0.6\left[\begin{array}{c} {[0.30)} \\ 1909 \end{array}\right]$ | $0.6\left[\begin{array}{c} {[0.30} \\ 1900 \end{array}\right]$ | $0.7\left[\begin{array}{c} {[0.36)} \\ (68) \\ 1.5] \\ \hline \end{array}\right.$ | $0.7\left[\begin{array}{c} {[0.3 ;)^{3}(1.5]} \\ \hline \end{array}\right.$ | $0.9\left[\begin{array}{c} {[0.40 ;} \\ (830) \\ 1.9] \\ \hline \end{array}\right.$ | $0.9 \underset{(0.455}{[1.4 ;} 1.9]$ |  |
| INNEX CR (Zimmer Biomet) | Innex Mobile (Zimmer Biomet) | 5,006 | 67 | $73_{(65-78)}$ | 32/68 | 2012-2022 |  | $0.6\left[\begin{array}{c} {[0.4,4 ; 20} \\ (3) \\ 0.9] \end{array}\right.$ | 0.8 [0.655 [1.1] | $0.9\left[\begin{array}{l}\text { [0.724i } \\ \text { (2, } 1.3]\end{array}\right.$ | $1.0\left[\begin{array}{ll} {[0.7949} \\ 10.3] \end{array}\right.$ | $1.0\left[\begin{array}{c} {[0.773} \\ (873) \\ \hline \end{array}\right.$ |  |  |
| INNEX CR GSF (Zimmer Biomet) | Innex Mobile (Zimmer Biomet) | 4,092 | 62 | $72{ }_{(64-78)}$ | $19 / 81$ | 2013-2022 |  | $0.9\left[\begin{array}{l} {[0.6,650} \\ 1.3] \\ 1.3] \end{array}\right.$ | $1.1\left[\begin{array}{l} {[0.84 \cdot 81.5]} \\ 2,46 \end{array}\right.$ | $1.2\left[\begin{array}{ll} {[0.9989} \\ 0,7.7] \end{array}\right.$ | $1.3\left[\begin{array}{ll} {[0.996} \\ 0.96 \\ 1.7] \end{array}\right.$ | $1.3\left[\begin{array}{ll} {[.997)} \\ \hline 9.7] \\ \hline \end{array}\right.$ | $1.3[0.9 .96 .7]$ |  |
| Standard TKA, pivot, fixed bearing, cemented |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| ADVANCE ${ }^{\text {® }}$ (MicroPort) | ADVANCE® II (MicroPort) | 455 | 8 | $72_{(66-78)}$ | 51/49 | 2014-2022 | (411) | $1.3\left[\begin{array}{c} {[0.5 ; 3 ; 0]} \\ (368) \\ \hline \end{array}\right.$ | $1.3\left[\begin{array}{l} {[0.5 ; 3.0]} \\ (291) \end{array}\right.$ | $1.6\left[\begin{array}{c} {[0.79 ; 3.6]} \\ (219) \end{array}\right.$ | $2.1[1.0: 4.5]$ |  |  |  |
| EVOLUTION® (MicroPort) | EVOLUTION® (MicroPort) | 1,908 | 24 | $69_{(61-76)}$ | $36 / 64$ | 2016-2022 | $0.4 \begin{gathered} {[0.2 ; 3 ; 0.9]} \\ (1,36) \end{gathered}$ | $0.7\left[\begin{array}{c} {[0.49 ; 9} \\ (990 \end{array}\right]$ | $0.8 \underset{(0,52)}{[0.5]}$ | $1.2\left[\begin{array}{c} \left.[0.73]^{2}\right) \\ 2.2] \\ \hline \end{array}\right.$ | $1.2 \text { [0.7.70 } 2.2]$ |  |  |  |
| GMK SPHERE (Medacta) | GMK (Medacta) | 1,707 | 35 | $69_{(61-76)}$ | 42/58 | 2014-2022 | $0.4\left[\begin{array}{l} {[0.2 ; 10 ; 1.0]} \\ {[1,0)} \end{array}\right.$ |  | $1.2\left[\begin{array}{l} {[0.72 ; 2} \\ (240) \end{array}\right)$ | $1.5{ }_{\substack{\text { [0, } \\ \text { (24) }}}^{\text {2 }}$ 2.7] |  |  |  |  |
| GMK SPHERE (Medacta) | GMK SPHERE (Medacta) | 310 | 27 | $68{ }_{(62-76)}$ | 7/93 | 2015-2022 | $0.8\left[\begin{array}{c} {[0.2 ; 5]} \\ (195) \\ \hline \end{array}\right.$ | $0.8[0.2 ; 3.3]$ |  |  |  |  |  |  |
| Legacy 3D Knee (Mathys) | Legacy 3D Knee (Mathys) | 1,566 | 21 | $71_{(63-77)}$ | $36 / 64$ | 2014-2022 | $0.2[0.170 .0]^{(1.37)} 0$ | $0.9\left[\begin{array}{c} {[0.562} \\ (0.22) \\ 1.5] \end{array}\right.$ | $1.0\left[\begin{array}{ll} {[0.6 ; 9} & 1.6] \\ (u, 02] \end{array}\right.$ |  | $1.1[0.6 ; 1.8]$ | $1.2\left[\begin{array}{l} \left.[0.72)^{4} 2.0\right] \\ \hline 142 \end{array}\right.$ |  |  |
| Persona CR (Zimmer Biomet) | Persona Tibia (Zimmer Biomet) | 1,660 | 20 | $70_{(62-77)}$ | 40/60 | 2016-2022 | $0.2 \underset{(898)}{[0.0 ;} ; 0.8]$ | $0.2\left[\begin{array}{l} {[0.0 ; 0.0} \\ \langle 49\rangle \end{array}\right.$ | $0.2[0.0 ; 0.8]$ | $0.2 \underset{(0.000}{(0.0)} 0.8]$ |  |  |  |  |

[^5]| Knee arthroplasties without primary patellar resurfacing |  | Number | Hosp. | Age | m/f | Period | Probability of secondary patellar resurfacing ... |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Femoral component | Tibial component |  |  |  |  |  | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Standard TKA, pivot, fixed bearing, cemented |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| PHYSICA KR FEMUR. CEMENTED (Lima) | PHYSICA SYSTEM TIBIA. CEMENTED (Lima) | 307 | 14 | $69_{(61-76)}$ | $39 / 61$ | 2015-2022 | $0.4{ }^{[0.17}$ [17) 2.5$]$ |  | $0.4{ }_{\text {[0.188) }}^{\text {(18) }} \mathbf{2}$ 2.5] | $0.9\left[\begin{array}{c} 0.2,2 ; 66 \\ \text { (ibe } \\ 3.7] \end{array}\right.$ |  |  |  |  |
| Standard TKA, posterior-stabilised, fixed bearing, cemented |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| ATTUNE ${ }^{\text {TM }}$ Femur (DePuy) | ATTUNETM Tibia (DePuy) | 3,079 | 91 | $71_{(62-78)}$ | 38/62 | 2013-2022 | $0.3\left[\begin{array}{c} {[0.2090} \\ (0,0) \\ 0 \end{array}\right.$ |  | $1.3\left[\begin{array}{ll} {[0.906} \\ 10.9] \\ 1.9] \end{array}\right.$ | $1.4\left[\begin{array}{ll} {[0.93]} \\ {[i z e} \\ 2.1] \end{array}\right.$ | $1.6[1.0 ; 2.3]$ | $1.6[1.0 ; 2 ; 3]$ |  |  |
| balanSys BICONDYLAR PS cem. (Mathys) | balanSys BICONDYLAR fix (Mathys) | 1,371 | 26 | $71_{\text {(66-78) }}$ | 40/60 | 2013-2022 | $0.2\left[\begin{array}{l} {[0.0 ; 0 ; 0.6]} \\ (1,0) \end{array}\right.$ | $0.7\left[\begin{array}{c} {[0.30 ;} \\ (907) \\ 1.4] \end{array}\right]$ | $0.8 \text { [0.4:4; } 1.6]$ | $0.8 \underset{\substack{[0.4 ; 7 \\(007)}}{0.6]}$ | $0.8\left[\begin{array}{l} {[0.4 ; 7} \\ 120 \end{array}\right)$ | $0.8\left[\begin{array}{c} 0.4 ; 9_{1}^{\prime} \\ 1.6] \end{array}\right.$ |  |  |
| COLUMBUS (Aesculap) | COLUMBUS (Aesculap) | 572 | 40 | $69_{(62-76)}$ | 35/65 | 2013-2022 | $0.4 \underset{(4,10)}{[0.1 ; ~} 1.6]$ | $0.4\left[\begin{array}{ll} {[0.115)} & 1.6] \\ 4.45 \end{array}\right.$ | $0.7\left[\begin{array}{ll} {[0.23)} \\ (3.2) \\ 2.1] \end{array}\right.$ | $0.7\left[\begin{array}{ll} {[0.2020} \\ \text { L2. } 2.1] \end{array}\right.$ | $0.7 \text { [0.2; 2.1] }$ | $0.7[0.2 ; 2.1]$ | $0.7\left[\begin{array}{ll} {[0.2 ; 2} \\ (62) \\ 2.1] \end{array}\right.$ |  |
| E.MOTION (Aesculap) | E.MOTION (Aesculap) | 2,597 | 39 | $6^{69}{ }_{(62-76)}$ | $36 / 64$ | 2012-2022 | $0.4\left[\begin{array}{l} {[0.2 ; 4 ; 0.8]} \\ (2,4) \end{array}\right.$ | $1.7[1.2 .2 \cdot 2.3]$ | $2.4\left[\begin{array}{c} 11.8 ; 8.2] \\ 10.268) \\ \hline \end{array}\right.$ | $2.6\left[\begin{array}{l} {[20.03} \\ (923) \end{array} 3.5\right]$ | $2.8\left[\begin{array}{l} {[628} \\ (623) \\ \hline \end{array}\right)$ | $2.9[2.2 ; 4.0]$ |  |  |
| E.MOTION PS PRO (Aesculap) | E.MOTION (Aesculap) | 428 | 26 | $64_{(57-73)}$ | $19 / 81$ | 2015-2022 | $1.6 \underset{\substack{0.744 \\(0.7)}}{ } 3.6]$ |  | $5.0\left[\begin{array}{c} {[3.0 ; 6} \\ 1206 \\ 8.0] \end{array}\right.$ | $5.9[3.7 .79 .4]$ | 5.9 [3.77, 9.4 .4$]$ |  |  |  |
| GEMINI SL Total Knee System, Femoral Component, Fixed Bearing PS, cemented (Waldemar Link) | GEMINI SL Total Knee System, Tibial Component, Fixed Bearing, cemented (Waldemar Link) | 1,203 | 22 | $71_{(64-78)}$ | 36/64 | 2014-2022 | $0.2\left[\begin{array}{c}\text { [0.0; } \\ (964)\end{array} 0.7\right]^{\text {a }}$ |  |  | ${ }^{1.1}\left[\begin{array}{l}\text { [0.658] } \\ \text { (12) } 2.0]\end{array}\right.$ |  | $1.8\left[\begin{array}{c} (.55) \\ (54 \\ 4 \end{array} 4\right]$ |  |  |
| GENESIS II PS COCR (Smith \& Nephew) | Genesis II (Smith \& Nephew) | 3,075 | 65 | $71_{(63-77)}$ | 36/64 | 2013-2022 | $0.4[0.2 ; 0.7]$ | $1.6[1.2 .2,2.2]$ | $2.0\left[1.5 \cdot \frac{2.7]}{(1,224)} 2 .\right.$ | $\begin{gathered} 2.2[1.7 ; 2.9] \\ (1.50)] \end{gathered}$ | $2.4 \underset{(9776}{1.8 ;} 3.1]$ | $2.7 \underset{\substack{[4 b j\rangle \\ \hline 2 ; 0 ; \\ 3.5]}}{ }$ | $2.7{ }_{(1168)}^{[20 ; 5]}$ |  |
| GENESIS II PS OXINIUM (Smith \& Nephew) | Genesis II (Smith \& Nephew) | 616 | 54 | $64_{(58-72)}$ | 23/77 | 2013-2022 | $0.6[0.2 ; 1.8]$ | ${ }^{1.8}{ }_{\substack{\text { [0.90) } \\ \text { (30) }}}^{1.5]}$ | $2.6\left[\begin{array}{c} 1.550 \\ (130) \\ 4.7] \end{array}\right.$ | $2.6[1.554 .50$ |  | $\left.2.6{ }_{(17.57}^{[87} 4.7\right]$ |  |  |
| JOURNEY II BCS COCR (Smith \& Nephew) | JOURNEY (Smith \& Nephew) | 873 | 32 | 70 (62-77) | 42/58 | 2017-2022 | $1.0 \underset{\substack{[0.517 \\(617}}{ } 2.1]$ |  | $3.8\left[\begin{array}{l} {[2.45)^{[2 ;} 6} \\ 6.0] \end{array}\right.$ | $4.4\left[\begin{array}{c} (2.77017 .1] \\ (101) \end{array}\right.$ |  |  |  |  |
| JOURNEY II BCS OXINIUM (Smith \& Nephew) | JOURNEY (Smith \& Nephew) | 1,441 | 36 | 68 (61-75) | 32/68 | 2014-2022 | $0.9\left[\begin{array}{c} {[0.5 ; ~} \\ (1.24) \\ 1.6] \end{array}\right.$ | $2.2\left[\begin{array}{l} {[1.553 .53 .1]} \\ \hline(1.53) \end{array}\right.$ | $2.6[1.8: 3.6]$ | $3.0\left[\begin{array}{c} (202), 1 \\ \hline 021 \end{array} 4\right]$ | $3.0\left[\begin{array}{l}\text { [2.1.14 } 4.1]\end{array}\right.$ | $4.2[2.8 ; 6.3]$ |  |  |
| LEGION PS COCR (Smith \& Nephew) | Genesis II (Smith \& Nephew) | 6,767 | 113 | $70_{(62-77)}$ | 40/60 | 2014-2022 | $\left.0.6\left[\begin{array}{c} {[0.4030} \\ {[5030} \end{array}\right) .8\right]$ | $1.9[1.5 \cdot 52.3]$ |  | $2.3[1.9 ; 2.9]$ | $2.4\left[\begin{array}{ll} {[6.0 ; 8]} \\ \hline 1.0] \\ \hline \end{array}\right.$ | $2.4\left[\begin{array}{l} {[2.034} \\ {[3.0} \end{array}\right]$ | $2.4[2.0 .36 .0]$ |  |
| LEGION PS OXINIUM (Smith \& Nephew) | Genesis II (Smith \& Nephew) | 1,913 | 112 | $66_{(59-74)}$ | 22/78 | 2012-2022 | $0.6\left[\begin{array}{c} {[0.3 ; 3 ;)} \\ (1.19) \end{array}\right.$ | $1.6[1.1,2,2.5]$ |  | $2.5[1.7,3.6]$ | 2.7 [1.99, 3.9] | $\underset{\substack{1755}}{2.7} \mathbf{1 . 9 ;} 3.9]$ |  |  |
| NexGen LPS-Flex-Gender (Zimmer Biomet) | NexGen CR (Zimmer Biomet) | 3,537 | 82 | $69{ }_{(61-76)}$ | $9 / 91$ | 2012-2022 | $0.2\left[\begin{array}{c} {[0.1 ; 80)} \\ {[0.4]} \\ \hline \end{array}\right.$ | $0.4\left[\begin{array}{l} {[0.2 .208)} \\ \hline 2.7] \end{array}\right.$ | $0.7\left[\begin{array}{ll} {[0.5088} \\ {[2.58} \\ 1.1] \end{array}\right]$ | $0.9\left[\begin{array}{ll} {[0.651} \\ 1.4 .4] \end{array}\right.$ | $0.9[0.6 ; 1.4]$ | $1.0 \underset{(500)}{[0.7 ; ~ 1.6]}$ | $1.0\left[\begin{array}{c}\text { [0.729 } \\ 139 \\ 1.6]\end{array}\right.$ |  |
| NexGen LPS-Flex (Zimmer Biomet) | NexGen CR (Zimmer Biomet) | 12,640 | 220 | $69^{611-76)}$ | 30/70 | 2012-2022 |  | $0.6\left[\begin{array}{ll} {[0.5955} \\ 0.5] \\ 0.8] \end{array}\right.$ | $0.6[0.5: 0.8]$ | $0.7\left[\begin{array}{c} {[0.573)} \\ 0.0 .9] \\ \hline \end{array}\right.$ | $0.7 \begin{gathered} {[0.50 ; 0.9]} \\ (0.04) \\ {[0.9]} \end{gathered}$ | $0.8\left[\begin{array}{l} {[0.6 ; 1.07} \\ (x .10) \end{array}\right.$ | ${ }_{\substack{0 \\ 0.8 \\ \text { [0.6.6 } \\ \text { (10) }}}^{1.17}$ | $0.8\left[\begin{array}{c} {[0.686} \\ (236) \\ 1.1] \\ \hline \end{array}\right.$ |
| NexGen LPS (Zimmer Biomet) | NexGen CR (Zimmer Biomet) | 9,566 | 36 | $69_{(62-76)}$ | 41/59 | 2012-2022 | $0.1\left[\begin{array}{c} {[0.00040} \\ (0.04) \\ 0.2] \\ \hline \end{array}\right.$ | $0.5\left[\begin{array}{ll} {[0.3: 3,39]} \\ 0.6] \end{array}\right.$ | $0.6\left[\begin{array}{ll} {[5.5744]} \\ 0.9] \end{array}\right.$ | $0.7\left[\begin{array}{c} {[0.6 ; 261.0]} \\ 4.260 \end{array}\right.$ | $0.7 \underset{(0.075)}{[0.0 ; 1.0]}$ | $0.8[0.6 ; 1.1]$ | $0.8\left[\begin{array}{ll} (0.60 ; & 61.1] \end{array}\right.$ | $0.8\left[\begin{array}{ll} {[0.6 ;} & 1.1] \\ (15) \end{array}\right.$ |
| Persona PS (Zimmer Biomet) | Persona Tibia (Zimmer Biomet) | 2,985 | 70 | $71_{(62-78)}$ | $37 / 63$ | 2013-2022 | $0.4\left[\begin{array}{l} {[0.2 ; 55)} \\ 0.8] \\ \hline \end{array}\right.$ | $1.0\left[\begin{array}{ll} {[0.7081} \\ 0,7.7] \\ \hline \end{array}\right.$ |  | $1.1\left[\begin{array}{c} {[0.7 ; 1.8]} \\ (065) \end{array}\right.$ | $1.1\left[\begin{array}{l} {[0.7 ; 1.8]} \\ 1212 \end{array}\right.$ | ${ }^{1.1}[0.7$ [95] 1.8$]$ |  |  |
| SIGMA ${ }^{\text {TM }}$ Femur ( ${ }^{\text {dePuy }}$ ) | MBT Tibia (DePuy) | 657 | 40 | 73 (66-79) | 30/70 | 2014-2022 | $0.5{\underset{(0.256}{[5 ;} ; 1.6]}^{[10}$ | $0.9\left[\begin{array}{c} {[0.468)} \\ \hline 468 \end{array}\right)$ | $0.9\left[\begin{array}{c} {[0.460} \\ {[36)} \\ 2.1] \end{array}\right.$ | $\left.1.2\left[\begin{array}{l} {[0.5 ;} \\ (25 i \\ \hline \end{array}\right) .6\right]$ | $1.2[0.5 ; 2.6]$ |  |  |  |
| SIGMA ${ }^{\text {TM }}$ Femur ( ${ }^{\text {dePuy) }}$ | SIGMA ${ }^{\text {TM }}$ Tibia (DePuy) | 3,343 | 107 | $71_{\text {(64-78) }}$ | $33 / 67$ | 2013-2022 | $0.6\left[\begin{array}{l} {[0.4 ; 70 ; 0.9]} \\ (2,9) \end{array}\right.$ | $1.3\left[\begin{array}{l} {[0.9 .931 .8]} \\ (2.35) \\ \hline \end{array}\right.$ | $1.6[1.2,2.2 .2]$ | $1.6[1.2,2.2]$ | ${ }^{1.7}$ [1.33: 2.3 ] | $1.9[1.45 ; 2.6]$ | $1.9[1.4 ; 2.2 .6]$ |  |
| Triathlon PS (Stryker) | Triathlon (Stryker) | 3,552 | 65 | $71_{(64-78)}$ | 36/64 | 2013-2022 | $0.5\left[\begin{array}{c} {[0.3 ; 65)} \\ (0.8] \end{array}\right.$ | $1.2\left[\begin{array}{l} {[0.83 i j} \\ (2,7) \\ 1.7] \end{array}\right.$ | $1.4[11.02 .00]$ | $1.4[1.0 .02 .0]$ | $1.7[1.2 ; 2 ; 4]$ | $1.7[1.23 ; 2.4]$ |  |  |
| Triathlon PS (Stryker) | Triathlon TS (Stryker) | 369 | 35 | $69{ }_{(61-77)}$ | 36/64 | 2013-2022 | $0.3\left[\begin{array}{c} {[0.0 ; 6} \\ (286 \\ \hline \end{array}\right.$ | $0.3[0.0 ; 2.1]$ | $0.3\left[\begin{array}{ll} {[0.0 ; 2} \\ \text { (132) } \\ 2.1] \end{array}\right.$ | $0.3[0.0 ; 2.1]$ |  |  |  |  |
| Vanguard PS (Zimmer Biomet) | Vanguard Tibia Cruciate (Zimmer Biomet) | 2,680 | 47 | 72 (64-78) | 35/65 | 2014-2022 | $0.4\left[\begin{array}{l} {[0.2 ; 50} \\ {[2.75} \\ \hline \end{array}\right.$ | $\left.0.9{ }_{(0.1674}^{[0.64} 1.4\right]$ | $\left.0.9{ }^{[0.66060} 11.4\right]$ | $1.0\left[\begin{array}{c} (0.664) \\ (664) \\ 1.6] \end{array}\right.$ | $1.2\left[\begin{array}{c} {[1.717 ; 2} \end{array}\right.$ | $\left.1.2\left[\begin{array}{c} {[0.738} \\ (238) \end{array}\right) .0\right]$ | $1.2[0.7 ; 2.0]$ |  |
| VEGA (Aesculap) | VEGA (Aesculap) | 1,659 | 49 | 70 (61-77) | 31/69 | 2013-2022 | $0.4\left[\begin{array}{l} {[0.126 i} \\ (0.20 \end{array}\right)$ | $1.7\left[\begin{array}{l} 1.1,1,2.7] \\ (990) \end{array}\right.$ | $2.5\left[\begin{array}{l} 1.7 .73 .3] \\ 1260 \end{array}\right.$ | ${ }^{3.0}\left[{ }_{(2,19} / 4.2\right]$ | $\left.{ }^{3.2}\left[\begin{array}{l}\text { [2.2; } \\ 129\end{array}\right) 4.5\right]$ |  | 3.2 $\left.{ }_{\text {[2. } 28 ;} 4.5\right]$ |  |

### 5.5 Re-revision probability of hip and knee arthroplasties

While the previous sections focused on the period between primary arthroplasty and the first revision, the current section investigates the period after revision and the survival of revised arthroplasties. The EPRD currently has data on a total of 102,005 revisions backed by plausible documentation, for which it also receives follow-up information from health insurance providers. For the vast majority of these procedures, the EPRD is not aware of the patient's medical history. In most cases, patients' EPRD data entry starts with a reoperation, e.g., because the primary arthroplasty predates EPRD data collection.

In some cases, however, the complete arthroplasty history is known, starting with the primary surgery. This means that all subsequent revisions can be listed consecutively. Table 52 details the revisions with a known history under observation. Over the next few years, the percentage of revisions with previously documented primary procedures will increase in the EPRD. At this stage, there is already a clear trend of significantly higher revision probabilities for revision reoperations.

| Category |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Hip revisions, due to infection | 13,860 | 3,689 | 1,141 | 373 | 185 | 8,472 |
| Hip revisions, not due to infection | 44,280 | 6.966 | 711 | 126 | 66 | 36,411 |
| Knee revisions, due to infection | 10,163 | 2,163 | 625 | 184 | 94. | $\begin{aligned} & 7,097 \\ & \text { nual Report } 2023 \end{aligned}$ |
| Knee revisions, not due to infection | 33,702 | 6,343 | 806 | 136 | 52 | 26,365 |

Figure 36 presents the probabilities of repeat revisions (re-revisions) for all documented revisions under observation, over time - irrespectively of their previous history, and therefore also independently of the number of revisions involved. The revisions have been broken down by the joint operated on and whether they were infection-related or not. Although hip and knee re-revision probabilities initially differ, they gradually converge over time.

For infection-related revisions the risk of re-revision within two years is more than twice that of non-infection-related revisions 29.7 \% vs. 11.8 \% for hips, 23.4 \% vs. $9.2 \%$ for knees). This highlights the serious consequences of periprosthetic infection for the patient, particularly since these cases also entail a significantly higher mortality rate as shown in Chapter 6.

The following trends can be observed when focusing on revisions with a known medical history, which include the primary arthroplasty. On the one hand, the probability of re-revision increases as the number of revisions increases. However, as this increase is significantly greater for non-infection-related than for infection-related revisions, the numbers for both types of revisions

Table 52: Summary of revisions under observation.


Figure 36: Probability of re-revision over time ( $p<0.0001$ )
continue to converge with each additiona revision registered. On the other hand, the percentage of non-infection-related and in-fection-related revisions continues to diverge more and more. While significantly more first revisions are non-infection-related than infection-related, by the third revision, most are septic procedures. It should be noted however, that due to the relatively short documentation period in the EPRD of not quite 11 years, septic revisions are still over-represented among first revisions, as they predominantly occur within the first few years of the primary arthroplasty. Figure 37 presents outcomes separately after a first, second and third revision.

## In brief:

The probability of re-revision ...

- increases with each additional revision, although the rate of increase is lower for infection-related revisions.
after periprosthetic infection is more than twice that of non-infection-related revisions.



Numbers
at risk

| $\square 373$ | 194 | 142 | 101 |
| ---: | ---: | ---: | ---: |
| $\square$ | 126 | 68 | 43 |
| $\square$ | 112 | 86 | 49 |
| 184 | 77 | 43 | 29 |
| $\square$ |  |  |  |



Figure 37: Probability of re-revision after first, second and third revision. Due to the low number of cases, confidence intervals have been omitted for clarity.

## 6 Patient mortality

## 6 Patient mortality

For the first time in an EPRD annual report, In the following patient mortality tables, the this chapter details patient mortality fol- arthroplasty surgery and the death of the relowing arthroplasty. Once a year, the EPRD receives information directly from the participating federal health insurance provider associations about the vital status of participating patients. However, this is limited to information on whether the patient is still alive or has died and in which month the death occurred. The cause of death is not included in this information.
spective patient are thus not necessarily related.

As stated in Chapter 5 above, the choice of treatment often hinges on the patient's physical condition. This introduces a certain degree of patient selection.

Table 53 presents the cumulative mortality of patients at various points in time ${ }^{5}$ up to three years after primary or revision arthroplasty. These summarised values only lend themselves to a direct comparison to a very limited extent, as the mean age of several of these patient groups already differs significantly at the current time point.

However, these figures already illustrate the serious consequences of a femoral fracture near the hip joint: Non-elective THA or hemiarthroplasty patients have the highest mortality rate of all the primary procedures analysed. This cannot solely be rationalised by the older age of non-elective THA patients,

5 Since the EPRD is only notified of the month, but not the day, of death, these dates can only be determined for individual patients with an accuracy of around two weeks (also refer to the explanations in Chapter 3 .).

| Male patients |  | 1 -year mortality expressed as a percent of the age group ... (age in years) |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | e of procedure | $\leq 54$ | 55 to 59 | 60 to 64 | 65 to 69 | 70 to 74 | 75 to 79 | 80 to 84 | 285 |
|  | Elective THAs with uncemented stems | $\begin{gathered} 0.42 \\ \hline 0.40 .5010 \\ \hline 0.05051) \end{gathered}$ |  |  |  |  |  |  |  |
|  | Elective THAs with cemented stems |  |  |  |  |  |  |  |  |
|  | Non-elective THAs |  |  |  |  |  |  |  |  |
|  | Hemiarthroplasties |  |  |  |  | $\begin{gathered} 30.94 \\ 18.48 .9641 \end{gathered}$ |  |  |  |
|  | Standard TKAs |  |  |  |  | $\begin{gathered} 1.16 \\ \text { and } 1.1 .321 \\ 1,17.301 \end{gathered}$ |  |  | $\begin{gathered} 4.78 \\ \substack{40.56 \\ 0.05020} \end{gathered}$ |
|  | Constrained TKAs | $\begin{gathered} 1.47 \\ \substack{10.45050 \\ \hline 10.501} \end{gathered}$ |  |  | $\begin{aligned} & 3.31 .31 \\ & \text { andi.200 } \end{aligned}$ |  | $\begin{gathered} 4.89 \\ \substack{3.89690 \\ \hline 6007} \end{gathered}$ |  |  |
|  | Unicondylar knee arthroplasties |  |  |  |  |  |  |  |  |
|  | Patellofemoral arthroplasties | $0.00$ | $\begin{gathered} 0.00 \\ \text { ckit } \end{gathered}$ | $0.00$ | $0.00$ | $\begin{aligned} & 14.29 \\ & 12.414659 \\ & \hline 6.659 \end{aligned}$ | 0.00 | 0.00 ${ }_{\text {B1 }}$ | ${ }_{\text {0, }}^{0.00}$ |
|  | Hip revisions, not due to infection |  |  |  |  |  |  |  |  |
|  | Hip revisions, due to infection |  |  |  |  |  |  |  |  |
|  | Knee revisions, not due to infection |  |  |  |  |  |  | $\begin{gathered} 4.03 \\ 130.0 .5010 \end{gathered}$ |  |
|  | Knee revisions, due to infection |  |  |  |  |  |  |  |  |
| Corresponding DESTATIS figures |  | $<0.5$ | 0.57-0.87 | 0.96-1.43 | 1.57-2.17 | $2.32-3.21$ | $3.43-4.98$ | $5.58-8.94$ | >10.0 |

Table 54: 1-year mortality after arthroplasty in male patients by age category and type of arthroplasty

In general, mortality after revision surgery is significantly higher than after elective primary procedures, but lower than after non-elective hip arthroplasty. Postoperative mortality after hip revision is higher than after knee revision, which cannot be explained by age differences alone

Mortality tends to be higher for infection-related procedures. It is noteworthy in this context that in reoperations unrelated to periprosthetic infections, the mortality rate is higher for operations involving the exchange of bone fixation components than for those involving the retention of such components, whereas the reverse is true for reoperations due to infection. The EPRD

6 Mortaity tables can be downloaded from hittps://www.destatis.de/DE/Themen/Gesellschaft-Umwelt/Bevoelkerung/Sterbefaelle-


| Female patients |  | 1 -year mortality expressed as a percent of the age group ... (age in years) |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | e of procedure | $\leq 54$ years | 55 to 59 | 60 to 64 | 65 to 69 | 70 to 74 | 75 to 79 | 80 to 84 | $\geq 85$ |
|  | Elective THAs with uncemented stems |  |  |  |  | $\begin{gathered} 0.67 \\ \text { andi. } 0.6707 \end{gathered}$ |  |  |  |
|  | Elective THAs with cemented stems |  |  |  |  |  |  |  |  |
|  | Non-elective THAs |  |  |  |  |  |  |  |  |
|  | Hemiarthroplasties |  |  |  |  |  |  |  |  |
|  | Standard TKAs |  |  |  | $\begin{gathered} 0.39 .39 \\ \text { and } \\ \text { ani.0.07 } \end{gathered}$ | $\begin{gathered} 0.52 \\ \substack{0.50 .80 \\ \hline 6.5050} \end{gathered}$ |  |  | $\begin{aligned} & 2.47 \\ & \substack{21: 28, ~ 28] ~} \end{aligned}$ |
|  | Constrained TKAs |  |  | $\begin{gathered} 1.29 \\ 0.0,2.212101 \end{gathered}$ |  | $\underset{\substack{2,0.31 \\ \left[\begin{array}{c} 20,3,5)^{2} \\ 10,53 \end{array}\right]}}{ }$ |  |  |  |
|  | Unicondylar knee arthroplasties |  | $\begin{gathered} 0.12 \\ \substack{0.0 .929 \\ 0 \\ 0.9090} \end{gathered}$ | $\begin{gathered} 0.23 \\ \substack{0.12,2414 \\ \hline, i 24)} \end{gathered}$ | $\begin{gathered} 0.22 .22 \\ \text { and } 0.72020 \end{gathered}$ | $\begin{gathered} 0.38 \\ \substack{0.3 .854 \\ 0.3640} \end{gathered}$ |  |  |  |
|  | Patellofemoral arthroplasties | $0.00$ | $\begin{gathered} 0.00 \\ 1820 \\ \hline \end{gathered}$ |  | $\begin{aligned} & 0.00 \\ & 1220 \end{aligned}$ | 0.00 | $\begin{aligned} & 0.00 \\ & 12 \pi \end{aligned}$ | ${ }^{0.00}$ | ${ }^{0.00}$ |
|  | Hip revision, not due to infection |  |  |  |  | $\begin{gathered} 2.89 .890 \\ \text { Rif:3000 } \end{gathered}$ |  |  |  |
|  | Hip revision, due to infection |  |  |  | $\begin{gathered} 4.34 \\ \substack{30.5090 \\ 10.6091} \end{gathered}$ |  |  |  |  |
|  | Knee revisions, not due to infection |  | $\begin{gathered} 0.37 \\ \text { and } 0.30,024 \end{gathered}$ | $\begin{gathered} 0.42 \\ \text { and } 20.2060 \end{gathered}$ | $\begin{gathered} 0.63 \\ \hline 0.99999 \end{gathered}$ |  | $\begin{gathered} 1.96 \\ 11.5,5 i, 24] \end{gathered}$ | $\begin{gathered} 4.85 \\ {[4.0 .5,5]} \end{gathered}$ | $\begin{gathered} 14.42 \\ 1220.76 .690 \end{gathered}$ |
|  | Knee revisions, due to infection |  |  |  |  | $\begin{gathered} 2.93 \\ \substack{1.9 .948) \\ \hline 16890} \end{gathered}$ | $\begin{gathered} 7.25 \\ \substack{58,58010} \\ \hline 6.901 \end{gathered}$ |  |  |
|  | Corresponding DESTATIS figures | <0.28 | 0.31-0.46 | $0.51-0.73$ | 0.81-1.16 | $1.27-1.86$ | 2.03-3.12 | $3.56-6.34$ | >7.33 |

Table 55: 1-year mortality after arthroplasty in female patients by age category and type of arthroplasty
knee hemiarthroplasties is in part markedly lower than the corresponding figures from the German Federal Statistical Office. One possible reason for this could be that these procedures tend to be performed on healthier patients.

For elective arthroplasties with cemented stems and constrained TKAs, the corresponding DESTATIS figures are lower for younger age groups, but comparable or even higher for older age groups. Furthermore, for elective THAs with cemented stems, the mor tality rate observed in the EPRD does not rise steadily with age, but initially declines again in men aged 70 and over as well as in women aged 60 and over. This is where the earlier aspect of patient selection comes into play: This type of treatment is probably only preferred for younger patients in very poor physical condition and no longer solely for older patients.

Patient mortality following revision surgery is almost always higher than the correspond ing figures from the German Federal Statistical Office for the respective age group. With the notable exception of non-infection-related knee revisions.

## 7 <br> Mismatch detection for more patient safety

## 7 Mismatch detection for more patient safety

A very important objective of the EPRD is the improvement of patient safety, for example, by reducing so-called mismatches in hip and knee arthroplasty procedures. Among the many arthroplasties documented annually in the EPRD, there are always some cases where the combination of implanted components is not authorised or unsuitable. Incompatible components should, in theory, never be combined in primary arthroplasty. The fact that mismatches still occasionally occur is in all likelihood due to oversight, ignorance or, under certain circumstances, the lack of suitable components in the hospital. These cases must be avoided at all costs. Unfortunately, in revision surgery mismatches are sometimes unavoidable. However, such a decision should be carefully considered and discussed with the respective patient. [7]

To help hospitals avoid or quickly correct mismatches, the EPRD provides timely feedback on the components used. In the event
of a mismatch, a corresponding warning message is issued directly in the data acquisition software after scanning the labels of the implant components (Illustration 4). The case queries provided with the monthly summary reports of the EPRD also point out potential mismatches. However, an easy correction is then no longer possible. The earlier a procedure is documented in the hospital, the greater the chances the mismatch can be corrected without harming the patient. The EPRD therefore recommends that procedures be documented during surgery, provided that the workflow in the hospital allows this. Documentation mistakes in hospitals (e.g. wrong label scanned) and classification errors in the product database of the EPRD may, however, lead to false alerts in some cases. Continuous processing of such cases will further reduce the number of false alarms.

## S ACHTUNG

A Die Online-Plausiprüfung hat Warnungen zurückgegeben. Wenn Sie trotzdem Die Online-Plausiprüfung hat Warnung
fortfahren möchten, wâhlen Sie OK.

## $\checkmark$ OK $\times$ Abbrechen

Illustration 5: An EPRD-Edit software mismatch notification during data entry. The text shown is: The online plausibility check has returned warnings. If you still want to continue, select ok. OP 1: There may be a size mismatch in the head and acetabular component.

For the year 2022, the following potential observed in two hemiarthroplasty procemismatch cases were identified in other- dures. In these cases, the bipolar head or its wise plausibly documented primary arthroplasties:

- In 55 THAs, the documented sizes of the head component and the insert or acetabular component differed. The selected head was too large for the insert or cup in 27 cases and too small in 28 cases (Table 56 and an example in Table 57). Heads that are too large may result in malalignment, and heads that are too small in impingement and insert damage. Similar size mismatches were also
- In two arthroplasties, the stem taper did not match the taper of the ceramic head (see example in Table 58). Such a taper mismatch increases the risk of head fracture.
- In 16 total knee arthroplasties, components intended solely for the left knee were combined with components approved only for the right knee (see example in Table 59). Whether this type of mismatch has conse-

|  |  | Inner diameter of insert/acetabular component |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | 22 mm | 28 mm | 32 mm | 36 mm | 40 mm |
| $\begin{aligned} & \stackrel{N}{n} \\ & \stackrel{\rightharpoonup}{0} \\ & \stackrel{\sim}{x} \end{aligned}$ | 22 mm |  | 3 | 1 |  |  |
|  | 28 mm |  |  | 8 | 2 |  |
|  | 32 mm | 1 | 6 |  | 13 |  |
|  | 36 mm |  | 1 | 19 |  | 1 |


| Component type | Identification | Manufacturer |
| :--- | :--- | :--- |
| Acetabular component | Allofit IT Alloclassic Schale $56 /$ KK | Zimmer Biomet |
| Acetabular insert | IT acetabular insert Longevity XLPE neutral $\mathbf{3 6}$ KK | Zimmer Biomet |
| Femoral component | Avenir Müller Schaft 5 Lateral | Zimmer Biomet |
| Head component | Biolox Delta Head $12 / 14$ Size $\mathbf{3 2} \times \mathbf{- 3 . 5}$ | Zimmer Biomet |
| TabRRD Anual Report 2023 |  |  |

Table 57: Example of a head size mismatch in total hip arthroplasty

| Component type | Identification | Manufacturer |
| :--- | :--- | :--- |
| Femoral component | BICONTACT S PLASMAPORE 12/14 SIZE 13MM | Aesculap AG |
| Head component | ISODUR PROSTHESIS HEAD $\mathbf{1 4 / 1 6} \mathbf{2 8 M M ~ S}$ | Aesculap AG |
| Head component | BIPOLAR CUP ID28MM OD43MM SELF-CENTERING | Aesculap AG |
| OEPRD Anual Report 2023 |  |  |

Table 58: Example of a taper mismatch in hemiarthroplasty of the hip
quences for the arthroplasty itself and the - In 17 total knee arthroplasties a postepatient depends on the specific design of the respective knee system. However, since all side-specific components are available for both sides, such a mismatch is unnecessary and preventable.

- For 415 total knee arthroplasties and 2 unicondylar replacements, the documented side of all components implanted in the procedure did not match the side specification stored in the product database. It is hoped that the majority of these cases are not actual mismatches, but merely incorrect side entries in the registry documentation. However, through feedback from enquiries to the hospitals the EPRD is also aware of some cases in which components were actually implanted in the wrong side.
- Unicondylar arthroplasties can be performed either medially on the inside or laterally on the outside of the knee. However, in 25 unicondylar knee replacements, components approved only for medial use were combined with components approved only for lateral use.
- In 17 total knee arthroplasties a poste-
rior-stabilised insert component was documented together with a femoral component not designed for this type of stabilisation (see example in Table 60). Depending on the design, this may result in impingement problems, extension deficit and partial dislocation upon leg extension.

Mismatch checks are based on the EPRD's own product database but cannot yet identify all mismatch scenarios. For example, it is currently impossible to automatically detect size mismatches in knee arthroplasties. However, the EPRD product database will be expanded by the end of the year to include the option of mapping the size compatibility tables for most available knee systems, so that automated verification of knee components can begin in 2024 as well. The verifications should also be expanded in other respects: The register, for example, includes documented cases in which strictly uncemented components have been used together with bone cement. In some cases, there may be a medical indication for this. However, the surgeons bear sole responsibility for this

| Component type | Identification | Manufacturer |
| :--- | :--- | :---: |
| Tibial tray | GNS ॥ CMT TIB SIZE 7 LEFT | Smith \& Nephew |
| Insert component | GII C/R ART INS SZ 7-8 11MM | Smith \& Nephew |
| Femoral component | GNS ॥ C/R FEM SIZE 8 RIGHT | Smith \& Nephew |
|  |  |  |

Table 59. Example of a side mismatch in total knee arthroplasty

| Component type | Identification | Manufacturer |
| :--- | :--- | :---: |
| Tibial tray | Triathlon Tritanium Base Plate, Size 6 | Stryker |
| Insert component | TRIATHLON PS X3 TIBIAL INSERT 6,10 mm | Stryker |
| Femoral component | TRIATHLON P/A CR FEM COMP CEMENTLESS 6 L | Stryker |
|  | ©EPRD Annual Report 2 22 |  |

Table 60: Example of a PS insert and non-PS femoral component mismatch
type of arthroplasty and should ensure that they inform the patients concerned about this deviation from the instructions for use and the reasons for it. The EPRD will therefore continue to issue corresponding alerts in these cases.

Unfortunately, to date the EPRD has not been able to detect a sustained decline in the annual mismatch rates. Compared to 2021, the number of mismatch cases detected in 2022 is even significantly higher than the corresponding increase in documentation figures. This is very unfortunate and may prove to be a serious problem for the patients concerned.

## 8 <br> Summary

## 8 Summary

The EPRD has been documenting the practice of hip and knee arthroplasty in Germany for more than ten years. After a decline in the annual procedure volume registered in the EPRD during the years of the pandemic, volumes increased by $9 \%$ in 2022, compared to 2019. This is the highest number of procedures recorded since inception of the registry. The EPRD has documented more than two million procedures from data provided on a strictly voluntary basis.

In the spring of this year, the first pilot hospitals began using PROMs (Patient Reported Outcome Measures) to assess patient satisfaction following arthroplasty. The EPRD is also planning to document individual surgeon data, provided on a voluntary basis. Regular operation of the German national implant registry (IRD) for hip and knee arthroplasty is still currently scheduled to start in 2025.

The 2022 operating year
In 2022, the EPRD documented a total of 347,702 hip and knee arthroplasty procedures performed in 751 hospitals. $41 \%$ of the patients treated were men. 177,826 of the documented cases involved primary hip arthroplasties. Total arthroplasties accounted for more than $88 \%$ of cases. With $77.2 \%$ of uncemented THAs performed in 2022, this figure is comparable to previous years and the procedure continues to be the standard. Hybrid THAs increased slightly. In 2022, hemiarthroplasties of the hip were still relying on cemented stems in almost $89 \%$ of documented cases. In recent years, short stem THAs have steadily increased to $13.3 \%$. The use of monobloc cups continued
to decline to less than $9 \%$. A ceramic head is the general rule for THAs performed in Germany. The proportion of metal heads has continued to decline to $6.6 \%$. There is also a continuing trend favouring larger head sizes; 36 mm heads accounted for $47.1 \%$ of head components in 2022. In more than $41 \%$ of cases, short head-neck lengths, i.e. XS or S, are now being used. The standard bearing material is ceramic with (cross-linked) PE, while bearings with ceramic inserts have declined continuously in recent years, currently amounting to only $7.5 \%$. Inserts made of highly cross-linked polyethylene are now used in more than $80 \%$ of THAs, which represents an increase of 28 percentage points since 2014.

Of the 18,145 hip reoperations documented for 2022 , the most common reasons for revision were loosening ( $22.7 \%$ ), infection ( $16.4 \%$ ), periprosthetic fractures ( $15.9 \%$ ), and dislocation ( $13.6 \%$ ). The proportion of reoperations with loosening as a documented indication has therefore almost declined by half since 2014. What has also been striking in recent years is that revisions for periprosthetic infections that retain bone fixation components have become increasingly common. While in 2014 at least one bone fixation component was replaced in almost $68 \%$ of reoperations due to infection, in 2022 this was only the case in less than half of cases. A strong trend towards switching to a dual mobility cup in acetabular revisions has been observed in the EPRD since 2014 (from $10 \%$ in 2014 to $38.5 \%$ in 2022).

A total of 137,030 primary knee arthroplasties were documented in the EPRD in
2022. Knee arthroplasty patients tended to be younger than hip arthroplasty patients. However, at 48 \%, significantly more knee arthroplasty patients were classified as morbidly obese based on their BMI. By far the most common type of fixation in both TKA $(95.6 \%)$ and unicondylar arthroplasties ( $88.9 \%$ ) is the fully cemented fixation. Since 2016, the percentage of fully cemented fixation systems in TKAs has risen by 5 points The use of mobile bearings has been trending downwards since 2016. While they were still used in $18.7 \%$ of all TKAs in 2016, their use fell to $9.3 \%$ in 2022. Cruciate retaining systems continue to be the most common choice in TKAs (proportion in 2022: 46.9 \%). However, they have been steadily losing ground since 2015 in favour of posterior stabilised systems (proportion in 2022: $25.6 \%$ ). Patellar resurfacing at primary TKA was performed in $10.5 \%$ of TKAs in 2022.

As in previous years, the most common reason given for the 14,379 documented knee arthroplasty reoperations was loosening ( $22.8 \%$ ). However, their proportion has also declined over the years (from 33.8 \% in 2014 to $22.8 \%$ in 2022), although not as much as for hip arthroplasties. Secondary patellar resurfacing accounted for $13 \%$ of reoperations. As with hip arthroplasty, there has been an increase in implant-retaining procedures for periprosthetic infections in knee arthroplasty: in 2022, at least one of the bone fixation components was replaced in only half of these cases. Overall, however, almost $56 \%$ of knee reoperations involved the replacement of all components, with over $60 \%$ of these involving a switch to a constrained knee system.

Hip and knee arthroplasty survival Valid follow-up data on some 960,000 primary arthroplasties and 102,000 revisions were available for the arthroplasty survival analysis in this report. In primary arthroplas-
ty, this data shows higher revision probabilities for non-elective hip arthroplasties compared to elective cases and for unicondylar arthroplasties compared to standard TKAs.

Patient-specific factors such as age, sex, BMI, and the presence of comorbidities have a significant impact on early revision probabilities in particular. Patient age appears to affect the outcomes of hip and knee arthroplasty differently. For knee arthroplasties, the probability of revision surgery decreases with increasing patient age, while in hip arthroplasties it rises with increasing age. This is because arthroplasties with uncemented stem components are much more likely to be revised in older patients, especially in cases of periprosthetic fractures. The EPRD therefore recommends the use of cemented stems in older patients. A BMI of over 40 leads to a sharp increase in the revision probability of hip and knee arthroplasty.

In addition to patient-specific factors, the hospitals also have an effect on arthroplasty outcome: in hospitals with high patient volumes, the risk of elective arthroplasty revisions tends to be lower. In the EPRD, this socalled volume outcome effect is particularly evident for unicondylar arthroplasties.

One of the objectives of the EPRD is the reduction of revision rates in arthroplasty. When considering the revision probabilities in elective THA by operating year however, this envisaged improvement is not yet reflected in the short and medium-term outcomes currently available. However, the EPRD is still a relatively young registry with ten years of data collection and has only started within the last three years to make cautious recommendations for certain types of arthroplasties. The fact that, unlike in hip arthroplasties, the revision probability in knee arthroplasties is already lower cannot therefore be attributed to the existence and work of the EPRD. Nevertheless, the fact
that these developments can be identified in a valid manner is already one of the successes of the registry.

The EPRD data shows that the probability of a re-revision after a first revision is generally significantly higher than that of a first revision after the primary arthroplasty. The probability of a re-revision after periprosthetic infection is more than twice that of a non-infection-related revision. However, the risk of revision surgery increases with each additional revision. This increase is lower for infection-related than for non-infection-related revisions.

## Patient mortality

For the first time, the EPRD also presents the patient mortality rate following arthroplasty procedures. The death of the patient is however not necessarily related to the arthroplasty operation per se. For most of the primary arthroplasties documented in the EPRD, patient mortality is less than the benchmark figures published by the German Federal Statistical Office. This suggests that arthroplasty patients tend to be healthier than the general population by respective age groups. One exception is the treatment of femoral fractures close to the hip joint: in the overall analysis across all age groups, the 1-year mortality rate for non-elective THAs is $12 \%$ and for hemiarthroplasties as high as $30.6 \%$. In the EPRD, mortality after elective primary arthroplasties is less than these figures, but significantly higher than those for elective primary arthroplasty - it tends to be higher for infection-related revisions than for other indications.

## Mismatch detection for more patient safety

A very important objective of the EPRD is the improvement of patient safety, for example, by reducing so-called mismatches in hip and knee arthroplasty procedures. With
the help of the product database, the EPRD also identified a three-digit number of mismatched implant combinations in 2022. Compared to previous years, the number of documented mismatch cases has increased. In the event of a mismatch, a corresponding alert is issued directly in the data acquisition software after scanning the labels of the implant components. This allows the respective hospital to check the case promptly and correct it, if necessary. The EPRD is working on continuing to improve the accuracy of mismatch detection and expanding it to include scenarios not yet covered. Automated size compatibility check for knee systems is expected to start in 2024. The EPRD aims to make an important contribution to avoiding implant mismatches in the future by detecting mismatch cases at an early stage and providing feedback to the hospitals.

## Glossary and indexes

## Glossary

The following summary explains the terms and designations used in the tables and text.

## Term

Acetabular componen
Antioxidant

ASA status
Bearing

## Body Mass Inde (acronym: BMI)

Bone cement
Comented

Cementless/Uncemented

## Censoring events

Ceramicised metal

Coated metal

## Explanation

Part of the hip arthroplasty that replaces the acetabulum. The acetabular component can either consist of one part (monobloc) or of several parts (modular acetabular component) Typically, a modular acetabular compo nent consists of a metal cup and an acetabular insert.
Additive/chemical compound, such as Vitamin E , which decreases oxidation of the polyethylene used in arthroplasty.
ASA status refers to a patient health status classification system which estimates perioperative risk. The classification system was established over 60 years ago by the American Society of Anesthesiologists (ASA). The anaesthesiologist assigns each patient a status between I (normal, withou relevant concomitant diseases) and VI (brain dead). In the EPRD, the spectrum ranges from I to V (a moribund patient who is not expected to surviv
without the operation).

Describes the materials of the two surfaces that move against each other in a joint replacement. Examples are: metal/polyethylene, metal/metal ceramic/polyethylene, ceramic/ceramic. In this report, the first materia mentioned always refers to the femoral component of the articulation.
Ratio between the height and weight of a person, defined as their weight (in kilograms) divided by their squared height (in metres).
Material used to anchor prosthetic components in the bone. The material used is polymethyl methacrylate (PMMA). Antibiotics reduce the risk of in fection and can be added to the bone cement either during production or during the surgery.
Component fixation with cement
Component fixation without cement
In some cases events such as patient death or lost-to-follow-up, may oc In some cases events such as patient deare the patient requires a subsequent arthroplasty revision (end point). Up to the occurrence of these so-called censoring events the outcome is still accounted, but the patient is no longer followed up.
Implant components that consist of a zirconium alloy substrate and a ceramic surface modification - oxidised zirconium alloy. It is therefore neither all-ceramic nor a coated metal.
Implant components that have been coated with titanium nitride, titanium niobium nitride or zirconium nitride. In the EPRD, these coated components are treated separately from components made of ceramicised metal or all-ceramic components.

Confidence interval
Constraint

Cruciate retaining
Cruciate retaining/sacrificing

## Cruciate sacrificing

Dual mobility

Elixhauser Comorbidity Score

Femoral component (hip)

Femoral component (knee)

## Femoral neck prosthesis

Fixed bearing

## Explanation

Patella resurfacing following primary bicondylar knee arthroplasty on the same joint affected by "normal" progression of the disease (including ex change of the insert for prophylactic reasons), is a complementary oper tion, rather than a revision.

Interval that contains the true value within a specified probability range (confidence level).
Knee replacements are characterised by their level of constraint (stabilisation). In this report, we define "standard" knee systems as cruciate-retaining, cruciate-retaining/sacrificing, pure cruciate-sacrificing and also posterior-stabilised systems without varus-valgus stabilisation. Varus-valgus-stabilised and (rigid/rotational) hinge systems are considered as "constrained".
Design preserving the posterior cruciate ligament without constraining knee motion/kinematics.
The design is suitable for both a cruciate ligament-retaining or a replace ment procedure.

Design replacing the posterior cruciate ligament with kinematics, which partially permits a limited relative motion in all three planes.
See Acetabular component
Acronym for debridement, antibiotics, implant retention. Refers to a surgical procedure for periprosthetic infections. An implant retaining procedure may be indicated in certain circumstances (acute early infection, solid implant fixation, etc.). This also includes procedures where components that are not bone-anchored, such as inserts and modular heads, are also replaced.
Case of a dual mobility arthroplasty the acetabular insert is designed (convex surface) to articulate with a dual mobility acetabular component. It is inserted into the concave surface of this bone facing shell. The femoral head is usually inserted into the dual mobility insert which is in turn inserted into the bone facing shell.

Comorbidity index which is checked for the presence and the overall se verity of certain comorbidities based on the diagnosis codes from the billing data. This is then used to calculate a measure of the patient's state of health. The higher the score, the worse the patient's health and the higher the mortality risk.
Arthroplasty component inserted into the proximal femur. It is either already inseparably connected to the femoral head (monobloc) or a modular head can be attached to obtain a complete femoral component (modular head stem), it can also include a modular structure with a modular neck or proximal section (modular stem).
Arthroplasty component inserted onto the distal femur. It can form either one single femoral condyle or both femoral condyles, and the femoral trochlear.
Generally refers to a hip stem component anchored in the femoral neck but it also refers to the "mid-head resection" prosthesis.

Monobloc design of the tibial tray or modular connection between the tibial tray and the tibial insert that does not permit any relative movement between these components. Hinged systems with a rotating hinge are also classified as fixed bearings, as opposed to a mobile bearing.

| Term | Explanation |
| :---: | :---: |
| German ICPM code | German hospitals use the German ICPM (International Classification of Procedures in Medicine) codes to document inpatient procedures tor health insurance claims. Each procedure has been assigned a numerical code. For example, code 5-820.01 refers to cemented total hip arthroplasty. |
| Head (component) | See Modular head. |
| Head-neck length | Describes the distance between the centre of the head and a reference point on the taper in the direction of the taper axis. The size specifications which range from XS to XXXL vary between manufacturers. |
| Hemiarthroplasty | In contrast to a total arthroplasty, a hemiarthroplasty (hemi = half) does not replace the entire joint but only part of it. A typical example is a dual-head arthroplasty, in which only the femoral component of the hip joint is replaced with the head, but not the acetabular component. |
| Hinge | Describes coupled knee systems with lateral joint stability and with a simple (single degree of mobility = a "rigid hinge") or a rotating hinge joint between the femoral component and the tibial tray. |
| Hip stem | See Femoral component (hip). |
| hXLPE | Highly cross-linked polyethylene (UHMWPE). Also refer to Polyethylene (PE). |
| Hybrid | Arthroplasty in which one component is cemented while the other is not cemented. In hip replacement, "hybrid" refers to the combination of a cemented stem and an uncemented acetabular component, while "reverse hybrid" refers to the combination of an uncemented stem and a cemented acetabular component. In the case of knee arthroplasty, "hybrid" refers to the combination of cemented tibial tray and uncemented femoral component and "reverse hybrid" the reverse combination. |
| ICD-10 code | The International Statistical Classification of Diseases and Related Health Problems (Version 10) is an internationally accepted system for documenting principal diagnoses and concomitant diseases. German hospitals use the German ICD-10 codes to document the diagnoses determined during the patient's stay in hospital to the health insurance providers. For example, S72.0 is the code for "fracture of neck of femur". |
| Impingement | Mechanical complication due to inappropriate contact of implant components and/or bone. |
| Insert | Tibial inserts are part of a knee replacement and are attached to the superior surface of the tibial tray and provide the articulating surface with the femoral component. Acetabular Inserts are part of a hip replacement and are inserted inside of a modular acetabular component. |
| Kaplan-Meier estimator | Statistical methodology to determine the probability that a given event of interest will not occur within a specified time interval. Events that make it impossible to observe the occurrence of the given events can be taken into account in the calculation and can be censored. |
| Mismatch | Arthroplasty involving a combination of components that are either incompatible or a component that is incompatible with existing components. |
| Mobile bearing | Mobile connection between the tibial tray and the tibial insert. As opposed to a fixed bearing. Hinged systems with a rotating hinge are not classified as mobile bearings. See Fixed bearing | to a fixed bearing. Hinged systems with a rotating hinge are not classified as mobile bearings. See Fixed bearing


| Term | Explanation |
| :---: | :---: |
| Modular cup | An acetabular component designed to accommodate a separate bearing surface within its internal diameter. Also refer to Monobloc cup and Acetabular component. |
| Modular head | Femoral head with an upper convex surface which articulates with the acetabular articular surface. At its distal aspect, there is a female taper which is designed to engage with the male taper of the modular femoral stem or modular femoral neck. Heads are available in varying sizes to match the internal diameter of the acetabular articulating surface. |
| Modular stem | A femoral stem component that is composed of several parts and which also requires a modular head. Also refer to Monobloc stem and Femoral component (hip). |
| Monobloc | A component consisting of one part, e.g. for hip replacement a stem component with an integrated head or a polyethylene cup that does not require a separate insert. |
| Monobloc cup | An acetabular component, which usually consists of one part or parts that have been "inseparably" pre-assembled/connected. In contrast, modular cups consist of at least two parts, which are usually only connected to one another during the implantation. Also refer to Modular cup and Femoral component (hip). |
| Monobloc stem | A femoral stem component that consists of one part and does not require a separate head component. In contrast, other stems consist of at least two parts. Also refer to Modular stem and Femoral component (hip). |
| Mortality | Refers to the number of deaths in a given period as a percentage of the total number of individuals considered. |
| mXLPE | Moderately cross-linked polyethylene (UHMWPE). |
| Offset | The distance from the center of rotation of the femoral head to a line bisecting the longitudinal axis of the femoral stem. |
| Partial knee arthroplasty | A partial knee prosthesis only replaces part of the joint surface. A typical example is a unicondylar prosthesis which only replaces the medial/lateral part of the knee joint, not the entire knee joint.. Also refer to Total knee arthroplasty |
| Partially cemented | Partially cemented indicates that one component is not cemented and the other is. Also refer to Hybrid. |
| Patellar component | Component of patellar resurfacing. While this often only consists of a polyethylene cap, which is cemented into the posterior surface of the patella, there are also designs in which a polyethylene cap is fixed to a metal base plate. Also refer to Patellar resurfacing. |
| Patellar resurfacing | Use of an implant replacing the articulation surface of the kneecap. For secondary patella resurfacing following primary bicondylar knee arthroplasty also refer to Complementary surgery. |
| Patellofemoral arthroplasty | Artificial replacement of the trochlea (groove in the distal femur) and usually of the patellar surface too, also applies to cases with an additional unicondylar replacement. |
| Periprosthetic joint infection | These infections are generally a bacterial colonisation of an implanted endoprosthesis. This is a particularly dreaded complication, which is difficult and time-consuming to treat surgically. Typically, the infection is caused by pathogens that are part of the normal human skin and mucosal flora. |


| Term | Explanation |
| :---: | :---: |
| Pivot | Describes knee systems designed to support natural rotation/translation kinematics. |
| Polyethylene (PE) | Polyethylene (abbreviation PE) is a thermoplastic made by chain polymerisation of ethene $[\mathrm{CH} 2=\mathrm{CH} 2]$, from which prosthetic components (e.g. inserts) can be produced. In arthroplasty, ultra high molecular weight polyethylene (UHMWPE) is usually used. This can subsequently be modified by irradiation and coupling to antioxidants. Also refer to hXLPE or mXLPE. |
| Posterior stabilised | Design allowing the posterior cruciate ligament to be replaced with a mechanical element such as an articulated polyethylene extension which controls and limits anterior and/or posterior movement. |
| Primary surgery/arthroplasty | The primary implantation of one or more arthroplasty components in a specific joint. |
| $p$-value | Lowest significance level at which a statistical test would still reject the null hypothesis. Values below 0.05 are usually referred to as being statistically significant. |
| Reconstruction shell | A device to provide structural stability to the pelvis prior to implanting the definitive acetabular articular component. Such a device may be required in bony defect situations. This may be the case in revision surgery, but also in primary surgery where pelvic discontinuity arises secondary to bone loss, e.g. tumour or post-traumatic reconstructions. |
| Reoperation | Umbrella term including revision arthroplasty, where components are exchanged and complementary surgery where further arthroplasty components are added to compensate for natural disease progression. |
| Reverse-hybrid | See Hybrid. |
| Revision (surgery/arthroplasty) | Surgery referring to the removal and, if necessary, the replacement of previously implanted hip or knee arthroplasty components. Revision surgery may or may not be followed by re-implantation of new arthroplasty components during the same operation (one-stage revision) or at a later date (multi-stage revision) and is interpreted as failure of the index arthroplasty. In contrast, the reoperation of a knee replacement with patellofemoral-resurfacing as a consequence of progressive patellofemoral osteoarthritis is not interpreted as failure of the initial arthroplasty. Also refer to Reoperation and Complementary surgery. |
| Revision cup | Monobloc or modular acetabulum component with added design characteristics for bridging acetabular bone defects or for added bony fixation (e.g. additional screw hole). |
| Revision stem | A hip stem component that is specifically designed for revision hip arthroplasties. |
| Routine data | Data stored by public health insurance companies, in particular for administrative and billing purposes, in accordance with §301 SGB V (German Social Code, Book V). This data, which includes ICD codes for main and secondary diagnoses as well as OPS codes for treatments, is delivered to the EPRD together with the vital status of the participating patients twice a year. The data is used to supplement the case documentation submitted directly to the registry from participating hospitals. |


| Term | Explanation |
| :---: | :---: |
| Short stem | Hip stem components that are specified by the manufacturer as anchoring in the metaphyseal area. These include: Femoral neck-preserving systems, in which only the femoral head is removed and the femoral neck is left intact, femoral neck-preserving systems, in which parts of the femoral neck are also removed, and femoral neck-resecting systems, in which the femoral neck is also completely removed. |
| Standard TKA | Describes "unconstrained/minimally stabilised" knee systems such as cruciate-retaining/sacrificing, pure cruciate-sacrificing and also posterior stabilised systems without varus-valgus stabilisation. |
| Surface replacement (hip) | Surface replacement of the femoral head (resurfacing head) and/or the acetabular cup (surface replacement cup). The "resurfacing head" is used to describe a femoral component that is designed only to cover the patient's own femoral head. There may be an anchoring device for epiphyseal fixation (e.g.; central pins). The head is used with a corresponding "surface replacement cup" which is made of one piece of material (monobloc). |
| Tibial tray | The component that replaces/resurfaces the upper tibia can be modular (more than one piece and accept an insert, monobloc (one piece), preassembled (the insert and tibial tray are assembled by the manufacturer but can be separated) or prefixed (where the tibial tray and insert are assembled by the manufacturer and cannot be separated). |
| Total hip arthroplasty (acronym: THA) | Orthopaedic implant which replaces a hip joint. In contrast to a hemiarthroplasty, a total hip arthroplasty replaces the entire joint. |
| Total knee arthroplasty (acronym: TKA) | A knee arthroplasty replacing all three compartments of the knee joint (medial and lateral compartment of the tibiofemoral joint, and the patellofemoral compartment). Current practice in knee arthroplasty in Germany rarely includes patellar resurfacing. Strictly speaking, these cases should therefore not be classified as total knee arthroplasties, but rather as bicompartmental arthroplasties. However, the term "total knee arthroplasty" to refer to a bicompartmental knee arthroplasty is widely used in Germany. |
| Tumour stem | Primarily refers to a modular stem system, implanted as a reconstruction option for extensive bony defects after femoral tumour resection or at repeat revision (re-revision). |
| Two-stage revision surgery | The EPRD defines this as a procedure in which the removal and the re-implantation (replacement) of prosthetic components are performed separately and not during the same operation. This is usually performed as part of infection-related revision surgery. As further interventions may be necessary between explantation and re-implantation (e.g. spacer replacement, etc.), these procedures are also referred to as "two-/multi-stage revisions". See Revision arthroplasty |
| Uncoated metal | Implant components that have not been ceramic coated. |
| Unicondylar knee arthroplasty | Replacement of only one femoral condyle and the corresponding portion of the tibial plateau of the knee joint. |

## References

[1] Kendir C, Bienassis Kd, Slawomirski L, Klazinga N, Turnau M, Terner M, Webster G, Bohm E, Hallstrom B, Rolfson O, Wilkinson JM, Lübbeke-Wolff A. International assessment of the use and results of patient-reported outcome measures for hip and knee replacement surgery 2022. https://doi.org/10.1787/6da7f06b-en
[2] EPRD Deutsche Endoprothesenregister gGmbH German Arthroplasty Registry (EPRD) Annual Report 2021 Berlin, 2021 https://doi.org/10.36186/reporteprd042021
[3] Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data
Med Care 2005;43(11): 1130-9.
https://doi.org/10.1097/01.mlr.0000182534.19832.83
[4] Steinbrück A, Grimberg AW, Elliott J, Melsheimer O, Jansson V. Short versus conventional stem in cementless total hip arthroplasty: An evidence-based approach with registry data of mid-term survival. Der Orthopade 2021;50(4): 296-305. https://doi.org/10.1007/s00132-021-04083-y
[5] Hunt LP, Matharu GS, Blom AW, Howard PW, Wilkinson JM, Whitehouse MR. Patellar resurfacing during primary total knee replacement is associated with a lower risk of revision surgery.
Bone Joint 」 2021:103-B(5): 864-871
https://doi.org/10.1302/0301-620X.103B5.BJJ-2020-0598.R2
[6] EPRD Deutsche Endoprothesenregister gGmbH German Arthroplasty Registry (EPRD) Annual Report 2022 Berlin, 2022. https://doi.org/10.36186/reporteprd062022
[7] Tucker K, Gunther KP, Kjaersgaard-Andersen P, Lutzner J, Kretzer JP, Nelissen R, Lange T, Zagra L. EFORT recommendations for off-label use, mix \& match and mismatch in hip and knee arthroplasty RT Open Rev 2021:6(11): 982-1005 https://doi.org/10.1302/2058-5241.6.210080

## List of figures

Figure 1: Annual procedure volume by operation date ..... 13
Figure 2: Number of hospitals submitting data each year .....  13
Figure 3: $\quad$ Trends in THA fixations over time .....  .33
Figure 4: Trends in THA insert materials over time .....  34
Figure 5: $\quad$ Trends in THA head sizes over time .....  34
Figure 6: $\quad$ Trends in THA head-neck lengths over time .....  35
Figure 7: $\quad$ Trends in the reasons given for hip reoperations over time .....  38
Figure 8: Trends in bone fixation component replacements in infection-related hip reoperations over time .....  39
Figure 9: Trends in the types of acetabular components used for cup revisions over time .....  39
Figure 10: Trends in the types of TKA bearings over time .....  45
Figure 11: Trends in standard TKA knee systems over time ..... 46
Figure 12: Trends in TKA insert materials over time .....  46
Figure 13: Trends in bone fixation component replacements for infection-related knee reoperations over time .....  50
Figure 14: Revision probabilities of elective and non-elective hip arthroplasties .....  53
Figure 15: Revision probabilities of elective total hip arthroplasties with cemented and uncemented stems .....  55
Figure 16: Revision probabilities of elective total hip arthroplasties with uncemented stems by primary diagnosis .....  55
Figure 17: Revision probabilities of total and unicondylar knee arthroplasties .....  58
Figure 18: Revision probabilities of total knee arthroplasties by degree of constraint .....  59
Figure 19: Revision probabilities of standard total knee arthroplasties by primary diagnosis (based on the documented ICD-10 codes). ..... 61
Figure 20: Revision probabilities of standard total knee arthroplasties by patient sex .....  64
Figure 21: Revision probabilities of standard total knee arthroplasties by age group .....  64
Figure 22: Revision probabilities of elective total hip arthroplasties with uncemented stems by age group .....  65
Figure 23: Revision probabilities of elective total hip arthroplasties with uncemented stems by patient body mass index
Figure 24: Revision probabilities of standard total knee arthroplasties by concomitant disease diagnoses included in the Elixhauser Comorbidity Score... 66
Figure 25: Revision probabilities of elective total hip arthroplasties with uncemented stems by the hospital's annual volume of primary elective hip arthroplasties 66
Figure 26: Revision probabilities of standard total knee arthroplasties by the hospital s annual volume of primary total knee arthroplasties not including unicondyla arthroplasties .....  67
Figure 27: Revision probabilities of unicondylar knee arthroplasties by the hospital's annual volume of primary unicondylar knee arthroplasties .....  .67
Figure 28: - Funnel plot comparing outcomes of elective primary hip arthroplasties with uncemented stems between hospitals .....  69
Figure 29: Revision probabilities of uncemented and cemented partial hip arthroplasties .....  80
Figure 30: Revision probabilities of elective total hip arthroplasties with cemented stems by head size .....  80
Figure 31: Revision probabilities of elective total hip arthroplasties with uncemented stems by head-neck lengths .....  81
Figure 32: Revision probabilities of elective total hip arthroplasties with uncemented stems by stem type .....  82
Figure 33: Revision probabilities of standard total knee arthroplasties by knee system .....  94
Figure 34: Revision probabilities of standard total knee arthroplasties by bearing mobility .....  95
Figure 35: Revision probabilities of standard primary total knee arthroplasties with and without patellar resurfacing at primary TKA .....  95
Figure 36: Probability of re-revision over time ..... 143
Figure 37: Probability of re-revision after first, second and third revision .....  .144

## List of tables

Table 1: Annual primary arthroplasty and reoperation volumes ..... 12
Table 2: Proportion of registered procedures by joint and type of intervention in 2022 .....  28
Table 3: Primary hip arthroplasties in 2022 by patient age, sex and BMI .....  .29
Table 4: Previous surgeries reported for primary hip arthroplasties in 2022 .....  29
Table 5: Types of primary hip replacements in 2022 .....  29
Table 6: Fixations in primary total hip arthroplasties in 2022 .....  30
Table 7: Fixations in primary hip hemiarthroplasties in 2022 .....  30
Table 8: Stem types in primary total hip arthroplasties in 2022 ..... 30
Table 9: Stem types in primary hip hemiarthroplasties in 2022 ..... 30
Table 10: Acetabular components in primary total hip arthroplasties in 2022 .....  31
Table 11: Reconstruction shells in primary total hip arthroplasties in 2022. .....  31
Table 12: Head sizes in primary total hip arthroplasties in 2022 .....  31
Table 13: Head-neck lengths in primary total hip arthroplasties in 2022 ..... 31
Table 14: Acetabular bearing materials in primary total hip arthroplasties in 2022 .....  32
Table 15: Modular head materials in primary total hip arthroplasties in 2022 .....  32
Table 16: Bearing materials in primary total hip arthroplasties in 2022 .....  32
Table 17: Modular head materials in primary hip hemiarthroplasties in 2022 ..... 32
Table 18: Hip reoperations in 2022 by patient age, sex and BMI ..... 36
Table 19: Reasons for hip reoperations in 2022 .....  .37
Table 20: Components replaced or complemented in hip reoperations in 2022. ..... 37
Table 21: Primary knee arthroplasties in 2022 by patient age, sex and BMI .....  .40
Table 22: Prior surgeries reported for primary knee arthroplasties in 2022 .....  .41
Table 23: Types of primary knee replacements in 2022 ..... 41
Table 24: Grade of constraint in primary total knee arthroplasties in 2022 .....  41
Table 25: Fixations in primary total knee arthroplasties in 2022 .....  42
Table 26: Fixations in primary unicondylar knee arthroplasties in 2022 .....  42
Table 27: Bearing mobility in primary total knee arthroplasties in 2022. .....  42
Table 28: Bearing mobility in primary unicondylar knee arthroplasties in 2022 .....  42
Table 29: Patellar resurfacing in primary total knee arthroplasties in 2022 .....  42
Table 30: Femoral bearing materials in primary total knee arthroplasties in 2022 .....  43
Table 31: Tibial bearing materials in primary total knee arthroplasties in 2022 .....  43
Table 32: Bearing materials in primary total knee arthroplasties in 2022 ..... $\ldots . .43$
Table 33: Femoral bearing materials in primary unicondylar knee arthroplasties in 2022 .....  43
Table 34: Tibial bearing materials in primary unicondylar knee arthroplasties in 2022 .....  44
Table 35: Bearing materials in primary unicondylar knee arthroplasties in 2022 . .....  44
Table 36: Knee reoperations in 2022 by patient age, sex and BMI .....  47
Table 37: Reasons for knee reoperations in 2022 .....  48
Table 38: Components replaced or complemented during knee reoperations in 2022 .....  49
Table 39: Revision probabilities of elective total hip arthroplasties with uncemented stems by operating year. .....  .54
Table 40: Revision probabilities of elective total hip arthroplasties with cemented stems by operating year. ..... $\ldots . .54$
Table 41: Revision probabilities for different types of hip arthroplasties and diagnoses .....  56
Table 42: Outcomes for standard total knee arthroplasties by operating year .....  60
Table 43: Outcomes for unicondylar knee arthroplasties by operating year. .....  60
Table 44: Revision probabilities for different types of knee arthroplasties and diagnoses .....  62
Table 45: Revision probabilities for different types of arthroplasties by non-implant- related factors .....  70
Table 46: Revision probabilities for different types and characteristics of hip arthroplasties .....  82
Table 47: Revision probabilities for different types and characteristics of knee arthroplasties ....... 96
Table 48: Implant outcomes for stem/cup combinations in elective total hip arthroplasties ..... 102
Table 49: Implant outcomes for femoro-tibial combinations in primary knee arthroplasties without patellar resurfacing at primary TKA ..... 116
Table 50: Implant outcomes for femoro-tibial combinations in primary knee arthroplasties with patellar resurfacing at primary TKA ..... 128
Table 51: Implant outcomes for secondary patellar resurfacing ..... 132
Table 52: Summary of revisions under observation ..... 142
Table 53: Summary of patient mortality, 3, 6, 12, 24, and 36 months after primary arthroplasty or revision ..... 146
Table 54: 1-year mortality after arthroplasty in male patients by age category and type of arthroplasty ..... 147
Table 55: $\quad 1$-year mortality after arthroplasty in female patients by age category and type of arthroplasty ..... 148
Table 56: Number of mismatches due to deviations between head size and inner diameter of insert or cup in 2022 ..... 153
Table 57: Example of a head size mismatch in total hip arthroplasty ..... 151
Table 58: Example of a taper mismatch in hemiarthroplasty of the hip ..... 153
Table 59: Example of a side mismatch in total knee arthroplasty ..... 154
Table 60: Example of a PS insert and non-PS femoral component mismatch ..... 154
Table 61: Outcomes for femoral stems in elective total hip arthroplasties ..... 176
Table 62: Outcomes for acetabular cups in elective total hip arthroplasties ..... 184

Appendix: Separate implant outcomes for acetabular and femoral components

| Elective total hip arthroplasties | Number | Hosp. | Age | m/f | Period | Revision probabilities after ... |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Femoral stem |  |  |  |  |  | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Uncemented femoral component |  |  |  |  |  |  |  |  |  |  |  |  |  |
| A2 Kurzschaft (ARTIQO) | 9,339 | 73 | $64_{(57-71)}$ | 40/60 | 2016-2022 | $2.0\left[\begin{array}{c} {[1.79 ; 2)} \\ (6.3] \\ \hline \end{array}\right.$ | $2.2 \underset{(1.909)}{[1.6]}$ | $2.4\left[\begin{array}{l} {[2.1576)} \\ \hline 1.8] \\ \hline \end{array}\right.$ | $2.6\left[\begin{array}{l} {[2.2241} \\ (2,0) \end{array}\right]$ | 2.6 [2.2.230 3.0$]$ | $2.8[2.35 ; 3.4]$ |  |  |
| ABG II Stem (Stryker) | 493 | 15 | $66_{(59-71)}$ | $40 / 60$ | 2014-2022 | $4.5\left[\begin{array}{l} {[3.0 ; 3 ;} \\ (4.3] \end{array}\right.$ | $6.4[4.5 \cdot 5 ; 9.0]$ | $6.8[4.9 .99 .9]$ | $7.4\left[\begin{array}{l} [5.3 ; 7) 10.3] \\ {[279} \end{array}\right.$ | $7.4\left[\begin{array}{c} {[5.3 ;} \\ {[21 i} \end{array} 10.3\right]$ | $7.9[5.7 ; 10.9]$ | $7.9[5.77 ; 10.9]$ |  |
| Accolade II Stem (Stryker) | 10.742 | 64 | $68{ }_{(60-75)}$ | 41/59 | 2014-2022 | $2.6\left[\begin{array}{ll} (2.3932) \\ \hline 82.9] \end{array}\right.$ | $3.0[2.6 ; 3.3]$ | $3.2\left[\begin{array}{l} {[2.8064)} \\ {[5.5]} \end{array}\right.$ | $3.4\left[\begin{array}{l} {[3.0203)} \\ 3.8] \\ \hline \end{array}\right.$ | $3.6\left[\begin{array}{ll} {[3.29 ; 4,40]} \\ \hline 1.98 \end{array}\right.$ | $3.7\left[\begin{array}{ll} {[3.31 .4 .1]} \\ u, 10 \end{array}\right.$ |  |  |
| Actinia cementless (Implantcast) | 2,947 | 24 | $72(65-78)$ | 33/67 | 2015-2022 | $3.5\left[\begin{array}{l} {[2.950)} \\ \hline \end{array}\right.$ | $3.8\left[\begin{array}{l} {[3.2 ; 4.6]} \\ \mid 2,34] \end{array}\right.$ | $3.9\left[\begin{array}{l} {[3.321 .37 .7]} \\ (1.31) \end{array}\right.$ | $4.3[3.5 ; 5.1]$ | $4.6[3.8 ; 5.5]$ | $4.6[3.8 ; 5.7]$ |  |  |
| ACTIS ${ }^{\text {TM -Hüftschaft ( }}$ (ePuy) | 1,614 | 36 | $62_{(55-69)}$ | 43/57 | 2018-2022 | $1.7[1.1 .1 ; 2.5]$ | $2.2\left[\begin{array}{l} {[1.4 ; 4 ; 3]} \\ (4, i) \end{array}\right.$ | $2.2[1.4 ; 3 \cdot 3]$ |  |  |  |  |  |
| Alloclassic (Zimmer Biomet) | 10,843 | 85 | $69_{(62-76)}$ | 34/66 | 2012-2022 | $2.9[2.6 ; 3.3]$ | $3.4\left[\begin{array}{l} \{3.1300 ; \\ {[3.8]} \\ \hline \end{array}\right.$ | $3.8\left[\begin{array}{l} {[3.500} \\ {[0.54} \\ 4.2] \end{array}\right.$ | $4.2\left[\begin{array}{c} {[3.8959} \\ \hline 5.6] \end{array}\right.$ | $4.4[4.0 \times 139]$ | $4.7\left[\begin{array}{c} {[4.2 ; 29} \\ k .15 \\ 5 \end{array}\right.$ | $4.8[4.3 .5 .5 .3]$ |  |
| Alpha-Fit (Corin) | 691 | 3 | $75{ }_{(69}$-79) | 30/70 | 2014-2022 | $1.9[1.1 .13 .3]$ | $2.0[1.2 ; 3.4]$ |  | $2.3[1.4 ; 3 ; 3]$ | $2.9[1.8 ; 4.6]$ | $2.9[1.8 ; 4.6]$ | $3.8[2.3 ; 6.0]$ |  |
| AMISTEM-H (Medacta) | 1,000 | 28 | $67_{(58-74)}$ | 43/57 | 2015-2020 | $3.2\left[\begin{array}{l\|l\|l\|l\|} {[9.5]} \\ \hline \end{array}\right.$ | $3.5[2.5: 4.9]$ | $3.8[2.7 .7 ; 5.1]$ | $4.2\left[\begin{array}{l} {[3,1 ; 7)} \\ (5.7) \\ 5.7] \end{array}\right.$ | $4.6[3.4 ; 46.3]$ | $5.8[4.2 ; 4.80]^{(14)}$ |  |  |
| AMISTEM-H ProxCoat (Medacta) | 348 | 3 | $60_{(525.566)}$ | 48/52 | 2016-2022 | $1.8[0.8 \cdot 3 \cdot 3]$ | $2.1[1.0 ; 4.4]$ | $2.6[1.3 ; 5.5]$ | $3.3 \underset{\|87\rangle}{[1.77} 6.5]$ |  |  |  |  |
| AMISTEM-P (Medacta) | 764 | 24 | $66_{(59 .-73)}$ | 41/59 | 2019-2022 | $2.7[1.7 .74 .2]$ | $2.7(1.7 .75 .2]$ |  |  |  |  |  |  |
| ANA.NOVA ${ }^{\bullet}$ Alpha Schaft (ARTIQO) | 2,141 | 13 | 70 (63-76) | 40/60 | 2015-2022 | $2.4\left[\begin{array}{c} {[1.8 .85 \cdot 5)} \\ 4.2] \end{array}\right.$ | $2.9\left[\begin{array}{l} {[2.505]} \\ {[.7 .7]} \end{array}\right.$ | $3.1\left[\begin{array}{ll} {[2.4254 .4 .0]} \\ \hline 1.25) \end{array}\right.$ | $3.4\left[\begin{array}{l\|l\|l\|l\|} {[2.3 .3]} \\ \hline \end{array}\right.$ | $3.7\left[\begin{array}{c} {[5894} \\ \hline .94 \\ 4.7] \end{array}\right.$ | $3.9\left[\begin{array}{l} (362) \\ (362) \\ 5.0] \end{array}\right.$ | ${ }^{3.9} 93.30 ; 5000$ |  |
| ANA.NOVA® SL-complete ${ }^{\oplus}$ Schaft (ARTIQO) | 604 | 10 | $72_{(64-78)}$ | $40 / 60$ | 2015-2022 | $3.5\left[\begin{array}{l} \left.[2.37)^{[367}\right) \\ 5.4] \end{array}\right.$ | $3.9\left[\begin{array}{l} {[2.633} \\ 50.9] \\ \hline \end{array}\right.$ | $4.2\left[\begin{array}{l} {[288)} \\ \hline 18 ; \end{array}\right)$ | $\left.4.5\left[\begin{array}{l} {[3,0 ; 0} \\ (230 \end{array}\right) 67\right]$ | $4.5[3.0 .0 .6 .7]$ | $6.6\left[\begin{array}{c} {[3.9 \cdot 9.90 .9]} \\ \text { ibi } \end{array} 10.9\right]$ |  |  |
| ANA.NOVA® Solitär Schaft (ARTIQO) | 543 | 7 | $74_{(66-80)}$ | 35/65 | 2015-2022 | $4.0\left[\begin{array}{l} {[2.6766} \\ \mid 476 \\ \hline 6.0] \end{array}\right.$ | $4.2\left[\begin{array}{l} {[2.8 ; 4)} \\ (24) \\ \hline 6 \end{array}\right.$ | $4.6[3.12 ; 6.8]$ | $5.1\left[\begin{array}{c} {[3.4 ; 7,7.6]} \\ (180) \end{array}\right.$ | $6.0[3.8 ; 9.3]$ | $6.0\left[\begin{array}{l} 3 ; 8 ; 9.3] \\ \langle 52] \end{array}\right.$ |  |  |
| Anato Stem (Stryker) | 423 | 9 | $68{ }_{(60-75)}$ | 45/55 | 2016-2022 |  | $3.7[2.2,2 ; 60]$ | $3.7\left[\begin{array}{l} {[2.23 ; 3} \\ \hline 10.0] \end{array}\right.$ | $3.7[2.2 ; 2 ; 6]$ | $3.7[2.2 ; 6 ; 0]$ |  |  |  |
| Avenir (Zimmer Biomet) | 27,945 | 198 | $69_{(62-76)}$ | 40/60 | 2013-2022 | $3.1\left[\begin{array}{l} {[21,949 ; 3]} \\ \hline \end{array}\right.$ | $\begin{gathered} 3.3[3.1 ; 3.6] \\ {[1,4,43]} \end{gathered}$ | $3.6[3.3 ; 3.8]$ | $3.6[3.4 ; 3.8]$ | $3.8[3.5: 5.0]$ | $3.8\left[\begin{array}{l} {[2.536} \\ {[.50} \\ \hline \end{array}\right.$ | $3.8[3.5 ; 4.1]$ | $3.8[3.5 ; 4.1]$ |
| Avenir Complete (Zimmer Biomet) | 1,506 | 46 | $67_{(60-74)}$ | 40/60 | 2020-2022 | $2.9[2.1 .1 ; 4.0]$ | $2.9[2.7 ; 4.0]$ |  |  |  |  |  |  |
| BICONTACT (Aesculap) | 18,808 | 130 | $71_{(63-77)}$ | 40/60 | 2013-2022 | $3.2\left[\begin{array}{ll} {[3.0 .0 ; 3,5]} \\ (1,68) \end{array}\right.$ | $3.6[3.3 ; 3.9]$ |  | $3.8[3.6 ; 4.1]$ | $3.9[3.7 .74 .2]$ | $4.0\left[\begin{array}{l} {[3.72 ; 4.3]} \\ 4.24) \\ \hline \end{array}\right.$ | $4.0\left[\begin{array}{l} {[3.7 .754 .3]} \\ k, 259 \end{array}\right.$ | $4.0[3.7 .7 \% 4.4]$ |
| Brexis (Zimmer Biomet) | 976 | 33 | $59{ }_{(53-66)}$ | 47/53 | 2016-2022 | $2.2\left[\begin{array}{c} 1.4,4 ; 3.3] \\ {[1 ; 3)} \end{array}\right.$ | $2.8\left[\begin{array}{c} (1.999) \\ (54.1] \\ \hline \end{array}\right.$ | $2.8[1.9 ; 4.1]$ | $2.8[1.9 .94 .1]$ | $3.5\left[\begin{array}{l} (60)] \\ (6.8] \\ 5.8] \end{array}\right.$ |  |  |  |
| C.F.P. Hip Prosthesis Stem (Waldemar Link) | 1,347 | 31 | $61_{(54-67)}$ | 55/45 | 2012-2022 | $2.1\left[\begin{array}{l} {[1.52 ; 3.1]} \\ (1,21) \end{array}\right.$ | $2.9[(1.108 ; 4.0]$ | $3.2[2.3 ; 4.3]$ | $3.5\left[\begin{array}{l} {[2.6464 .7]} \\ (2464) \\ \hline \end{array}\right.$ | $3.7\left[\begin{array}{ll} {[2679,850]} \\ 5.0] \end{array}\right.$ | $3.9\left[\begin{array}{l} {[2.955} \\ \hline .9 .2] \\ 5.2] \end{array}\right.$ | $3.9[2.9: 5.2]$ | $3.9[2.9 ; 5.5 .2]$ |
| CBC Evolution (Mathys) | 831 | 14 | $68_{(62-75)}$ | 44/56 | 2013-2022 | $3.2[2.2 .2 ; 4.7]$ | $4.1\left[\begin{array}{l} {[2.995)} \\ {[5.8]} \end{array}\right.$ | $4.5[3.22 ; 6.2]$ | $5.1\left[\begin{array}{c} {[3.73 ; 6.9]} \\ {[3 / 2]} \end{array}\right.$ | $5.1\left[\begin{array}{c} {[3.76 ; 6.9]} \\ (361) \end{array}\right.$ | $5.1\left[\begin{array}{l} {[3.77} \\ {[37)} \end{array}, 6.9\right]$ | $5.1\left[\begin{array}{l} {[3.7 ; 3]} \\ (93) \\ 6 \end{array}\right.$ | $5.1\left[\begin{array}{l} {[3.77]} \\ {[5]} \\ 6 \end{array} .9\right]$ |
| CBH (Mathys) | 301 | 7 | $74_{(69-78)}$ | $29 / 71$ | 2013-2022 | $1.7\left[\begin{array}{c} {[0.774 .0]} \\ (27) \end{array}\right.$ | $2.8[1.4 ; 5.6]$ | $2.8\left[\begin{array}{c} 1.44: 4.65] \\ 1206 \end{array}\right.$ | $2.8[1.4 ; 5.56]$ | $2.8\left[\begin{array}{c} {[1.4 ; 5)} \\ (1,4) \\ 5.6] \\ \hline \end{array}\right.$ | $2.8(1.4 ; 5.6]$ |  |  |
| CLS Spotorno (Zimmer Biomet) | 26,315 | 201 | $65_{(58-72)}$ | 43/57 | 2012-2022 | $2.8\left[\begin{array}{l} {[2,6 ; 2 ; 3)} \\ (2,1) \end{array}\right.$ |  | $3.6[3.3 ; 3.8]$ | $3.7[3.5 ; 4.0]$ | $3.8\left[\begin{array}{c} {[3.60} \\ \hline 9.080 \\ \hline 4.1] \end{array}\right.$ | $4.0\left[\begin{array}{c} {[3.8 ; 4.3]} \\ {[6.30]} \end{array}\right.$ | $4.1\left[\begin{array}{c} {[3.9 .968)} \\ \hline 4.4] \end{array}\right.$ | $4.3[4.09 ; 4.6]$ |
| CORALLTM AMT-Hüftschaft mit Kragen (DePuy) | 11,792 | 103 | $69^{(61-76)}$ | $36 / 64$ | 2012-2022 | $1.7[1.5: 51.9]$ | $2.1[1.9 ; 2.4]$ | $2.4\left[\begin{array}{l} {[2.1 .30]} \\ 20.7] \end{array}\right.$ | $2.5\left[\begin{array}{l} {[2.2,2 ; 7)} \\ 2.8] \end{array}\right.$ | $2.6\left[\begin{array}{ll} {[2.31 \cdot 3 \cdot 3.0]} \end{array}\right.$ | $3.0\left[\begin{array}{c} {[9.574} \\ {[7.4]} \\ 3 \end{array}\right.$ | $3.0[2.5 ; 3.4]$ | $3.0[2.5 ; 3.4]$ |
| CORAILTM AMT-Hüftschaft ohne Kragen (DePuy) | 34,824 | 171 | $70_{(62-76)}$ | 38/62 | 2012-2022 | $2.9[2.8 .8 \cdot 3.1]$ | $3.3\left[\begin{array}{l} {[3.1 ; 93.5]} \\ k, 63] \end{array}\right.$ | $\begin{aligned} & 3.6[3.4,4.3 .9] \\ & \hline 1.8202) \end{aligned}$ | $3.9[3.7 .7 .4 .1]$ | $4.0\left[\begin{array}{l} {[3.8534]} \\ \hline 9.3] \end{array}\right.$ | $\left.{ }_{4}^{4.3}{ }_{(5.355)}^{[4.0} 4.5\right]$ | $4.5[4.2 .2,4.8]$ | $5.2\left[\begin{array}{l}\text { [437) } \\ (63.8]\end{array}\right.$ |
| COREHIP (Aesculap) | 4,610 | 59 | ${ }^{68}{ }_{(61-75)}$ | 38/62 | 2017-2022 | $2.1[1.7 ; 2.6]$ | $2.5\left[\begin{array}{l} {[2.0 ; 0 ; 3)} \\ (0.1) \end{array}\right.$ | $3.0\left[\begin{array}{l} {[2.3 ; 3.8]} \\ {[6090} \end{array}\right]$ | $3.0[2.3 ; 3.3]$ |  |  |  |  |
| EcoFit $133^{\circ} \mathrm{cpTi}$ (Implantcast) | 493 | 6 | $73_{(67-80)}$ | 29/71 | 2019-2022 | $4.4\left[\begin{array}{l}\text { [1313] }\end{array}\right.$ | $5.5[3.6 ; 8.2]$ |  |  |  |  |  |  |

Table 61: Outcomes for femoral stems in elective total hip arthroplasties. For each type of fixation, the femoral stems are listed alphabetically by their designation.

| Elective total hip arthroplasties | Number | Hosp. | Age | m/f | Period | Revision probabilities after ... |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Femoral stem |  |  |  |  |  | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Uncemented femoral component |  |  |  |  |  |  |  |  |  |  |  |  |  |
| EcoFit $133^{\circ} \mathrm{HA}$ (Implantcast) | 324 | 5 | $71.5{ }_{(64-77)}$ | 43/57 | 2018-2022 |  |  | ${ }^{3.3}{ }^{[17.88]}$ (84) 6.2$]$ |  |  |  |  |  |
| EcoFit cpTi (Implantcast) | 1,035 | 17 | $73_{(66-78)}$ | 30/70 | 2014-2022 | $4.9\left[\begin{array}{l} {[3,720} \\ (920) \\ 6.4] \end{array}\right.$ | $5.6[4.4 ; 7.2]$ | $6.1\left[\begin{array}{c} {[4788)} \\ {[7.7 .7]} \\ \hline \end{array}\right.$ | $6.5\left[\begin{array}{l} {[5,1 ;)} \\ {[5.2]} \\ \hline \end{array}\right.$ |  | $\left.6.7{ }_{\substack{\text { [5.2; } \\(194)}} 8.4\right]$ |  |  |
| EcoFit HA (Implantcast) | 868 | 8 | $70_{(66-78)}$ | 43/57 | 2014-2022 | $2.9[2.0 ; 4.3]$ | $3.2[2.2 .264 .7]$ | $3.2\left[\begin{array}{l} {[2.2555} \\ \langle 4.2 .7] \\ 4.7 \end{array}\right.$ | $3.2\left[\begin{array}{c} {[2.2 ; 2 ; 4]} \\ (300) \end{array}\right.$ | $3.2\left[\begin{array}{ll} {[2.268)} \\ 4.7] \end{array}\right.$ | $3.2[2.254 .7]$ |  |  |
| EcoFit Short cpTi (Implantcast) | 459 | 8 | $69_{(61-76)}$ | 43/57 | 2018-2022 | $4.5\left[\begin{array}{l} \left.[2.98)^{2}\right) \\ 6.8] \end{array}\right.$ | $4.5\left[\begin{array}{l} \left.[2.92)^{2} 6.8\right] \\ 6.8] \end{array}\right.$ | $4.5\left[\begin{array}{l} {[2.92)} \\ (6.8] \\ \hline \end{array}\right.$ |  |  |  |  |  |
| EXCEPTION (Zimmer Biomet) | 1,486 | 14 | $68.5{ }_{(61-75)}$ | 49/51 | 2015-2022 | $4.4\left[\begin{array}{l} {[3.5525)} \\ 5.6] \\ \hline \end{array}\right.$ | $4.8\left[\begin{array}{l} {[3.9296 .1]} \\ 1.26) \\ \hline \end{array}\right.$ | $5.4[4.3 ; 5) 6.7]$ | $5.4[4.3 ; 6.7]$ | $6.1\left[\begin{array}{l} {[4.8 ; 7)} \\ \langle 7.7] \end{array}\right.$ | $6.1[4.8 ; 7.7 .7]$ |  |  |
| EXCIA (Aesculap) | 11,830 | 116 | $70_{(62-76)}$ | 40/60 | 2013-2022 |  | $3.7\left[\begin{array}{l} 13.3 ; 29, ~ 4.0] \end{array}\right.$ | $3.8[(5.5771)]$ |  | $3.9\left[\begin{array}{l} 3.6 .6973 \\ {[2.37} \end{array}\right]$ | $4.0{ }_{\text {¢ }}^{\text {(9906 }}$ ( 4.4$]$ | $4.2\left[3.77{ }_{\text {(168) }} 4.7\right]$ |  |
| Fitmore (Zimmer Biomet) | 28,041 | 239 | $62_{(55-69)}$ | 46/54 | 2012-2022 | $2.3\left[\begin{array}{l} {[2,2.2,200)} \\ 2,5] \end{array}\right.$ | $2.7 \begin{gathered} [12.6 ; 2 ; 9]) \\ {[19.9]} \end{gathered}$ | $3.0[2.8: 3.3 .2]$ | $3.1\left[\begin{array}{ll} {[1.9 .973 .3]} \\ \hline 1.4] \end{array}\right.$ | $3.2\left[\begin{array}{l} {[3.0006} \\ {[0.50]} \\ 3.5] \end{array}\right.$ | $3.4\left[\begin{array}{l} {[3.1 .733 .3 .6]} \\ 44.54) \end{array}\right.$ | $3.4\left[\begin{array}{l} {[3.278]} \\ {[1.78]} \\ \hline \end{array}\right.$ | $3.6\left[\begin{array}{l} {[3,3 ;)^{3}} \\ 3.9] \end{array}\right.$ |
| GTS (Zimmer Biomet) | 1,902 | 30 | $64_{(57-71)}$ | 41/59 | 2013-2022 | $3.5\left[\begin{array}{ll} {[1.866} \\ 0.84 \\ 4.5] \end{array}\right.$ | $4.4\left[\begin{array}{l} {[3.605} \\ (1.50) \\ 5.5] \end{array}\right.$ | $4.7\left[\begin{array}{l} {[3.80 .8015} \\ 10.7] \\ \hline \end{array}\right.$ | $5.0\left[\begin{array}{c} (4,198) \\ \hline 9.1] \end{array}\right.$ | $5.2\left[\begin{array}{c} {[4.2,2 ; 3)} \\ {[6.4]} \end{array}\right.$ | $5.5\left[\begin{array}{l} {[4.4 ; 7 ;} \\ (3 ; 8] \end{array}\right.$ | $5.5[4.4,4.6 .8]$ |  |
| Konusprothese (Zimmer Biomet) | 1,439 | 125 | $58{ }_{(48-67)}$ | $16 / 84$ | 2013-2022 | $3.0\left[\begin{array}{l} (2.2262) \\ \hline 1.0] \end{array}\right.$ | $3.7 \underset{(1.055)}{[2.8 ; 4.9]}$ | $4.1\left[\begin{array}{c} {[3.2 ; 505} \\ (3,3] \\ \hline \end{array}\right.$ | $4.2\left[\begin{array}{l} {[3,3 ; 5)} \\ (165) \\ 5.5] \end{array}\right.$ | $4.5[3.505 .5]$ | $4.7[3.6 ; 6.1]$ | $4.7 \begin{gathered} {[3.6 ; 6} \\ (200 \\ {[6.1]} \\ \hline \end{gathered}$ | $4.7[3.6 ; 6.1]$ |
| LCU Hip System, cementless (Waldemar Link) | 3,316 | 40 | $68{ }_{(61-7.5)}$ | 44/56 | 2014-2022 | $2.7\left[\begin{array}{l} {[2.2741)} \\ (2,3] \end{array}\right.$ | $3.0\left[\begin{array}{l} {[2.5250} \\ {[2.75]} \end{array}\right.$ | $3.3\left[\begin{array}{l} {[2.777)} \\ (0.07) \end{array}\right.$ | $3.4\left[\begin{array}{ll} {[2.825: 8.1]} \\ \hline \end{array}\right.$ | $3.6\left[\begin{array}{l} {[2.933} \\ \hline 4.4] \end{array}\right.$ | $4.2[3.2 ; 5.6]$ |  |  |
| M/L Taper (Zimmer Biomet) | 6,121 | 25 | $68{ }_{(61-74)}$ | 42/58 | 2012-2022 | $3.1\left[\begin{array}{l} {[2.62515} \\ 3.5] \\ 3.5] \end{array}\right.$ | $3.5\left[\begin{array}{l} {[3,1.193,4.0]} \\ 4.0] \end{array}\right.$ | $3.8\left[\begin{array}{l} {[3.3635} \\ \hline, 4.3] \\ \hline \end{array}\right.$ | $4.0\left[\begin{array}{l} {[3.504} \\ (3.54 \\ 4.5] \end{array}\right.$ | $4.2\left[\begin{array}{l} {[3.7 .74 .47]} \\ (2.021 \end{array}\right)$ |  | $4.6[4.0757 .3]$ |  |
| METABLOC (Zimmer Biomet) | 713 | 14 | $72{ }_{(65-78)}$ | $39 / 61$ | 2012-2020 | $2.4[1.553 .8]$ | $2.7[1.7 .74 .2]$ | $2.8[1.8: 4.4]$ | $3.5[2.4 ; 5.2]$ |  | $3.5[2.4 ; 5 \cdot 5.2]$ | $3.5[2.4 .45 .5 .2]$ | ${ }^{3.5[2.45 ; 5.2]}$ |
| Metafix (Corin) | 1,657 | 17 | $72{ }_{(65-78)}$ | 42/58 | 2014-2022 | $1.6[1.1 ; 2.4]$ | $1.9[1.3: 3.2 .7]$ | $2.1\left[\begin{array}{c} {[1.5098} \\ (0.08) \\ 2.9] \\ \hline \end{array}\right.$ | $2.2[1.5 \cdot 3 \cdot 3]$ | $2.4\left[\begin{array}{c} {[1.739} \\ {[.39)} \\ 3.4] \\ \hline \end{array}\right.$ | $2.4[1.79 ; 3.4]$ | $2.4[1.773 .4]$ |  |
| METHA (Aesculap) | 7,836 | 160 | $57_{(52-63)}$ | 47/53 | 2012-2022 |  | $3.4\left[\begin{array}{c} {[3.00013 .8]} \\ {[5.501} \end{array}\right.$ | $3.6\left[\begin{array}{c} {[3.2686} \\ 4.24 \\ 4.1] \end{array}\right.$ | $3.7\left[\begin{array}{l} {[3.3,3 / 3: 4.2]} \end{array}\right.$ | $3.8\left[\begin{array}{l} {[3.457)} \\ \hline \end{array}\right.$ | $4.0\left[\begin{array}{ll} {[3.521 .515} \\ 4.5] \\ \hline \end{array}\right.$ | $4.0 \underset{(3,68)}{[3.65} 4.6]$ | $\left.4.0{ }_{(303)} 3.6 ; 4.6\right]$ |
| MiniHip (Corin) | 2,409 | 46 | $61_{(54-67)}$ | 46/54 | 2013-2022 | $2.8\left[\begin{array}{l} {[2.25 ; 3.6]} \\ (1,95) \end{array}\right.$ | $3.4[2.7 .7 ; 4.2]$ | $3.6\left[\begin{array}{l} {[2.92121)} \\ 4.5] \end{array}\right.$ | $\begin{gathered} 3.8[3.0 ; 4.7] \\ (1,122) \\ 4.7] \\ \hline \end{gathered}$ | $4.1\left[\begin{array}{c} {[3.3: 5.1]} \\ (761) \end{array}\right.$ | $4.4\left[\begin{array}{l} {[3.5 ; 5.5]} \\ \hline(43) \end{array}\right.$ | $4.4 \underset{(3,53)}{[3.5]}$ |  |
| MRP-TITAN (Peter Brehm) | 366 | 130 | $74_{(62-81)}$ | 35/65 | 2013-2022 | $13.5\left[\begin{array}{l} {[10.356)} \\ \hline 17.6] \end{array}\right.$ | $15.6[12.1 ; 20.0]$ | $15.6[12.1 ; 20.0]$ | $15.6[12.1 ; 20.0]$ | $16.9[12.8 ; 22.1]$ |  |  |  |
| Nanos Schenkelhalsprothese (OHST/Smith \& Nephew) | 5,073 | 116 | $59{ }_{(53-66)}$ | 47/53 | 2013-2022 | $2.2\left[\begin{array}{l} 11.8: 2.85) \\ 4.6] \\ \hline \end{array}\right.$ |  | $2.9\left[\begin{array}{c} {[2.4,4,3.45)} \\ \hline(2) \end{array}\right.$ | $3.1\left[\begin{array}{ll} {[2.7535} \\ {[2.75]} \end{array}\right.$ | $3.3\left[\begin{array}{c} {[1.86 ; 3.9]} \\ 10.85 \end{array}\right.$ | $3.3[(2.8 ; 3 ; 9.9]$ | $3.6[3.0 ; 4.4]$ |  |
| optimys (Mathys) | 22,504 | 128 | $64_{(57-71)}$ | 44/56 | 2013-2022 | $1.8[11.7 ; 2.0]$ | $2.1\left[\begin{array}{l} {[1.92 ; 2 ; 23]} \\ \hline(12) \end{array}\right.$ | $2.2\left[\begin{array}{l} {[9.0 .0 ; 5)} \\ 2.4] \end{array}\right.$ | $2.3\left[\begin{array}{l} {[2.1 .3 ; 22.5]} \\ \hline(6) \end{array}\right.$ | $2.4 \underset{(3.833)}{[2.2 ;} 2.6]$ | $2.4\left[\begin{array}{ll} {[2.2,2 ; 2)} & 2.7] \\ (u, z) \end{array}\right.$ | $2.5\left[\begin{array}{l} {[50.2 ; 6} \\ \hline 2.8] \\ \hline \end{array}\right.$ | $2.5[2.2 .2 .2 .8]$ |
| Peira Schaft (ARTIQO) | 385 | 6 | $72{ }_{(66-77)}$ | $36 / 64$ | 2015-2022 | $3.4\left[\begin{array}{c} {[2.0 ; 5 \cdot 5.8]} \\ (3.3) \end{array}\right.$ | $3.4\left[\begin{array}{l} {[2.05454} \\ {[5.8]} \end{array}\right.$ | $3.7 \begin{aligned} & \text { [2.2.2; } 6.1] \\ & (320) \end{aligned}$ | $3.7\left[\begin{array}{l} {[2.2 ; 38.1]} \\ \hline(23) \end{array}\right.$ |  |  |  |  |
| Polarschaft (Smith \& Nephew) | 14,057 | 118 | $69_{(22-76)}$ | 41/59 | 2013-2022 | $2.7\left[\begin{array}{l} [2.4,535), 9] \\ \hline(2) \end{array}\right.$ | $3.0\left[\begin{array}{l} {[2.75 ; 3.3]} \\ 9.53) \end{array}\right.$ | $3.2\left[\begin{array}{ll} {[2,956} \\ \hline, 3.5] \end{array}\right.$ | $3.3\left[\begin{array}{l} {[3.055]} \\ {[5]} \end{array}\right.$ | $3.4 \underset{(3,589)}{[3.1 ; 3.7]}$ | $3.5\left[\begin{array}{ll} {[3.2565} \\ 0.93] \end{array}\right.$ | $3.9[3.4 ; 4.4]$ | $3.9\left[(136)^{[3.4 ; 4.4]}\right.$ |
| PROFEMUR ${ }^{\text {® GLADIATOR (MicroPort) }}$ | 399 | 8 | $71_{(64-76)}$ | 34166 | 2014-2022 | $2.9[1.6 .65 .2]$ | $3.2\left[\begin{array}{c} 1.8 .850 \\ (1250 \end{array}\right)$ | $4.1[2.4 ; 7.0]$ | $4.8[2[1.850 .8]$ | $4.8[2.8 ; 8.0]$ |  |  |  |
| PROFEMUR® GLADIATOR CLASSIC (MicroPort) | 982 | 16 | $70_{(63-76)}$ | $36 / 64$ | 2014-2022 | $2.9\left[\begin{array}{c} {[2.099)} \\ (6.2] \end{array}\right.$ | $3.3[2.3 ; 4.8]$ | $4.2\left[\begin{array}{l} {[3.0 ; 4} \\ (3,5) \\ 5.9] \\ \hline \end{array}\right.$ | $4.2\left[\begin{array}{c} {[3.097} \\ {[29.5} \\ 5.9] \\ \hline \end{array}\right.$ | $4.2\left[\begin{array}{l} {[3,0.55)} \\ 5.9] \\ \hline 1.9] \end{array}\right.$ | $4.2[3.0 ; 5.9]$ |  |  |
| PROFEMUR® L Classic (MicroPort) | 367 | 10 | $69_{(62-76)}$ | 40160 | 2015-2022 | $1.9\left[\begin{array}{c} {[0.975} \\ 125 \end{array}, 4.0\right]$ | $1.9[0.90 \cdot 4.0]$ | $1.9[0.9 ; 4.0]$ |  |  |  |  |  |
| PROFEMUR ${ }^{\text {P }}$ Preserve (MicroPort) | 645 | 18 | $62_{(55-68)}$ | 49/51 | 2014-2022 | $2.4[1.5 ; 4.0]$ | $3.2\left[\begin{array}{l} {[2,088} \\ {[20.1]} \\ 5.1] \end{array}\right.$ | $3.2\left[\begin{array}{ll} {[18020} \\ (182) \\ 5.1] \end{array}\right.$ | $3.2\left[\begin{array}{l} {[1.0 ; 2]} \\ \hline 132 \\ 5.1] \end{array}\right.$ | $\left.4.2\left[\begin{array}{l} {[2,3 ;} \\ (27) \end{array}\right] .5\right]$ |  |  |  |
| Proxy PLUS Schaft (Smith \& Nephew) | 879 | 24 | $69^{(62-75)}$ | 44/56 | 2013-2022 | $3.7\left[\begin{array}{l} {[2.6858} \\ (820) \\ 5.1] \end{array}\right.$ | $4.3\left[\begin{array}{l} {[3.1555} \\ (1,5) \\ 5.8] \\ \hline \end{array}\right.$ | $4.5\left[\begin{array}{l} {[3.3 ; 7)} \\ (6.1] \\ \hline \end{array}\right.$ | $4.7 \text { [3.4; } 4.6 .3]$ | $4.9[3.6 ; 6.6]$ | $5.3\left[\begin{array}{l} {[3,9,9,7.1]} \end{array}\right.$ | $5.3\left[\begin{array}{l} (3,9,7) \\ (1 i) \\ 7.1] \end{array}\right.$ |  |
| Pyramid (Atesos) | 2,944 | 25 | $71_{(64-77)}$ | $36 / 64$ | 2014-2022 | $3.0\left[\begin{array}{l} {[2.52513} \\ {[2.7]} \end{array}\right.$ | $3.3\left[\begin{array}{l} {[2.7 .700 .0]} \\ {[2.00} \end{array}\right.$ | $3.6\left[\begin{array}{l} {[3.0000} \\ 4.4] \end{array}\right.$ | $3.7\left[\begin{array}{l} {[3.0364 .4]} \\ (4.56) \end{array}\right.$ | $3.7[(3.1 .1 ; 4.5]$ | $3.8\left[\begin{array}{l} {[52.29} \\ {[5]} \\ 4.7] \\ \hline \end{array}\right.$ | $3.8\left[\begin{array}{c} {[3.2 ; 8)} \\ (180) \\ 4.7] \\ \hline \end{array}\right.$ |  |
| QUADRA-H (Medacta) | 9,779 | 65 | $68{ }_{(61-75)}$ | $39 / 61$ | 2015-2022 | $\left.2.7\left[\begin{array}{ll} {[2,4 ; 409} \\ \hline \end{array}\right] .0\right]$ | $3.2{ }_{[5.564)}^{[2.993 .6]}$ |  | $3.9[3.5: 4.4]$ | $4.2\left[\begin{array}{c} (3.8999) \\ \hline \end{array}\right.$ |  | $4.8[4.17 ; 5$ 5.6] |  |

Table 61 (continued)

| Elective total hip arthroplasties |  |  |  |  |  | Revision probabilities after ... |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Femoral stem | Number | Hosp. | Age | m/f | Period | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Uncemented femoral component |  |  |  |  |  |  |  |  |  |  |  |  |  |
| S-ROM ${ }^{\text {TM-Hüftschaft ( }}$ (DePuy) | 363 | 32 | $59_{(48-68)}$ | $29 / 71$ | 2013-2022 | $\left.5.2\left[\begin{array}{l} {[3,3 ;} \\ {[269} \end{array}\right) 8.2\right]$ | $5.2\left[\begin{array}{l} {[3.3 ; 7} \\ (187) \\ \hline \end{array}\right.$ | $5.2\left[\begin{array}{l} {[3,32]} \\ (122) \\ 8 \end{array}\right.$ | 5.2 [3.3; 8.2 .2] |  |  |  |  |
| SBG-Schaft (Smith \& Nephew) | 513 | 10 | $72_{(64-78)}$ | $37 / 63$ | 2013-2022 | $4.9 \begin{gathered} {[3.3 ; 6 ; 7.2]} \\ 1460 \end{gathered}$ | $\underset{\substack{3955}}{5.3 ; 7.7]}$ | $5.8[4.1 .1 ; 8.3]$ | $6.1[4.3 ; 8.8 .6]$ | $6.5[4.6 ; 9.1]$ | $6.5[4.6 ; 9.1]$ | $6.5[4.6 ; 9.1]$ |  |
| SL-PLUS Schaft (Smith \& Nephew) | 5,357 | 63 | $69_{(62-76)}$ | $36 / 64$ | 2012-2022 | $3.2[2.7 ; 3.7]$ | $4.0\left[\begin{array}{l} {[3.5 ; 4.6]} \\ \langle 4,23] \\ \hline \end{array}\right.$ | $4.5[(3.98 ; 5.1]$ | $4.9\left[\begin{array}{l} {[3.3,353} \\ \hline 3.5] \\ 5.5] \end{array}\right.$ | $5.2\left[\begin{array}{c} {[4.6 ; 4 ; 4)} \\ (2,9] \end{array}\right.$ | $5.7\left[\begin{array}{ll} 1,0.083 \\ 6.6 .4] \end{array}\right.$ | $6.4\left[\begin{array}{l} {[520 ;} \\ {[9.2]} \\ 7.2] \\ \hline \end{array}\right.$ |  |
| SL MIA HA Schaft (Smith \& Nephew) | 6,292 | 52 | $70_{(61.5-77)}$ | $36 / 64$ | 2013-2022 | $2.9\left[\begin{array}{l} {[2.52 ; 3 ; 3]} \\ {[.37)} \end{array}\right.$ | $3.3\left[\begin{array}{l} {[4.936)} \\ \hline, 36) \\ \hline \end{array}\right.$ | $3.6[3.1 .74 .1]$ | $3.8\left[\begin{array}{l} {[3.3504 .3]} \\ 2.54 \\ \hline \end{array}\right.$ | $3.9[3.4 ; 4.5]$ | $4.3\left[\begin{array}{c} (3,750 \\ (950) \\ 5.0] \\ \hline \end{array}\right.$ | $5.0\left[\begin{array}{l} {[4.2 ; 7)} \\ (447) \\ 5.9] \\ \hline \end{array}\right.$ | $5.0\left[\begin{array}{l} {[1.22 ; 2)} \\ \hline 1.9] \\ \hline \end{array}\right.$ |
| SP-CL Hip Stem, uncemented (Waldemar Link) | 3,673 | 46 | $64_{(57-70)}$ | $39 / 61$ | 2014-2022 | $3.4\left[\begin{array}{l} {[2.9 ; 9 ; 5)} \\ \hline 4.1] \end{array}\right.$ | $4.1[3.5 ; 4.8]$ | $4.5\left[\begin{array}{l} {[3.8 ; 8 ; 5.3]} \\ {[1.89)} \end{array}\right.$ |  | $4.8[4.1 .15 \cdot 5.6]$ | $5.1[4.3 ; 6 ; 0]$ | $5.1[4.3 ; 6.0]$ |  |
| SPS Evolution (Symbios) | 1,089 | 15 | $63_{(57-70)}$ | 45/55 | 2013-2022 | $2.3[1.6 ; 3.4]$ | $2.7 \underset{(18,9]}{[1.9]} 3]$ | $3.1[2.2 ; 4.4]$ | $3.4\left[\begin{array}{l} {[2,40]} \\ \hline(4.8] \end{array}\right.$ | $3.4\left[\begin{array}{l} (2.47) ; 4.8] \end{array}\right.$ | $3.4[2.4,4 ; 4.8]$ |  |  |
| Stemcup (IO-International Orthopaedics) | 412 | 11 | $68{ }_{(60-74.5)}$ | 42/58 | 2018-2022 | $1.8 \underset{\substack{[0.850 \\(250}}{ } ; .7]$ |  | $1.8[0.08 ; 3.7]$ |  |  |  |  |  |
| STEMSYS Schaft (ARTIQO) | 352 | 10 | $74{ }_{(70-79)}$ | 38/62 | 2018-2022 | $6.6[4.4 ; 9 ; 9.8]$ | $6.6[4.4 ; 9.8]$ | $6.6[4.4,49.8]$ |  |  |  |  |  |
| Taperloc (Zimmer Biomet) | 4,727 | 36 | $69_{(62-76)}$ | $37 / 63$ | 2014-2022 | $2.9\left[\begin{array}{c} [2.4 ; 3 ; 3) .4] \\ (3.36) \end{array}\right.$ | $3.4\left[\begin{array}{l} (2.98 ;) \\ \hline 1.0] \end{array}\right.$ | $3.9\left[\begin{array}{l} {[3.3 ; 3 ; 4.5]} \\ \hline(21) \end{array}\right.$ | $4.3\left[\begin{array}{l} {[3.7 .753 .50]} \\ (4,0] \end{array}\right.$ | $4.8 \text { [4.1.1.5.6] }$ | $4.9[4[4.2 ; 5.5]$ | $5.3[4.5 ; 5 ; 6.4]$ |  |
| TAPERLOC COMPLETE (Zimmer Biomet) | 4,429 | 31 | $66_{(58-73)}$ | 44/56 | 2015-2022 | $2.3(1.9 ; 2.88]$ | $2.6[([2.2 ; 3 ; 1]$ | $2.7\left[\begin{array}{l} {[2.3 ; 3 ; 3)} \\ (2,3] \\ \hline \end{array}\right.$ | $2.9\left[\begin{array}{l} {[2.45: 3.5 .4]} \\ 10.515 \end{array}\right.$ | $3.0\left[\begin{array}{l} {[2.54]} \\ (941) \\ \hline \end{array}\right.$ | $3.0[2.5 ; 3.5]$ |  |  |
| TRENDHIP (Aesculap) | 6,132 | 58 | $69_{(62-76)}$ | 40/60 | 2013-2022 | $2.5{ }_{[5.008)}^{[2 ; 30]}$ | $2.8\left[\begin{array}{l} {[2.4 ; 3 ; 3]} \\ {[.364)} \end{array}\right.$ | $2.9\left[\begin{array}{l} {[2.506]} \\ {[3.4]} \\ \hline \end{array}\right.$ | $3.0\left[\begin{array}{ll} {[2,6535} \\ {[2.5]} \\ 3.5] \end{array}\right.$ | $3.2\left[\begin{array}{ll} {[1,8262} \\ \hline 1.8] \end{array}\right.$ | $3.3\left[\frac{1683}{[2.8 ;} ; 3\right]$ |  |  |
| TRILOCK ${ }^{\text {TM-Hüftschaft ( }}$ ( ${ }^{\text {PePuy) }}$ | 5.015 | 50 | ${ }^{61} 1_{(55-67)}$ | $49 / 51$ | 2013-2022 | $1.9[1.6 ; 2.3]$ | $2.5[(0.153 ; 3.0]$ | $2.9\left[\begin{array}{l} {[2.458} \\ {[2.43]} \end{array}\right.$ | $3.2\left[\begin{array}{l} {[2.71,7.3 .8]} \end{array}\right.$ | $3.2\left[\begin{array}{l} [2.77 ; 7), 8] \\ (x, 2) \end{array}\right.$ | $\begin{gathered} 3.3\left[\begin{array}{l} 2.8 ; 0 ; 3.9] \\ (1.030 \end{array}\right) \end{gathered}$ | $3.5\left[\begin{array}{l} {[2.93 ;} \end{array} 4.3\right]$ | $4.1[3.005 .5]$ |
| TRJ (Aesculap) | 1,040 | 28 | $71_{(63-77)}$ | $34 / 66$ | 2013-2022 | $2.7 \underset{(1857)}{[1.9 ;} 3.9]$ | $3.5[2.5 ; 4.8]$ | $3.7 \underset{(12060}{[2 ; 75} 5$ | $4.2\left[\begin{array}{l} (3,0,0,50.5 \\ (1.7] \end{array}\right.$ | $4.2\left[\begin{array}{l} {[300 ;} \\ 3085] \\ 5.7] \\ \hline \end{array}\right.$ | $4.5\left[\begin{array}{l} 32.25 \\ (205) \\ 6 \end{array}\right.$ | $4.5[3.2 .26 .3]$ |  |
| twinSys uncem. (Mathys) | 5,616 | 55 | $73_{(66-78)}$ | $37 / 63$ | 2013-2022 | $2.6\left[\begin{array}{l} {[2.26 ; 6)} \\ (2,0] \end{array}\right.$ | $2.9\left[\left(\frac{2.4 ; 9 ; 3)}{(3)}\right.\right.$ | $3.0\left[\begin{array}{l} (2,6 ; 9 ; 5) \\ \hline \end{array}\right.$ | $3.2\left[\begin{array}{l} {[2.7045)} \\ \hline \end{array}\right.$ | $3.3\left[\begin{array}{ll} {[2.853 \cdot 3.9]} \end{array}\right.$ | $3.6\left[\begin{array}{l} (3.04) ; 4.2] \end{array}\right.$ | $3.6\left[\begin{array}{l} \text { [3.0;9; } 4.2] \\ \hline \text { an } \end{array}\right.$ | 3.6 [30.0; 4.2 ] |
| VEKTOR-TITAN (Peter Brehm) | 317 | 8 | $66_{(59-73)}$ | 42/58 | 2014-2021 |  | $2.8 \underset{(13015}{[5.4]}$ | $3.5[2.0 ; 6.2]$ | $4.2\left[\begin{array}{l} {\left[2.577^{2} 7.1\right]} \\ \hline \end{array}\right.$ | $4.6[2.7 .7 .7 .6]$ | $4.6[2.7 .7 ; 7.6]$ | $6.1\left[\begin{array}{l} {[3.8 ; 9.8]} \\ (13) \end{array}\right.$ |  |
| Cemented femoral component |  |  |  |  |  |  |  |  |  |  |  |  |  |
| ABG II Stem (Stryker) | 674 | 11 | $79{ }^{76-88)}$ | 22/78 | 2014-2022 | $2.7 \underset{(1632)}{[1.7 ; ~ 4.2]}$ | $3.2 \underset{(5999}{[2.1 ;} ; 4.8]$ | $3.3\left[\begin{array}{c} {[220)} \\ (520] \\ 5.0] \\ \hline \end{array}\right.$ | $3.3 \underset{(398)}{ } 3.2 ; 5.0]$ | $3.7\left[\begin{array}{l} {[2.400} \\ (230) \\ 5.6] \end{array}\right.$ | $3.7\left[\begin{array}{l} {[2,400} \\ (130) \\ 5.6] \\ \hline \end{array}\right.$ |  |  |
| Actinia cemented (Implantcast) | 591 | 15 | $80_{\text {(77- -83) }}$ | 20/80 | 2015-2022 | $3.6 \underset{(534)}{[2.33} 5.4]$ |  | $4.3[2.98 ; 6.3]$ | $4.6[3.2 ; 6.6]$ | $5.4\left[\begin{array}{c} {[3.5 ; 8.1]} \\ (5,5) \end{array}\right.$ |  |  |  |
| AS PLUS Schaft (Smith \& Nephew) | 688 | 23 | $80_{(7,5-83)}$ | 21/79 | 2013-2022 | $3.1[2.0 ; 4.7]$ | $3.4[(5.3585 .1]$ | $3.8[(5.6 ; 5) 5.6]$ | $4.0\left[\begin{array}{l} {[2.8 ; 59.9]} \\ \langle .39] \end{array}\right.$ | $4.3[2.9 ; 6.2]$ | $4.3[2.9,9 ; 6.2]$ |  |  |
| Avenir (Zimmer Biomet) | 5,233 | 141 | $80_{\text {(76-83) }}$ | 23/77 | 2014-2022 | $2.6\left[\begin{array}{l} {[2.2523} \\ {[2]} \end{array}\right)$ | $2.8\left[\begin{array}{l} {[2.3 ; 3 ; 3]} \\ {[23)} \end{array}\right.$ | $3.0\left[\begin{array}{l} {[2.5 ; 2 ; 5]} \\ (1,2) \end{array}\right.$ | $3.1\left[\begin{array}{l} {[844)} \\ \hline(84) \\ 3.7] \end{array}\right.$ | $3.4[2.88 ; 4.1]$ | $3.4\left[\begin{array}{l} (2.89) \\ \hline 2.1] \end{array}\right.$ | $3.4\left[\begin{array}{c} \text { [2.8;3) } \\ \text { (103) } \end{array}\right.$ |  |
| BHR (Smith \& Nephew) | 375 | 23 | $55{ }_{(51-59)}$ | 99/1 | 2014-2022 | $1.1 \begin{gathered} {[0.4 ; 2 ; 2.9]} \\ (318) \end{gathered}$ | $1.8\left[\begin{array}{c} {[0.8 ; 8} \\ (288) \end{array} ;\right.$ | $2.2[1.0 ; 4.6]$ | $2.2[1.0 .04 .6]$ | $2.2[1.004 .6]$ | $2.2[1.0 ; 4.6]$ |  |  |
| Bicana (Implantcast) | 391 | 18 | $78{ }_{(75-81)}$ | 28/72 | 2013-2022 | $3.1[1.85 ; 5.4]$ | $3.7[(2.2 ; 56.1]$ | $3.9\left[\begin{array}{l} {[3.4 ; 0 ;} \\ (3.5] \\ \hline \end{array}\right.$ | $4.3[2.6 ; 6.9]$ | $4.3\left[\begin{array}{l} {[2.6 ; 6} \\ {[200} \end{array}\right)$ | $4.7\left[\begin{array}{l} {[2.96 \cdot 9.7 .5]} \\ \hline(9) \end{array}\right.$ | $4.7\left[\begin{array}{l} \left.[2.97)^{7.5]}\right] \\ (1.5] \end{array}\right.$ |  |
| BICONTACT (Aesculap) | 3,896 | 107 | $80_{(76-83)}$ | 23/77 | 2013-2022 | $2.5\left[\begin{array}{l} (2.03 ; 6) \\ (3.0] \end{array}\right.$ | $2.6\left[\begin{array}{l} {[2.2 ; 6 ; 3]} \\ {[2]} \end{array}\right.$ | $3.0[2.5 ; 3.6]$ | $3.2\left[\begin{array}{ll} {[1.7773} \\ 10.93] \end{array}\right.$ | $\begin{gathered} 3.3\left[\begin{array}{l} {[2.828 ; 4.0]} \\ {[1,0]} \end{array}\right] \end{gathered}$ | $3.4 \text { [2.8; } 4.1]$ | $3.5\left[\begin{array}{l} {[4.92)} \\ \hline \end{array}\right.$ | $3.8[3[0 ; 4.6]$ |
| C-STEM ${ }^{\text {TM }}$ AMT-Hüftschaft ( DePuy $^{\text {a }}$ | 653 | 13 | $80_{(76.84)}$ | $19 / 81$ | 2013-2022 | $1.7[1.003 .3]$ | $2.2 \underset{\substack{14.35 \\[45 ; \\[4] \\ \hline}}{ }$ | $2.9 \underset{\substack{1356 \\[8 ;}}{ } 4.8]$ | $3.5\left[\begin{array}{l} {[2.2 ; 5,5.6]} \\ (30) \end{array}\right.$ | $4.3[2.7 ; 6.8]$ | $4.3[2.7 .76 .8]$ | $4.3[2.7 ; 6.8]$ |  |
| CCA (Mathys) | 1,468 | 25 | $78{ }_{(74.82)}$ | 28/72 | 2012-2022 | $2.9\left[\begin{array}{l} {[1,2 ; 2 ; 2 ; 0]} \\ \hline \end{array}\right.$ | $3.7\left[\begin{array}{l} {[1.92 ; 24.9]} \\ \hline(12) \end{array}\right.$ | $4.0\left[\begin{array}{l} \text { [3.17b } 1 ; \\ 5.2] \\ \hline \end{array}\right.$ | $4.3[3.4 ; 5.5 .6]$ | $4.6[3.665 .5]$ | $5.1\left[\begin{array}{l} {[4,0 ; 3]} \\ \hline 4.5] \end{array}\right.$ | $5.4[4.2 ; 2 ; 7.1]$ | $6.3[(4.7 ; 5) 8.4]$ |
| CORAILTM AMT-Hüftschaft ohne Kragen (DePuy) | 7.261 | 149 | $80_{(75-83)}$ | 21/79 | 2012-2022 | $2.9\left[\begin{array}{l} {[5.524 ;} \\ \hline 53] \\ \hline \end{array}\right.$ | $3.2\left[\begin{array}{l} (2,850 ; 51) \\ \hline 1.7] \end{array}\right.$ | $3.5\left[\begin{array}{l} {[3.0 ; 30} \\ {[2.86)} \\ 3 \end{array}\right.$ | $3.9\left[\begin{array}{l} 3.4,4 ; 4.4] \\ 10.90 \\ \hline \end{array}\right.$ | $4.4\left[\begin{array}{l} {[3.82 ; 5.1]} \\ (120) \end{array}\right.$ | $4.8[4.10 ; 5.6]$ |  |  |
| COREHIP (Aesculap) | 798 | 32 | $8^{81}{ }_{(78-84)}$ | 17/83 | 2018-2022 | $4.3[3.0 ; 6.0]$ | $4.5{ }_{\substack{13966}}^{3 ; 2 ; 3]}$ | $4.5\left[3.2 ;{ }_{(i 5)} ; 6.3\right]$ |  |  |  |  |  |

Table 61 (continued)

| Elective total hip arthroplasties | Number | Hosp. | Age | m/f | Period | Revision probabilities after ... |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Femoral stem |  |  |  |  |  | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Cemented femoral component |  |  |  |  |  |  |  |  |  |  |  |  |  |
| CS PLUS Schaft (Smith \& Nephew) | 937 | 33 | $78{ }_{(75-82)}$ | 26/74 | 2014-2020 | $1.7[1.1 .12 .8]$ | $2.4[1.65 ; 3.6]$ | $2.6[1.8 ; 3.9]$ | $2.6\left[\begin{array}{ll} {[1.8 ;} \\ (70) \\ \hline \end{array}\right.$ | $2.6\left[\begin{array}{c} 1,8 ; i) \\ \mid\langle 4.9] \\ \hline \end{array}\right.$ | $2.9[1.9 .94 .4]$ | $2.9\left[1.989_{(98)}^{4.4]}\right.$ |  |
| EXCEPTION (Zimmer Biomet) | 758 | 14 | $79{ }_{(75-82)}$ | 20/80 | 2016-2022 |  | $3.0\left[\begin{array}{l} {[50.00} \\ \hline 5.5] \\ 4.5] \end{array}\right.$ | $3.1\left[\begin{array}{l} {[398)} \\ {[2.1 ; 4]} \end{array}\right.$ | $3.1\left[\begin{array}{l} {[21212)} \\ \hline 1.7] \end{array}\right.$ | $3.6\left[\begin{array}{l} (2,32)^{2} \\ 5.5] \\ \hline \end{array}\right.$ |  |  |  |
| EXCIA (Aesculap) | 4,592 | 112 | $79{ }_{775-83)}$ | 23/77 | 2014-2022 | $2.2\left[\begin{array}{c} (1, .584) \\ \hline(2.6] \end{array}\right.$ | $2.5[2.1 ; 3 ; 30]$ | $2.8[2.4 ; 3.4]$ | $3.1\left[\begin{array}{l} {[1.4740)} \\ \hline 1.7] \end{array}\right.$ | $3.3\left[\begin{array}{l} {[2,72 ;} \\ (92.9] \\ \hline \end{array}\right.$ | $3.3\left[\begin{array}{l} {[2.7 \% ; 3.9]} \\ {[8.9]} \end{array}\right.$ | $3.4 \underset{(221)}{[2.8 ; 4.2]}$ |  |
| Exeter Stem (Stryker) | 567 | 22 | $80_{(77-84)}$ | $24 / 76$ | 2015-2022 | $3.4\left[\begin{array}{l} {[2.22 ; 2]} \\ \mid 123] \end{array}\right.$ | $3.4\left[\begin{array}{l} (2.244) \\ \hline(3.3] \end{array}\right.$ | $3.4\left[\begin{array}{l} {[2.27)} \\ (207) \\ 5.3] \end{array}\right.$ | $4.2[2.50 .5 .9]$ | $4.2[2.556 .9]$ |  |  |  |
| ICON (IO-International Orthopaedics) | 304 | 13 | $56_{(51-62)}$ | 87/13 | 2013-2022 | $1.0\left[\begin{array}{ll} {[0.355} \\ {[.3 .0]} \\ 3.0] \end{array}\right.$ | $1.3\left[\begin{array}{ll} {[0.56} \\ {[8.5]} \\ 3 \end{array}\right.$ | $2.0[0.9 ; 4.5]$ | $2.8[1.4 ; 5.5]$ |  |  |  |  |
| LCU Hip System, cemented, CoCrMo (Waldemar Link) | 553 | 16 | $78{ }_{144-82)}$ | 29/71 | 2019-2022 | $3.1\left[\begin{array}{l} {[1.975)} \\ {[5.0]} \end{array}\right.$ | $3.1[1.995 .0]$ |  |  |  |  |  |  |
| Lubinus Classic Plus, cemented, CoCrMo (Waldemar Link) | 661 | 8 | $81_{(78-84)}$ | $14 / 86$ | 2012-2022 | $2.8[1.8 ; 4.4]$ | $2.8[1.8 ; 4.4]$ | $3.0[1.9 ; 5 ; 5.7]$ | $3.0\left[\begin{array}{c} {[1.9 ; 5]} \\ 127.7] \\ \hline \end{array}\right.$ | $3.6\left[\begin{array}{l} {[1222 ;} \\ 5.7] \\ \hline \end{array}\right.$ | $4.9[2.9 ; 8.1]$ |  |  |
| M.E.M. Geradschaft (Zimmer Biomet) | 27,626 | 194 | $79^{(75-82)}$ | 26/74 | 2012-2022 | $2.2\left[\begin{array}{ll} {[21.0933]} \\ 2.4] \end{array}\right.$ | $2.4\left[\begin{array}{l} [1.3 ; 3 ; 4) .6] \\ (17.49) \end{array}\right.$ | $2.6\left[\begin{array}{l} [2.4 ; 5 ; 2) .8] \\ (\mid, 52) \end{array}\right.$ | $2.8\left[\begin{array}{l} {[2.659]} \\ {[9.0]} \\ \hline \end{array}\right.$ | $3.0\left[\begin{array}{l} {[2.823]} \\ (623) \\ \hline \end{array}\right.$ | $3.1\left[\begin{array}{l} {[2.82 \cdot 303]} \\ 3.30 \end{array}\right.$ | $\begin{aligned} & 3.3\left[\begin{array}{l} {[3.0 ; 3 ; 3]} \\ (x, 48) \end{array}\right] \end{aligned}$ |  |
| METABLOC (Zimmer Biomet) | 2,288 | 28 | $79{ }_{175-82)}$ | 27/73 | 2013-2022 | $2.7\left[\begin{array}{l} {[2.1 ; 1 ; 54.4]} \\ k, 54 \end{array}\right.$ | $3.0\left[\begin{array}{l} {[2.390 ;} \\ (1,8] \end{array}\right.$ | $3.2\left[\begin{array}{l} {[1.688)} \\ (1.08 \end{array}\right.$ | $3.3\left[\begin{array}{l} {[1.62 ; 3 ;} \\ {[.1]} \end{array}\right.$ | $3.6[9.82 ; 4.5]$ | $3.8\left[\begin{array}{c} \left.(349)^{2} ; 4.8\right] \\ 4.8] \end{array}\right.$ | $3.8\left[\begin{array}{l} {[3208} \\ {[28)} \\ 4.8] \end{array}\right.$ | $3.8[3.0 ; 4.8]$ |
| MS-30 (Zimmer Biomet) | 4,139 | 37 | ${ }^{78}{ }_{(44-81)}$ | $26 / 74$ | 2013-2022 | $1.7 \begin{gathered} {[1.3 ; 27)} \\ (3.22] \end{gathered}$ | $1.9[1.5 .52 .3]$ | $2.1[1.7 ; 2.6]$ | $2.3\left[\begin{array}{l} 1.9 ; 9 ; 2.9] \\ (2,9) \end{array}\right.$ | $2.4[1.9 ; 2.9]$ | $2.5\left[\begin{array}{ll} {[1.0 ; 34} \\ \hline(3) & 3.1] \end{array}\right.$ | $2.5\left[\begin{array}{l} {[2.0 ; 5)} \\ (3.1] \end{array}\right.$ |  |
| MUELLER V40 Stem (Stryker) | 322 | 13 | $79_{14 .-83)}$ | 26/74 | 2014-2022 | $2.8[1.505 .5]$ | $3.5[1.9 ; 6.2]$ | $3.8[2.25 ; 6.6]$ | $4.2\left[\begin{array}{c} {[2.5 ; 0 ;} \\ (200 \end{array}\right)$ | $5.0 \underset{(1,02)}{[3.2]}$ | $5.0\left[\begin{array}{l} {[3.0 ;} \\ 4.13) \\ 4.2] \end{array}\right.$ | $5.0[3.0 ; 8.2]$ |  |
| Müller Geradschaft (OHST Medizintechnik) | 1,966 | 48 | $79{ }_{(75-82)}$ | 26/74 | 2014-2022 |  | $2.7[(2.152 ; 3.6]$ | $2.8\left[\begin{array}{ll} {[1.132 ;} & 3.6] \\ (u) \end{array}\right.$ | $2.9\left[\begin{array}{l} {[2.3 ; 02]} \\ (3.8] \end{array}\right.$ | $3.1[2.4 ; 4.0]$ | $3.3[2.55: 4.3]$ | $3.3[2.504 .3]$ |  |
| MV40 Schaft (OHST Medizintechnik) | 341 | 19 | $80_{(76-83)}$ | 23/77 | 2015-2022 | $0.9\left[\begin{array}{c} {[0.3 ;} \\ (301) \end{array} 2.7\right]$ | $0.9\left[\begin{array}{l} {[2.3 ; 7]} \\ {[2.7]} \\ \hline \end{array}\right.$ | $1.3\left[\begin{array}{c} {[0.5 ; 3 ; 5]} \\ 120 \end{array}\right.$ | $1.3\left[\begin{array}{c} {[145]} \\ (145) \\ 3.5] \\ \hline \end{array}\right.$ | $1.3\left[\begin{array}{c} 0.5: 5 \cdot 5] \\ (102) \\ \hline 105] \end{array}\right.$ |  |  |  |
| Polarschaft Cemented (Smith \& Nephew) | 2,907 | 81 | $79^{176-83)}$ | $24 / 76$ | 2013-2022 | $3.1 \underset{(2.264)}{[2.5 ; 3.8]}$ | $3.4\left[\begin{array}{l} (2.755) \\ \hline \end{array}\right.$ | $3.5\left[\begin{array}{l} {[1.88 ; 4.24]} \\ (n, 2] \end{array}\right.$ | $3.6\left[\begin{array}{l} {[3.0 ; 4 ; 4.4]} \\ (1,28) \end{array}\right.$ | $3.8[3.1 ; 4.7]$ | $3.8\left[\begin{array}{l} {[3,1 ; 14} \\ (26) \\ 4.7] \end{array}\right.$ | $4.2[3.3 .3 .5]$ |  |
| PROFEMUR® ${ }^{\text {GLADIATOR CEMENTED (MicroPort) }}$ | 436 | 4 | $80_{\text {(77--83) }}$ | 26/74 | 2015-2022 | $\left.1.4\left[\begin{array}{c} {[0.6 ; 9} \\ {[390} \end{array}\right] .1\right]$ | $2.1[1.0 ; 4.2]$ | $2.9[1.5 ; 5.4]$ | $2.9[1.5 ; 5.5]$ | $2.9[1.5 ; 5.4]$ |  |  |  |
| QUADRA-C (Medacta) | 2,095 | 47 | $80_{\text {(77-83) }}$ | 22/78 | 2015-2022 |  | $2.8\left[\begin{array}{ll} {[2.122 ; 3]} \\ \hline \end{array}\right.$ | $2.8\left[\begin{array}{l\|l\|l\|l\|l\|}  & 3.6] \\ \hline \end{array}\right.$ | $2.8\left[\begin{array}{l} {[511 ;)} \\ (51.6] \end{array}\right.$ | $3.1[2.3 ; 4.3]$ | $3.1[2.3 ; 4.3]$ |  |  |
| SPECTRON (Smith \& Nephew) | 509 | 13 | $80_{(76-83)}$ | 25/75 | 2013-2022 | $1.4\left[\begin{array}{c} {[0.76]_{6}^{2}} \\ 2.9] \end{array}\right.$ | $1.6[0.8 ; 3.3]$ | $1.6\left[\begin{array}{ll} {[0.8 ; 4} \\ k .54 \\ \hline \end{array}\right]$ | $1.6 \underset{(1,8)}{[0 ; 3 ; 3]}$ |  | $1.6\left[\begin{array}{c} {[0.8 ; 3} \\ {[3,3]} \end{array}\right.$ |  |  |
| SPII Model Lubinus Hip Stem (Waldemar Link) | 13,359 | 142 | $78{ }_{(14.82)}$ | 26/74 | 2012-2022 | $2.1[1.82 .82 .3]$ | $2.6[(2.3 ; 3 ; 2.9]$ | $2.9\left[\begin{array}{c} (1.682) \\ \hline 6 ; 2] \\ \hline \end{array}\right.$ | $3.1\left[\begin{array}{l} {[5.855]} \\ {[3.5]} \\ \hline \end{array}\right.$ | $3.4 \underset{\substack{[3.004] \\[3.7]}}{ }$ | $3.6\left[\begin{array}{l} {[3.3686} \\ k .236 \\ \hline \end{array}\right.$ | $4.0\left[\begin{array}{c} {[3.505} \\ (1.070) \\ 4.6] \end{array}\right.$ | $4.3\left[\begin{array}{c} 3.777) \\ (37.9] \\ \hline \end{array}\right.$ |
| Standard C, cemented (Waldemar Link) | 430 | 6 | $77.5{ }_{(74-81)}$ | 33/67 | 2014-2022 | $1.2[0.5 ; 2.8]$ | $1.9[1.0 ; 3.8]$ | $2.4 \underset{\substack{1378 \\[1.3 ; ~}}{2.5]}$ | $3.0$ | $3.0\left[\begin{array}{c} 1.7700 \\ 1200 \\ 5 \end{array}\right)$ | $\begin{aligned} & 3.0[1.7 \cdot 7 \cdot 5.2] \\ & \text { (i09) } \end{aligned}$ |  |  |
| Taperloc Cemented (Zimmer Biomet) | 1,567 | 32 | $8_{(75-83)}$ | 20/80 | 2014-2022 | $2.4\left[\begin{array}{c} {[1.7 .78 .3 .3]} \\ (1,28) \end{array}\right.$ | $2.9\left[\begin{array}{l\|l\|l\|l\|} {[9.9]} \\ \hline \end{array}\right.$ | $3.0[2.2 ; 4.0]$ | $3.0[2.2 ; 4.0]$ | $3.0\left[\begin{array}{l} {[2.235} \\ {[250} \end{array}\right]$ | $3.0[2.2 .2,4.0]$ |  |  |
| TRENDHIP (Aesculap) | 673 | 35 | $80_{(76-83)}$ | 23/77 | 2016-2022 | $2.2\left[1.3 .33_{[53]}^{3} \cdot 7\right]$ | $2.2 \underset{(1,355}{[1.3 ;})$ | $2.7[1.77 ; 4.5]$ | $2.7[1.7 ; 4.5]$ | $2.7[1.7 ; 4.5]$ |  |  |  |
| twinSys cem. (Mathys) | 1,965 | 42 | ${ }^{79}{ }_{144}$-82) | 23/77 | 2013-2022 | $2.1\left[\begin{array}{ll} 11.5 \cdot 5 \cdot 6] \\ 4.9] \end{array}\right.$ | $\left.2.4{ }_{(1,328)}^{[1.8 ;} 3.2\right]$ | $2.5\left[\begin{array}{ll} (1.8 ; 3 ; 3] \\ (1.3) \end{array}\right.$ | $2.8\left[\begin{array}{l} {[2.1 ; 2]} \\ (0,7] \end{array}\right.$ | $3.3\left[\begin{array}{l} {[2.4 ; 5 ; 4.4]} \\ (46) \end{array}\right.$ | $3.7\left[\begin{array}{l} {[2.653} \\ 1203 \\ 5.3] \end{array}\right.$ | $3.7[2.6 ; 5.5]$ |  |
| Weber (Zimmer Biomet) | 344 | 30 | $81_{(77-84)}$ | 21/79 | 2014-2022 |  | $2.5[1.2 .24 .4 .9]$ | ${ }^{3.4}{ }_{(11.86)}$ |  | $4.8[2.6 ; 8.8]$ |  |  |  |


| Elective total hip arthroplasties | Number | Hosp. | Age | m/f | Period | Revision probabilities after ... |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Acetabular component |  |  |  |  |  | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Uncemented acetabular component |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Alloclassic (Zimmer Biomet) | 535 | 12 | $68{ }_{(59-77)}$ | 30/70 | 2014-2022 | $3.2\left[\begin{array}{l} {[2001)} \\ (50.1) \\ 5.1] \\ \hline \end{array}\right.$ | $3.8[2.5479 .58]$ | $4.2\left[\begin{array}{c} {[2.800} \\ (160) \\ \hline 6.3] \\ \hline \end{array}\right.$ | $4.6\left[\begin{array}{l}\text { [1.195] }\end{array}\right.$ 6.8] |  |  |  |  |
| Alloclassic Variall (Zimmer Biomet) | 560 | 14 | $70_{(61-78)}$ | $34 / 66$ | 2013-2022 | $0.5\left[\begin{array}{l} {[0.2 ; 6 ;} \\ {[5]} \end{array} 1.7\right]$ |  | $1.4\left[\begin{array}{c} {[0.755} \\ \hline(2.8] \\ 2.8] \end{array}\right.$ | $1.7\left[\begin{array}{c} {[0.89)} \\ (39) \end{array} 3.4\right]$ | $1.7\left[\begin{array}{c} {[0.8 ;} \\ 1088 \\ 3.4] \end{array}\right.$ | $2.2[1.1 .16 .4 .6]$ | $2.2[1.1 ; 4.6]$ |  |
| Allofit (Zimmer Biomet) | 141,312 | 376 | $70{ }_{(61-77)}$ | 38/62 | 2012-2022 |  | $2.9\left[\begin{array}{l} {[2.82 ; 35]} \\ (123) \end{array}\right.$ | $3.2\left[\begin{array}{c} {[3.1,4122]} \\ \hline \end{array}\right.$ | $3.3[(3.2 ; 2 ; 3.4]$ |  | $3.6[3.5 ; 9.8]$ | ${ }^{3.8} 8$ [3.7.7.4.4.0] |  |
| Allofit IT (Zimmer Biomet) | 10,160 | 116 | $65_{(57-74)}$ | 39/61 | 2012-2022 | $2.9\left[\begin{array}{c} {[2.646} \\ (0.40 \end{array}\right)$ | $3.5[3.2 ; 3.9]$ | $3.7\left[\begin{array}{l} {[3.533} \\ \hline, 4.2] \\ \hline \end{array}\right.$ | $3.9\left[\begin{array}{l} {[3.535} \\ 4.55 \\ 4.3] \end{array}\right.$ | $4.2\left[\begin{array}{c} {[3.8,8,4.6]} \\ 12,43 \\ \hline \end{array}\right.$ | $4.3\left[\begin{array}{c} (1.9994 .9 .8] \\ 4.8 \end{array}\right.$ | $4.3\left[\begin{array}{c} 13996 \\ 1996 \\ 4.8] \end{array}\right.$ | $4.5 \underset{(353)}{[4.0 ;} 5.1]$ |
| ANA.NOVA® Alpha Pfanne (ARTIQO) | 5,723 | 51 | $66_{(59-74)}$ | 42/58 | 2015-2022 | $2.4\left[\begin{array}{l} {[2.0 ; 2 ; 2)} \\ \langle 2.9] \end{array}\right.$ | $2.6\left[\begin{array}{l} {[3.2 ; 2 ; 3]} \\ \hline \end{array}\right.$ | $2.8\left[\begin{array}{l} [2.4 ; 3 ; 3) 3] \end{array}\right.$ | $3.2\left[\begin{array}{ll} {[2.75 \cdot 75} \\ \hline 1.8] \\ \hline \end{array}\right.$ | $3.5\left[\begin{array}{ll} {[2.973} \\ {[8 ; 2]} \\ 4.2] \end{array}\right.$ | $3.6\left[\begin{array}{l} {[3.0 ; 7)} \\ {[4.4]} \end{array}\right.$ | $3.6\left[\begin{array}{l} {[320} \\ (62) \end{array} 4.4\right]$ |  |
| ANA.NoVA® Hybrid Pfanne (ARTIQO) | 8,756 | 53 | $68_{(59-75)}$ | $36 / 64$ | 2015-2022 | $2.3\left[\begin{array}{l} {[2.00 ; 2.6]} \\ {[0,04]} \end{array}\right.$ | $2.6\left[\begin{array}{l} {[2.3023]} \\ \hline 5.0] \\ \hline \end{array}\right.$ | $2.8\left[\begin{array}{l} {[2.543,3.2]} \\ 4,23) \end{array}\right.$ | $2.9\left[\begin{array}{l} {[2.525 \cdot 5} \\ 3.3] \end{array}\right.$ | $3.1\left[\begin{array}{ll} {[1.7,744} \\ 3.6] \end{array}\right.$ | $3.4\left[\begin{array}{l\|l\|:\|r\|} {[18]} \\ 4.0] \end{array}\right.$ | ${ }^{3.9} 9$ |  |
| aneXys Cluster (Mathys) | 433 | 28 | $60{ }_{(55-69)}$ | 38/62 | 2016-2022 | $3.3[1.92 ; 5.7]$ | $4.2 \underset{(183)}{[2.5 ; ~ 7.0]}$ | $4.2[2.5 ; 7.0]$ | $4.2[2.5 ; 7.0]$ | $4.2[2.5 ; 7.0]$ |  |  |  |
| aneXys Flex (Mathys) | 4,928 | 64 | $64_{(58-72)}$ | 45/55 | 2016-2022 | $2.5{ }_{[(2,33 i}^{[2.1 ; 3]}$ | $\left.2.9\left[\begin{array}{l} {[2.53 ;} \end{array}\right) .5\right]$ | $3.1[(2.6 ; 3.7]$ |  | $3.2\left[\begin{array}{c} {[2.77\rangle} \\ \mid 4.8] \end{array}\right.$ | $3.2[2.7 .73 .8]$ |  |  |
| aneXys Uno (Mathys) | 326 | 12 | $55_{(48 \cdot 64)}$ | 41/59 | 2019-2022 | $2.0\left[\begin{array}{c} {[0.9 ; 845]} \\ (218) \end{array}\right.$ | $3.2 \underset{(1.61)}{[1.65]}$ |  |  |  |  |  |  |
| APRIL Poly (Symbios) | 560 | 15 | $63_{(56-70)}$ | 40/60 | 2014-2022 | $1.5\left[\begin{array}{l} {[0.72,2.9]} \\ \langle 462 \end{array}\right.$ | $1.9[1.0 ; 3.5]$ | $1.9[1.0 ; 3.5]$ | $2.2\left[\begin{array}{c} 1.272 ; \\ \mid 120] \end{array}\right.$ | $2.2\left[\begin{array}{ll} 1.2 ; 2 ; 4.0] \\ (1,3) \end{array}\right.$ |  |  |  |
| AVANTAGE (Zimmer Biomet) | 311 | 46 | $77_{(67-83)}$ | 33/67 | 2013-2022 | $4.0\left[\begin{array}{l} 20.3 ; 9] \\ {[209]} \end{array}\right.$ | $5.2[3[1,7 ; 8.9]$ | $5.2\left[\begin{array}{l} 3.1 ; 1 ; 8.9] \\ (101) \end{array}\right.$ | $5.2\left[\begin{array}{l} {[3,7 ;} \\ (65) \\ 8.9] \end{array}\right.$ |  |  |  |  |
| BHR (Smith \& Nephew) | 375 | 23 | $55_{(51-59)}$ | $99 / 1$ | 2014-2022 | $1.1\left[\begin{array}{c} {[0.4 ;} \\ (38) \\ ; \end{array} 2.9\right]$ | $1.8 \underset{\substack{0.888 \\(268)}}{[4.0]}$ | $2.2[1.02 ; 4.6]$ | $2.2[1.004 .67$ | $2.2\left[\begin{array}{ll} 2.0 ; \\ \text { (108) } 4.6] \end{array}\right.$ | $2.2[1.0 ; 4.6]$ |  |  |
| BICON-PLUS (Smith \& Nephew) | 2,907 | 51 | 71 (63-77) | 36/64 | 2013-2022 | $2.4[1.9 ; 3.1]$ | $3.2\left[\begin{array}{l} {[2.6065} \\ {[.00]} \end{array}\right.$ | ${ }^{3.9}{ }_{[2,1373}^{[3 ; 2 ; 4]}$ | $4.5\left[\begin{array}{l} {[3.85 .85 .4]} \\ (1,54) \end{array}\right.$ | $4.8[4.1 .15 .5 .7]$ | $5.6[4.7 .76 .6]$ |  |  |
| BiMobile Dual Mobility System, uncemented (Waldemar Link) | 337 | 27 | $74_{(65-80)}$ | $34 / 66$ | 2017-2022 | $3.4[1,9 ; 4 ; 6)$ | $3.9[2.20 .6 .9]$ |  |  |  |  |  |  |
| CombiCup (Waldemar Link) | 4,747 | 55 | $71_{(62-78)}$ | 38/62 | 2013-2022 | $2.1[1.7 ; 2.5]$ | $2.6\left[\begin{array}{l} {[3.2 ; 2 ; 3)} \\ \\ \hline 1.1] \end{array}\right.$ | $2.9\left[\begin{array}{ll} {[2.43: 3.3 .4]} \end{array}\right.$ | $3.2\left[\begin{array}{c} (2.743) \\ {[2.7)} \\ \hline \end{array}\right.$ | $3.4[(1.595) 5.0]$ | $3.6 \text { [3.0; } 4.3]$ | $3.8\left[\begin{array}{l} 3(3.1 ; 2 ; 4.6] \\ (2) \end{array}\right.$ |  |
| dURALOCTM OPTIONTM Press Fit-Hüftpanne (DePuy) | 1,425 | 13 | $70_{(61-76)}$ | 39/61 | 2013-2022 | $3.1\left[\begin{array}{l} (2.22 ; 2 ; 4.2] \end{array}\right.$ |  | $4.1\left[\begin{array}{ll} {[3.266} \\ 1.26 \\ 5.3] \end{array}\right.$ | $4.5[3.5 ; 5.8]$ | $4.7\left[\begin{array}{l} {[3.688)} \\ (6.0] \\ \hline \end{array}\right.$ | $\left.4.7{ }^{[3.6 ; 6)} 6.0\right]$ |  |  |
| EcoFit cpTi (Implantcast) | 1,336 | 25 | $73_{(64-79)}$ | 35/65 | 2014-2022 | $3.4\left[\begin{array}{l} {[1.5: 5 ; 4.5]} \\ {[1.24]} \end{array}\right.$ | $4.0\left[\begin{array}{l} {[1,135]} \\ (135] \end{array}\right.$ | $4.1\left[\begin{array}{l} {[3.2 .2 .5 .4]} \\ (1.007 \end{array}\right.$ | $4.5[3.5 \cdot 5.5]$ | $4.8[3.8 ; 6 ; 6]$ | $4.8 \text { [3.8:8 ; 6.2] }$ |  |  |
| EcoFit EPORE (Implantcast) | 1,990 | 28 | ${ }^{73}{ }_{(66-79)}$ | 31/69 | 2016-2022 | $4.5\left[\begin{array}{l} {[3.7505} \\ (1.50) \\ 5.6] \end{array}\right.$ | $5.1\left[\begin{array}{c} (4.12 ; 4 ;) \\ (2 ; 2] \end{array}\right.$ | $5.5[4.5: 5.6]$ |  |  |  |  |  |
| EcoFit EPORE NH (Implantcast) | 678 | 6 | $71_{(64-79)}$ | 41/59 | 2018-2022 | $2.9[1.8 ; 4.5]$ | $3.1[(2.0 ; 44.7]$ | $3.1\left[\begin{array}{l} {[2.0 ; 7)} \\ (187) \end{array}\right.$ |  |  |  |  |  |
| EcoFit NH cpTi (Implantcast) | 2,448 | 15 | $72_{(64-78)}$ | $34 / 66$ | 2014-2022 | $3.3 \text { [2.7; } 7 ; 4.1]$ | $3.5\left[\begin{array}{l} {[2.8 ; 2 ; 4.3]} \\ (1,2) \end{array}\right.$ | $3.6\left[\begin{array}{ll} {[1.950 ; 1} \end{array}\right)$ | $3.6\left[\begin{array}{l} (2.929) \\ (6.4] \end{array}\right.$ | $3.9 \underset{(3214)}{[3.9]}$ | $4.9[3.5 ; 6.9]$ | $5.6[3.8 ; 8.2]$ |  |
| EcoFit SC (Implantcast) | 359 | 7 | $73_{(65-79)}$ | $29 / 71$ | 2014-2022 | $4.4\left[\begin{array}{l} 2.778 ; 7.3] \\ \hline 120 \end{array}\right.$ |  | $6.4[4.1 .1 ; 10.0]$ | $7.2[4.6 ; 11.3]$ | $7.2[4.6 .6311 .3]$ |  |  |  |
| EL PFANNE (Smith \& Nephew) | 350 | 4 | $71_{(63-77)}$ | 32/68 | 2013-2015 | $4.9 \underset{\substack{3 \\ 3 \\ 3 \\ \hline 172}}{[7.8]}$ | $4.9 \underset{\substack{[31.1 ; ~ \\ \text { Bio }}}{ } 7.8]$ | $5.2\left[\begin{array}{c} {[3.3 ; 3 ; 4} \\ (304) \\ 8.1] \end{array}\right.$ | $5.8\left[\begin{array}{c} {[388,8 ; 4} \\ {[189]} \end{array}\right.$ | $5.8\left[\begin{array}{c} 31.875 \\ {[25} \end{array} 8.9\right]$ | $5.8\left[\begin{array}{c} {[3.8 ;} \\ {[261} \\ \hline \end{array}\right.$ | $5.8\left[\begin{array}{l} (3.8 ; 6 ; \\ (2.9] \\ \hline \end{array}\right.$ | $5.8[3.8 .8 .9]$ |
| EP-FIT PLUS (Smith \& Nephew) | 3,730 | 66 | $69{ }_{(61-76)}$ | 43/57 | 2013-2022 | $2.6\left[\begin{array}{l} {[2.233]} \\ {[3.2]} \end{array}\right.$ | $3.0\left[\begin{array}{l} {[2.59 ; 9]} \\ {[2.6]} \end{array}\right.$ | $3.1\left[\begin{array}{l} {[2.698)} \\ \hline 2.75] \end{array}\right.$ |  | $3.3\left[\begin{array}{ll} {[1.7986} \\ 10.9 .9] \end{array}\right.$ | $3.4\left[\begin{array}{ll} {[1.888)} \\ \hline 1.88 \end{array}\right.$ | $3.4\left[\begin{array}{l} {[2.852} \\ {[4.0]} \\ \hline \end{array}\right.$ | ${ }^{3.6}{ }_{\text {[10, }}^{\text {[1.9\% }}$; 4.5$]$ |
| Exceed (Zimmer Biomet) | 339 | 10 | $72{ }_{(63-77)}$ | 34166 | 2013-2019 | $2.9[1.6 ; 5.4]$ | $3.6\left[\begin{array}{l} \text { [2006 } \\ \\ \hline 0 ; 6 \\ 6.2] \\ \hline \end{array}\right.$ | $3.6\left[\begin{array}{l} (2.08 \\ \hline 128) \\ 6.2] \end{array}\right.$ | $3.6\left[\begin{array}{ll} {[20,0 ; 0} \\ 6.2] \\ 6.2] \end{array}\right.$ | $3.6\left[\begin{array}{l} {[2.090} \\ k i, j \\ 6.2] \end{array}\right.$ | $4.3\left[\begin{array}{l} \text { 21266 } \\ 126 \\ 7 \\ 7.2] \end{array}\right.$ | $4.7\left[\begin{array}{l} {[2.854)} \\ \hline(164) \end{array}\right.$ |  |
| Fitmore (Zimmer Biomet) | 732 | 12 | $68_{(59-76)}$ | $34 / 66$ | 2012-2022 | $2.1[1.2 ; 3.4]$ | $2.5\left[\begin{array}{c} {[1.6 ; 0 ; 3]} \\ \hline(8) \end{array}\right.$ | $2.8[1.85 ; 4.3]$ | $2.8[1.8 ; 4.3]$ | $3.4\left[\begin{array}{l} {[2.2 ; 5 ; 5.1]} \end{array}\right.$ | $3.4\left[\begin{array}{l} {[2.2 ; 3 ; 5.1]} \\ 5.1] \end{array}\right.$ | $3.4[2.2 ; 5.51]$ |  |
| G7 (Zimmer Biomet) | 4,222 | 28 | $70{ }_{(62-77)}$ | 35/65 | 2014-2022 | $3.0\left[\begin{array}{c} {[2.6 ; 6 ; 3.6]} \\ (2306) \end{array}\right.$ | $3.9\left[\begin{array}{l} {[3.3 ; 4.54} \\ (2,5) \end{array}\right.$ | $4.5\left[\begin{array}{c} {[3.8: 8 \cdot 5.2]} \\ k .26] \end{array}\right.$ | $5.1\left[\begin{array}{l} {[4.4 .4010)} \\ \hline(0.9] \end{array}\right.$ | $5.6\left[\begin{array}{c} {[4.92 ; 6)} \\ (1.03) \end{array}\right.$ | $5.9[5.0 ; 6.8]$ | $6.1\left[\begin{array}{l} {[5 ; 2 ; 8)} \\ (8,2] \\ 7 \end{array}\right.$ |  |

Table 62: Outcomes for acetabular cups in elective total hip arthroplasties. For each type of fixation, the cups are listed alpha betically by their designation.

| Elective total hip arthroplasties | Number | Hosp. | Age | m/f | Period | Revision probabilities after ... |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Acetabular component |  |  |  |  |  | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Uncemented acetabular component |  |  |  |  |  |  |  |  |  |  |  |  |  |
| HI Lubricer Schale (Smith \& Nephew) | 5,945 | 39 | 70 (62-77) | $36 / 64$ | 2013-2022 | $2.4\left[\begin{array}{l} {[2,02 ; 2 ;)} \\ {[2.8]} \\ \hline \end{array}\right.$ |  | $3.1\left[\begin{array}{l} {[2,73 ; 3)} \\ \hline 1.6] \\ \hline \end{array}\right.$ | $3.4\left[\begin{array}{l} {[3.0222)} \\ \hline \end{array}\right.$ | $3.7\left[\begin{array}{l} (1.292) 2] \end{array}\right.$ | $4.0\left[\begin{array}{ll} {[3.4535} \\ {[4.53} \\ \hline \end{array}\right.$ | $4.6\left[\begin{array}{l} {[3.9 ; 3)} \\ 5.6] \\ \hline \end{array}\right.$ |  |
| ICON (IO-International Orthopaedics) | 304 | 13 | $56_{(51-62)}$ | 87/13 | 2013-2022 | $1.0\left[\begin{array}{l} {[0.355} \\ {[25]} \\ 3 \end{array}\right.$ | $1.3\left[\begin{array}{c} {[0.586} \\ {[286} \\ 3 \end{array}\right.$ | $2.0\left[\begin{array}{l}{[0.975)} \\ \text { 4.5] }\end{array}\right.$ | $2.8\left[\begin{array}{c} 1.4,4 ; 5.5] \\ \|22\| \end{array}\right.$ | $2.8(1.45 \cdot 5.5]$ | $2.8[1,4,5.5]$ |  |  |
| MobileLink, Cluster Hole (Waldemar Link) | 2,744 | 46 | $71{ }_{(62-78)}$ | 36/64 | 2017-2022 | $3.6\left[\begin{array}{l} {[2.9224} \\ (1.4) \\ \hline \end{array}\right.$ | $\underset{(838)}{4.5} 5$ | $4.5\left[\begin{array}{c} {\left[3,78 \theta_{i}\right.} \\ (2.4] \\ \hline \end{array}\right.$ | $4.5[3.77 ; 5.4]$ |  |  |  |  |
| PINNACLETM Press Fit-Hüftpfanne (DePuy) | 55,626 | 198 | $70_{(61-77)}$ | $37 / 63$ | 2012-2022 | $2.5\left[\begin{array}{l} {[2,4,4 ; 2 ; 2]} \end{array}\right.$ | $2.9\left[\begin{array}{c} {[3.85 ; 41)} \\ \hline(3.1] \\ \hline \end{array}\right.$ | $3.2\left[\begin{array}{l} {[3.0 ; 73.4]} \\ 226,7) \end{array}\right.$ | $3.5\left[\begin{array}{ll} {[13.3: 330]} \\ \hline 3.6] \end{array}\right.$ | $3.6[3.4 ; 3.81$ | $3.8[(3.6 ; 54.1]$ | $4.1\left[\begin{array}{c} {[3.8 ; 474]} \\ (2,47) \end{array}\right.$ | $4.8[4.3 ; 5.3]$ |
|  | 440 | 18 | $74{ }_{(65-79)}$ | 26/74 | 2013-2020 | $3.9 \text { [2.4; 6.2] }$ | $4.4 \underset{[386}{[2.8 ;} ; 6.7]$ | $4.6 \underset{(3804)}{[3.0]} 7$ | $4.6[3.0 .075 .0]$ | $5.2\left[\begin{array}{l} {[3,5 ; 0} \\ (2,8] \\ \hline \end{array}\right.$ | $5.2\left[\begin{array}{c} {[3.5 ; 7.8]} \\ (180) \end{array}\right.$ | $5.2\left[\begin{array}{c} {[3.57} \\ (1,5) \\ 7 \end{array} .8\right]$ |  |
| PLASMACUP (Aesculap) | 8,696 | 58 | $69_{(61-76)}$ | $38 / 62$ | 2013-2022 | $\left.2.2\left[\begin{array}{l} {[1.9090} \end{array}\right) 2.6\right]$ | $2.6 \underset{(2.554)}{[2 ; 3]}$ | $2.7\left[\begin{array}{l} {[5.46 ; 3)} \\ {[6.1]} \\ \hline \end{array}\right.$ | $2.9\left[\begin{array}{l} {[2.5 ; ~} \\ 4.57) \\ 3.2] \\ \hline \end{array}\right.$ | $2.9\left[\begin{array}{l} {[2,6595} \\ {[3.3]} \\ \hline \end{array}\right.$ | $2.9\left[\begin{array}{l} {[2.643 ; 3]} \\ {[2,3]} \\ \hline \end{array}\right.$ | $2.9\left[\begin{array}{ll} {[1,68 ;)} \\ \hline, 3] \end{array}\right.$ | $3.0\left[\frac{12.683}{} ; 3.4\right]$ |
| PLASMAFIT (Aesculap) | 48.729 | 245 | $69_{(61-77)}$ | $39 / 61$ | 2013-2022 | $2.9\left[\begin{array}{l} (2,8,4 ; 2]) \\ \hline 1.1] \end{array}\right.$ | $3.3[3.1 ; 3.4]$ | $3.5\left[\begin{array}{l} {[3.3 ; 5 ; 5.6]} \\ \hline(25) \end{array}\right.$ | $3.6\left[\begin{array}{c} {[1.4 .433)} \\ \hline 1.3 \\ \hline \end{array}\right.$ | $3.6[3.5 ; 3.8]$ | $3.7\left[\begin{array}{l} {[3.5193)} \\ (6,9] \end{array}\right.$ | $3.7\left[\begin{array}{c} {[3.52 ; 9)} \\ (2,3) \\ 3.9] \end{array}\right.$ | $3.8[3[5 ; 5 ; 4.0]$ |
| PROCOTYL® L BEADED (MicroPort) | 1,161 | 25 | $68_{(60-75)}$ | 41/59 | 2014-2021 | $2.5\left[\begin{array}{ll} {[1,719 ; 3.6]} \\ 4.19 \end{array}\right.$ | $3.2[2.3 ; 4.4]$ | $3.7\left[\begin{array}{l} {[672 ; 2)} \\ {[6.0]} \\ \hline \end{array}\right.$ |  | $4.2\left[\begin{array}{l} {[3,0 \cdot 0 \cdot 5} \\ {[3.7]} \end{array}\right.$ | $5.0[3.5 \cdot 7.1]$ |  |  |
| PROCOTYL® P (MicroPort) | 1,099 | 19 | $68{ }_{(61-75)}$ | 38/62 | 2020-2022 | $2.9[2.0 ; 4.2]$ |  |  |  |  |  |  |  |
| Pyramid (Atesos) | 3,111 | 26 | $71_{(64-77)}$ | 35/65 | 2014-2022 | $3.0\left[\begin{array}{c} (2.4,45 ; 3.6] \end{array}\right.$ | $3.2\left[\begin{array}{l} {[2.7353,9]} \\ {[2,9]} \end{array}\right.$ | $3.5[(1.9 ; 44 ; 3]$ | $3.6[3.0054 .3]$ | $3.7\left[\begin{array}{l} {[3.1 .9 ; 4.5]} \\ (1,03) \end{array}\right.$ | $3.8[3.2 .204 .7]$ | ${ }^{3.8} 8$ [3.2; 4.7 .7$]$ |  |
| R3 (Smith \& Nephew) | 18,881 | 136 | $6^{69}(61-77)$ | 39161 | 2013-2022 | $3.0\left[\begin{array}{l} {[2.73 ; 34]} \\ {[1.2]} \\ \hline \end{array}\right.$ | $3.3[3.0 ; 3.6]$ | $3.5\left[\begin{array}{l} {[3,272]} \\ {[9.8]} \\ \hline \end{array}\right.$ | $3.7[3.4,4 ; 4.0]$ | $3.8\left[\begin{array}{l} (3.994) \\ \hline 1.2] \end{array}\right.$ | $3.9[3.6 ; 4.3]$ | $4.0\left[\begin{array}{l} {[3.727} \\ {[5.5]} \\ \hline \end{array}\right.$ | $4.0[3.7 .7 ; 4.5]$ |
| REFLECTION (Smith \& Nephew) | 1,146 | 9 | $699_{(60-77)}$ | 36/64 | 2013-2022 | $1.5 \underset{(1,003)}{[0.9 ; 2.4]}$ | $1.9[1.3 ; 2 ; 9]$ | $2.3[1.5 ; 3.4]$ | $2.3[1.5 \cdot 3.4]$ | $2.3[1.5 ; 3.4]$ | $2.5[1.77 ; 3.8]$ |  |  |
| RM Classic (Mathys) | 2,061 | 20 | $76_{69-80)}$ | 31/69 | 2013-2022 |  | $3.0\left[\begin{array}{l} {[2.4 ; 4 ; 3.9]} \\ (1,4) \end{array}\right.$ | $3.2\left[\begin{array}{c} {[1.50 ; 8)} \\ (1.0) \end{array}\right.$ | $3.5\left[\begin{array}{l} {[2.773 / 4.4]} \\ \hline(2)] \end{array}\right.$ | $3.6[2.9794 .6]$ | $4.0\left[\begin{array}{l} 3.12 ; 5.0] \\ (127) \end{array}\right.$ |  |  |
| RM Pressfit (Mathys) | 1,288 | 13 | $74{ }_{(66-79)}$ | 41/59 | 2013-2022 | $2.6[1.8 ; 3 ; 6]$ | $3.1\left[\begin{array}{l} {[2.3 ; 524.2]} \\ (1.02) \end{array}\right.$ | $3.4\left[\begin{array}{l} {[9.52 ;} \\ \hline 9.6] \\ \hline \end{array}\right.$ | $3.7\left[\begin{array}{ll} {[2.8 ; 9)} & 4.9] \\ \|c\| 09 \end{array}\right.$ | $3.9[2.920 .51]$ | $3.9\left[\begin{array}{l} {[2.90 ; 1} \\ \hline 3.1] \end{array}\right.$ | $3.9\left[\begin{array}{ll} {[139]} \\ \hline 1.9 .1] \end{array}\right.$ |  |
| RM Pressfit vitamys (Mathys) | 17,767 | 90 | $68{ }_{(60-75)}$ | 41/59 | 2013-2022 | $1.8[1.6 ; 2.0]$ | $2.0[1.8 ; 2.3]$ | $2.1\left[\begin{array}{c} 1.9 .9 ; 9.4] \\ \hline 8.096 \end{array}\right.$ | $2.3\left[\begin{array}{l} {[2.0020} \\ \hline 502 \\ 2.5] \end{array}\right.$ | $2.4 \underset{[8,262]}{[2.7]}$ | $2.6\left[\begin{array}{l} {[2.350} \\ (1.50) \end{array} 2.9\right]$ | $2.6\left[\begin{array}{l} {[5631} \\ {[50} \end{array}\right)$ |  |
| SCREWCUP SC (Aesculap) | 2,251 | 59 | $73_{(64-78)}$ | 34166 | 2013-2022 | $3.1\left[\begin{array}{l} {[2.596} \\ {[1.96)} \\ 3 \end{array}\right.$ | $3.9\left[\begin{array}{l} {[3,2 ; 2 ; 4)} \\ \hline, 8] \\ \hline \end{array}\right.$ | $4.4\left[\begin{array}{l} {[1.65 ; 5.4]} \\ (1,46) \end{array}\right.$ | $4.7\left[\begin{array}{l} {[3.9 .956 .7]} \\ (1.07) \end{array}\right.$ | $5.5[4.5 ; 6.7]$ | $5.8\left[\begin{array}{l} 43,8 ; 7 \\ \hline 7.2] \\ \hline \end{array}\right.$ | $6.9\left[\begin{array}{c}\text { [5.4; } \\ (199)\end{array}\right.$ | $8.3[5.66: 12.1]$ |
| seleXys PC (Mathys) | 559 | 7 | $70{ }_{(61-77)}$ | $39 / 61$ | 2015-2022 | $0.9[0.4 ; 2.1]$ | $0.9\left[\begin{array}{c} \left.[4.4 ;)^{2} ; 2.1\right] \\ \hline(4) \end{array}\right.$ | $0.9\left[\begin{array}{l} {[.42 ; 2} \\ (246) \\ \hline \end{array}\right.$ | $1.7\left[\begin{array}{l} {[.830} \\ (330) \\ 3.4] \end{array}\right.$ | $\left.1.7\left[\begin{array}{ll} {[0.833} \end{array}\right] .4\right]$ | $1.7\left[\begin{array}{l} {[0.8 ; 3.4]} \\ \mid 2 ; 2] \end{array}\right.$ |  |  |
| Stemcup (IO-International Orthopaedics) | 527 | 15 | $70{ }_{(61-77)}$ | $39 / 61$ | 2018-2022 | $\underset{\substack{1316}}{2.3} \mathbf{1 1 . 3 ;} 4.1]$ | $2.6[1.5 ; 4.6]$ | $2.6[1.554 .6]$ |  |  |  |  |  |
| T.O.P., HX (Waldemar Link) | 353 | 8 | $6^{65}{ }_{(56-69)}$ | 50/50 | 2012-2022 | $2.3\left[\begin{array}{c} {[1.1 ; 4 ; 4.5]} \\ \substack{3} \\ \hline \end{array}\right.$ | $\underset{\substack{13.50 \\[130}}{2.2]}$ | $3.2 \underset{\substack{1319 \\[19 ;}}{5.6]}$ |  | $3.8[2.2 ; 6.4]$ | $4.1\left[\begin{array}{l} {[2.50 ;} \\ 1200 \\ 6.9] \end{array}\right.$ | $4.1 \underset{(1 i 73}{[2.5 ; ~ 6.9]}$ | $4.1\left[\begin{array}{l} {[2.5 ; 6.9]} \\ \mid 120) \end{array}\right.$ |
| TM Modular (Zimmer Biomet) | 1,492 | 139 | $65_{(54-75)}$ | $29 / 71$ | 2012-2022 | $6.3\left[\begin{array}{l} {[5.2 ; 827.7]} \\ u, 1) \end{array}\right.$ | $7.2\left[\begin{array}{l} \text { [6;0; } \\ \hline 98) \\ 8.7] \\ \hline \end{array}\right.$ | $7.6\left[\begin{array}{c} {[8.30} \\ (8.0) \\ \hline \end{array}\right.$ | $7.8[6.5 \cdot 59.4]$ | $8.1 \text { [6.8:9.9.8] }$ |  | $8.6\left[\begin{array}{ll} {[7.1 .13)} \\ (130) & 10.4] \end{array}\right.$ |  |
| Trident Cup (Stryker) | 9,094 | 57 | $69_{(61-76)}$ | 40/60 | 2014-2022 | $2.6\left[\begin{array}{l} {[2.2 ; 92 ; 9]} \\ (0,99) \end{array}\right.$ | $3.0\left[\begin{array}{l} [2.792 ; 3) 4] \\ \hline \end{array}\right.$ | $3.2\left[\begin{array}{l} {[2.84 ; 3]} \\ \langle 4.6] \\ \hline \end{array}\right.$ | $3.3\left[\begin{array}{l} {[3,0 ; 9]} \\ 2,98] \\ 3 \end{array}\right]$ | $3.4\left[\begin{array}{ll} {[3,040 \cdot 3 \cdot 9]} \\ (x, 4) \end{array}\right.$ | $3.6[3.2 .2 ; 4.1]$ | $3.6\left[\begin{array}{l} {[3.2 ; 5]} \\ (2.1] \end{array}\right.$ |  |
| Trident II Tritanium Cup (Stryker) | 404 | 16 | $73_{(66-79)}$ | $37 / 63$ | 2018-2022 |  |  |  |  |  |  |  |  |
| Trident TC Cup (Stryker) | 833 | 15 | $73_{(65-78)}$ | 32/68 | 2014-2021 | $2.5[1.77 ; 3.9]$ | $3.0 \underset{(2,188)}{[2.1 ; 4.5]}$ | $3.4[2.4 ; 4.9]$ | $3.8[2.7 .7 ; 5.4]$ | $4.2\left[\begin{array}{l} {[3.0 ; 3.5 .9]} \\ \hline 1.9] \end{array}\right.$ | $4.2[3.0 ; 5.9]$ | $4.2[3.0 .0 \cdot 5.9]$ |  |
| Trilogy (Zimmer Biomet) | 6.411 | 31 | $68_{(60-75)}$ | 38/62 | 2012-2022 | $2.1[1.8 ; 2.5]$ | $2.7 \underset{(4,420)}{[2.3 ;} 3.1]$ | $2.9\left[\begin{array}{l} {[2,5 ; 5 ;)} \\ \hline(3) \\ \hline \end{array}\right.$ | $3.1\left[\begin{array}{l} {[2,6 ; 9 ; 3.5]} \\ 3.5] \end{array}\right.$ | $3.2\left[\begin{array}{l} {[2.860)} \\ {[2.7]} \end{array}\right.$ | $3.2\left[\begin{array}{ll} {[2.8,8 ; 3)} & 3.7] \end{array}\right.$ | $3.3 \underset{(2,922}{[9]} 3]$ | $3.3[2.9 ; 3.8]$ |
| Trilogy IT (Zimmer Biomet) | 1,531 | 6 | $71_{(62-77)}$ | 39161 | 2013-2022 | $\begin{gathered} 3.3[2.5 ; 4.3] \\ (1.276) \end{gathered}$ | $3.4\left[\begin{array}{l} (2,16 ; 2) \\ \hline 12) \\ \hline \end{array}\right.$ |  | $4.0\left[\begin{array}{l} {[3,1 ; 7)} \\ (15.2] \end{array}\right.$ | $4.3[3.45 ; 5.6]$ | $4.9\left[\begin{array}{l} {[3.861} \\ (361) \\ 6.4] \\ \hline \end{array}\right.$ | $4.9\left[\begin{array}{l} {[3.82 ;} \\ {[6.4]} \\ \hline \end{array}\right.$ |  |
| Trinity Hole (Corin) | 2,378 | 44 | $66_{(88-75)}$ | 42/58 | 2013-2022 | $2.3[1.7 ; 3.0]$ | $2.4\left[\begin{array}{c} {[1.9 ; 543} \\ (1.54) \\ \hline \end{array}\right.$ | $2.6\left[\begin{array}{l} {[1.2,272} \\ \hline 1.3] \\ \hline \end{array}\right.$ | $2.7\left[\begin{array}{l} {[2.1955} \\ \hline(3.4] \end{array}\right.$ | $2.8[(2.1 ; 3 ; 6]$ | $2.8\left[\begin{array}{l} {[21.16]} \\ \hline 1.6] \\ \hline \end{array}\right.$ | $3.0\left[\begin{array}{l} {[1.364)} \\ \hline 1.1] \end{array}\right.$ |  |
| Trinity no Hole (Corin) | 2,493 | 30 | $68{ }_{(60-75)}$ | 42/58 | 2014-2022 | $2.2[1.7 ; 2.9]$ | $2.7{ }_{\text {2 }}^{\text {[2.08i }}$ [ 3.4$]$ |  | $\left.3.1{ }_{[0.4 .950} 3.9\right]$ | ${ }^{3.5}{ }_{[1.0898}(2.84 .4]$ |  | $4.2\left[{ }_{[233]}[3.35]\right.$ |  |

Table 62 (continued)

| Elective total hip arthroplasties |  |  |  |  |  | Revision probabilities after ... |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Acetabular component | Number | Hosp. | Age | m/f | Period | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
| Uncemented acetabular component |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Tritanium Cup (Stryker) | 2,835 | 28 | $70{ }_{(62-77)}$ | 39161 | 2014-2022 | $2.8\left[\begin{array}{l} {[2.2 ; 01]} \\ (2.5] \\ 3 \end{array}\right.$ | $3.2\left[\begin{array}{c} (2.973) \\ \hline(4.0] \end{array}\right.$ | $3.6\left[\begin{array}{ll\|l\|:\|:\|c\|} 4.4] \\ 4.4] \end{array}\right.$ | $3.9\left[\begin{array}{c} (3,2 ; 9) \\ (4.8] \\ 4.8] \\ \hline \end{array}\right.$ | $4.1\left[\begin{array}{c} {[3.39)} \\ (6.9] \\ \hline \end{array}\right.$ | $4.1 \begin{gathered} {[3.355} \\ (325 \\ 4.9] \\ \hline \end{gathered}$ | $4.5[3.555 .9]$ |  |
| VERSAFITCUP CC TRIO (Medacta) | 13,341 | 67 | $69_{(61-77)}$ | 38/62 | 2015-2022 | $2.6\left[\begin{array}{c} {[1.3 ; 272)} \\ (120) \end{array}\right.$ | $3.0\left[\begin{array}{l} {[2.70 ; 65)} \\ \hline 1.3] \\ \hline \end{array}\right.$ | $3.3\left[\begin{array}{l} {[3.00069} \\ \hline 10.7] \\ \hline \end{array}\right.$ | $3.7[3.3 ; 4.0]$ | $4.0\left[\begin{array}{l} {[3.6954 .4]} \\ (k, 23) \end{array}\right.$ | $4.5\left[\begin{array}{l} \text { (302) } \\ (002) \\ 5.1] \end{array}\right.$ | $4.6[4.005 .5]$ |  |
| Cemented acetabular component |  |  |  |  |  |  |  |  |  |  |  |  |  |
| All POLY CUP (Aesculap) | 4,102 | 149 | $80_{(76-83)}$ | $22 / 78$ | 2013-2022 | $2.9\left[\begin{array}{l} (2,4,424) \\ (2,5] \\ \hline \end{array}\right.$ | $3.3\left[\begin{array}{c} {[2.8 ; 8 ; 3.9]} \end{array}\right.$ | $3.6[3.0 \cdot 54.2]$ | $\begin{gathered} 3.8[3.2 ; 8 ; 4.4] \\ (k .138) \end{gathered}$ | $4.0\left[\begin{array}{l} {[3.4 ; 4.4 .7]} \\ (2,28) \\ \hline \end{array}\right.$ | $4.1[3.4 ; 7 ; 4.8]$ | $4.4\left[\begin{array}{l} {[3.6 ; 7)} \\ \hline 3.2] \end{array}\right.$ | $5.3[3.9 .9 .7 .2]$ |
| AVANTAGE (Zimmer Biomet) | 1,141 | 133 | 79 (12-84) | 27/73 | 2014-2022 | $5.3\left[4.17{ }_{4}(6.8]\right.$ | $5.4[4.2 ; 7.0]$ | $5.9\left[\begin{array}{c} {[3.68)} \\ (3.6] \\ 7.6] \\ \hline \end{array}\right.$ | $6.4\left[\begin{array}{c} {[4.8 ; 8)} \\ (190) \end{array}\right.$ | $5.4[4.8 ; 8 ; 8.4]$ | $7.4\left[5.2 ;{ }_{[50} ; 10.6\right]$ |  |  |
| CCB (Mathys) | 1,075 | 43 | $79{ }_{(74-83)}$ | 22/78 | 2013-2022 | $2.8\left[\begin{array}{l} {[8,044} \\ {[4.0]} \\ 4.0 \end{array}\right.$ | $3.5\left[\begin{array}{l} {[672)} \\ {[6.9]} \\ \hline \end{array}\right.$ | $3.5\left[\begin{array}{l} {[2486} \\ \hline 4.64] \\ 4.9] \end{array}\right.$ | $3.8\left[\begin{array}{l} {[2.700} \\ \hline 1.3] \\ \hline \end{array}\right.$ | $4.2\left[\begin{array}{l} \text { [2.92 } \\ {[229} \end{array} 5.9\right]$ | $4.2[2.9 .95 .9]$ | $4.2[2.995 .59]$ |  |
| Cemented Acetabular Cup System, Endo-Model Cup, UHMWPE (Waldemar Link) | 601 | 6 | $77_{(72-82)}$ | 17/83 | 2012-2022 |  | $\underset{(5513)}{2.8} \underset{(1.7 ; 4]}{ }$ |  | $3.4 \underset{(4144)}{[2.2 ; 5]}$ | $3.4 \underset{(333)}{[2.2 ;} 5.2]$ | $3.4\left[\begin{array}{l} {[2.2 ; 2 ; 5)} \\ \hline(3) 2] \end{array}\right.$ | $\left.{ }_{3.4}^{[2.2 .25)} 5.2\right]^{(25)}$ | $4.2{ }_{(173)}^{[2.73 .6 .6]}$ |
| Cemented Acetabular Cup System, IP Cup, UHMWPE (Waldemar Link) | 429 | 18 | $80_{(76-83)}$ | $27 / 73$ | 2013-2022 | $2.4[1.3 ; 4.4]$ | $2.9 \underset{\substack{1322}}{[1.75} 5.0]$ |  | $3.2[1.92 ; 5.4]$ | $3.2\left[\begin{array}{ll} {[1.979 .5 .4]} \\ (17) \end{array}\right.$ | $3.2[1.9 .9 .4]$ | $3.2[1.975 .5]$ |  |
| Cemented Acetabular Cup System, IP Cup, X-Linked (Waldemar Link) | 965 | 32 | $81{ }_{(78.84)}$ | 26/74 | 2014-2022 | $2.4\left[\begin{array}{c} (184) \\ (140) \\ \hline 3.6] \\ \hline \end{array}\right.$ | $2.8[1.9 ; 4.1]$ | $3.2\left[\begin{array}{c} (2.2 ; 9) \\ (64) \\ 4.6] \end{array}\right.$ | $3.8\left[\begin{array}{l} {\left[2.733^{2} 5.3\right]} \\ \hline \end{array}\right.$ | $3.8\left[\begin{array}{l} {[2322} \\ {[3.3]} \\ 5.3] \end{array}\right.$ | $4.1\left[\begin{array}{l} {[19965} \\ (196) \\ 5.8] \\ \hline \end{array}\right.$ |  |  |
| Cemented Acetabular Cup System, Lubinus, UHMWPE (Waldemar Link) | 530 | 29 | $80{ }_{(75.84)}$ | $19 / 81$ | 2013-2022 | $2.0\left[\begin{array}{c} {[1.1 .133)} \\ \langle 4.6] \end{array}\right.$ | $\underset{(1855)}{2.0[1.6]}$ | $\underset{\substack{(103) \\(103) \\ 4.8]}}{ }$ | $3.1\left[\begin{array}{c}\text { (1254) } 9: 3.3] \\ \hline\end{array}\right.$ | $4.0\left[\begin{array}{l} (2,4 ;) \\ \hline, 6.5] \end{array}\right.$ | $4.0[2.4 ; 4 ; 5]$ | $4.0\left[{ }_{\text {[2, }} 96 ; 6.5\right]$ |  |
| Cemented Acetabular Cup System, Lubinus, X-Linked (Waldemar Link) | 628 | 17 | $79{ }_{(14-82)}$ | 27/73 | 2014-2022 | $1.9[1.1 ; 3.4]$ | $2.3(1.4 ; 3.9]$ | $2.8\left[\begin{array}{c} 1.7 .755 \\ 13.7] \\ 4.7] \\ \hline \end{array}\right.$ | $2.8[1.7 ; 4.7]$ | $2.8[1.75 ; 4.7]$ | $2.8[11.74 .7]$ |  |  |
| EcoFit 2M cemented (Implantcast) | 348 | 64 | $78{ }_{\text {(69-83) }}$ | 33/67 | 2014-2022 |  | $9.3[6.4 .43 .13 .3]$ | $10.0[6.9 ; 14.3]$ |  |  |  |  |  |
| Flachprofil (Zimmer Biomet) | 8,545 | 294 | $80_{(76-83)}$ | 23/77 | 2012-2022 | $3.0\left[\begin{array}{c} {[1.793)} \\ (6,43) \\ \hline \end{array}\right.$ | $3.4\left[\begin{array}{l} {[3.172 ;} \\ {[3.9]} \\ \hline \end{array}\right.$ | $3.8\left[\begin{array}{l} {[3.4,4.4 .2]} \\ 4.624) \\ \hline \end{array}\right.$ | $3.9[3.5 ; 4.3]$ | $4.2\left[\begin{array}{l} {[3.7364 .7]} \\ {[2.36} \end{array}\right.$ | $4.4\left[\begin{array}{l} {[3.994 .9 .9]} \\ (1,40) \end{array}\right.$ | $4.4\left[\begin{array}{l} {[3.92 ;} \\ (62) \\ 5 \end{array}\right.$ | $4.6[4.0 .05 .4]$ |
| Mueller II (Implantcast) | 447 | 34 | $79{ }_{(74-83)}$ | 23/77 | 2014-2022 | $4.0\left[\begin{array}{c} {[2.50)} \\ (30) \\ \hline 6.3] \\ \hline \end{array}\right.$ | $5.2\left[\begin{array}{l} {[3.4 ; 4 ; 4.9]} \\ \substack{264} \\ \hline \end{array}\right.$ | $5.6\left[\begin{array}{c} 3.7 .78 .8] \\ k 20\rangle \end{array}\right.$ | $6.8[4.5 \cdot 5 \cdot 10.4]$ | $7.8[5.0 ; 120.0]$ |  |  |  |
| Müller II Pfanne (OHST Medizintechnik) | 2,729 | 111 | $80_{(76-83)}$ | 23/77 | 2013-2022 | $3.0\left[\begin{array}{l} {[2,4 ; 3 ; 2 ; 7]} \end{array}\right.$ | $3.5\left[\begin{array}{l} {[2.9 ; 144)} \\ 4.3] \end{array}\right.$ | $\underset{\substack{3.8 .1 \\ \left[\begin{array}{ll} 1.87\rangle \\ \hline \end{array} 4.6\right] \\ \hline}}{ }$ | $3.9\left[\begin{array}{c} 1.53 ; 58) \\ (4.8] \end{array}\right.$ | $4.1\left[\begin{array}{l} {[3.414 .5 .0]} \\ (0.16) \end{array}\right.$ | $\underset{(623)}{4.2}[3.4 ; 5.1]$ |  |  |
| POLARCUP cemented (Smith \& Nephew) | 351 | 54 | $79{ }_{(71-84)}$ | $29 / 71$ | 2013-2022 | $3.7 \begin{gathered} {[2.12 ; 6.4]} \\ {[224} \end{gathered}$ | $4.6\left[\begin{array}{l} {[2.764} \\ (164) \\ 7.7] \\ \hline \end{array}\right.$ | $5.3\left[\begin{array}{c} {[3.18, ~ 8.7]} \\ (13) \\ \hline \end{array}\right.$ | $5.3[3.7 ; 8.7]$ |  |  |  |  |
| PROCOTYL* C (MicroPort) | 353 | 6 | $80_{(76-83)}$ | 25/75 | 2015-2022 | $0.9\left[\begin{array}{c} {[0.388} \\ (288) \end{array} 2.7\right]$ | $1.6\left[\begin{array}{c} {[0.726} \\ {[26)} \\ \hline .9] \\ \hline \end{array}\right.$ | $2.6[1.2 ; 5.5]$ | $3.3[1.6 ; 6.7]$ |  |  |  |  |
| TRILOC® II-PE-Hüftpfanne (DePuy) | 1,328 | 95 | $79_{(74-83)}$ | 18/82 | 2013-2022 | $3.5\left[\begin{array}{c} {[2.66444} \\ (0.74 \end{array}\right.$ | $3.6 \underset{(941)}{[2.7 ; ~ 4.8]}$ | $3.8\left[\begin{array}{l} {[2,966} \\ (76) \\ 5.0] \end{array}\right.$ | $3.9 \underset{[3877}{[3 ; 0 ;} 5.2]$ | $4.5\left[\begin{array}{l} {[3255} \\ \hline 4 ; 6.0] \\ \hline \end{array}\right.$ | $4.8\left[\begin{array}{c} {[3666} \\ (26.3] \\ \hline \end{array}\right.$ | $6.1[4.1 ; 9.0]$ |  |

## Appendix:

Publications based on EPRD data

## Publications based on EPRD data

The following list, in reverse chronological order, includes all publications and study collaborations, that appeared in journals since 2012, and that are based on the systematic approach and objectives of the EPRD and the underlying data. Analyses based on data from the EPRD or extracts from its collective database can be requested for scientific purposes. Details on the procedures, formalities and any potential fees are listed on the EPRD website at https://www. eprd.de/de/downloads/auswertungsantraege.

Leopold VJ, Krull P, Hardt S, Hipfl C, Melsheimer O, Steinbrück A, Perka C, Giebel GM. Is Elective Total Hip Arthroplasty Safe in Nonagenarians?: An Arthroplasty Registry Analysis. J Bone Joint Surg Am 2023. https://doi.org/10.2106/JBJS. 23.00092
Leta TH, Fenstad AM, Lygre SHL, Lie SA, Lindberg-Larsen M, Pedersen AB, A WD, Rolfson O, Bulow E, Ashforth JA, Van Steenbergen LN, Nelissen R, Harries D, De Steiger R, Lutro O Hakulinen E, Makela K, Willis J, Wyatt M, Frampton C, Grimberg A, Steinbrück A, Wu Y, Armaroli C, Molinari M, Picus R, Mullen K, Illgen R, Stoica IC, Vorovenci AE, Dragomirescu D, Gjertsen JE, Chang RN, Prentice HA, Paxton EW, Furnes O.
The use of antibiotic-loaded bone cement and systemic antibiotic prophylactic use in 2,971,357 primary The use of antibiotic-loaded bone cement and systemic antibiotic prophylactic use in $2,971,357$ primary
total knee arthroplasties from 2010 to 2020: an international register-based observational study among total knee arthroplasties from 2010 to 2020: an internation
countries in Africa, Europe, North America, and Oceania.
Acta Orthop 2023;94: 416-425. https://doi.org/10.2340/17453674.2023.17737
Lützner J, Melsheimer 0, Steinbrück A, Postler AE.
High revision rates and mortality after distal femoral replacement for periprosthetic distal femoral fractures: analysis from the German Arthroplasty Registry (EPRD).
Eur J Orthop Surg Traumatol 2023. https://doi.org/10.1007/s00590-023-03582-2
Szymski D, Walter N, Krull P, Melsheimer 0, Schindler M, Grimberg A, Alt V, Steinbrück A, Rupp M Comparison of mortality rate and septic and aseptic revisions in total hip arthroplasties for osteoarthritis and femoral neck fracture: an analysis of the German Arthroplasty Registry. J Orthop Traumatol 2023;24(1): 29. https://doi.org/10.1186/s10195-023-00711-9
Grimberg AW, Steinbrück A.
10 Jahre Endoprothesenregister Deutschland (EPRD): was wurde erreicht?
Die Orthopädie 2023. https://doi.org/10.1007/s00132-023-04385-3
Szymski D, Walter N, Melsheimer O, Grimberg A, Alt V, Steinbrück A, Rupp M.
Mortalität nach Hemiarthroplastik bei Schenkelhalsfrakturen -
Auswertung des Endoprothesenregisters Deutschland (EPRD).
Dtsch Arztebl Int 2023;120: 297-8. https://doi.org/10.3238/arztebl.m2023.0007
Szymski D, Walter N, Krull P, Melsheimer O, Grimberg A, Alt V, Steinbrück A, Rupp M. Infection after intracapsular femoral neck fracture - does antibiotic-loaded bone cement reduce infection risk after hemiarthroplasty and total hip arthroplasty? Bone Joint Res 2023;12(5): 331-338. https://doi.org/10.1302/2046-3758.125.BJR-2022-0314.R1

Szymski D, Walter N, Krull P, Melsheimer O, Lang S, Grimberg A, Alt V, Steinbrück A, Rupp M The Prophylactic Effect of Single vs. Dual Antibiotic-Loaded Bone Cement against Periprosthetic Joint Infection Following Hip Arthroplasty for Femoral Neck Fracture: An Analysis of the German Arthroplasty Registry
Antibiotics (Basel) 2023;12(4). https://doi.org/10.3390/antibiotics12040732
Krull P, Steinbrück A, Grimberg AW, Melsheimer O, Morlock MM, Perka C
Standard- und Spezialinlays in primarer Huftendoprothetik: Aktuelle Studien- und Umfrageergebnisse aus dem Endoprothesenregister Deutschland (EPRD).
Die Orthopädie 2023;52(3): 222-232. https://doi.org/10.1007/s00132-022-04333-7
Szymski D, Walter N, Krull P, Melsheimer O, Grimberg A, Alt V, Steinbrück A, Rupp M. Aseptic revisions and pulmonary embolism after surgical treatment of femoral neck fractures with cemented and cementless hemiarthroplasty in Germany: an analysis from the German Arthroplasty Registry (EPRD).
J Orthop Traumatol 2023;24(1): 9. https://doi.org/10.1186/s10195-023-00689-4
Krull P, Steinbrück A, Grimberg AW, Melsheimer O, Morlock M, Perka C.
Modified acetabular component liner designs are not superior to standard liners at reducing the risk of revision: An analysis of 151,096 cementless total hip arthroplasties from the German Arthroplasty Registry
Bone Joint J 2022:104-B(7): 801-810
https://doi.org/10.1302/0301-620X.104B7.BJJ-2021-1791.R1
Steinbrück A, Grimberg AW, Elliott J, Melsheimer O, Jansson V.
Short versus conventional stem in cementless total hip arthroplasty: An evidence-based approach with registry data of mid-term survival. Der Orthopade 2021;50(4): 296-305. https://doi.org/10.1007/s00132-021-04083-y

## Steinbruck A, Jansson V

Endoprothesenregister Deutschland (EPRD) - Stellenwert in Deutschland und international was können wir lernen, was nicht?
Orthopädie und Unfallchirurgie up2date 2022;17(4): 1-15
https://doi.org/10.1055/a-1588-2644
Konow T, Baetz J, Melsheimer O, Grimberg A, Morlock M.
Factors influencing periprosthetic femoral fracture risk - A German registry study
Bone Joint J 2021:103-B(4): 650-658.
https://doi.org/10.1302/0301-620X.103B4.BJJ-2020-1046.R2
Renner L, Perka C, Melsheimer O, Grimberg A, Jansson V, Steinbrück A.
Ceramic-on-Ceramic Bearing in Total Hip Arthroplasty Reduces the Risk for Revision for Periprosthetic Joint Infection Compared to Ceramic-on-Polyethylene: A Matched Analysis of118,753 Cementless THA Based on the German Arthroplasty Registry.
J Clin Med 2021;10(6). https://doi.org/10.3390/jcm10061193
Grimberg AW, Grupp TM, Elliott J, Melsheimer O, Jansson V, Steinbrück A.
Ceramic Coating in Cemented Primary Total Knee Arthroplasty is Not Associated With Decreased Risk of Revision due to Early Prosthetic Joint Infection.
J Arthroplasty 2021;36(3): 991-997. https://doi.org/10.1016/j.arth.2020.09.011
Bauer L, Woiczinski M, Thorwachter C, Melsheimer O, Weber P, Grupp TM, Jansson V, Steinbrück A. Secondary Patellar Resurfacing in TKA: A Combined Analysis of Registry Data and Biomechanical Testing. J Clin Med 2021;10(6). https://doi.org/10.3390/jcm10061227

Steinbrück A, Melsheimer O, Grimberg A, Jansson V.
Einfluss der institutionellen Erfahrung auf die Ergebnisse in Hüft- und Knietotalendoprothetik.
Der Orthopade 2020. https://doi.org/10.1007/s00132-020-03963-z
Steinbrück A, Melsheimer O, Grimberg A, Jansson V.
Warum versagen unikondyläre Knieendoprothesen in Deutschland?
Knie Journal 2020. https://doi.org/10.1007/s43205-020-00069-6
Hey A, Grimberg A, Mühlnikel I, Kleinfeld A.
Das Endoprothesenregister Deutschland (EPRD) als Prototyp für das neue staatliche Implantateregister.
In: Uwe Repschläger CSuNOb, BARMER Institut für Gesundheitssystemforschung,
ed. Gesundheitswesen aktuell 2020 Beiträge und Analysen. 2020
Jansson V, Grimberg A, Melsheimer O, Perka C, Steinbrück A.
Orthopaedic registries: the German experience.
EFORT Open Rev 2019;4(6): 401-408. https://doi.org/10.1302/2058-5241.4.180064
Jansson V, Steinbrück A, Hassenpflug J.
Welcher Zusatznutzen ergibt sich in Zukunft aus den Daten des EPRD im Vergleich zu anderen Registern?
Unfallchirurg 2016;119(6): 488-92. https://doi.org/10.1007/s00113-016-0171-7
Hassenpflug J, Liebs TR.
Register als Werkzeug für mehr Endoprothesensicherheit.
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2014;57(12): 1376-83.
https://doi.org/10.1007/s00103-014-2057-6
Sternkopf J, Liebs TR, Schultz C.
Endoprothesenregister: Große Akzeptanz in Krankenhäusern.
Dtsch Arztebl 2014;111(43): 1848-50.
Liebs TR, Melsheimer O, Hassenpflug J.
Frühzeitige Detektion systematischer Schadensfälle durch Endoprothesenregister.
Orthopäde 2014;43(6): 549-54. https://doi.org/10.1007/s00132-014-2293-3
Hassenpflug J.
The German Arthroplasty Register (EPRD).
In : Structure, procedures and organisation.
Paper presented at the EFORT Congress, Berlin. 2012


[^0]:    XS
    S

[^1]:    2 Only surgical documentation identifying alitems in the product database are considered here. Explantations in two-stage revision procedures
    are counted as total replacements. In single-stage revisions the EPRD only resisters the components implanted, but not those explanted.
    The explanted components are inferred based on the products documented at the time of the reoperation. 1 . for example, a new acetabular component is documented, it may be assumed that the existing acetabular component had to be explanted.

[^2]:    
    is documented, it may be assumed that the existing femoral component had to be explanted.

[^3]:    Table 46 (continued)

[^4]:    Table 49: Implant outcomes for femoro-tibial combinations in primary knee arthroplasties without patellar resurfacing at
    primary TKA. Within the groups comprising type of arthroplasty, type of fixation, knee system, and degree of constraint,

[^5]:    Table 51 (continued)

